

08-09-2017

10:00 - 11:30	Type: Special Session Title: Medical oncology as a contributor to global policy: How to improve national cancer plans Chair(s): G. Curigliano, IT; L. Stevens, US	Palma Auditorium
10:00 - 10:05	Introduction <u>L. Stevens</u> , Rio De Janeiro, BR	
10:05 - 10:20	Overview of NCCP, including forming the multi-disciplinary and multi-sectoral partnership <u>A. Ilbawi</u> , Geneva, CH	
10:20 - 10:35	Example from Central Asia Leadership Forum <u>D. Kaidarova</u> , Almaty, KZ	
10:35 - 10:50	Example from Central Europe <u>J. Jassem</u> , Gdańsk, PL	
10:50 - 11:05	Example from Eastern Europe <u>S. Krasny</u> , Minsk, BY	
11:05 - 11:30	Interactive Q&A <u>G. Curigliano</u> , Milan, IT	

12:00 - 13:30	Type: Opening session Title: Opening session and Award lectures Chair(s): F. Ciardiello, IT	Madrid Auditorium
12:00 - 12:10	ESMO Presidential Address <u>F. Ciardiello</u> , Naples, IT	
12:10 - 12:15	EACR Presidential Address <u>A. Berns</u> , Amsterdam, NL	
12:15 - 12:20	Welcome to Madrid <u>M. Martin Jimenez</u> , Madrid, ES	
12:20 - 12:25	ESMO 2017 Scientific Address <u>A. Sobrero</u> , Genova, IT	
12:25 - 12:30	EACR 2017 Scientific Address <u>R. Marais</u> , Manchester, GB	
12:30 - 12:32	Presentation of the ESMO Award by <u>C. Zielinski</u> , Vienna, AT	
12:32 - 12:47	ESMO Award lecture - Oncology: The importance of teamwork <u>M. Martin Jimenez</u> , Madrid, ES	
12:47 - 12:49	Presentation of the ESMO Translational Research Award by <u>C. Zielinski</u> , Vienna, AT	
12:49 - 13:04	ESMO Translational Research Award lecture: Monitoring and targeting colorectal cancer evolution <u>A. Bardelli</u> , Candiolo, (TO)/IT	
13:04 - 13:06	Presentation of the ESMO Lifetime Achievement Award by <u>C. Zielinski</u> , Vienna, AT	
13:06 - 13:21	ESMO Lifetime Achievement Award lecture <u>J. Baselga</u> , New York, NY/US	
13:21 - 13:21	Close and Welcome refreshments in the exhibition	
14:00 - 15:30	Type: Proffered Paper session Title: Gastrointestinal tumours, non-colorectal 1 Chair(s): E. Van Cutsem, BE; Y.-K. Kang, KR	Barcelona Auditorium

- 14:00 - 14:12 LBA27_PR - Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
S.-E. Al-Batran¹, C. Pauligk², N. Homann³, H. Schmalenberg⁴, H.-G. Kopp⁵, G.M. Haag⁶, K. Luley⁷, G. Folprecht⁴, S. Probst⁸, P. Thuss-Patience⁹, J. Trojan², M. Koenigsmann¹⁰, U. Lindig¹¹, M. Pohl¹², S. Kasper¹³, M. Möhler¹⁴, T. Goetze¹, M. Schuler¹³, E. Jaeger¹, R.D. Hofheinz¹⁵; ¹Frankfurt Am Main, DE, ²Frankfurt, DE, ³Wolfsburg, DE, ⁴Dresden, DE, ⁵Tübingen, DE, ⁶Heidelberg, DE, ⁷Lübeck, Schleswig-Holstein/DE, ⁸Bielefeld, DE, ⁹Berlin, DE, ¹⁰Hannover, DE, ¹¹Jena, DE, ¹²Bochum, DE, ¹³Essen, DE, ¹⁴Mainz, DE, ¹⁵Mannheim, DE
- 14:12 - 14:24 615O_PR - Hybrid minimally invasive vs. open esophagectomy for patients with esophageal cancer: Long-term outcomes of a multicenter, open-label, randomized phase III controlled trial, the MIRO trial
C. Mariette¹, S. Markar², T.S. Dabakuyo-Yonli³, B. Meunier⁴, D. Pezet⁵, D. Collet⁶, X. D'journo⁷, C. Brigand⁸, T. Perniceni⁹, N. Carrere¹⁰, F. Bonnetain¹¹, G. Piessen¹²; ¹Lille, CEDEX/FR, ²London, GB, ³Dijon, FR, ⁴Rennes, FR, ⁵Clermont Ferrand, FR, ⁶Bordeaux, FR, ⁷Marseille, FR, ⁸Strasbourg, FR, ⁹Paris, FR, ¹⁰Toulouse, FR, ¹¹Besançon, CEDEX/FR, ¹²Lille, FR
- 14:24 - 14:39 Invited Discussant LBA27_PR and 615O_PR
A. Roth, Geneva, CH
- 14:39 - 14:51 616O - Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)
J. Taberero¹, P. Hoff², L. Shen³, A. Ohtsu⁴, M. Shah⁵, K. Cheng⁶, C. Song⁶, H. Wu⁷, J. Eng-Wong⁶, Y.-K. Kang⁸; ¹Barcelona, ES, ²Sao Paulo, BR, ³Beijing, CN, ⁴Kashiwa, Chiba/JP, ⁵New York, NY/US, ⁶San Francisco, US, ⁷Shanghai, CN, ⁸Seoul, Songpa-gu/KR
- 14:51 - 15:03 617O - A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02)
N. Boku¹, Y.-K. Kang², T. Satoh³, Y. Chao⁴, K. Kato⁵, H.C. Chung⁶, J.-S. Chen⁷, K. Muro⁸, W.K. Kang⁶, T. Yoshikawa⁹, S.C. Oh⁶, T. Tamura¹⁰, K.-W. Lee¹¹, L.-T. Chen¹²; ¹Kawasaki, Kanagawa/JP, ²Seoul, Songpa-gu/KR, ³Suita, Osaka/JP, ⁴Taipei, TW, ⁵Tokyo, JP, ⁶Seoul, KR, ⁷Taoyuan, TW, ⁸Nagoya, Aichi/JP, ⁹Yokohama, JP, ¹⁰Osaka, JP, ¹¹Seongnam, KR, ¹²Tainan, TW
- 15:03 - 15:15 LBA28_PR - KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer
Z. Wainberg¹, S. Jalal², K. Muro³, H. Yoon⁴, M. Garrido⁵, T. Golan⁶, T. Doi⁷, D. Catenacci⁸, R. Geva⁶, G. Ku⁹, J. Bleeker¹⁰, Y.-J. Bang¹¹, H. Hara¹², H.C. Chung¹¹, M. Savage¹³, J. Wang¹³, M. Koshiji¹³, R. Dalal¹⁴, C. Fuchs¹⁵; ¹Los Angeles, CA/US, ²Indianapolis, IN/US, ³Nagoya, Aichi/JP, ⁴Rochester, MN/US, ⁵Santiago, CL, ⁶Tel Aviv, IL, ⁷Kashiwa, Chiba/JP, ⁸Chicago, IL/US, ⁹New York, NY/US, ¹⁰Sioux Falls, SD/US, ¹¹Seoul, KR, ¹²Saitama, JP, ¹³Kenilworth, NJ/US, ¹⁴Rahway, US, ¹⁵New Haven, CT/US
- 15:15 - 15:30 Invited Discussant 616O, 617O and LBA28
E. Van Cutsem, Leuven, BE

14:00 - 15:30	Type: Proffered Paper session Title: Genitourinary tumours, prostate Chair(s): J. de Bono, GB; A. Omlin, CH; S. Gillessen, CH	Sevilla Auditorium
14:00 - 14:12	LBA31_PR - Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476) <u>M. Sydes</u> ¹ , M. Mason ² , M. Spears ³ , N. Clarke ⁴ , D. Dearnaley ⁵ , A. Ritchie ⁶ , M. Russell ⁷ , C. Gilson ⁶ , R. Jones ⁷ , J. de Bono ⁶ , S. Gillessen ⁸ , R. Millman ³ , S. Tolan ⁹ , J. Wagstaff ¹⁰ , S. Chowdhury ⁶ , J. Lester ¹¹ , D. Sheehan ¹² , J. Gale ¹³ , M. Parmar ¹⁴ , N. James ¹⁵ ; ¹ London, UK/GB, ² Cardiff, GB, ³ Wcb Nh, GB, ⁴ M Hd, GB, ⁵ Sutton, GB, ⁶ London, GB, ⁷ Glasgow, GB, ⁸ St. Gallen, CH, ⁹ Wirral, GB, ¹⁰ Swansea, GB, ¹¹ Wales, GB, ¹² Exeter, GB, ¹³ Portsmouth, GB, ¹⁴ London, London/GB, ¹⁵ Birmingham, GB	
14:12 - 14:24	783O - Benefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO) <u>K. Chi</u> ¹ , A. Protheroe ² , A. Rodriguez Antolin ³ , G. Facchini ⁴ , H. Suttman ⁵ , N. Matsubara ⁶ , Z.-Q. Ye ⁷ , B. Keam ⁸ , T. Li ⁹ , K. McQuarrie ¹⁰ , B. Jia ¹¹ , P. De Porre ¹² , J. Martin ¹³ , M. Todd ⁹ , K. Fizazi ¹⁴ ; ¹ Vancouver, British Columbia/CA, ² Oxford, GB, ³ Madrid, ES, ⁴ Napoli, IT, ⁵ Hamburg, DE, ⁶ Kashiwa, Chiba/JP, ⁷ Wuhan, CN, ⁸ Seoul, KR, ⁹ Raritan, NJ/US, ¹⁰ Horsham, PA/US, ¹¹ Shanghai, CN, ¹² Antwerp, BE, ¹³ Buckinghamshire, GB, ¹⁴ Villejuif Cedex, FR	
14:24 - 14:36	784O - Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial <u>S. Oudard</u> ¹ , I. Latorzeff ² , A. Caty ³ , L. Miglianico ⁴ , E. Sevin ⁵ , A.-C. Hardy Bessard ⁶ , R. Delva ⁷ , F. Rolland ⁸ , C. Chevreau ² , F. Priou ⁹ , P. Beuzeboc ¹⁰ , G. Gravis ¹¹ , C. Linassier ¹² , P. Gomez ¹³ , E. Voog ¹⁴ , P. Chinet ¹ , X. Muracciole ¹⁵ , C. Abraham Jaillon ¹⁶ , R. Elaidi ¹ , S. Culine ¹⁷ ; ¹ Paris, FR, ² Toulouse, FR, ³ Lille Cedex, FR, ⁴ St. Grégoire, FR, ⁵ Caen, FR, ⁶ Plérin, FR, ⁷ Angers, FR, ⁸ Saint-Herblain, CEDEX/FR, ⁹ La Roche Sur Yon, CEDEX 9/FR, ¹⁰ Paris, CEDEX 5/FR, ¹¹ Marseille, CEDEX 9/FR, ¹² Tours, CEDEX 9/FR, ¹³ Rouen, FR, ¹⁴ Le Mans, FR, ¹⁵ Marseille, FR, ¹⁶ Le Chesnay, FR, ¹⁷ Paris, CEDEX 10/FR	
14:36 - 14:51	Invited Discussant LBA31, 783O and 784O <u>C. Sternberg</u> , Roma, IT	
14:51 - 15:03	785O - Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA <u>M. Hofman</u> ¹ , S. Sandhu ² , P. Eu ² , J. Price ² , T. Akhurst ² , A. Irvani ² , G. Kong ² , A. Ravi-Kumar ² , S. Williams ² , S.-P. Thang ² , D. Murphy ² , M. Scalzo ² , R. Hicks ² , J. Violet ² ; ¹ Melbourne, AU, ² Melbourne, VIC/AU	
15:03 - 15:15	LBA32 - PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC)	

E. Castro Marcos¹, N. Romero Laorden², J.M. Piulats Rodriguez³, A. del Pozo¹, M.I. Sáez⁴, A. Medina Colmenero¹, J. Puente¹, J.C. Silla-Castro¹, R. Lozano Mejorada⁵, I. Garcia-Carbonero⁶, L. Rivera¹, M.J. Mendez Vidal⁷, R. Morales Barrera⁸, E.M. Fernandez Parra⁹, Y. Cendón Flórez¹, P. Borrega¹⁰, M.A. Gonzalez Del Alba Baamonde¹¹, C. Pritchard¹², P. Lapunzina¹, D. Olmos Hidalgo¹; ¹Madrid, ES, ²Madrid, Madrid/ES, ³Barcelona, Barcelona/ES, ⁴Malaga, ES, ⁵Salamanca, ES, ⁶Toledo, ES, ⁷Cordoba, ES, ⁸Barcelona, ES, ⁹Sevilla, ES, ¹⁰Caceres, Cáceres/ES, ¹¹Palma De Mallorca, ES, ¹²Washington, US

15:15 - 15:30 Invited Discussant 785O and LBA32
J. Mateo, Sutton, GB

14:00 - 15:30 Type: Proffered Paper session Pamplona Auditorium
Title: Breast cancer, early stage
Chair(s): N. Harbeck, DE; E. Senkus-Konefka, PL

14:00 - 14:12 LBA9 - Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minimal breast cancer. Results of the UNICANCER-eoPAL study
P. cottu¹, V. D'Hondt², S. Dureau¹, F. Lerebours³, I. Desmoulin⁴, P.-E. Heudel⁵, F. Duhoux⁶, C. Levy⁷, M.-A. Mouret-Reynier⁸, F. Dalenc⁹, J.-S. Frenel¹⁰, C. Jouannaud¹¹, L. Venat-Bouvet¹², S. Nguyen¹³, J.-M. Ferrero¹⁴, J.-L. Canon¹⁵, J. Grenier¹⁶, J. Lemonnier¹, A. Vincent-Salomon¹, S. Delalogue¹⁷; ¹Paris, FR, ²Montpellier, CEDEX 5/FR, ³Saint Cloud, FR, ⁴Dijon, Cedex/FR, ⁵Lyon, FR, ⁶Brussels, BE, ⁷Caen, CEDEX 5/FR, ⁸Clermont-Ferrand, FR, ⁹Toulouse, CEDEX 3/FR, ¹⁰Saint-Herblain, CEDEX/FR, ¹¹Reims, CEDEX/FR, ¹²Limoges, FR, ¹³Beauvais, CEDEX/FR, ¹⁴Nice, CEDEX 2/FR, ¹⁵Charleroi, BE, ¹⁶Avignon, CEDEX 2/FR, ¹⁷Villejuif, FR

14:12 - 14:24 LBA10_PR - Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)
C. Saura¹, E. de Azambuja², D. Hlauschek³, M. Oliveira¹, D. Zardavas², A. Jallitsch-Halper³, L. de la Pena⁴, P. Nuciforo¹, A. Ballestrero⁵, M. Fournier⁶, K. Boer⁷, E. Ciruelos⁸, V. Valero⁹, T. Wilson¹⁰, T. Stout¹⁰, J. Hsu¹⁰, Y. Shi¹⁰, M. Piccart², M. Gnant³, J. Baselga⁶; ¹Barcelona, ES, ²Brussels, BE, ³Vienna, AT, ⁴Barcelona, Spain/ES, ⁵Genova, IT, ⁶New York, NY/US, ⁷Budapest, HU, ⁸Madrid, ES, ⁹Houston, TX/US, ¹⁰South San Francisco, CA/US

14:24 - 14:36 148O - Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study
M. Ruiz-Borrego¹, M. Martin Jimenez², A. Ruiz³, A. Lluch⁴, M. Ramos⁵, J. Cruz Jurado⁶, J.M. Baena-Canada⁷, B. Cirauqui⁸, A. Rodriguez-Lescure⁹, E. Alba Conejo¹⁰, N. Martínez Jañez², M. Muñoz¹¹, S. Antolin¹², I. Álvarez López¹³, S. Del Barco¹⁴, L. Garcia-Estevez², J.I. Chacon Lopez-Muniz¹⁵, A. Anton Torres¹⁶, E. Carrasco²; ¹Sevilla, ES, ²Madrid, ES, ³Valencia, ES, ⁴Valencia, Valencia/ES, ⁵A Coruña, ES, ⁶San Cristobal De La Laguna, Santa Cruz de Tenerife, Canary Islands/ES, ⁷Cadiz, ES, ⁸Badalona, ES, ⁹Elche Alicante, ES, ¹⁰Malaga, ES, ¹¹Barcelona, ES, ¹²Coruña, ES, ¹³Donostia, ES, ¹⁴Girona, ES, ¹⁵Toledo, ES, ¹⁶Zaragoza, ES

- 14:36 - 14:51 Invited Discussant LBA9, LBA10_PR and 148O
N. Harbeck, Munich, DE
- 14:51 - 15:03 149O - Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial
M. Martin Jimenez¹, F.A. Holmes², B. Ejlersen³, S. Delaloge⁴, B. Moy⁵, H. Iwata⁶, G. von Minckwitz⁷, S. Chia⁸, J. Mansi⁹, C. Barrios¹⁰, M. Gnant¹¹, Z. Tomasevic¹², N. Denduluri¹³, R. Separovic¹⁴, S.-B. Kim¹⁵, E. Jakobsen¹⁶, R. Bryce¹⁷, F. Xu¹⁷, M. Buyse¹⁸, A. Chan¹⁹; ¹Madrid, ES, ²Houston, TX/US, ³Copenhagen, DK, ⁴Villejuif, FR, ⁵Boston, MA/US, ⁶Chikusa-Ku, Nagoya, JP, ⁷Neu-Isenburg, DE, ⁸Vancouver, BC/CA, ⁹London, GB, ¹⁰Porto Alegre, BR, ¹¹Vienna, AT, ¹²Belgrade, RS, ¹³Arlington, VA/US, ¹⁴Zagreb, HR, ¹⁵Seoul, KR, ¹⁶Vejle, DK, ¹⁷Los Angeles, CA/US, ¹⁸San Francisco, CA/US, ¹⁹Perth, AU
- 15:03 - 15:15 150O_PR - Not all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy
K. Tryfonidis¹, C. Poncet¹, L. Slaets¹, G. Viale², F. de Snoo³, K. Aalders¹, L. Van'T Veer⁴, E. Rutgers³, M. Piccart¹, J. Bogaerts¹, F. Cardoso⁵; ¹Brussels, BE, ²Milan, IT, ³Amsterdam, NL, ⁴San Francisco, US, ⁵Lisbon, PT
- 15:15 - 15:30 Invited Discussant 149O and 150O_PR
H. Rugo, San Francisco, CA/US
- 14:00 - 15:30 Type: Educational session Cordoba Auditorium
Title: Optimal therapy in localised rectal cancer
Chair(s): A. Cervantes, ES; J. Taieb, FR
- 14:00 - 14:25 Imaging and re-imaging
R. Beets-Tan, Maastricht, NL
- 14:25 - 14:50 What treatment should be skipped or intensified?
B. Glimelius, Uppsala, SE
- 14:50 - 15:15 Adjuvant therapy
A. Cervantes, Valencia, Valencia/ES
- 15:15 - 15:30 Discussion

14:00 - 15:30 Type: Joint Symposium Granada Auditorium
 Title: ESMO-EACR: Preclinical models for developing combination therapeutics
 Chair(s): F. Ciardiello, IT; A. Berns, NL

14:00 - 14:05 Introduction
F. Ciardiello, Naples, IT

14:05 - 14:25 Tumour organoids to test drug responses
M. Garnett, Cambridge, GB

14:25 - 14:45 The Achilles heel of acquired drug resistance
R. Bernards, Amsterdam, NL

14:45 - 15:05 Optimising drug combinations to overcome resistance
R. Corcoran, Boston, MA/US

15:05 - 15:25 Accelerated clinical evaluation of drug combinations based on biological insight
E. Garralda, Barcelona, ES

15:25 - 15:30 Conclusions
A. Berns, Amsterdam, NL

14:00 - 15:30 Type: Joint Symposium Valencia Auditorium
 Title: ESMO-ESP: The evolution of pathological reporting - GI focus
 Chair(s): D. Arnold, PT; P. Bedossa, FR

14:00 - 14:05 Introduction
P. Bedossa, Clichy, FR

14:05 - 14:25 The clinician's perspective: What is expected from the pathologist?
D. Arnold, Lisbon, PT

14:25 - 14:45 Pathologist: From descriptive to synoptic reports
I. Nagtegaal, Nijmegen, NL

14:45 - 15:05 Molecular pathology in GI cancer: What is useful and how to integrate it into the pathological report
T. Kirchner, Munich, DE

15:05 - 15:25 Immunology in GI cancer: What is useful and how to integrate it into the pathological report
C. Badoual, Paris, FR

15:25 - 15:30 Conclusions
D. Arnold, Lisbon, PT

14:00 - 15:30 Type: Educational session Tarragona Auditorium
Title: Standard of diagnosis and care in brain tumours
Chair(s): P. Wen, US; E. Le Rhun, FR

14:00 - 14:25 The new WHO classification
G. Reifenberger, Dusseldorf, DE

14:25 - 14:50 How do I use the Response Assessment in Neuro-Oncology (RANO) criteria?
P. Wen, Boston, MA/US

14:50 - 15:15 How to manage complications of radiotherapy and chemotherapy?
E. Le Rhun, Lille, CEDEX/FR

15:15 - 15:30 Discussion

14:00 - 15:30 Type: Joint Symposium Bilbao Auditorium
Title: ESMO-ESOP: The growing need for collaboration between clinicians and oncology pharmacists
Chair(s): S. Rauh, LU; K. Meier, DE

14:00 - 14:05 Introduction
S. Rauh, Esch Sur Alzette, LU

14:05 - 14:25 Access to anti-cancer medicines: How Germany is tackling the issue
B. Woermann, Berlin, DE

14:25 - 14:45 Contamination with cytotoxic drugs in the workplace - MASHA project
K. Meier, Hamburg, DE

14:45 - 15:05 Challenges in adherence to oral cancer therapies: The clinician's perspective
S. Rauh, Esch Sur Alzette, LU

15:05 - 15:25 Challenges in adherence to oral cancer therapies: The oncology pharmacist's perspective
K. Meier, Hamburg, DE

15:25 - 15:30 Conclusions
K. Meier, Hamburg, DE

14:00 - 15:30 Type: Joint Symposium Alicante Auditorium
 Title: ESMO-WHO: Workforce optimisation: a WHO-ESMO study on health workforce requirements, using the example of breast cancer care
 Chair(s): A. Eniu, RO; J. Campbell, CH

14:00 - 14:15 What works in workforce optimisation: The WHO perspective
J. Campbell, Geneva, CH

14:15 - 14:30 Predicting the future: How many oncology professionals will your country need?
M. Boniol, Geneva, CEDEX 8/CH

14:30 - 14:45 It's about the people: Assessing the gaps and planning the workforce. The example of breast cancer care
G. Curigliano, Milan, IT

14:45 - 15:00 Workforce strategies: Which ones work best?
C. Rodriguez, Salamanca, ES

15:00 - 15:25 Participant discussion and Q&A
J. Campbell, Geneva, CH

15:25 - 15:30 Conclusions
A. Eniu, Cluj-Napoca, RO

14:00 - 15:30 Type: Special Session Cartagena Auditorium
 Title: Primary and secondary prevention of cancer: Where do we stand?
 Chair(s): A. Costa, CH; J.-Y. Douillard, CH

14:00 - 14:05 Introduction
A. Costa, Bellinzona, CH

14:05 - 14:30 The concept and achievements of therapeutic prevention
A. De Censi, Genova, IT

14:30 - 14:55 Aspirin for prevention and adjuvant treatment of cancer
R. Langlely, London, GB

14:55 - 15:20 Tobacco cessation and cancer incidence and recurrence
E. Quoix, Strasbourg, CEDEX/FR

15:20 - 15:30 Conclusions
J.-Y. Douillard, Lugano - Viganello, CEDEX/CH

14:00 - 15:30 Type: Educational session Madrid Auditorium
Title: Immunotherapy: The next steps
Chair(s): J. Larkin, GB; P. Nathan, GB

14:00 - 14:25 Combination of drugs acting on the immune system
S. Topalian, Baltimore, Md, US

14:25 - 14:50 How to sequence immunotherapy
J. Larkin, London, GB

14:50 - 15:15 When to discontinue immunotherapy
C. Robert, Villejuif, FR

15:15 - 15:30 Discussion

14:00 - 14:30 Type: Patient Advocacy Track Palma Auditorium
Title: Welcome

14:00 - 14:10 Welcome by ESMO
P.G. Casali, Milan, IT

14:10 - 14:20 Welcome by the ESMO PAWG Chair
B. Ryll, SE

14:20 - 14:30 Welcome by EACR
R. Marais, Manchester, GB

14:45 - 15:45 Type: Patient Advocacy Track Palma Auditorium
 Title: Science by patients for patients
 Chair(s): B. Ryll, SE; C. Roffiaen, IT

14:45 - 14:50 Introduction
B. Ryll, SE

14:50 - 15:05 Science and advocacy: Why care about science? How to involve patients in research
J. Geissler, DE

15:05 - 15:20 How to run clinical trials that matters to patients
E. Low, London, GB

15:20 - 15:35 The citizen scientist: Statistics for citizen
K. Curtin, Tipperary, IE

15:35 - 15:45 Discussion

16:00 - 17:30 Type: Educational session Sevilla Auditorium
 Title: What is new in germ cell tumours
 Chair(s): A. López-Beltran, PT; A. Bamias, GR

16:00 - 16:25 What is new in the biology of germ cell tumours
A. López-Beltran, Lisbon, PT

16:25 - 16:50 Refining prognosis assessment in germ cell tumours
J. Oldenburg, Eiksmarka, NO

16:50 - 17:15 The role of high dose chemotherapy in refractory resistant germ cell tumours
J. Beyer, Zurich, CH

17:15 - 17:30 Discussion

16:00 - 17:30 Type: Educational session Pamplona Auditorium
Title: Genome instability, its relevance to cancer and therapeutic potential
Chair(s): S. Nik-Zainal, GB; J. Bartek, DK

16:00 - 16:25 What is DNA replication stress and what is its relevance to cancer?
J. Bartek, Copenhagen, DK

16:25 - 16:50 Aneuploidy and cancer
T. Watkins, London, GB

16:50 - 17:15 Kateagis and Apobec- relevance to cancer
S. Nik-Zainal, Cambridge, GB

17:15 - 17:30 Discussion

16:00 - 17:30 Type: Proffered Paper session Cordoba Auditorium
Title: Gynaecological cancers
Chair(s): D. Lorusso, IT; S. Pignata, IT

16:00 - 16:12 929O_PR - ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis
A. Clamp¹, I. McNeish², A. Dean³, D. Gallardo⁴, J. Weon- Kim⁵, D. O'Donnell⁶, J. Hook⁷, C. Coyle⁸, S. Blagden⁹, J. Brenton¹⁰, R. Naik¹¹, T. Perren⁷, S. Sundar¹², A. Cook⁸, E. James⁸, A.M. Swart¹³, S. Stenning⁸, R. Kaplan¹⁴, J. Ledermann⁸; ¹Manchester, GB, ²Glasgow, GB, ³Subiaco, AU, ⁴Mexico, MX, ⁵Seoul, KR, ⁶Dublin, IE, ⁷Leeds, Yorkshire/GB, ⁸London, GB, ⁹Oxford, GB, ¹⁰Cambridge, GB, ¹¹Gateshead, GB, ¹²Birmingham, GB, ¹³No City Provided, NA, ¹⁴Leeds, GB

16:12 - 16:24 LBA40_PR - ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)
J. Ledermann¹, A. Oza², D. Lorusso³, C. Aghajanian⁴, A. Oaknin⁵, A. Dean⁶, N. Colombo³, J. Weberpals⁷, A. Clamp⁸, G. Scambia⁹, A. Leary¹⁰, R. Holloway¹¹, D. O'Malley¹², T. Cameron¹³, L. Maloney¹⁴, S. Goble¹⁵, K. Lin¹⁵, J. Sun¹⁶, H. Giordano¹⁷, R. Coleman¹⁸; ¹London, GB, ²Toronto, Ontario/CA, ³Milan, IT, ⁴New York, NY/US, ⁵Barcelona, ES, ⁶Subiaco, AU, ⁷Ottawa, Ontario/CA, ⁸Manchester, GB, ⁹Roma, IT, ¹⁰Villejuif, FR, ¹¹Orlando, FL/US, ¹²Columbus, OH/US, ¹³Cambridge, GB, ¹⁴Boulder, Colorado/US, ¹⁵Boulder, CO/US, ¹⁶Cambridge, MA/US, ¹⁷San Francisco, California/US, ¹⁸Houston, TX/US

16:24 - 16:36 930O - Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial

A. Oza¹, U. Matulonis², S. Malander³, J. Sehouli⁴, J. del Campo⁵, D. Berthon-Rigaud⁶, S. Banerjee⁷, G. Scambia⁸, J. Berek⁹, B. Lund¹⁰, A. Tinker¹¹, F. Hilpert¹², I. Palacio Vázquez¹³, V. D'hondt⁶, B. Benigno¹⁴, D. Provencher¹⁵, J. Buscema¹⁶, S. Hudgens¹⁶, S. Agarwal¹⁷, M.R. Mirza¹⁸; ¹Toronto, Ontario/CA, ²Boston, MA/US, ³Lund, SE, ⁴Berlin, DE, ⁵Barcelona, ES, ⁶Montpellier, FR, ⁷London, GB, ⁸Roma, IT, ⁹Palo Alto, CA/US, ¹⁰Aalborg, DK, ¹¹Vancouver, BC/CA, ¹²Hamburg, DE, ¹³Oviedo, ES, ¹⁴Atlanta, GA/US, ¹⁵Montreal, CA, ¹⁶Tuscon, AZ/US, ¹⁷Waltham, MA/US, ¹⁸Copenhagen, DK

16:36 - 16:51 Invited Discussant 929O, 930O and LBA40

S. Pignata, Napoli, IT

16:51 - 17:03 LBA41 - A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma

J. Ledermann¹, J. Sehouli², B. Zurawski³, F. Raspagliesi⁴, U. De Giorgi⁵, S. Banerjee¹, J. Arranz Arija⁶, M. Romeo Marin⁷, A. Lisyanskaya⁸, R.L. Póka⁹, S. Mihutiu¹⁰, J. Markowska¹¹, C. Cebotaru¹², A. Casado Herraiz⁶, N. Colombo⁴, N. Kovalenko¹³, E. Kutarska¹⁴, M. Hall¹⁵, R. Belli¹⁶, A. Zurlo^{2, 1}; ¹London, GB, ²Berlin, DE, ³Bydgoszcz, PL, ⁴Milan, IT, ⁵Meldola, Forli-Cesena/IT, ⁶Madrid, ES, ⁷Badalona, Barcelona/ES, ⁸St.-Petersburg, RU, ⁹Debrecen, HU, ¹⁰Oradea, RO, ¹¹Poznan, PL, ¹²Cluj-Napoca, RO, ¹³Volzhskiy, RU, ¹⁴Lublin, PL, ¹⁵Middlesex, GB, ¹⁶Royston, GB

17:03 - 17:15 931O - A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

I. Vergote¹, E. Dean², U. Lassen³, J. de Bono⁴, Y. Drew⁵, J.-P. Machiels⁶, D. Nielsen⁷, H.-T. Arkenau⁴, M. Forster⁸, R. Jones⁹, B. Slomovitz¹⁰, J. Spicer⁴, M. Johnson¹¹, N. Cornez¹², C. Gennigens¹³, B. Fulton¹⁴, S. Lisby³, L. Basse³, R. Coleman¹⁵, D. Hong¹⁶; ¹Leuven, BE, ²Manchester, GB, ³Copenhagen, DK, ⁴London, GB, ⁵Newcastle Upon Tyne, GB, ⁶Brussels, BE, ⁷Herlev, DK, ⁸London, London/GB, ⁹Cardiff, GB, ¹⁰Miami, US, ¹¹Nashville, TN/US, ¹²Mons, BE, ¹³Liège, BE, ¹⁴Glasgow, GB, ¹⁵Houston, TX/US, ¹⁶Houston, US

17:15 - 17:30 Invited Discussant LBA41 and 931O

M.R. Mirza, Copenhagen, DK

16:00 - 17:30 Type: Joint Symposium Granada Auditorium
 Title: ESMO-KACO: Molecular targets in breast cancer
 Chair(s): C. Zielinski, AT; Y.-H. Im, KR

16:00 - 16:05 Introduction
Y.-H. Im, Seoul, KR

16:05 - 16:25 Molecular targets in overcoming treatment resistance
C. Zielinski, Vienna, AT

16:25 - 16:45 Optimising treatment for luminal breast cancer: Luminal A vs. Luminal B
S.-B. Kim, Seoul, KR

16:45 - 17:05 Developing strategies for overcoming drug resistance in HER2–positive breast cancer
S.-A. Im, Seoul, KR

17:05 - 17:25 Molecular divergence in an ‘entity’?: Triple-negative breast cancer
F. André, Villejuif, CEDEX/FR

17:25 - 17:30 Conclusions
C. Zielinski, Vienna, AT

16:00 - 17:30 Type: Joint Symposium Valencia Auditorium
 Title: ESMO-ASCO: Evidence from single-arm trials
 Chair(s): F. Ciardiello, IT; B. Johnson, US

16:00 - 16:05 Introduction
F. Ciardiello, Naples, IT

16:05 - 16:25 The settings and the challenges of single-arm trials
P.G. Casali, Milan, IT

16:25 - 16:45 Evidence from single-arm trials that lead to regulatory approval
B. Johnson, Ann Arbor, NJ/US

16:45 - 17:05 Early clinical data for new drug approval in Europe: Help or hindrance?
F. Pignatti, London, GB

17:05 - 17:25 Generating evidence outside the traditional randomized controlled trial
G. Blumenthal, Silver Spring, US

17:25 - 17:30 Conclusions
B. Johnson, Ann Arbor, NJ/US

16:00 - 17:30 Type: Joint Symposium Tarragona Auditorium
Title: ESMO-JSMO: Combinations with immuno-oncology agents for gastrointestinal cancer: Which ones make the best partners?
Chair(s): J. Tabernero, ES; H. Minami, JP

16:00 - 16:05 Introduction
J. Tabernero, Barcelona, ES

16:05 - 16:25 Combinations with immune-oncology agents for GI cancers: Their scientific rationales
K. Shitara, Kashiwa, Chiba/JP

16:25 - 16:45 Combinations of checkpoint inhibitors and immunostimulation for immune-ignorant tumours
I. Melero, Pamplona, ES

16:45 - 17:05 Combinations with immune-oncology agents for upper GI cancers: Update of clinical trial results
K. Muro, Nagoya, Aichi/JP

17:05 - 17:25 Combinations with immune-oncology agents for colorectal cancer: Current status of clinical development
J. Tabernero, Barcelona, ES

17:25 - 17:30 Conclusions
H. Minami, Kobe, Hyogo/JP

16:00 - 17:30 Type: Joint Symposium Bilbao Auditorium
Title: ESMO-EONS: Promoting patient safety at clinical and organisational levels
Chair(s): G. Pentheroudakis, GR; D. Kelly, GB

16:00 - 16:05 Introduction
G. Pentheroudakis, Ioannina, GR

16:05 - 16:25 Patient safety at the clinical and organisational level
D. Kelly, Cardiff, GB

16:25 - 16:45 Promoting safety for cancer patients: The ESMO EONS Guidelines for the management of extravasation
J.A. Perez Fidalgo, Valencia, Valencia/ES

16:45 - 17:05 Ethical and financial dimensions of patient safety
S. Rauh, Esch Sur Alzette, LU

17:05 - 17:25 Evidence of the impact of nursing interventions on patients with cancer: Results from a systematic review
M. Wells, Stirling, GB

17:25 - 17:30 Conclusions
D. Kelly, Cardiff, GB

16:00 - 17:30	Type: Proffered Paper session Title: CNS tumours Chair(s): M. Weller, CH; M. van den Bent, NL	Alicante Auditorium
16:00 - 16:12	325O - Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM) <u>M. Lim</u> ¹ , A. Omuro ² , G. Vlahovic ³ , D. Reardon ⁴ , S. Sahebjam ⁵ , T. Cloughesy ⁶ , J. Baehring ⁷ , N. Butowski ⁸ , V. Potter ⁹ , R. Zwiros ⁹ , P. Paliwal ⁹ , M. Carleton ⁹ , J. Sampson ¹⁰ , A. Brandes ¹¹ ; ¹ Baltimore, US, ² Miami, US, ³ Durham, US, ⁴ Boston, MA/US, ⁵ Tampa, FL/US, ⁶ Los Angeles, US, ⁷ New Haven, CT/US, ⁸ San Francisco, US, ⁹ Princeton, US, ¹⁰ Durham, NC/US, ¹¹ Bologna, IT	
16:12 - 16:24	326O - The association of programmed death-ligand 1 (PD-L1), programmed cell death (PD-1), tumor infiltrating lymphocytes(TILs) and isocitrate dehydrogenase (IDH-1) mutation in glioblastoma multiforme(GBM) D. sener dede, H. Tatli Dogan, F. Asan, B. Gumuskaya Ocal, S. Ayik, M. Sendur, A. Ulas, B. Bilgin, M. Hizal, M. Akinci, K. Silay, B. Yalçın, <u>M. Sendur</u> ; Ankara, TR	
16:24 - 16:39	Invited Discussant 325O and 326O <u>M. van den Bent</u> , Rotterdam, NL	
16:39 - 16:51	LBA16 - REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients <u>G. Lombardi</u> ¹ , G.L. De Salvo ¹ , A. Brandes ² , M. Eoli ³ , R. Rudà ⁴ , M. Faedi ⁵ , I. Lolli ⁶ , A. Pace ⁷ , S. Rizzato ⁸ , D. Germano ⁹ , F. Pasqualetti ¹⁰ , M. Farina ¹ , G. Magni ¹ , A. Pambuku ¹ , E. Bergo ¹ , G. Cabrini ¹¹ , S. Indraccolo ¹ , M. Gardiman ¹ , V. Zagonel ¹ ; ¹ Padova, IT, ² Bologna, IT, ³ Milano, IT, ⁴ Torino, IT, ⁵ Cesena, IT, ⁶ Castellana Grotte, IT, ⁷ Roma, IT, ⁸ Udine, IT, ⁹ Benevento, IT, ¹⁰ Pisa, IT, ¹¹ Verona, IT	
16:51 - 17:03	327O - Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized clinical trials in glioblastoma <u>M. van den Bent</u> ¹ , L. Roberts-Rapp ² , P. Ansell ³ , J. Lee ⁴ , J. Looman ⁵ , E. Bain ² , C. Ocampo ³ , K. Holen ² , E. Gomez ² , A. Lassman ⁶ ; ¹ Rotterdam, NL, ² North Chicago, IL/US, ³ North Chicago, US, ⁴ Des Plaines, IL/US, ⁵ Amsterdam, NL, ⁶ New York, NY/US	
17:03 - 17:15	328O - Low grade glioma patients with IDH mutation and 1p19q codeletion: What to do after surgery? <u>E. Franceschi</u> ¹ , A. Mura ¹ , A. Mandrioli ¹ , S. Minichillo ¹ , A. Tosoni ¹ , A. Pession ¹ , D. De Biase ¹ , D. Danieli ² , S. Pizzolitto ³ , A. Fioravanti ¹ , L. Volpin ² , R. Agati ¹ , S. Bartolini ¹ , A. Paccapelo ¹ , A. Brandes ¹ ; ¹ Bologna, IT, ² Vicenza, IT, ³ Udine, IT	
17:15 - 17:30	Invited Discussant LBA16, 327O and 328O <u>J. Sepulveda Sanchez</u> , Madrid, ES	

16:00 - 17:30	Type: Special Symposium Title: Cancer stem cell properties Chair(s): A. Trumpp, DE; A. Berns, NL	Cartagena Auditorium
16:00 - 16:05	Introduction <u>A. Trumpp</u> , Heidelberg, DE	
16:05 - 16:25	Stem cell re-programming in cancer tissues <u>A. Behrens</u> , London, GB	
16:25 - 16:45	Clonal tracking of stem cells <u>L. Shlush</u> , Rehovot, IL	
16:45 - 17:05	Stem and progenitor cells in epithelial cancer <u>R. Toftgård</u> , Tockholm, SE	
17:05 - 17:25	Normal and malignant stem cells <u>A. Trumpp</u> , Heidelberg, DE	
17:25 - 17:30	Conclusions and clinical perspectives <u>A. Berns</u> , Amsterdam, NL	
16:00 - 17:30	Type: Proffered Paper session Title: NSCLC, metastatic 1 Chair(s): R. Dziadziuszko, PL; S. Peters, CH	Madrid Auditorium
16:00 - 16:12	1295O - Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) <u>D. Gandara</u> ¹ , M. Kowanetz ² , T.S.K. Mok ³ , A. Rittmeyer ⁴ , L. Fehrenbacher ⁵ , D. Fabrizio ⁶ , G. Otto ⁶ , C. Malboeuf ⁶ , D. Lieber ⁶ , S. Paul ² , L. Amler ² , T. Riehl ² , E. Schleifman ² , C. Cummings ² , P. Hegde ² , W. Zou ² , A. Sandler ² , M. Ballinger ² , D. Shames ² ; ¹ Sacramento, CA/US, ² South San Francisco, US, ³ Shatin, HK, ⁴ Immenhausen, DE, ⁵ Vallejo, US, ⁶ Cambridge, US	
16:12 - 16:24	1296O - Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study <u>S. Gadgeel</u> ¹ , M. Kowanetz ² , W. Zou ² , F. Hirsch ³ , K. Kerr ⁴ , D. Gandara ⁵ , F. Barlesi ⁶ , K. Park ⁷ , M. McClelland ² , H. Koeppen ² , M. Ballinger ² , A. Sandler ² , P. Hegde ² , A. Rittmeyer ⁸ ; ¹ Ann Arbor, US, ² South San Francisco, US, ³ Aurora, US, ⁴ Aberdeen, GB, ⁵ Sacramento, CA/US, ⁶ Marseille, FR, ⁷ Seoul, KR, ⁸ Immenhausen, DE	
16:24 - 16:39	Invited Discussant 1295O and 1296O <u>J. Jassem</u> , Gdańsk, PL	
16:39 - 16:51	1297O - Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)	

D. Spigel¹, M. McLeod², M. Hussein³, D. Waterhouse⁴, L. Einhorn⁵, L. Horn⁶, B. Creelan⁷, S. Babu⁸, N. Leigh⁹, F. Couture¹⁰, J. Chandler¹¹, G. Goss¹², G. Keogh¹³, E. Garon¹⁴, K. Blankstein¹⁵, D. Daniel¹⁶, M. Mohamed¹⁷, A. Li¹⁸, N. Aanur¹⁸, R. Jotte¹⁹; ¹Nashville, TN/US, ²Cape Coral, US, ³Lady Lake, US, ⁴Cincinnati, US, ⁵Indianapolis, US, ⁶Nashville, US, ⁷Tampa, US, ⁸Fort Wayne, US, ⁹Toronto, CA, ¹⁰Quebec, CA, ¹¹Southaven, US, ¹²Ottawa, CA, ¹³Charleston, US, ¹⁴Santa Monica, US, ¹⁵Flemington, US, ¹⁶Chattanooga, US, ¹⁷Greensboro, US, ¹⁸Princeton, US, ¹⁹Denver, US

16:51 - 17:03 LBA48 - ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)

D. Morgensztern¹, T.J. Ong², M. Cobo Dols³, S. Ponce Aix⁴, P. Postmus⁵, C. Lewanski⁶, J. Bennouna⁷, J. Fischer⁸, O.J. Vidal⁹, D. Stewart¹⁰, G. Fasola¹¹, A. Ardizoni¹², J. Weaver², M. Wolfsteiner¹³, D. Talbot¹⁴, R. Govindan¹⁵; ¹St Louis, US, ²Summit, NJ/US, ³Malaga, ES, ⁴Madrid, ES, ⁵Wirral, Merseyside/GB, ⁶London, GB, ⁷Nantes, CEDEX/FR, ⁸Löwenstein, Baden-Württemberg, DE, ⁹Valencia, ES, ¹⁰Ottawa, ON/CA, ¹¹Udine, IT, ¹²Bologna, IT, ¹³Lenexa, KS/US, ¹⁴Oxford, Oxfordshire/GB, ¹⁵St. Louis, MO/US

17:03 - 17:15 LBA49 - Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC

H. Borghaei¹, C. Langer², S. Gadgeel³, V. Papadimitrakopoulou⁴, A. Patnaik⁵, S. Powell⁶, R. Gentzler⁷, R. Martins⁸, J. Stevenson⁹, S. Jalal¹⁰, A. Panwalkar¹¹, J.C.-H. Yang¹², M. Gubens¹³, L. Sequist¹⁴, M. Awad¹⁵, J. Fiore¹⁶, S. Saraf¹⁶, H. Raftopoulos¹⁶, L. Gandhi¹⁷; ¹Philadelphia, US, ²Philadelphia, PA/US, ³Ann Arbor, US, ⁴Houston, US, ⁵San Antonio, TX/US, ⁶Sioux Falls, SD/US, ⁷Charlottesville, VA/US, ⁸Seattle, US, ⁹Cleveland, OH/US, ¹⁰Indianapolis, IN/US, ¹¹Fargo, ND/US, ¹²Taipei, TW, ¹³San Francisco, CA/US, ¹⁴Boston, MA/US, ¹⁵Boston, US, ¹⁶Kenilworth, NJ/US, ¹⁷New York, NY/US

17:15 - 17:30 Invited Discussant LBA48, LBA49 and 1297O

M. Reck, Grosshansdorf, DE

16:15 - 17:15	Type: Patient Advocacy Track Title: Health services research in cancer Chair(s): K. Apostolidis, GR; G. Mountzios, GR	Palma Auditorium
16:15 - 16:17	Introduction <u>K. Apostolidis</u> , GR	
16:17 - 16:32	Health services research in Europe and its use for informing cancer policy <u>T. Albreht</u> , Ljubljana, SI	
16:32 - 16:47	Cancer patient experience from referral to hospital performance <u>G. Lyratzopoulos</u> , London, GB	
16:47 - 16:57	What cancer patients want <u>K. Benn</u> , Milan, IT	
16:57 - 17:07	The importance of healthcare systems research for improving health in CEE <u>V. Voiculescu</u> , RO	
17:07 - 17:12	Discussion	

17:30 - 19:00 Type: Patient Advocacy Track Palma Auditorium
Title: Debate: Working with industry: Inherent conflicts of interest?
Chair(s): J. Geissler, DE; D. Haerry, CH

17:30 - 17:37 Introduction on the opportunities and controversies of the collaboration
J. Geissler, DE

17:37 - 17:44 A medical society's perspective on disclosure and conflict of interest
P.G. Casali, Milan, IT

17:44 - 17:51 Does industry collaboration with clinicians and patient advocates compromise their objectivity?
N. Moll, Brussels, BE

17:51 - 17:58 The impartial patient voice when advising regulators and industry
D. Haerry, Bern, CH

17:58 - 18:05 A regulatory perspective on disclosure of interests of clinicians, patient experts and their organisations
J. Garcia Burgos, London, GB

18:05 - 18:12 The media perspective on disclosure and conflict of interests
A. Wagstaff, Oxford, OXON/GB

18:12 - 19:00 Moderated panel discussion

18:00 - 20:00 Type: Industry Satellite Symposium Barcelona Auditorium
Title: Industry Satellite Symposium 1

18:00 - 20:00 Type: Industry Satellite Symposium Sevilla Auditorium
Title: Industry Satellite Symposium 2

18:00 - 20:00 Type: Industry Satellite Symposium Pamplona Auditorium
Title: Industry Satellite Symposium 3

18:00 - 20:00 Type: Industry Satellite Symposium Cordoba Auditorium
Title: Industry Satellite Symposium 4

18:00 - 20:00 Type: Industry Satellite Symposium Granada Auditorium
Title: Industry Satellite Symposium 5

18:00 - 20:00 Type: Industry Satellite Symposium Valencia Auditorium
Title: Industry Satellite Symposium 6

18:00 - 20:00 Type: Industry Satellite Symposium Tarragona Auditorium
Title: Industry Satellite Symposium 7

18:00 - 20:00 Type: Industry Satellite Symposium
Title: Industry Satellite Symposium 8
Bilbao Auditorium

18:00 - 20:00 Type: Industry Satellite Symposium
Title: Industry Satellite Symposium 9
Alicante Auditorium

18:00 - 20:00 Type: Industry Satellite Symposium
Title: Industry Satellite Symposium 10
Cartagena Auditorium

18:00 - 20:00 Type: Industry Satellite Symposium
Title: Industry Satellite Symposium 11
Salamanca Auditorium

18:00 - 20:00 Type: Industry Satellite Symposium
Title: Industry Satellite Symposium 12
Jerez Auditorium

09-09-2017

08:00 - 09:00 Type: Controversy session
Title: Is trastuzumab single agent obsolete in early breast cancer
Chair(s): F. Cardoso, PT
Granada Auditorium

08:00 - 08:10 Introduction and 1st vote
F. Cardoso, Lisbon, PT

08:10 - 08:30 Yes
H. Bonnefoi, Bordeaux, CEDEX/FR

08:30 - 08:50 No
G. Bianchini, Milano, IT

08:50 - 09:00 2nd vote and conclusions
F. Cardoso, Lisbon, PT

08:00 - 09:00 Type: Challenge Your Expert (CYE) session
Title: Germline aberrations and prostate cancer
Chair(s): R. Eeles, GB
Bilbao Auditorium

08:00 - 08:10 Germline aberrations and prostate cancer
E. Castro Marcos, Madrid, ES

08:10 - 09:00 Discussion led by Chair
R. Eeles, London, GB

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Alicante Auditorium
Title: Multimodality therapy of early stage mesothelioma
Chair(s): P. Van Schil, BE

08:00 - 08:10 Multimodality therapy of early stage mesothelioma
P. Baas, Amsterdam, NL

08:10 - 09:00 Discussion led by Chair
P. Van Schil, Edegem, BE

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Cartagena Auditorium
Title: Practical management of toxicities of immunotherapy in cancer patients
Chair(s): P. Ascierto, IT

08:00 - 08:10 Practical management of toxicities of immunotherapy in cancer patients
B. Besse, Villejuif, FR

08:10 - 09:00 Discussion
P. Ascierto, Napoli, IT

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Salamanca Auditorium
Title: Progress in pancreatic cancer
Chair(s): A. Berns, NL

08:00 - 08:10 Progress in pancreatic cancer
D. Tuveson, New York, NY/US

08:10 - 09:00 Discussion led by Chair
A. Berns, Amsterdam, NL

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Palma Auditorium
Title: How to use molecular biology in neuro-oncology
Chair(s): M. Weller, CH

08:00 - 08:10 How to use molecular biology in neuro-oncology
M. van den Bent, Rotterdam, NL

08:10 - 09:00 Discussion led by Chair
M. Weller, Zürich, CH

- 08:15 - 09:00 Type: Keynote Lecture Barcelona Auditorium
Title: Clinical implications of tumour evolution
Chair(s): A. Bardelli, IT
- 08:15 - 09:00 Clinical implications of tumour evolution
C. Swanton, London, GB
- 09:00 - 10:45 Type: Proffered Paper and Poster Discussion session Pamplona Auditorium
Title: Translational research
Chair(s): J. Seoane, ES; R. Marais, GB
- 09:00 - 09:12 LBA59_PR - Expanding the use of approved drugs: The CPCT's Drug Rediscovery Protocol (DRUP)
D. van der Velden¹, L. Hoes¹, H. van der Wijngaart¹, H. Bloemendaal², K. Grunberg³, A. Huitema¹, E. Lugtenburg⁴, F. De Vos⁵, C. Herpen³, D.J. de Groot⁶, P. Hamberg⁴, E. Smit¹, E. Cuppen⁵, N. Steeghs¹, S. Sleijfer⁴, H. Verheul¹, H. Gelderblom⁷, E. Voest¹; ¹Amsterdam, NL, ²Amersfoort, NL, ³Nijmegen, NL, ⁴Rotterdam, NL, ⁵Utrecht, NL, ⁶Groningen, NL, ⁷Leiden, NL
- 09:12 - 09:24 1628O - Development of the Manchester Cancer Research Centre Molecular Tumour Board for matching patients to clinical trials based on tumour and ctDNA genetic profiling
A. Gupta, M. Ayub, C. Miller, D. Rothwell, A. Wallace, A. Jordan, N. Cook, F. Thistlethwaite, L. Carter, C. O'Brien, S. Aruketty, E. Dean, A. Hudson, K. Frese, J. Dransfield, A. Hughes, R. Marais, C. Dive, G. Brady, M. Krebs; Manchester, GB
- 09:24 - 09:36 1629O - A systematic rapid autopsy program tracks temporal and spatial heterogeneity of human tumors and identifies mechanisms of resistance to targeted therapies
C. Walmsley¹, D. Juric², A. Bardia³, L. Henderson², J. Gurski², J. Stone², C. Pinto², S. Isakoff², D. Fitzgerald², J. Gainor², L. Goyal², M. Broudo²; ¹Boston, US, ²Boston, Ma, US, ³Boston, MA/US
- 09:36 - 09:51 Invited Discussant LBA59, 1628O and 1629O
J. Seoane, Barcelona, ES
- 09:51 - 09:51 84PD - Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028)
P. Ott¹, Y.-J. Bang², A. Razak³, J. Bennouna⁴, J.-C. Soria⁵, H. Rugo⁶, R. Cohen⁷, B. O'Neil⁸, J. Mehnert⁹, J. Lopez¹⁰, T. Doi¹¹, E. van Brummelen¹², D. Levitan¹³, G. Zhao¹⁴, K. Emancipator¹³, K. Stein¹³, A. Joe¹³, M. Ayers¹³, J. Lunceford¹³, S. Piha-Paul¹⁵; ¹Boston, MA/US, ²Seoul, KR, ³Toronto, CA, ⁴Nantes, CEDEX/FR, ⁵Villejuif, CEDEX/FR, ⁶San Francisco, CA/US, ⁷Philadelphia, PA/US, ⁸Indianapolis, IN/US, ⁹New Brunswick, US, ¹⁰Sutton, Surrey/GB, ¹¹Kashiwa, Chiba/JP, ¹²Amsterdam, NL, ¹³Kenilworth, NJ/US, ¹⁴Beijing, CN, ¹⁵Houston, TX/US
- 09:51 - 09:51 1630PD - Association of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort

K. Kerr¹, E. Thunnissen², U. Dafni³, A. Soltermann⁴, S. Finn⁵, L. Bubendorf⁶, E. Verbeke⁷, W. Biernat⁸, A. Warth⁹, A. Marchetti¹⁰, E.-J. Speel¹¹, S. Pokharel¹², A.M. Quinn¹³, K. Monkhorst², A. Navarro¹⁴, V. Polydoropoulou¹⁵, R. Kammler¹⁶, S. Peters¹⁷, R.A. Stahel¹⁸, O. Lungscape Consortium¹⁶; ¹Aberdeen, GB, ²Amsterdam, NL, ³Athens, Attica/GR, ⁴Zürich, CH, ⁵Dublin, IE, ⁶Basel, CH, ⁷Leuven, BE, ⁸Gdansk, PL, ⁹Heidelberg, DE, ¹⁰Chieti, IT, ¹¹Maastricht, NL, ¹²Buffalo, US, ¹³Wythenshawe, GB, ¹⁴Valencia, ES, ¹⁵Athens, GR, ¹⁶Bern, CH, ¹⁷Lausanne, CH, ¹⁸Zurich, CH

- 09:51 - 09:51 1631PD - Prominent immune suppressive tumor microenvironment in female never-smoker lung cancer patients with EGFR mutations
B. Park, D.-E. Ryu, H.K. Kim, J.H. Cho, J. Lee, J. Lee, H.-O. Lee, J.-G. Joung, W.-Y. Park, J. Kim; Seoul, KR
- 09:51 - 09:51 1632PD - A novel radiomic based imaging tool to monitor tumor lymphocyte infiltration and outcome of patients treated by anti-PD-1/PD-L1
R. Sun¹, E.J. Limkin¹, L. Dercle¹, S. Champiat², S. Reuzé¹, D. Brandao¹, L. Verlingue³, S. Ammari¹, S. Aspeslagh¹, A. Schernberg³, S. Postel-Vinay¹, A. Hollebecque¹, C. Massard¹, A. Marabelle¹, C. Robert¹, J.-C. Soria², E. Deutsch², C. Ferté¹; ¹Villejuif, FR, ²Villejuif, CEDEX/FR, ³Paris, FR
- 09:51 - 10:06 Invited Discussant 84PD, 1630PD, 1631Pd and 1632PD
S. Singh, Hamilton, CA
- 10:06 - 10:16 Questions to discussant
- 10:16 - 10:16 85PD - Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve non-small cell lung cancer (NSCLC) harboring EGFR mutation: Results of the nationwide program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT)
C. Leduc¹, E. Pencreach², J.-P. Merlio³, P.-P. Bringuier⁴, F. de Fraipont⁵, F. Escande⁶, A. Lemoine⁷, O. L'Houcine⁸, H. Blons⁹, M. Denis¹⁰, P. Hofman¹¹, R. Lacave⁹, S. Melaabi¹², A. Langlais⁹, P. missy⁹, F. Morin⁹, F. Barlesi⁸, D. Moro-Sibilot⁵, J. Cadranet⁹, M. Beau-Faller²; ¹Strasbourg, CEDEX/FR, ²Strasbourg, FR, ³Pessac, FR, ⁴Lyon, FR, ⁵La Tronche, FR, ⁶Lille, FR, ⁷Villejuif, FR, ⁸Marseille, FR, ⁹Paris, FR, ¹⁰Nantes, CEDEX 1/FR, ¹¹Nice, FR, ¹²France, FR
- 10:16 - 10:16 86PD - Biomarker prevalence study and phase I trial of afatinib in children with malignant tumours
K. Nysom¹, P. Leblond², D. Frappaz³, I. Aerts⁴, P. Varlet⁵, F. Giangaspero⁶, M. Gambart⁷, D. Hargrave⁸, L. Marshall⁹, P. Kearns¹⁰, G. Makin¹¹, S. Gallego¹², M. Kieran¹³, M. Casanova¹⁴, A. Lahogue¹⁵, S. Wind¹⁶, B. Stolze¹⁶, D. Roy¹⁷, M. Uttenreuther-Fischer¹⁸, B. Geoerger¹⁹; ¹Copenhagen, DK, ²No City Provided, NA, ³Lyon, FR, ⁴Paris Cédex, FR, ⁵Paris, FR, ⁶Roma, IT, ⁷Toulouse, FR, ⁸London, GB, ⁹Sutton, GB, ¹⁰Birmingham, GB, ¹¹Manchester, GB, ¹²Barcelona, ES, ¹³Boston, US, ¹⁴Milano, IT, ¹⁵Woluwe-Saint-lambert, BE, ¹⁶Biberach, DE, ¹⁷Ridgefield, CT/US, ¹⁸Ingelheim Am Rhein, DE, ¹⁹Villejuif, FR
- 10:16 - 10:16 87PD - Prospective study assessing the expression of angiogenesis-related genes as markers of anti-VEGFR2 response in advanced renal cell carcinoma

J. Garcia-Donas¹, N. Lainez², M. Santos-Romero¹, J. Puente¹, D. Castellano¹, J.F. Rodriguez-Moreno¹, E. Esteban³, E. Grande Pulido¹, E.M. Fernandez Parra⁴, L. Rodriguez Lajusticia⁵, M. Domenech⁶, E. Gonzalez Billalabeitia⁷, M.I. Sáez⁸, E. Gallardo Diaz⁹, S. Hernando Polo¹⁰, A. Herrador¹, L. Inglada-Pérez¹, M. Robledo¹, C. Rodriguez-Antona¹; ¹Madrid, ES, ²Pamplona, ES, ³Oviedo, ES, ⁴Sevilla, ES, ⁵Fuenlabrada, ES, ⁶Manresa, ES, ⁷Murcia, ES, ⁸Malaga, ES, ⁹Sabadell, ES, ¹⁰Alcorcon, Madrid/ES

- 10:16 - 10:16 1633PD - Co-amplification of KIT/KDR/PDGRA in over 100,000 advanced cancer cases
U. Disel¹, R. Madison², J. Chung², M. Gounder³, A. Oztan⁴, A. Benson⁴, J. Webster⁴, S. Klemper⁵, S.-H. Ou⁶, S. Ganesan⁷, K. Janeway⁸, P. Stephens², J. Ross⁹, A. Schrock⁴, V. Miller², S. Ali⁴; ¹Adana, TR, ²Cambridge, MA/US, ³New York, US, ⁴Cambridge, US, ⁵Los Angeles, CA/US, ⁶Orange, CA/US, ⁷New Brunswick, US, ⁸Boston, US, ⁹Albany, NY/US
- 10:16 - 10:31 Invited Discussant 85PD, 86PD, 87PD and 1633PD
R. Marais, Manchester, GB
- 09:15 - 10:45 Type: Special Symposium Barcelona Auditorium
Title: Immunotherapy in thoracic malignancies: What can we expect in 2017?
Chair(s): P. Garrido Lopez, ES; J. Vansteenkiste, BE
- 09:15 - 09:20 Introduction
P. Garrido Lopez, Madrid, ES
- 09:20 - 09:40 The role of immunotherapy in non-metastatic NSCLC
J. Vansteenkiste, Leuven, BE
- 09:40 - 10:00 Upfront immune strategies in advanced NSCLC
N. Rizvi, New York, Ny, US
- 10:00 - 10:20 Present and future of immunotherapy in small cell lung cancer
J. Brahmer, Baltimore, Md, US
- 10:20 - 10:40 Is immunotherapy an option in mesothelioma?
J. Aerts, Rotterdam, NL
- 10:40 - 10:45 Conclusions and clinical perspectives
J. Vansteenkiste, Leuven, BE

- 09:15 - 10:45 Type: Proffered Paper session Madrid Auditorium
Title: Genitourinary tumours, non-prostate
Chair(s): B. Escudier, FR; A. Omlin, CH; M. Staehler, DE
- 09:15 - 09:30 845O - Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)
M. Retz¹, J. Bedke², E. Herrmann³, M.-O. Grimm⁴, U. Zimmermann⁵, L. Müller⁶, C. Leiber⁷, D. Teber⁸, M. Wirth⁹, C. Bolenz¹⁰, R. van Alphen¹¹, M. De Santis¹², A. Beeker¹³, M. Frank⁷, J. Gschwend¹; ¹München, DE, ²Tübingen, DE, ³Münster, DE, ⁴Jena, DE, ⁵Greifswald, DE, ⁶Leer, DE, ⁷Freiburg, DE, ⁸Heidelberg, DE, ⁹Dresden, DE, ¹⁰Ulm, DE, ¹¹Tilburg, NL, ¹²Coventry, GB, ¹³Hoofddorp, NL
- 09:30 - 09:45 LBA35 - Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)
A. Bex¹, P. Mulders², M. Jewett³, J. Wagstaff⁴, R. van Velthoven⁵, P. Laguna Pes¹, L. Wood⁶, H. van Melick⁷, P. Soetekouw⁸, J.B. Lattouf⁵, T. Powles⁹, E. Boleti⁹, I.-J. de Jong¹⁰, S. Rottey⁵, B. Tombal⁵, S. Marreaud⁵, L. Collette⁵, S. Collette⁵, C. Blank¹, J. Haanen¹; ¹Amsterdam, NL, ²Nijmegen, NL, ³Toronto, CA, ⁴Swansea, GB, ⁵Brussels, BE, ⁶Halifax, CA, ⁷Nieuwegein, NL, ⁸Maastricht, NL, ⁹London, GB, ¹⁰Groningen, NL
- 09:45 - 10:00 Invited Discussant 845O and LBA35
M. Staehler, Munich, DE
- 10:00 - 10:15 846O - Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies
R. Nadal¹, A. Mortazavi², M. Stein³, S. Pal⁴, N. Davarpanah⁵, H.L. Parnes⁵, Y.M. Ning⁵, L.M. Cordes⁵, J. Lin⁵, M. Bagheri⁵, L. Linderberg⁵, M. Berniger⁵, S.M. Steinberg⁵, T. Moore⁴, T. Lancaster², M. Aviles³, R. Costello⁵, D.P. Bottaro⁵, W.L. Dahut⁵, A. Apolo¹; ¹Bethesda, US, ²Columbus, OH/US, ³New Brunswick, US, ⁴Duarte, CA/US, ⁵Bethesda, MD/US
- 10:15 - 10:30 847O - A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma
C.-H. Lee¹, V. Makker¹, D. Rasco², M. Taylor³, C. Dutcus⁴, R. Shumaker⁵, E. Schmidt⁶, D. Stepan⁷, D. Li⁵, R. Motzer⁸; ¹New York, US, ²San Antonio, TX/US, ³Portland, US, ⁴Woodcliff Lake, New Jersey/US, ⁵Woodcliff Lake, US, ⁶North Wales, PA/US, ⁷Woodcliff Lake, CA/US, ⁸New York, NY/US
- 10:30 - 10:45 Invited Discussant 846O and 847O
L. Albiges, Villejuif, CEDEX/FR

09:15 - 10:45 Type: Educational session Sevilla Auditorium
 Title: Controversial issues in the neoadjuvant approach to early breast cancer
 Chair(s): N. Harbeck, DE; J. Cortes Castan, ES

09:15 - 09:40 Luminal
C. Thomssen, Halle, DE

09:40 - 10:05 Triple Negative Breast Cancer (TNBC)
A. Tutt, London, GB

10:05 - 10:30 HER2
J. Cortes Castan, Madrid, ES

10:30 - 10:45 Discussion

09:15 - 10:45 Type: Special Symposium Cordoba Auditorium
 Title: Predictive biomarkers for response to immunotherapy
 Chair(s): D. Speiser, CH; F. Thistlethwaite, GB

09:15 - 09:20 Introduction
F. Thistlethwaite, Manchester, GB

09:20 - 09:40 New biomarkers for response to immunotherapy
C. Blank, Amsterdam, NL

09:40 - 10:00 Biomarkers from biological basis to clinical relevance
D. Speiser, Lausanne, CH

10:00 - 10:20 Can microbiota be a biomarker for immunotherapy?
L. Zitvogel, Villejuif, FR

10:20 - 10:40 Tumour microenvironment: The role of the innate cell
M. Colombo, Milan, IT

10:40 - 10:45 Conclusions and clinical perspectives
D. Speiser, Lausanne, CH

09:15 - 10:15 Type: Controversy session Granada Auditorium
Title: Prostate cancer liquid biopsies: Ready for prime time?
Chair(s): H. Beltran, US

09:15 - 09:25 Introduction and 1st vote
H. Beltran, New York, NY/US

09:25 - 09:45 Yes
G. Attard, Sutton, Surrey/GB

09:45 - 10:05 No
D. Waugh, Belfast, GB

10:05 - 10:15 2nd vote and conclusions
H. Beltran, New York, NY/US

09:15 - 10:45 Type: Special Session Tarragona Auditorium
Title: Access to novel targeted therapies and clinical trials in Europe
Chair(s): J. Tabernero, ES; T. Cufer, SI

09:15 - 09:20 Introduction
J. Tabernero, Barcelona, ES

09:20 - 09:40 Access to molecular diagnosis: The French model
F. Barlesi, Marseille, FR

09:40 - 10:00 Inequalities in access to treatment
T. Cufer, Golnik, SI

10:00 - 10:20 The patient's view
B. Ryll, SE

10:20 - 10:40 Drug repurposing: New tricks for old drugs
R. Bernards, Amsterdam, NL

10:40 - 10:45 Conclusions
T. Cufer, Golnik, SI

09:15 - 10:45 Type: Poster Discussion session Bilbao Auditorium
Title: Supportive and palliative care
Chair(s): A. Charalambous, CY; P. Gascon, ES; J. Herrstedt, DK

09:15 - 09:15 1542PD - Anticipative approach to improve safety: An innovative daily hospital organisation

F. Scotté¹, R.T. Elaidi¹, H. Haboudagga¹, C. Thibault¹, J. Stevens², B. Bonan³, S. Oudard¹; ¹Paris, FR, ²Boulogne, FR, ³Suresnes, FR

09:15 - 09:15 1387PD - Prevalence and recent time trend in aggressiveness of cancer care near the end of life: an expanded assessment in a cohort study
D. Martins Branco¹, S. Lopes¹, R. Canario², J. Freire¹, G. Sousa³, N. Lunet⁴, B. Gomes⁵; ¹Lisbon, PT, ²Porto, PT, ³Coimbra, PT, ⁴Oporto, PT, ⁵London, GB

09:15 - 09:15 LBA54_PR - Proactive referral to palliative care: Model of a new integrated palliative care and oncology service
J. Wood, A.-M. Stevens, Y. Kano, J. Nevin, S. Popat, T. Wiseman, J. Droney; London, GB

09:15 - 09:35 Invited Discussant 1542PD, 1387PD and LBA54
A. Charalambous, Limassol, CY

09:35 - 09:45 Q&A led by Discussant

09:45 - 09:45 1388PD - Open-label randomized study of individualized pharmacokinetically (PK)-guided dosing versus body surface area (BSA) dosing of paclitaxel (PTX) in advanced Non-Small Cell Lung Cancer (NSCLC) NCT02058433
S. Salamone¹, J. Zhang², H. Qi², H. Ni², Y. Li³, J. Courtney³, C. Zhou²; ¹Bethlehem, US, ²Shanghai, CN, ³Bethlehem, PA/US

09:45 - 09:45 1389PD - Prognostic impact of drug interactions in patients with advanced cancer
M. Joerger¹, A. Hömme², M. Haschke³, S. Krähenbühl³, F. Strasser¹, C. Lehner¹, A. von Kameke¹, T. Wälti⁴, B. Thürlimann¹, M. Früh¹, C. Driessen¹; ¹St. Gallen, CH, ²Ulm, DE, ³Basel, CH, ⁴Bern, CH

09:45 - 09:45 1544PD - Development of an online drug-drug interaction resource to support prescribing of oncolytics
N. Lankheet¹, F. Jansman², S. Gibbons³, D. Burger¹, K. McAllister³, S. Khoo³, N. Van Erp⁴; ¹Nijmegen, NL, ²Deventer, NL, ³Liverpool, GB, ⁴Leiden, NL

09:45 - 09:45 1545PD - The effect of cannabis use on tumor response to nivolumab in patients with advanced malignancies
T. Taha, S. Talhamy, M. Wollner, A. Peer, G. Bar-Sela; Haifa, IL

09:45 - 09:45 1546PD - Impact of sarcopenia on dose limiting toxicities in metastatic colorectal cancer patients (mCRC pts) receiving palliative systemic treatment
S. Kurk¹, P. Peeters¹, R. Stellato¹, B. Dorresteijn¹, M. Jourdan¹, G.-J. Creemers², F. Erdkamp³, F. de Jongh⁴, P. Kint⁵, B. Poppema⁶, S. Radema⁷, L. Simkens⁸, B. Tanis⁹, M. Tjin-A-Ton¹⁰, A. Van der Velden¹¹, C. Punt⁸, M. Koopman¹, A. May¹; ¹Utrecht, NL, ²Eindhoven, NL, ³Sittard, NL, ⁴Rotterdam, Zuid-Holland/NL, ⁵Breda, NL, ⁶Groningen, NL, ⁷Nijmegen, NL, ⁸Amsterdam, NL, ⁹Gouda, NL, ¹⁰Tiel, NL, ¹¹Hilversum, NL

09:45 - 10:05 Invited Discussant 1388PD, 1389PD, 1544PD, 1545Pd and 1546PD

P. Gascon, Barcelona, ES

10:05 - 10:15 Q&A led by Discussant

10:15 - 10:15 1547PD - Phase 3 safety evaluation of an intravenous formulation of NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron

L. Schwartzberg¹, Z. Andric², D. Kowalski³, D. Voisin⁴, G. Rizzi⁴, M. Karthaus⁵; ¹Teheran, TN/IR, ²Belgrade, RS, ³Warsaw, PL, ⁴Pazzallo - Lugano, CH, ⁵Munich, DE

10:15 - 10:15 1548PD - Quality of life (QOL) evaluation of patients in a phase 3 study comparing NEPA with an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV)

L. Zhang¹, S. Lu², J. Feng³, A. Dechaphunkul⁴, S. Chessari⁵, C. Lanzarotti⁵, K. Jordan⁶, M. Aapro⁷; ¹Guangzhou, Guangdong/CN, ²Shanghai, CN, ³Nanjing, CN, ⁴Hat Yai, TH, ⁵Lugano, CH, ⁶Heidelberg, DE, ⁷Genolier, CH

10:15 - 10:15 1549PD - Multicenter randomized controlled trial to evaluate the efficacy of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy

A. Beijers¹, F. Mols², J. Ophorst¹, J. Pijs³, J. de Vos-Geelen³, E. Jacobs⁴, L.V. van de Poll-Franse⁵, G. Vreugdenhil¹; ¹Veldhoven, NL, ²Tilburg, NL, ³Maastricht, NL, ⁴Helmond, NL, ⁵Eindhoven, NL

10:15 - 10:35 Invited Discussant 1547PD, 1548PD and 1549PD

B. Rapoport, Johannesburg, ZA

10:35 - 10:45 Q&A led by Discussant

09:15 - 10:45 Type: Poster Discussion session
Title: Gynaecological cancers

Cartagena Auditorium

Chair(s): I. Ray-Coquard, FR; A. Gonzalez Martin, ES; C. Sessa, CH

09:15 - 09:15 932PD - Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)

R. Penson¹, M.-C. Kaminsky-Forrett², J. Ledermann³, C. Brown⁴, M. Plante⁵, J. Korach⁶, T. Huzarski⁷, A. Gomez de Liano Lista⁸, C. Pisano⁹, M. Friedlander¹⁰, N. Colombo¹¹, M. Gropp-Meier¹², H. Nakai¹³, G. Sonke¹⁴, J.-W. Kim¹⁵, I. Vergote¹⁶, A. Allen¹⁷, E. Pujade-Lauraine¹⁸; ¹Boston, US, ²Vandoeuvre Les Nancy, CEDEX/FR, ³London, GB, ⁴Sydney, AU, ⁵Quebec, CA, ⁶Tel Hashomer, IL, ⁷Szczecin, PL, ⁸Barcelona, ES, ⁹Napoli, IT, ¹⁰Randwick, AU, ¹¹Milan, IT, ¹²Ravensburg, DE, ¹³Osaka, JP, ¹⁴Amsterdam, NL, ¹⁵Seoul, KR, ¹⁶Leuven, BE, ¹⁷Gaithersburg, MD/US, ¹⁸Paris, FR

09:15 - 09:15 933PD - The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial

J. Wang¹, Z.-Y. Zhang¹, M.R. Mirza², L. Gilbert³, M. Fabbro⁴, A. Tinker⁵, X. Wang¹, A. Redondo⁶, J. Berek⁷, L. Woelber⁸, H. Pentikis⁹, K. Moore¹⁰, D. Lorusso¹¹, B. Benigno¹², S. Hazard¹³, P. Follana¹⁴, B. Rimel¹⁵, U. Matulonis¹⁶, S. Agarwal¹, V. Kansra¹; ¹Waltham, MA/US, ²Copenhagen, DK, ³Montreal, QC/CA, ⁴Montpellier, CEDEX 5/FR, ⁵Vancouver, BC/CA, ⁶Madrid, ES, ⁷Palo Alto, CA/US, ⁸Hamburg, DE, ⁹Baltimore, MD/US, ¹⁰Oklahoma City, Oklahoma/US, ¹¹Milan, IT, ¹²Atlanta, GA/US, ¹³Waltham, US, ¹⁴Nice, CEDEX 2/FR, ¹⁵West Hollywood, CA/US, ¹⁶Boston, MA/US

- 09:15 - 09:15 934PD - Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC)
M. Fabbro¹, K. Moore², A. Dørum³, A. Tinker⁴, S. Mahner⁵, I. Bover⁶, S. Banerjee⁷, G. Tognon⁸, F. Goffin⁹, R. Shapira-Frommer¹⁰, R. Wenham¹¹, K. Hellman¹², D. Provencher¹³, P. Harter¹⁴, I. Palacio Vázquez¹⁵, P. Follana¹⁶, M. Pineda¹⁷, M.R. Mirza¹⁸, S. Hazard¹⁹, U. Matulonis²⁰; ¹Montpellier, CEDEX 5/FR, ²Oklahoma City, Oklahoma/US, ³Oslo, NO, ⁴Vancouver, BC/CA, ⁵Munich, DE, ⁶Palma De Mallorca, ES, ⁷London, GB, ⁸Brescia, IT, ⁹Liege, BE, ¹⁰Ramat Gan, IL, ¹¹Tampa, FL/US, ¹²Stockholm, SE, ¹³Montreal, CA, ¹⁴Essen, DE, ¹⁵Oviedo, ES, ¹⁶Nice, CEDEX 2/FR, ¹⁷Chicago, IL/US, ¹⁸Copenhagen, DK, ¹⁹Waltham, US, ²⁰Boston, MA/US
- 09:15 - 09:15 LBA42 - Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer
A. Martinez Bueno¹, M.A. Molina¹, A. Fielding², J. Bertran-Alamillo¹, B. Dougherty³, Z. Lai³, D. Hodgson², C. Mayo de las Casas¹, P. Rowe², M. Gil¹, S. Spencer⁴, S. Viteri¹, J. Lobera⁵, R. Rosell⁶, A. Gasco Hernandez⁵; ¹Barcelona, ES, ²Macclesfield, GB, ³Waltham, MA/US, ⁴Cambridge, GB, ⁵Madrid, ES, ⁶Badalona, Barcelona/ES
- 09:15 - 09:35 Invited Discussant 932PD, 933PD, 934PD and LBA42
I. Ray-Coquard, Lyon, CEDEX/FR
- 09:35 - 09:45 Q&A led by Discussant
- 09:45 - 09:45 935PD - BRCA1&2 tumoral and germline status for ovarian cancer patients in first line setting within the PAOLA-01 trial
C. Callens¹, D. Vaur², I. Soubeyran³, E. Rouleau⁴, P.-A. Just¹, E. Guiller¹, L. Golmard¹, N. Goardon², N. Sevenet⁵, O. Cabaret⁶, P. Harter⁷, A. Gonzalez Martin⁸, K. Fujiwara⁹, S. Pignata¹⁰, N. Colombo¹¹, C. Marth¹², I. Vergote¹³, J. Mäenpää¹⁴, E. Pujade-Lauraine¹, I. Ray-Coquard¹⁵; ¹Paris, FR, ²Caen, FR, ³Bordeaux, FR, ⁴Paris, CEDEX 5/FR, ⁵Bordeaux Cedex, FR, ⁶Villejuif Cedex, FR, ⁷Essen, DE, ⁸Madrid, ES, ⁹Saitama, JP, ¹⁰Napoli, IT, ¹¹Milan, IT, ¹²Innsbruck, AT, ¹³Leuven, BE, ¹⁴Tampere, FI, ¹⁵Lyon, CEDEX/FR
- 09:45 - 09:45 936PD - Actionable molecular alterations in advanced gynecologic malignancies: First results from the ProfILER program (NCT01774409) in France
R. Varnier¹, I. Ray-Coquard², V. Corset¹, C. Baudet¹, D. Pissaloux¹, V. Attignon¹, M. Ezzalfani¹, O. Le Saux¹, P. Heudel², O. Derbel¹, B. You³, O. Tredan², P. Cassier⁴, N. Bonnin³, P. Biron², G. Freyer³, V. Trillet-Lenoir³, T. Bachelot², D. Perol², J.-Y. Blay¹; ¹Lyon, FR, ²Lyon, CEDEX/FR, ³Pierre Bénite, CEDEX/FR, ⁴La Défense, FR

- 09:45 - 09:45 937PD - PD-L1 expression and prognosis significance in advanced ovarian cancer
E. Høgdall¹, C. Høgdall¹, T. Vo², W. Zhou³, M. Busch-Sørensen⁴, S. Soerensen¹, D. Chappell⁴, J. Georgsen⁵, E. Mejlgaard⁵, L. Nedergaard¹, T. Steiniche⁶; ¹Copenhagen, DK, ²Kenilworth, US, ³North Wales, US, ⁴Kenilworth, NJ/US, ⁵Aarhus, DK, ⁶Aarhus C, DK
- 09:45 - 09:45 938PD - Prognostic relevance of immune-related gene expression signatures (irGES) in patients (pts) with ovarian clear cell carcinomas (OCCC)
V. Heong, D. Lim, T.Z. Tan, J. Ye, Y.W. Lim, S.E. Lim, J. Ng, A. Ilancheran, J. Loh, R. Soong, D. Tan, R. Huang; Singapore, SG
- 09:45 - 09:45 939PD - An increased ratio of cytotoxic to suppressive T cells after neoadjuvant chemotherapy (NACT) is prognostic in advanced ovarian cancer
A. Khairallah¹, A. Auguste¹, A. Leary¹, C. Genestie¹, P. Pautier², J. Michels¹, P. Morice¹, E. Bentivegna¹, A. Maulard¹, F. Drusch¹, S. Mesnage¹, S. Gouy¹; ¹Villejuif, FR, ²Villejuif, CEDEX/FR
- 09:45 - 10:05 Invited Discussant 935PD, 936PD, 937PD, 938PD, 939PD and 939PD
A. Gonzalez Martin, Madrid, ES
- 10:05 - 10:15 Q&A led by Discussant
- 10:15 - 10:15 940PD - Long term quality of life among epithelial ovarian cancer patients: The GINECO case/control VIVROVAIRE Study
F. Joly Lobbedez¹, A. Floquet², E. Kalbacher³, N. Heutte⁴, D. Berton-Rigaud⁵, O. Tredan⁶, M. Fabbro⁷, A.M. Savoye⁸, J.E. Kurtz⁹, J. Alexandre¹⁰, P. Follana¹¹, V. Delecroix¹², N. Dohollou², C. Roemer-Becuwe¹³, A. Lesoin¹⁴, A. Lortholary¹⁵, G. De Rauglaudre¹⁶, J.-M. Grellard⁴, D. Ahmed-Lecheheb⁴, C. Lhomme¹⁷; ¹Caen, CEDEX 5/FR, ²Bordeaux, CEDEX/FR, ³Besançon, CEDEX/FR, ⁴Caen, FR, ⁵Saint-Herblain, CEDEX/FR, ⁶Lyon, CEDEX/FR, ⁷Montpellier, CEDEX 5/FR, ⁸Reims, CEDEX/FR, ⁹Strasbourg, FR, ¹⁰Paris, FR, ¹¹Nice, CEDEX 2/FR, ¹²Saint-Nazaire, FR, ¹³Nancy, FR, ¹⁴Lille, FR, ¹⁵Nantes, CEDEX 2/FR, ¹⁶Avignon, FR, ¹⁷Villejuif, CEDEX/FR
- 10:15 - 10:15 LBA43 - Health-related quality of life after hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer: Results of the phase III OVHIPEC study
S. Koole¹, W. van Driel¹, J. Kieffer¹, K. Sikorska¹, J. Schagen van Leeuwen², H. Schreuder³, R. Hermans⁴, I. de Hingh⁴, J. van der Velden¹, H. Arts⁵, L. Massuger⁶, A. Aalbers¹, V. Verwaal⁷, K. Van de Vijver¹, N. Aaronson¹, G. Sonke¹; ¹Amsterdam, NL, ²Nieuwegein, NL, ³Utrecht, NL, ⁴Eindhoven, NL, ⁵Groningen, NL, ⁶Nijmegen, NL, ⁷Aarhus, DK
- 10:15 - 10:15 941PD - An investigator initiated, open label, randomized, controlled, multicentric study, to assess the safety and efficacy of nimotuzumab (BIOMAb-EGFR) concurrent with cisplatin and radiotherapy (RT) in histologically documented squamous cell carcinoma of the cervix
B. Ajaikumar¹, K. Swamy¹, N. Radheshyam¹, S. Patil¹, H.P. Shashidhara¹, M.S.A. Vishweshwara², N. Rao¹, Y. Madhavi³, N. Ravi⁴, R. Bilimagga¹, R. Rao¹, D. Pawar¹; ¹Bangalore, IN, ²Mysore, Karnataka/IN, ³Mysore, IN, ⁴Shimoga, IN

10:15 - 10:15 942PD - Vanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179
A. Oaknin¹, I. Vergote², I. Ray-Coquard³, A. Leary⁴, V. Rodriguez Freixinos¹, N. Concin⁵, P. Toussaint⁶, C. Massard⁷, L. Fariñas-Madrid¹, E. Van Nieuwenhuysen⁵, A. Lahr⁸, I. Franjkovic⁸, S. Rossomanno⁹, P. Gerber⁹, T. Nayak⁹, F. Heil⁸, C. Boetsch⁹, A. Sahbi¹⁰, K. Longauer⁹, O. Krieter⁸; ¹Barcelona, ES, ²Leuven, BE, ³Lyon, CEDEX/FR, ⁴Villejuif, FR, ⁵Leuven, NL, ⁶Lyon, FR, ⁷Villejuif, CEDEX/FR, ⁸Penzberg, DE, ⁹Basel, CH, ¹⁰Welwyn, GB

10:15 - 10:35 Invited Discussant 940PD, LBA43, 941PD and 942PD
C. Sessa, Bellinzona, CH

10:35 - 10:45 Q&A led by Discussant

09:30 - 10:30 Type: Multidisciplinary Session
Title: Midgut neuroendocrine tumour progressing on 1st line somatostatin analog: What treatment approach?
Chair(s): J. Strosberg, US
Valencia Auditorium

09:30 - 09:35 Presentation of case/condition
J. Strosberg, Tampa, US

09:35 - 09:45 Systemic therapies for tumour and syndrome control
J. Strosberg, Tampa, US

09:45 - 09:55 Peptide receptor radionuclide therapy
G. Nicolas, Basel, CH

09:55 - 10:05 Hepatic transarterial embolisation: When should it be recommended and which product should be selected?
T. de Baere, Villejuif, FR

10:05 - 10:30 General Discussion

09:30 - 10:30 Type: Challenge Your Expert (CYE) session Alicante Auditorium
 Title: Adjuvant systemic therapy in STS and GIST for whom?
 Chair(s): R. Jones, GB

09:30 - 09:40 Adjuvant systemic therapy in STS and GIST for whom?
S. Stacchiotti, Milan, IT

09:40 - 10:30 Discussion led by Chair
R. Jones, London, GB

09:30 - 10:30 Type: Young Oncologist Special session Room 1&2
 Title: Clinical cases of solid tumours: Discussion forum for practicing and young oncologists

09:30 - 09:50 Metastatic colorectal cancer clinical case discussion
E. Martinelli, Naples, IT

09:50 - 09:50 Table coordinator
C. Cardone, Naples, IT

09:50 - 10:10 Unknown primary carcinoma clinical case discussion
G. Pentheroudakis, Ioannina, GR

10:10 - 10:10 Table coordinator
M. Karamouzis, Athens, GR

10:10 - 10:30 Breast Cancer, adjuvant setting, clinical case discussion
O. Pagani, Bellinzona, CH

10:30 - 10:30 Table coordinator
R. Vidra, Cluj-Napoca, RO

11:00 - 12:30	Type: Special Symposium Title: Oligometastatic NSCLC Chair(s): S. Senan, NL; S. Popat, GB	Barcelona Auditorium
11:00 - 11:05	Introduction <u>S. Popat</u> , London, GB	
11:05 - 11:25	Definitions and implications of oligometastatic disease <u>W. Eberhardt</u> , Essen, DE	
11:25 - 11:45	Management of oligometastasis in patients with driver oncogenes <u>L. Sequist</u> , Boston, MA/US	
11:45 - 12:05	Pro-cons of choice of ablative modality <u>S. Senan</u> , Amsterdam, NL	
12:05 - 12:25	Controversies and ongoing clinical trials <u>A.-M. Dingemans</u> , Maastricht, NL	
12:25 - 12:30	Conclusions and clinical perspectives <u>S. Senan</u> , Amsterdam, NL	

11:00 - 12:30	Type: Proffered Paper session Title: Breast cancer, metastatic Chair(s): F. André, FR; V. Guarneri, IT	Madrid Auditorium
11:00 - 11:15	2370 - A phase II trial of pan-HER inhibitor Pozitotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial <u>Y.H. Park</u> ¹ , K.-H. Lee ¹ , J. Sohn ¹ , K.S. Lee ² , K.H. Jung ³ , J.H. Kim ⁴ , K.H. Lee ⁵ , J.S. Ahn ¹ , T.-Y. Kim ¹ , G.M. Kim ¹ , I.H. Park ⁶ , S.-B. Kim ¹ , S.H. Kim ⁴ , H.S. Han ⁵ , Y.-H. Im ¹ , J.H. Ahn ¹ , J.-Y. Kim ² , J. Kang ¹ , S.-A. Im ¹ ; ¹ Seoul, KR, ² Goyang, KR, ³ Seoul, KP, ⁴ Seongnam, Gyeonggi-do/KR, ⁵ Cheongju, KR, ⁶ Gyeonggi-Do, KR	
11:15 - 11:30	2170 - A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy <u>C. Criscitiello</u> ¹ , M.A. Bayar ² , G. Curigliano ¹ , F. Symmans ³ , C. Desmedt ⁴ , H. Bonnefoi ⁵ , B. Sinn ³ , G. Pruneri ¹ , C. Vicier ² , J.-Y. Pierga ⁶ , C. Denkert ⁷ , S. Loibl ⁸ , C. Sotiriou ⁴ , S. Michiels ² , F. André ⁹ ; ¹ Milan, IT, ² Villejuif, FR, ³ Houston, TX/US, ⁴ Brussels, BE, ⁵ Bordeaux, CEDEX/FR, ⁶ Paris, FR, ⁷ Berlin, DE, ⁸ Neu-Isenburg, DE, ⁹ Villejuif, CEDEX/FR	
11:30 - 11:45	Invited Discussant 2370 and 2170 <u>V. Guarneri</u> , Padua, IT	
11:45 - 12:00	LBA13 - Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 <u>S. Loi</u> ¹ , S. Adams ² , P. Schmid ³ , J. Cortés ⁴ , D. Cescon ⁵ , E. Winer ⁶ , D. Toppmeyer ⁷ , H. Rugo ⁸ , M. De Laurentiis ⁹ , R. Nanda ¹⁰ , H. Iwata ¹¹ , A. Awada ¹² , A. Tan ¹³ , A. Wang ¹⁴ , G. Aktan ¹⁴ , V. Karantza ¹⁴ , R. Salgado ¹⁵ ; ¹ Melbourne, VIC/AU, ² New York, NY/US, ³ London, GB, ⁴ Barcelona, ES, ⁵ Toronto, CA, ⁶ Boston, MA/US, ⁷ New Brunswick, US, ⁸ San Francisco, CA/US, ⁹ Naples, IT, ¹⁰ Chicago, IL/US, ¹¹ Nagoya, JP, ¹² Brussels, BE, ¹³ Charlotte, NC/US, ¹⁴ Kenilworth, NJ/US, ¹⁵ Melbourne, AU	
12:00 - 12:15	LBA14 - Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial <u>M. Kok</u> ¹ , H. Horlings ¹ , K. van de Vijver ¹ , T. Wiersma ¹ , N. Russell ¹ , L. Voorwerk ¹ , K. Sikorska ¹ , E. van Werkhoven ¹ , I. Mandjes ¹ , I. Kemper ¹ , J. Foekema ¹ , S. Wilgenhof ² , M. Chalabi ¹ , J. Stouthard ¹ , G. Sonke ¹ , D. Cullen ³ , R. Salgado ² , T. Schumacher ¹ , C. Blank ¹ , S. Linn ¹ ; ¹ Amsterdam, NL, ² Brussels, BE, ³ Princeton, US	
12:15 - 12:30	Invited Discussant LBA13 and LBA14 <u>G. Curigliano</u> , Milan, IT	

11:00 - 12:30	Type: Proffered Paper session Title: Gastrointestinal tumours, colorectal 1 Chair(s): P. Pfeiffer, DK; D. Arnold, PT	Sevilla Auditorium
11:00 - 11:12	4740 - Treatment outcome according to tumor RAS mutation status in TRICOLERE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer <u>Y. Komatsu</u> ¹ , A. Takashima ² , T. Denda ³ , M. Gamoh ⁴ , I. Iwanaga ⁵ , H. Shimodaira ⁶ , M. Nakamura ⁷ , T. Yamaguchi ² , H. Takahashi ⁸ , K. Kobayashi ⁹ , M. Tsuda ¹⁰ , Y. Kobayashi ¹¹ , H. Baba ¹² , M. Kotake ¹³ , C. Ishioka ⁶ , A. Sato ¹⁴ , S. Yuki ¹ , S. Morita ¹⁵ , S. Takahashi ⁶ , K. Shimada ² ; ¹ Sapporo, Hokkaido/J, ² Tokyo, JP, ³ Chiba, Chiba/J, ⁴ Osaki, Miyagi/J, ⁵ Kitami, Hokkaido Prefecture/J, ⁶ Sendai, JP, ⁷ Matsumoto, JP, ⁸ Ishinomaki, JP, ⁹ Yokohama, JP, ¹⁰ Akashi, JP, ¹¹ Kushiro, Hokkaido/J, ¹² Kumamoto, JP, ¹³ Takaoka, JP, ¹⁴ Hirosaki, JP, ¹⁵ Kyoto, JP	
11:12 - 11:24	4750 - mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109) <u>M. Geissler</u> ¹ , U. Martens ² , R. Knorrenschield ³ , J. Greeve ⁴ , A. Florschuetz ⁵ , A. Tannapfel ⁶ , S. Wessendorf ¹ , T. Seufferlein ⁷ , S. Kanzler ⁸ , V. Heinemann ⁹ , S. Held ¹⁰ , A. Reinacher-Schick ⁶ ; ¹ Esslingen, DE, ² Heilbronn, DE, ³ Marburg, DE, ⁴ Paderborn, DE, ⁵ Dessau, DE, ⁶ Bochum, DE, ⁷ Ulm, DE, ⁸ Schweinfurt, DE, ⁹ Munich, DE, ¹⁰ Leverkusen, DE	
11:24 - 11:39	Invited Discussant 4740 and 4750 <u>D. Arnold</u> , Lisbon, PT	
11:39 - 11:51	4760 - Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22) <u>M. Karoui</u> ¹ , A. Rullier ² , C. Mariette ³ , E. Maillard ⁴ , A. Bardier ⁵ , F. Poizat ⁶ , A. Luciani ⁷ , A. Sarran ⁶ , J.-L. Legoux ⁸ , C. De Chaisemartin ⁶ , C. Lecaille ² , O. Bouche ⁹ , F. Mauvais ¹⁰ , F. Brunetti ⁷ , M. Prudhomme ¹¹ , J.-F. Seitz ¹² , C. Lepage ¹³ , J. Taieb ⁵ ; ¹ Paris Cedex, FR, ² Bordeaux, FR, ³ Lille, CEDEX/FR, ⁴ Dijon, FR, ⁵ Paris, FR, ⁶ Marseille, FR, ⁷ Créteil, FR, ⁸ Orleans, FR, ⁹ Reims, FR, ¹⁰ Beauvais, FR, ¹¹ Nîmes, FR, ¹² Marseille, CEDEX 5/FR, ¹³ Dijon, Cedex/FR	
11:51 - 12:03	4770 - Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18) <u>J. Bennouna</u> ¹ , S. Huret ² , C. Borg ³ , A. Bertaut ⁴ , O. Bouche ⁵ , G. Deplanque ⁶ , E. Francois ⁷ , T. Conroy ⁸ , F. Ghiringhelli ⁹ , G. des Guetz ¹⁰ , J.-F. Seitz ¹¹ , P. Artru ¹² , T. Stanbury ¹⁰ , S. Charpentier ¹³ , M. Denis ¹⁴ , A. Adenis ¹⁵ ; ¹ Nantes, CEDEX/FR, ² Saint-Herblain, CEDEX/FR, ³ Besançon, FR, ⁴ Dijon, FR, ⁵ Reims, FR, ⁶ Vevey, CH, ⁷ Nice, FR, ⁸ Vandoeuvre Les Nancy, CEDEX/FR, ⁹ Dijon, Cedex/FR, ¹⁰ Paris, FR, ¹¹ Marseille, CEDEX 5/FR, ¹² Lyon, CEDEX 8/FR, ¹³ Nantes, FR, ¹⁴ Nantes, CEDEX 1/FR, ¹⁵ Lille, CEDEX/FR	
12:03 - 12:18	Invited Discussant 4760 and 4770 <u>R. Adams</u> , Cardiff, GB	

11:00 - 12:30 Type: Special Symposium Pamplona Auditorium
Title: Immuno-oncology in upper GI cancer: PD1 and beyond
Chair(s): S.A. Quezada, GB; F. Lordick, DE

11:00 - 11:05 Introduction
F. Lordick, Leipzig, DE

11:05 - 11:25 Relationship between microbiota and immunotherapy
L. Zitvogel, Villejuif, FR

11:25 - 11:45 The role of the environment and stroma
S.R. Hingorani, Seattle, Wa, US

11:45 - 12:05 Biomarkers to predict the effects of immunotherapy
S.A. Quezada, London, GB

12:05 - 12:25 Overview of clinical activity of immunomodulating agents in upper GI cancer
C. Borg, S. Kim; Besançon, FR

12:25 - 12:30 Conclusions and clinical perspectives
S.A. Quezada, London, GB

11:00 - 12:30 Type: Special Symposium Cordoba Auditorium
Title: Mechanisms of intrinsic and acquired resistance to current treatment strategies
Chair(s): D. Peeper, NL; R. Marais, GB

11:00 - 11:05 Introduction
D. Peeper, Amsterdam, NL

11:05 - 11:25 Intrinsic in immuno
G. McArthur, Melbourne, AU

11:25 - 11:45 Intrinsic in targeted
R. Marais, Manchester, GB

11:45 - 12:05 Acquired in immuno
A. Ribas, Los Angeles, CA/US

12:05 - 12:25 Acquired in targeted
D. Peeper, Amsterdam, NL

12:25 - 12:30 Conclusions and clinical perspectives
R. Marais, Manchester, GB

11:00 - 12:30	Type: Proffered Paper session Title: Sarcoma Chair(s): S. Bauer, DE; R. Jones, GB	Granada Auditorium
11:00 - 11:15	1473O - Encouraging activity of novel pan-KIT and PDGFR α inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST) <u>F. Janku</u> ¹ , A. Razak ² , M. Gordon ³ , D. Flynn ⁴ , M. Kaufman ⁴ , J. Pitman ⁵ , B. Smith ⁴ , N. Somaiah ¹ , J. Jennings ⁶ , S. Salah ² , D. Westwood ⁵ , D. Greensmith ⁵ , J. Jacobson ⁵ , O. Rosen ⁷ , S. George ⁸ ; ¹ Houston, TX/US, ² Toronto, CA, ³ Scottsdale, AZ/US, ⁴ Lawrence, US, ⁵ Waltham, US, ⁶ Boston, US, ⁷ New York, MA/US, ⁸ Boston, MA/US	
11:15 - 11:30	LBA55 - Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial <u>P.G. Casali</u> ¹ , A. Le Cesne ² , A. Poveda ³ , D. Kotasek ⁴ , P. Rutkowski ⁵ , P. Hohenberger ⁶ , E. Fumagalli ¹ , I. Judson ⁷ , A. Italiano ⁸ , H. Gelderblom ⁹ , N. Penel ¹⁰ , H.-G. Kopp ¹¹ , D. Goldstein ¹² , J. Martin Broto ¹³ , A. Gronchi ¹ , E. Wardelmann ¹⁴ , S. Marreaud ¹⁵ , J. Zalcberg ¹⁶ , S. Litière ¹⁵ , J.-Y. Blay ¹⁷ ; ¹ Milan, IT, ² Villejuif, FR, ³ Valencia, ES, ⁴ Adelaide, SA/AU, ⁵ Warsaw, PL, ⁶ Mannheim, DE, ⁷ London, GB, ⁸ Bordeaux, FR, ⁹ Leiden, NL, ¹⁰ Lille, CEDEX/FR, ¹¹ Tübingen, DE, ¹² Sydney, NSW/AU, ¹³ Seville, ES, ¹⁴ Münster, DE, ¹⁵ Brussels, BE, ¹⁶ Melbourne, VIC/AU, ¹⁷ Lyon, FR	
11:30 - 11:45	Invited Discussant 1473O and LBA55 <u>S. Bauer</u> , Essen, DE	
11:45 - 12:00	1474O - Improved overall and progression free survival after surgery in expert sites for sarcoma patients: A nationwide study of FSG-GETO/NETSARC <u>J.-Y. Blay</u> ¹ , E. Stoeckle ² , A. Italiano ² , R.A. Rochwerger ³ , F. Duffaud ⁴ , S. Bonvalot ⁵ , C. Honore ⁶ , G. Decanter ⁷ , C. Maynou ⁷ , P. Anract ⁵ , G. Ferron ⁸ , F. Guillemin ⁹ , F. Gouin ¹⁰ , M. Rios ¹¹ , J.E. Kurtz ¹² , P. Meeus ¹³ , J.M. Coindre ¹⁴ , I. Ray-Coquard ¹³ , N. Penel ¹⁵ , A. Le Cesne ⁶ ; ¹ Lyon, FR, ² Bordeaux, FR, ³ Marseille, FR, ⁴ Marseille, CEDEX 5/FR, ⁵ Paris, FR, ⁶ Villejuif, FR, ⁷ Lille, FR, ⁸ Toulouse, CEDEX 3/FR, ⁹ Reims, FR, ¹⁰ Nantes, FR, ¹¹ Vandoeuvre Les Nancy, CEDEX/FR, ¹² Strasbourg, FR, ¹³ Lyon, CEDEX/FR, ¹⁴ Bordeaux, CEDEX/FR, ¹⁵ Lille, CEDEX/FR	
12:00 - 12:15	LBA56 - Long-term efficacy of denosumab in giant cell tumor of bone: Results of an open-label phase 2 study <u>E. Palmerini</u> ¹ , J.-Y. Blay ² , A. Le Cesne ³ , P. Reichardt ⁴ , P. Rutkowski ⁵ , H. Gelderblom ⁶ , R. Grimer ⁷ , A. Feng ⁸ , D. Jandial ⁸ , S. Chawla ⁹ ; ¹ Bologna, IT, ² Lyon, FR, ³ Villejuif, FR, ⁴ Berlin-Buch, DE, ⁵ Warsaw, PL, ⁶ Leiden, NL, ⁷ Birmingham, GB, ⁸ Thousand Oaks, US, ⁹ Santa Monica, CA/US	
12:15 - 12:30	Invited Discussant 1474O and LBA56 <u>W. van der Graaf</u> , Sutton, GB	

11:00 - 12:00 Type: Multidisciplinary Session Valencia Auditorium
 Title: Lymph involvement in GU cancer
 Chair(s): P. Bono, FI

11:00 - 11:05 Presentation of case/condition
P. Bono, Helsinki, FI

11:05 - 11:15 The medical oncology perspective
P. Bono, Helsinki, FI

11:15 - 11:25 The radiation therapy perspective
V. Khoo, London, GB

11:25 - 11:35 The surgery perspective
A. Bex, Amsterdam, NL

11:35 - 12:00 General Discussion

11:00 - 12:30 Type: Special Symposium Tarragona Auditorium
 Title: Immunotherapy and targeted therapies in lymphomas
 Chair(s): M. Provencio Pulla, ES; A. Ferreri, IT

11:00 - 11:05 Introduction
A. Ferreri, Milan, IT

11:05 - 11:30 Immune checkpoint inhibition
T.A. Eyre, Oxford, GB

11:30 - 11:55 Bispecific T-cell engager
A. Viardot, Ulm, DE

11:55 - 12:20 CAR T cell therapy in lymphoma
G. Enblad, Uppsala, SE

12:20 - 12:30 Conclusions and clinical perspectives
M. Provencio Pulla, Majadahonda, Madrid/ES

11:00 - 12:30	Type: Joint Symposium Title: ESMO-IPOS: Working together to prevent professional burnout and improve patient care Chair(s): S. Banerjee, GB; L. Travado, PT	Bilbao Auditorium
11:00 - 11:05	Introduction <u>L. Travado</u> , Lisbon, PT	
11:05 - 11:20	Burnout: The scale of the problem facing oncology professionals <u>S. Banerjee</u> , London, GB	
11:20 - 11:35	Communication skills with cancer patients: Improving patient experience <u>L. Fallowfield</u> , Brighton, GB	
11:35 - 11:50	The value of psychosocial care for cancer patients <u>L. Travado</u> , Lisbon, PT	
11:50 - 12:05	Psychosocial interventions to reduce professional burnout <u>M. Die-Trill</u> , Madrid, ES	
12:05 - 12:30	Panel discussion led by <u>M. Preusser</u> ¹ , <u>J. Geissler</u> ² ; ¹ Vienna, AT, ² DE	

- 11:00 - 12:30 Type: Special Session Alicante Auditorium
Title: Women 4 Oncology
Chair(s): S. Peters, CH; F. Shepherd, CA
- 11:00 - 11:05 Numbers and perspectives: The situation of women medical oncologist
S. Peters, Lausanne, CH
- 11:05 - 11:30 Round-table: Gender disparities in the medical field: the Basic Researches and Surgeon perspective
M. Casiraghi¹, S. Peters², J. Tabernero³, F. Shepherd⁴, C. Dive⁵; ¹Milan, IT, ²Lausanne, CH, ³Barcelona, ES, ⁴Toronto, CA, ⁵Manchester, GB
- 11:30 - 11:55 How to address equal gender opportunities at a political level? What politicians can do
C. Diaz¹, S. Peters², J. Tabernero³, F. Shepherd⁴, C. Dive⁵, P. Cornet⁶; ¹Valencia, ES, ²Lausanne, CH, ³Barcelona, ES, ⁴Toronto, CA, ⁵Manchester, GB, ⁶Lawrenceville, US
- 11:55 - 12:15 Discussion: Step by step: How could ESMO drive changes?
S. Peters¹, F. Ciardiello², J. Tabernero³, F. Shepherd⁴; ¹Lausanne, CH, ²Naples, IT, ³Barcelona, ES, ⁴Toronto, CA
- 12:15 - 12:17 W4O Award Presentation
F. Ciardiello, Naples, IT
- 12:17 - 12:25 W4O Award Recipient lecture
F. Shepherd, Toronto, CA
- 12:25 - 12:30 Q&A and closing remarks
S. Peters¹, F. Shepherd²; ¹Lausanne, CH, ²Toronto, CA

11:00 - 12:00 Type: Multidisciplinary Session Cartagena Auditorium
Title: Diagnosis and management of leptomeningeal metastasis
Chair(s): E. Le Rhun, FR

11:00 - 11:05 Presentation of case/condition
E. Le Rhun, Lille, CEDEX/FR

11:05 - 11:15 Systemic versus intrathecal chemotherapy
E. Le Rhun, Lille, CEDEX/FR

11:15 - 11:25 Is there a role for surgery?
J.-C. Tonn, Munich, DE

11:25 - 11:35 Treatment concepts in radiation oncology
S. Villà, Barcelona, ES

11:35 - 12:00 General Discussion

11:00 - 11:45 Type: Young Oncologist Brunch Salamanca Auditorium
Title: Communicating with cancer patients in the era of personalised medicine
Chair(s): M.A. Ozturk, TR; C. Cardone, IT

11:00 - 11:45 Communicating with cancer patients in the era of personalised medicine
G. Prager, Vienna, AT

12:30 - 14:30	Type: Patient Advocacy Track Title: Managing side effects from immunotherapy Chair(s): G. Spurrier-Bernard, FR; A.-M. Forsea, RO	Palma Auditorium
12:30 - 12:45	Immuno-oncology: Overview of existing therapies and what is coming next? <u>J. Haanen</u> , Amsterdam, NL	
12:45 - 13:00	Predicting response to immune therapies <u>T. Kirchoff</u> , New York, NY/US	
13:00 - 13:15	Managing side effects on Immune therapies <u>P. Ascierto</u> , Napoli, IT	
13:15 - 13:30	The patient advocate's perspective <u>G. Spurrier</u> , Clermont-Ferrand, FR	
13:30 - 14:00	Discussion	
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 13	Sevilla Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 14	Pamplona Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 15	Cordoba Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 16	Granada Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 17	Valencia Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 18	Tarragona Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 19	Bilbao Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 20	Alicante Auditorium
13:15 - 14:15	Type: Poster Display session Title: Poster display session	Hall 8

13:15 - 13:15 GASTROINTESTINAL TUMOURS, COLORECTAL

R. Adams¹, R. Glynn-Jones²; ¹Cardiff, GB, ²Northwood, Middlesex/GB

13:15 - 13:15 487P - International comparison of stage-specific treatment of and survival from colorectal cancer: England, Norway and Sweden, 2010-2012

S. Benitez Majano, C. Di Girolamo, M. Morris, B. Rachet, M. Coleman, S. Walters; London, GB

13:15 - 13:15 488P - Early postoperative PET-CT in patients with pathological stage III colon cancer may change their outcome: Results from a large single institution study

A. Moore¹, I. Ben-Aharon², O. Purim², G. Perl², O. Ulitsky², L. Amit², Y. Kundel², R. Lewin², N. Wasserberg², H. Kashtan², B. Brenner²; ¹Petah Tikva, IL, ²Petach Tikva, IL

13:15 - 13:15 489P - Role of body composition in early stage colorectal cancer (CRC) outcomes

J. Hopkins¹, D. Bigam¹, D. Eurich¹, V. Baracos², M. Sawyer¹; ¹Edmonton, CA, ²Alberta, CA

13:15 - 13:15 490P - North Japan multicenter phase II study of FOLFOX as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003): Analysis of tumor location

A. Ishiguro¹, S. Yuki², Y. Kawamoto², H. Nakatsumi², N. Takahashi¹, T. Shichinohe¹, T. Kusumi¹, I. Iwanaga³, T. Miyagishima⁴, K. Hatanaka⁵, K. Oomori⁶, M. Nakamura¹, N. Senmaru⁷, K. Iwai⁸, M. Koike¹, N. Sakamoto¹, A. Taketomi¹, S. Hirano¹, Y. Ito¹, Y. Komatsu²; ¹Sapporo, JP, ²Sapporo, Hokkaido/JP, ³Kitami, Hokkaido Prefecture/JP, ⁴Kushiro, JP, ⁵Hakodate, Hokkaido/JP, ⁶Ebetsu, JP, ⁷Muroran, JP, ⁸Tomakomai, JP

13:15 - 13:15 491P - Factors predicting adherence to a tailored-dose adjuvant treatment based on geriatric assessment in elderly people with colorectal cancer: A prospective study

M. Antonio¹, J. Saldaña², A. Carmona-Bayonas³, R. Salazar¹, V. Navarro¹, C. Tebé², J. Borrás¹; ¹Barcelona, ES, ²L'hospitalet De Llobregat, Barcelona, ES, ³Murcia, ES

13:15 - 13:15 492P - Benefits of upfront primary tumour resection (UPTR) according to sidedness in mCRC: Retrospective analyses of TTD MACRO-2 and PLANET randomised trials

M. Benavides¹, A. Abad², A. Carrato³, C. Gravalos³, A. Fernández-Montes⁴, E. Falcó⁵, E. González-Flores⁶, T. Garcia Garcia⁷, J. Martin-Valades³, J. Gallego Plazas⁸, M. Valladares-Ayerbes⁹, C. García-Girón¹⁰, R. Dueñas¹¹, A. García-Tapiador¹², C. Pericay¹³, F. Losa¹⁴, A. Viudez¹⁵, P. García-Tejido¹⁶, E. Diaz Rubio³, E. Aranda Aguilar¹⁷; ¹Malaga, ES, ²Badalona, Barcelona/ES, ³Madrid, ES, ⁴Orense, ES, ⁵Palma De Mallorca, ES, ⁶Granada, ES, ⁷Murcia, ES, ⁸Elche, Alicante/ES, ⁹A Coruna, ES, ¹⁰Burgos, ES, ¹¹Jaén, ES, ¹²Ciudad Real, ES, ¹³Sabadell, ES, ¹⁴Hospitalet, ES, ¹⁵Pamplona, ES, ¹⁶Avilés, ES, ¹⁷Cordoba, ES

13:15 - 13:15 493P - Surgical quality and the impact of liver resection on outcome in the new EPOC study

S. Pugh¹, J. Bridgewater², M. Finch-Jones³, M. Rees⁴, D. O'Reilly², M. Peterson⁵, B. Davidson², R. Hutchins², N. Heaton², L. Jiao², S. Mudan², A. Allen¹, J. Mellor¹, G. Griffiths¹, D. Cunningham⁶, T. Maughan⁷, J. Garden⁸, J. Primrose¹; ¹Southampton, GB, ²London, GB, ³Bristol, GB, ⁴Basingstoke, GB, ⁵Sheffield, GB, ⁶Sutton, GB, ⁷Oxford, GB, ⁸Edinburgh, GB

- 13:15 - 13:15 494P - Short-term clinical outcome from a randomized controlled trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colon cancer: Japan Clinical Oncology Group study JCOG1006
Y. Takii¹, K. Komori², M. Shiozawa³, M. Ohue⁴, Y. Nishimura⁵, S. Ikeda⁶, N. Takiguchi⁷, T. Kobatake⁸, H. Ike³, T. Sato⁹, N. Tomita¹⁰, J. Mizusawa¹¹, H. Katayama¹¹, Y. Shimada¹², Y. Kanemitsu¹¹; ¹Niigata-Shi, JP, ²Nagoya, JP, ³Yokohama, JP, ⁴Osaka, JP, ⁵Kitaadachi, JP, ⁶Hiroshima, JP, ⁷Chiba, Chiba/J, ⁸Matsuyama, JP, ⁹Yamagata, JP, ¹⁰Nishinomiya, JP, ¹¹Tokyo, JP, ¹²Kochi, Kochi/J
- 13:15 - 13:15 495P - Prognostic impact of tumor deposits in colorectal cancer with lymph nodes metastasis
F. Liu, J. Zhao, L. Yang, Y. Xu; Shanghai, CN
- 13:15 - 13:15 496P - Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
S. Zunder¹, G. van Pelt¹, H. Gelderblom¹, R. Tollenaar¹, C. Mancao², W. Mesker¹; ¹Leiden, NL, ²Basel, CH
- 13:15 - 13:15 497P - Tumor-stroma interactions and response to targeted agents in preclinical models of colorectal cancer (CRC)
C. Bazzichetto¹, F. Conciatori², I. Falcone², F. Cognetti², L. Ciuffreda², M. Milella¹; ¹Roma, IT, ²Rome, IT
- 13:15 - 13:15 498P - Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio
T. Sandberg, J. Oosting, G. van Pelt, H. Putter, J.T. van Wezel, R. Tollenaar, J. Morreau, W. Mesker; Leiden, NL
- 13:15 - 13:15 499P - The characteristics and prognostic factors in colorectal cancer containing signet ring cell
X.Q. Kong, X.Q. Zhang, J.L. Li, Y.P. Dong, J.X. Wu; Fuzhou, CN
- 13:15 - 13:15 500P - Effect of lateral lymph node dissection for lower rectal cancer: An ad hoc analysis of the ACTS-RC randomized clinical trial
E. Oki¹, M. Shimokawa¹, A. Murata², T. Takahashi³, K. Maeda⁴, T. Kusumoto¹, Y. Munemoto⁵, K. Ando¹, R. Nakanishi¹, M. Sugiyama¹, Y. Nakashima¹, H. Saeki¹, S. Saji⁶, Y. Maehara¹; ¹Fukuoka, JP, ²Aomori, JP, ³Gifu, JP, ⁴Osaka, JP, ⁵Fukui, Fukui/J, ⁶Tokyo, JP
- 13:15 - 13:15 502P - Effects of mesorectal fascia (MRF) status for locally advanced rectal cancer: Results of a multicenter, randomized, controlled, phase II trial (FDRT-002)
J. Zhu, C. Li; Shanghai, CN
- 13:15 - 13:15 503P - Planned organ preservation for selected T2, T3 rectal cancer: French experience using chemo radiotherapy and contact X ray boost
J.-P. Gérard¹, N. Barbet², K. Benezery Sanna¹, R. Coquard³, Y. Chateau¹, J. Gal¹, J. Doyen¹; ¹Nice, FR, ²Macon, FR, ³Lyon Villeurbanne, FR
- 13:15 - 13:15 504P - Comparison between magnetic resonance imaging (MRI) and pathology in the assessment of tumour regression grade (TRG) in rectal cancer (RC)

F. Sclafani¹, G. Brown², D. Cunningham², A. Wotherspoon², L. Sena Teixeira Mendes², J. Evans², C. Peckitt², R. Begum², D. Tait¹, J. Capdevila³, B. Glimelius⁴, S. Roselló⁵, J. Thomas², J. Oates², I. Chau⁶; ¹London, GB, ²Sutton, GB, ³Barcelona, ES, ⁴Uppsala, SE, ⁵Valencia, ES, ⁶Sutton, Surrey/GB

- 13:15 - 13:15 505P - FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial
J.-B. BACHET¹, O. Lucidarme², C.B. Levache³, E. Maillard⁴, J.L. Raoul⁵, T. Lecomte⁶, C. Desauw⁷, F. Brocard⁸, S. Pernot⁹, G. Breysacher¹⁰, J.-P. Lagasse¹¹, F. Di Fiore¹², P.L. Etienne¹³, O. Dupuis¹⁴, A. Aleba¹⁵, C. Lepage¹⁶, J. Taieb¹; ¹Paris, FR, ²Paris, CEDEX 13/FR, ³Périgueux, 24004/FR, ⁴Dijon, FR, ⁵Marseille, FR, ⁶Chambrey-Lès-tours, FR, ⁷Lille, CEDEX/FR, ⁸Nancy, FR, ⁹Boulogne-Billancourt, FR, ¹⁰Colmar, FR, ¹¹Orleans, FR, ¹²Rouen, FR, ¹³St. Brieuc, FR, ¹⁴Le Mans, FR, ¹⁵Niort, CEDEX/FR, ¹⁶Dijon, Cedex/FR
- 13:15 - 13:15 506P - Neoadjuvant treatment with mFOLFOXIRI alone versus chemoradiotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective trials
J. Zhang¹, Y. Cai², H. Hu¹, D. Chen¹, J. Xiao¹, W. Wang¹, P. Lan¹, M. Huang¹, L. Wang¹, X. Wu¹, L. Kang¹, J. Wang¹, Y. Deng¹; ¹Guangzhou, CN, ²Guangzhou, Guangdong/CN
- 13:15 - 13:15 507P - Updated survival results of FACT trial: Multicenter phase II trial of neoadjuvant chemotherapy with mFOLFOX6 for stage II/III rectal cancer with a T3/T4 tumor.
H. Hasegawa¹, K. Okabayashi¹, M. Tsuruta¹, J. Koike¹, K. Funahashi¹, H. Yokomizo¹, K. Yoshimatsu¹, H. Kan¹, T. Yamada¹, H. Ishida², K. Ishibashi², Y. Saida¹, T. Enomoto¹, K. Katsumata¹, K. Koda³, T. Ochiai¹, K. Sakamoto¹, S. Ogawa¹, M. Itabashi¹, S. Kameoka¹; ¹Tokyo, JP, ²Saitama, JP, ³Ichihara, Chiba/Jp
- 13:15 - 13:15 508P - Phase II randomized trial of capecitabine + radiation therapy with/without bevacizumab as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: Final results of 3 and 5-year disease free survival, distant relapse free survival and overall survival
C. Gravalos¹, J. Capdevila², L. Layos³, C. Pericay⁴, M. Martínez-Villacampa², C. López López⁵, F. Losa², M.J. Safont⁶, A. Gómez-España⁷, V. Alonso⁸, P. Escudero⁸, J. Gallego⁹, B. García-Paredes¹, A. Palacios¹⁰, S. Biondo², R. Salazar², E. Aranda Aguilar⁷; ¹Madrid, ES, ²Barcelona, ES, ³Badalona, ES, ⁴Sabadell, ES, ⁵Santander, ES, ⁶Valencia, ES, ⁷Cordoba, ES, ⁸Zaragoza, ES, ⁹Alicante, ES, ¹⁰Córdoba, ES
- 13:15 - 13:15 509P - Immunological features of resected tumor after neoadjuvant chemotherapy (NAC) and chemoradiotherapy (CRT) become the superior prediction markers for recurrence in rectal cancer
K. Imaizumi, T. Suzuki, M. Shimomura, Y. Tsukada, T. Sasaki, Y. Nishizawa, M. Kojima, M. Ito, T. Nakatsura; Kashiwa, JP
- 13:15 - 13:15 510P - The ADC value of post-RT might predict TRG after neoadjuvant radiotherapy for local advanced rectal cancer
W. Junxin, L. Jinluan, D. Kaixin; Fuzhou, CN
- 13:15 - 13:15 511P - Polyethylene glycol embolics loaded with irinotecan for chemoembolization of refractory liver metastases from colorectal cancer

G. Fiorentini¹, D. Sarti¹, R. Carandina², M. Nardella³, L. Mulazzani¹, A. Felicioli¹, D. Barnes Navarro⁴, F. Mugnos Gomez⁵, O. Zoras⁶, C. Aliberti²; ¹Pesaro, IT, ²Padova, IT, ³Matera, IT, ⁴Barcelona, ES, ⁵Valencia, ES, ⁶Crete, GR

- 13:15 - 13:15 512P - Neoadjuvant systemic chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis from colorectal cancer
N. Asher, G. Lahat, R. Geva; Tel Aviv, IL
- 13:15 - 13:15 513P - Efficacy and tolerability of chronomodulated FOLFIRINOX (chronofLO) as 1st or 2nd line treatment in patients (pts) with metastatic colorectal cancer (MCC): Final results from an international trial (EORTC 05011)
C. Garufi¹, F. Levi², A. Karaboué³, A. Torsello⁴, C. Focan⁵, P. Chollet⁶, P. INNOMINATO²; ¹Pescara, IT, ²Coventry, GB, ³Vitry-Sur-seine, FR, ⁴Roma, IT, ⁵Liège, BE, ⁶Clermont-Ferrand, CEDEX 1/FR
- 13:15 - 13:15 514P - A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with mFOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)
A. Avallone¹, G. Nasti¹, G. Rosati², C. Carlomagno¹, C. Romano¹, D. Bilancia², A. De Stefano¹, A. Ottaiano¹, A. Cassata¹, L. Silvestro¹, S. Tafuto¹, F. Bianco¹, P. Delrio¹, F. Izzo¹, E. Di Gennaro¹, S. Lastoria¹, C. Gallo³, F. Perrone¹, A. Budillon¹, M.C. Piccirillo¹; ¹Napoli, IT, ²Potenza, IT, ³Naples, IT
- 13:15 - 13:15 515P - First-in-human Phase I study of bacterial RNA interference therapeutic CEQ508 in patients with familial adenomatous polyposis (FAP)
V. Trieu¹, L. Hwang², K. Ng³, O. D'Cruz³, S. Qazi³, A. Fong³; ¹Costa Mesa, CA/US, ²City Of Industry, CA/US, ³Costa Mesa, US
- 13:15 - 13:15 516P - A Multicentre Phase I/II Study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-task force: EPOC1410)
K. Yamazaki¹, Y. Kuboki², E. Shinozaki², H. Hara³, Y. Komatsu⁴, T. Nishina⁵, K. Yamaguchi², S. Yuki⁴, H. Bando⁶, M. Asayama⁷, T. Tsushima⁸, S. Hamauchi¹, H. Nakatsumi⁴, T. Kajiwara⁵, M. Wakabayashi⁹, S. Nomura², A. Sato⁹, T. Doi⁶, A. Ohtsu⁶, T. Yoshino⁶; ¹Shizuoka, Shizuoka/Jp, ²Tokyo, JP, ³Saitama, JP, ⁴Sapporo, Hokkaido/Jp, ⁵Matsuyama, JP, ⁶Kashiwa, Chiba/Jp, ⁷Ina, JP, ⁸Shizuoka, JP, ⁹Chiba, JP
- 13:15 - 13:15 517P - BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)
S. Huijberts¹, J. Schellens¹, E. Elez², P.-J. Cuyle³, E. Van Cutsem⁴, R. Yaeger⁵, M. Fakhri⁶, C. Montagut², M. Peeters⁷, J. Desai⁸, T. Yoshino⁹, F. Ciardiello¹⁰, H. Wasan¹¹, A. Grothey¹², K. Maharry¹³, A. Gollerkeri¹⁴, S. Kopetz¹⁵; ¹Amsterdam, NL, ²Barcelona, ES, ³Bonheiden, BE, ⁴Leuven, BE, ⁵New York, US, ⁶Duarte, CA/US, ⁷Edegem, BE, ⁸Melbourne, VIC/AU, ⁹Kashiwa, Chiba/Jp, ¹⁰Naples, IT, ¹¹London, GB, ¹²Rochester, MN/US, ¹³Boulder, US, ¹⁴Cambridge, US, ¹⁵Houston, US
- 13:15 - 13:15 518P - Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: A retrospective, registry-based analysis

T. Buchler¹, R. Chloupkova², A. Poprach³, O. Fiala⁴, I. Kiss³, K. Kopeckova⁵, L. Dusek², L. Slavicek⁶, M. Kohoutek⁷, J. Finek⁴, M. Svoboda², L. Petruzelka⁸, B. Melichar⁹; ¹Prague, 4/CZ, ²Brno, CZ, ³Brno, South Moravian/CZ, ⁴Pizen, Plzen/CZ, ⁵Prague, 5/CZ, ⁶Jihlava, Vysocina/CZ, ⁷Zlin, Zlin/CZ, ⁸Prague, 2/CZ, ⁹Olomouc, CZ

- 13:15 - 13:15 519P - Outcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC)
F. Rivera Herrero¹, J.-B. Bachet², D. Modest³, F. de Braud⁴, F. Pietrantonio⁴, R. Koukakis⁵, G. Demonty⁶, J.-Y. Douillard⁷; ¹Santander, ES, ²Paris, CEDEX 13/FR, ³Munich, DE, ⁴Milan, IT, ⁵Uxbridge, GB, ⁶Zug, CH, ⁷Lugano - Viganello, CEDEX/CH
- 13:15 - 13:15 520P - AMALTHEA: A prospective, single-arm study of the Hellenic Cooperative Oncology Group evaluating the efficacy and safety of 1st line FOLFIRI+Aflibercept in patients with metastatic colorectal cancer
G. Pentheroudakis¹, V. Kotoula², G.-A. Koliou², I. Tikas², V. Karavasilis², E. Samantas², G. Aravantinos², E. Daskalaki², I. Souglakos³, G. Koumakis², I. Efstratiou², C. Petraki², C. Poulivos², D. Bafaloukos², D. Pectasides², E. Vrettou², G. Fountzilas²; ¹Ioannina, GR, ²Athens, GR, ³Heraklion, GR
- 13:15 - 13:15 521P - Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)
Y. Mori¹, N. Suzuki², T. Nagasaka¹, H. Tanioka¹, Y. Iwamoto³, Y. Neki⁴, T. Yamatsuji⁵, M. Kobayashi⁶, M. Nakajima², Y. Ojima⁷, S. Ikeda⁷, K. Kawamoto⁸, K. Shinozaki⁷, A. Tsuji⁹, T. Hinoi¹⁰, Y. Yamaguchi⁸, K. Yamashita¹, M. Shimokawa¹¹, M. Okajima⁷, S. Hazama²; ¹Okayama, JP, ²Ube, JP, ³Hiroshima, Hiroshima/Jp, ⁴Kochi, JP, ⁵Okayama, Okayama/Jp, ⁶Nangoku, JP, ⁷Hiroshima, JP, ⁸Kurashiki, JP, ⁹Kagawa, JP, ¹⁰Kure, JP, ¹¹Fukuoka, JP
- 13:15 - 13:15 522P - Sex-related differences in circadian-dependent tolerance of Irinotecan (I) added to chronomodulated (chrono) 5-Fluorouracil (F), Leucovorin (L) and Oxaliplatin (O): Final results from international randomised time-finding study in patients with metastatic colorectal cancer (MCC)
F. Levi¹, C. Garufi², A. Karaboué³, C. Focan⁴, P. Chollet⁵, X.-M. Li⁶, P. INNOMINATO¹; ¹Coventry, GB, ²Pescara, IT, ³Vitry-Sur-seine, FR, ⁴Liège, BE, ⁵Clermont-Ferrand, CEDEX 1/FR, ⁶Villejuif, FR
- 13:15 - 13:15 523P - Mechanism of pelareorep (Pel)-mediated cell death in a Phase I study in combination with irinotecan/fluorouracil/leucovorin/bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC)
S. GOEL¹, A. Ocean², I. Chaudhary³, M. Ghalib³, E. Kaledzi³, U. Shah³, A. GUTIERREZ⁴, M. Coffey⁴, G. Gill⁴, R. Maitra³; ¹Bronx, US, ²New York, NY/US, ³Bronx, NY/US, ⁴Calgary,, CA
- 13:15 - 13:15 524P - Bevacizumab first line and impact on subsequent anti-EGFR activity
T. Price¹, J. Hardingham², C. Karapetis³, E. Smith⁴, R. Padbury⁴, A. Roy³, D. Roder⁴, M. Burge⁵, A. Townsend¹; ¹Woodville, SA/AU, ²Adelaide, AU, ³Bedford Park, SA/AU, ⁴Adelaide, SA/AU, ⁵Brisbane, QLD/AU
- 13:15 - 13:15 525P - Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: A systematic review and metanalysis

L. Belluomini, I. Carandina, F. Bonetti, B. Urbini, F. Daniel, F. Lancia, L.R. Martella, I. Toma, A. Moretti, E. Bannò, C. Nisi, L. Da Ros, A. Frassoldati; Ferrara, IT

- 13:15 - 13:15 526P - Efficacy of panitumumab and cetuximab in elderly patients (aged ≥ 75) with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC): Retrospective analysis of data from nationwide drug-reimbursement-access program
M. Swierkowski, A. Ptak-Chmielewska, A. Sliwczynski, T. Czeleko, Z. Teter, C. Szczylik; Warsaw, PL
- 13:15 - 13:15 527P - Toxicity and efficacy of flat-dosed versus body-surface area (BSA)-dosed capecitabine
F. Man, G. Veerman, E. Oomen-De Hoop, E. Meerten, T. van Gelder, R. Mathijssen; Rotterdam, NL
- 13:15 - 13:15 528P - Efficacy of panitumumab and cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC): Retrospective analysis of data from nationwide drug-reimbursement-access program
M. Swierkowski, A. Ptak-Chmielewska, A. Sliwczynski, T. Czeleko, Z. Teter, C. Szczylik; Warsaw, PL
- 13:15 - 13:15 529P - Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)
E. Samalin¹, H. Senellart², S. Thezenas³, S. Jacquot⁴, S. Ellis⁵, F. Khemissa⁵, M. Ramdani⁶, F. Portales³, E. Assenat³, T. Mazard³, L. Mineur⁷, M. Ychou¹; ¹Montpellier, CEDEX 5/FR, ²Saint-Herblain, CEDEX/FR, ³Montpellier, FR, ⁴Teheran, IR, ⁵Perpignan, FR, ⁶Béziers, CEDEX/FR, ⁷Avignon, FR
- 13:15 - 13:15 530P - Safety analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
H. Taniguchi¹, Y. Kito², H. Satake³, Y. Horie⁴, T. Yamada⁵, T. Esaki⁶, T. Denda⁷, K. Mori⁸, K. Yamazaki⁹; ¹Nagoya, Aichi/JP, ²Kanazawa, JP, ³Kobe, JP, ⁴Kawasaki, JP, ⁵Tsukuba, JP, ⁶Fukuoka, JP, ⁷Chiba, Chiba/JP, ⁸Shizuoka, JP, ⁹Shizuoka, Shizuoka/JP
- 13:15 - 13:15 531P - Prognostic factors and specific populations in the pharmacogenetic randomized phase II trial of FOLFIRI with high-dose (HD) of irinotecan vs standard doses in metastatic colorectal cancer (mCRC) patients (pts) according to UGT1A1 genotype
M. Tobeña¹, D. Paez¹, A. Sebio Garcia¹, J. Fernandez-Plana², M. Martín¹, A. Virgili¹, L. Cirera³, P. Riera¹, I. Sullivan¹, J. Salazar¹; ¹Barcelona, ES, ²Terrassa, ES, ³Terrassa, Barcelona/ES
- 13:15 - 13:15 532P - Analysis of efficacy and prognostic factors in second-line chemotherapy for BRAF V600E mutant metastatic colorectal cancer
S. Mitani¹, H. Taniguchi¹, K. Honda², T. Masuishi¹, Y. Narita¹, S. Kadowaki¹, T. Ura², M. Ando², M. Tajika¹, K. Muro¹; ¹Nagoya, Aichi/JP, ²Nagoya, JP
- 13:15 - 13:15 533P - A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability

D. Tougeron¹, R. Cohen², B. Sueur³, D. Sefrioui⁴, L. Gentilhomme⁴, T. Lecomte⁵, T. Aparicio⁶, G. Des Guetz⁷, P. Artru⁸, C. de la Fouchardiere⁹, V. Moulin¹⁰, V. Hautefeuille¹¹, R. Coriat¹², Y. Touchefeu¹³, C. Lecaille¹⁴, G. Goujon², A. Ferru³, J. Taieb², T. André¹⁵, A. Zaanani²; ¹Poitiers, CEDEX/FR, ²Paris, FR, ³Poitiers, FR, ⁴Rouen, FR, ⁵Chambray-Lès-tours, FR, ⁶Bobigny, CEDEX/FR, ⁷Limoges, FR, ⁸Lyon, CEDEX 8/FR, ⁹Lyon, CEDEX/FR, ¹⁰La Rochelle, FR, ¹¹Amiens, CEDEX/FR, ¹²Paris, CEDEX 14/FR, ¹³Nantes, CEDEX 1/FR, ¹⁴Bordeaux, FR, ¹⁵Paris, CEDEX 12/FR

- 13:15 - 13:15 534P - Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial
K. Köchert¹, G. Beckmann¹, M. Teufel²; ¹Berlin, DE, ²Whippany, NJ/US
- 13:15 - 13:15 535P - Investigation of MSI status in acquired resistance to 5-fluorouracil treatment in colorectal cancer using a SILAC-based quantitative proteomic analysis method
M. Ortega Duran, S. Shnyder, C. Sutton, S.-U. Shaheed; Bradford, GB
- 13:15 - 13:15 536P - Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study)
S. Kim¹, E. Francois², F.-C. Bidard³, E. Samalin⁴, F. El Hajbi⁵, N. Baba-Hamed³, S. Dumont⁶, S. Pernot⁷, D. Peiffert⁸, F. Ghiringhelli⁹, O. Bouche¹⁰, J. Desrame¹¹, M. Zoubir¹², A. Parzy¹³, D. Smith¹⁴, C. de la Fouchardiere¹⁵, B. Buecher¹⁶, V. Vendrely¹⁴, F. Bonnetain¹⁷, C. Borg¹; ¹Besançon, FR, ²Nice, FR, ³Paris, FR, ⁴Montpellier, FR, ⁵Lille, FR, ⁶Paris, CEDEX 12/FR, ⁷Boulogne-Billancourt, FR, ⁸Nancy, FR, ⁹Dijon, Cedex/FR, ¹⁰Reims, FR, ¹¹Lyon, CEDEX 8/FR, ¹²La Défense, FR, ¹³Caen, FR, ¹⁴Bordeaux, FR, ¹⁵Lyon, CEDEX/FR, ¹⁶Paris, CEDEX 5/FR, ¹⁷Besançon, CEDEX/FR
- 13:15 - 13:15 537P - P2 study of ADXS11-001 Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer
C. Eng¹, M. Fakh², M. Amin³, V. Morris¹, H. Hochster⁴, P. Boland⁵, H. Uronis⁶; ¹Houston, TX/US, ²Duarte, CA/US, ³St. Louis, MO/US, ⁴New Haven, CT/US, ⁵Buffalo, NY/US, ⁶Durham, NC/US
- 13:15 - 13:15 538P - Relationship between pretreatment levels of circulating DNA, circulating tumor cells, CEA, CA19.9 and tumor burden on CT scan in patients treated for a metastatic colorectal cancer
M. Hassine, C. Savoye-Collet, D. Sefrioui, L. Beaussire, A. Gillibert, A. Gangloff, N. Sarafan-Vasseur, P. Michel, F. Di Fiore; Rouen, FR
- 13:15 - 13:15 539P - Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISNÚ Program
J. Sastre¹, V. de la Orden¹, A. Martínez², I. Bando¹, I. Santamaría³, B. Bellosillo Paricio⁴, S. Palanca⁵, I. Peligros¹, B. Mediero¹, P. Llovet¹, V. Moreno², J.M. Viéitez³, P. Garcia-Alfonso¹, S. Gil⁶, M.J. Ortiz Morales², M.A. Salud Salvia⁵, G. Quintero⁷, F.A. Gesto⁸, E. Aranda Aguilar², E. Diaz Rubio¹; ¹Madrid, ES, ²Cordoba, ES, ³Oviedo, ES, ⁴Barcelona, ES, ⁵Valencia, ES, ⁶Malaga, ES, ⁷No City Provided, NA, ⁸Santander, ES
- 13:15 - 13:15 540P - Analysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the CAPRI GOIM clinical trial

N. Normanno¹, R. Esposito Abate¹, M. Lambiase¹, L. Forgione¹, C. Cardone², A. Iannaccone¹, A. Sacco¹, A. Rachiglio¹, E. Martinelli², D. Rizzi³, S. Pisconti⁴, G. Carteni¹, R. Bordonaro⁵, T. Troiani¹, F. Giuliani³, S. Leo⁶, S. Romito⁷, A. Rinaldi⁸, E. Maiello⁹, F. Ciardiello²; ¹Napoli, IT, ²Naples, IT, ³Bari, IT, ⁴Statte, IT, ⁵Catania, IT, ⁶Lecce, IT, ⁷Foggia, IT, ⁸Castellaneta, IT, ⁹San Giovanni Rotondo, IT

13:15 - 13:15 541P - Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer

J. Schou¹, B. Sørensen², F. Larsen¹, R. Abrantes², A. Boysen³, J. Johansen¹, B. Vittrup Jensen¹, D. Nielsen¹, K.-L. Spindler³; ¹Herlev, DK, ²Århus, DK, ³Aarhus C, DK

13:15 - 13:15 542P - Circulating tumor (ct) DNA captures inpatient heterogeneity in metastatic colorectal (mCRC) patients (pts) progressing to FOLFIRI+panitumumab

J. Vidal¹, J.M. Viéitez², D. Paez¹, C. Santos¹, E. Falcó³, C. López López⁴, M. Valladares-Ayerbes⁵, L. Robles⁶, P. Garcia-Alfonso⁷, G. Duran Ogaya⁶, D. Azuara¹, A. Dalmases¹, B. Bellosillo Paricio¹, G. CAPELLA¹, R. Salazar¹, E. Aranda Aguilar⁸, C. Montagut¹; ¹Barcelona, ES, ²Oviedo, ES, ³Palma De Mallorca, ES, ⁴Santander, ES, ⁵A Coruna, ES, ⁶Malaga, ES, ⁷Madrid, ES, ⁸Cordoba, ES

13:15 - 13:15 543P - Dynamic changes in levels of gene mutations using circulating tumor DNA (ctDNA) and efficacy of 1st-line modified (m)-FOLFOXIRI plus bevacizumab (bev) for metastatic colorectal cancer (mCRC) harboring RAS mutation (mt) (JACCRO CC-11)

Y. Sunakawa¹, T. Sekikawa¹, J. Usher², H. Satake³, Y. Jaimes², Y. Miyamoto⁴, M. Nakamura⁵, H. Nakayama⁶, K. Kazama¹, A. Takagane⁷, A. Makiyama⁸, K. Kobayashi⁹, Y. Kubota¹⁰, M. Mori¹¹, M. Kotaka³, M. Takeuchi¹⁰, M. Fujii¹⁰, K. Danenberg¹², H.-J. Lenz², W. Ichikawa¹; ¹Yokohama, JP, ²Los Angeles, CA/US, ³Kobe, JP, ⁴Kumamoto, JP, ⁵Matsumoto, JP, ⁶Nagoya, JP, ⁷Hakodate, JP, ⁸Kita-Kyusyu, JP, ⁹Nagasaki, JP, ¹⁰Tokyo, JP, ¹¹Shimotsuke, JP, ¹²New York, CA/US

13:15 - 13:15 544P - The frequency of RAS mutation in circulating tumor DNA predicts worse survival in patients with mCRC

L. Yang, Y. Cai, J. Zhang, H. Hu, Z. Wu, R. Deng, Y. Deng; Guangzhou, CN

13:15 - 13:15 545P - Epidermal growth factor receptor (EGFR) copy number (CN) as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC)

J. Seligmann¹, H. Wood², S. Richman², F. Elliott², M. Taylor², E. Tinkler-Hundal², J. Barrett², M. Seymour¹, P. Quirke²; ¹Leeds, Yorkshire/GB, ²Leeds, GB

13:15 - 13:15 546P - Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial

E. Martinelli¹, C. Cardone¹, T. Troiani², N. Normanno², S. Pisconti³, R. Bordonaro⁴, A. Nappi², F. Giuliani⁵, M. Biglietto², C. Barone⁶, A. Rachiglio², V. Montesarchio², S. Cinieri⁷, D. Rizzi⁵, A. Febbraro⁸, T.P. Latiano⁹, G. Modoni¹⁰, G. Colucci⁵, E. Maiello⁹, F. Ciardiello¹; ¹Naples, IT, ²Napoli, IT, ³Statte, IT, ⁴Catania, IT, ⁵Bari, IT, ⁶Roma, IT, ⁷Brindisi, IT, ⁸Benevento, IT, ⁹San Giovanni Rotondo, IT, ¹⁰Taranto, IT

13:15 - 13:15 547P - ULTRA clinical trial: Prospective comparative clinical outcome analysis of three different RAS/BRAF sensitivity mutational cut-offs. A Phase II study of the Spanish TTD Group

R. Salazar¹, D. Azuara¹, J.M. Viéitez², D. Paez¹, C. Santos¹, E. Falcó³, E. Elez¹, C. López López⁴, M. Valladares-Ayerbes⁵, L. Robles⁶, P. Garcia-Alfonso⁷, C. Buges⁸, G. Duran Ogaya⁶, M.A. Salud Salvia⁹, V. Navarro¹, G. CAPELLA¹, E. Aranda Aguilar¹⁰; ¹Barcelona, ES, ²Oviedo, ES, ³Palma De Mallorca, ES, ⁴Santander, ES, ⁵A Coruna, ES, ⁶Malaga, ES, ⁷Madrid, ES, ⁸Badalona, Barcelona/ES, ⁹Valencia, ES, ¹⁰Cordoba, ES

13:15 - 13:15

548P - Prognostic impact of BRAF and KRAS mutations according to the consensus molecular subtypes of colorectal cancer

J. Smeby¹, A. Sveen¹, C. Bergsland¹, J. Bruun¹, M. Merok², S. Danielsen¹, M. Hektoen¹, M. Eknæs¹, I. Eilertsen¹, M. Grønlie Guren¹, A. Nesbakken¹, R. Lothe¹; ¹Oslo, NO, ²Lørenskog, NO

13:15 - 13:15

549P - Gene expression signatures in BRAF V600E mutant colorectal cancer in relation to WNT signaling cascade

K. YASUI¹, T. Nagasaka¹, A. Nyuya¹, T. Toshima¹, T. Kawai¹, K. Shigeyasu¹, S. Yano¹, Y. Mori¹, J. Haraga¹, K. Nakamura¹, Y. Umeda¹, A. Goel², T. Fujiwara¹; ¹Okayama, JP, ²Texas, TX/US

13:15 - 13:15

550P - Prognostic significance of BRAF mutation-associated gene signature in colorectal cancer

J.E. Hwang¹, W.K. Bae², H.-J. Shim³, S.H. Cho¹, I.J. Chung⁴, K. Kim¹, E.C. Hwang¹; ¹Hwasun, KR, ²Hwasun-Gun, KR, ³Hwasun, Jeollanam-do/KR, ⁴Hwasun, Jeonnam/KR

13:15 - 13:15

551P - Comparative and multimodal analysis of the EGFR, HER2, c-MYC, and MET copy number alteration using in situ hybridization in Korean colorectal cancer patients with integration of array-based copy number data from The Cancer Genome Atlas

Y. Kwak¹, S. Yun¹, S.K. Nam², A.N. Seo³, K.S. Lee², H.-K. Oh², D.W. Kim², S.B. Kang², W.H. Kim¹, H.S. Lee²; ¹Seoul, KR, ²Sungnam, KR, ³Daegu, KR

13:15 - 13:15

552P - Mutational status and metastatic pattern in a cohort of advanced colorectal cancer (aCRC) patients (pts): The ROAD study

E. Ongaro, G. De Maglio, L. Gerrata, M. Bonotto, S.K. Garattini, D. Basile, M. Cattaneo, V. Andreotti, F. Cortiula, A. Parnofiello, V. Fanotto, S. Pizzolitto, G. Cardellino, M. Casagrande, F. Puglisi, G. Aprile, N. Pella, G. Fasola; Udine, IT

13:15 - 13:15

553P - First-line panitumumab (P) plus capecitabine (C) for the treatment of elderly patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Preliminary results of the phase II, PANEL GITuD-2011-01 study

J.C. Méndez Méndez¹, M. Ramos¹, J.C. De la Cámara Gómez², M.L. Pellón², M. Covela³, G.A. Quintero Aldana³, M. Salgado Fernandez⁴, A. Fernández-Montes⁵, M. Reboredo⁶, M. Valladares-Ayerbes⁶, M. Jorge Fernandez⁷, P. González Villarroel⁸, C. Romero Reinoso⁸; ¹A Coruña, ES, ²Ferrol, ES, ³Lugo, ES, ⁴Ourense, ES, ⁵Orense, ES, ⁶A Coruna, ES, ⁷Vigo, Pontevedra/ES, ⁸Vigo, ES

13:15 - 13:15

554P - Prevalence of KRAS/NRAS/BRAF mutations detected by massive parallel sequencing and differential outcomes in mCRC patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy

G. Bruera¹, F. Pepe², U. Malapelle², P. Pisapia², A. Dal Mas¹, G. Calvisi¹, G. Troncone², E. Ricevuto¹; ¹L'aquila, IT, ²Napoli, IT

- 13:15 - 13:15 555P - Analysis of angiogenesis biomarkers for ramucirumab (RAM) efficacy in patients with metastatic colorectal cancer (mCRC) from RAISE, a global, randomized, double-blind, Phase 3 study
J. Taberero¹, R. Hozak², T. Yoshino³, A. Cohn⁴, R. Obermannova⁵, G. Bodoky⁶, R. Garcia-Carbonero⁷, T.-E. Ciuleanu⁸, D. Portnoy⁹, K. Muro¹⁰, H. Ouyang², S. Melemed¹¹, D. Ferry¹², F. Nasroulah¹³, E. Van Cutsem¹⁴; ¹Barcelona, ES, ²Indianapolis, IN/US, ³Kashiwa, Chiba/JP, ⁴Somerset, NJ/US, ⁵Brno, South Moravian/CZ, ⁶Budapest, HU, ⁷Madrid, ES, ⁸Cluj-Napoca, RO, ⁹Memphis, TN/US, ¹⁰Nagoya, Aichi/JP, ¹¹New York, IN/US, ¹²Bridgewater, NJ/US, ¹³Buenos Aires, AR, ¹⁴Leuven, BE
- 13:15 - 13:15 556P - A novel CpG panel is independently associated with colorectal cancer survival
M. Jia¹, Y. Zhang¹, L. Jansen¹, V. Walter¹, D. Edelmann¹, M. Maiertaler¹, K. Tagscherer², W. Roth², M. Bewerunge-Hudler¹, E. Herpel¹, M. Kloor¹, A. Ulrich¹, B. Burwinkel¹, H. Bläker³, J. Chang-Claude¹, H. Brenner¹, M. Hoffmeister¹; ¹Heidelberg, DE, ²Mainz, DE, ³Berlin, DE
- 13:15 - 13:15 557P - Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trial
T. Aparicio¹, J. Bennouna², K. Le Malicot³, V. Boige⁴, J. Taieb⁵, O. Bouche⁶, E. Francois⁷, J.-M. Phelip⁸, C. Borel⁹, R. Faroux¹⁰, L. Dahan¹¹, J.-B. Bachet¹², J. Egretieu¹³, M.-C. Kaminsky-Forrett¹⁴, J.-M. Gornet¹⁵, O. Cojocarasu¹⁶, M. Gasmi¹⁷, V. Guerin-Meyer¹⁸, F. Ghiringhelli¹⁹, C. Lepage¹⁹; ¹Bobigny, CEDEX/FR, ²Nantes, CEDEX/FR, ³Dijon, FR, ⁴Villejuif, FR, ⁵Paris, FR, ⁶Reims, FR, ⁷Nice, FR, ⁸Saint-Etienne, FR, ⁹Strasbourg, CEDEX/FR, ¹⁰La Roche Sur Yon, CEDEX 9/FR, ¹¹Marseille, CEDEX 5/FR, ¹²Paris, CEDEX 13/FR, ¹³Lorient, FR, ¹⁴Vandoeuvre Les Nancy, CEDEX/FR, ¹⁵Paris, CEDEX 10/FR, ¹⁶Le Mans, FR, ¹⁷Marseille, FR, ¹⁸Angers, FR, ¹⁹Dijon, Cedex/FR
- 13:15 - 13:15 558P - High PD-L1 expression and high CD8+ T-cell infiltration identifies a new subpopulation of colorectal cancer with high risk of relapse and poor outcome
M. Fakhri¹, C. Ouyang¹, C. Wang¹, T. Tu¹, M. Cho¹, M. Sy², J. Longmate¹, P. Lee¹; ¹Duarte, CA/US, ²Duarte, US
- 13:15 - 13:15 559P - Clinical impact of molecular positive lymph node status in colorectal cancer
N. Matsuura¹, N. Tomita², M. Inomata³, K. Murata⁴, S. Hayashi⁵, Y. Miyake⁶, S. Igarashi⁷, M. Itabashi⁵, T. Kato⁸, S. Noura⁹, T. Furuhashi¹⁰, H. Ozawa⁷, I. Takemasa¹⁰, M. Yasui¹¹, H. Takeyama⁶, O. Okamura¹², H. Yamamoto¹²; ¹Osaka, JP, ²Nishinomiya, JP, ³Yufu, Oita/JP, ⁴Amagasaki, JP, ⁵Tokyo, JP, ⁶Minoh, JP, ⁷Utsunomiya, JP, ⁸Amagasaki, Hyogo/JP, ⁹Sakai, JP, ¹⁰Sapporo, JP, ¹¹Kaizuka, JP, ¹²Suita, JP
- 13:15 - 13:15 560P - Impact of Immune response-associated gene polymorphisms on tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatin and radiation in the ACCORD-12/PRODIGE-2 phase III trial
B. Valerie¹, C. Mollevi², N. Chaput³, S. Gourgou², D. Azria⁴, J.F. Seitz⁵, L. Bigot¹, B. Juzyna⁶, I. Miran¹, J.-P. Gérard⁷, P. Laurent-Puig⁶; ¹Villejuif, FR, ²Montpellier, FR, ³Villejuif, CEDEX/FR, ⁴Montpellier, CEDEX 5/FR, ⁵Marseille, CEDEX 5/FR, ⁶Paris, FR, ⁷Nice, FR
- 13:15 - 13:15 561P - Improving treatment decisions in colon cancer: The tumor-stroma ratio (TSR) additional to the TNM classification

W. Mesker¹, G. van Pelt¹, A. Huijbers¹, J. van der Laak², E. Dequeker³, J.-F. Fléjou⁴, R. Al Dieri⁵, D. Kerr⁶, J. Van Krieken², R. Tollenaar¹; ¹Leiden, NL, ²Nijmegen, NL, ³Leuven, BE, ⁴Paris, FR, ⁵Brussels, BE, ⁶Oxford, Oxfordshire/GB

13:15 - 13:15 562P - Development and validation of multiplex biomarker assay to stratify colorectal cancer (CRC) patient samples into subtypes

A. Sadanandam¹, K. Eason¹, E. Fontana², G. Nyamundanda³, M. Del Rio⁴, K. Si-Lin⁵, T. Siew⁵, P. Martineau⁴, I. Tan⁵, C. Ragulan¹; ¹London, GB, ²Sutton, Surrey/GB, ³Sutton, GB, ⁴Montpellier, FR, ⁵Singapore, SG

13:15 - 13:15 563P - HER2 overexpression and amplification in patients with colorectal cancer (HOLIC): A large-scale retrospective study in Chinese population

S. NI, J. Peng, D. Huang, H. Sun, L. Wang, C. Tan, J. Cai, W. Sheng; Shanghai, CN

13:15 - 13:15 564P - The inflamed immune phenotype can be induced by systemic treatment in angiogenic colorectal liver metastases in contrast to non-angiogenic liver metastases

S. Stremitzer¹, P. Vermeulen², M. Kockx², L. Dirix³, S. Graver⁴, S. Scherer⁵, D. Yang⁶, W. Zhang⁶, J. Stift¹, F. Wrba¹, T. Gruenberger¹, H.-J. Lenz⁶; ¹Vienna, AT, ²Antwerp, BE, ³Wilrijk, BE, ⁴Wuerzburg, DE, ⁵East Hanover, New Jersey/US, ⁶Los Angeles, CA/US

13:15 - 13:15 565P - Whole-exome sequencing of matched germline and plasma cell-free DNA portrays the somatic mutation landscape of refractory metastatic colorectal cancer and identifies mutated KDR/VEGFR2 as new cause of therapy resistance

R. TOLEDO¹, E. Garralda², T. Pons¹, J. Monsech¹, E. Vega¹, R. Alvarez¹, A. Cubillo¹, C. Blanco-Aparicio¹, O. Dominguez¹, J.L. Martinez¹, M. Hidalgo³; ¹Madrid, ES, ²Barcelona, ES, ³Boston, MA/US

13:15 - 13:15 566P - The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer

S. Yuki¹, T. Kato², H. Taniguchi³, T. Hamaguchi⁴, K. Akagi⁵, T. Denda⁶, T. Mizukami⁷, E. Oki⁸, T. Yamada⁹, M. Shiozawa⁷, T. Kudo¹⁰, T. Tamura¹¹, T. Esaki¹², D. Naruge¹³, T. Kajiwara¹⁴, S. Nomura⁴, S. Fujii¹⁵, K. Shitara¹⁶, A. Ohtsu¹⁶, T. Yoshino¹⁶; ¹Sapporo, Hokkaido/JP, ²Amagasaki, Hyogo/JP, ³Nagoya, Aichi/JP, ⁴Tokyo, JP, ⁵Saitama, JP, ⁶Chiba, Chiba/JP, ⁷Kanagawa, JP, ⁸Fukuoka, Fukuoka/JP, ⁹Tsukuba, JP, ¹⁰Suita, Osaka/JP, ¹¹Osaka, JP, ¹²Fukuoka, JP, ¹³Mitaka, Tokyo, JP, ¹⁴Matsuyama, JP, ¹⁵Kashiwa, JP, ¹⁶Kashiwa, Chiba/JP

13:15 - 13:15 567P - Clinical utility of quasi-monomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01

W. Okamoto¹, H. Bando², T. Fukui³, T. Yamanaka⁴, K. Akagi⁵, T. Yoshino²; ¹Kashiwa, JP, ²Kashiwa, Chiba/JP, ³Kyoto, JP, ⁴Yokohama, JP, ⁵Saitama, JP

13:15 - 13:15 568P - The impact of antithrombotics on immunochemical fecal occult blood testing for colorectal cancer screening

V. Van der Voort¹, L. Wauters², P. Dobbels², K. Hendrickx², V. Casneur³, J. Vandervoort²; ¹Utrecht, NL, ²Aalst, BE, ³Aalst, Oost VI/BE

- 13:15 - 13:15 569P - miR-93 regulates epithelial-to-mesenchymal transition process in metastatic colorectal cancer by targeting EphA4
S. Gao, Taiyuan, CN
- 13:15 - 13:35 571P - Multiplatform assay to classify formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) samples into molecular subtypes with mutational profiles
E. Fontana¹, C. Ragulan², D. Cunningham², S. Hulkki-Wilson², F. Sclafani³, G. Nyamundanda², K. Eason³, R. Begum², I. Chong³, C. Peckitt², M. Bali², J. Oates², D. Watkins¹, S. Rao³, M. Hubank², A. Wotherspoon², N. Valeri², I. Chau¹, N. Starling³, A. Sadanandam²; ¹Sutton, Surrey/GB, ²Sutton, GB, ³London, GB
- 13:35 - 13:35 572P - A robust gene signature for the detection of early relapse in stage I-III colon cancer
W. Dai, Y. Li, S. Mo, G. Cai; Shanghai, CN
- 13:35 - 13:35 573P - microRNA(miR) subtypes correlates with colorectal cancer(CRC) molecular subtypes: Validation of miR-30b interaction with genes up-regulated in the high-stroma subtype
B. Perez-Villamil, M. Paz-Cabezas, T. Calvo-López, J. Ogando-Castro, J. Sastre, S. Mañes, E. Díaz-Rubio; Madrid, ES
- 13:35 - 13:35 575P - Prognostic value of microsatellite instability status in stage II/III rectal cancer patients who received upfront surgery
C.R. Oh¹, J.E. Kim¹, Y.S. Hong², S.Y. Kim¹, T.W. Kim¹; ¹Seoul, KR, ²Seoul, Songpa-gu/KR
- 13:35 - 13:35 570P - Array based profiling of emerging molecules in colorectal cancer
E. Shinozaki, S. Sakata, T. Konishi, H. Osumi, M. Ueno, K. Yamaguchi, K. Takeuchi; Tokyo, JP
- 13:35 - 13:35 574P - Gene expression changes in the immunotherapy targets CTLA4 and LAG3 in right- and left-sided colorectal cancer tissues during preoperative oral uracil and tegafur/leucovorin chemotherapy
S. Sadahiro¹, T. Suzuki¹, A. Tanaka¹, K. Okada¹, G. Saito², H. miyakita², H. Nagase³; ¹Isehara, Kanagawa/JP, ²Isehara, JP, ³Tokushima, JP
- 13:35 - 13:35 576P - Biomarker testing practices in the SECURE (proSpective obsErvational clinical practiCe stUdy in the first-line management of metastatic colorectal cancer [mCRC] with eRbitux in combination with chemothErapy) study
G. Aravantinos¹, A. Shahrabi², M. Oukkal³, B. Larbaoui⁴, P. Ronga⁵, D. Messinger⁶, J. Hamad⁷, W. Benbrahim⁸; ¹Athens, GR, ²Tehran, IR, ³Algiers, DZ, ⁴Oran, DZ, ⁵Maisons-Alfort, FR, ⁶Mannheim, DE, ⁷Dubai, AE, ⁸Batna, DZ
- 13:35 - 13:35 577P - Exosomal ECM1 protein expression in plasma from the tumor-draining vein (mesenteric vein) and time to relapse in colon cancer patients
S. Santasusagna¹, A. Navarro¹, I. Moreno², R. Ibeas², F. Martinez², J.J. Castellano¹, C. Muñoz¹, J. Canals¹, S. Morales¹, R. Hernandez², J. Moreno², M. Monzo¹; ¹Barcelona, ES, ²Badalona, ES
- 13:35 - 13:35 578P - LAG-3 expression in tumor infiltrating immune cells is associated with poor prognosis in patients with microsatellite instability high colon cancer
I. Lee¹, S.J. Lee¹, B.W. Kang¹, Y.S. Chae¹, H.J. Kim¹, S.Y. Park¹, J.S. Park¹, G.S. Choi¹, J.G. Kim²; ¹Daegu, KR, ²Seoul, KR

- 13:35 - 13:35 579P - Primary efficacy results and clinical impact of UGT1A1 genotype on safety from a Phase II study of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: The QUATTRO study
H. Bando¹, T. Kato², T. Yoshino³, K. Muro⁴, K. Yamazaki⁵, T. Yamaguchi⁶, E. Oki⁷, S. Iwamoto⁸, A. Tsuji⁹, G. Nakayama⁴, Y. Emi¹⁰, T. Touyama¹¹, M. Nakamura¹², M. Kotaka¹³, Y. Kagawa¹⁴, H. Taniguchi⁴, H. Sakisaka¹⁵, T. Yamanaka¹⁶, A. Kanazawa¹⁷; ¹Kashiwa, JP, ²Amagasaki, Hyogo/J, ³Kashiwa, Chiba/J, ⁴Nagoya, Aichi/J, ⁵Shizuoka, Shizuoka/J, ⁶Tokyo, JP, ⁷Fukuoka, Fukuoka/J, ⁸Hirakata, Osaka/J, ⁹Kagawa, JP, ¹⁰Fukuoka, JP, ¹¹Okinawa, JP, ¹²Matsumoto, JP, ¹³Kobe, Hyogo/J, ¹⁴Amagasaki, JP, ¹⁵Osaka, JP, ¹⁶Yokohama, JP, ¹⁷Izumo, JP
- 13:35 - 13:35 580P - The expression of interleukin 17 receptor A is associated with poor prognosis in patients with colorectal cancer and its knockdown inhibits tumor growth and modulates tumor-infiltrating immune cells in mice tumor
C.-Y. Yang, C.-H. Lin, J.-K. Jiang; Taipei, TW
- 13:35 - 13:35 588P - Differences in prescribing attitudes and treatment patterns between right-sided and left-sided mCRC in EU5 and the US
F. Bermudez, A. Franceschetti; London, GB
- 13:35 - 13:35 584P - Predictive value of primary tumor location: Results from randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)
T. Tamura¹, D. Sakai², N. Sugimoto¹, S. Tokunaga¹, A. Tsuji³, H. Ishida⁴, S. Otsu⁵, T. Moriwaki⁶, H. Satake⁷, K. Uchino⁸, S. Matsumoto⁹, E. Baba⁸, M. Sato¹⁰, H. Taniguchi¹¹, J. Kishimoto⁸, N. Boku¹², I. Hyodo⁶, K. Muro¹¹; ¹Osaka, JP, ²Suita, Osaka/J, ³Kagawa, JP, ⁴Higashi Ibaraki-Gun, JP, ⁵Oita, JP, ⁶Tsukuba, Ibaraki/J, ⁷Kobe, JP, ⁸Fukuoka, JP, ⁹Kyoto, JP, ¹⁰Ryugasaki, JP, ¹¹Nagoya, Aichi/J, ¹²Kawasaki, Kanagawa/J
- 13:35 - 13:35 582P - Comparison of performances of three technologies for detection of RAS mutations in cfDNA (NGS strategy, BEAMing assay and ddPCR BioRAD assay)
J. Garcia¹, J. Forestier¹, E. Dusserre¹, C. Rodriguez-Lafrasse¹, V. Cheynet¹, A.S. Wosny¹, C. Ferraro Peyret¹, K. Brengel-Pesce¹, M. Guillet¹, M. Chauvenet², S. Couraud², M. Brevet³, T. Walter⁴, L. Payen¹; ¹Lyon, FR, ²Pierre Bénite, CEDEX/FR, ³Bron, CEDEX/FR, ⁴Hamburg, DE
- 13:35 - 13:35 587P - Survival by sidedness of metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor antibodies (EGFR-Ab) in the refractory setting: A population-based study of 1509 patients
E. Segelov¹, C. Earle², A. Venook³, R. Saskin², L. Mofid², S. Singh⁴; ¹Melbourne, NSW/AU, ²Toronto, ON/CA, ³San Francisco, CA/US, ⁴Toronto, Ontario/CA
- 13:35 - 13:35 583P - Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC): Retrospective analyses of the randomized MACRO-2 and PLANET trials from TTD Group

M. Benavides¹, A. Carrato², A. Abad³, C. Guillen-Ponce², P. Garcia-Alfonso², S. Gil¹, M.T. Cano Osuna⁴, M.J. Safont⁵, C. Gravalos², J.L. Manzano-Mozo⁶, A. Sanchez⁷, J. Alcaide-Garcia⁸, R. López⁹, B. Massuti Sureda¹⁰, J. Sastre², E. Martinez de Castro¹¹, P. Escudero¹², M. Méndez-Ureña², E. Diaz Rubio², E. Aranda Aguilar⁴; ¹Malaga, ES, ²Madrid, ES, ³Badalona, Barcelona/ES, ⁴Cordoba, ES, ⁵Valencia, ES, ⁶Badalona, ES, ⁷Majadahonda, ES, ⁸Marbella, Málaga/ES, ⁹Santiago De Compostela, ES, ¹⁰Alicante, ES, ¹¹Santander, ES, ¹²Zaragoza, ES

13:35 - 13:35 586P - The prognostic value of sidedness of the primary tumor after local treatment for oligometastatic colorectal cancer: A Danish population based study

A. Boysen¹, K.-L. Spindler¹, M. Høyer¹, F. Mortensen¹, T. Christensen¹, A. Ording²; ¹Aarhus C, DK, ²Aarhus, DK

13:35 - 13:35 589P - Tumor sidedness and enriched gene groups for efficacy of 1st-line cetuximab (cet) treatment in metastatic colorectal cancer (mCRC)

W. Ichikawa¹, K. Mogushi¹, H.-J. Lenz², W. Zhang², A. Tsuji³, T. Takahashi¹, T. Denda⁴, K. Shimada¹, M. Kochi¹, M. Nakamura⁵, M. Kotaka⁶, Y. Segawa⁷, B. Lafleur⁸, J. Luecke⁸, D. Thompson⁸, M. Moran², S.H. Astrow⁹, J. Hsiang², M. Fujii¹, Y. Sunakawa¹⁰; ¹Tokyo, JP, ²Los Angeles, CA/US, ³Miki, JP, ⁴Chiba, Chiba/JP, ⁵Matsumoto, JP, ⁶Kobe, JP, ⁷Hidaka, JP, ⁸Tucson, AZ/US, ⁹Santa Monica, CA/US, ¹⁰Yokohama, JP

13:35 - 13:35 590P - Correlation between RECIST-criteria, morphologic response by CT and pathologic regression in hepatic metastasis secondary to colorectal cancer: The AVAMET study

R. Vera¹, M. Gómez¹, J.R. Ayuso², J. Figueras³, P. Garcia-Alfonso⁴, V. Martinez⁴, A. Lacasta⁵, A. Ruiz⁴, M.J. Safont⁶, J. Aparicio⁶, J. Campos⁶, J. Cámara⁶, M. Martin⁷, C. Montagut², C. Pericay⁸, J.M. Viéitez⁹, E. Falcó¹⁰, M. Jorge¹¹, M. Marín Vera¹², M. Salgado Fernandez¹³; ¹Pamplona, ES, ²Barcelona, ES, ³Gerona, ES, ⁴Madrid, ES, ⁵San Sabastian, ES, ⁶Valencia, ES, ⁷Sant Pau, ES, ⁸Sabadell, ES, ⁹Oviedo, ES, ¹⁰Palma De Mallorca, ES, ¹¹Vigo, ES, ¹²Murcia, ES, ¹³Ourense, ES

13:35 - 13:35 591P - Tumor staging with magnetic resonance imaging after neoadjuvant chemoradiation for locally advanced rectal cancer and comparison of pathologic staging

C. De la Pinta, M. Martin, F. López, E. Fernández, A. Hervás, S. Sancho; Madrid, ES

13:35 - 13:35 592P - Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): Results from the FOXFIRE prospective randomized studies

A. Gray¹, J. Wolstenholme¹, F. Fusco¹, I. Chau², L. Dunham¹, S. Love¹, A. Roberts³, J. Moschandreas¹, P. Virdee¹, V. Lewington², G. Wilson⁴, P. Tait², N. Khan², D. Berry⁵, A. Wotherspoon², B. Morgan⁶, H. Wasan², G. Van Hazel⁷, P. Gibbs⁸, R. Sharma²; ¹Oxford, GB, ²London, GB, ³Cambridge, GB, ⁴Manchester, GB, ⁵Cardiff, GB, ⁶Leicester, GB, ⁷Perth, WA/AU, ⁸Footscray, VIC/AU

13:35 - 13:35 593P - Quality of life (QoL) analyses in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with first-line FOLFOX-4 ± cetuximab in the phase 3 TAILOR trial

T. Liu¹, J. Li², J. Xu³, L. Wang⁴, Y. Cheng⁵, W. Chen³, J. Chen³, C. Pescott⁶, S. Qin⁷; ¹Shanghai, Changning/CN, ²Beijing Shi, CN, ³Beijing, CN, ⁴Shanghai, CN, ⁵Jilin, CN, ⁶Darmstadt, DE, ⁷Nanjing, CN

- 13:35 - 13:35 594P - Implementation, participation and satisfaction rates of a web-based decision support tool for patients with metastatic colorectal cancer
L. Keikes¹, R. The², K. Karssen², A. Mels³, J. De Vos-geelen⁴, J.W. de Groot⁵, M. Koopman⁶, M. van Oijen¹; ¹Amsterdam, NL, ²Delft, NL, ³Amersfoort, NL, ⁴Maastricht, NL, ⁵Zwolle, NL, ⁶Utrecht, NL
- 13:35 - 13:35 595P - Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI – Interim results of the non-interventional AIO study QoLiTrap
R. von Moos¹, G. Derigs², F. Scholten³, J. Thaler⁴, C. Losem⁵, H. Kroening⁶, C. Windemuth-Kieselbach⁷, R.D. Hofheinz⁸; ¹Chur, CH, ²Frankfurt, DE, ³Frankfurt Am Main, DE, ⁴Wels, AT, ⁵Berlin, DE, ⁶Magdeburg, DE, ⁷Gießen, DE, ⁸Mannheim, DE
- 13:35 - 13:35 596P - Chemotherapy-induced thrombocytopenia (CIT) in metastatic colorectal cancer (mCRC) patients
K. Cetin¹, A. Toler², M. Eisen², G. Soff³; ¹Thousand Oaks, US, ²Thousand Oaks, CA/US, ³New York City, NY/US
- 13:35 - 13:35 597P - Real world use of palliative systemic therapy (tx) in patients (pts) with metastatic early onset colorectal cancer (mEOCRC) within a UK specialist cancer centre
A. Georgiou¹, S. Khakoo¹, A. Minchom¹, K. Kouvelakis¹, R. Kalaitzaki¹, N. Nobar¹, V. Calamai¹, M. Ifijen¹, M. Lethby¹, F. Aroui¹, I. Chau², D. Watkins², S. Rao¹, D. Cunningham³, N. Starling¹; ¹London, GB, ²Sutton, Surrey/GB, ³Sutton, GB
- 13:35 - 13:35 585P - Differences in survival (sv) and clinicopathologic characteristics (cpc) between right and left-sided colorectal cancer (CRC): A CARESS-CCR group study
J. Alcaide-Garcia¹, I. Zarcos-Pedrinaci², A. Rueda Domínguez², F. Rivas-Ruiz², T. Tellez², M.M. Morales Suarez-Varela³, E. Briones⁴, M. Bare⁵, A. Escobar⁶, C. Sarasqueta⁷, N. Fernández de Larrea⁴, J.M. Quintana⁸, E. Pérez-Ruiz², R. Villatoro⁹, D. Perez², M. Redondo²; ¹Marbella, Málaga/ES, ²Marbella, ES, ³Valencia, ES, ⁴Madrid, ES, ⁵Sabadell, ES, ⁶Bilbao, ES, ⁷San Sebastián, ES, ⁸Galdakao, ES, ⁹Málaga, ES
- 13:35 - 13:35 599P - Real life registry data of primary localisation of a well-defined colon cancer population of western Austria (Salzburg, Tyrol and Vorarlberg), eastern Switzerland (St. Gallen and Graubünden) and Liechtenstein
B. Hartmann¹, W. Oberaigner², H. Frick³, L. Weiss⁴, T. Winder¹, K. Philipp-Abbrederis², C. Herrmann³, M. Huynh⁵, G. Spizzo², C. Lang⁵, A. Seeber², J. Schneider¹, E. Wöll⁶, P. Mosler⁷, R. Greil⁴, M. Rössle⁷, H. Rumpold⁸, G. Gastl², R. von Moos⁷, A. Lang¹; ¹Feldkirch, AT, ²Innsbruck, AT, ³St. Gallen, CH, ⁴Salzburg, AT, ⁵Bregenz, AT, ⁶Zams, AT, ⁷Chur, CH, ⁸Linz, AT
- 13:35 - 13:35 598P - PD-L1 expression in resected colorectal adenocarcinomas is associated with micrometastasis
K.U. Park, I. Hwang, H.-M. Ryoo, M.H. Heo; Daegu, KR
- 13:35 - 13:35 600P - Improving visualization and adherence by converting the Dutch colorectal cancer guidelines into decision trees: The Oncoguide project
M. van Oijen¹, X. Verbeek², T. van Vegchel², I. Nagtegaal³, M. Lahaye¹, A. Méndez Romero⁴, H. Rütten³, S. de Bruijn⁵, H. Verheul¹, P. Tanis¹, C. Punt¹, L. Keikes¹; ¹Amsterdam, NL, ²Utrecht, NL, ³Nijmegen, NL, ⁴Rotterdam, NL, ⁵Delft, NL

- 13:35 - 13:35 601P - Colon and rectal cancer incidence are rising among young Europeans: Results from the cancer registry of Crete
D. Sifaki-Pistolla¹, E. Saloustros², G. Pitsoulis¹, L. Vamvakas², D. Mavroudis¹, V. Georgoulas¹, C. Lionis¹; ¹Heraklion, GR, ²Heraklion, Crete/GR
- 13:35 - 13:35 602P - Epidemiology of colorectal cancer in Korea: Korean National Health insurance bigdata analysis
S.K. Baek, J.S. Lee, H.J. Ha, S.-C. Lee, S.-B. Bae, I.G. Hwang, J.G. Kim, T.W. Kim; Seoul, KR
- 13:35 - 13:35 603P - Watch and wait versus surgery with pathological complete response: Single institution experience
J. Souza, R. Guimarães, M. Siqueira, R. Gil, R. Araujo, M. Valadão; Rio De Janeiro, BR
- 13:35 - 13:35 604P - A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer [HGCSG1503]: Updated analysis
S. Yuki¹, Y. Komatsu¹, M. Yagisawa², Y. Tsuji¹, K. Harada³, K. Hatanaka⁴, H. Okuda¹, A. Hosokawa⁵, K. Ogawa⁶, K. Furukawa⁷, S. Minami⁸, A. Ishiguro², T. Honda⁹, T. Ohta², M. Dazai¹, K. Eto⁸, T. Sasaki¹, J. Nakajima¹⁰, N. Sakamoto², Y. Sakata¹¹; ¹Sapporo, Hokkaido/Jp, ²Sapporo, JP, ³Kushiro, JP, ⁴Hakodate, Hokkaido/Jp, ⁵Toyama, JP, ⁶Takaoka, JP, ⁷Niigata, JP, ⁸Tomakomai, JP, ⁹Nagasaki, JP, ¹⁰Obihiro, JP, ¹¹Misawa, Aomori/Jp
- 13:35 - 13:35 605P - Preliminary results on germline and somatic molecular investigations in Romanian Lynch syndrome patients
L. Negura, A. Chicos, R. Avadanei, A.M. NEGURA; Iasi, RO
- 13:35 - 13:35 606P - Clinical manifestations and prognostic factors of bone metastasis in colorectal cancer
Y.J. Chun, S.W. Lee, J.H. Kim, E.-A. Choe, H.S. Park, S.H. Beom, S.J. Shin, J.B. Ahn; Seoul, KR
- 13:35 - 13:35 607P - Outcomes of adjuvant chemotherapy for stage II and III colorectal cancer in Korea, 2011-2014: A nationwide study based on the database of quality assessment and the health insurance
I.G. Hwang¹, J.S. Lee¹, S.-C. Lee², S.K. Baek¹, J.G. Kim³, T.W. Kim¹; ¹Seoul, KR, ²Cheonan, KR, ³Daegu, KR
- 13:35 - 13:35 608P - Variations in clinicopathological features, treatment patterns, and outcomes of young adults with colorectal cancer in the United States and Egypt
A. Heeke¹, N. Rashad², H. Khaled², N. Ali Eldin², G. Motaal², H. Wang¹, B. Weinberg¹, M. Salem³; ¹Washington Dc, US, ²Cairo, EG, ³Washington Dc, DC/US
- 13:35 - 13:35 609TiP - PRODIGE 50 - ASPIK French: French double blind randomised study of aspirin versus placebo in resected stage III or high risk stage II colon cancer with PIK3CA mutation
P. Michel¹, T. André², V. Boige³, T. Aparicio⁴, E. Maillard⁵, J. bez⁵, J. Blot¹, J.-B. Bachet⁶, L. Dahan⁷, R. Guimbaud⁸, S. Manfredi⁹, D. Tougeron¹⁰, J. Taieb¹¹, J. Selves¹², C. Lepage¹³, F. Di Fiore¹; ¹Rouen, FR, ²Paris, CEDEX 12/FR, ³Villejuif, FR, ⁴Bobigny, CEDEX/FR, ⁵Dijon, FR, ⁶Paris, CEDEX 13/FR, ⁷Marseille, CEDEX 5/FR, ⁸Toulouse, CEDEX 3/FR, ⁹Rennes, CEDEX/FR, ¹⁰Poitiers, CEDEX/FR, ¹¹Paris, FR, ¹²Toulouse, FR, ¹³Dijon, Cedex/FR

- 13:35 - 13:35 610TiP - A randomized Phase 2 study comparing different dosing approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients
G. Argilés Martínez¹, E. Sanz-García¹, M. Valladares-Ayerbes², J.M. Viéitez³, P. Garcia-Alfonso⁴, C. Gravalos⁴, M. Tobeña¹, G. Duran Ogaya⁵, M.T. Cano Osuna⁶, B. García-Paredes⁴, C. Santos¹, M. Rodríguez-Garrote⁴, F. Rivera Herrero⁷, M.J. Safont⁸, A. Falcone⁹, F. Ciardiello¹⁰, R. Goldberg¹¹, J. Bennouna¹², J. Tabernero¹, E. Aranda Aguilar⁶; ¹Barcelona, ES, ²A Coruna, ES, ³Oviedo, ES, ⁴Madrid, ES, ⁵Malaga, ES, ⁶Cordoba, ES, ⁷Santander, ES, ⁸Valencia, ES, ⁹Pisa, IT, ¹⁰Naples, IT, ¹¹Columbus, OH/US, ¹²Nantes, CEDEX/FR
- 13:35 - 13:35 611TiP - Nivolumab, ipilimumab and COX2-inhibition in early stage colon cancer
M. Chalabi¹, M. Van Leerdam¹, A. Aalbers¹, J. Van den Berg¹, G. Beets¹, C. Grootsholten¹, P. Snaebjornsson¹, M. Kuiper¹, P. Den Hartog¹, F. Weeber¹, K. Dijkstra¹, M. Kok¹, D. Cullen², T. Schumacher¹, J. Haanen¹, E. Voest¹; ¹Amsterdam, NL, ²Princeton, US
- 13:35 - 13:35 612TiP - TRIUMPH Study: A multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer (EPOC1602)
Y. Nakamura¹, W. Okamoto², K. Sawada², Y. Komatsu³, K. Kato⁴, H. Taniguchi⁵, T. Kato⁶, T. Nishina⁷, T. Esaki⁸, H. Nomura¹, M. Fukutani⁹, M. Fukui², H. Hasegawa², M. Yonemura², N. Fuse², A. Sato⁹, S. Fujii², A. Ohtsu¹, T. Yoshino¹; ¹Kashiwa, Chiba/JP, ²Kashiwa, JP, ³Sapporo, Hokkaido/JP, ⁴Tokyo, JP, ⁵Nagoya, Aichi/JP, ⁶Amagasaki, Hyogo/JP, ⁷Matsuyama, JP, ⁸Fukuoka, JP, ⁹Chiba, JP
- 13:35 - 13:35 613TiP - Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapy
T. Kudo¹, T. Kato², Y. Kagawa³, K. Murata³, H. Ohta⁴, S. Noura⁵, J. Hasegawa⁶, H. Tamagawa⁷, K. Ohta⁸, M. Ikenaga⁸, S. Miyazaki⁷, T. Komori⁷, J. Nishimura⁹, T. Hata⁹, C. Matsuda⁹, T. Satoh¹, T. Mizushima¹, H. Yamamoto⁹, Y. Doki⁹, M. Mori⁹; ¹Suita, Osaka/JP, ²Amagasaki, Hyogo/JP, ³Amagasaki, JP, ⁴Ikeda, JP, ⁵Sakai, JP, ⁶Saki, JP, ⁷Osaka, JP, ⁸Higashiosaka, JP, ⁹Suita, JP
- 13:35 - 13:35 614TiP - Phase II study of Ccr-based dose-control of S-1 in the first-line chemotherapy of S-1/oxaliplatin (SOX) + bevacizumab regimen for advanced colorectal cancer
D. MANAKA, R. Nishitai, S. Konishi, T. Ohta, T. Hattori, H. Ann, K. Kawaguchi, Y. Nishikawa, R. Kudo, S. Hamasu; Kyoto, JP
- 13:35 - 13:35 GASTROINTESTINAL TUMOURS, NON-COLORECTAL
E. Van Cutsem¹, T. Seufferlein²; ¹Leuven, BE, ²Ulm, DE
- 13:35 - 13:35 628P - Treatment outcome of gastric cancer associated with esophageal cancer
N. Mori, T. Tanaka, S. Matono, Y. Akagi; Kurume, JP
- 13:35 - 13:35 629P - Sarcopenia, myosteatosis, and weight loss as determinants of survival and toxicity in patients with resectable esophageal and gastroesophageal junction (GEJ) cancer receiving preoperative chemoradiotherapy (CRT)
A.G. Lui¹, A. Gallivan², M. Iafoffa³, Z. Abdelaziz², D. Yusuf², S. Ghosh², J. Spratlin², K. Mulder², M. Sawyer⁴; ¹Davao City, PH, ²Edmonton, AB/CA, ³Hamilton, CA, ⁴Edmonton, CA

- 13:35 - 13:35 630P - Optimal extent of abdominal lymph node dissection for advanced Siewert type II and III esophagogastric junction carcinoma
J.-X. Lin, H. Chang-Ming, C. Zheng, P. Li, J. Xie; Fuzhou, CN
- 13:35 - 13:35 631P - Prognostic stratification of pathologic stage in patients with preoperative chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma
J. Kang, S.R. Park, Y.-H. Kim, H.R. Kim, J.H. Kim, H.-Y. Jung, G.-H. Lee, H.J. Song, D.H. Kim, K.D. Choi, J.-S. Ryu, K.-J. Cho, S.-B. Kim; Seoul, KR
- 13:35 - 13:35 632P - Thromboembolic complications in patients with oesophagogastric adenocarcinoma undergoing preoperative chemotherapy
T. Germetaki¹, K. Kamposioras², G. Papaxoinis¹, J. Weaver¹, S. Galloway¹, S. Stamatopoulou¹, M. Nasralla¹, Z. Kordatou¹, A. Anthoney³, W. Mansoor¹; ¹Manchester, GB, ²Wakefield, West Yorkshire/GB, ³Leeds, GB
- 13:35 - 13:35 633P - Endoscopic resection for Barrett's esophagus: Uzbekistan experience
S. Rasul, Tashkent, UZ
- 13:35 - 13:35 634P - Risk of second malignancies after definitive therapy for esophageal cancer: A competing risk analysis
S. Mitani¹, I. Oze², S. Kadowaki¹, T. Masuishi¹, Y. Narita¹, H. Taniguchi¹, T. Ura², M. Ando², M. Tajika¹, C. Makita², T. Kodaira², N. Uemura², T. Abe², K. Muro¹; ¹Nagoya, Aichi/Jp, ²Nagoya, JP
- 13:35 - 13:35 635P - Prognostic significance of local immunity factors in esophageal cancer
E. Kolesnikov, O. Kit, E. Zlatnik, A. Bazaev, A. Maksimov, I. Novikova, O. Selyutina, E. Bondarenko, V. Trifanov, L. Kharin, P. Gabrichidze, M. Kozhushko, S. Mezentsev, L. Vladimirova; Rostov-On-don, RU
- 13:35 - 13:35 636P - Recent advance in enhanced recovery after esophagectomy: A systematic review and meta-analysis
Y. Wang, Shijiazhuang, CN
- 13:35 - 13:35 637P - High thromboembolic event rate in patients with locally advanced esophageal cancer during perioperative therapy: A pre-planned analysis of the intergroup phase III trial SAKK 75/08
M. Fehr¹, H. Hawle², S. Hayoz³, P. Thuss-Patience⁴, S. Schacher⁵, J. Riera Knorrenschild⁶, D. Dürr⁷, W. Knoefel⁸, H. Rumpold⁹, M. Bitzer¹⁰, M. Zweifel³, P. Samaras⁷, U. Mey¹¹, R. Winterhalden¹², M. Kueng¹³, W. Eisterer¹⁴, V. Hess², M.-A. Gerard³, M. Stahl¹⁵, T. Ruhstaller¹; ¹St. Gallen, CH, ²Basel, CH, ³Bern, CH, ⁴Berlin, DE, ⁵Winterthur, CH, ⁶Marburg, DE, ⁷Zürich, CH, ⁸Duesseldorf, DE, ⁹Linz, AT, ¹⁰Tübingen, DE, ¹¹Chur, CH, ¹²Luzern, CH, ¹³Fribourg, CH, ¹⁴Klagenfurt, AT, ¹⁵Essen, DE
- 13:35 - 13:35 638P - Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07)
Y. Kitagawa¹, Y. Doki², K. Kato¹, T. Ura³, T. Kojima⁴, T. Tsushima⁵, S. Hironaka⁶, H. Hara⁷, T. Kudo⁸, S. Iwasa¹, K. Muro⁹, Y. Hamamoto¹, H. Yasui⁵, K. Minashi¹⁰, K. Yamaguchi¹, A. Ohtsu¹¹; ¹Tokyo, JP, ²Suita, JP, ³Nagoya, JP, ⁴Kashiwa, JP, ⁵Shizuoka, JP, ⁶Chiba, Chiba/Jp, ⁷Saitama, JP, ⁸Suita, Osaka/Jp, ⁹Nagoya, Aichi/Jp, ¹⁰Chiba, JP, ¹¹Kashiwa, Chiba/Jp

- 13:35 - 13:35 643P - The research progress in randomized, multicenter, controlled evaluation of S-1 and oxaliplatin as neoadjuvant chemotherapy for advanced gastric cancer patients
X. Wang, L. Chen; Beijing, CN
- 13:35 - 13:35 639P - A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies
T. Kojima¹, H. Kasai², T. Tsushima³, H. Hara⁴, Y. Mori², R. Ishihara⁵, K. Kato⁶, S. Hironaka⁷, K. Mukai², O. Kikuchi², K. Enomoto², H. Tada², R. Uozumi², A. Kawaguchi⁸, M. Muto²; ¹Kashiwa-Shi, JP, ²Kyoto, JP, ³Shizuoka, JP, ⁴Saitama, JP, ⁵Osaka, JP, ⁶Tokyo, JP, ⁷Chiba, Chiba/Jp, ⁸Saga, JP
- 13:35 - 13:35 640P - Dual CDK 4/6 inhibitor demonstrates potent antitumor efficacy in vitro and in vivo against esophageal adenocarcinoma
A. Omstead¹, J. Kosovec¹, M. Biedka¹, R. Biederman¹, R. Kelly², A. Zaidi³, B. Jobe¹; ¹Pittsburgh, PA/US, ²Baltimore, MD/US, ³Pittsburgh, US
- 13:35 - 13:35 641P - The influence of body composition on the systemic exposure of paclitaxel in esophageal cancer patients
L. Van Doorn¹, H. Rier², J. van Vught¹, C. van Kesteren², S. Bins¹, R. Mathijssen¹, M.-D. Levin², S. Koolen¹; ¹Rotterdam, NL, ²Dordrecht, NL
- 13:35 - 13:35 642P - Survival in advanced oesophagogastric adenocarcinoma (OGA) improves with the use of multiple lines of therapy: Results from an analysis of over 500 patients (pts)
C. Cafferkey¹, M. Davidson¹, E. Goode¹, D. Hughes¹, P. Reguera¹, R. Kalaitzaki¹, K. Kouvelakis¹, C. Peckitt², I. Chau³, D. Watkins³, S. Rao¹, D. Cunningham², N. Starling¹; ¹London, GB, ²Sutton, GB, ³Sutton, Surrey/GB
- 13:35 - 13:35 644P - The N stages for early gastric cancer should differ from those of advanced gastric cancer: Results based on the SEER database
J.-X. Lin, H. Chang-Ming, C. Zheng, P. Li, J. Wang; Fuzhou, CN
- 13:35 - 13:35 645P - Young-onset gastric cancer: The role of microbial factors
I. Ben-Aharon¹, A. Moore², E. Hikri¹, T. Goshen-Lago², T. Lazar¹, H. Kashtan³, B. Brenner³; ¹Tel-Aviv, IL, ²Petah Tikva, IL, ³Petach Tikva, IL
- 13:35 - 13:35 646P - Comprehensive complication index (CCI) predicts cancer-specific survival of patients with postoperative complications after curative resection of gastric cancer
R. Tu, H. Chang-Ming, J.-X. Lin, P. Li, C. Zheng; Fuzhou, CN
- 13:35 - 13:35 647P - ATM loss, MSI and survival in the MAGIC trial
E. Smyth¹, M. Fassan², K. Kouvelakis¹, M. Nankivell¹, C. Peckitt³, A. Wotherspoon³, N. Valeri³, M. Ruge², W. Allum¹, R. Langley¹, D. Cunningham³; ¹London, GB, ²Padua, IT, ³Sutton, GB
- 13:35 - 13:35 648P - Negative lymph node count is a significant prognostic factor in patient with stage IV gastric cancer after palliative gastrectomy
C. Zhuo¹, M. Ying², R. Lin², X. Wu², S. Guan², C. Yang²; ¹Fuzhou, Fujian/CN, ²Fuzhou, CN

- 13:35 - 13:35 649P - PD-L1 expression in primary tumours and paired lymph node metastases in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma: Relationship with MSI status and prognosis
M. Svensson, D. Borg, C. Hedner, J. Eberhard, B. Nodin, K. Leandersson, K. Jirström; Lund, SE
- 13:35 - 13:35 650P - Effects of preoperative malnutrition on short- and long-term outcomes of patients with gastric cancer: Can we do better?
J. Lu, H. Chang-Ming, H. Huang, C. Zheng, P. Li; Fuzhou, CN
- 13:35 - 13:35 651P - Is there any relationship between Helicobacter pylori infection and HER2 expression in gastric cancer?
E. Algin¹, M. Baykara², G. Yilmaz¹, B. Cetin³, O. Ekinci¹, A. Uner¹, A. Ozet¹; ¹Ankara, TR, ²Sakarya, TR, ³Sivas, TR
- 13:35 - 13:35 652P - Iron deficiency anemia in gastric cancer: A Canadian single site retrospective cohort study
C. Brezden-Masley, G. Tang, R. Hart, M. Sholzberg; Toronto, CA
- 13:35 - 13:35 653P - Is surgical resection beneficial in recurrent or metastatic gastric cancer?
Y. Choi, M.S. Ahn, H.W. Lee, S.Y. Kang, J.-H. Choi; Suwon, KR
- 13:35 - 13:35 654P - Nomograms for pre- and post- operative prediction of long-term survival for patients of proximal gastric cancer: A large-scale, single-centre retrospective study
Q. Chen, H. Chang-Ming, C. Zheng, P. Li, J. Xie; Fuzhou, CN
- 13:35 - 13:35 655P - Safety of neoadjuvant/adjuvant chemotherapy for gastroesophageal cancers: A single cancer centre experience
A. Madi¹, M. Gore², M. McKay², H. Wong², G. Cave³, R. Rao⁴, J. Nicholson⁴, H. Smart⁴, N. Howes⁴, J. Wood²; ¹Wirral, Merseyside/GB, ²Wirral, GB, ³Prescot, GB, ⁴Liverpool, GB
- 13:35 - 13:35 656P - Peritoneal lavage CEA mRNA levels predict conversion gastrectomy outcomes after induction chemotherapy in gastric cancer patients with peritoneal metastasis
H. Yamaguchi¹, Y. Sato², H. Ishigami², H. Oozawa¹, M. Kurihara², Y. Yatomi², J. Kitayama³; ¹Shimotsuke, JP, ²Tokyo, JP, ³Tochigi, JP
- 13:35 - 13:35 657P - Nutritional recovery after open and laparoscopic distal gastrectomy for early gastric cancer: A prospective multicenter comparative trial (CCOG1204)
C. Tanaka¹, M. Kanda¹, K. Misawa¹, S. Ito¹, Y. Ito¹, Y. Mochizuki², K. Ishigure³, T. Yaguchi⁴, J. Teramoto⁵, H. Nakayama¹, Y. Kawase⁶, M. Fujiwara¹, Y. Kodera¹; ¹Nagoya, JP, ²Komaki, JP, ³Konan, JP, ⁴Yatomi, JP, ⁵Yokkaichi, JP, ⁶Seto, JP
- 13:35 - 13:35 658P - Randomized, controlled Phase III trial comparing 3D and 2D laparoscopic gastrectomy for gastric cancer
J. Lu, H. Chang-Ming, C. Zheng, P. Li, J. Xie, J.-X. Lin; Fuzhou, CN
- 13:35 - 13:35 659P - Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in advanced gastric cancer: AGAMENON study data

I. MACIAS¹, A. Carmona-Bayonas², M. Ferrer¹, R. Hernandez³, A. Custodio⁴, A. Lacalle⁵, J.E. Lorenzo Barreto⁶, I. Echavarría Diaz-Guardamino⁴, L. Visa⁷, E. Buxo Orra⁷, M. Mangas Izquierdo⁸, A. Azkarate⁹, A. Diaz⁴, A. Viudez⁵, M. Sanchez Canovas², A. Ramchandani Vaswani¹⁰, F. Longo⁴, E. Martinez de Castro¹¹, J. Gallego Plazas¹², P. Jimenez Fonseca¹³; ¹Sabadell, ES, ²Murcia, ES, ³Santa Cruz, ES, ⁴Madrid, ES, ⁵Pamplona, ES, ⁶San Cristobal De La Laguna, ES, ⁷Barcelona, ES, ⁸Galdakao, ES, ⁹Palma De Mallorca, ES, ¹⁰Las Palmas, Canary Islands/ES, ¹¹Santander, ES, ¹²Elche, Alicante/ES, ¹³Oviedo, ES

- 13:35 - 13:35 660P - First-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancer
U. Sahin¹, M. Schuler², S. Bauer³, A. Krilova⁴, M. Utsch¹, C. Huber¹, Ö. Türeci¹; ¹Mainz, DE, ²Essen, DE, ³Lebach, DE, ⁴Liepaja, LV
- 13:35 - 13:35 661P - Bidirectional chemotherapy in gastric cancer (GC) with peritoneal carcinomatosis (PC) combining intravenous chemotherapy with pressurized intraperitoneal aerosol chemotherapy (PIPAC): Results of 103 procedures in 52 patients
V. Khomyakov, A. Ryabov, L. Bolotina, A. Utkina, A. Ivanov, O. Kuznetsova; Moscow, RU
- 13:35 - 13:35 662P - Gastrectomy after response to intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology
H. Ishigami¹, H. Yamaguchi², H. Yamashita¹, M. Asakage¹, J. Kitayama³; ¹Tokyo, JP, ²Shimotsuke, JP, ³Tochigi, JP
- 13:35 - 13:35 663P - Change in the molecular profile of tumor tissues during treatment with trastuzumab, as analyzed by next-generation sequencing and immunohistochemistry: A multicenter prospective biomarker study on HER2-positive gastric cancer
N. Takahashi¹, S. Iwasa², T. Sawada³, Y. Sasaki⁴, H. Taniguchi², I. Oda², T. Honda⁵, Y. Kojima², H. Hara⁶, Y. Honma², A. Takashima², K. Kato², T. Hamaguchi², Y. Yamada⁷; ¹Ina-Machi, Kita-adachi-gun, JP, ²Tokyo, JP, ³Kanazawa, JP, ⁴Hokkaido, JP, ⁵Nagasaki, JP, ⁶Saitama, JP, ⁷Shizuoka, JP
- 13:35 - 13:35 664P - Phase 1 Study of IMAB362 with immunomodulation in patients with advanced gastric cancer
S.-E. Al-Batran¹, Z. Zvirbule², F. Lordick³, P. Thuss-Patience⁴, M. Just⁵, M. Bitzer⁶, V. Brass⁷, A. Krilova⁸, D. Maurus⁹, Ö. Türeci⁹, U. Sahin⁹; ¹Frankfurt Am Main, DE, ²Riga, LV, ³Leipzig, DE, ⁴Berlin, DE, ⁵Bielefeld, DE, ⁶Tübingen, DE, ⁷Freiburg, DE, ⁸Liepaja, LV, ⁹Mainz, DE
- 13:35 - 13:35 665P - Modified Glasgow prognostic score, prognostic nutritional index and ECOG score could be new prognostic factors for survival in metastatic gastric cancer
B. Demirelli, N. Babacan, S. Koca, B. Uzun, Ö. Ercelep, M. Ozturk, S. Kaya, E. Simsek, S. Khalil, R. Hasanov, O. Alan, T.A. Telli, M. Aribal, F. Dane, F. Yumuk; Istanbul, TR
- 13:35 - 13:35 666P - Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer

A. Vasista¹, A. Martin¹, N. Pavlakis², K. Sjoquist³, S. Snow¹, D. Jonker⁴, Y.J. Chua⁵, R. Epstein⁶, A. Bonaventura⁷, M. Khasraw⁸, S.C. Varma⁹, N. Singhal¹⁰, D. Ransom¹¹, F. Aubin¹², R. Burkes¹³, H. Lim¹⁴, F. Lemay¹⁵, S. Begbie¹⁶, M. Stockler³, B. Kiely³; ¹Camperdown, AU, ²St Leonards, NSW/AU, ³Camperdown, NSW/AU, ⁴Ottawa, CA, ⁵Garran, ACT/AU, ⁶Darlinghurst, NSW/AU, ⁷Newcastle, NSW/AU, ⁸Geelong, VIC/AU, ⁹Douglas, QLD/AU, ¹⁰Adelaide, SA/AU, ¹¹Subiaco, WA/AU, ¹²Montreal, CA, ¹³Toronto, ON/CA, ¹⁴Vancouver, British Columbia/CA, ¹⁵Sherbrooke, CA, ¹⁶Port Macquarie, NSW/AU

- 13:35 - 13:35 667P - ERBB3 mutations in advanced gastric signet-ring cell carcinoma (SRCC) and the implications for targeted therapy
J. Wei, B. XU, S. Jin, L. Yu, B. Liu; Nanjing, CN
- 13:35 - 13:35 668P - Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The "Gastric Life" nomogram
F. Pietrantonio¹, F. Barretta¹, V. Fanotto², M. Niger¹, F. Morano¹, F. Bergamo³, N. Silvestris⁴, L. Fornaro⁵, R. Bordonaro⁶, M. Baretta⁷, D. Santini⁸, G. Tomasello⁹, L. Antonuzzo¹⁰, S. Noventa¹¹, A. Avallone¹², S. Di Donato¹³, E. Maiello¹⁴, F. De Vita¹⁵, R. Miceli¹, G. Aprile²; ¹Milan, IT, ²Udine, IT, ³Padova, IT, ⁴Bari, IT, ⁵Pisa, IT, ⁶Catania, IT, ⁷Rozzano, (MI)/IT, ⁸Roma, IT, ⁹Cremona, (CR)/IT, ¹⁰Firenze, IT, ¹¹Brescia, IT, ¹²Napoli, IT, ¹³Prato, IT, ¹⁴San Giovanni Rotondo, IT, ¹⁵Naples, IT
- 13:35 - 13:35 669P - TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas
S. Dueland¹, J. Valle², K. Bell¹, O. Faluy³, H. Staiger², T. Gjertsen¹, A.-S. Møller¹, A.-K. Aksnes¹, D. Palmer⁴; ¹Oslo, NO, ²Manchester, GB, ³Wirral, Merseyside/GB, ⁴Liverpool, GB
- 13:35 - 13:35 670P - A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)
C. Pauligk¹, S. Lorenzen², T. Goetze³, J. Riera Knorrenschild⁴, S. Hegewisch Becker⁵, J. Seraphin⁵, P. Thuss-Patience⁵, H.-G. Kopp⁶, T. Dechow⁷, A. Vogel⁸, K. Luley⁹, D. Pink¹⁰, M. Stahl¹¹, F. Kullmann¹², H. Hebart¹³, J. Siveke¹¹, M. Egger¹⁴, N. Homann¹⁵, S. Probst¹⁶, S.-E. Al-Batran³; ¹Frankfurt, DE, ²Munich, DE, ³Frankfurt Am Main, DE, ⁴Marburg, DE, ⁵Berlin, DE, ⁶Tübingen, DE, ⁷Ravensburg, DE, ⁸Hannover, DE, ⁹Lübeck, Schleswig-Holstein/DE, ¹⁰Bad Saarow, DE, ¹¹Essen, DE, ¹²Weiden, DE, ¹³Mutlangen, DE, ¹⁴Lahr, DE, ¹⁵Wolfsburg, DE, ¹⁶Bielefeld, DE
- 13:35 - 13:35 671P - Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)
Y.-K. Kang¹, K. Kato², H.C. Chung³, K. Minashi⁴, K.-W. Lee⁵, H. Cho⁶, W.K. Kang³, Y. Komatsu⁷, M. Tsuda⁸, K. Yamaguchi², H. Hara⁹, S. Fumita¹⁰, M. Azuma¹¹, N. Boku¹², L.-T. Chen¹³; ¹Seoul, Songpa-gu/KR, ²Tokyo, JP, ³Seoul, KR, ⁴Chiba, JP, ⁵Seongnam, KR, ⁶Yokohama, JP, ⁷Sapporo, Hokkaido/JP, ⁸Akashi, JP, ⁹Saitama, JP, ¹⁰Ikoma, JP, ¹¹Kanagawa, JP, ¹²Kawasaki, Kanagawa/JP, ¹³Tainan, TW
- 13:35 - 13:35 672P - A multicentre, phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach (CABAGAST)

T. Götze¹, S.-E. Al-Batran¹, T. Zander², A. Reichart¹, U. Lindig³, M. Kleiss⁴, L. Mueller⁵, C. Bolling¹, T. Seufferlein⁶, P. Reichardt⁷, F. Kullmann⁸, H. Eschenburg⁹, A. Schmittel¹⁰, M. Egger¹¹, A. Block¹², C. Pauligk¹³, H. Schmalenberg¹⁴; ¹Frankfurt Am Main, DE, ²Cologne, DE, ³Jena, DE, ⁴Kassel, DE, ⁵Leer, DE, ⁶Ulm, DE, ⁷Berlin-Buch, DE, ⁸Weiden, DE, ⁹Güstrow, DE, ¹⁰Berlin, DE, ¹¹Lahr, DE, ¹²Hamburg, DE, ¹³Frankfurt, DE, ¹⁴Dresden, DE

- 13:35 - 13:35 673P - Comparison of cytotoxic backbones for first line trastuzumab-containing regimens in HER2-positive advanced esophagogastric cancer: A meta-analysis
E. ter Veer, A. Creemers, L. de Waal, M. van Oijen, H. van Laarhoven; Amsterdam, NL
- 13:35 - 13:35 674P - Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032
P. Ott¹, D. Le², J. Kim³, P. Ascierto⁴, P. Sharma⁵, P. Bono⁶, K. Peltola⁶, D. Jäger⁷, T.R.J. Evans⁸, F. de Braud⁹, I. Chau¹⁰, J. Bendell¹¹, M. Tschaike¹², C. Harbison¹², H. Zhao¹², E. Calvo¹³, Y. Janjigian¹⁴; ¹Boston, MA/US, ²Baltimore, MD/US, ³New Haven, US, ⁴Napoli, IT, ⁵Houston, TX/US, ⁶Helsinki, FI, ⁷Heidelberg, DE, ⁸Glasgow, GB, ⁹Milan, IT, ¹⁰Sutton, Surrey/GB, ¹¹Nashville, TN/US, ¹²Princeton, US, ¹³Madrid, ES, ¹⁴New York, NY/US
- 13:35 - 13:35 675P - Involvement of the immunoregulator MZB1 in progression of gastric cancer
Y. TANAKA, M. Kanda, C. Tanaka, D. Kobayashi, H. Tanaka, H. Takami, M. Hayashi, N. Iwata, Y. Niwa, S. Yamada, G. Nakayama, H. Sugimoto, M. Koike, M. Fujiwara, Y. Kodera; Nagoya, JP
- 13:35 - 13:35 676P - PD-L1 immunohistochemistry (IHC) by three different assays and molecular profiling in tissue microarray (TMA) of gastric cancer
Y. Narita¹, E. Sasaki², Y. Yatabe¹, K. Kato², H. Okano², S. Mitani¹, K. Honda², T. Masuishi¹, H. Taniguchi¹, S. Kadowaki¹, T. Ura², M. Ando², M. Tajika¹, S. Ito², K. Muro¹; ¹Nagoya, Aichi/JP, ²Nagoya, JP
- 13:35 - 13:35 677P - Treatment of advanced gastric cancer based on Lauren's histological: Real-world data from the AGAMEMON National Cancer Registry
A. Carmona-Bayonas¹, P. Jiménez-Fonseca², R. Hernández³, A. Custodio⁴, J.M. Cano⁵, A. Lacalle⁶, I. Echavarría Diaz-Guardamino⁴, I. MACIAS⁷, M. Mangas Izquierdo⁸, L. Visa⁹, E. Buxo Orra⁹, A. Azkarate¹⁰, A. Ramchandani Vaswani¹¹, E. Martínez de Castro¹², A. Fernández Montes¹³, F. Longo⁴, R. Sánchez Bayona⁶, M.L. Limón¹⁴, A. Martín Carnicero¹⁵, J. Gallego Plazas¹⁶; ¹Murcia, ES, ²Oviedo, ES, ³Tenerife, ES, ⁴Madrid, ES, ⁵Ciudad Real, ES, ⁶Pamplona, ES, ⁷Sabadell, ES, ⁸Galdakao, ES, ⁹Barcelona, ES, ¹⁰Palma De Mallorca, ES, ¹¹Las Palmas, Canary Islands/ES, ¹²Santander, ES, ¹³Orense, ES, ¹⁴Seville, ES, ¹⁵Logroño, ES, ¹⁶Elche, Alicante/ES
- 13:35 - 13:35 678P - Comparison of oxaliplatin-related spleen enlargement in patient with gastric cancer who received S-1 versus capecitabine as a combination partner of oxaliplatin
S. Seo¹, M. Kim², M.J. Kim³, M.-J. Kim³, Y.I. Park³, S.R. Park²; ¹Seoul, Songpa-gu/KR, ²Seoul, KR, ³Goyang, KR
- 13:35 - 13:35 679P - Safety and efficacy of S-1 treatment in elderly patients with advanced or recurrent gastric cancer: A subgroup analysis from the phase III JFMC36-0701 trial

K. Nishikawa¹, S. Yoshino², S. Morita³, T. Takahashi⁴, K. Sakata⁵, J. Nagao⁶, H. Nemoto⁷, N. Murakami⁸, H. Hasegawa⁹, R. Shimizu¹⁰, T. Yoshikawa⁷, H. Osana¹¹, M. Imano¹², H. Naitoh¹³, A. Tanaka¹⁴, J. Sakamoto⁶, S. Saji⁶, M. Oka⁹; ¹Osaka, JP, ²Ube, Yamaguchi/JP, ³Kyoto, JP, ⁴Suita, JP, ⁵Shimonoseki, JP, ⁶Tokyo, JP, ⁷Yokohama, JP, ⁸Takaoka, JP, ⁹Yamaguchi, JP, ¹⁰Sanyo-Onoda, JP, ¹¹Sapporo, JP, ¹²Osakasayama, JP, ¹³Maebashi, JP, ¹⁴Mine, JP

- 13:35 - 13:35 680P - Phase II study of modified docetaxel, cisplatin and S-1 (mDCS) combination chemotherapy in patients with unresectable metastatic gastric cancer
Y. Sato¹, H. Ohnuma¹, K. Okamoto², H. Miyamoto², M. Hirakawa¹, N. Uemura¹, S. Kikuchi¹, T. Sagawa¹, K. Fujikawa¹, Y. Takahashi¹, S. Minami³, T. Okuda³, M. Takahashi¹, J. Kato¹, T. Takayama²; ¹Sapporo, JP, ²Tokushima, JP, ³Tomakomai, JP
- 13:35 - 13:35 681P - Clinical impact of programmed death ligand-1 and -2 expression after platinum based chemotherapy in metastatic gastric cancer
J.H. Yang, S. Park, E.K. Joung, M.A. Lee, S.Y. Roh, I.-H. Kim; Seoul, KR
- 13:35 - 13:35 682P - Clinical practice observation of trastuzumab (TRA) in patients (pts) with HER2-positive metastatic adenocarcinoma of the stomach (mGC) or the gastro-oesophageal junction (GEJ): Final analysis from the German non-interventional study HerMES
S.-E. Al-Batran¹, E. Moorahrend², C. Maintz³, D. Hempel⁴, P. Thuss-Patience³, V. Gaillard⁵, S. Hegewisch Becker³; ¹Frankfurt Am Main, DE, ²Porta Westfalica, DE, ³Berlin, DE, ⁴Donauwörth, DE, ⁵Grenzach Wyhlen, DE
- 13:35 - 13:35 683P - Intratumoral PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer
B.W. Kang¹, A.N. Seo¹, I. Lee¹, S.J. Lee¹, Y.S. Chae¹, J.G. Kim²; ¹Daegu, KR, ²Seoul, KR
- 13:35 - 13:35 684P - Targeting c-met and DNA double-strand break (DSB) repair pathways for BRCA-mutated gastric carcinomas
M. Karamouzis¹, C. Mihailidou¹, P. Papakotoulas², A. Anestis¹, E. Koustas¹, A. Papavassiliou³; ¹Athens, GR, ²Thessaloniki, GR, ³Athens, Attiki/GR
- 13:35 - 13:35 685P - Clinical efficacy observation for endostar combined with chemotherapy treating gastric cancer peritoneal carcinomatosis
H. Ma, A. Huang, J. Yao, T. Zhang; Wuhan, CN
- 13:35 - 13:35 686P - Modified epirubicin and oxaliplatin plus capecitabine (EOX) Regimen as second-line therapy after failure of modified docetaxel and cisplatin plus fluorouracil (DCF) regimen in advanced gastric cancer
Y. Bozkaya, O. Yazici, N. Ozdemir, G. Erdem, N. Demirci, N. Zengin; Ankara, TR
- 13:35 - 13:35 687P - Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer
Y. Horita, M. Nishino, S. Sugimoto, A. Kida, A. Mizukami, M. Yano, F. Arihara, K. Matsuda, M. Matsuda, A. Sakai; Toyama, JP
- 13:35 - 13:35 688P - Beyond first line treatment for advanced esophagogastric adenocarcinoma (EGAC): A phase 1 dose escalation study of regorafenib (Reg) combined with paclitaxel (PTX) (REPEAT study)

S. Schokker, S. Van der Woude, R. Mathot, M. Bijlsma, M. Van Oijen, C. Punt, H. van Laarhoven;
Amsterdam, NL

- 13:35 - 13:35 689P - Phase I dose escalation study with expansion cohort of the addition of nab-paclitaxel (nab-P) to capecitabine and oxaliplatin (CAPOX) as first line treatment of advanced esophagogastric adenocarcinoma (EGAC) (ACTION study)
S. Schokker, D. Van Zoen, S. Van der Woude, S. Meijer, R. Mathot, M. Bijlsma, M. Van Oijen, C. Punt, H. van Laarhoven; Amsterdam, NL
- 13:35 - 13:35 690P - KRAS status and HER2 targeted treatment in advanced gastric cancer
E. Shinozaki, H. Osumi, K. Chin, M. Ogura, D. Takahari, T. Ichimura, T. Matsushima, T. Wakatsuki, I. Nakayama, Y. Imamura, M. Watanabe, K. Yamaguchi; Tokyo, JP
- 13:35 - 13:35 691P - Inter-patient and intra-tumoral heterogeneity of oncogenic copy number alterations (CNAs) in gastric and gastroesophageal junction (GEJ) adenocarcinomas
J. Chao¹, V. Bedell¹, M. Li¹, P. Chu¹, Y.-C. Yuan¹, S. Klempner², R.-J. Lin¹; ¹Duarte, US, ²Los Angeles, CA/US
- 13:35 - 13:35 692P - Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening
M. Bingham¹, I. Bhamra¹, R. Armer¹, B. Thompson¹, S. Woodcock¹, A. Thomason¹, C. Phillips¹, H. McKeever¹, J. Bradford², B. Chaffey³, L. Little³, G. Clack²; ¹Manchester, GB, ²Sheffield, GB, ³Newcastle-Upon-tyne, GB
- 13:35 - 13:35 693P - Prognostic effect of surgery of metastases in patients with advanced gastric cancer: Real-world data from the AGAMENON registry
P. Jiménez-Fonseca¹, R. Hernandez², A. Custodio³, A. Ramchandani Vaswani⁴, M. Sánchez Cánovas⁵, R. Sánchez Bayona⁶, C. López López⁷, I. Echavarria Diaz-Guardamino³, L. Visa⁸, E. Buxo Orra⁸, D. Arias⁹, A. Viudez⁶, A. Martin Carnicero¹⁰, P. Cerdà⁸, M. Ferrer¹¹, J.E. Lorenzo Barreto¹², M.L. Limón¹³, I. MACIAS¹¹, P. Felices¹⁴; ¹Oviedo, ES, ²Santa Cruz, ES, ³Madrid, ES, ⁴Las Palmas, Canary Islands/ES, ⁵Murcia, ES, ⁶Pamplona, ES, ⁷Santander, ES, ⁸Barcelona, ES, ⁹Orense, ES, ¹⁰Logrono, ES, ¹¹Sabadell, ES, ¹²San Cristobal De La Laguna, ES, ¹³Seville, ES, ¹⁴Zaragoza, ES
- 13:35 - 13:35 694P - Comparison of HER2 related molecular expression and its significance for clinical outcomes between the primary and paired liver metastasis in advanced gastric cancer
H. Osumi, E. Shinozaki, N. Yamamoto, K. Chin, M. Ogura, D. Takahari, T. Wakatsuki, T. Ichimura, I. Nakayama, T. Matsushima, A. Saiura, T. Yamaguchi, K. Yamaguchi; Tokyo, JP
- 13:35 - 13:35 695P - Real world data about clinical efficacy and safety of apatinib in the treatment of advanced gastric cancer
J. feng¹, B. Shen¹, Z. He², L. Deng³, A. Dai⁴, X. Shen², L. Chen¹, H. Jiang⁵, X. Li⁶, G. Zhou¹, J. Yu⁷, L. Yang⁸, P. Chen⁹, M. Zhuang¹⁰; ¹Nanjing, CN, ²Suzhou, CN, ³Jiangyin, CN, ⁴Kunshan, CN, ⁵Changzhou, CN, ⁶Zhenjiang, CN, ⁷Xinghua, CN, ⁸Nantong, CN, ⁹Yancheng, CN, ¹⁰Lianyungang, CN
- 13:35 - 13:35 696P - Correlation between SPARC expression and efficacy of nab-paclitaxel for advanced gastric cancer refractory to fluoropyrimidine: An exploratory analysis of a phase II trial, CCOG1303

D. Kobayashi¹, A. Enomoto², Y. Mochizuki³, T. Matsui⁴, H. Nakayama², Y. Kawase⁵, K. Ishigure⁶, T. Shikano⁷, K. Torii⁸, Y. Kodera²; ¹Nagoya, Aichi/JP, ²Nagoya, JP, ³Komaki, JP, ⁴Okazaki, JP, ⁵Seto, JP, ⁶Konan, JP, ⁷Yokkaichi, JP, ⁸Nakatsugawa, JP

- 13:35 - 13:35 697P - Detection of microsatellite instability (MSI) with a novel panel of biomarkers in gastric cancer samples
B. De Craene¹, Z. Feng², E. Rondelez¹, L. Vandenbroeck¹, K. Peeters¹, G. Maertens¹, E. Sablon¹, T. Cai²; ¹Mechelen, BE, ²Billerica, US
- 13:35 - 13:35 698P - A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB
J. Ajani¹, A. Udrea², T. Sarosiek³, M. Shenker⁴, C. Morgan⁵, J. Pikiel⁶, E. Wojcik⁷, D. Swinson⁸, M. Joseph⁹, A. Luft¹⁰, T. Salek¹¹, C. Tournigand¹², D. Ferry¹³, Y. Zhang¹³, A. Long¹³, W.-L. Kuo¹³, L. Gao¹³, J. Kauh¹³, W. Mansoor¹⁴; ¹Lyngby, DK, ²Cluj-Napoca, RO, ³Warszawa, PL, ⁴Craiova, RO, ⁵Cardiff, GB, ⁶Gdańsk, PL, ⁷Poznań, PL, ⁸Leeds, GB, ⁹Wolverhampton, GB, ¹⁰St. Petersburg, RU, ¹¹Bratislava, SK, ¹²Creteil Cedex, FR, ¹³Bridgewater, NJ/US, ¹⁴Manchester, GB
- 13:35 - 13:35 699P - The effectiveness of the 8th American Joint Committee on Cancer TNM classification in the prognosis evaluation of stage III gastric cancer patients: A comparative study between the 7th and 8th editions
J. Lu, H. Chang-Ming, C. Zheng, Q. Chen, R. Tu; Fuzhou, CN
- 13:35 - 13:35 711P - Selective Internal Radiation Therapy (SIRT) with Yttrium-90-glass-microspheres plus chemotherapy in first-line treatment of advanced cholangiocarcinoma (MISPHEC study)
J. Edeline¹, Y. Touchefeu², B. Guiu³, O. Farges⁴, D. Tougeron⁵, P. Compagnon⁶, L. Chone⁷, B. Campillo-Gimenez⁸, M. Pracht¹, A. Lievre⁸, S. Le Sourd⁸, K. Boudjema⁸, E. Garin⁸, E. Boucher¹; ¹Rennes, CEDEX/FR, ²Nantes, CEDEX 1/FR, ³Montpellier, FR, ⁴Clichy, FR, ⁵Poitiers, CEDEX/FR, ⁶Creteil, FR, ⁷Nancy, FR, ⁸Rennes, FR
- 13:35 - 13:35 700P - Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database
H. Samawi¹, S. Hao-Wen², K. Chan², M. Alghamdi³, R. Lee-Ying³, J. Knox², P. Gill⁴, A. Romagnino², E. Batuyong³, Y.-J. Ko², W. Cheung³, V. Tam³; ¹Calgary, CA, ²Toronto, ON/CA, ³Calgary, AB/CA, ⁴Vancouver, BC/CA
- 13:35 - 13:35 701P - Final data from a phase Ib trial of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC)
S. Qin¹, T.-Y. Kim², H.Y. Lim², B.-Y. Ryoo², D. Zhou³, C. Zhao⁴, A. Becker⁵, A.-L. Cheng⁶; ¹Nanjing, CN, ²Seoul, KR, ³Beijing, CN, ⁴Billerica, GB, ⁵Frankfurt An Der Oder, DE, ⁶Taipei, TW
- 13:35 - 13:35 707P - Network meta-analysis (NMA) of treatments for unresectable hepatocellular carcinoma (uHCC)
G. Tremblay¹, G. Meier², D. Misurski³, M. Baig³, T. Tamai⁴, S. Kraljevic⁵, A. Shor⁶, A. Forsythe⁶; ¹Levis, CA, ²Woodcliff Lake, US, ³Woodcliff Lake, NJ/US, ⁴Tokyo, JP, ⁵Hatfield, Herts/GB, ⁶New York, US

- 13:35 - 13:35 703P - Cost effectiveness of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma patients in the UK
D. Palmer¹, P. Ross², T. Shah³, D. Yu², S. Shergill², K. Patterson⁴, N. Brereton⁴, D. Lee⁴; ¹Liverpool, GB, ²London, GB, ³Birmingham, GB, ⁴Sheffield, GB
- 13:35 - 13:35 709P - A Phase II study of sorafenib and yttrium-90 glass microspheres for advanced hepatocellular carcinoma, BCLC stage C
A. Kaseb, R. Abdel-Wahab, R. Murthy, M. Hassan, K. Raghav, L. Xiao, J. Morris, R. Avritscher, B. Odisio, C. Ohaji, R. Wolff, J. Yao, A. Mahvash; Houston, US
- 13:35 - 13:35 702P - Correlation between overall survival (OS) and time to progression (TTP) and between OS and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC)
L. Huang¹, Y. De Sanctis², M. Shan², J. Bruix³, J. Llovet³, A.-L. Cheng⁴, G. Meinhardt⁵, K. Nakajima²; ¹Whippany, NJ/US, ²Whippany, US, ³Barcelona, ES, ⁴Taipei, TW, ⁵New York, NJ/US
- 13:35 - 13:35 704P - Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib
A. Casadei Gardini¹, G. Marisi¹, F.G. Foschi¹, M. Scartozzi², G.L. Frassinetti¹; ¹Meldola, IT, ²Ancona, IT
- 13:35 - 13:35 706P - Overall survival (OS) by platelet count at baseline in patients with hepatocellular carcinoma (HCC) treated with sorafenib (SOR) in the SHARP and AP trials and regorafenib (REG) in the RESORCE trial
G. Meinhardt¹, Y. De Sanctis², M.-A. Leberre³, K. Nakajima²; ¹New York, NJ/US, ²Whippany, US, ³Loos, FR
- 13:35 - 13:35 705P - Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial
M. Teufel¹, H. Seidel², K. Köchert², G. Meinhardt³, R. Finn⁴, J. Llovet⁵, J. Bruix⁶; ¹Whippany, NJ/US, ²Berlin, DE, ³New York, NJ/US, ⁴Los Angeles, CA/US, ⁵New York, US, ⁶Barcelona, ES
- 13:35 - 13:35 708P - Epidemiological study of histologically proven advanced hepatocholangiocarcinoma: An AGEO multicenter retrospective study
Y. Touchefeu¹, C. Prieux-Klotz², D. Tougeron³, T. Lecomte⁴, M. Caulet⁴, T. Matysiak Budnik¹, V. Hautefeuille⁵, M. Tiako-Meyo², A. Zaanani², M. Salimon⁶; ¹Nantes, CEDEX 1/FR, ²Paris, FR, ³Poitiers, CEDEX/FR, ⁴Chambray-Lès-tours, FR, ⁵Amiens, CEDEX/FR, ⁶Nantes, FR
- 13:35 - 13:35 710P - Assessing cancer risk in patients with HFE gene variants and type 1 hereditary hemochromatosis
K. Youkhana¹, V. Tutaeva¹, H. Williams¹, O. Corbali², S. Krishnamurthy¹, R. Metpally¹, N. Kip¹; ¹Danville, US, ²Istanbul, TR
- 13:35 - 13:35 720P - Inoperable carcinoma gallbladder: Comparison of two palliative chemotherapy regimens (gemcitabine-platinum versus CAPEOX)
H. Malhotra¹, A. Daga², D. Gangopadhyay², A. Yadav², A. Mathur², B. Malhotra²; ¹Jaipur, Rajasthan/IN, ²Jaipur, IN
- 13:35 - 13:35 712P - Effect of adjuvant chemotherapy and chemoradiotherapy in patients with ampullary carcinoma: A NCDB analysis

G. Westin¹, B. Huffman¹, S. Alsidawi², A. Mahipal³; ¹Jacksonville, US, ²Rochester, MN/US, ³Tampa, FL/US

13:35 - 13:35 713P - The mutational landscape of periampullary adenocarcinomas in relation to morphological subtype and patient survival

S. Lundgren, E. Karnevi, J. Elebro, B. Nodin, J. Eberhard, K. Leandersson, G. Jönsson, K. Jirstrom; Lund, SE

13:35 - 13:35 714P - Gemcitabine and platinum- based chemotherapy in first line treatment of hepatocholangiocarcinoma: An AGEO multicenter retrospective study

M. Salimon¹, C. Prioux-Klotz², D. Tougeron³, T. Lecomte⁴, M. Caulet⁴, T. Matysiak Budnik⁵, V. Hautefeuille⁶, M. Tiako-Meyo², A. Zaanani², Y. Touchefeu⁵; ¹Nantes, FR, ²Paris, FR, ³Poitiers, CEDEX/FR, ⁴Chambray-Lès-tours, FR, ⁵Nantes, CEDEX 1/FR, ⁶Amiens, CEDEX/FR

13:35 - 13:35 715P - Jab1 silencing inhibits proliferation and sensitizes to cisplatin in biliary tract cancer

J.-W. Kim, A.-R. Nam, J.E. Park, J.-H. Bang, M.H. Jin, D.-Y. Oh, Y.-J. Bang; Seoul, KR

13:35 - 13:35 716P - The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-screen: Efficient identification of cancer genome alterations in advanced biliary tract cancer

M. Ueno¹, C. Morizane², Y. Kawamoto³, H. Takahashi⁴, D. Naruge⁵, S. Shimizu⁶, K. Nakamura⁷, T. Nakajima⁸, T. Kato⁹, T. Kudo¹⁰, N. Mizuno¹¹, K. Ohtsubo¹², S. Itoh¹³, H. Ishii¹⁴, T. Sudo⁷, S. Nomura², S. Fujii¹⁵, K. Shitara⁴, A. Ohtsu⁴, T. Yoshino⁴; ¹Yokohama, JP, ²Tokyo, JP, ³Sapporo, Hokkaido/JP, ⁴Kashiwa, Chiba/JP, ⁵Mitaka, Tokyo, JP, ⁶Saitama, JP, ⁷Chiba, JP, ⁸Kanagawa, JP, ⁹Amagasaki, Hyogo/JP, ¹⁰Suita, Osaka/JP, ¹¹Nagoya, JP, ¹²Kanazawa, JP, ¹³Fukuoka, JP, ¹⁴Matsuyama, JP, ¹⁵Kashiwa, JP

13:35 - 13:35 717P - Prognostic implication of inflammation-based prognostic scores in patients with intrahepatic cholangiocarcinoma (iCCA) treated with first-line Gemcitabine plus Cisplatin (GEMCIS)

H. Cho, C. Yoo, K.-P. Kim, H.-M. Chang, B.-Y. Ryoo; Seoul, KR

13:35 - 13:35 718P - Phase 2 study of triplet chemotherapy with oxaliplatin, irinotecan and S-1 (OIS) as first-line treatment in patients with advanced biliary tract cancer (BTC)

C. Yoo¹, B. Han², K.-P. Kim³, H.S. Kim², J.H. Kim³, H.-M. Chang³, B.-Y. Ryoo³, D.Y. Zang²; ¹Seoul, Songpa-gu/KR, ²Anyang, KR, ³Seoul, KR

13:35 - 13:35 719P - Prognostic impact of hepatitis B virus (HBV) infection in advanced intrahepatic cholangiocarcinoma (iCCA) patients (pts) treated with first-line gemcitabine plus cisplatin (GEMCIS)

E. Kim, H. Cho, C. Yoo, K.-P. Kim, H.-M. Chang, B.-Y. Ryoo; Seoul, KR

13:35 - 13:35 721P - Surgical indication for advanced intrahepatic cholangiocarcinoma according to the optimal preoperative carbohydrate antigen 19-9 cut-off value

Y. Yamamoto, T. Sugiura, Y. Okamura, T. Ito, R. Ashida, K. Uesaka; Shizuoka, JP

13:35 - 13:35 722P - A phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results

M. Ikeda¹, T. Sasaki², C. Morizane², N. Mizuno³, F. Nagashima², S. Shimizu⁴, N. Hayata², H. Ikezawa², T. Suzuki², R. Nakajima², C. Dutcus⁵, M. Ueno⁶; ¹Kashiwa, Chiba/JP, ²Tokyo, JP, ³Nagoya, JP, ⁴Saitama, JP, ⁵Woodcliff Lake, New Jersey/US, ⁶Yokohama, JP

13:35 - 13:35 723P - Genotyping and mRNA profiling reveal actionable targets in biliary tract cancers

K. Papadopoulou¹, S. Murray¹, K. Manousou¹, I. Tikas¹, C. Dervenis¹, J. Sgouros¹, D. Rontogianni¹, S. Lakis¹, C. Poullos¹, S. Pervana¹, G. Lazaridis¹, G. Fountzilas¹, V. Kotoula²; ¹Athens, GR, ²Thessaloniki, Central Macedonia/GR

13:35 - 13:35 724P - HER-2/HER-3 pathway as a potentially-actionable target in biliary tract cancers (BTCs): A retrospective analysis

A. Lamarca, S. Galdy, S. Moghadam, J. Rogan, M. McNamara, R. Hubner, A. Cramer, J. Valle; Manchester, GB

13:35 - 13:35 725P - Actionable molecular alterations in advanced biliary tract carcinomas: Preliminary data from the ProfILER program (NCT01774409)

P. Cassier¹, C. de la Fouchardiere², P. Guibert¹, D. Pissaloux¹, C. Pacaux¹, C. Terret², L. Eberst³, M. Sarabi², V. Attignon¹, Q. Wang², V. Corset¹, D. Perol², J.-Y. Blay¹, F. Desseigne²; ¹Lyon, FR, ²Lyon, CEDEX/FR, ³Lyon, Cedex 08/FR

13:35 - 13:35 726P - Precision medicine for patients with advanced biliary tract cancers: Updated results from the prospective MOSCATO trial

L. Verlingue¹, D. Malka², A. Allorant², C. Massard², C. Ferte², L. Lacroix², E. Rouleau³, N. Auger², J. Delahousse², R. Sun², T. de Baere², L. Tselikas², B. Ba², J.-Y. Scoazec², S. Michiels², V. Boige², M. Ducreux², J.-C. Soria⁴, A. Hollebecque²; ¹Paris, FR, ²Villejuif, FR, ³Paris, CEDEX 5/FR, ⁴Villejuif, CEDEX/FR

13:35 - 13:35 727P - Preoperative chemoradiotherapy after induction FOLFIRINOX improve R0 resection margins rate and histological response in patients secondary resected in borderline or locally advanced pancreatic adenocarcinoma

D. PIETRASZ¹, O. Turrini², V. Vendrely³, C. Laurent³, E. Terrebbonne⁴, O. Hentic Dhome⁵, A. Sauvanet⁵, J.-M. Simon¹, R. Coriat⁶, F. Portales⁷, B. Le Roy⁸, A.-L. Pointet¹, L. Marthey⁹, N. Regenet¹⁰, D. Goere¹¹, P. Artru¹², J.-C. Vaillant¹, J.-R. Delpero², J.-B. Bachet¹³, A. Sa Cunha¹¹; ¹Paris, FR, ²Marseille, FR, ³Bordeaux, FR, ⁴Giroud, FR, ⁵Clichy, FR, ⁶Paris, CEDEX 14/FR, ⁷Montpellier, FR, ⁸Clermont Ferrand, FR, ⁹Le Kremlin Bicetre, FR, ¹⁰Nantes, FR, ¹¹Villejuif, FR, ¹²Lyon, CEDEX 8/FR, ¹³Paris, CEDEX 13/FR

13:35 - 13:35 728P - Intratumoral heterogeneity of SMAD4 immunohistochemical (IHC) expression and its role in prediction of recurrence patterns in patients with resectable pancreatic cancer (PC)

I. Pokataev¹, A. Kudaibergenova¹, A. Artemyeva², D. Podluzhnyi¹, N. Kudashkin¹, Y. Patyutko¹, E. Moroz¹, E. Kharchenko², A. Popova¹, M. Fedyanin¹, A. Rumyantsev¹, I. Bazin¹, A. Tryakin¹, E. Glukhov¹, O. Sekhina¹, D. Chekini¹, S. Tjulandin¹; ¹Moscow, RU, ²Saint Petersburg, RU

13:35 - 13:35 729P - Outcome of patients with pancreatic adenocarcinoma with complete pathological response following neo-adjuvant therapy

H.R. Kourie¹, A. Sa Cunha², S. Pernot³, R. Coriat⁴, A. Sauvanet⁵, N. Regenet⁶, S. Louafi⁷, J.-B. Bachet⁸, D. Pietrasz⁹, J. Taieb⁹; ¹Brussels, BE, ²Villejuif, FR, ³Boulogne-Billancourt, FR, ⁴Paris, CEDEX 14/FR, ⁵Clichy, FR, ⁶Nantes, FR, ⁷Longjumeau, CEDEX/FR, ⁸Paris, CEDEX 13/FR, ⁹Paris, FR

- 13:35 - 13:35 730P - Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)
F. Portales¹, P. Philip², P. Hammel³, M. Buscaglia⁴, R. Pazo-Cid⁵, J.L. Manzano-Mozo⁶, E. Kim⁷, S. Dowden⁸, A. Zakari⁹, C. Borg¹⁰, E. Terrebbonne¹¹, F. Rivera Herrero¹², J. Shiansong Li¹³, T.J. Ong¹³, T. Nydam¹⁴, J. Lacy¹⁵; ¹Montpellier, FR, ²Detroit, MI/US, ³Clichy, FR, ⁴Genova, IT, ⁵Zaragoza, ES, ⁶Badalona, ES, ⁷Charlotte, NC/US, ⁸Calgary, Alberta/CA, ⁹Orlando, FL/US, ¹⁰Besaçon, FR, ¹¹Giround, FR, ¹²Santander, ES, ¹³Summit, NJ/US, ¹⁴Summit, US, ¹⁵New Haven, CT/US
- 13:35 - 13:35 731P - Prognosis of familial pancreatic cancer (FPC): A matched case analysis
G. O'Kane¹, A. Borgida², A. Dodd², K. Aung³, S. Holter⁴, J. Knox⁵, S. Gallinger⁵; ¹Dublin, IE, ²Z, CA, ³Toronto, NB/CA, ⁴Toronto, CA, ⁵Toronto, ON/CA
- 13:35 - 13:35 732P - Should pancreatic cancer be included in BRCA1/2 testing criteria?
M. Venturelli¹, A. Toss¹, S. Pipitone¹, I. Marchi¹, E. Tenedini¹, V. Medici¹, E. Tagliafico¹, E. Razzaboni¹, F. Spaggiari¹, E. De Matteis², S. Cascinu¹, L. Cortesi¹; ¹Modena, IT, ²Lecce, IT
- 13:35 - 13:35 733P - Sequential chemo-chemoradiation (CCRT) in locally advanced pancreas cancer in an irish high volume centre
R. Abdul Rahman¹, M.Y. Teo², M. Moriarty³, R. McDermott¹, G. McVey³; ¹Dublin, Belgard Square North/IE, ²New York, NY/US, ³Rathgar, IE
- 13:35 - 13:35 735P - The prognostic significance of infiltrating lymphocytes in resectable pancreatic ductal adenocarcinoma in untreated versus neoadjuvant treated patients
J. Goldstein¹, D. Chatterjee¹, M. Zaid¹, B. Chaudhury¹, D. Elganainy¹, D. Halperin¹, R. Nejati¹, H. Wang¹, M. Katz¹, J. Lee¹, J. Fleming¹, J. Rodriguez Canales², J. Blando², I. Wistuba², A. Maitra¹, R. Wolff¹, H. Wang¹, G. Varadhachary¹, E. Koay¹; ¹Houston, US, ²Houston, TX/US
- 13:35 - 13:35 736P - Randomized phase 2 trial of peri- or post-operative chemotherapy in resectable pancreatic adenocarcinoma
M. Reni¹, S. Zanon¹, G. Balzano¹, R. Castoldi¹, A. Zerbi², M.C. Tronconi², D. Pinelli³, S. Mosconi³, C. Doglioni¹, M. Falconi¹, L. Gianni¹; ¹Milan, IT, ²Rozzano, IT, ³Bergamo, IT
- 13:35 - 13:35 737P - TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study
M. Sinn¹, J. Budczies¹, F. Damm¹, P. Lohneis¹, R. Schmuck¹, D. Treue¹, J. Striefler¹, M. Bahra¹, U. Pelzer¹, A. Jühling¹, H. Bläker¹, S. Bischoff¹, H. Oettle², C. Denkert³, H. Riess¹, B. Sinn⁴; ¹Berlin, DE, ²Friedrichshafen, DE, ³Heidelberg, DE, ⁴Houston, TX/US
- 13:35 - 13:35 738P - Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC)

P. Corrie¹, W. Qian², A. Gopinathan², M. Williams², R. Brais², J. Valle³, B. Basu², S. Falk⁴, C. Iwuji⁵, H. Wasan⁶, D. Palmer⁷, M. Scott-Brown⁸, J. Wadsley⁹, S. Arif¹⁰, L. Bax², P. Bundi², R. Skells², A. Neesse¹¹, D. Tuveson¹², D. Jodrell²; ¹Cambridge, Cambridgeshire/GB, ²Cambridge, GB, ³Manchester, GB, ⁴Bristol, GB, ⁵Leicester, GB, ⁶London, GB, ⁷Liverpool, GB, ⁸Coventry, GB, ⁹Sheffield, South Yorkshire/GB, ¹⁰Cardiff, GB, ¹¹Göttingen, DE, ¹²New York, NY/US

- 13:35 - 13:35 739P - Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma
M. Reni, S. Zanon, C. Pircher, M. Chiaravalli, M. Macchini, U. Peretti, E. Mazza, G. Balzano, P. Passoni, R. Nicoletti, P.G. Arcidiacono, G. Pepe, C. Doglioni, S. Romi, D. Ceraulo, M. Falconi, L. Gianni; Milan, IT
- 13:35 - 13:35 740P - The impact of UGT1A1 genetic polymorphism on safety in unresectable pancreatic cancer patients receiving FOLFIRINOX therapy: A subset analysis of JASPAC 06 study
H. Shirasu¹, K. Omae², H. Fujii³, N. Mizuno⁴, M. Ozaka⁵, H. Ueno⁵, S. Kobayashi⁶, K. Uesugi⁷, N. Kobayashi⁶, H. Hayashi⁸, K. Sudo⁹, N. Okano¹⁰, Y. Horita¹¹, K. Kamei¹², Y. Seigo³, H. Takafumi⁵, T. Henmi⁵, M. Kobayashi⁵, A. Todaka², A. Fukutomi¹³; ¹Shizuoka, JP, ²Sunto-Gun, JP, ³Tochigi, JP, ⁴Nagoya, JP, ⁵Tokyo, JP, ⁶Yokohama, JP, ⁷Matsuyama, JP, ⁸Sapporo, JP, ⁹Chiba, JP, ¹⁰Mitaka, JP, ¹¹Toyama, JP, ¹²Osakasayama, JP, ¹³Shizuoka, Shizuoka/Jp
- 13:35 - 13:35 744P - Overall survival and immunologic responses in metastatic pancreatic adenocarcinoma (PDAC) on PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX)
J.R. Hecht¹, A. Naing², G. Falchook³, M. Patel⁴, J. Infante⁵, R. Aljumaily⁶, D. Wong¹, K. Autio⁷, Z. Wainberg¹, M. Javle², J. Bendell⁵, S. Pant⁶, A. Hung⁸, P. Van Vlasselaer⁸, G. Brown⁹, M. Off⁸, K. Papadopoulos¹⁰; ¹Los Angeles, CA/US, ²Houston, TX/US, ³New York, CO/US, ⁴Sarasota, FL/US, ⁵Nashville, TN/US, ⁶Oklahoma City, OK/US, ⁷New York, US, ⁸Redwood City, US, ⁹New York, CA/US, ¹⁰San Antonio, TX/US
- 13:35 - 13:35 741P - Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone
R. Hubner¹, L.-T. Chen², C.-P. Li³, G. Bodoky⁴, A. Dean⁵, K.-H. Lee⁶, D. Cunningham⁷, J. Siveke⁸, F. Braithe⁹, F. de Jong¹⁰, B. Belanger¹¹, R. Walls¹¹, P. Mody¹¹, D. von Hoff¹², A. Wang-Gillam¹³; ¹Manchester, GB, ²Tainan, TW, ³Taipei, TW, ⁴Budapest, HU, ⁵Subiaco, AU, ⁶Seoul, KR, ⁷Sutton, GB, ⁸Essen, DE, ⁹Las Vegas, US, ¹⁰Zug, CH, ¹¹Basking Ridge, US, ¹²Phoenix, AZ/US, ¹³St. Louis, US
- 13:35 - 13:35 742P - IDO1 expression as biomarker in erlotinib-treated patients with advanced pancreatic cancer: translational results from the AIO-PK0104 phase III trial
S. Kruger¹, S. Ormanns¹, V. Roesgen¹, M.-L. Legenstein¹, M. Haas¹, B. Westphalen², P. Diewell¹, M. Schnurr¹, V. Heinemann¹, T. Kirchner¹, S. Boeck¹; ¹Munich, DE, ²München, DE
- 13:35 - 13:35 743P - Tumor hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)

A. Hendifar¹, A. Bullock², T. Seery³, L. Zheng⁴, D. Sigal⁵, P. Ritch⁶, F. Braiteh⁷, M. Zalupski⁸, N. Bahary⁹, W. Harris¹⁰, J. Pu¹¹, F. Lian¹¹, J. Zhu¹¹, W. Wu¹², D. Chondros¹², P. Jiang¹², S.R. Hingorani¹³; ¹Los Angeles, US, ²Boston, US, ³Irvine, US, ⁴Baltimore, MD/US, ⁵La Jolla, CA/US, ⁶Milwaukee, US, ⁷Las Vegas, US, ⁸Ann Arbor, US, ⁹Pittsburgh, US, ¹⁰Seattle, US, ¹¹Tucson, US, ¹²San Diego, CA/US, ¹³Seattle, Wa, US

- 13:35 - 13:35 745P - Circulating levels of ADAM12, a stromal activation biomarker, are predictive of survival in pancreatic ductal adenocarcinoma (PDAC)
H. van Laarhoven¹, H. Damhofer², V. Veenstra¹, C. Waasdorp¹, L. van Rijssen¹, F. Dijk¹, J. Wilmink¹, M. Besselink¹, O. Busch¹, J.P. Medema¹, J. Shiansong Li³, R. Jiang³, D. Pierce³, M. Bijlsma¹; ¹Amsterdam, NL, ²København N, NL, ³Summit, NJ/US
- 13:35 - 13:35 746P - COnsensus statement on mandatory measurements in PANcreatic cancer trials for systemic treatment of unresectable disease (COMM-PACT)
L.B. van Rijssen¹, E. ter Veer¹, M. Besselink¹, R. Mali¹, J. Berlin², S. Boeck³, F. Bonnetain⁴, T. Conroy⁵, G. Deplanque⁶, D. Goldstein⁷, B. Glimelius⁸, J. Neoptolemos⁹, M. Reni¹⁰, W. Scheithauer¹¹, J. van der Meer¹, J. Wilmink¹, M. van der Poel¹, O. Busch¹, M. van Oijen¹, H. van Laarhoven¹; ¹Amsterdam, NL, ²Nashville, TN/US, ³Munich, DE, ⁴Besançon, CEDEX/FR, ⁵Vandoeuvre Les Nancy, CEDEX/FR, ⁶Vevey, CH, ⁷Sydney, NSW/AU, ⁸Uppsala, SE, ⁹Liverpool, GB, ¹⁰Milan, IT, ¹¹Vienna, AT
- 13:35 - 13:35 747P - Phase I study of resminostat/S-1 combination in patients with pre-treated biliary tract or pancreatic cancer
C. Morizane¹, I. Ohno², H. Ueno¹, S. Mitsunaga³, Y. Hashimoto³, T. Okusaka¹, S. Kondo¹, M. Sasaki³, Y. Sakamoto¹, H. Takahashi², R. Hara¹, S. Kobayashi¹, O. Nakamura¹, M. Ikeda²; ¹Tokyo, JP, ²Kashiwa, Chiba/Jp, ³Kashiwa, JP
- 13:35 - 13:35 748P - Comparisons of outcomes of patients with advanced pancreatic cancer (APC) treated with FOLFIRINOX (FX) versus gemcitabine and nab-paclitaxel (GN): A population-based cohort study
N. Papneja¹, C. Olson², H. Chalchal³, M. Moser¹, N. Iqbal², K. Haider², A. Zaidi², J. Shaw¹, B. Brunet², D.-A. Dueck², T. Abbas², S. Ahmed²; ¹Saskatoon, SK/CA, ²Saskatoon, CA, ³Regina, Saskatchewan/CA
- 13:35 - 13:35 749P - Musculoskeletal Events (MSEs) with PEGPH20 treatment and management in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDA)
A. Bullock¹, P. Vervaeet², W. Wu², D. Chondros², S.R. Hingorani³, A. Hendifar⁴; ¹Boston, US, ²San Diego, CA/US, ³Seattle, Wa, US, ⁴Los Angeles, US
- 13:35 - 13:35 750P - Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma
M. Noel¹, M. Lowery², D. Ryan³, B. Wolpin³, A. Bullock³, C. Britten⁴, B. Jin⁵, B. Ganguly⁶, C. Taylor⁷, D. Yin⁷, D. Wunderlich⁸, E. Gamelin⁷, D. Linehan¹; ¹Rochester, US, ²New York, US, ³Boston, US, ⁴Charleston, US/US, ⁵Cambridge, MA/US, ⁶South San Francisco, US, ⁷San Diego, CA/US, ⁸Groton, US
- 13:35 - 13:35 751P - Metastatic pancreatic cancer: Real Life data from the german quality of life and translational research on pancreatic cancer study (QoliXane)

S.-E. Al-Batran¹, A. Reichart¹, C. Schoenherr¹, G. zur Hausen¹, C. Pauligk², B. Schöttger³, G. Siegler⁴, S. Doerfel⁵, A. Aldaoud⁶, L. Hahn⁷, J. Schubert⁸, O. Waidmann¹, J. Trojan², H.-G. Hoeffkes⁹, R. Schnell¹⁰, M. Koenigsmann¹¹, W. Blau¹², J. Uhlig¹³, N. Homann¹⁴, T. Götze¹; ¹Frankfurt Am Main, DE, ²Frankfurt, DE, ³Würzburg, DE, ⁴Nürnberg, DE, ⁵Dresden, DE, ⁶Leipzig, DE, ⁷Berlin, DE, ⁸Riesa, DE, ⁹Fulda, DE, ¹⁰Frechen, DE, ¹¹Hannover, DE, ¹²Giessen, DE, ¹³No City Provided, NA, ¹⁴ Wolfsburg, DE

- 13:35 - 13:35 752P - FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis from the nation-wide multicenter observational study (JASPAC06)
- N. Kobayashi¹, K. Omae², Y. Horita³, H. Ueno⁴, N. Mizuno⁵, K. Uesugi⁶, K. Sudo⁷, M. Ozaka⁴, H. Hayashi⁸, N. Okano⁹, K. Kamei¹⁰, A. Yamaguchi¹¹, S. Kobayashi¹, S. Suzuki¹², S. Ishihara¹³, T. Uchiyama¹⁴, A. Todaka², A. Fukutomi²; ¹Yokohama, JP, ²Sunto-Gun, JP, ³Toyama, JP, ⁴Tokyo, JP, ⁵Nagoya, JP, ⁶Matsuyama, JP, ⁷Chiba, JP, ⁸Sapporo, JP, ⁹Mitaka, JP, ¹⁰Osakasayama, JP, ¹¹Kure, JP, ¹²Yamagata, JP, ¹³Toyoake, JP, ¹⁴Kikugawa, JP
- 13:35 - 13:35 753P - Quality of life (QoL) of patients (pts) with metastatic pancreatic cancer (mPAC) initiating first-line chemotherapy (CT) in routine practice
- B. Laquente¹, T. Macarulla², C. Bugés³, M. Martín², C. García⁴, E. Dotor⁵, S. Merino⁶, L. Visa², T. Martín⁷, M. Pedraza⁸, R. Guardedeño⁹, L. Pellín¹⁰, D. Vilanova¹⁰, A. García⁹; ¹L'hospitalet De Llobregat, ES, ²Barcelona, ES, ³Badalona, ES, ⁴Burgos, ES, ⁵Sabadell, ES, ⁶Reus, ES, ⁷Salamanca, ES, ⁸León, ES, ⁹Girona, ES, ¹⁰Madrid, ES
- 13:35 - 13:35 754P - Impact of the duration of diabetes mellitus (DM) on the outcomes of metastatic pancreatic cancer (mPC) treated with gemcitabine (G): A retrospective study
- K. OHASHI¹, S. Iizumi¹, A. Kuchiba¹, M. Ikeda², Y. Sakamoto¹, S. Kondo¹, C. Morizane¹, H. Ueno¹, K. Osame¹, S. Mitsunaga³, I. Ohno², H. Imaoka³, Y. Hashimoto³, H. Takahashi², M. Sasaki³, T. Okusaka¹; ¹Tokyo, JP, ²Kashiwa, Chiba/Jp, ³Kashiwa, JP
- 13:35 - 13:35 755P - Prognostic value of neutrophil-lymphocyte ratio in first line treatment for metastatic pancreatic adenocarcinoma
- Y.S. Rho, J. Ranger, S. Hamalova, I. Barrera, A. Mamo, G. Batist, P. Kavan; Montreal, QC/CA
- 13:35 - 13:35 756P - Treatment patterns, clinical characteristics, and outcomes of patients (pts) with metastatic pancreatic cancer (MPC) treated with nab-paclitaxel (nab-P) plus gemcitabine (GEM) in real-life practice: ANICE-Pac trial
- A. Fernández¹, M. Salgado¹, A. García², E. Buxó³, R. Vera⁴, J. Adeva⁵, P. Jiménez⁶, G. Quintero⁷, C. Llorca⁸, M. Cañabate⁹, L. López¹⁰, A. Muñoz⁵, P. Ramírez¹¹, P. González¹², C. López¹³, M. Reboredo¹⁴, E. Gallardo¹⁵, M. Sánchez¹⁶, J. Gallego¹⁷, C. Guillén⁵; ¹Ourense, ES, ²Girona, ES, ³Barcelona, ES, ⁴Pamplona, ES, ⁵Madrid, ES, ⁶Oviedo, ES, ⁷No City Provided, NA, ⁸Elda, ES, ⁹Xàtiva, ES, ¹⁰Toledo, ES, ¹¹Cádiz, ES, ¹²Vigo, ES, ¹³Santander, ES, ¹⁴A Coruna, ES, ¹⁵Pontevedra, ES, ¹⁶Murcia, ES, ¹⁷Elche, ES
- 13:35 - 13:35 757P - Safety and efficacy of gemcitabine/nabpaclitaxel in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis

J. Ventriglia¹, M.M. Laterza¹, B. Savastano¹, A. Petrillo¹, G. Tirino¹, L. Pompella¹, A. Pappalardo¹, M. Orditura¹, F. Ciardiello², F. De Vita²; ¹Napoli, IT, ²Naples, IT

13:35 - 13:35 758P - Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer

B. Han¹, H.S. Kim¹, D.R. Choi¹, B.Y. Shim², K.H. Lee³, J.W. Kim⁴, J.H. Kim⁵, H.Y. Kim¹, H. Song¹, D.Y. Zang¹; ¹Anyang, KR, ²Suwon, KR, ³Daegu, KR, ⁴Seongnam, KR, ⁵Seoul, KR

13:35 - 13:35 759P - PANOVA: a phase II study of TTFIELDS (150 kHz) with concomitant standard chemotherapy for front-line advanced pancreatic adenocarcinoma: Updated efficacy results

M. Kueng¹, C. Guillen-Ponce², F. Rivera Herrero³, J. Gallego Plazas⁴, J. Lopez-Martin², M. Benavides⁵; ¹Fribourg, CH, ²Madrid, ES, ³Santander, ES, ⁴Elche, Alicante/ES, ⁵Malaga, ES

13:35 - 13:35 760P - Risk factors for febrile neutropenia (FN) in unresectable/recurrent pancreatic cancer(PC) patients(pts) receiving FOLFIRINOX (FFX) from JASPAC06 study

M. Sasaki¹, H. Ueno¹, K. Omae², T. Goto³, G. Murohisa⁴, N. Mizuno⁵, M. Ozaka¹, S. Kobayashi⁶, K. Uesugi⁷, N. Kobayashi⁶, H. Hayashi⁸, K. Sudo⁹, N. Okano¹⁰, Y. Horita¹¹, K. Kamei¹², T. Hosokawa¹, T. Henmi¹, M. Kobayashi¹, A. Todaka¹³, A. Fukutomi¹³; ¹Tokyo, JP, ²Shizuoka, JP, ³Asahikawa, JP, ⁴Hamamatsu, JP, ⁵Nagoya, JP, ⁶Yokohama, JP, ⁷Matsuyama, JP, ⁸Sapporo, JP, ⁹Chiba, JP, ¹⁰Mitaka, JP, ¹¹Toyama, JP, ¹²Osakasayama, JP, ¹³Shizuoka, Shizuoka/JP

13:35 - 13:35 761P - A Phase I study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastasized pancreatic cancer

K. Lee¹, R. Molenaar¹, R. Klaassen¹, M. Bijlsma¹, M. Weterman¹, D. Richel¹, M. Wymenga², H. van Laarhoven¹, J. Wilmink¹; ¹Amsterdam, NL, ²Enschede, NL

13:35 - 13:35 762P - Impact of advances in systemic chemotherapy for unresectable pancreatic ductal adenocarcinoma (PDAC) in Alberta, Canada

R. Lee-Ying¹, J. Loree², W. Cheung³, P. Tang¹; ¹Calgary, CA, ²Vancouver, British Columbia/CA, ³Calgary, AB/CA

13:35 - 13:35 763P - Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)

S.R. Hingorani¹, A. Bullock², T. Seery³, L. Zheng⁴, D. Sigal⁵, P. Ritch⁶, F. Braiteh⁷, M. Zalupski⁸, N. Bahary⁹, W. Harris¹⁰, J. Pu¹¹, C. Aldrich¹¹, S. Khelifa¹¹, W. Wu¹², D. Chondros¹², P. Jiang¹², A. Hendifar¹³; ¹Seattle, WA, US, ²Boston, US, ³Irvine, US, ⁴Baltimore, MD/US, ⁵La Jolla, CA/US, ⁶Milwaukee, US, ⁷Las Vegas, US, ⁸Ann Arbor, US, ⁹Pittsburgh, US, ¹⁰Seattle, US, ¹¹Tucson, US, ¹²San Diego, CA/US, ¹³Los Angeles, US

13:35 - 13:35 764P - Crucial relationship of neural wiskott aldrich syndrome protein(N-WASP) and lysyl oxidase-like 2(LOXL2) in the promotion of pancreatic cancer metastasis

H. Kim, J.S. Park; Seoul, KR

13:35 - 13:35 765P - The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced small intestine cancer

K. Takayoshi¹, W. Okamoto², S. Hironaka³, Y. Honma⁴, H. Ebi⁵, R. Nakanishi¹, T. Kajiwara⁶, T. Kudo⁷, T. Tamura⁸, Y. Komatsu⁹, H. Hara¹⁰, D. Naruge¹¹, T. Moriwaki¹², I. Miki², T. Sudo¹³, S. Nomura⁴, S. Fujii², K. Shitara¹⁴, A. Ohtsu¹⁴, T. Yoshino¹⁴; ¹Fukuoka, JP, ²Kashiwa, JP, ³Chiba, Chiba/Jp, ⁴Tokyo, JP, ⁵Kanazawa, JP, ⁶Matsuyama, JP, ⁷Suita, Osaka/Jp, ⁸Osaka, JP, ⁹Sapporo, Hokkaido/Jp, ¹⁰Saitama, JP, ¹¹Mitaka, Tokyo, JP, ¹²Tsukuba, Ibaraki/Jp, ¹³Chiba, JP, ¹⁴Kashiwa, Chiba/Jp

- 13:35 - 13:35 766P - Frequent ERBB3 (HER3) activating mutations in small bowel adenocarcinomas
L. Cabel¹, I. Bieche², T. Aparicio³, M. Svrcek², A. Zaanan², P. Afchain², F. Di Fiore⁴, J.-M. Gornet⁵, D. Le Corre², S. Vacher², C. Callens², V. Bernard², P. Laurent-Puig², F.-C. Bidard²; ¹Paris, CEDEX 14/FR, ²Paris, FR, ³Bobigny, CEDEX/FR, ⁴Rouen, FR, ⁵Paris, CEDEX 10/FR
- 13:35 - 13:35 767TiP - CLASS-05 trial: A randomized controlled phase III trial of cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) + systemic chemotherapy versus systemic chemotherapy alone for patients with limited peritoneal carcinomatosis of gastric cancer
H. Liu¹, G. Li¹, J. Yu¹, X. Su², Y. Sun³, J. Hu⁴, L. Huang⁵, Z. Zhou¹, Y. Li¹, J. Yu¹, H. Wei¹, J. Peng¹, Z. Wu⁶, H. Chen⁷, S. Cui¹, Y. Hu¹; ¹Guangzhou, CN, ²Beijing, CN, ³Shanghai, CN, ⁴Chengdu, CN, ⁵Fuzhou, CN, ⁶Meizhou, CN, ⁷Zhongshan, CN
- 13:35 - 13:35 768TiP - A prospective multicenter, phase II trial (NAC-GA trial) to evaluate the effect of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival in patients with borderline resectable pancreatic cancer
K.-I. Okada, T. Shimokawa, S. Hirono, M. Kawai, M. Miyazawa, Y. Kitahata, H. Yamaue; Wakayama, JP
- 13:35 - 13:35 769TiP - Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG1407)
A. Fukutomi¹, J. Mizusawa², H. Katayama², T. Okusaka², T. Ito³, N. Okano⁴, N. Mizuno⁵, M. Ikeda⁶, M. Ueno⁷, K. Shioji⁸, M. Ozaka², S. Shimizu⁹, Y. Sakamoto², S. Kondo², K. Kawabe³, J. Eba², H. Ishii¹⁰, H. Fukuda², J. Furuse²; ¹Shizuoka, Shizuoka/Jp, ²Tokyo, JP, ³Fukuoka, JP, ⁴Mitaka, JP, ⁵Nagoya, JP, ⁶Kashiwa, Chiba/Jp, ⁷Yokohama, JP, ⁸Niigata, JP, ⁹Saitama, JP, ¹⁰Matsuyama, JP
- 13:35 - 13:35 770TiP - NIFE-trial: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced biliary-tract cancer: An open label, randomized, multicenter phase II trial of the AIO
T. Etrich¹, L. Perkhofer¹, A. Berger², T. Seufferlein¹; ¹Ulm, DE, ²Halle, DE
- 13:35 - 13:35 771TiP - A feasibility study of TAS-118 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer
A. Takashima¹, D. Takahari², N. Ishizuka¹, H. Katai¹, T. Nakajima³, M. Ohashi¹, S. Mikami³, S. Takahashi¹, T. Sano¹, N. Boku⁴, K. Yamaguchi¹; ¹Tokyo, JP, ²Nagoya, Aichi/Jp, ³Kanagawa, JP, ⁴Kawasaki, Kanagawa/Jp
- 13:35 - 13:35 772TiP - A phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma

H. Shoji¹, H. Miyamoto², H. Hara³, D. Takahari¹, N. Machida⁴, T. Esaki⁵, K. Nagashima⁶, K. Aoki¹, K. Honda¹, Y. Nagata¹, T. Miyamoto¹, N. Boku⁷, K. Kato¹; ¹Tokyo, JP, ²Osaka, JP, ³Saitama, JP, ⁴Shizuoka, JP, ⁵Fukuoka, JP, ⁶Chiba, JP, ⁷Kawasaki, Kanagawa/JP

- 13:35 - 13:35 773TiP - PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma
- A. Zaanan¹, E. Samalin², C. Louvet¹, C. Montérymard³, F. Khemissa⁴, O. Bouche⁵, S. Louafi⁶, F. Ghiringhelli⁷, P. Bernard⁸, B. Chibaudel⁹, P. Artru¹⁰, Y. Molin¹¹, N. Baba-Hamed¹, O. Romano¹², T. Aparicio¹³, P. Michel¹⁴, P. Rougier¹, D. Tougeron¹⁵, S. Manfredi¹⁶, J. Taieb¹; ¹Paris, FR, ²Montpellier, FR, ³Dijon, FR, ⁴Perpignan, FR, ⁵Reims, FR, ⁶Corbeil Essonnes, FR, ⁷Dijon, Cedex/FR, ⁸Hyerres, FR, ⁹Levallois Perret, FR, ¹⁰Lyon, CEDEX 8/FR, ¹¹Lyon, FR, ¹²Lille, CEDEX/FR, ¹³Bobigny, CEDEX/FR, ¹⁴Rouen, FR, ¹⁵Poitiers, CEDEX/FR, ¹⁶Rennes, CEDEX/FR
- 13:35 - 13:35 774TiP - Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma (PDA)
- E. Van Cutsem¹, A. Hendifar², M. Reni³, L. Zheng⁴, M. Ducreaux⁵, W. Harris⁶, P. Corrie⁷, T. Seery⁸, D. Chondros⁹, A. Bullock¹⁰; ¹Leuven, BE, ²Los Angeles, US, ³Milan, IT, ⁴Baltimore, MD/US, ⁵Paris, FR, ⁶Seattle, US, ⁷Cambridge, Cambridgeshire/GB, ⁸Irvine, US, ⁹San Diego, CA/US, ¹⁰Boston, US
- 13:35 - 13:35 775TiP - KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
- R. Finn¹, S. Chan², A. Zhu³, J. Knox⁴, A.-L. Cheng⁵, A. Siegel⁶, O. Bautista⁷, M. Kudo⁸; ¹Los Angeles, CA/US, ²Shatin, HK, ³Boston, US, ⁴Toronto, ON/CA, ⁵Taipei, TW, ⁶Kenilworth, US, ⁷Kenilworth, NJ/US, ⁸Osaka, JP
- 13:35 - 13:35 776TiP - PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
- I. Chen¹, J. Johansen¹, T. Zimmers², C. Dehlendorff³, V. Kirk Parner¹, B. Vittrup Jensen¹, D. Nielsen¹; ¹Herlev, DK, ²Indianapolis, IN/US, ³Copenhagen, DK
- 13:35 - 13:35 777TiP - ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer
- L.-T. Chen¹, Y.-K. Kang², M. Tanimoto³, N. Boku⁴; ¹Tainan, TW, ²Seoul, Songpa-gu/KR, ³Osaka-Shi, JP, ⁴Kawasaki, Kanagawa/JP
- 13:35 - 13:35 778TiP - ATTRACTION-05 (ONO-4538-38/BMS CA209844): a randomized, multicenter, double-blind, placebo- controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer
- M. Terashima¹, Y.-W. Kim², T.-S. Yeh³, H.C. Chung⁴, J.-S. Chen³, N. Boku⁵, Y.-K. Kang⁶, L.-T. Chen⁷, M. Sasako⁸; ¹Shizuoka, Shizuoka/JP, ²Goyang, KR, ³Taoyuan, TW, ⁴Seoul, KR, ⁵Kawasaki, Kanagawa/JP, ⁶Seoul, Songpa-gu/KR, ⁷Tainan, TW, ⁸Nishinomiya, JP

- 13:35 - 13:35 779TiP - Adjuvant oxaliplatin plus S-1 (SOX) with concurrent radiotherapy versus SOX alone for gastric cancer with D2 lymph node dissection and high risk factors: a randomized phase III trial
X. Wang¹, Y. Shen¹, Q. Li¹, M. Qiu¹, Z. Li¹, J. Liu¹, H. Gou¹, Y. Yang¹, D. Cao¹, C. Yi¹, D. Luo¹, H. Zhu¹, Z. Zhou¹, S. Tan², W. Wang², X. Ye³, X. Su⁴, F. Xu¹, F. Bi¹; ¹Chengdu, CN, ²Guiyang, CN, ³Deyang, CN, ⁴Leshan, CN
- 13:35 - 13:35 780TiP - Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: Phase III EPIC trial
E. Hutt¹, A. Da Silva¹, D. Pannier¹, E. Bogart¹, F. El-Hajbi¹, S. Villet¹, S. Clisant², M.-C. Le Deley¹, A. Adenis²; ¹Lille, FR, ²Lille, CEDEX/FR
- 13:35 - 13:35 781TiP - Apatinib and irinotecan combination treatment in first-line chemotherapy refractory esophageal squamous cell carcinoma: A phase I dose escalation study
J. Jia, J. Yu, Z. Sun, Y. Yang, C. Liu, Y. Xiao, X. Zhang; Beijing, CN
- 13:35 - 13:35 782TiP - PANOVA-3: A phase 3 study of TTFIELDS with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC)
O. Farber¹, U. Weinberg², Z. Bomzon¹, M. Giladi¹, E. Kirson¹; ¹Haifa, IL, ²Luzern, CH
- 13:35 - 13:35 GYNAECOLOGICAL CANCERS
A. Gonzalez Martin, Madrid, ES
- 13:35 - 13:35 943P - Location of mutation in BRCA2 gene and survival in patients with ovarian cancer
S.I. Labidi-Galy¹, T. Olivier¹, M. Rodrigues², D. Ferraioli³, O. Derbel³, A. Bodmer¹, P. Petignat¹, N. Chopin³, O. Tredan⁴, P. Heudel⁴, V. Viassolo¹, A. Ayme¹, P.O. Chappuis¹, M.-H. Stern², C. Houdayer², D. Stoppa-Lyonnet², A. Buisson³, L. Golmard², V. Bonadona³, I. Ray-Coquard⁴; ¹Geneva, CH, ²Paris, FR, ³Lyon, FR, ⁴Lyon, CEDEX/FR
- 13:35 - 13:35 944P - POLE mutations and MSI were positive predictive factors for progression free survival in endometrial cancer patients at the risk of recurrence
A. Nyuya¹, J. Haraga¹, T. Nagasaka¹, K. Nakamura¹, T. Haruma¹, T. Nishida¹, K. YASUI¹, T. Fujiwara¹, A. Goel², H. Masuyama¹; ¹Okayama, JP, ²Texas, TX/US
- 13:35 - 13:35 945P - Evaluation of circulating tumor DNA in patients with ovarian cancer harboring somatic PIK3CA or KRAS mutations
A. Ogasawara¹, T. Hihara², A. Yabuno¹, S. Shimoyokkaichi¹, D. Shintani¹, Y. Ikeda³, K. Tai², K. Fujiwara³, K. Watanabe², K. Hasegawa¹; ¹Hidaka, JP, ²Tsukuba, JP, ³Saitama, JP
- 13:35 - 13:35 946P - Predictive and prognostic value of tumor cells and circulating plasma free DNA in advanced epithelial ovarian carcinoma
J. Martinez-Garcia¹, A. Minguela Puras¹, P.A. Cascales Campos¹, M.V. Martinez Sanchez¹, J. Gil Martinez¹, F. Barcelo Valcarcel¹, J.R. Rodriguez Hernandez¹, M.A. Torroba Caron¹, A. Soto-Gutierrez¹, P. Sanchez Henarejos¹, A. Puertes Boix¹, S. Montenegro Luis¹, P. Ruiz Carreño¹, E. Rodriguez Braun², M.D. Jimenez Lucas¹, M. Guirao Marín¹, M.A. Cuellar Rivas¹, A. Cano Jimenez¹, A. Anton Garcia¹, J.L. Alonso Romero¹; ¹Murcia, ES, ²Cartagena, ES

- 13:35 - 13:35 947P - Circulating tumor cells as prognostic marker in ovarian carcinoma: Results from the ANTHALYA study
T. de La Motte Rouge¹, P. Cottu², P. Pautier³, M. Provansal⁴, A. Floquet⁵, F. Selle⁶, M. Fabbro⁷, E. Kalbacher⁸, P. Follana⁹, A.F. Lesoin¹⁰, J. Medioni⁶, J. Dupin¹¹, R.-M. Ferri¹¹, F.-C. Bidard⁶, C. Dubot¹², R. Rouzier¹², F. Joly Lobbedez¹³; ¹Rennes, FR, ²Paris, CEDEX 5/FR, ³Villejuif, CEDEX/FR, ⁴Marseille, FR, ⁵Bordeaux, CEDEX/FR, ⁶Paris, FR, ⁷Montpellier, CEDEX 5/FR, ⁸Besançon, CEDEX/FR, ⁹Nice, CEDEX 2/FR, ¹⁰Lille, CEDEX/FR, ¹¹Boulogne Billancourt, FR, ¹²St. Cloud, FR, ¹³Caen, CEDEX 5/FR
- 13:35 - 13:35 948P - Genomic instability is associated with increased immune infiltration and PDL1 expression in epithelial ovarian cancer
A. Leary¹, C. Genestie¹, Y. Boursin¹, J. Adam¹, A. Leformal-Ensarguex¹, S. Gouy¹, P. Morice¹, E. Bentivegna¹, P. Pautier², J. Michels¹, B. Job¹, M. Deloger¹, S. Mesnage¹, A. Auguste¹; ¹Villejuif, FR, ²Villejuif, CEDEX/FR
- 13:35 - 13:35 949P - Tumor microenvironment in high serous ovary cancer: Characterization of the infiltration pattern and analysis of its prognostic value
F. Herrera Cañizares¹, A. Chipirliu¹, C. Caballero¹, A. HERREROS POMARES¹, S. Calabuig Fariñas¹, L. Valdivieso¹, M. Mosqueda¹, J. Marí Alexandre¹, E. Jantus¹, J. Gilabert², C. Camps Herrero¹; ¹Valencia, ES, ²València, ES
- 13:35 - 13:35 950P - Gene mutational analyses in 154 ovarian cancer (OC) samples from the ROSiA study of front-line bevacizumab (BEV)-containing therapy for OC
R. Deurloo¹, N. Colombo², C. Mendiola³, F. Selle⁴, J. Korach⁵, M. Oestergaard¹, M. Bylesjo⁶, H.-J. Urban¹, Y. Ghazi¹, A. Oza⁷; ¹Basel, CH, ²Milan, IT, ³Madrid, ES, ⁴Paris, FR, ⁵Tel Hashomer, IL, ⁶Edinburgh, GB, ⁷Toronto, CA
- 13:35 - 13:35 951P - A retrospective study of endocrine therapy in high grade serous ovarian carcinoma
B. Stanley¹, R. Hollis², J. Towler², X. Yan², H.D.S.M. Nunes³, T. Rye², S. Herrington², M. Churchman², M. MacKean¹, F. Nussey², C. Gourley²; ¹Edinburgh, Midlothian/GB, ²Edinburgh, GB, ³Lisbon, PT
- 13:35 - 13:35 952P - Randomised prospective study of maintenance tamoxifen versus post adjuvant chemotherapy surveillance only in advanced ovarian cancer patients
V. Goel¹, A. Jain¹, S. Tiwari¹, M. John², V. Talwar³, P. Dash³, N. Patnaik⁴, S. Raina³, D.C. Doval¹; ¹New Delhi, Rohini/IN, ²Trissur, IN, ³New Delhi, IN, ⁴Delhi, IN
- 13:35 - 13:35 953P - A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1)
M.R. Mirza¹, J. Wang², M. Mau-Sørensen¹, M. Birrer³, X. Wang², M. Jørgensen¹, Z.-Y. Zhang², H. Roed¹, S. Malander⁴, F. Nielsen⁵, L. Bjørge⁶, U. Lassen¹, L. Boufercha¹, K. Brøsen⁵, V. Kansra², J. Mäenpää⁷; ¹Copenhagen, DK, ²Waltham, MA/US, ³Boston, MA/US, ⁴Lund, SE, ⁵Odense, DK, ⁶Bergen, NO, ⁷Tampere, FI

- 13:35 - 13:35 954P - Prospective cohort study of bevacizumab plus standard platinum based chemotherapy as front-line treatment for advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer: Japanese Gynecologic Oncology Group study (JGOG3022)
K. Kato¹, S. Komiyama¹, N. Takeshima¹, H. Takano², A. Inoue³, A. Hongo⁴, M. Asai-Sato⁵, A. Arakawa⁶, K. Kubushiro¹, S. Kamiura⁷, T. Sugiyama⁸; ¹Tokyo, JP, ²Kashiwa, JP, ³Ehime, JP, ⁴Takamatsu, JP, ⁵Yokohama, JP, ⁶Nagoya, JP, ⁷Osaka, JP, ⁸Morioka, Iwate/JP
- 13:35 - 13:35 955P - A landmark analysis of overall survival in PR-OC patients treated with chemotherapy and bevacizumab using early tumor shrinkage as covariate
A. Sostelly, F. Jaminion, F. Mercier; Basel, CH
- 13:35 - 13:35 956P - Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC)
H. Wopen¹, P. Wimberger², A. Mustea³, G. Oskay-Oezcelik¹, M. Keller¹, R. Richter¹, J. Harde⁴, S. Klawitter⁵, A. Wegenaer⁶, O. Tomé⁷, J. Sehouli¹; ¹Berlin, DE, ²Dresden, DE, ³Greifswald, DE, ⁴Freiburg, DE, ⁵Grenzach Wyhlen, DE, ⁶Grenzach-Wyhlen, DE, ⁷Karlsruhe, DE
- 13:35 - 13:35 957P - Feasibility and effectiveness of multiple lines of bevacizumab-based therapy in patients with recurrent tuboovarian carcinoma
V. Kallage, A.T. Kurbacher, S. Herz, G. Kolberg, C. Schweitzer, J. Kurbacher, C. Kurbacher; Bonn, DE
- 13:35 - 13:35 958P - Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC) (on behalf of the North-Eastern German Society of Gynaecological Oncology, NOGGO)
J. Sehouli¹, A. Mustea², G. Oskay-Oezcelik¹, J. Grabowski¹, M. Keller¹, R. Richter¹, J. Harde³, S. Klawitter⁴, A. Wegenaer⁵, O. Tomé⁶, P. Wimberger⁷; ¹Berlin, DE, ²Greifswald, DE, ³Freiburg, DE, ⁴Grenzach Wyhlen, DE, ⁵Grenzach-Wyhlen, DE, ⁶Karlsruhe, DE, ⁷Dresden, DE
- 13:35 - 13:35 959P - A prospective study to evaluate the role of Cytoreductive surgery (CRS)+ HIPEC in advanced epithelial ovarian malignancy -100 consecutive cases -INDIAN experience
R. Kumar C¹, S. Somashekhar², A. Rauthan³, R. Ashwin², Y. Ramya²; ¹Bangalore, IN, ²Bengaluru, IN, ³Bangalore, Karnataka/IN
- 13:35 - 13:35 960P - Role of laparotomy-based parameters in assessment of optimal primary debulking surgery and long-term outcomes in patients with stage iiic epithelial ovarian cancer
M. Zhou, X. Wang, L. Li, C. Wang, D. Wang; Shenyang, CN
- 13:35 - 13:35 961P - ICON7: Ovarian cancer, platinum second-line chemotherapy and overall survival
A. Cook¹, A. Embleton², G. Jayson³, R. Kaplan⁴, G. Kristensen⁵, M. Parmar⁶, J. Pfisterer⁷, E. Pujade-Lauraine⁸, A. Oza⁹, T. Perren¹⁰; ¹London, GB, ²London, UK/GB, ³Manchester, GB, ⁴Leeds, GB, ⁵Oslo, NO, ⁶London, London/GB, ⁷Kiel, DE, ⁸Paris, FR, ⁹Toronto, Ontario/CA, ¹⁰Leeds, Yorkshire/GB
- 13:35 - 13:35 962P - Disease burden during the "watchful waiting" period in patients with recurrent ovarian cancer
B. Harrow¹, K. Travers², B. Davis³, P. Smith³, A. Gilligan³, M. Bala²; ¹Waltham, US, ²Waltham, MA/US, ³Cambridge, MA/US

- 13:35 - 13:35 963P - Impact of chemotherapy (CT) in heavily pretreated BRCA1/2 mutation carrier ovarian cancer (BMCOC) patients (pts)
V. Rodriguez Freixinos¹, L. Fariñas Madrid¹, M. Gil Martin¹, P. Barretina², M. Romeo Marin³, G. Villacampa Javierre¹, C. VIAPLANA¹, B. Pardo¹, H. Ahmed Ouahid², S. Recalde⁴, J.M. Piulats Rodriguez⁵, M. Gomez⁶, A. Gil-Moreno¹, E. Sala², S. Martinez-Román⁶, C. Melendez², E. Carballas⁶, R. Dienstmann¹, A. Oaknin¹; ¹Barcelona, ES, ²Girona, ES, ³Badalona, Barcelona/ES, ⁴L'hospitalet, ES, ⁵Barcelona, Barcelona/ES, ⁶Badalona, ES
- 13:35 - 13:35 964P - Modeling and impact of organ function on the population pharmacokinetics (PK) of niraparib, a selective poly (ADP-Ribose) polymerase (PARP)-1 and -2 inhibitor
Z.-Y. Zhang¹, X. Wang¹, J. Wang¹, H. Pentikis², V. Kansra¹; ¹Waltham, MA/US, ²Baltimore, MD/US
- 13:35 - 13:35 965P - Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21)
A. Oza¹, P. Combe², J. Ledermann³, S. Marschner⁴, A. Amit⁵, T. Huzarski⁶, N. Lainez Milagro⁷, A. Savarese⁸, C. Scott⁹, M. Nicoletto¹⁰, P. Harter¹¹, T. Enomoto¹², G. Sonke¹³, J.-W. Kim¹⁴, I. Vergote¹⁵, A. Allen¹⁶, E. Pujade-Lauraine²; ¹Toronto, Ontario/CA, ²Paris, FR, ³London, GB, ⁴Sydney, AU, ⁵Haifa, IL, ⁶Szczecin, PL, ⁷Pamplona, ES, ⁸Rome, IT, ⁹Melbourne, AU, ¹⁰Padova, IT, ¹¹Essen, DE, ¹²Niigata, Niigata/JP, ¹³Amsterdam, NL, ¹⁴Seoul, KR, ¹⁵Leuven, BE, ¹⁶Gaithersburg, MD/US
- 13:35 - 13:35 966P - Outcomes of the combination trabectedin and pegylated liposomal doxorubicin (T-PLD) in recurrent platinum-sensitive ovarian cancer (OC): a GINECO cohort study
F. Selle¹, P.-E. Heudel², Y. Tazi³, A. Pozet⁴, A.-C. Hardy-Bessard⁵, J. Meunier⁶, L. Gladieff⁷, J.-P. Lotz¹, M. Provansal⁸, P. Augereau⁹, J.-S. Frenel¹⁰, N. Bonichon-Lamichhane¹¹, H. Orfeuvre¹², F. Pommeret¹³, M. Torres-Macque¹, E. Kalbacher¹⁴, C. Roemer-Becuwe¹⁵; ¹Paris, FR, ²Lyon, FR, ³Strasbourg, FR, ⁴Besançon, FR, ⁵Plerin-Sur-mer, FR, ⁶Orleans, FR, ⁷Toulouse, FR, ⁸Marseille, FR, ⁹Angers, FR, ¹⁰Saint-Herblain, FR, ¹¹Bordeaux, FR, ¹²Bourg-En-bresse, FR, ¹³Villejuif, FR, ¹⁴Besançon, CEDEX/FR, ¹⁵Nancy, FR
- 13:35 - 13:35 967P - An observational, multicenter, prospective study of trabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC)
D. Reichert¹, P. Wimberger², U. Ringsdorf³, M. Krohn⁴, I. Runnebaum⁵; ¹Berlin, DE, ²Dresden, DE, ³Wetzlar, DE, ⁴Rotenburg, DE, ⁵Jena, DE
- 13:35 - 13:35 968P - PRO-002, a phase Ib dose-escalation study of NUC-1031 with carboplatin for recurrent ovarian cancer
S. Blagden¹, A. Sukumaran², L. Spiers³, V. Woodcock³, A. Lipplaa¹, S. Nicum¹, C. Gnanaranjan², D. Harrison⁴, E. Ghazaly²; ¹Oxford, GB, ²London, GB, ³Oxford, Oxfordshire/GB, ⁴Fife, GB
- 13:35 - 13:35 969P - Phase 1/2 trials of peptides cocktail vaccine for resistant cervical and ovarian cancer: QoL analysis
S. Takeuchi¹, M. Kagabu², T. Nagasawa², H. Omi², Y. Nitta¹, H. Itamochi¹, T. Sugiyama²; ¹Morioka, Iwate/JP, ²Morioka, JP

- 13:35 - 13:35 970P - A phase 1 study of selinexor (S) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced ovarian (OC) or endometrial cancers (EC)
V. Makker¹, N. Boucicaut², K. Cadoo², R. Grisham², D. Hyman², R. O'Cearbhaill², A. Snyder Charen², W. Tew², M. Martin², C. Aghajanian²; ¹New York, US, ²New York, NY/US
- 13:35 - 13:35 971P - Pazopanib and oral cyclophosphamide in women with platinum resistant epithelial ovarian cancers
S. Gulia, S. Gupta, J. Ghosh, J. Bajpai, A. Maheshwari, R. Kerkar, S. Thumkur, K. Deodhar, M. Thakur; Mumbai, IN
- 13:35 - 13:35 972P - Apatinib as a salvage treatment in gynecologic cancer patients failed from two or more lines of prior chemotherapy
C. Xie, X. Jin; Wenzhou, CN
- 13:35 - 13:35 973P - A GINECO phase II study of Navitoclax (ABT 263) in women with platinum resistant/refractory recurrent ovarian cancer (ROC)
P.E. Brachet¹, M. Fabbro², A. Leary³, J. Medioni⁴, P. Follana⁵, A. Lesoin⁶, J.-S. Frenel⁷, S. Abadie Lacourtoisie⁸, A. Floquet⁹, L. Gladiéff¹⁰, B. You¹¹, C. Gavaille¹², E. Kalbacher¹³, M. Briand¹, P.-A. Just⁴, C. Blanc-Fournier¹, A. Leconte¹, J. Lequesne¹, L. Poulain¹, F. Joly Lobbedez¹; ¹Caen, FR, ²Montpellier, CEDEX 5/FR, ³Villejuif, FR, ⁴Paris, FR, ⁵Nice, CEDEX 2/FR, ⁶Lille, FR, ⁷Saint-Herblain, CEDEX/FR, ⁸Angers, FR, ⁹Bordeaux, CEDEX/FR, ¹⁰Toulouse, Haute-Garonne/FR, ¹¹Pierre Bénite, CEDEX/FR, ¹²Vandoeuvre Les Nancy, CEDEX/FR, ¹³Besançon, CEDEX/FR
- 13:35 - 13:35 974P - Reproductive function in patients (pts) with malignant ovarian germ cell tumors (MOGCT) following chemotherapy (ChT)
D. Chekini¹, A. Tryakin¹, M. Fedyanin¹, I. Pokataev¹, A. Bulanov², T. Zakharova¹, K. Zhordania¹, O. Sekhina¹, S. Tjulandin¹; ¹Moscow, RU, ²Teheran, IR
- 13:35 - 13:35 975P - Preoperative MRI versus intra-operative frozen section in surgical management of clinically early endometrial cancer
A. Maheshwari, R. Ranade, R. Kerkar, S. Ts, K. Deodhar, B. Rekhi, S. Menon, S. Gupta; Mumbai, IN
- 13:35 - 13:35 976P - Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients
J. Ko¹, G. Gelowitz², A. Tinker³, C. Holloway⁴, A. Kumar⁵; ¹Abbotsford, British Columbia/CA, ²Abbotsford, BC/CA, ³Vancouver, BC/CA, ⁴Victoria, BC/CA, ⁵Surrey, BC/CA
- 13:35 - 13:35 977P - Is chemotherapy worthwhile in patients with FIGO stage 1B, lymph nodes negative, grade 3 endometrial cancer?
C. Fontanella¹, S. Lepori², A. Barcellini², G. Maltese², C. Andreetta¹, E. Tripodi², F. Martinelli², A. Cerrotta², G. Bogani², A. Ditto², M. Signorelli², C. Scaffa², C. Sacco¹, F. Raspagliesi², D. Lorusso²; ¹Udine, IT, ²Milan, IT
- 13:35 - 13:35 978P - Significance of MSH2 promoter methylation in endometrial cancer with MSH2 deficiency
J. Haraga¹, T. Nagasaka¹, K. Nakamura¹, T. Haruma¹, T. Nishida¹, A. Nyuya¹, K. YASUI¹, T. Fujiwara¹, A. Goel², H. Masuyama¹; ¹Okayama, JP, ²Texas, TX/US

- 13:35 - 13:35 979P - Achievement of complete response (CR) in metastatic or recurrent cervical cancer (MRCC): Does it matter?
J.F. Grau Béjar, V. Rodriguez Freixinos, L. Fariñas Madrid, G. Villacampa Javierre, A. Gil-Moreno, R. Verges, M.A. Pérez Benavente, A. García, R. Dienstmann, A. Oaknin; Barcelona, ES
- 13:35 - 13:35 980P - Factors Negatively Affecting Voluntary Cervical Cancer Screening Among Educated Indians Above Poverty Line
A. Shukla¹, R. Dokala², J. Philomen²; ¹Bangalore, Karnataka/IN, ²Bangalore, IN
- 13:35 - 13:35 982P - Phase II study of the safety and efficacy of oral capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma
S. Lepori¹, C. Fontanella², G. Maltese¹, E. Tripodi¹, F. Martinelli¹, G. Bogani¹, A. Ditto¹, M. Signorelli¹, C. Scaffa¹, F. Raspagliesi¹, D. Lorusso¹; ¹Milan, IT, ²Udine, IT
- 13:35 - 13:35 983P - Investigation of the clinicopathological features of vulva cancer: a retrospective survey of the JGOG Net Work study
S. Nishio¹, T. Shibata², S. Yamaguchi³, H. Kanao⁴, A. Kojima⁵, M. Takekuma⁶, A. Tozawa⁷, H. Tokunaga⁸, E. Miyagi⁹, H. Kato⁹, K. Kurihara¹⁰, T. Yanase¹¹, K. Ushijima¹², M. Mikami², T. Sugiyama⁵; ¹Kurume, Fukuoka/J, ²Isehara, JP, ³Akashi, JP, ⁴Tokyo, JP, ⁵Morioka, JP, ⁶Shizuoka, JP, ⁷Kawasaki, JP, ⁸Sendai, JP, ⁹Yokohama, JP, ¹⁰Saitama, JP, ¹¹Niigata, JP, ¹²Kurume, JP
- 13:35 - 13:35 984TiP - Japan CHARLOTTE: Characterizing the cross-sectional approach to ovarian cancer: Genetic testing of BRCA
T. Sugiyama¹, D. Aoki², T. Enomoto³, N. Takeshima², Y. Watanabe⁴, K. Fujikawa⁵, T. Jinnai⁵, J. Kigawa⁶; ¹Morioka, JP, ²Tokyo, JP, ³Niigata, Niigata/J, ⁴Sendai, JP, ⁵Osaka, JP, ⁶Matsue, JP
- 13:35 - 13:35 985TiP - IMagyn050 / GOG3015 / ENGOT-ov39: A randomized, double-blind, phase III study of atezolizumab vs placebo combined with chemotherapy + bevacizumab in stage III-IV ovarian, fallopian tube & peritoneal cancers (OC)
K. Moore¹, A. Okamoto², F. Wu³, Y. Lin⁴, S. Pignata⁵; ¹Oklahoma City, Oklahoma/US, ²Tokyo, JP, ³Beijing, CN, ⁴South San Francisco, US, ⁵Napoli, IT
- 13:35 - 13:35 986TiP - A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy
A. Gonzalez Martin¹, L. Rojas², P. Braly³, J. Barter⁴, D. O'Malley⁵, A. Oza⁶, A. Haggerty⁷, C. Vulsteke⁸, D. Provencher⁹, W. Graybill¹⁰, Y. Li¹¹, I. Malinowska¹¹, M.R. Mirza¹², I. Vergote⁸, B. Pothuri¹³, B. Monk¹⁴; ¹Madrid, ES, ²Sioux Falls, SD/US, ³Covington, LA/US, ⁴Silver Spring, MD/US, ⁵Columbus, OH/US, ⁶Toronto, Ontario/CA, ⁷Philadelphia, PA/US, ⁸Leuven, BE, ⁹Montreal, CA, ¹⁰Charleston, SC/US, ¹¹Waltham, MA/US, ¹²Copenhagen, DK, ¹³New York, NY/US, ¹⁴Phoenix, AZ/US
- 13:35 - 13:35 987TiP - OReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer

E. Pujade-Lauraine¹, N. Colombo², R. Glasspool³, B. Asselain¹, T. Huzarski⁴, J. Korach⁵, F. Marme⁶, M.R. Mirza⁷, A. Redondo⁸, G. Scambia⁹, C. Blakeley¹⁰, A. Milner¹¹, F. Selle¹, I. Vergote¹²; ¹Paris, FR, ²Milan, IT, ³Glasgow, GB, ⁴Szczecin, PL, ⁵Tel Hashomer, IL, ⁶Heidelberg, DE, ⁷Copenhagen, DK, ⁸Madrid, ES, ⁹Roma, IT, ¹⁰London, GB, ¹¹Cambridge, GB, ¹²Leuven, BE

- 13:35 - 13:35 988TiP - ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer
R. Kristeleit¹, D. Lorusso², A. Oaknin³, T. Safra⁴, E. Swisher⁵, I. Bondarenko⁶, T. Huzarski⁷, J. Klat⁸, V. Moiseyenko⁹, R.L. Póka¹⁰, L. Viola¹¹, C. Tankersley¹², L. Maloney¹³, S. Goble¹², C. Unger¹², A. Dowson¹², H. Giordano¹⁴, A. Oza¹⁵; ¹London, GB, ²Milan, IT, ³Barcelona, ES, ⁴Tel Aviv, IL, ⁵Seattle, WA/US, ⁶Dnepropetrovsk, UA, ⁷Szczecin, PL, ⁸Ostrava, CZ, ⁹Saint Petersburg, RU, ¹⁰Debrecen, HU, ¹¹Porto Alegre, BR, ¹²Boulder, CO/US, ¹³Boulder, Colorado/US, ¹⁴San Francisco, California/US, ¹⁵Toronto, Ontario/CA
- 13:35 - 13:35 989TiP - OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinum-resistant ovarian cancer
S. Nicum¹, V. Strauss¹, N. McGregor¹, I. McNeish², R. Roux¹, M. Hall³, A. Michael⁴, C. Roberts¹; ¹Oxford, GB, ²Glasgow, GB, ³Middlesex, GB, ⁴Surrey, GB
- 13:35 - 13:35 990TiP - A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
K. Moore¹, K. Cadoo², S. Chambers³, S. Ghamande⁴, G. Konecny⁵, A. Oza⁶, L.-M. Chen⁷, P. Konstantinopoulos⁸, J. Lea⁹, D. Spitz¹⁰, D. Uyar¹¹, G. Mugundu¹², N. Laing¹³, D. Strickland¹⁴, S. Jones¹⁴, H. Burris¹⁵, D. Spigel¹⁴, E. Hamilton¹⁴; ¹Oklahoma City, Oklahoma/US, ²New York, NY/US, ³Tucson, AZ/US, ⁴Augusta, GA/US, ⁵Los Angeles, CA/US, ⁶Toronto, Ontario/CA, ⁷San Francisco, CA/US, ⁸Boston, MA/US, ⁹Dallas, TX/US, ¹⁰West Palm Beach, FL/US, ¹¹Milwaukee, WI/US, ¹²Waltham, US, ¹³Waltham, MA/US, ¹⁴Nashville, TN/US, ¹⁵Nashville, US
- 13:35 - 13:35 991TiP - FORWARD I: A phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRa)-positive, platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or primary fallopian tube cancer
K. Moore¹, I. Vergote², A. Oaknin³, N. Colombo⁴, S. Banerjee⁵, A. Oza⁶, P. Pautier⁷, C. Kelly⁸, K. Malek⁹, M. Birrer¹⁰; ¹Oklahoma City, Oklahoma/US, ²Leuven, BE, ³Barcelona, ES, ⁴Milan, IT, ⁵London, GB, ⁶Toronto, Ontario/CA, ⁷Villejuif, CEDEX/FR, ⁸Dublin, IE, ⁹Waltham, MA/US, ¹⁰Boston, MA/US
- 13:35 - 13:35 992TiP - N-DUR: Matched pair pharmacodynamics study of neoadjuvant durvalumab in combination with chemotherapy in frontline ovarian cancer
J. Taylor¹, S. Westin², S. Sharafi¹, A. Jazaeri², M. Frumovitz¹, P. Soliman¹, A. Sood¹, K. Lu¹, K. Savelieva¹, G. Mills¹, A. Vergara-Silva³, R. Coleman¹; ¹Houston, TX/US, ²Houston, US, ³Gaithersburg, US
- 13:35 - 13:35 993TiP - Comparing doses and fractionation regimens for high dose rate brachytherapy in locally advanced cervical carcinoma: A randomized controlled trial
A. Manirakiza, F. Rubagumya, D. Msemo, N. Dharsee; Dar Es Salaam, TZ

13:35 - 13:35 HAEMATOLOGICAL MALIGNANCIES

J. Gomez Codina, Valencia, ES

- 13:35 - 13:35 1010P - Event free survival at 24 months: A new endpoint in diffuse large B-cell lymphoma
B. Cantos¹, J.C. Sanchez², V. Calvo de Juan³, M. Mendez Garcia¹, C. Maximiano Alonso³, D. Perez Callejo¹, F.F. Franco², L. Gutierrez Sanz³, A. Gonzaga López³, B. Nuñez², M. Provencio Pulla³; ¹Madrid, ES, ²Majadahonda, ES, ³Majadahonda, Madrid/ES
- 13:35 - 13:35 1011P - Interpreting progression-free survival and overall survival data in biosimilar clinical studies: considerations based on a recent rituximab biosimilar study
J. Amersdorffer¹, Y. Li², S. Alexandrova², A. Zube¹, E. Sasse¹, H. Mellstedt³; ¹Holzkirchen, DE, ²Princeton, US, ³Stockholm, SE
- 13:35 - 13:35 1012P - Role of prephase treatment prior to definitive chemotherapy in diffuse large B-cell lymphoma (DLBCL)
A. Rudresha¹, V. Asati², L. Kuntegowdanahalli², G. Babu², D. Lokanatha³, L. Jacob³, S. Babu², C. Premalatha², L. Rajeev², K.N. Lokesh¹, S. Saldanha², R. Patidar²; ¹Bangalore, Karnataka/IN, ²Bangalore, IN, ³Bengaluru, IN
- 13:35 - 13:35 1013P - The role of FDG-PET/CT in detecting bone marrow involvement in diffuse large b-cell lymphoma
A. Bulbul¹, E.A. Mino¹, S. Chouial¹, A. Bautista¹, A. Mustafa², H. Abboud³, S. Rashad⁴, T. Braik¹, K. Masoud¹; ¹Carlsbad, NM/US, ²Jammu, IN, ³Monee, IL/US, ⁴Chicago, IL/US
- 13:35 - 13:35 1014P - Evaluation of various prognostic scores and impact of cell of origin on survival in limited stage DLBCL: retrospective study
M. Rauf, S. Akhtar, T. Ahmed M. Elhassan, Q. Shaikh, F. A. Almugbel, M. N. Zahir, N. Bakshi, I. Maghfoor; Riyadh, SA
- 13:35 - 13:35 1015P - The prognostic impact of serum albumin and absolute neutrophil count in patients with newly diagnosed diffuse large B-cell lymphoma
B. Spassov, D. Vassileva, G. Arnaudov, S. Nikolov, G. Mihaylov, G. Balatzenko, M. Guenova; Sofia, BG
- 13:35 - 13:35 1016P - Autologous stem cell transplantation (ASCT) is safe and effective for the treatment of non-hodgkin lymphoma (NHL) in an elderly population of patients over 65 years old: A single center experience
M. TARDY¹, J. Viotti¹, A. Boscagli Melaine¹, A. Thyss², F. Peyrade², L. Gastaud¹; ¹Nice, FR, ²Nice, CEDEX 2/FR
- 13:35 - 13:35 1017P - Phenotypic and functional characterization of tumor infiltrating lymphocytes (TIL) grown from non-hodgkin lymphoma tumors: Implications for the development of novel therapies for lymphoma
L. Karyampudi¹, A. Gokuldass², M. Blaskovich², M. Fardis³, M. Lotze²; ¹Tampa, US, ²Tampa, FL/US, ³San Carlos, CA/US
- 13:35 - 13:35 1018P - International prognostic scores (IPS-7, IPS-3 and IPS-3 new) for prediction of FFS and OS in cases with Hodgkin Lymphoma. Which is more practical and accurate?
S. Paydas¹, M. Dogan², V. Ercolak³, G. Seydaoglu¹; ¹Adana, TR, ²Ankara, TR, ³Mersin, TR

- 13:35 - 13:35 1019P - Evaluation of indoleamine 2,3-dioxygenase expression (IDO), transforming growth factor beta (TGF-β) and interleukin 13 (IL13) expression on clinical outcome in patients with Hodgkin's lymphoma
T. Skrypets¹, O. Novosad², Y. Pastushenko², O. Skachkova¹, O. Gorbach¹, N. Khranovska¹, I. Kryachok¹; ¹Kiev, UA, ²Kyiv, UA
- 13:35 - 13:35 1020P - Clinical impact of atypical phenotypes in adult t cell lymphoma/leukemia among HTLV carriers
D. Enriquez Vera, G. De la Cruz Ku, J. Haro Varas, P. Rioja, Z. Morante Cruz, N.I. Valdiviezo Lama, R. Luque, E. Eyzaguirre, M. Lujan, A. Saavedra, M. Mayuri Monsefu, G. Ferreyros, M. Retamozo Alvarado, J. Vidal Ayllón, S. Neciosup Delgado, L.A. Mas Lopez; Lima, PE
- 13:35 - 13:35 1021P - Evaluation of the PI3K pathway in peripheral t-cell lymphoma
S.T. Lim¹, M.-L. Nairismägi¹, S.H. Tan¹, E.E. Thit¹, O. Politz², N. Liu², C.K. Ong¹; ¹Singapore, SG, ²Berlin, DE
- 13:35 - 13:35 1022P - Safety and tolerability of chemotherapy (CT) containing high doses of methotrexate (HD-MTX) and cytarabine (Ara-C) in patients with primary central nervous system lymphoma (PCNSL) and hepatitis B virus (HBV) infection
T. Calimeri, P. Lopedote, M. Repetto, A. Vignati, M. Sassone, C. Cecchetti, S. Perrone, M. Foppoli, G. Ciboddo, S. Girlanda, J. Peccatori, A. Chiara, M. Memoli, A. Ferreri; Milan, IT
- 13:35 - 13:35 1023P - Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice
M. Dreyling¹, G. Hess², G. Krekeler³; ¹Munich, DE, ²Mainz, DE, ³Berlin, DE
- 13:35 - 13:35 1024P - Clinical impact of FISH analysis in extramedullary plasmacytomas
H.A. Jung¹, C.H. Maeng², J.H. Jang², C.W. Jung², K. Kim²; ¹Hwaseong-Si, Gyeong-Ki-Do/KR, ²Seoul, KR
- 13:35 - 13:35 1025P - Independent predictors of one year mortality in patients with primary systemic immunoglobulin light chain cardiac amyloidosis
V. Srinivasalu¹, M. Subramaniam², A. Shanmugam², A. Philip², A. Susan², R. Prabhu², M. Unni², N. Sidharthan², W. Jose², S. N V², H. Ahamed², N. Mathew², P. Keechilat²; ¹Cochin, IN, ²Kochi, IN
- 13:35 - 13:35 1026P - Endoscopic evaluation of acute intestinal GVHD after allogeneic hematopoietic cell transplantation?
I. Tek, R. Altun, A. Gokmen, E. Soydan, M. Kurt Yuksel; Ankara, TR
- 13:35 - 13:35 1027P - Surveillance stool culture and its association with febrile neutropenia in patients with acute leukemia (AL) undergoing induction chemotherapy
N. Jadhav¹, B. Dubashi¹, J. Mandal¹, S. Kayal¹, J. Pattnaik¹, P. Madasamy², J. Singh¹; ¹Puducherry, IN, ²Pondicherry, IN
- 13:35 - 13:35 1028P - L-arginine – targeted for the anthracycline cardiotoxicity prevention in patients with acute leukemia of high cardiological risk
T. Lymanets, I. Skrypnyk, G. Maslova; Poltava, UA
- 13:35 - 13:35 1029P - Multiple myeloma complicated by concomitant cardiac pathology

S. Semochkin, E. Yurova; Moscow, RU

- 13:35 - 13:35 1030P - Evaluation of dose intensification of cytarabine in postremission therapy in older AML patients within the prospective phase II AMLSG 06-04 study
L. Häcker¹, M. Tassara², P. Brossart³, G. Held⁴, H. Horst⁵, M. Ringhoffer⁶, C.-H. Köhne⁷, S. Kremers⁸, A. Raghavachar⁹, G. Wulf¹⁰, H. Kirchen¹¹, D. Nachbaur¹², M. Wattad¹³, A. Benner¹⁴, D. Weber¹, V. Gaidzik¹, P. Paschka¹, K. Döhner¹, H. Döhner¹, R. Schlenk¹⁴; ¹Ulm, DE, ²Milan, IT, ³No City Provided, NA, ⁴Homburg, DE, ⁵Kiel, DE, ⁶Karlsruhe, DE, ⁷Oldenburg, DE, ⁸Lebach, DE, ⁹Wuppertal, DE, ¹⁰Göttingen, DE, ¹¹Trier, DE, ¹²Innsbruck, AT, ¹³Essen, DE, ¹⁴Heidelberg, DE
- 13:35 - 13:35 1031P - The EUROSki biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia
S. Rinaldetti¹, C. Sticht¹, M. Pffirmann², D. Nowak¹, A. Fabarius¹, W. Seifarth¹, B. Spiess¹, P. Panayiotidis³, M. Pagoni³, M. Dimou³, J. Dengler⁴, C. Waller⁵, T. Brümmendorf⁶, A. Burchert⁷, G. Freunek⁸, W.-K. Hofmann¹, F.-X. Mahon⁹, S. Saussele¹; ¹Mannheim, DE, ²Munich, DE, ³Athens, GR, ⁴Heilbronn, DE, ⁵Freiburg, DE, ⁶Aachen, DE, ⁷Marburg, DE, ⁸Straubing, DE, ⁹Bordeaux, FR
- 13:35 - 13:35 1032P - Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients
D. Bixby¹, C. Vigli², J. Jurcic³, R. Cook⁴, M. Sekeres⁵, D. Rizzieri⁶, J. Cortes⁷, R. Redner⁸, D. Steensma⁹, G. Roboz¹⁰, T. Moyo¹¹, M. McKeown¹², N. Waters¹², K. Stephens¹², E. di Tomaso¹², D. Roth¹², E. Stein³; ¹Ann Arbor, MI/US, ²Iowa City, IA/US, ³New York, NY/US, ⁴Portland, OR/US, ⁵Cleveland, US, ⁶Durham, US, ⁷Houston, US, ⁸Pittsburgh, PA/US, ⁹Boston, MA/US, ¹⁰New York, US/US, ¹¹Nashville, TN/US, ¹²Cambridge, US
- 13:35 - 13:35 1033P - Quantitative assessment of inotuzumab ozogamicin (InO) response relative to investigator's choice of chemotherapy (ICC) in adults with relapsed or refractory (R/R) CD22+ B-Cell acute lymphoblastic leukemia (ALL)
A. Ruiz-Garcia¹, E. Vandendries², D. Deangelo³, H. Kantarjian⁴, J. Boni⁵; ¹San Diego, CA/US, ²Cambridge, MA/US, ³Boston, MA/US, ⁴Houston, TX/US, ⁵Collegeville, PA/US
- 13:35 - 13:35 1034TiP - Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL): CHRONOS-3 and CHRONOS-4
J. Gerecitano¹, H. Zheng², L. Mongay Soler², R. Ito², D. Reis³, C. Lu², J. Shen², B. Childs⁴, P.L. Zinzani⁵; ¹New York, US, ²Whippany, NJ/US, ³São Paulo, BR, ⁴New York, New York/US, ⁵Bologna, IT
- 13:35 - 13:35 1035TiP - A multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO
E. Terpos¹, M. Dimopoulos², E. Kastritis², J. Schecter³, J. Ukrepec⁴, E. Smith⁵, P. Sonneveld⁶; ¹Athens, Neo Psychiko/GR, ²Athens, GR, ³Raritan, US, ⁴Horsham, PA/US, ⁵High Wycombe, GB, ⁶Rotterdam, NL
- 13:35 - 13:35 1036TiP - Phase 2, multicenter, single-arm, open label study evaluating the combination of daratumumab + cyclophosphamide, bortezomib and dexamethasone (Dara-CyBorD) in previously untreated and relapsed patients (pts) with multiple myeloma (MM)

M. Sharma¹, L. Ey², H. Parros³, S. Murphy², M. Darif⁴, A. Londhe⁵, J. Ukropec², M. Qi⁶, Y. Lutska¹, T. Lin¹, S. Gunawardena¹; ¹Horsham, US, ²Horsham, PA/US, ³Titusville, US, ⁴Titusville, PA/US, ⁵Titusville, NJ/US, ⁶Spring House, US

- 13:35 - 13:35 1037TiP - A double blind randomized phase 2 PILOT study of ERYASPASE in patients with acute lymphoblastic leukemia/lymphoma
N. Soule¹, C. Holford², R. Kay², D. Tilton², N. Biswas-Baldwin², I. El Hariry¹; ¹Cambridge, US, ²Lyon, FR
- 13:35 - 13:35 1038TiP - Phase 2 randomized study of daratumumab (dara), lenalidomide (R), bortezomib (V), and dexamethasone (d; Dara-RVd) vs. RVd in patients (pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT)
T. Lin¹, L. Hydutsky¹, H. Parros², S. Murphy³, H. Pei², A. Londhe⁴, J. Ukropec³, M. Qi⁵, Y. Lutska¹, M. Sharma¹; ¹Horsham, US, ²Titusville, US, ³Horsham, PA/US, ⁴Titusville, NJ/US, ⁵Spring House, US
- 13:35 - 13:35 1039TiP - Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma
M. Payton¹, D. Pinchasik², A. Mehta³, S. Goel⁴, J. Zain⁵, L. Sokol⁶, E. Jacobsen⁷, M. Patel⁸, S. Horwitz⁹, F. Meric-Bernstam¹⁰, A. Shustov¹¹, D. Weinstock⁷, M. Aivado², D. Annis²; ¹Cambridge, US, ²Cambridge, MA/US, ³Birmingham, US, ⁴Bronx, NY/US, ⁵Duarte, CA/US, ⁶Tampa, FL/US, ⁷Boston, MA/US, ⁸Sarasota, FL/US, ⁹New York, NY/US, ¹⁰Houston, US, ¹¹Seattle, WA/US
- 13:35 - 13:35 1040TiP - QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)
R. Schlenk¹, H. Dombret², S. Amadori³, P. Montesinos⁴, M. Levis⁵, M. Sekeres⁶, J. Cortes⁷, A. Perle⁸, O. Zernovak⁹, D. Mires⁹, N. Ge⁹, H. Zhang⁹, J. Hanyok⁹, S. Macintyre⁹, S. Gökmen⁹, K. Kobayashi⁹, H. Erba¹⁰; ¹Heidelberg, DE, ²Paris, FR, ³Rome, IT, ⁴Valencia, ES, ⁵Baltimore, MD/US, ⁶Cleveland, US, ⁷Houston, US, ⁸Philadelphia, US, ⁹Edison, US, ¹⁰Birmingham, US
- 13:35 - 13:35 1041TiP - MP0250 – a dual inhibitor of VEGF and HGF - plus bortezomib + dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM)
M. Raab¹, R. Ria², J. Schlenzka¹, T. Krahnke¹, J. Haunschild³, F. Herrmann³, U. Fiedler⁴, K. Dawson⁴, M. Stump³, K. Tadjalli Mehr¹, A. Harstrick³, A. Vacca², H. Goldschmidt¹; ¹Heidelberg, DE, ²Bari, IT, ³Schlieren, CH, ⁴Zurich, CH
- 13:35 - 13:35 NSCLC, EARLY STAGE
A.-M. Dingemans, Maastricht, NL
- 13:35 - 13:35 1279P - Factors predicting worse outcomes in patients with N0 lung adenocarcinoma of 3cm or smaller
J.-J. Hung, W.-H. Hsu; Taipei, TW
- 13:35 - 13:35 1280P - Regulatory variants in cancer-related pathway genes predict survival of patients with surgically resected non-small cell lung cancer
M.J. Hong, K.M. Shin, S.Y. Lee, J.H. Lee, J.Y. Park; Daegu, KR

- 13:35 - 13:35 1281P - Relevance between PD-L1 and radiological invasiveness in pathological stage I lung adenocarcinoma
G. Toyokawa¹, K. Takada², T. Okamoto², Y. Kozuma², T. Matsubara², S. Takamori², T. Akamine², M. Katsura², F. Shoji², Y. Maehara²; ¹Fukuoka, Fukuoka/JP, ²Fukuoka, JP
- 13:35 - 13:35 1282P - Characterization of cancer stem cell and immune microenvironment interactions in non-small cell lung cancer (NSCLC)
S. Torres, R. Sirera, C. Aguilar, S. Calabuig Fariñas, M. Mosqueda, A. Herreros-Pomares, E. Escorihuela, E. García del Olmo, E. Jantus-Lewintre, C. Camps Herrero; Valencia, ES
- 13:35 - 13:35 1283P - Non-invasive detection of lung cancer by identifying copy number aberrations in circulating cell-free DNA with next generation sequencing to aid early detection
F. Taylor¹, J. Bradford², P. Woll³, D. Teare², A. Cox⁴; ¹Sheffield, S. Yorks/GB, ²Sheffield, GB, ³Sheffield, South Yorkshire/GB, ⁴Rx, GB
- 13:35 - 13:35 1284P - HOXA-related long non-coding RNAs impact prognosis in early stage NSCLC patients
A. Navarro, S. Santasusagna, N. Vinolas Segarra, J.J. Castellano, J. Moises, S. Morales, J. Canals, C. Muñoz, J. Ramírez, R. Marrades, L. Molins, M. Monzo; Barcelona, ES
- 13:35 - 13:35 1285P - Association between polymorphisms in microRNA target sites and survival in early-stage non-small cell lung cancer
J.H. Lee, S.S. Yoo, M.J. Hong, J.E. Choi, S.Y. Lee, J.Y. Park; Daegu, KR
- 13:35 - 13:35 1286TiP - Neo-adjuvant chemo/immunotherapy for the treatment of resectable stage IIIA non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study" NADIM trial
V. Calvo de Juan¹, A. Insa Molla², M. Cobo Dols³, B. Massuti Sureda⁴, G. Lopez-Vivanco⁵, J. Casal Rubio⁶, J. de Castro⁷, M. Majem Tarruella⁸, R. Bernabe Caro⁹, J. Gonzalez-Larriba⁷, I.C. Barneto Aranda¹⁰, E. Nadal¹¹, A. Martinez Marti⁸, N. Vinolas Segarra⁸, M. Guillot Morales¹², D. Vicente Baz⁹, C. Camps Herrero¹³, M. Domine Gomez⁷, D. Rodriguez Abreu¹⁴, M. Provencio Pulla¹; ¹Majadahonda, Madrid/ES, ²Valencia, Valencia/ES, ³Malaga, ES, ⁴Alicante, ES, ⁵Bizcaia, ES, ⁶Vigo, ES, ⁷Madrid, ES, ⁸Barcelona, ES, ⁹Sevilla, ES, ¹⁰Cordoba, ES, ¹¹Barcelona, Barcelona/ES, ¹²Palma De Mallorca, ES, ¹³Valencia, ES, ¹⁴Las Palmas De Gran Canaria, ES
- 13:35 - 13:35 NSCLC, LOCALLY ADVANCED
P. Garrido Lopez, Madrid, ES
- 13:35 - 13:35 1290P - DNA repair gene expression in bronchial washing fluid as new molecular tool for clinical outcome decision
D. Schweigert¹, R. Askinis², J. Fadejeva², V. Sapoka², A. Krasauskas², S. Cicenias²; ¹Cairo, EG, ²Vilnius, LT
- 13:35 - 13:35 1291P - Diagnosis and monitoring of non-small cell lung cancer patients by next generation sequencing and droplet digital PCR on circulating tumor DNA
P. Vannuffel, C. De Rop; Gosselies, BE

- 13:35 - 13:35 1292P - Safety data from randomized phase II study of cisplatin (CDDP)+S-1 versus CDDP+pemetrexed (PEM) combined with thoracic radiotherapy (TRT) for locally advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): SPECTRA study
S. Niho¹, T. Yoshida², T. Akimoto³, K. Sakamaki⁴, T. Takahashi⁵, T. Seto⁶, M. Nishio⁷, N. Yamamoto⁷, T. Hida⁸, H. Okamoto⁹, T. Kurata¹⁰, M. Satouchi¹¹, K. Goto³, T. Yamanaka⁴, Y. Ohe⁷; ¹Kashiwa, Chiba/JP, ²Aichi, JP, ³Kashiwa, JP, ⁴Yokohama, JP, ⁵Shizuoka, JP, ⁶Fukuoka, Fukuoka/JP, ⁷Tokyo, JP, ⁸Nagoya, Aichi/JP, ⁹Yokohama, Kanagawa/JP, ¹⁰Hirakata, JP, ¹¹Akashi, JP
- 13:35 - 13:35 1293P - Preliminary analysis of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): NORA trial (GCEP 15/02)
M. Majem Tarruella¹, L. Isla Casado², M. Guirado³, B. Massuti Sureda⁴, A. Ortega Granados⁵, R. Marse Fabregat⁶, M. Domine Gomez⁷, R. de las Peñas⁸, M.T. Moran Bueno⁹, S. Vazquez Estevez¹⁰, M.A. Sala Gonzalez¹¹, J. Coves Sarto¹², J.M. Sánchez-Torres⁷, D. Vicente Baz¹³, J. Gonzalez-Larriba⁷, A. Paredes¹⁴, N. Farré¹, L. Fernández Fornos¹⁵, A. Mena⁶, M. Provencio Pulla¹⁶; ¹Barcelona, ES, ²Zaragoza, ES, ³Elche, Alicante/ES, ⁴Alicante, ES, ⁵Jaén, ES, ⁶Palma De Mallorca, ES, ⁷Madrid, ES, ⁸Castellón, ES, ⁹Badalona, Barcelona/ES, ¹⁰Lugo, ES, ¹¹Bilbao, ES, ¹²Palma De Mallorca, Islas Baleares/ES, ¹³Sevilla, ES, ¹⁴San Sebastián, ES, ¹⁵Elche, ES, ¹⁶Majadahonda, Madrid/ES
- 13:35 - 13:35 1294P - Real world data of practice patterns and outcomes for pemetrexed plus platinum as neoadjuvant chemotherapy in adenocarcinomas of lung from a tertiary cancer center of India: Looking beyond the usual paradigm
A. Kapoor¹, S. Zanwar², A. Joshi², V. Noronha², V. Patil², A. Chougule², A. Mahajan², P. Bhargava², K. Prabhash²; ¹Varanasi, Uttar Pradesh/IN, ²Mumbai, IN
- 13:35 - 13:35 NSCLC, METASTATIC
R. Dziadziuszko, Gdansk, PL
- 13:35 - 13:35 1309P - Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC)
B. Besse¹, P. Garrido Lopez², J. Puente², A. Cortot³, M.E. Olmedo Garcia², M. Perol⁴, M. Gil⁵, G. Chao⁶, J. Shahidi⁷, J. Bennouna⁸; ¹Villejuif, FR, ²Madrid, ES, ³Lille, FR, ⁴Lyon, CEDEX/FR, ⁵Warsaw, PL, ⁶Bridgewater, NJ/US, ⁷Indianapolis, US, ⁸Nantes, CEDEX/FR
- 13:35 - 13:35 1310P - Survival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study
F. de Marinis¹, F. Barlesi², A. Rittmeyer³, J. von Pawel⁴, J.-Y. Han⁵, M. Kozloff⁶, A. Spira⁷, L. Fehrenbacher⁸, D. Gandara⁹, W. Yu¹⁰, P. He¹¹, C. Yun¹⁰, M. Ballinger¹⁰, M. Gandhi¹⁰, S. Gadgeel¹²; ¹Milan, IT, ²Marseille, FR, ³Immenhausen, DE, ⁴Gauting, DE, ⁵Goyang, KR, ⁶Harvey, US, ⁷Fairfax, US, ⁸Vallejo, US, ⁹Sacramento, CA/US, ¹⁰South San Francisco, US, ¹¹South San Francisco, CA/US, ¹²Ann Arbor, US
- 13:35 - 13:35 1311P - LKB1 loss is a novel genomic predictor of de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma

F. Skoulidis¹, M. Hellman², M. Awad³, J. Gainor⁴, H. Rizvi⁵, B. Carter⁶, W. Denning⁶, P. Villalobos¹, E. Parra¹, Y. Elamin¹, J. Zhang¹, G. Leonardi⁷, D. Halpenny⁵, V. Papadimitrakopoulou⁶, I. Wistuba¹, J. Wolchok⁵, A. Shaw⁷, P. Jänne⁴, C. Rudin², J. Heymach¹; ¹Houston, TX/US, ²New York, NY/US, ³Boston, US, ⁴Boston, Ma, US, ⁵New York, US, ⁶Houston, US, ⁷Boston, MA/US

- 13:35 - 13:35 1312P - Prediction of survival with durvalumab in locally advanced or metastatic NSCLC using early tumor assessments
X. Zhang¹, K. Park², N. Rizvi³, P. Dennis¹, R. Narwal⁴, Y. Huang¹, R. Arani⁴, P. Mukhopadhyay⁴; ¹Gaithersburg, US, ²Seoul, KR, ³New York, NY, US, ⁴Gaithersburg, MD/US
- 13:35 - 13:35 1313P - Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK
D. Cortinovis¹, J. von Pawel², K. Syrigos³, J. Mazieres⁴, R. Dziadziuszko⁵, L. Fehrenbacher⁶, P. Conkling⁷, J. Goldschmidt⁸, C. Thomas⁹, R. Bordoni¹⁰, M. Kosty¹¹, F. Braiteh¹², P. He¹³, M. Ballinger¹⁴, M. Gandhi¹⁴, H. Patel¹⁴, D. Gandara¹⁵; ¹Monza, IT, ²Gauting, DE, ³Athens, GR, ⁴Toulouse, FR, ⁵Gdansk, PL, ⁶Vallejo, US, ⁷Norfolk, VA/US, ⁸Blacksburg, US, ⁹Scarborough, ME/US, ¹⁰Marietta, US, ¹¹La Jolla, US, ¹²Las Vegas, US, ¹³South San Francisco, CA/US, ¹⁴South San Francisco, US, ¹⁵Sacramento, US
- 13:35 - 13:35 1314P - Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK
J. von Pawel¹, K. Syrigos², J. Mazieres³, D. Cortinovis⁴, R. Dziadziuszko⁵, D. Gandara⁶, P. Conkling⁷, J. Goldschmidt⁸, C. Thomas⁹, R. Bordoni¹⁰, M. Kosty¹¹, F. Braiteh¹², S. Hu¹³, M. Ballinger¹³, H. Patel¹³, M. Gandhi¹³, L. Fehrenbacher¹⁴; ¹Gauting, DE, ²Athens, GR, ³Toulouse, FR, ⁴Monza, IT, ⁵Gdansk, PL, ⁶Sacramento, CA/US, ⁷Norfolk, VA/US, ⁸Blacksburg, US, ⁹Scarborough, ME/US, ¹⁰Marietta, US, ¹¹La Jolla, US, ¹²Las Vegas, US, ¹³South San Francisco, US, ¹⁴Vallejo, US
- 13:35 - 13:35 1315P - Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy
L. Crinò¹, P. Bidoli², F. Roila³, E. Cortesi⁴, M. Garassino⁵, F. Cappuzzo⁶, F. Grossi⁷, G. Tonini⁴, G. Sarobba⁸, G. Pinotti⁹, G. Numico¹⁰, R. Samaritani⁴, L. Ciuffreda¹¹, A. Frassoldati¹², M. Bregni¹³, A. Santo¹⁴, F.V. Piantedosi¹⁵, I. Alfonso¹⁵, F. De Marinis¹⁶, A. Delmonte¹⁷; ¹Perugia, (PG)/IT, ²Monza (mi), IT, ³Terni, IT, ⁴Roma, IT, ⁵Milan, IT, ⁶Ravenna, IT, ⁷Genova, IT, ⁸Nuoro, IT, ⁹Varese, IT, ¹⁰Alessandria, IT, ¹¹Torino, IT, ¹²Ferrara, IT, ¹³Busto Arsizio, IT, ¹⁴Verona, IT, ¹⁵Napoli, IT, ¹⁶Milano, IT, ¹⁷Meldola, Forlì-Cesena/IT
- 13:35 - 13:35 1316P - Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update
D. Wong¹, J. Schneider², R. Aljumaily³, M. Korn⁴, K. Autio⁵, J. Infante⁶, M. Patel⁷, K. Papadopoulos⁸, A. Naing⁹, N. Gabrail¹⁰, P. Munster⁴, J. Goldman¹, P. Van Vlasselaer¹¹, A. Hung¹¹, G. Brown¹², M. Off¹¹, E. Garon¹³; ¹Los Angeles, CA/US, ²Mineola, US, ³Oklahoma City, OK/US, ⁴San Francisco, CA/US, ⁵New York, US, ⁶Nashville, TN/US, ⁷Sarasota, FL/US, ⁸San Antonio, TX/US, ⁹Houston, TX/US, ¹⁰Ohio, US, ¹¹Redwood City, US, ¹²New York, CA/US, ¹³Santa Monica, US

- 13:35 - 13:35 1317P - Multicenter observational study of the efficacy and safety of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim analysis
K. Laktionov¹, A. Arzumanyan¹, L. Bolotina¹, V. Breder¹, N. Buevich², A. Danilova¹, E. Filippova³, A. Kornietskaya¹, M. Kramchaninov³, E. Kushniruk², D. Latipova², F. Moiseenko³, T. Nikitina³, S. Orlov³, R. Orlova³, S. Protsenko², K. Sarantseva¹, D. Stroyakovskiy⁴, T. Ionova³; ¹Moscow, RU, ²Saint-Petersburg, RU, ³Saint Petersburg, RU, ⁴Moscow, Krasnogorski District/RU
- 13:35 - 13:35 1318P - Italian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients
M. Garassino¹, E. Cortesi², F. Grossi³, R. Chiari⁴, H. Soto Parra⁵, S. Cascinu⁶, F. Cognetti², D. Turci⁷, L. Blasi⁸, C. Bengala⁹, E. Mini¹⁰, E. Baldini¹¹, T. Gamucci¹², G.L. Ceresoli¹³, P. Antonelli¹⁴, E. Vasile¹⁵, M. Pagano¹⁶, M. Macerelli¹⁷, A. Lagroscino¹⁸, F. De Marinis¹⁹; ¹Milan, IT, ²Roma, IT, ³Genova, IT, ⁴Perugia, IT, ⁵Catania, IT, ⁶Ancona, IT, ⁷Ravenna, IT, ⁸Palermo, IT, ⁹Grosseto, IT, ¹⁰Firenze, IT, ¹¹Lucca, IT, ¹²Sora, Frosinone/IT, ¹³Bergamo, IT, ¹⁴Busto Arsizio, IT, ¹⁵Pisa, IT, ¹⁶Reggio Emilia, IT, ¹⁷Udine, IT, ¹⁸Bari, IT, ¹⁹Milano, IT
- 13:35 - 13:35 1319P - Efficiency of nivolumab in the treatment of second-line advanced non-squamous non-small cell lung cancer (NSCLC) in Spain
P. González¹, N. Ortega-Joaquín², M. Provencio Pulla³, C. Garrido¹, M. Echave²; ¹Madrid, ES, ²Pozuelo De Alarcón (madrid), ES, ³Majadahonda, Madrid/ES
- 13:35 - 13:35 1320P - Use of nivolumab in elderly patients with advanced non-squamous NSCLC: Results from the Italian expanded access program (EAP)
M.R. Migliorino¹, A. Gelibter², F. Grossi³, D. Fagnani⁴, P. Bordi⁵, T. Franchina⁶, D. Turci⁷, L. Di Lauro², S. Cascinu⁸, L. Calabro⁹, M. Brighenti¹⁰, N. Tedde¹¹, A. Bearz¹², S. Giusti¹³, E. Vasile¹⁴, G. Surico¹⁵, G. Carteni¹⁶, P. Marchetti¹, F. Verderame¹⁷, B. Melotti¹⁸; ¹Roma, IT, ²Rome, IT, ³Genova, IT, ⁴Vimercate, IT, ⁵Parma, IT, ⁶Messina, IT, ⁷Ravenna, IT, ⁸Ancona, IT, ⁹Siena, IT, ¹⁰Cremona, IT, ¹¹Olbia, IT, ¹²Pordenone, IT, ¹³Arezzo, IT, ¹⁴Pisa, IT, ¹⁵Lecce, IT, ¹⁶Napoli, IT, ¹⁷Palermo, IT, ¹⁸Bologna, IT
- 13:35 - 13:35 (Withdrawn)
- 13:35 - 13:35 1322P - Real life experience with nivolumab in patients (pts) with advanced non-squamous NSCLC (nSq-NSCLC) exhibiting KRAS mutations: The Italian Expanded Access Program (EAP)
F. Cappuzzo¹, P. Bidoli², R. Chiari³, A. Chirco⁴, D. Turci¹, A. Ardizzoni⁵, A. Santoro⁶, C. Natoli⁷, G. Francini⁸, M. Giordano⁹, G. Borra¹⁰, C. Defferrari¹¹, L. Livi¹², A. Berruti¹³, M. Minelli¹⁴, E. Ricevuto¹⁵, A. Illiano¹⁶, G. Puppo¹⁷, A. Delmonte¹⁸, A. Misino¹⁹; ¹Ravenna, IT, ²Monza, IT, ³Perugia, IT, ⁴Bergamo, IT, ⁵Bologna, IT, ⁶Rozzano, (MI)/IT, ⁷Chieti, IT, ⁸Siena, IT, ⁹San Fermo Della Battaglia, CO/IT, ¹⁰Novara, IT, ¹¹Genova, IT, ¹²Florence, IT, ¹³Brescia, IT, ¹⁴Roma, IT, ¹⁵L'aquila, IT, ¹⁶Napoli, IT, ¹⁷Pisa, IT, ¹⁸Meldola, IT, ¹⁹Bari, IT
- 13:35 - 13:35 1323P - Baseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients

G. Martínez Bernal¹, L. Mezquita², E. Auclin³, R. Ferrara⁴, D. Planchard², J. Remon Masip², J. Lahmar², M.-E. Boucher², C. CARAMELLA², J. Adam², A. Gazzah², J.-C. Soria⁵, B. Besse²; ¹Sevilla, ES, ²Villejuif, FR, ³Paris, FR, ⁴Verona, IT, ⁵Villejuif, CEDEX/FR

13:35 - 13:35 1324P - Practical effectiveness efficacy and safety of nivolumab for advanced non-small cell lung cancer: A retrospective multicenter analysis

K. Kobayashi¹, I. Nakachi², K. Naoki¹, Y. Oyamada¹, M. Nakamura¹, T. Inoue³, H. Tateno⁴, F. Sakamaki⁵, K. Sayama⁶, T. Terashima⁷, H. Koh⁸, D. Arai², H. Yasuda¹, I. Kawada¹, K. Soejima¹, T. Betsuyaku¹; ¹Tokyo, JP, ²Utsunomiya, JP, ³Sano, JP, ⁴Saitama, JP, ⁵Hachioji, JP, ⁶Kawasaki, JP, ⁷Ichikawa, JP, ⁸Tachikawa, JP

13:35 - 13:35 1325P - Generalization and representativeness of phase III immune checkpoint inhibitor trials in NSCLC
S.H. Yoo, M. Kim, B. Keam, T.M. Kim, D.-W. Kim, D.S. Heo; Seoul, KR

13:35 - 13:35 1326P - Long-term follow-up results of stage III-IV non-small-cell lung cancer (NSCLC) patients treated with an epitope derived from Indoleamine 2,3 Dioxygenase (IDO) in a phase I study

J. Kjeldsen, T. Iversen, L. Noerregaard, A. Mellempgaard, M. Andersen, I.-M. Svane; Herlev, DK

13:35 - 13:35 1327P - The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients

L. Mezquita¹, E. Auclin², M. Charrier¹, R. Ferrara³, J. Remon Masip¹, D. Planchard¹, S. Ponce Aix⁴, L. Paz-Ares⁴, J. Lahmar¹, L. Leroy⁵, C. Audigier-Valette⁶, J. Zeron-Medina Cuairan⁷, P. Garrido Lopez⁴, S. Brosseau², J. Mazieres⁸, C. CARAMELLA¹, J. Adam¹, N. Chaput⁹, J.-C. Soria⁹, B. Besse¹; ¹Villejuif, FR, ²Paris, FR, ³Verona, IT, ⁴Madrid, ES, ⁵Bordeaux, FR, ⁶Toulon, FR, ⁷Barcelona, ES, ⁸Toulouse, FR, ⁹Villejuif, CEDEX/FR

13:35 - 13:35 1328P - Association of single nucleotide polymorphisms with efficacy in nivolumab-treated NSCLC patients

E. Basak¹, S. Bins¹, S. El Bouazzaoui¹, S. Koolen¹, E. Oomen-De Hoop¹, C. van der Leest², A. van der Veldt¹, S. Sleijfer¹, R. Debets¹, R. van Schaik¹, R. Mathijssen¹, J. Aerts¹; ¹Rotterdam, NL, ²Breda, NL

13:35 - 13:35 1329P - Systematic inflammation and histologic grade in non-small cell lung carcinoma

K. Tsapakidis¹, N. Tsoukalas², C. Giaginis², I. Gioulbasanis², M. Tolia¹, E. Aravantinou², M. Galanopoulos², M. Kiakou², I. Kostakis², I. Litos¹, M. Liontos³, E. Sogka¹, V. Tzouda², K. Liaskonis², S. Theocharis²; ¹Larissa, GR, ²Athens, GR, ³Athens, Attiki/GR

13:35 - 13:35 1330P - Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine

R. Riedel¹, A. Kron¹, S. Michels², J. Fassunke¹, M. Scheffler², R. Fischer², L. Nogova², D. Abdulla², C. Heydt¹, F. Ueckerth¹, B. Pauli¹, M. Serke³, S. Krueger⁴, C. Grohe⁵, M. Sebastian⁶, D. Koschel⁷, K.-O. Kambartel⁸, T. Zander¹, R. Büttner¹, J. Wolf²; ¹Cologne, DE, ²Köln, DE, ³Hemer, DE, ⁴Düsseldorf, DE, ⁵Berlin, DE, ⁶Frankfurt Am Main, DE, ⁷Coswig, DE, ⁸Moers, DE

13:35 - 13:35 1331P - Detection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms

C. Zhou¹, M. Wang², Y. Cheng³, Y. Chen⁴, X. Ye¹, Y. Sun¹, X. Huang⁵, S. Patel⁵, Y. Chen¹, Y.-L. Wu⁶
 ; ¹Shanghai, CN, ²Beijing, CN, ³Jilin, CN, ⁴Wuhan, CN, ⁵Cambridge, GB, ⁶Guangzhou, CN

- 13:35 - 13:35 1332P - Influence of plasma T790M mutation on clinical decision after 1st generation EGFR-TKI resistance in a Real-world study
S. Zhang, L. Zhu, B. Xia, X. Chen, S. Ma; Hangzhou, CN
- 13:35 - 13:35 1333P - Detectability of RET fusions by amplicon-based next generation sequencing in nationwide lung cancer genomic screening project: LC-SCRUM-Japan
Y. Usui¹, K. Kirita², S. Matsumoto¹, Y. Ohe³, M. Nishio³, T. Seto⁴, M. Kodani⁵, K. Taima⁶, Y. Hattori⁷, T. Kohno³, K. Yoh², K. Goto⁸; ¹Kashiwa-Shi, JP, ²Kashiwa, Chiba/Jp, ³Tokyo, JP, ⁴Fukuoka, Fukuoka/Jp, ⁵Yonago, JP, ⁶Hirosaki, JP, ⁷Akashi, JP, ⁸Kashiwa, JP
- 13:35 - 13:35 1334P - A comparison of Bronchial Washing Fluid (BWF) and histologic samples in the analysis of EGFR mutation in NSCLC patients
X. Zhang¹, M. Ye¹, C. Li², Q. Hu¹, M. Du¹, X. Wang¹, Z. Gong¹, D. Zhang¹, Q. Hong¹, J. Hu¹, L. Mei¹, Y. Hou¹, X. Zhang¹; ¹Shanghai, CN, ²Shanghai, Changning/CN
- 13:35 - 13:35 1335P - EGFR T790M detection in TKI-naïve NSCLCs carrying sensitive EGFR mutations
G. Pinotti, R. Cerutti, N. Sahnane, L. Lettig, C. Albeni, A. Tuzi, F. Franzi, A. Pastore, F. Ogliari, F. Sessa, D. Furlan; Varese, IT
- 13:35 - 13:35 1336P - ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer
A. Mc Leer¹, M. Duruisseaux², J. Pinsolle¹, S. Dubourg¹, J. Mondet¹, M. Phillips-Houlbracq¹, N. Magnat¹, J. Fauré¹, A. Chatagnon¹, F. de Fraipont¹, M. Giaj Levra¹, A.C. Toffart¹, G. Ferretti¹, E. Brambilla², P. Hainaut³, D. Moro-Sibilot¹, S. Lantuéjoul¹; ¹La Tronche, FR, ²La Tronche, CEDEX 9/FR, ³Lyon, FR
- 13:35 - 13:35 1337P - A meta-analysis on epidemiology of ROS1 rearrangement in Asian and non-Asian population
V. Gupta¹, N. Godre¹, M. Alam²; ¹Mumbai, IN, ²West Ryde, AU
- 13:35 - 13:35 1338P - EGFR mutation detection in plasma cell-free DNA correlates with clinical outcomes in non-small cell lung cancer
J. Shi, J. Mong, T.M. Chin, Y.H. Lim, W.L. Tan, C.K. Toh, H.S. Tan, S.-W. Wong, A. Tee, D. Chan, K. Wong, S. Yeap, L. Ngo, Y.-O. Tan, M.-H. Tan; Singapore, SG
- 13:35 - 13:35 1339P - A large prospective cohort study of the clinical features of advanced lung cancer harboring HER2 aberrations (HER2-CS STUDY)
T. Tanaka¹, H. Yoshioka¹, A. Bessho², N. Ishikawa³, M. Yamasaki³, T. Shibayama⁴, K. Aoe⁵, T. Kozuki⁶, N. Fujimoto⁴, K. Genba⁷, Y. Ueda⁸, M. Inoue⁹, T. Murakami¹⁰, S. Kuyama¹¹, H. Kawai⁴, K. Fujitaka³, K. Inoue⁶, M. Takata¹², H. Yanai⁴, K. Kiura⁴; ¹Kurashiki, JP, ²Okayama, Okayama Prefecture/Jp, ³Hiroshima, JP, ⁴Okayama, JP, ⁵Ube, JP, ⁶Matsuyama, JP, ⁷Fukuyama, JP, ⁸Takamatsu, JP, ⁹Shimonoseki, JP, ¹⁰Himeji, JP, ¹¹Iwakuni, JP, ¹²Kyoto, JP
- 13:35 - 13:35 1340P - Transcriptomic analysis of bronchoalveolar lavage cells from advanced non-small cell lung cancer identifies overexpressed immunoglobulin genes of immunosuppressive implication

C.-H. Kuo, C.-Y. Liu, Y.-L. Lo, Y.-W. Wang, T.-H. Wang, C.-T. Yang; Taipei, TW

- 13:35 - 13:35 1341P - Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA
S. Goldberg¹, A. Narayan¹, A. Kole¹, R. Decker¹, J. Teysir¹, N. Carriero², A. Lee¹, R. Nemati¹, S. Nath¹, S. Mane¹, Y. Deng¹, N. Sukumar¹, D. Zelterman¹, D. Boffa¹, K. Politi¹, S. Gettinger³, L. Wilson¹, R. Herbst¹, A. Patel¹; ¹New Haven, US, ²New York, US, ³New Haven, CT/US
- 13:35 - 13:35 1342P - Detection of epidermal growth factor receptor mutations in circulating cell-free DNA versus tumor biopsy
I.-J. Oh¹, H.-W. Seo¹, H.-J. Cho¹, C.-K. Park¹, J.-H. Lim¹, Y.-C. Kim², Y.-D. Choi¹; ¹Hwasun, KR, ²Hwasun, Jeollanam-do/KR
- 13:35 - 13:35 1343P - Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) previously treated with 2nd-generation ALK TKIs
E. Felip Font¹, A. Shaw², B. Solomon³, T. Bauer⁴, S.-H. Ou⁵, S. Gadgeel⁶, R. Soo⁷, T. Seto⁸, J. Clancy⁹, L. James¹⁰, A. Abbattista¹¹, B. Besse¹²; ¹Barcelona, ES, ²Boston, MA/US, ³Melbourne, VIC/AU, ⁴Nashville, TN/US, ⁵Orange, CA/US, ⁶Ann Arbor, US, ⁷Singapore, SG, ⁸Fukuoka, Fukuoka/JP, ⁹Princeton, NJ/US, ¹⁰New York, US, ¹¹Milan, IT, ¹²Villejuif, FR
- 13:35 - 13:35 1344P - Brigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial
L. Bazhenova¹, S. Gettinger², C. Langer³, R. Salgia⁴, K. Gold¹, R. Rosell⁵, A. Shaw⁶, G. Weiss⁷, J. Haney⁸, V. Rivera⁸, D. Kerstein⁸, R. Camidge⁹; ¹La Jolla, CA/US, ²New Haven, CT/US, ³Philadelphia, PA/US, ⁴Chicago, IL/US, ⁵Badalona, Barcelona/ES, ⁶Boston, MA/US, ⁷Goodyear, AZ/US, ⁸Cambridge, MA/US, ⁹Aurora, CO/US
- 13:35 - 13:35 1345P - Intracranial efficacy of brigatinib (BRG) in patients (Pts) With crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases
S.-H. Ou¹, M. Tiseo², R. Camidge³, M.-J. Ahn⁴, R. Huber⁵, M. Hochmair⁶, S.-W. Kim⁴, H. West⁷, K. Reckamp⁸, J. Molina⁹, G. Liu¹⁰, A. Delmonte¹¹, S. Viteri¹², A. Bearz¹³, Y. Summers¹⁴, W. Reichmann¹⁵, D. Kerstein¹⁵, S. Gettinger¹⁶, D.-W. Kim⁴; ¹Orange, CA/US, ²Parma, IT, ³Aurora, CO/US, ⁴Seoul, KR, ⁵Munich, DE, ⁶Vienna, AT, ⁷Seattle, WA/US, ⁸Duarte, CA/US, ⁹Rochester, US, ¹⁰Toronto, Ontario/CA, ¹¹Meldola, IT, ¹²Barcelona, ES, ¹³Pordenone, IT, ¹⁴Manchester, GB, ¹⁵Cambridge, MA/US, ¹⁶New Haven, CT/US
- 13:35 - 13:35 1346P - CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC
J. de Castro¹, S. Novello², J. Mazieres³, I.-J. Oh⁴, M. Migliorino⁵, A. Helland⁶, R. Dziadziuszko⁷, F. Griesinger⁸, F. de Marinis⁹, A. Zeaiter¹⁰, A. Cardona¹⁰, B. Balas¹⁰, H. Johannsdottir¹⁰, M. Chlistalla¹⁰, V. Smoljanovic¹⁰, J. Wolf¹¹; ¹La Pa, ES, ²Torino, IT, ³Toulouse, FR, ⁴Hwasun, KR, ⁵Rome, IT, ⁶Oslo, NO, ⁷Gdansk, PL, ⁸Oidenburg, DE, ⁹Milan, IT, ¹⁰Basel, CH, ¹¹Köln, DE
- 13:35 - 13:35 1347P - Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC

N. Leigh¹, J. Kuo², A. Pavel¹, M. Prescilla¹, F. Shepherd¹, G. Liu³, P. Bradbury¹, M. Moskovits⁴; ¹Toronto, CA, ²Melbourne, VIC/AU, ³Toronto, Ontario/CA, ⁴Haifa, IL

- 13:35 - 13:35 1348P - Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies
T. Mitsudomi¹, M.-J. Ahn², L. Bazhenova³, F. Blackhall⁴, T. Hida⁵, M. Majem Tarruella⁶, S. Vowler⁷, G. Laus⁷, P. Jänne⁸, J.C.-H. Yang⁹; ¹Osaka, JP, ²Seoul, KR, ³San Diego, CA/US, ⁴Manchester, GB, ⁵Nagoya, Aichi/JP, ⁶Barcelona, ES, ⁷Cambridge, GB, ⁸Boston, Ma, US, ⁹Taipei, TW
- 13:35 - 13:35 1349P - Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7
L. Sequist¹, Y.-L. Wu², M. Schuler³, T. Kato⁴, J. Yang⁵, H. Tanaka⁶, T. Hida⁷, S. Lu⁸, K. Park⁹, S. Laurie¹⁰, J. Bennouna¹¹, D. Moro Sibilot¹², A. Märten¹³, B. Peil¹⁴, E. Ehrnrooth¹⁴, N. Yamamoto¹⁵, K. Nakagawa¹⁶; ¹Boston, MA/US, ²Guangzhou, CN, ³Essen, DE, ⁴Yokohama, JP, ⁵Taipei, TW, ⁶Nagoya, JP, ⁷Nagoya, Aichi/JP, ⁸Shanghai, CN, ⁹Seoul, KR, ¹⁰Ottawa, ON/CA, ¹¹Nantes, FR, ¹²Grenoble, FR, ¹³Ingelheim Am Rhein, DE, ¹⁴Copenhagen, DK, ¹⁵Wakayama, JP, ¹⁶Osaka, JP
- 13:35 - 13:35 1350P - Phase I study of TAS-121, a novel third-generation epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC)
H. Murakami¹, Y. Ohe², T. Hida³, H. Sakai⁴, K. Kasahara⁵, F. Imamura⁶, T. Baba⁷, K. Kubota², Y. Hosomi², T. Shimokawa⁸, H. Hayashi⁶, K. Miyadera², T. Tamura², M. Nishio²; ¹Shizuoka, Shizuoka/JP, ²Tokyo, JP, ³Nagoya, Aichi/JP, ⁴Ina, JP, ⁵Kanazawa, JP, ⁶Osaka, JP, ⁷Yokohama, JP, ⁸Yokohama, Kanagawa/JP
- 13:35 - 13:35 1351P - The addition of apatinib to gefitinib or icotinib for advanced non-small cell lung cancer with acquired resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitor: An assessment of effectiveness and safety
C. Ying, Y. Wu; Hangzhou, CN
- 13:35 - 13:35 1352P - Leptomeningeal carcinomatosis from EGFR-mutated non-small cell lung cancer
T. Iuchi¹, M. Shingyoji², T. Setoguchi², Y. Yoshida², H. Ashinuma², Y. Hasegawa², T. Sakaida²; ¹Chiba, Chiba/JP, ²Chiba, JP
- 13:35 - 13:35 1353P - CNS response to osimertinib in Asian-Pacific patients (pts) with T790M-positive advanced NSCLC: data from an open-label Phase II trial (AURA17)
C. Zhou¹, Y. Cheng², Y. Lu³, M. Shi⁴, J.-Y. Han⁵, M. Wang⁶, S.-W. Kim⁷, J. Wang¹, Y. Chen¹, Y.-L. Wu⁸; ¹Shanghai, CN, ²Jilin, CN, ³Chengdu, CN, ⁴Nanjing, CN, ⁵Goyang, KR, ⁶Beijing, CN, ⁷Seoul, KR, ⁸Guangzhou, CN
- 13:35 - 13:35 1354P - Osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: Updated Phase II study results including progression-free survival (PFS)
C. Zhou¹, M. Wang², Y. Cheng³, Y. Chen⁴, Y. Zhao⁵, Y.-K. Shi², M.-J. Ahn⁶, Y. Chen¹, X. Huang⁷, M. Cantarini⁸, Y.-L. Wu⁹; ¹Shanghai, CN, ²Beijing, CN, ³Changchun, Jilin/CN, ⁴Wuhan, CN, ⁵Zhengzhou, CN, ⁶Seoul, KR, ⁷Cambridge, GB, ⁸Macclesfield, Cheshire/GB, ⁹Guangzhou, CN

- 13:35 - 13:35 1355P - Activity of afatinib in heavily pretreated patients (pts) with HER2 mutation-positive (HER2m+) advanced non-small cell lung cancer (NSCLC): findings from a global named patient use (NPU) program
S. Peters¹, A. Curioni-Fontecedro², H. Nechushtan³, J.-Y. Shih⁴, W.-Y. Liao⁴, O. Gautschi⁵, V. Spataro⁶, M. Unk⁷, J.C.-H. Yang⁴, R. Lorence⁸, P. Carrière⁸, A. Cseh⁹, G.-C. Chang¹⁰; ¹Lausanne, CH, ²Zurich, CH, ³Jerusalem, IL, ⁴Taipei, TW, ⁵Lucerne, CH, ⁶Bellinzona, CH, ⁷Ljubljana, SI, ⁸Ridgefield, CT/US, ⁹Vienna, AT, ¹⁰Taichung, TW
- 13:35 - 13:35 1356P - Octogenarians with EGFR-mutated non-small cell lung Cancer (NSCLC) treated by Tyrosine Kinase Inhibitor (TKI): A multicentric real world study assessing tolerance and efficacy. OCTOMUT study GFPC 07-15
R. Corre¹, R. Gervais², L. Tassy³, F. Guisier⁴, R. Lamy⁵, G. Fraboulet⁶, L. Greillier³, H. Double⁷, C. chouaid⁸, J.B. Auliac⁹; ¹Rennes, FR, ²Caen, CEDEX 5/FR, ³Marseille, FR, ⁴Rouen, FR, ⁵Lorient, FR, ⁶Pontoise, FR, ⁷Suresnes, FR, ⁸Créteil, FR, ⁹Mantes La Jolie, FR
- 13:35 - 13:35 1357P - Prospective evaluation of the relationship between erlotinib concentration and efficacy in patients with non-small cell lung cancer harboring EGFR-activating mutations
H. Kenmotsu¹, C. Imamura², T. Kawamura³, T. Oyakawa³, S. Omori³, K. Nakashima³, K. Wakuda³, A. Ono¹, T. Taira¹, T. Naito³, H. Murakami¹, N. Yamamoto⁴, T. Takahashi³, Y. Tanigawara²; ¹Shizuoka, Shizuoka/J, ²Tokyo, JP, ³Shizuoka, JP, ⁴Wakayama, JP
- 13:35 - 13:35 1358P - First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI
H. Husain¹, R. Martins², S. Goldberg³, P. Senico⁴, W. Ma⁵, J. Masters⁶, N. Pathan⁷, D.-W. Kim⁸, M. Socinski⁹, Z. Goldberg¹⁰, B.C. Cho⁸; ¹San Diego, CA/US, ²Seattle, US, ³New Haven, US, ⁴Philadelphia, US, ⁵New York, US, ⁶La Jolla, US, ⁷San Diego, US, ⁸Seoul, KR, ⁹Pittsburgh, PA/US, ¹⁰New London, US
- 13:35 - 13:35 1359P - Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ pts: Results of the NOWEL network
J. Roeper¹, A. Lueers², M. Netchaeva³, M. Falk⁴, C. Hallas⁵, M. Tiemann¹, N. Neemann⁶, L. Heukamp⁶, C. Wessler⁵, G. Wiest⁵, D. Ukena³, S. Sackmann³, F. Griesinger⁷; ¹Berlin, DE, ²Oldenburg, DE, ³Bremen, DE, ⁴Hamburg, Hamburg/DE, ⁵Hamburg, DE, ⁶Köln, DE, ⁷Oidenburg, DE
- 13:35 - 13:35 1360P - Phase II trial of AZD9291 in second line treatment after acquired resistance with T790M mutation detected from circulating tumor DNA (LiquidLung-O-Cohort 2)
Y.-C. Kim¹, C.K. Park², I.-J. Oh², J.-H. Lim², Y.-D. Choi², H. Cho², S.-J. Ahn², S.-Y. Song², J.S. Yun², K.-J. Na²; ¹Hwasun, Jeollanam-do/KR, ²Hwasun, KR
- 13:35 - 13:35 1362P - Safety and clinical activity of DS-6051b, a ROS1/NTRK inhibitor, in Japanese patients with NSCLC harboring ROS1 fusion gene
M. Takeda¹, T. Seto², Y. Fujiwara³, N. Yamamoto³, K. Nosaki⁴, R. Toyozawa⁴, C. Abe³, R. Shiga³, K. Nakamaru³, K. Nakagawa¹; ¹Osaka, JP, ²Fukuoka, Fukuoka/J, ³Tokyo, JP, ⁴Fukuoka, JP
- 13:35 - 13:35 1363P - Efficacy and safety of abemaciclib combined with either LY3023414 or pembrolizumab in stage IV NSCLC

P. Garrido Lopez¹, J. Goldman², K. Kelly³, E. Kim⁴, T. Beck⁵, M. Alonso Garcia⁶, Z. Yang⁷, K.-J. Ingram⁷, L. Amstutz⁷, W. John⁷, M. Provencio Pulla⁸; ¹Madrid, ES, ²Santa Monica, US, ³Sacramento, US, ⁴Charlotte, US, ⁵Fayetteville, US, ⁶Sevilla, ES, ⁷Indianapolis, US, ⁸Majadahonda, Madrid/ES

- 13:35 - 13:35 1364P - Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer
- R. Palmero¹, P. Bidoli², I. Bondarenko³, M. Boyer⁴, P. Germonpre⁵, D. Ghizdavescu⁶, A. Kotsakis⁷, H. Lena⁸, G. Losonczy⁹, K. Park¹⁰, M. Reck¹¹, W.-C. Su¹², N. Kallinteris¹³, M. Tang¹⁴, J. Lai¹⁵, J. Shan¹³, D. Spigel¹⁶; ¹Barcelona, ES, ²Monza, IT, ³Dnepropetrovsk, UA, ⁴Camperdown, AU, ⁵Gent, BE, ⁶Ploiesti, RO, ⁷Heraklion, GR, ⁸Rennes, CEDEX/FR, ⁹Budapest, HU, ¹⁰Seoul, KR, ¹¹Grosshansdorf, DE, ¹²Tainan, TW, ¹³New York, CA/US, ¹⁴Tustin, CA/US, ¹⁵New York, US, ¹⁶Nashville, TN/US
- 13:35 - 13:35 1365P - Effect on quality of life (QOL) of adding cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicentre, randomized, phase 3 MILES-3 and MILES-4 studies
- M.C. Piccirillo¹, A. Morabito¹, P. Maione², A. Luciani³, L. Cavanna⁴, L. Bonanno⁵, E. Piazza³, S. Leo⁶, S. Cinieri⁷, F. Morgillo¹, M.A. Burgio⁸, D. Bilancia⁹, F. Rosetti¹⁰, A. Montanino¹, A. Manzo¹, L. Arenare¹, S. Signoriello¹¹, C. Gallo¹¹, F. Perrone¹, C. Gridelli²; ¹Napoli, IT, ²Avellino, IT, ³Milano, IT, ⁴Piacenza, IT, ⁵Padova, IT, ⁶Lecce, IT, ⁷Brindisi, IT, ⁸Meldola, IT, ⁹Potenza, IT, ¹⁰Mirano, IT, ¹¹Naples, IT
- 13:35 - 13:35 1366P - Effect of nab-paclitaxel/carboplatin (nab-P/C) induction therapy on quality of life (QoL) of patients with squamous (SCC) non-small cell lung cancer (NSCLC) (ABOUND.sqm)
- S. Ponce Aix¹, V. Villaflor², J. Knoble³, M. Thomas⁴, J. von Pawel⁵, S. Bailey⁶, M. Hussein⁷, M.A. Razaq⁸, K. Sabbath⁹, P. Staib¹⁰, T. Chen¹¹, N. Trunova¹¹, D. Spigel¹²; ¹Madrid, ES, ²Chicago, US, ³Columbus, US, ⁴Heidelberg, DE, ⁵Gauting, DE, ⁶Hazard, US, ⁷Lady Lake, US, ⁸Oklahoma City, US, ⁹Waterbury, US, ¹⁰Eschweiler, DE, ¹¹Summit, US, ¹²Nashville, TN/US
- 13:35 - 13:35 1367P - Quality of life (QoL) in elderly NSCLC patients (pts) treated with nab-paclitaxel/carboplatin (nab-P/C) in the ABOUND.70+ trial
- C. Langer¹, E. Anderson², R. Jotte³, J. Goldman⁴, D. Haggstrom⁵, D. Smith⁶, C. Dahkil⁷, K. Konduri⁸, E. Kim⁹, A. Sanford¹⁰, K. Amiri¹⁰, J. Weiss¹¹; ¹Philadelphia, PA/US, ²Portland, US, ³Denver, US, ⁴Santa Monica, US, ⁵Charlotte, US, ⁶Vancouver, US, ⁷Wichita, US, ⁸Dallas, Texas/US, ⁹Dallas, US, ¹⁰Summit, US, ¹¹New York, US
- 13:35 - 13:35 1368P - Phase I/II trial of weekly nab-paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303)
- T. Ninomiya¹, K. Hotta¹, K. Ohashi¹, T. Kubo¹, D. Harada², T. Kozuki², N. Nogami², I. Oze³, S. Hosokawa¹, A. Bessho⁴, H. Yoshioka⁵, K. Kudo⁶, S. Kuyama⁷, S. Harita⁸, I. Takata⁸, N. Fujimoto¹, T. Moritaka², H. Ichikawa⁹, N. Takigawa¹, K. Kiura¹; ¹Okayama, JP, ²Matsuyama, JP, ³Nagoya, JP, ⁴Okayama, Okayama Prefecture/Jp, ⁵Kurashiki, JP, ⁶Tokyo, JP, ⁷Iwakuni, JP, ⁸Fukuyama, JP, ⁹Takamatsu, JP
- 13:35 - 13:35 1369P - nab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): Interim safety results from ABOUND.sqm

C. Gridelli¹, M. McCleod², D. Morgensztern³, D. Daniel⁴, R. Page⁵, T. Wehler⁶, O. Juan⁷, B. Levy⁸, A. Ardizzone⁹, T. Berry¹⁰, T. Chen¹⁰, N. Trunova¹⁰, R. Jotte¹¹; ¹Avellino, IT, ²Cape Coral, US, ³St Louis, US, ⁴Chattanooga, US, ⁵Fort Worth, US, ⁶Mainz, DE, ⁷Valencia, ES, ⁸New York, US, ⁹Valencia, IT, ¹⁰Summit, US, ¹¹Denver, US

- 13:35 - 13:35 1370P - Comparison of platinum agents cisplatin and carboplatin in routine treatment of advanced NSCLC: Results from prospective German TLK cohort study
N. Marschner¹, U. von Verschuer², R. Schnell³, M.-O. Zahn⁴, J. Eggert⁵, A. Binnering¹, L. Spring¹, M. Jänicke¹; ¹Freiburg, DE, ²Essen, DE, ³Frechen, DE, ⁴Goslar, DE, ⁵Moers, DE
- 13:35 - 13:35 1371P - Diagnostic and therapeutic strategies for elderly patients with advanced non-small cell lung cancer (NSCLC): Results from an EORTC pan-European survey
M. Gij Levra¹, J. Menis², A. Luciani³, E. De Maio⁴, B. Hasan⁴, T. Berghmans⁴, M.A. Massiani⁵, M. De Waele⁶, A.-M. Dingemans⁷, J. Donckele⁴, C. Faivre-Finn⁸, N. Girard⁹, L. Greillier¹⁰, S. Lantuéjoul¹, M. O'Brien¹¹, M. Reck¹², K. Tryfonidis⁴, H. Wildiers¹³, B. Besse², S. Novello¹⁴; ¹La Tronche, FR, ²Villejuif, FR, ³Milano, IT, ⁴Brussels, BE, ⁵Paris, FR, ⁶Edegem, BE, ⁷Maastricht, NL, ⁸Manchester, GB, ⁹Bron, FR, ¹⁰Marseille, FR, ¹¹London, GB, ¹²Grosshansdorf, DE, ¹³Leuven, BE, ¹⁴Orbassano, IT
- 13:35 - 13:35 1372P - Diversity of brain metastasis (BM) management in non-small cell lung cancer (NSCLC) in Europe (EU): Results of the Young Investigators European Organisation for Research and Treatment of Cancer Lung Cancer Group (YI EORTC LCG) survey
L. Hendriks¹, C. Faivre-Finn², B. Hasan³, E. de Maio³, A. Berghoff⁴, A.-M. Dingemans¹, S. Novello⁵, T. Berghmans³, B. Besse⁶, A. Levy⁶; ¹Maastricht, NL, ²Manchester, GB, ³Brussels, BE, ⁴Vienna, AT, ⁵Torino, IT, ⁶Villejuif, FR
- 13:35 - 13:35 1373P - Clinical features of never smoker patients with lung squamous cell carcinoma: A retrospective multicenter study
S. Frega¹, M. Macerelli², A. Del Conte³, L. Bonanno¹, M. Bartoletti², V. Polo¹, G. Zago¹, A. Follador², I. Attili¹, A. Pavan¹, L. Urso¹, S. Basso⁴, G. Fasola², P.F. Conte¹, G. Pasello¹; ¹Padova, IT, ²Udine, IT, ³Aviano, IT, ⁴Pordenone, IT
- 13:35 - 13:35 1374P - Characteristics and prognostic impact of advanced non-small-cell lung cancer patients who were ineligible for clinical trials
H. Kawachi¹, D. Fujimoto¹, T. Morimoto², M. Ito¹, S. Teraoka¹, Y. Sato¹, K. Nagata¹, A. Nakagawa¹, K. Otsuka¹, Y. Imai¹, K. Tomii¹; ¹Kobe, JP, ²Nishinomiya, JP
- 13:35 - 13:35 1375P - Treatment paradigm shift in NSCLC: Patient data analysis from 2005 to 2016
L. Mitrofan¹, M. Sahni², D. Dhingra², H. Mistry³, C. Anger³; ¹Paris, FR, ²Gurgaon, IN, ³London, GB
- 13:35 - 13:35 1376TiP - Phase III study of atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with treatment-naïve advanced, recurrent or metastatic NSCLC unsuitable for platinum (plat)-based chemo
S.M. Lee¹, C. Schulz², A. Cardona³, P. Bartakova³, S. Peters⁴; ¹London, GB, ²Regensburg, DE, ³Basel, CH, ⁴Lausanne, CH

- 13:35 - 13:35 1377TiP - JAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung cancer (NSCLC)
M. Reck¹, C.-H. Yang², P. Postmus³, F. Barlesi⁴, E. Font⁵, M. Thomas⁶, T. Kim⁷, M. Cobo Dols⁸, H. Skuladottir⁹, K. Park⁷, R. Sullivan⁸, A. Veatch¹⁰, N. Pavlakis¹¹, L. Dreosti¹², M. Özgüroğlu¹³, F. Morgillo¹⁴, M. Schlichting¹⁵, F. Teofilovici¹⁶, V. Chand¹⁷, V. Westeel¹⁸; ¹Grosshansdorf, DE, ²Taipei City, TW, ³Liverpool, GB, ⁴Marseille, FR, ⁵Barcelona, ES, ⁶Heidelberg, DE, ⁷Seoul, KR, ⁸Málaga, ES, ⁹Herning, DK, ¹⁰Puyallup, WA/US, ¹¹Sydney, AU, ¹²Pretoria, ZA, ¹³Istanbul, TR, ¹⁴Naples, IT, ¹⁵Darmstadt, DE, ¹⁶Billerica, US, ¹⁷Billerica, MA/US, ¹⁸Besançon Cedex, FR
- 13:35 - 13:35 1378TiP - A phase 3 study of first-line durvalumab vs platinum-based chemotherapy in patients with advanced NSCLC and high PD-L1 expression: PEARL
Y.-L. Wu¹, S. Lu², S. Clarke³, K. Laktionov⁴, P. Li⁵, M. Kirkby⁵, Y. Xie², P. Stockman⁶; ¹Guangzhou, CN, ²Shanghai, CN, ³St Leonards, NSW/AU, ⁴Moscow, RU, ⁵Beijing, CN, ⁶Alderley Park, GB
- 13:35 - 13:35 1379TiP - Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor
K. Park¹, F. Ciardiello², T. Hida³, W. Lim⁴, C.-C. Lin⁵, H. Murakami⁶, M. Nishio⁷, F. Cantero⁸, V. Cattani⁸, C. Gabarrocá⁸, E. Gandossi⁸, L. Paz-Ares⁹; ¹Seoul, KR, ²Naples, IT, ³Nagoya, Aichi/Jp, ⁴Singapore, SG, ⁵Taipei, TW, ⁶Shizuoka, Shizuoka/Jp, ⁷Tokyo, Jp, ⁸Suresnes, FR, ⁹Madrid, ES
- 13:35 - 13:35 1380TiP - A randomized, open-label comparison of lorlatinib versus crizotinib as first-line treatment for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer
A. Shaw¹, T. Bauer², T. Takahashi³, C. Baik⁴, A. Polli⁵, M. Carpentieri⁶, J.-F. Martini⁷, B. Solomon⁸; ¹Boston, MA/US, ²Nashville, TN/US, ³Shizuoka, JP, ⁴Seattle, US, ⁵Milan, IT, ⁶Milan, Italia/IT, ⁷San Diego, CA/US, ⁸Melbourne, VIC/AU
- 13:35 - 13:35 1381TiP - A randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial
S. Postel-Vinay¹, D. Planchard¹, A. Ortega Granados², A. Gazzah¹, M.A. Sala Gonzalez³, M. Majem⁴, C.J. Camps⁵, A. Abou-Lauvergne¹, J.-P. Pignon⁶, J. Cadranel⁷, J. Bennouna⁸, F. Barlesi⁹, M.R. Garcia Campelo¹⁰, S. Viteri⁴, B. Besse¹, J. Coves Sarto¹¹, B. Massuti Sureda¹², J.-C. Soria⁶, R. Rosell¹³; ¹Villejuif, FR, ²Jaén, ES, ³Bilbao, ES, ⁴Barcelona, ES, ⁵Valencia, ES, ⁶Villejuif, CEDEX/FR, ⁷Paris, FR, ⁸Nantes, CEDEX/FR, ⁹Marseille, FR, ¹⁰A Coruña, ES, ¹¹Palma De Mallorca, Islas Baleares/ES, ¹²Alicante, ES, ¹³Badalona, Barcelona/ES
- 13:35 - 13:35 1382TiP - Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: Non-interventional LUME-BioNIS study
M. Reck¹, A. Staal-van den Brekel², A. Mellempgaard³, N. Morsli⁴, K. Pietzko⁵, T. Kitzing⁵, J. Braunger⁵, K. Kerr⁶; ¹Grosshansdorf, DE, ²Almelo, NL, ³Herlev, DK, ⁴Paris, FR, ⁵Biberach, DE, ⁶Aberdeen, GB
- 13:35 - 13:35 1383TiP - Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC

T.S.K. Mok¹, S. Gadgeel², E. Kim³, V. Velcheti⁴, S. Hu⁵, T. Riehl⁵, E. Schleifman⁵, S. Paul⁵, S. Mocci⁶, D. Shames⁵, S. Phan⁵, C. Yun⁵, M. Mathisen⁵, M. Kowanzetz⁵, U. Sweere⁷, M. Socinski⁸; ¹Shatin, HK, ²Ann Arbor, US, ³Charlotte, US, ⁴Cleveland, OH/US, ⁵South San Francisco, US, ⁶South San Francisco, CA/US, ⁷Basel, CH, ⁸Orlando, FL/US

- 13:35 - 13:35 1384TiP - Prospective comparison of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, non-small cell lung cancer (NSCLC) patients (pts)
R. Palmero¹, Á. Taus¹, M. Majem Tarruella¹, S. Viteri¹, E. Carcereny Costa², J. Garde³, J. Garde¹, E. Felip Font¹, C. Cassidy⁴, D. Dix⁴, N. Karachaliou¹, R. Rosell²; ¹Barcelona, ES, ²Badalona, Barcelona/ES, ³Valencia, ES, ⁴Redwood City, CA/US
- 13:35 - 13:35 1385TiP - Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC AIO-TRK-0315
F. Griesinger¹, W. Eberhardt², N. Marschner³, M. Jänicke³, A. Fleitz³, L. Spring³, J. Sahlmann³, A. Karatas⁴, A. Hipper⁴, W. Weichert⁵, M. Sebastian⁶, M. Thomas⁷; ¹Oidenburg, DE, ²Essen, DE, ³Freiburg, DE, ⁴Berlin, DE, ⁵Munich, DE, ⁶Frankfurt Am Main, DE, ⁷Heidelberg, DE
- 13:35 - 13:35 SCLC
P. Garrido Lopez, Madrid, ES
- 13:35 - 13:35 1532P - The role of thoracic radiotherapy on peripheral lymphocyte subsets in patients with limited-stage small cell lung cancer
Y. Chen, Y. Jin, M. Chen; Hangzhou, CN
- 13:35 - 13:35 1534P - Antidepressants simulate enriched environment enhance platinum chemosensitivity of small cell lung cancer
Y. Wu, Q. Wang, H. Tang; Zhengzhou, CN
- 13:35 - 13:35 1535TiP - KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)
C. Rudin¹, L. Shen², M.C. Pietanza³; ¹New York, NY/US, ²Kenilworth, NJ/US, ³Rahway, NJ/US
- 13:35 - 13:35 1536TiP - An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
I. Okamoto¹, H. Udagawa², S. Kanda³, T.H. Han⁴, I. Lakatos⁴, F. Zhang⁴, S. Okubo⁵, C. Scripture⁴, M. Takeda⁵, H. Akamatsu⁶, T. Tamura³; ¹Fukuoka, JP, ²Chiba, JP, ³Tokyo, JP, ⁴South San Francisco, US, ⁵Osaka, JP, ⁶Wakayama, JP
- 13:35 - 13:35 1537TiP - A phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinum-based chemotherapy
P. Komarnitsky¹, H.-J. Lee², M. Shah², S. Wong², S. Gulbranson², J. Dziubinski², L. Caffrey², P. Tanwani², M. Motwani², F. Zhang³; ¹Cambridge, MA/US, ²North Chicago, US, ³South San Francisco, US
- 13:35 - 13:35 1538TiP - A phase 1/2 study on safety of rovalpituzumab tesirine in combination with nivolumab or nivolumab + ipilimumab in small cell lung cancer

C. Scripture¹, G. Selvaggi², I. Lakatos¹, K. Boynton¹, S. Lally¹, T.H. Han¹, S. Peng³, S.J. Dylla¹; ¹ South San Francisco, US, ²Lawrenceville, NJ/US, ³New York, CA/US

13:35 - 13:35 THORACIC MALIGNANCIES, OTHER

P. Garrido Lopez, Madrid, ES

13:35 - 13:35 1620P - Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated with immune-oncology drugs (IO) in clinical trials

S. Cedres, A. Martinez Marti, A. Navarro, N. Pardo, J. Remon, I. Matos, M. Ochoa de Olza, C. Hierro, J. Martin Liberal, J.M. Miquel, C. VIAPLANA, G. Villacampa Javierre, R. Dienstmann, E. Felip Font; Barcelona, ES

13:35 - 13:35 1621P - Baseline hyperglycemia was predictive of poor outcome in pleural malignant mesothelioma

J.C. Ruffinelli¹, J.C. Pardo², S. Recalde¹, J.C. Benítez³, L. Cancel¹, R. Palmero⁴, R. Llatjós¹, M.R. Escoda², S. Padrones¹, I. Brao¹, E. Dalmau², Y. Garcia², F. Cardenal¹, E. Nadal⁵; ¹L'hospitalet, ES, ²Sabadell, ES, ³Terrassa, ES, ⁴Barcelona, ES, ⁵Barcelona, Barcelona/ES

13:35 - 13:35 1622P - Evaluation of quality of life in survivors with malignant pleural mesothelioma in Japan

I. Oze¹, Y. Nagamatsu², K. Aoe², K. Hotta³, K. Kato³, J. Nakagawa³, K. Hara³, T. Kishimoto³, N. Fujimoto³; ¹Nagoya, JP, ²Ube, JP, ³Okayama, JP

13:35 - 13:35 1623P - Staging and assessment of the response to PET-CT treatment in non-small cell lung carcinoma

M. Mendez Garcia¹, M. Brenes¹, R. Gómez¹, M. Soriano¹, M. Torrente¹, C. Maximiano¹, G. Díaz¹, B. Rodríguez¹, M.D.M. Córdoba¹, M. Provencio Pulla²; ¹Madrid, ES, ²Majadahonda, Madrid/ES

13:35 - 13:35 1624P - "Liquid Withdarw" technique prominently reduced the incidence of pneumothorax and improved tumor tissue amount of CT-guided cutting needle lung biopsy: A retrospective study

R. Li, W. Ren, J. Gao, Y. Zhang, P. Jiang, X. Zhou, H. Zhang, X. Shen, J. Liu, S. Gao, L. Wang, B. Liu; Nanjing, CN

13:35 - 13:35 1625P - Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma

Y. Okuma, Y. Goto, F. Ohyanagi, K. Sunami, Y. Nakahara, S. Kitazono, Y. Tambo, N. Yanagitani, S. Kanda, H. Horinouchi, A. Horiike, Y. Fujiwara, H. Nokihara, N. Yamamoto, M. Nishio, Y. Ohe, Y. Hosomi; Tokyo, JP

13:35 - 13:35 1626P - Detects esophageal squamous cell carcinoma via liquid biopsy of circulating exosomes

Z. An¹, A. Chen², J. Zhang², W. Guo², Z. Ling², W. Mao³; ¹Hangzhou, CN, ²Hangzhou, CN, ³Hangzhou, Zhejiang/CN

13:35 - 13:35 1627TiP - ONCOS-102 and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma

S. Ponce Aix¹, S. Viteri², J. Bosch-Borrera³, L. Kuryk⁴, T. Hakonen⁴, S. Vetthus⁵, M. Jäderberg⁵, L. Paz-Ares¹; ¹Madrid, ES, ²Barcelona, ES, ³Girona, ES, ⁴Helsinki, FI, ⁵Oslo, NO

14:45 - 16:15	Type: Educational session Title: Molecular targeted therapy of advanced colorectal cancer Chair(s): G. Middleton, GB; R. Glynne-Jones, GB	Barcelona Auditorium
14:45 - 15:10	BRAF mutant patients <u>M. Ducreux</u> , Villejuif, FR	
15:10 - 15:35	MSI <u>G. Middleton</u> , Birmingham, GB	
15:35 - 16:00	Rare mutations <u>L. Trusolino</u> , Turin, IT	
16:00 - 16:15	Discussion	

14:45 - 16:15	Type: Proffered Paper session Title: Melanoma and other skin tumours Chair(s): R. Dummer, CH; O. Michielin, CH	Madrid Auditorium
14:45 - 15:00	1213O - Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone <u>C. Robert</u> ¹ , J. Larkin ² , P. Ascierto ³ , G. Long ⁴ , J. Hassel ⁵ , D. Schadendorf ⁶ , F.S. Hodi ⁷ , C. Lebbé ⁸ , J.-J. Grob ⁹ , K. Grossmann ¹⁰ , J. Wagstaff ¹¹ , J. Chesney ¹² , D. Hogg ¹³ , O. Bechter ¹⁴ , I. Márquez-Rodas ¹⁵ , A. Pavlick ¹⁶ , D. Walker ¹⁷ , R. Bhore ¹⁷ , M. Postow ¹⁶ , J. Wolchok ¹⁶ ; ¹ Villejuif, FR, ² London, GB, ³ Napoli, IT, ⁴ Sydney, AU, ⁵ Heidelberg, DE, ⁶ Essen, DE, ⁷ Boston, US, ⁸ Paris, FR, ⁹ Marseille, FR, ¹⁰ Salt Lake City, US, ¹¹ Swansea, GB, ¹² Louisville, US, ¹³ Toronto, CA, ¹⁴ Leuven, BE, ¹⁵ Madrid, ES, ¹⁶ New York, US, ¹⁷ Princeton, US	
15:00 - 15:15	1214O - Epcadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037 <u>O. Hamid</u> ¹ , T. Gajewski ² , A. Frankel ³ , T. Bauer ⁴ , A. Olszanski ⁵ , J. Luke ⁶ , A. Balmanoukian ¹ , E. Schmidt ⁷ , B. Sharkey ⁸ , J. Maleski ⁸ , M. Jones ⁸ , T. Gangadhar ⁵ ; ¹ Los Angeles, CA/US, ² Chicago, US, ³ Dallas, TX/US, ⁴ Nashville, TN/US, ⁵ Philadelphia, PA/US, ⁶ Chicago, IL/US, ⁷ Kenilworth, NJ/US, ⁸ Wilmington, DE/US	
15:15 - 15:30	Invited Discussant 1213O and 1314O <u>O. Michielin</u> , Lausanne, CH	
15:30 - 15:45	1215O - Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma <u>R. Dummer</u> ¹ , P. Ascierto ² , H. Gogas ³ , A. Arance ⁴ , M. Mandala ⁵ , G. Liskay ⁶ , C. Garbe ⁷ , D. Schadendorf ⁸ , I. Krajsová ⁹ , R. Gutzmer ¹⁰ , V. Chiarion Sileni ¹¹ , C. Dutriaux ¹² , J.W. de Groot ¹³ , N. Yamazaki ¹⁴ , C. Loquai ¹⁵ , L. de Parseval ¹⁶ , M. Pickard ¹⁷ , V. Sandor ¹⁷ , C. Robert ¹⁸ , K. Flaherty ¹⁹ ; ¹ Zürich, CH, ² Napoli, IT, ³ Athens, Attiki/GR, ⁴ Barcelona, ES, ⁵ Bergamo, IT, ⁶ Budapest, HU, ⁷ Tuebingen, DE, ⁸ Heidelberg, DE, ⁹ Prague, CZ, ¹⁰ Hannover, DE, ¹¹ Padua, IT, ¹² Bordeaux, FR, ¹³ Zwolle, NL, ¹⁴ Tokyo, JP, ¹⁵ Mainz, DE, ¹⁶ Basel, CH, ¹⁷ Boulder, CO/US, ¹⁸ Villejuif, FR, ¹⁹ Boston, MA/US	
15:45 - 16:00	1216O - KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma <u>A. Ribas</u> ¹ , F.S. Hodi ² , D. Lawrence ³ , V. Atkinson ⁴ , S. Agarwal ⁵ , M. Carlino ⁶ , R. Fisher ⁷ , G. Long ⁶ , W. Miller ⁸ , Y. Huang ⁹ , B. Homet Moreno ¹⁰ , N. Ibrahim ¹¹ , O. Hamid ¹ ; ¹ Los Angeles, CA/US, ² Boston, US, ³ Boston, MA/US, ⁴ Brisbane, AU, ⁵ Goshen, IN/US, ⁶ Sydney, AU, ⁷ Auckland, NZ, ⁸ Montreal, CA, ⁹ East Hanover, NJ/US, ¹⁰ Kenilworth, NJ/US, ¹¹ Kenilworth, US	
16:00 - 16:15	Invited Discussant 1215O and 1216O <u>P. Lorigan</u> , Manchester, GB	

14:45 - 16:15 Type: Educational session Sevilla Auditorium
Title: How to manage ovarian cancer in 2017
Chair(s): S. Pignata, IT; I. Vergote, BE

14:45 - 15:05 Biological implications for clinical practice
S. Pignata, Napoli, IT

15:05 - 15:25 Front line surgery: Criteria for selection
P. Harter, Essen, DE

15:25 - 15:45 Medical management of recurrent disease
A. Gonzalez Martin, Madrid, ES

15:45 - 16:05 Is there a role for surgical management of recurrent disease?
I. Vergote, Leuven, BE

16:05 - 16:15 Discussion

14:45 - 16:15 Type: Poster Discussion session Pamplona Auditorium
Title: Breast cancer, early stage
Chair(s): I. Tannock, CA; R. Salgado, BE; L. Gianni, IT; J. Bliss, GB; A. Tutt, GB

14:45 - 14:45 151PD - Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer
G. von Minckwitz¹, O. Ponomarova², S. Morales³, N. Zhang⁴, V. Hanes⁴; ¹Neu-Isenburg, DE, ²Kiev, UA, ³Lleida, ES, ⁴Thousand Oaks, US

14:45 - 14:45 152PD - Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)
F. Esteva¹, Y. Baranau², V. Baryash², A. Manikhas³, V. Moiseyenko³, G. Dzagnidze⁴, E. Zhavrid², D. Boliukh⁵, D. Stroyakovskiy⁶, J. Pikiel⁷, A. Eniu⁸, D. Komov⁹, Z. Zautashvili⁴, G. Morar-Bolba⁸, R. Li¹⁰, I. Lifirenko¹¹, A. Rusyn¹², S.J. Lee¹³, S. Yu¹³, J. Stebbing¹⁴; ¹Houston, TX/US, ²Minsk, BY, ³Saint Petersburg, RU, ⁴Tbilisi, GE, ⁵Vinnytsya, UA, ⁶Moscow, Krasnogorski District/RU, ⁷Gdańsk, PL, ⁸Cluj-Napoca, RO, ⁹Moscow, RU, ¹⁰Quezon City, PH, ¹¹Kursk, RU, ¹²Uzhorod, Zakarpattia/UA, ¹³Incheon, KR, ¹⁴London, GB

14:45 - 14:45 153PD - One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment
X. Pivot¹, I. Bondarenko², Z. Nowecki³, M. Dvorkin⁴, E. Trishkina⁵, J.H. Ahn⁶, Y. Vinnyk⁷, S.-A. Im⁶, T. Sarosiek⁸, S. Chatterjee⁹, M. Wojtukiewicz¹⁰, V. Moiseyenko⁵, Y. Shparyk¹¹, M. Bello III¹², V. Semiglazov⁵, L. Younju¹³, J. Lim¹³; ¹Besançon, CEDEX/FR, ²Dnepropetrovsk, UA, ³Warsaw, PL, ⁴Omsk, RU, ⁵Saint Petersburg, RU, ⁶Seoul, KR, ⁷Kharkiv, UA, ⁸Warszawa, PL, ⁹Kolkata, West Bengal/IN, ¹⁰Bialystok, Podlaskie/PL, ¹¹Lviv, UA, ¹²Quezon City, PH, ¹³Suwon, KR

- 14:45 - 14:45 154PD - A randomized, double-blind study of PF-05280014 (a potential biosimilar) vs trastuzumab, both given with docetaxel (D) and carboplatin (C), as neoadjuvant treatment for operable human epidermal growth factor receptor 2-positive (HER2+) breast cancer
P. Lammers¹, M. Dank², R. Masetti³, R. Abbas⁴, F. Hilton⁵, J. Coiro⁶, I. Jacobs⁶; ¹Nashville, TN/US, ²Budapest, HU/HU, ³Rome, IT, ⁴Collegeville, PA/US, ⁵Groton, CT/US, ⁶New York, NY/US
- 14:45 - 15:00 Invited Discussant 151PD, 152PD, 153PD and 154PD
I. Tannock, Toronto, Ontario/CA
- 15:00 - 15:05 Q&A led by Discussant
- 15:05 - 15:05 155PD - Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
P. Nuciforo¹, A. Prat¹, A. Llombart², R. Fasani¹, L. Paré¹, T. Pascual³, M. Oliveira¹, N. Martínez Jañez³, B. Bermejo De Las Heras⁴, M. Vidal¹, S. Pernas Simon¹, R. López⁵, M. Muñoz¹, I. Garau⁶, L. Manso³, J. Alarcon Company⁶, E. Martinez de Dueñas⁷, P. Villagrana Gonzalez¹, J. Cortes Castan³, E. Holgado³; ¹Barcelona, ES, ²Lerida, ES, ³Madrid, ES, ⁴Valencia, Valencia/ES, ⁵Santiago De Compostela, ES, ⁶Palma De Mallorca, ES, ⁷Castellon, ES
- 15:05 - 15:05 156PD - Targeted NGS profiling identifies genomic alterations associated with high-risk eBC
T. Wilson, A. Udyavar, C.-W. Chang, J. Giltnane, J. Spoerke, J. Aimi, H. Savage, A. Daemen, R. Bourgon, M. Lackner; South San Francisco, CA/US
- 15:05 - 15:05 157PD - 10 years follow up of the RASTER study; implementing a genomic signature in daily practice
S. Vlieg¹, V. Retel¹, C. Drukker², E. Rutgers¹, H. van Tinteren¹, M.J. van de Vijver¹, J.M. Bueno-De-Mesquita¹, J. Wesseling¹, W. van Harten¹, S. Linn¹; ¹Amsterdam, NL, ²Dordrecht, NL
- 15:05 - 15:05 LBA11 - Prognostic impact of recurrence score (RS), grade/Ki67 central pathological review, and acycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results
O. Gluz¹, U. Nitz¹, M. Christgen², W. Malter³, M. Clemens⁴, T. Reimer⁵, B. Nuding⁶, B. Aktas⁷, A. Stefek⁸, A. Pplmanns⁹, F. Lorenz-Salehi¹⁰, C. Uleer¹¹, P. Krabisch¹², S. Kümmel⁷, C. Liedtke¹³, S. Shak¹⁴, R. Kates¹, R. Wurstein¹⁵, H.H. Kreipe², N. Harbeck¹⁵; ¹Mönchengladbach, DE, ²Hannover, DE, ³Cologne, DE, ⁴Trier, DE, ⁵Rostock, DE, ⁶Bergisch Gladbach, DE, ⁷Essen, DE, ⁸Stenadal, DE, ⁹Oberhausen, DE, ¹⁰Wiesbaden, DE, ¹¹Hildesheim, DE, ¹²Chemnitz, DE, ¹³Lübeck, DE, ¹⁴Redwood City, CA/US, ¹⁵Munich, DE
- 15:05 - 15:20 Invited Discussant 155PD, 156PD, 157PD and LBA11
R. Salgado, Brussels, BE
- 15:20 - 15:25 Q&A led by Discussant

- 15:25 - 15:25 158PD - Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTO trial (BIG 2-06)
M. Lambertini¹, C. Campbell², J. Bines³, L. Korde⁴, M.A. Izquierdo Delso⁵, D. Fumagalli¹, K. Pritchard⁶, A. Wolff⁷, C. Jackisch⁸, I. Lang⁹, M. Untch¹⁰, I. Smith¹¹, F. Boyle¹², B. Xu¹³, C. Barrios¹⁴, J. Baselga¹⁵, A. Moreno-Aspitia¹⁶, M. Piccart¹, R. Gelber¹⁷, E. De Azambuja¹; ¹Brussels, BE, ²Kingussie, GB, ³Rio De Janeiro, BR, ⁴Bethesda, US, ⁵Basel, CH, ⁶Toronto, Ontario/CA, ⁷Baltimore, MD/US, ⁸Offenbach, DE, ⁹Budapest, HU, ¹⁰Berlin, DE, ¹¹London, GB, ¹²Sydney, AU, ¹³Beijing, CN, ¹⁴Porto Alegre, BR, ¹⁵New York, NY/US, ¹⁶Jacksonville, US, ¹⁷Boston, MA/US
- 15:25 - 15:25 159PD - Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20)
N. Masuda¹, S. Ohtani², T. Takano³, K. Inoue⁴, E. Suzuki⁵, R. Nakamura⁶, H. Bando⁷, Y. Ito³, K. Ishida⁸, T. Yamanaka⁹, K. Kuroi³, H. Yasojima¹, H. Kasai⁵, T. Takasuka³, T. Sakurai⁵, T. Kataoka⁵, S. Morita⁵, S. Ohno³, M. Toi⁵; ¹Osaka, JP, ²Hiroshima, Hiroshima/JJ, ³Tokyo, JP, ⁴Kita-Adachi Ina, JP, ⁵Kyoto, JP, ⁶Chiba, JP, ⁷Tsukuba, Ibaraki/JJ, ⁸Morioka, JP, ⁹Yokohama, JP
- 15:25 - 15:40 Invited Discussant 158PD and 159PD
L. Gianni, Milan, IT
- 15:40 - 15:45 Q&A led by Discussant
- 15:45 - 15:45 160PD - Statistical model to predict brain metastasis risk in patients with early-stage breast cancer
B. Abderrahman¹, N. Ibrahim², K. Hess²; ¹Houston, US, ²Houston, TX/US
- 15:45 - 15:45 161PD - Surrogate endpoints for overall survival in randomized controlled trials evaluating adjuvant treatment for breast cancer: A meta-analysis
M. Savina¹, W. Jacot², S. Mathoulin-Pélissier¹, Y. Laghzali³, C. Bellera¹, S. Gourgou³; ¹Bordeaux, FR, ²Montpellier, CEDEX 5/FR, ³Montpellier, FR
- 15:45 - 15:55 Invited Discussant 160PD and 161PD
J. Bliss, Sutton, GB
- 15:55 - 16:00 Q&A led by Discussant
- 16:00 - 16:00 162PD - Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification (TNBCType-4)
I. Echavarria Diaz-Guardamino¹, A. Picornell¹, S. López-Tarruella¹, Y. Jerez¹, K. Hoadley², E. Alvarez¹, M. del Monte-Millán¹, J. Gayarre¹, R. Ramos-Medina¹, T. Massarrah¹, I. Ocaña¹, M. Cebollero¹, F. Moreno Antón¹, J.A. García-Saenz¹, H. Gomez Moreno³, H. Fuentes³, A.I. Ballesteros Garcia¹, U. Bohn Sarmiento⁴, C. Perou², M. Martin Jimenez¹; ¹Madrid, ES, ²Chapel Hill, NC/US, ³Lima, PE, ⁴Las Palmas, Canary Island/ES

- 16:00 - 16:00 163PD - Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto)
M. Untch¹, A. Schneeweiss², C. Salat³, M. Rezaei⁴, D.-M. Zahm⁵, P. Klare¹, J.-U. Blohmer¹, H. Tesch⁶, F. Khandan⁷, P.A. Fasching⁸, C. Jackisch⁹, V. Nekljudova¹⁰, G. von Minckwitz¹⁰, S. Loibl¹⁰; ¹Berlin, DE, ²Heidelberg, DE, ³München, DE, ⁴Düsseldorf, DE, ⁵Gera, DE, ⁶Frankfurt Am Main, DE, ⁷Frankfurt, DE, ⁸Erlangen, DE, ⁹Offenbach, DE, ¹⁰Neu-Isenburg, DE
- 16:00 - 16:10 Invited Discussant 162PD and 163PD
A. Tutt, London, GB
- 16:10 - 16:15 Q&A led by Discussant
- 14:45 - 16:15 Type: Special Session Granada Auditorium
Title: The incoming wave of biosimilars in oncology
Chair(s): J. Taberner, ES; E. Wolff-Holz, DE
- 14:45 - 14:55 Introduction
E. Wolff-Holz, Langen, DE
- 14:55 - 15:05 Biosimilars: European Medicines Agency's plan for healthcare professionals
J. Garcia Burgos, London, GB
- 15:05 - 15:15 Clinician's perspective: Building confidence to prescribe biosimilars
R. Giuliani, Roma, IT
- 15:15 - 15:25 Collaborative approach key for uptake of biosimilars
G. Befrits, Stockholm, SE
- 15:25 - 15:35 The crucial role of specialist nurses
J. De Munter, Gent, BE
- 15:35 - 15:45 Patient's perspective: What have we learned and what can be improved?
L. Avedano, Brussels, BE
- 15:45 - 15:55 Oncology: Impact of biosimilars on the sustainability of healthcare systems
M. Aitken, Parsippany, US
- 15:55 - 16:15 Discussion

14:45 - 16:15 Type: Joint Symposium Tarragona Auditorium
Title: ESMO-ESTRO: Lung cancer: Recent development of multimodal treatments
Chair(s): S. Peters, CH; Y. Lievens, BE

14:45 - 14:50 Introduction
S. Peters, Lausanne, CH

14:50 - 15:10 How to integrate radiotherapy innovations in the multimodality treatment of LA-NSCLC?
C. Faivre-Finn, Manchester, GB

15:10 - 15:30 Standard and perspectives for systemic treatments in stage 3?
P. Garrido Lopez, Madrid, ES

15:30 - 15:50 Oligometastatic NSCLC: What are the treatment paradigms and how does radiotherapy fit in?
M. Guckenberger, Zürich, CH

15:50 - 16:10 Oligometastatic NSCLC: When and how to combine systemic therapy and radiotherapy?
L. Coate, Dublin, IE

16:10 - 16:15 Conclusions
Y. Lievens, Gent, BE

14:45 - 16:15 Type: Joint Symposium Bilbao Auditorium
Title: ESMO-SIOPE: Tumours at the edge of paediatric and adult oncology: Emphasising collaboration
Chair(s): G. Mountzios, GR; S. Bielack, DE

14:45 - 14:50 Introduction
G. Mountzios, Athens, GR

14:50 - 15:10 Bone and soft tissue sarcomas in AYA as models of multidisciplinary management
S. Bielack, Stuttgart, DE

15:10 - 15:30 Leukaemias-Lymphomas: New insights from paediatric leukaemia research and clinical trials
A. von Stackelberg, Berlin, DE

15:30 - 15:50 CNS tumours in AYA: Overcoming obstacles with multidisciplinary care
E. Razis, Athens, GR

15:50 - 16:10 Mapping the cancer care for AYA in Europe: Current status and needs
D. Stark, Leeds, GB

16:10 - 16:15 Conclusion
S. Bielack, Stuttgart, DE

- 14:45 - 16:15 Type: Poster Discussion session Alicante Auditorium
Title: Head and neck cancer, excluding thyroid
Chair(s): A. Psyrri, GR; S. Oosting, NL; J. Bourhis, CH; J. Guigay, FR
- 14:45 - 14:45 1045PD - Adjuvant androgen deprivation therapy for high-risk androgen receptor-positive salivary duct carcinoma
W. Boxtel¹, L. Locati², S. Tooten¹, E. Bos¹, C. Bergamini³, A.C.H. van Engen-van Grunsven¹, E. Boon¹, E. Fiets⁴, S. Cavalieri², G. Verhaegh¹, J. Schalken¹, L. Licitra², C. Herpen¹; ¹Nijmegen, NL, ²Milan, IT, ³Milano, IT, ⁴Leeuwarden, NL
- 14:45 - 14:45 1046PD - Overexpression of the c-MET proto-oncogene in salivary duct carcinoma patients
C. Herpen¹, W. Boxtel¹, U. Flucke¹, E. Bloemena², E. Boon¹, G. Verhaegh¹, M.W. Aalders¹, M.A. Jonker¹, J. Schalken¹, Y.M.H. Versleijen-Jonkers¹; ¹Nijmegen, NL, ²Amsterdam, NL
- 14:45 - 14:45 1047PD - Mammary analogue secretory carcinoma (MASC): clinical characteristics in 28 ETV6-NTRK3 fusion gene confirmed patients
E. Boon¹, M. Valstar², W. van der Graaf³, E. Bloemena², S. Willems⁴, C. Meeuwis⁵, L. Smit², M. Merks¹, R. Takes¹, U. Flucke¹, C. Herpen¹; ¹Nijmegen, NL, ²Amsterdam, NL, ³Sutton, GB, ⁴Utrecht, NL, ⁵Rotterdam, NL
- 14:45 - 14:57 Invited Discussant 1045PD, 1046PD and 1047PD
J. Guigay, Nice, CEDEX 2/FR
- 14:57 - 15:07 Q&A led by Discussant
- 15:07 - 15:07 LBA46 - An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): Safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN)
R. Ferris¹, A. Gonçalves², S. Baxi³, U. Martens⁴, H. Gauthier⁵, M. Langenberg⁶, W. Spanos⁷, R. Leidner⁸, H. Kang⁹, J. Russell¹⁰, S. Chiosea¹¹, I. Soumaoro¹², S. Rao¹², Z.A. Cao¹³, S. Topalian⁹; ¹US, ²Marseille, FR, ³New York, US, ⁴Heilbronn, DE, ⁵Paris, CEDEX 10/FR, ⁶Utrecht, NL, ⁷Sioux Falls, US, ⁸Portland, US, ⁹Baltimore, MD/US, ¹⁰Tampa, FL/US, ¹¹Pittsburgh, PA/US, ¹²Ladeuze, BE, ¹³Princeton, US
- 15:07 - 15:07 1048PD - RetroSpective cohort stUdy of PD-L1 expression in REcurrent and/or MEtastatic squamous cell carcinoma of the head and neck (SUPREME-HN)
S. Pai¹, E. Cohen², D. Lin¹, G. Fountzilias³, E. Kim⁴, H. Mehlhorn⁵, N. Baste⁶, D. Clayburgh⁷, L. Lipworth⁸, C. Resteghini⁹, N. Shara¹⁰, T. Fujii¹¹, J. Zhang¹², M. Stokes¹³, D. Lawrence¹⁴, A. Khaliq¹⁵, G. Melillo¹⁶, N. Shire¹⁵; ¹Boston, US, ²La Jolla, IL/US, ³Thessaloniki, GR, ⁴Charlotte, US, ⁵Leipzig, DE, ⁶Barcelona, ES, ⁷Portland, US, ⁸Nashville, US, ⁹Milan, IT, ¹⁰Hyattsville, US, ¹¹Osaka, JP, ¹²Houston, US, ¹³Waltham, US, ¹⁴Cambridge, GB, ¹⁵Gaithersburg, US, ¹⁶Gaithersburg, Maryland/US
- 15:07 - 15:07 1049PD - Relationship between PD-L1 expression and survival in head and neck squamous cell carcinoma (HNSCC) patients (pts)

M. Stokes¹, R. Wang¹, S. Wildsmith², M. Secrier², H. Angell², C. Barker², J. Walker², P. Scorer², M. Rebelatto³, N. Shire³; ¹Waltham, US, ²Cambridge, GB, ³Gaithersburg, US

15:07 - 15:19 Invited Discussant LBA46, 1048PD and 1049PD

A. Psyrri, Athens, GR

15:19 - 15:29 Q&A led by Discussant

15:29 - 15:29 LBA47 - First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: A randomized phase IIb trial

P. Bossi¹, L. Hollander¹, R. Miceli¹, D. Ferrari¹, S. Vecchio², G. Moretti³, M. Merlano⁴, F. Caponigro⁵, C. Moro⁶, E. Vaccher⁷, O. Alabisio⁸, A. Caldara⁹, A. Russo¹⁰, F. Ferrau¹¹, F. Nolè¹, L. Licitra¹; ¹Milan, IT, ²Genova, IT, ³Reggio Emilia, IT, ⁴Cuneo, IT, ⁵Napoli, IT, ⁶Bergamo, IT, ⁷Aviano, IT, ⁸Novara, IT, ⁹Trento, IT, ¹⁰Palermo, IT, ¹¹Taormina, IT

15:29 - 15:29 1050PD - The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit

C. Mertens¹, H. Le Caer², C. Ortholan³, E. Blot⁴, C. Even⁵, H. Rousselot⁶, F. Peyrade⁷, C. Sire⁸, D. Cupissol⁹, Y. Pointreau¹⁰, P. Debourdeau¹¹, F. Rolland¹², J. Fayette¹³, O. Capitain¹⁴, X. Sun¹⁵, M. Debbah⁵, D. Schwob⁵, R. Boulahssass¹⁶, A. Aupérin⁵, J. Guigay⁷; ¹Bordeaux, FR, ²Saint Brieux, FR, ³Monaco, MC, ⁴Vannes, FR, ⁵Villejuif, FR, ⁶Vandoeuvre-Lès-nancy, FR, ⁷Nice, CEDEX 2/FR, ⁸Lorient, FR, ⁹Montpellier, CEDEX 5/FR, ¹⁰Le Mans, FR, ¹¹Avignon, FR, ¹²Saint-Herblain, CEDEX/FR, ¹³Lyon, FR, ¹⁴Angers, FR, ¹⁵Belfort, FR, ¹⁶Nice, FR

15:29 - 15:29 1051PD - A phase 1, multicenter, open-label, dose-escalation, combination study of RM-1929 and photoimmunotherapy in patients with recurrent head and neck cancer

S.T. Kochuparambil¹, D. McDonald¹, M. Fidler², K. Stenson², N. Vasan³, M.A. Razaq³; ¹Minneapolis, US, ²Chicago, US, ³Oklahoma City, US

15:29 - 15:41 Invited Discussant LBA47, 1050PD and 1051PD

S. Oosting, Groningen, NL

15:41 - 15:51 Q&A led by Discussant

15:51 - 15:51 1052PD - First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial

L. Zhang¹, Y. Huang², Y. Yang², S. Ma², X. Lin², L. Lin², T. Zhou², Y. Deng³, C. Zhang⁴, X. Ding⁵, S. Wang⁶, R. Wang⁷, G. Feng⁷, Y. Chen⁸, R. Xu⁶; ¹Guangzhou, Guangdong/CN, ²Guangzhou, CN, ³Foshan, CN, ⁴Dongguan, CN, ⁵Jiangmen, CN, ⁶Shenzhen, CN, ⁷Guangxi, CN, ⁸Hainan, CN

15:51 - 15:51 1053PD - Refining staging system for nasopharyngeal carcinoma treated with intensity-modulated radiation therapy

V. Lee¹, D. Kwong¹, T.W. Leung¹, C.-W. Choi¹, B. O'Sullivan², K.O. Lam¹, V. Lai¹, P.-L. Khong¹, S.-K. Chan¹, C.-Y. Ng¹, C.C. Tong¹, P.Y.P. Ho¹, W.L. Chan¹, L.-S. Wong¹, D. Leung¹, S.-Y. Chan¹, A. Lee¹;
¹Hong Kong, HK, ²Toronto, ON/CA

15:51 - 15:51 1054PD - A New Classification for Nasopharyngeal Carcinoma

H.C. Cheng, C.-F. Horng; Taipei, TW

15:51 - 16:03 Invited Discussant 1052PD, 1053PD and 1054PD

J. Bourhis, Lausanne, CH

16:03 - 16:13 Q&A led by Discussant

15:00 - 16:00 Type: Multidisciplinary Session Cordoba Auditorium
Title: Vomiting: One symptom, many causes
Chair(s): S. Kaasa, NO

15:00 - 15:05 Presentation of case/condition

S. Kaasa, Oslo, NO

15:05 - 15:15 The general perspective

S. Kaasa, Oslo, NO

15:15 - 15:25 The clinical and medical oncology perspective

C. Ruhlmann, Odense, DK

15:25 - 15:35 The surgery perspective

R. Audisio, Liverpool, GB

15:35 - 16:00 General Discussion

15:00 - 16:00	Type: Multidisciplinary Session Title: Brain progression on targeted therapies and immunotherapies Chair(s): S. Senan, NL	Valencia Auditorium
15:00 - 15:05	Presentation of case/condition <u>S. Senan</u> , Amsterdam, NL	
15:05 - 15:15	The radiation therapy perspective <u>S. Senan</u> , Amsterdam, NL	
15:15 - 15:25	The neurosurgery perspective <u>H.-S. Gwak</u> , Goyang-Si, KR	
15:25 - 15:35	The medical oncology perspective <u>L. Sequist</u> , Boston, MA/US	
15:35 - 16:00	General Discussion <u>S. Senan</u> , Amsterdam, NL	

15:00 - 16:00 Type: Multidisciplinary Session
Title: Management of toxicities
Chair(s): S. Cousin, FR Cartagena Auditorium

15:00 - 15:10 Presentation of melanoma case and the clinical oncology perspective
S. Cousin, Lille, FR

15:10 - 15:15 The dermatology perspective
H.B. Thio, Rotterdam, NL

15:15 - 15:20 The ophthalmology perspective
U. Urner-Bloch, Zürich, CH

15:20 - 15:30 Discussion with audience

15:30 - 15:40 Presentation of TKI resistance case and The clinical oncology perspective
S. Cousin, Lille, FR

15:40 - 15:45 The dermatology perspective
H.B. Thio, Rotterdam, NL

15:45 - 15:50 The ophthalmology perspective
U. Urner-Bloch, Zürich, CH

15:50 - 16:00 Discussion with audience

15:00 - 16:00 Type: Young Oncologist Special session
Title: ESMO for medical students and young physicians Room 55
Chair(s): A. Cervantes, ES; A. Berghoff, AT

15:00 - 15:10 ESMO-ESO Medical Students Course
A. Cervantes, Valencia, Valencia/ES

15:10 - 15:20 How to prepare and present your first poster at a congress
A. Berghoff, Vienna, AT

15:20 - 16:00 Guided poster walk
M. Petrova¹, M. Preusser², M. Strijbos³; ¹Sofia, BG, ²Vienna, AT, ³Brasschaat, BE

- 16:20 - 18:00 Type: Proffered Paper session Cordoba Auditorium
Title: Supportive and palliative care
Chair(s): M. Apro, CH; S. Kaasa, NO
- 16:20 - 16:32 1386O - Cancer cachexia (CAX), anorexia and muscle wasting (sarcopenia) assessment in non-small cell lung cancer (NSCLC): an observational study in 531 patients
D. Debievre¹, H. Morel², P.-J. Souquet³, V. Surmont⁴, D. Planchard⁵, F. Bonnetain⁶, I. Krakowski⁷, H. Gaudin⁸, S. Antoun⁵; ¹Mulhouse, FR, ²Orleans, FR, ³Pierre Bénite, CEDEX/FR, ⁴Gent, BE, ⁵Villejuif, FR, ⁶Besançon, CEDEX/FR, ⁷Vandoeuvre Les Nancy, CEDEX/FR, ⁸Paris, FR
- 16:32 - 16:44 1539O - Pre-chemotherapy nutritional status and chemotherapy response: An observational study
R. Rao, N. Saha, V. Mani, R. Amritanshu, R. Geetha, N. Radheshyam, S. Patil, H.P. Shashidhara, T. Satheesh, V. Agarwal, B. Ajaikumar; Bangalore, IN
- 16:44 - 16:59 Invited Discussant 1386O and 1539O
S. Kaasa, Oslo, NO
- 16:59 - 17:11 1540O - Fosaprepitant reduces the impact of nausea on daily function during five weeks of chemo-radiotherapy: A sub-study of the GAND-emesis trial
C. Ruhlmann¹, T. Christensen², L. Hammer Dohn³, M. Paludan⁴, E. Roennengart⁵, F. Hilpert⁶, P. Feyer⁷, G. Kristensen⁸, O. Hansen⁹, D. Keefe¹⁰, J. Herrstedt¹; ¹Odense, DK, ²Hillerød, DK, ³Copenhagen, DK, ⁴Aarhus, DK, ⁵Herlev, DK, ⁶Kiel, DE, ⁷Berlin, DE, ⁸Oslo, NO, ⁹Odense C, DK, ¹⁰Adelaide, AU
- 17:11 - 17:23 1422O - CTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physicians' and patients' scoring of toxicity in the "Panther trial"
Y. Brandberg¹, S. Loibl², T. Foukakis¹, H. Johansson¹, M. Gnant³, C. Singer³, G. von Minckwitz², N.-O. Bengtsson⁴, E. Karlsson⁵, B. Mlineritsch⁶, M. Hellström¹, G. Steger³, L. Carlsson⁴, D. Egle⁷, R. Greil⁸, J. Bergh¹; ¹Stockholm, SE, ²Neu-Isenburg, DE, ³Vienna, AT, ⁴Umeå, SE, ⁵Karlstad, SE, ⁶Salzburg, AT, ⁷Innsbruck, AT, ⁸Salzburg, AT
- 17:23 - 17:38 Invited Discussant 1540O and 1422O
K. Jordan, Heidelberg, DE
- 17:38 - 17:50 1541O_PR - Reproductive potential and performance of fertility-preserving procedures in BRCA mutation-positive (BRCA+) breast cancer (BC) patients (pts)
M. Lambertini¹, O. Goldrat¹, A. Ferreira², J. Dechene¹, J. Desir¹, A. Delbaere¹, M.-D. t'Kint de Roodenbeke¹, E. De Azambuja¹, M. Ignatiadis¹, I. Demeestere¹; ¹Brussels, BE, ²Lisbon, PT
- 17:50 - 18:00 Invited Discussant 1541O
O. Pagani, Bellinzona, CH

16:30 - 18:00	Type: Educational session Title: CDK4 inhibitors in metastatic breast cancer Chair(s): S. Loibl, DE; S. Loi, AU	Barcelona Auditorium
16:30 - 16:55	Rationale to target CDK4 <u>B. O'Leary</u> , London, AF	
16:55 - 17:20	Efficacy of CDK4 inhibitors: Data from clinical trials <u>S. Loibl</u> , Neu-Isenburg, DE	
17:20 - 17:45	Triple combination with PI3K <u>D. Juric</u> , Boston, Ma, US	
17:45 - 18:00	Discussion	

- 16:30 - 18:00 Type: Presidential Symposium
Title: Presidential Symposium I
Chair(s): F. Ciardiello, IT; R. Stahel, CH
Madrid Auditorium
- 16:30 - 16:45 LBA1_PR - PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
L. Paz-Ares¹, A. Villegas², D. Daniel³, D. Baz⁴, S. Murakami⁵, R. Hui⁶, T. Yokoi⁷, A. Chiappori⁸, K.H. Lee⁹, M. de Wit¹⁰, B.C. Cho¹¹, M. Bourhaba¹², X. Quantin¹³, T. Tokito¹⁴, T. Mekhail¹⁵, D. Planchard¹⁶, H. Jiang¹⁷, Y. Huang¹⁷, P. Dennis¹⁷, M. Özgüroğlu¹⁸; ¹Madrid, ES, ²Jacksonville, FL/US, ³Chattanooga, US, ⁴Seville, ES, ⁵Yokohama, JP, ⁶Sydney, AU, ⁷Hirakata, JP, ⁸Tampa, US, ⁹Cheongju, KR, ¹⁰Berlin, DE, ¹¹Seoul, KR, ¹²Liège, BE, ¹³Montpellier, FR, ¹⁴Kurume, JP, ¹⁵Orlando, US, ¹⁶Villejuif, FR, ¹⁷Gaithersburg, US, ¹⁸Istanbul, TR
- 16:45 - 17:00 Invited Discussant LBA1_PR
J. Vansteenkiste, Leuven, BE
- 17:00 - 17:15 1273O - Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)
V. Westeel¹, F. Barlesi², P. Foucher³, J.-J. Lafitte⁴, J. Domas⁵, P. Girard⁶, J. Tredaniel⁶, M. Wislez⁶, P. Dumont⁷, E. Quoix⁸, O. Raffy⁹, D. Braun¹⁰, M. Derollez¹¹, F. Goupil¹², J. Hermann¹³, E. Devin¹⁴, E. Pichon¹⁵, J.-P. Gury¹⁶, F. Morin⁶, P.-J. Souquet¹⁷; ¹Besançon, CEDEX/FR, ²Marseille, FR, ³Dijon, Cedex/FR, ⁴Lille, FR, ⁵Perpignan, FR, ⁶Paris, FR, ⁷Chauny, CEDEX/FR, ⁸Strasbourg, CEDEX/FR, ⁹Chartres, FR, ¹⁰Briey, FR, ¹¹Maubeuge, FR, ¹²Le Mans, FR, ¹³Metz, FR, ¹⁴Evreux, FR, ¹⁵Tours, CEDEX 9/FR, ¹⁶Vesoul, FR, ¹⁷Pierre Bénite, CEDEX/FR
- 17:15 - 17:30 Invited Discussant 1273O
E. Smit, Amsterdam, NL
- 17:30 - 17:45 LBA2_PR - Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
S. Ramalingam¹, T. Reungwetwattana², B. Chewaskulyong³, A. Dechaphunkul⁴, K.H. Lee⁵, F. Imamura⁶, N. Nogami⁷, Y. Ohe⁸, Y. Cheng⁹, B.C. Cho¹⁰, E.K. Cho¹¹, J. Vansteenkiste¹², P.J. Voon¹³, C. Zhou¹⁴, J. Gray¹⁵, R. Hodge¹⁶, Y. Rukazenkova¹⁷, J.-C. Soria¹⁸; ¹Atlanta, GA/US, ²Bangkok, TH, ³Chiang Mai, TH, ⁴Hat Yai, TH, ⁵Cheongju, KR, ⁶Osaka, JP, ⁷Matsuyama, JP, ⁸Tokyo, JP, ⁹Jilin, CN, ¹⁰Seoul, KR, ¹¹Incheon, KR, ¹²Leuven, BE, ¹³Kuching, MY, ¹⁴Shanghai, CN, ¹⁵Tampa, FL/US, ¹⁶Cambridge, GB, ¹⁷Macclesfield, Cheshire/GB, ¹⁸Villejuif, CEDEX/FR
- 17:45 - 18:00 The winner takes it all - Invited Discussion of LBA2_PR
T.S.K. Mok, Shatin, HK

16:30 - 18:00	Type: Educational session Title: Pancreatic cancer Chair(s): E. Van Cutsem, BE; T. Seufferlein, DE	Sevilla Auditorium
16:30 - 16:55	New approaches in genetic classification and translational studies <u>G. Tortora</u> , Verona, IT	
16:55 - 17:20	Neoadjuvant vs adjuvant <u>T. Seufferlein</u> , Ulm, DE	
17:20 - 17:45	New treatment combinations in metastatic disease <u>E. O'Reilly</u> , New York, Ny, US	
17:45 - 18:00	Discussion	

16:30 - 18:00	Type: Proffered Paper session Title: Basic science Chair(s): A. Berns, NL; C. Isacke, GB	Granada Auditorium
16:30 - 16:42	17000 - Genomic profiling of 114,200 advanced cancers identifies recurrent kinase domain duplications (KDD) and oncogenic rearrangements (RE) across diverse tumor types <u>L. Gay</u> ¹ , D. Pavlick ² , J. Chung ² , S. Ramkissoon ² , S. Daniel ² , J. Elvin ² , E. Severson ² , T. Bivona ³ , K. Reckamp ⁴ , S. Klemperer ⁵ , S.-H. Ou ⁶ , A. Schrock ⁷ , V. Miller ² , P. Stephens ² , J. Ross ⁸ , S. Ganesan ⁹ , C. Lovly ¹⁰ , A. Mansfield ¹¹ , S. Ali ² ; ¹ Cambridge, CA, ² Cambridge, MA/US, ³ San Francisco, US, ⁴ Duarte, CA/US, ⁵ Los Angeles, US, ⁶ Orange, CA/US, ⁷ Cambridge, US, ⁸ Albany, NY/US, ⁹ New Brunswick, US, ¹⁰ Nashville, TN/US, ¹¹ Rochester, MN/US	
16:42 - 16:54	17010 - Comprehensive Genomic Profiling (CGP) of Thymic Gland Carcinomas <u>J. Ross</u> ¹ , P. Vanden Borre ² , N. Almog ² , A. Schrock ³ , J. Chung ² , J.-A. Vergilio ² , J. Suh ² , S. Ramkissoon ² , E. Severson ² , S. Daniel ² , S. Ali ² , V. Miller ² , P. Stephens ² , J. Elvin ² , L. Gay ² ; ¹ Albany, NY/US, ² Cambridge, MA/US, ³ Cambridge, US	
16:54 - 17:06	17020 - Clinical implications of genomic variants identified in over 30,000 advanced-stage cancer patients by next-generation sequencing of circulating tumor DNA <u>S. Pal</u> ¹ , C. Brooks ² , D. Chudova ³ , J. Odegaard ³ , D. Gandara ⁴ , P. Mack ⁴ , S. Mortimer ³ , K. Banks ³ , R. Nagy ² , A. Baca ³ , R. Lanman ³ , H. Eltoukhy ³ , A. Talasz ³ ; ¹ Duarte, CA/US, ² Redwood City, US, ³ Redwood City, CA/US, ⁴ Sacramento, CA/US	
17:06 - 17:21	Invited Discussant 17000, 17010 and 17020 <u>U. McDermott</u> , Manchester, GB	
17:21 - 17:33	10 - Wild-type KRAS mediates growth inhibition and resistance to MEK inhibitors through dimerization with mutant KRAS in lung adenocarcinoma <u>C. Ambrogio</u> ¹ , J. Kohler ² , Z. Zhou ³ , H. Wang ⁴ , R. Paranal ² , M. Capelletti ² , C. Caffarra ² , S. Li ² , Q. Lv ⁴ , D. Santamaria ⁵ , K. Westover ³ , P. Jänne ⁶ ; ¹ Boston, US, ² Boston, MA/US, ³ Dallas, TX/US, ⁴ Shanghai, CN, ⁵ Pessac, FR, ⁶ Boston, Ma, US	
17:33 - 17:45	20 - CDCP1 initiates tumorigenesis and cooperates with PTEN loss to promote senescence evasion and prostate cancer progression <u>A. Alajati</u> , J. Chen, A. Alimonti; Bellinzona, CH	
17:45 - 18:00	Invited Discussant 10 and 20 <u>C. Isacke</u> , London, GB	

16:30 - 18:00	Type: Special Symposium Title: State of the science of targeted treatment in sarcoma Chair(s): G.D. Demetri, US; R. Jones, GB	Valencia Auditorium
16:30 - 16:35	Introduction <u>G.D. Demetri</u> , Boston, MA/US	
16:35 - 16:55	Managing GIST resistance to standard TKI therapy <u>H. Joensuu</u> , Helsinki , FI	
16:55 - 17:15	Inhibitors of MDM2, CDK4 and other approaches in MDM2 amplified sarcomas <u>O. Mir</u> , Villejuif, FR	
17:15 - 17:35	Immuno-oncology approaches to sarcomas <u>R. Maki</u> , New York, Ny, US	
17:35 - 17:55	Next generation targets and combinations in sarcomas <u>G.D. Demetri</u> , Boston, MA/US	
17:55 - 18:00	Conclusions and clinical perspectives <u>R. Jones</u> , London, GB	
16:30 - 17:45	Type: Poster Discussion session Title: Public health policy and health economics Chair(s): J. Martin-Moreno, ES; R. Giuliani, IT; F. Perrone, IT	Tarragona Auditorium
16:30 - 16:30	1440PD - The European Cancer Patient Coalition's white policy paper on the value of innovation in oncology <u>L. Makaroff</u> ¹ , F. De Lorenzo ² , K. Apostolidis ³ , J. Pelouchova ⁴ , A. Winterbottom ¹ , S. Chrostowski ⁵ , D. Cimpoeru ¹ , N. Bolanos Fernandez ⁶ , A. Rek ¹ , I. Manneh-Vangramberen ¹ , L. Baker ¹ , F. Florindi ¹ ; ¹ Brussels, BE, ² Roma, IT, ³ GR, ⁴ Prague, 2/CZ, ⁵ Warsaw, PL, ⁶ Madrid, ES	
16:30 - 16:30	1441PD - Magnitude of clinical benefit of randomized controlled trials supporting US Food and Drug Administration approval of drugs for solid tumours <u>C. Molto Valiente</u> ¹ , E. Amir ² , A. Ocana Fernandez ³ , A. Templeton ⁴ , L. del Carpio Huerta ¹ , J. Del Paggio ⁵ , A. Barnadas ¹ , C. Booth ⁶ , A. Tibau ¹ ; ¹ Barcelona, ES, ² Toronto, Ontario/CA, ³ Albacete, ES, ⁴ Basel, CH, ⁵ Kingston, CA, ⁶ Kingston, Ontario/CA	
16:30 - 16:30	1442PD - Review on adherence to breast cancer guidelines in Europe <u>L. Neamtiu</u> ¹ , L. Pytkkanen ¹ , C. Freeman ² , Z. Saz Parkinson ³ , S. Deandrea ¹ , A. Uluturk Tekin ¹ , N. Dimitrova ¹ , D. Lerda ¹ ; ¹ Ispra, IT, ² Barcelona, ES, ³ Ispra, Varese/IT	
16:30 - 16:45	Invited Discussant 1440PD, 1441PD and 1442PD <u>R. Giuliani</u> , Roma, IT	

- 16:45 - 16:55 Q&A led by Discussant
- 16:55 - 16:55 1443PD - Analysis of compliance factors for colorectal cancer screening using a Bayesian network
F. Eisinger¹, J. Viguier², J.-Y. Blay³, A. Cortot⁴, C. Touboul⁵, C. Lhomel⁶, L. Greillier⁷, S. Couraud⁸, J.-F. Morere⁹; ¹Marseille, CEDEX 9/FR, ²Tours, FR, ³Lyon, FR, ⁴Lille, FR, ⁵Paris, FR, ⁶Neuilly-Sur-seine, FR, ⁷Marseille, FR, ⁸Pierre Bénite, CEDEX/FR, ⁹Villejuif, CEDEX/FR
- 16:55 - 16:55 1401PD - Fluctuating cancer screening uptake in France: results of the 5th EDIFICE survey
J. Viguier¹, S. Couraud², L. Greillier³, J.-Y. Blay⁴, C. Touboul⁵, C. Lhomel⁶, A. Cortot⁷, J.-F. Morere⁸, F. Eisinger⁹; ¹Boulogne-Billancourt, FR, ²Pierre Bénite, CEDEX/FR, ³Marseille, FR, ⁴Lyon, FR, ⁵Paris, FR, ⁶Neuilly-Sur-seine, FR, ⁷Lille, FR, ⁸Villejuif, CEDEX/FR, ⁹Marseille, CEDEX 9/FR
- 16:55 - 17:05 Invited Discussant 1443PD and 1401PD
J. Martin-Moreno, Valencia, Valencia/ES
- 17:05 - 17:10 Q&A led by Discussant
- 17:10 - 17:10 1110PD_PR - Factors associated with reduced work ability in a nation-wide cohort of long-term cancer survivors treated in young adulthood (19-39 years): The NOR-CAYACS study
C. Kiserud, H. Lie, A. Finset, S. Fosså, J.H. Loge, E. Ruud, A. Dahl; Oslo, NO
- 17:10 - 17:10 1111PD - Economic burden of cancer patients and the job assistance from the society
N. Koinuma, Sendai, JP
- 17:10 - 17:10 1112PD_PR - Real-world productivity, healthcare resource utilization (HRU), and quality of life (QOL) in patients with advanced gastric cancer (GC) in Canada and Europe
G. Maglinte¹, A. Rider², M. Contente³, A. Boyers², B. Clarke², E. Calvo⁴; ¹Princeton, US, ²Manchester, GB, ³Ladeuze, BE, ⁴Madrid, ES
- 17:10 - 17:20 Invited Discussant 1110PD, 1111PD and 1112PD
F. Perrone, Napoli, IT
- 17:20 - 17:25 Q&A led by Discussant
- 17:25 - 17:25 1113PD - Using the ASCO's quality oncology practice initiative (QOPI) metrics and standards to improve value, meaningful use of resources and reduce waste
C. Pinto, F. Loiola, T. Garcia, E. Romano, L. Altoe, L. Garcia, D. Oliveira, A. Rodrigo, H. Fernandes; Sao Jose Dos Campos, BR
- 17:25 - 17:25 1444PD - Cancer Clinical Practice Guidelines: Evaluation of ESMO, NICE and SIGN diversity
E. Pallari, A. Fox, G. Lewison; London, GB
- 17:25 - 17:35 Invited Discussant 1113PD and 1444PD

M. Apro, Genolier, CH

17:35 - 17:40 Q&A led by Discussant

16:30 - 17:30 Type: Poster Discussion session Bilbao Auditorium
Title: CNS tumours
Chair(s): P. French, NL; J.-C. Tonn, DE

16:30 - 16:30 329PD - Prognostic factors for IDH mutant molecular astrocytomas

S. Minichillo¹, E. Franceschi¹, A. Mura¹, A. Mandrioli¹, A. Tosoni¹, G. Tallini¹, A. Pession¹, M.P. Foschini¹, C. Bortolotti¹, D. Danieli², A. Talacchi³, L. Cirillo¹, S. Bartolini¹, A. Paccapelo¹, A. Brandes¹;
¹Bologna, IT, ²Vicenza, IT, ³Verona, IT

16:30 - 16:30 330PD - Galectin-1 (Gal-1) expression as a prognostic factor in a homogenous cohort of glioblastoma (GB) (Gliocat study)

N. Vilariño Quintela¹, N. Martinez Bosch¹, C. Balana², F. Alameda¹, A. Estival², E. Pineda¹, S. Del Barco³, M. Gil¹, C. Mesia⁴, O. Gallego¹, C. Carrato⁵, T. Ribalta¹, N. Vidal¹, N. Dela Iglesia¹, O. Arpi¹, J. Capellades¹, N. Garcia⁵, J.M. Velarde⁵, P. Navarro¹, M. Martinez-Garcia¹; ¹Barcelona, ES, ²Badalona, Barcelona/ES, ³Girona, ES, ⁴Barcelona, Barcelona/ES, ⁵Badalona, ES

16:30 - 16:30 331PD - Impact of WHO 2016 update and molecular markers in pleomorphic xanthoastrocytoma

R. Tonse, T. Gupta, E. Sridhar, J. Shastri, A. Jain, N. Bano, R. Jalali; Mumbai, IN

16:30 - 16:30 332PD - Change of PD-L1 expression status of high grade glial tumors at recurrence and its effect on survival

B. Oyan, S. Eren, O. Sonmez, F. Ozkan, K. Yaltrak, U. Ture; Istanbul, TR

16:30 - 16:50 Invited Discussant 329PD, 330PD, 331PD and 332PD

P. French, Rotterdam, NL

16:50 - 17:00 Q&A led by Discussant

17:00 - 17:00 333PD - Meta-analysis of the effect of rituximab in the treatment of primary central nervous system lymphoma

S. Yavuz¹, M. Yildirim², G. Yazıcı³, V. Kaya⁴, S. Paydas¹; ¹Adana, TR, ²Gaziantep, TR, ³Ankara, TR, ⁴Antalya, TR

17:00 - 17:00 334PD - Tumor Treating Fields (TTFields) – A novel cancer treatment modality: Translating preclinical evidence and engineering into a survival benefit with delayed decline in quality of life

R. Stupp¹, M. Taphoorn², L. Dirven³, S. Taillibert⁴, J. Honorat⁵, T. Chen⁶, J. Sroubek⁷, S.H. Paek⁸, J. Bruna Escuder⁹, J. Easaw¹⁰, C. David¹¹, C.Y. Kim¹², R. Desai¹³, Y. Kew¹⁴, A. Olivi¹⁵, A. Hottinger¹⁶, E. Kirson¹⁷, G. Lavy-Shahaf¹⁷, M. Hegi¹⁶, Z. Ram¹⁸; ¹Zürich, CH, ²The Hague, NL, ³Leiden, NL, ⁴Paris, FR, ⁵Lyon, FR, ⁶Los Angeles, CA/US, ⁷Prague, CZ, ⁸Seoul, KR, ⁹Barcelona, ES, ¹⁰Calgary, CA, ¹¹Burlington, MA/US, ¹²Bundang, KR, ¹³Scarborough, ME/US, ¹⁴Houston, TX/US, ¹⁵Baltimore, MD/US, ¹⁶Lausanne, CH, ¹⁷Haifa, IL, ¹⁸Tel Aviv, IL

- 17:00 - 17:00 335PD - Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly-diagnosed glioblastoma
M. Fontanilles¹, F. Clatot², C. Alexandru², O. Langlois¹, O. Veresezan¹, F. Marguet¹, M. David¹, A. Laquerriere¹, C. Hanzen², I. Tennevet Bouilly², F. Di Fiore¹; ¹Rouen, FR, ²Rouen, CEDEX 1/FR
- 17:00 - 17:00 336PD - Treatment of recurrent glioblastoma (GB) after radiotherapy (RT) and temozolomide (TMZ): A retrospective analysis of the GLIOCAT study
M. Gil¹, J.M. Velarde², M. Martinez-Garcia¹, O. Gallego¹, S. del Barco³, E. Pineda¹, C. Mesia⁴, A. Estival⁵, N. Vilariño¹, J. Marruecos³, E. Verger¹, J. Craven¹, R. Fuentes², A. Lucas¹, M. Macià¹, C. Carrato², N. Vidal⁶, R. Velasco¹, S. Villa², C. Balana⁵; ¹Barcelona, ES, ²Badalona, ES, ³Girona, ES, ⁴Barcelona, Barcelona/ES, ⁵Badalona, Barcelona/ES, ⁶L'hospitalet, ES
- 17:00 - 17:20 Invited discussant 333PD, 334PD, 335PD and 336Pd
J.-C. Tonn, Munich, DE
- 17:20 - 17:30 Q&A led by Discussant
- 16:30 - 18:00 Type: Poster Discussion session Alicante Auditorium
Title: Developmental therapeutics
Chair(s): C. Massard, FR; S. Sleijfer, NL; U. Lassen, DK
- 16:30 - 16:30 LBA20 - Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial
I. Marquez Rodas¹, M. Rodriguez Ruiz², S. Lopez-Tarruella Cobo¹, J.L. Perez Gracia², M. Ponz Sarvise², R. Alvarez¹, E. de Miguel¹, Y. Jerez¹, A. Calvo Ferrandiz¹, M. Blanco Codesido¹, J. Gayarre¹, R. Ramos Medina¹, A. Calles¹, M.A. Aznar², L. Planelles³, M. Quintero³, S. Martin Algarra², M. Martin Jimenez¹, I. Melero²; ¹Madrid, ES, ²Pamplona, ES, ³Valencia, ES
- 16:30 - 16:30 366PD - Oncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018)
S. Danson¹, P. Woll¹, J. Edwards², K. Blyth³, P. Fisher¹, J. Roman⁴, K. Simpson⁴, R. Spavin⁴, K. Learmonth⁴, J. Conner⁴; ¹Sheffield, South Yorkshire/GB, ²Sheffield, GB, ³Glasgow, GB, ⁴Newhouse, GB
- 16:30 - 16:30 367PD - Early FDG-PET response correlates with dose and clinical efficacy in patients with microsatellite stable (MSS) metastatic CRC (mCRC) treated with the CEA-CD3 T-cell bispecific antibody plus atezolizumab

F. Sandoval¹, D. Sabanes Bove¹, S. Bouseida¹, V. Karanikas², A. Keelara¹, J. Saro², T. Nayak¹; ¹Basel, CH, ²Schlieren, CH

- 16:30 - 16:30 368PD - Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors
J. Lickliter¹, L. Mileskin², M. Voskoboynik¹, M. Millward³, A. Freimund², T. Meniawy³, T. Tang⁴, R. Wei⁴, M. Li⁵, V. Paton⁶; ¹Melbourne, AU, ²Melbourne, VIC/AU, ³Nedlands, WA/AU, ⁴Emeryville, CA/US, ⁵Beijing, CN, ⁶Emeryville, US
- 16:30 - 16:50 Invited Discussant LBA20, 366PD, 367PD and 368PD
C. Massard, Villejuif, FR
- 16:50 - 17:00 Q&A led by Discussant
- 17:00 - 17:00 370PD - Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer
A. Tsimberidou¹, C. Verschraegen², A. Weise³, J. Sarantopoulos⁴, G. Lopes⁵, J. Nemunaitis⁶, A. Victor⁷, J. Shaw⁷, R. Kaleta⁸, R. Kurzrock⁹; ¹Houston, TX/US, ²Cincinnati, US, ³Detroit, US, ⁴San Antonio, US, ⁵Miami, FL/US, ⁶Dallas, US, ⁷Darmstadt, DE, ⁸Billerica, US, ⁹San Diego, US
- 17:00 - 17:00 371PD - A Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors
D. Rasco¹, R. Sullivan², N. Lakhani³, S. Reddy⁴, N. Rao⁴, L. Denis⁵, A. Tolcher¹, K. Flaherty²; ¹San Antonio, TX/US, ²Boston, MA/US, ³Grand Rapids, MI/US, ⁴Lawrenceville, NJ/US, ⁵Bridgewater, New Jersey/US
- 17:00 - 17:00 372PD - First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors
Y. Kuboki¹, N. Matsubara², H. Bando², K. Shitara², K. Yoh², T. Kojima³, I. Ohno², H. Takahashi², K. Harano⁴, S. Kondo¹, H. HIRAI¹, C. Morizane¹, T. Doi²; ¹Tokyo, JP, ²Kashiwa, Chiba/Jp, ³Kashiwa, JP, ⁴Kawasaki, Kanagawa/Jp
- 17:00 - 17:20 Invited Discussant 370PD, 371PD and 372PD
S. Sleijfer, Rotterdam, NL
- 17:20 - 17:30 Q&A led by Discussant
- 17:30 - 17:30 373PD - Phase 1 Study of E7046, a PGE2 Receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment
D. Hong¹, A. Varga², A. Parikh³, G. Shapiro³, L. Reyderman⁴, M. Ren⁵, S. Dayal⁶, T. Binder⁵, C.E. Ooi⁵, O. Ataman⁶, A. Marabelle²; ¹Houston, US, ²Villejuif, FR, ³Boston, US, ⁴Woodcliff Lake, NJ/US, ⁵Woodcliff Lake, US, ⁶Hatfield, GB

17:30 - 17:30 374PD - A first in human phase 1 study of KPT-9274, a first in class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies or NHL
A. Naing¹, S. Leong², M. Pishvaian³, A. Razak⁴, A. Mahipal⁵, J. Berlin⁶, D. Cho⁷, W. Senapedis⁸, S. Shacham⁹, M. Kauffman¹⁰, J. Ellis¹¹, J. Meade⁹, E. Baloglu¹²; ¹Houston, TX/US, ²Aurora, CO/US, ³Washington, DC/US, ⁴Toronto, CA, ⁵Tampa, FL/US, ⁶Nashville, TN/US, ⁷New York, NY/US, ⁸Natick, MA/US, ⁹Newton, US, ¹⁰Natick, US, ¹¹Newton, MA/US, ¹²Rotterdam, NL

17:30 - 17:30 375PD - Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine (gem) in patients (pts) with refractory solid tumors
A. Italiano¹, J. Infante², G. Shapiro³, K. Moore⁴, P. Lorusso⁵, S. Postel-Vinay⁶, S. Cousin⁷, M. Toulmonde⁸, C. Lucchesi¹, E. Blackwood⁹, S. Mahrus⁹, X. Lu⁹, M. Tagen⁹, J. Schutzman⁹, J. Lauchle⁹, J.-C. Soria¹⁰; ¹Bordeaux, FR, ²Nashville, TN/US, ³Boston, US, ⁴Oklahoma City, Oklahoma/US, ⁵New Haven, CT/US, ⁶Villejuif, FR, ⁷Lille, FR, ⁸Bordeaux, CEDEX/FR, ⁹South San Francisco, US, ¹⁰Villejuif, CEDEX/FR

17:30 - 17:50 Invited Discussant 373PD, 374PD and 375PD
U. Lassen, Copenhagen, DK

17:50 - 18:00 Q&A led by Discussant

18:00 - 19:30 Type: Patient Advocacy Track
 Title: Bio-ethical controversies and what they mean to research and European inequalities
 Chair(s): A. Plate, BE; G. Henning, GB
 Palma Auditorium

18:00 - 18:15 The regulatory perspective
K. Steig, Oslo, NO

18:15 - 18:30 The academic perspective
I. De Lecuona, Barcelona, ES

18:30 - 18:45 The clinical researcher perspective
B. Woermann, Berlin, DE

18:45 - 19:00 Why an oncologist should care
G. Morgan, Lund, SE

19:00 - 19:15 The patient perspective
L. Bayne, London, GB

19:15 - 19:30 Discussion

18:30 - 20:00 Type: Industry Satellite Symposium Sevilla Auditorium
 Title: Industry Satellite Symposium 21

18:30 - 20:00 Type: Industry Satellite Symposium Pamplona Auditorium
 Title: Industry Satellite Symposium 22

18:30 - 20:00 Type: Industry Satellite Symposium Cordoba Auditorium
 Title: Industry Satellite Symposium 23

18:30 - 20:00 Type: Industry Satellite Symposium Granada Auditorium
 Title: Industry Satellite Symposium 24

18:30 - 20:00 Type: Industry Satellite Symposium Valencia Auditorium
 Title: Industry Satellite Symposium 25

18:30 - 20:00 Type: Industry Satellite Symposium Tarragona Auditorium
 Title: Industry Satellite Symposium 26

18:30 - 20:00 Type: Industry Satellite Symposium Bilbao Auditorium
 Title: Industry Satellite Symposium 27

10-09-2017

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Cordoba Auditorium
 Title: Management of patients on immunotherapy
 Chair(s): I.-M. Svane, DK

08:00 - 08:10 Management of patients on immunotherapy
P. Lorigan, Manchester, GB

08:10 - 09:00 Discussion led by Chair
I.-M. Svane, Herlev, DK

08:00 - 09:00 Type: Controversy session Granada Auditorium
Title: Which is the best TKI upfront in ALK + NSCLC patients?
Chair(s): E. Felip Font, ES

08:00 - 08:10 Introduction and 1st vote
E. Felip Font, Barcelona, ES

08:10 - 08:30 New generation TKI upfront
J. Wolf, Köln, DE

08:30 - 08:50 Crizotinib upfront
B. Besse, Villejuif, FR

08:50 - 09:00 2nd vote and conclusions
E. Felip Font, Barcelona, ES

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Valencia Auditorium
Title: Locoregional challenges with neoadjuvant systemic therapy
Chair(s): E. Senkus-Konefka, PL

08:00 - 08:10 Locoregional challenges with neoadjuvant systemic therapy
M. Gnant, Vienna, AT

08:10 - 09:00 Discussion led by Chair
E. Senkus-Konefka, Gdańsk, PL

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Tarragona Auditorium
Title: Multidisciplinary management of localised high risk bladder cancer
Chair(s): A. Bamias, GR

08:00 - 08:10 Multidisciplinary management of localised high risk bladder cancer
A. Necchi, Milan, IT

08:10 - 09:00 Discussion led by Chair
A. Bamias, Athens, GR

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Bilbao Auditorium
 Title: GE junction tumours
 Chair(s): H. van Laarhoven, NL

08:00 - 08:10 GE junction tumours
D. Cunningham, Sutton, GB

08:10 - 09:00 Discussion led by Chair
H. van Laarhoven, Amsterdam, NL

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Cartagena Auditorium
 Title: How a tumour's microenvironment may affect therapeutic response
 Chair(s): S.A. Quezada, GB

08:00 - 08:10 How a tumour's microenvironment may affect therapeutic response
J.W. Pollard, Edinburgh, GB

08:10 - 09:00 Discussion led by Chair
S.A. Quezada, London, GB

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Salamanca Auditorium
 Title: Secondary MDS and AML
 Chair(s): J. DE LA SERNA, ES

08:00 - 08:10 Secondary MDS and AML
M. Dennis, Manchester, GB

08:10 - 09:00 Discussion led by Chair
J. DE LA SERNA, Madrid, ES

08:15 - 09:00 Type: Keynote Lecture Barcelona Auditorium
 Title: Coping with escalating healthcare costs in 2017 and beyond
 Chair(s): P.G. Casali, IT

08:15 - 09:00 Coping with escalating healthcare costs in 2017 and beyond
J. Tabernero, Barcelona, ES

- 09:15 - 10:45 Type: Proffered Paper session
Title: Mesothelioma and SCLC
Chair(s): P. Garrido Lopez, ES; S. Popat, GB
Barcelona Auditorium
- 09:15 - 09:30 1615O - Pembrolizumab as second or further line treatment in relapsed malignant pleural mesothelioma: A Swiss registry
L. Mauti¹, D. Klingbiel², S. Schmid³, H. Bouchaab⁴, T. Bartnick⁵, O. Gautschi⁶, S. Rothschild⁷, M. Loeffler-Baumann⁸, P. Froesch⁹, U. Petrusch¹⁰, S. Wolleb Schild¹¹, W. Mingrone¹², S. Pratsch Peter¹⁰, S. Savic Prince⁷, M. Pless¹, R. von Moos¹³, Y. Metaxas¹³; ¹Winterthur, CH, ²Berne, CH, ³St. Gallen, CH, ⁴Lausanne, CH, ⁵Baden, CH, ⁶Luzern, CH, ⁷Basel, CH, ⁸Aarau, CH, ⁹Locarno, CH, ¹⁰Zürich, CH, ¹¹Uster, CH, ¹²Olten, Solothurn/CH, ¹³Chur, CH
- 09:30 - 09:45 LBA58_PR - Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial
G. Zalcman¹, J. Mazieres², L. Greillier³, S. Lantuejoul⁴, P. Dô⁵, O. Bylicki⁶, I. Monnet⁷, R. Corre⁸, C. Audigier-Valette⁹, M. Locatelli-Sanchez¹⁰, O. Molinier¹¹, L. Thiberville¹², T. Urban¹³, D. Planchard¹⁴, C. Ligeza-Poisson¹⁵, E. Amour¹⁶, F. Morin¹⁶, D. Moro-Sibilot¹⁷, A. Scherpereel¹⁸; ¹Paris, CEDEX 18/FR, ²Toulouse, FR, ³Marseille, FR, ⁴La Tronche, CEDEX 9/FR, ⁵Caen, FR, ⁶Clamart, FR, ⁷Créteil, FR, ⁸Rennes, CEDEX/FR, ⁹Toulon, FR, ¹⁰Pierre-Bénite, FR, ¹¹Le Mans, FR, ¹²Rouen, FR, ¹³Angers, CEDEX 9/FR, ¹⁴Villejuif, FR, ¹⁵Saint-Nazaire, FR, ¹⁶Paris, FR, ¹⁷La Tronche, FR, ¹⁸Lille, FR
- 09:45 - 10:00 Invited Discussant 1615O and LBA58_PR
P. Baas, Amsterdam, NL
- 10:00 - 10:15 1616O - Multicenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM)
J. Trigo Perez¹, E. van Brummelen², E. Levchenko³, M. Domine Gomez⁴, D. Fennell⁵, H. Kindler⁶, S. Viteri⁷, S. Gadgeel⁸, P. Garrido Lopez⁴, V. Kostorov⁹, D. Morgensztern¹⁰, S. Orlov³, P. Paik¹¹, J. Vansteenkiste¹², X. Wang¹³, A. Sharabidze¹³, M. Deyoung¹⁴, K. Baker¹⁵, L. Yan¹³, I. Mitrica¹³; ¹Malaga, ES, ²Amsterdam, NL, ³St. Petersburg, RU, ⁴Madrid, ES, ⁵Leicester, GB, ⁶Chicago, IL/US, ⁷Barcelona, ES, ⁸Ann Arbor, US, ⁹Kuzmolovsky, RU, ¹⁰St Louis, US, ¹¹New York, NY/US, ¹²Leuven, BE, ¹³Collegeville, PA/US, ¹⁴Abbotsford, AU, ¹⁵South San Francisco, US
- 10:15 - 10:30 1527O - Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod
M. Thomas¹, S. Ponce-Aix², A. Navarro Mendivil³, J. Riera Knorrenschild⁴, M. Schmidt⁵, M. Krikow⁵, E. Wiegert⁵, M. Domine Gomez², J. Kollmeier⁵, P. Sadjadian⁶, K. Fröhling⁷, R. Huber⁸, M. Wolf⁹; ¹Heidelberg, DE, ²Madrid, ES, ³Barcelona, ES, ⁴Marburg, DE, ⁵Berlin, DE, ⁶Minden, DE, ⁷Koblenz, DE, ⁸Munich, DE, ⁹Kassel, DE
- 10:30 - 10:45 Invited Discussant one LBA TBC and 1616O
S. Popat, London, GB

09:15 - 10:45 Type: Special Symposium Cordoba Auditorium
 Title: Innovative therapies in head and neck cancer
 Chair(s): J.-P. Machiels, BE; L. Siu, CA

09:15 - 09:20 Introduction
J.-P. Machiels, Brussels, BE

09:20 - 09:40 Sense and non-sense of TransOral Robotic Surgery (TORS)
P. Ceruse, Lyon, FR

09:40 - 10:00 Proton therapy
D. Weber, Villigen, CH

10:00 - 10:20 Precision medicine in head and neck cancer: Myth or reality?
L. Siu, Toronto, On, CA

10:20 - 10:40 Window of opportunity in clinical trials for biomarker discovery in head and neck cancer
C. Le Tourneau, Paris, FR

10:40 - 10:45 Conclusions and clinical perspectives
L. Siu, Toronto, On, CA

09:15 - 10:15 Type: Controversy session Granada Auditorium
 Title: Supportive and palliative care improve patient outcomes and decrease treatment costs
 Chair(s): F. Scotté, FR

09:15 - 09:25 Introduction and 1st vote
F. Scotté, Paris, FR

09:25 - 09:45 Yes
B. Rapoport, Johannesburg, ZA

09:45 - 10:05 No
A. Charalambous, Limassol, CY

10:05 - 10:15 2nd vote and conclusions
F. Scotté, Paris, FR

09:15 - 10:30 Type: Poster Discussion session Bilbao Auditorium
 Title: Genitourinary tumours, prostate
 Chair(s): D. Olmos Hidalgo, ES; S. Oudard, FR; R. de Wit, NL

09:15 - 09:15 786PD - DNA repair gene panel mutations in young onset and aggressive vs non aggressive prostate cancer cases in the UK

R. Eeles¹, E. Saunders², S. Wakerell², I. Whitmore², C. Cieza-Borrella², K. Govindasami², T. Dadaev², Z. Kote-Jarai², D. Leongamornlert³; ¹London, GB, ²Sutton, GB, ³Cambridge, GB

09:15 - 09:15

787PD - Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide

A. Armstrong¹, P. Lin², C. Higano³, P. Iversen⁴, C. Sternberg⁵, B. Tombal⁶, D. Phung⁷, T. Parli², A. Krivoshek⁸, T. Beer⁹; ¹Durham, US, ²San Francisco, US, ³Seattle, WA/US, ⁴Copenhagen, DK, ⁵Roma, IT, ⁶Brussels, BE, ⁷Leiden, NL, ⁸Chicago, US, ⁹Portland, OR/US

09:15 - 09:25

Invited Discussant 786PD and 787PD

D. Olmos Hidalgo, Madrid, ES

09:25 - 09:30

Q&A led by Discussant

09:30 - 09:30

788PD - Randomized controlled trial comparing radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG0401

A. Yokomizo¹, T. Satoh², K. Hashine³, T. Inoue⁴, K. Fujimoto⁵, S. Egawa⁶, T. Habuchi⁷, K. Kawashima⁸, O. Ishizuka⁹, N. Shinohara¹⁰, M. Sugimoto¹¹, Y. Yoshino¹², M. Wakabayashi⁶, K. Nihei⁶, H. Fukuda⁶, K.-I. Tobisu⁶, Y. Kakehi¹¹, S. Naito¹; ¹Fukuoka, JP, ²Sagamihara, JP, ³Matsuyama, JP, ⁴Kyoto, JP, ⁵Nara, JP, ⁶Tokyo, JP, ⁷Akita, JP, ⁸Utsunomiya, JP, ⁹Matsumoto, JP, ¹⁰Sapporo, JP, ¹¹Kagawa, JP, ¹²Nagoya, JP

09:30 - 09:30

LBA33 - What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis

C. Vale¹, D. Fisher², J. Carpenter², I. White², S. Burdett¹, N. Clarke³, K. Fizazi⁴, G. Gravis⁵, N. James⁶, M. Mason⁷, M. Parmar⁸, L. Rydzewska², C. Sweeney⁹, M. Spears¹⁰, M. Sydes¹, J. Tierney²; ¹London, UK/GB, ²London, GB, ³M Hd, GB, ⁴Villejuif, FR, ⁵Marseille, CEDEX 9/FR, ⁶Birmingham, GB, ⁷Cardiff, GB, ⁸London, London/GB, ⁹Boston, MA/US, ¹⁰Wcb Nh, GB

09:30 - 09:30

LBA34 - Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476)

N. James¹, J. de Bono², M. Spears³, N. Clarke⁴, M. Mason⁵, D. Dearnaley⁶, A. Ritchie², M. Russell⁷, C. Gilson², R. Jones⁷, S. Gillissen⁸, D. Matheson³, S. Aung⁹, A. Birtle¹⁰, S. Chowdhury², J. Gale¹¹, Z. Malik¹², J. O'Sullivan¹³, M. Parmar¹⁴, M. Sydes¹⁵; ¹Birmingham, GB, ²London, GB, ³Wcb Nh, GB, ⁴M Hd, GB, ⁵Cardiff, GB, ⁶Sutton, GB, ⁷Glasgow, GB, ⁸St. Gallen, CH, ⁹Devon, GB, ¹⁰Preston, GB, ¹¹Portsmouth, GB, ¹²Clatterbridge, GB, ¹³Belfast, GB, ¹⁴London, London/GB, ¹⁵London, UK/GB

09:30 - 09:30

789PD - Abiraterone acetate (AA) + prednisolone (P) for metastatic castration-resistant prostate cancer (mCRPC) with early progression or non-response to androgen deprivation therapy (ADT)

G. Arai¹, M. Ogi², K. Kobayashi³, N. Okuno³, T. Takahara², K. Fukushima², K. Yoshizawa²; ¹Saitama, JP, ²Tokyo, JP, ³Kanagawa, JP

- 09:30 - 09:50 Invited Discussant 788PD, LBA33, LBA34 and 789PD
S. Oudard, Paris, FR
- 09:50 - 10:00 Q&A led by Discussant
- 10:00 - 10:00 790PD - Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer
N. Shore¹, E. Heath², L. Nordquist³, H. Cheng⁴, K. Bhatt⁵, M. Morrow⁶, T. McMullan⁶, K. Kraynyak⁶, J. Lee⁶, B. Sacchetta⁶, L. Liu⁶, S. Rosencranz⁶, S. Tagawa⁷, R. Parikh⁸, R. Tutrone⁹, J. Garcia¹⁰, Y. Whang¹¹, W. Kelly¹², I. Csiki⁵, M. Bagarazzi⁵; ¹Myrtle Beach, US, ²Detroit, US, ³Omaha, US, ⁴Seattle, WA/US, ⁵Plymouth Meeting, US, ⁶Plymouth Meeting, PA/US, ⁷New York, US/US, ⁸Pittsburg, PA/US, ⁹Towson, MD/US, ¹⁰Cleveland, OH/US, ¹¹Chapel Hill, NC/US, ¹²Philadelphia, PA/US
- 10:00 - 10:00 791PD - Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence enhancement and tumor inhibition in advanced prostate cancer
D. Di Mitri¹, J. Vasilevska¹, A. Calcinotto¹, V. Gil², G. Boysen², A. Revandkar¹, D. Waugh³, S. Barry⁴, J. de Bono⁵, A. Alimonti¹; ¹Bellinzona, CH, ²Sutton, GB, ³Belfast, GB, ⁴Cambridge, GB, ⁵London, GB
- 10:00 - 10:00 792PD - Phase I, open-label, dose-finding study of GSK2636771, a phosphoinositide 3-kinase (PI3K) β inhibitor, in combination with enzalutamide in male subjects with metastatic castration-resistant prostate cancer (mCRPC)
P. Rescigno¹, J. de Bono², A. Aparicio³, S. Chowdhury², P. Twardowski⁴, N. Dawson⁵, U. Vaishampayan⁶, A. Pantuck⁷, Y. Zhou⁸, D. Fecteau⁸, G. Ganji⁹, J. Tolson¹⁰, D. Smith¹¹, J. Medina¹², L. Yan¹²; ¹Napoli, IT, ²London, GB, ³Houston, TX/US, ⁴Duarte, CA/US, ⁵Washington D.c., DC/US, ⁶Detroit, MI/US, ⁷Los Angeles, CA/US, ⁸Collegeville, US, ⁹King Of Prussia, PA/US, ¹⁰Rtp, NC/US, ¹¹Durham, NC/US, ¹²Collegeville, PA/US
- 10:00 - 10:00 793PD - Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
M. Morris¹, N. Vogelzang², O. Sartor³, A. Armour⁴, M. Groaning⁵, R. Messmann⁶, A. Roberts⁷, D. Petrylak⁸, A. Tolcher⁹, M. Gordon¹⁰, H. Babiker¹¹; ¹New York, NY/US, ²Las Vegas, NV/US, ³New Orleans, LA/US, ⁴Indianapolis, IN/US, ⁵Indianapolis, US, ⁶West Lafayette, US, ⁷New York, US, ⁸New Haven, CT/US, ⁹San Antonio, TX/US, ¹⁰Scottsdale, AZ/US, ¹¹Tucson, US
- 10:00 - 10:20 Invited Discussant 790PD, 791PD, 792PD and 793PD
R. de Wit, Rotterdam, NL
- 10:20 - 10:30 Q&A led by Discussant

- 09:15 - 10:45 Type: Special Symposium Madrid Auditorium
Title: Optimal treatment of RAS mutated patients
Chair(s): C.-H. Koehne, DE; A. Falcone, IT
- 09:15 - 09:20 Introduction
A. Falcone, Pisa, IT
- 09:20 - 09:40 Liquid biopsies
M. Ychou, Montpellier, CEDEX 5/FR
- 09:40 - 10:00 Molecular heterogeneity
F. Ciardiello, Naples, IT
- 10:00 - 10:20 New ways of targeting RAS
R. Corcoran, Boston, MA/US
- 10:20 - 10:40 Immunotherapy: MSI and beyond
J. Bendell, Nashville, TN/US
- 10:40 - 10:45 Conclusions and clinical perspectives
C.-H. Koehne, Oldenburg, DE
- 09:15 - 10:45 Type: Poster Discussion session Sevilla Auditorium
Title: Breast cancer, metastatic
Chair(s): A. Prat, ES; M.V. Dieci, IT; A. Gennari, IT
- 09:15 - 09:15 239PD - A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04
A. Ocana Fernandez¹, M. Ruiz-Borrego², M. Gil Martin³, S. Antolin⁴, M. Atienza², A. Montaña², N. Ribelles⁵, A. Guerrero⁶, M. Muñoz³, I. Fernández-Pérez⁷, A. Urruticoechea³, A. Falcon Gonzalez², S. Pernas Simon³, J. Prato Varela⁸, M.J. Escudero⁹, S. Benito⁹, R. Caballero⁹, E. Carrasco¹⁰, F. Rojo¹⁰, A. Pandiella¹¹; ¹Albacete, ES, ²Sevilla, ES, ³Barcelona, ES, ⁴Coruña, ES, ⁵Malaga, ES, ⁶Valencia, ES, ⁷Vigo, ES, ⁸A Coruna, ES, ⁹San Sebastian De Los Reyes, ES, ¹⁰Madrid, ES, ¹¹Salamanca, ES
- 09:15 - 09:15 LBA12 - Genomic analyses reveal potential recurrence markers of locally advanced triple negative breast cancer treated by combined neoadjuvant EGFR targeting and chemotherapy
N. Radosevic-Robin¹, E. Cocco², H. Won², M. Berger², M. Privat¹, C. Abrial³, F. Penault-Llorca³, M. Scaltriti²; ¹Clermont-Ferrand, FR, ²New York, NY/US, ³Clermont-Ferrand, CEDEX 1/FR
- 09:15 - 09:15 240PD - Comprehensive genomic profiling of primary and metastatic CDH1 mutated classic and pleomorphic invasive lobular breast carcinomas reveals markers of hormonal therapy resistance and opportunities for targeted therapies
J. Ross¹, L. Gay², J. Elvin², J. Suh², J.-A. Vergilio², S. Ramkissoon², E. Severson², S. Daniel², G. Frampton², D. Fabrizio², A. Schrock³, S. Ali², V. Miller², P. Stephens⁴, J. Chung²; ¹Albany, NY/US, ²Cambridge, MA/US, ³Cambridge, US, ⁴Cambridge, Massachusetts/US

- 09:15 - 09:15 LBA15 - STORM: A clinical cohort to identify genetic variability related to metastatic phenotypes
D. Cox¹, E. Blanc¹, G. Romieu², M. Rios³, C. Becuwe⁴, C. Jouannaud⁵, L. Chaigneau⁶, M. Arnedos⁷, H. Orfeuvre⁸, T. Petit⁹, N. Quenel Tueux¹⁰, J.-P. Jacquin¹¹, J.-M. Ferrero¹², S. Abadie Lacourtoisie¹³, F. Penault-Llorca¹⁴, C. Segura-Ferlay¹, I. Moullet¹, T. Bachelot¹⁵, X. Pivot¹⁶; ¹Lyon, FR, ²Montpellier, CEDEX 5/FR, ³Vandoeuvre Les Nancy, CEDEX/FR, ⁴Nancy, FR, ⁵Reims, CEDEX/FR, ⁶Besancon, FR, ⁷Villejuif, FR, ⁸Bourg-En-bresse, FR, ⁹Strasbourg, CEDEX/FR, ¹⁰Bordeaux, CEDEX/FR, ¹¹Saint Priest En Jarez, FR, ¹²Nice, CEDEX 2/FR, ¹³Angers, FR, ¹⁴Clermont-Ferrand, CEDEX 1/FR, ¹⁵Lyon, CEDEX/FR, ¹⁶Besançon, CEDEX/FR
- 09:15 - 09:35 Invited Discussant 239PD, LBA12, 240PD and LBA15
A. Prat, Barcelona, ES
- 09:35 - 09:45 Q&A led by discussant
- 09:45 - 09:45 241PD - BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
N. Turner¹, E. Alarcón², A. Armstrong³, M. Philco⁴, Y.A. López Chuken⁵, M.-P. Sablin⁶, K. Tamura⁷, A. Gomez Villanueva⁸, J.A. Pérez-Fidalgo⁹, A. Foxley¹⁰, J. Lindemann¹¹, R. Maudsley¹⁰, E. Outhwaite¹⁰, M. Pass¹⁰, P. Rugman¹⁰, G. Schiavon¹⁰, M. Oliveira¹²; ¹London, GB, ²Lima, PE, ³Manchester, GB, ⁴Bellavista, PE, ⁵Monterrey, MX, ⁶Paris, FR, ⁷Tokyo, JP, ⁸Toluca, MX, ⁹Ciberonc, ES, ¹⁰Cambridge, GB, ¹¹Melbourn, UK/GB, ¹²Barcelona, ES
- 09:45 - 09:45 242PD - Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792
M. Telli¹, S. Lord², E. Dean³, V. Abramson⁴, H.-T. Arkenau⁵, C. Becerra⁶, S. Tolaney⁷, R. Tang⁷, M. Penney⁷, J. Pollard⁷, G. Conboy⁷, S. Fields⁷, G. Shapiro⁸; ¹Stanford, CA/US, ²Oxford, GB, ³Manchester, GB, ⁴Nashville, TN/US, ⁵London, GB, ⁶Dallas, TX/US, ⁷Boston, MA/US, ⁸Boston, US
- 09:45 - 09:45 243PD - OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice
S. Delaloge¹, P.F. Conte², S.-A. Im³, E. Senkus-Konefka⁴, B. Xu⁵, S. Domchek⁶, N. Masuda⁷, W. Li⁸, N. Tung⁹, A. Armstrong¹⁰, W. Wu¹¹, C. Goessl¹², S. Runswick¹³, M. Robson¹⁴; ¹Villejuif, FR, ²Padova, IT, ³Seoul, KR, ⁴Gdańsk, PL, ⁵Beijing, CN, ⁶Philadelphia, US, ⁷Osaka, JP, ⁸Changchun, CN, ⁹Boston, MA/US, ¹⁰Manchester, GB, ¹¹Gaithersburg, MD/US, ¹²Gaithersburg, US, ¹³Macclesfield, GB, ¹⁴New York, NY/US
- 09:45 - 10:05 Invited Discussant 241PD, 242PD and 243PD
M.V. Dieci, Padova, IT
- 10:05 - 10:15 Q&A led by discussant

- 10:15 - 10:15 238PD - A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer
M. Pegram¹, E. Tan-Chiu², A. Freyman³, A. Vana⁴, F. Hilton⁵, C. Zacharchuk³, R. Ewesuedo³; ¹Stanford, CA/US, ²Plantation, FL/US, ³Cambridge, MA/US, ⁴San Diego, CA/US, ⁵Groton, CT/US
- 10:15 - 10:15 244PD - Everolimus (EVE) + letrozole (LET) in patients (pts) with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4
T. Bachelot¹, M. Royce², C. Villanueva³, F. Melo Cruz⁴, R. Hegg⁵, C. Falkson⁶, J. Jeong⁷, V. Srimuninnimit⁸, C. Arce⁹, A. Ridolfi¹⁰, C. Lin⁹, W. Gradishar¹¹, M. Ozguroglu¹², F. Cardoso¹³, S. Azevedo¹⁴; ¹Lyon, CEDEX/FR, ²Albuquerque, US, ³Besançon, CEDEX/FR, ⁴Mooca, BR, ⁵Sao Paulo, SP/BR, ⁶Birmingham, AL/US, ⁷Seoul, KR, ⁸Bangkok, TH, ⁹East Hanover, US, ¹⁰Rueil-Malmaison, FR, ¹¹Chicago, IL/US, ¹²Istanbul, TR, ¹³Lisbon, PT, ¹⁴Porto Alegre, BR
- 10:15 - 10:15 245PD - Duration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2- ABC
W. Janni¹, E. Alba Conejo², T. Bachelot³, S. Diab⁴, M. Gil⁵, T. Beck⁶, L. Ryvo⁷, R. López⁸, M. Tsai⁹, F. Esteva¹⁰, M.P. Zamora Aunon¹¹, Z. Kral¹², P. Ward¹³, P. Richards¹⁴, T. Pluard¹⁵, S. Sutradhar¹⁶, M. Miller¹⁷, M. Campone¹⁸; ¹Ulm, DE, ²Malaga, ES, ³Lyon, CEDEX/FR, ⁴Aurora, ON/CA, ⁵Barcelona, ES, ⁶Fayetteville, US, ⁷Tel Aviv, IL, ⁸Santiago De Compostela, ES, ⁹Minneapolis, MN/US, ¹⁰Houston, TX/US, ¹¹Madrid, ES, ¹²Brno, CZ, ¹³Kenwood, OH/US, ¹⁴Salem, VA/US, ¹⁵Kansas City, MO/US, ¹⁶East Hanover, US, ¹⁷East Hanover, New Jersey/US, ¹⁸Saint-Herblain, CEDEX/FR
- 10:15 - 10:15 246PD - Efficacy of two times four versus continuous eight cycles of paclitaxel/bevacizumab as first-line chemotherapy in metastatic breast cancer: The Stop&Go study of the Dutch Breast Cancer Research Group (BOOG)
A. Claessens¹, M. Bos², S. de Groot³, E. van Leeuwen - Stok³, M. Lopez-Yurda³, A. Honkoop⁴, H. de Graaf⁵, E. van Druten², L. van Warmerdam⁶, M. van der Sangen⁶, V. Tjan-Heijnen⁷, F. Erdkamp⁸; ¹Sittard-Geleen, NL, ²Delft, NL, ³Amsterdam, NL, ⁴Zwolle, NL, ⁵Leeuwarden, NL, ⁶Eindhoven, NL, ⁷Maastricht, NL, ⁸Sittard, NL
- 10:15 - 10:35 Invited Discussant 238PD, 244PD, 245PD and 246PD
A. Gennari, Genova, IT
- 10:35 - 10:45 Q&A led by discussant

09:15 - 10:45 Type: Educational session Pamplona Auditorium
Title: Immunotherapy beyond checkpoint inhibitors
Chair(s): M. Maus, US; R. Plummer, GB

09:15 - 09:40 Biomarkers for personalised immunotherapy
A. Marabelle, Villejuif, FR

09:40 - 10:05 Modulation of tumour microenvironments
L. Akkari, Amsterdam, NL

10:05 - 10:30 CAR-T and beyond
M. Maus, Charleston, US

10:30 - 10:45 Discussion

09:30 - 10:30 Type: Special Session Valencia Auditorium
Title: Oligometastatic disease: Immunotherapy and /or local treatment
Chair(s): B. Neyns, BE

09:30 - 09:50 Is immunotherapy first choice?
B. Neyns, Brussels, BE

09:50 - 10:10 Radiotherapy is it the treatment and/or the adjuvant?
P. Nathan, Northwood, Middlesex/GB

10:10 - 10:30 Does surgery still have a role?
A. van Akkooij, Amsterdam, NL

09:30 - 10:30 Type: Challenge Your Expert (CYE) session Tarragona Auditorium
Title: Personalised and stratified management of non-epithelial ovarian cancer
Chair(s): I. Ray-Coquard, FR

09:30 - 09:40 Personalised and stratified management of non-epithelial ovarian cancer
J. Ledermann, London, GB

09:40 - 10:30 Discussion led by Chair
I. Ray-Coquard, Lyon, CEDEX/FR

09:30 - 10:30	Type: Multidisciplinary Session Title: Challenges and opportunities in the treatment of Hodgkin's lymphoma Chair(s): <u>U. Ricardi</u> , IT	Alicante Auditorium
09:30 - 09:35	Presentation of case/condition <u>U. Ricardi</u> , Turin, IT	
09:35 - 09:45	The radiation therapy perspective <u>U. Ricardi</u> , Turin, IT	
09:45 - 09:55	The nuclear medicine perspective <u>S. Barrington</u> , London, GB	
09:55 - 10:05	The medical oncology perspective <u>A. Rueda Domínguez</u> , Marbella, ES	
10:05 - 10:30	General Discussion <u>U. Ricardi</u> , Turin, IT	
09:30 - 10:30	Type: Special Session Title: The "macro-economics" of cancer Chair(s): <u>A. Eniu</u> , RO; <u>Y. Lievens</u> , BE	Cartagena Auditorium
09:30 - 09:50	Global discrepancies in cancer outcomes <u>P. Boyle</u> , Ecully, FR	
09:50 - 10:10	Access to essential medicines <u>A. Eniu</u> , Cluj-Napoca, RO	
10:10 - 10:30	Cancer macroeconomics, policy and politics <u>J. Martin-Moreno</u> , Valencia, Valencia/ES	
10:00 - 10:30	Type: Industry Satellite Symposium Title: BRAFm Metastatic Melanoma	Hall 8

10:45 - 12:45 Type: ESMO Clinical Practice Guidelines session Granada Auditorium
 Title: ESMO Clinical Practice Guidelines 1
 Chair(s): C. Sessa, CH; G. Pentheroudakis, GR

10:45 - 10:55 Introduction to the ESMO Clinical Practice Guidelines
G. Pentheroudakis, Ioannina, GR

10:55 - 11:05 Questionnaire
C. Sessa, Bellinzona, CH

11:05 - 11:15 Resectable locally advanced oesophagogastric cancer case presentation
E. Smyth, London, GB

11:15 - 11:25 Discussant
F. Lordick, Leipzig, DE

11:25 - 11:30 Q&A

11:30 - 11:40 Renal cancer: Sequence of therapies, immunotherapy case presentation
L. Derosa, Villejuif, FR

11:40 - 11:50 Discussant
B. Escudier, Villejuif, FR

11:50 - 11:55 Q&A

11:55 - 12:05 Management of carcinomatous meningitis in patient with advanced lung adenocarcinoma case presentation
E. Le Rhun, Lille, CEDEX/FR

12:05 - 12:15 Discussant
M. Preusser, Vienna, AT

12:15 - 12:20 Q&A

12:20 - 12:30 Early stage NSCLC case presentation
A. Curioni, Zürich, CH

12:30 - 12:40 Discussant
P. Postmus, Wirral, Merseyside/GB

12:40 - 12:45 Q&A

11:00 - 12:30	Type: Proffered Paper session Title: Gastrointestinal tumours, non-colorectal 2 Chair(s): M. Hidalgo, US; L. Rimassa, IT	Barcelona Auditorium
11:00 - 11:15	LBA29 - Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial <u>J. Edeline</u> ¹ , F. Bonnetain ² , J.-M. Phelip ³ , J. Watelet ⁴ , P. Hammel ⁵ , J.-P. Joly ⁶ , M. Benabdelghani ⁷ , L. Fartoux ⁸ , K. Bouhier-Leporrier ⁹ , J.-L. Jouve ¹⁰ , R. Faroux ¹¹ , V. Guerin-Meyer ¹² , E. Assenat ¹³ , J.-F. Seitz ¹⁴ , D. Malka ¹⁵ , C. Louvet ⁸ , A. Bertaut ¹⁶ , B. Juzyna ⁸ , T. Stanbury ⁸ , E. Boucher ¹ , ¹ Rennes, CEDEX/FR, ² Besançon, CEDEX/FR, ³ Saint-Etienne, FR, ⁴ Nancy, FR, ⁵ Clichy, FR, ⁶ Amiens, FR, ⁷ Strasbourg, FR, ⁸ Paris, FR, ⁹ Caen, FR, ¹⁰ Dijon, Cedex/FR, ¹¹ La Roche Sur Yon, CEDEX 9/FR, ¹² Angers, FR, ¹³ Montpellier, FR, ¹⁴ Marseille, CEDEX 5/FR, ¹⁵ Villejuif, FR, ¹⁶ Dijon, FR	
11:15 - 11:30	6190 - JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma <u>S. Kobayashi</u> ¹ , K. Ueshima ² , M. Moriguchi ³ , T. Takayama ⁴ , N. Izumi ⁵ , H. Yoshiji ⁶ , K. Hino ⁷ , T. Oikawa ⁸ , T. Chiba ⁹ , K. Motomura ¹⁰ , J. Kato ¹¹ , K. Yasuchika ¹² , A. Ido ¹³ , J. Kinoshita ¹⁴ , T. Sato ¹⁵ , M. Ikeda ¹⁶ , T. Okusaka ¹⁵ , M. Kudo ¹⁷ , K. Tamura ¹⁸ , J. Furuse ¹⁵ ; ¹ Yokohama, JP, ² Sayama, JP, ³ Kyoto, JP, ⁴ Tokushima, JP, ⁵ Musashino, JP, ⁶ Kashihara, JP, ⁷ Kurashiki, JP, ⁸ Morioka, JP, ⁹ Chiba, JP, ¹⁰ Iizuka, JP, ¹¹ Bunkyo, JP, ¹² Sakyo, JP, ¹³ Kagoshima, JP, ¹⁴ Chiyodaku, JP, ¹⁵ Tokyo, JP, ¹⁶ Kashiwa, Chiba/Jp, ¹⁷ Osaka, JP, ¹⁸ Fukuoka, JP	
11:30 - 11:45	Invited Discussant LBA29 and 6190 <u>C. Verslype</u> , Leuven, BE	
11:45 - 12:00	LBA30 - Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC) <u>R. Finn</u> ¹ , M. Kudo ² , A.-L. Cheng ³ , L. Wyrwicz ⁴ , R. Ngan ⁵ , J.-F. Blanc ⁶ , A. Baron ⁷ , A. Vogel ⁸ , M. Ikeda ⁹ , F. Piscaglia ¹⁰ , K.-H. Han ¹¹ , S. Qin ¹² , Y. Minoshima ¹³ , Y. Funahashi ¹⁴ , M. Ren ¹⁵ , R. Dairiki ¹⁶ , P. Sachdev ¹⁷ , T. Tamai ¹⁶ , C. Dutcus ¹⁷ , T.R.J. Evans ¹⁸ ; ¹ Los Angeles, CA/US, ² Osaka, JP, ³ Taipei City, TW, ⁴ Warsaw, PL, ⁵ Kowloon, HK, ⁶ Pessac, FR, ⁷ San Fransisco, US, ⁸ Hannover, DE, ⁹ Kashiwa, Chiba/Jp, ¹⁰ Bologna, IT, ¹¹ Seoul, KR, ¹² Nanjing, CN, ¹³ Tsukuba, Ibaraki, JP, ¹⁴ Andover, US, ¹⁵ Woodcliff Lake, US, ¹⁶ Tokyo, JP, ¹⁷ Woodcliff Lake, New Jersey/US, ¹⁸ Glasgow, GB	
12:00 - 12:15	6180 - Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR) <u>A. Vogel</u> ¹ , S. Qin ² , M. Kudo ³ , S. Hudgens ⁴ , T. Yamashita ⁵ , J.-H. Yoon ⁶ , L. Fartoux ⁷ , K. Simon ⁸ , C. López López ⁹ , M. Sung ¹⁰ , C. Dutcus ¹¹ , S. Kraljevic ¹² , T. Tamai ¹³ , N. Grunow ¹⁴ , G. Meier ¹⁵ , V. Breder ¹⁶ ; ¹ Hannover, DE, ² Nanjing, CN, ³ Osaka, JP, ⁴ New York, Arizona/US, ⁵ Kanazawa, Ishikawa/Jp, ⁶ Seoul, KR, ⁷ Paris, FR, ⁸ Wroclaw, PL, ⁹ Santander, ES, ¹⁰ New York, NY/US, ¹¹ Woodcliff Lake, New Jersey/US, ¹² Hatfield, Herts/GB, ¹³ Tokyo, JP, ¹⁴ Tucson, US, ¹⁵ Woodcliff Lake, US, ¹⁶ Moscow, RU	
12:15 - 12:30	Invited Discussant one LBA30 and 6180	

L. Rimassa, Rozzano, (MI)/IT

11:00 - 12:30	Type: Educational session Title: Optimising treatment of metastatic prostate cancer Chair(s): N. James, GB; S. Gillessen, CH	Sevilla Auditorium
11:00 - 11:25	Why switch treatment? Response biomarkers <u>H. Scher</u> , New York, Ny, US	
11:25 - 11:50	When to treat? How do we define best sequence? <u>N. James</u> , Birmingham, GB	
11:50 - 12:15	Who to treat? Molecular stratification predictive biomarkers <u>J. Mateo</u> , Sutton, GB	
12:15 - 12:30	Discussion	
11:00 - 12:30	Type: Joint Symposium Title: ESMO-EORTC-EACR: Tumours with rare oncogenic lesions: From pre-clinical to clinical validation Chair(s): R. Stahel, CH; A. Berns, NL; R. Stupp, CH	Pamplona Auditorium
11:00 - 11:05	Introduction <u>A. Berns</u> , Amsterdam, NL	
11:05 - 11:25	Targeting the stem of cancer: Inhibition of the WNT pathway in colorectal tumours <u>A. Bardelli</u> , Candiolo, (TO)/IT	
11:25 - 11:45	Using rare mutations to guide treatment options for drug resistant melanoma <u>R. Marais</u> , Manchester, GB	
11:45 - 12:05	Vulnerabilities of gliomas with IDH1 mutations <u>D. Cahill</u> , Boston, US	
12:05 - 12:25	Biomarkers for PARP responders <u>L. Van'T Veer</u> , San Francisco, US	
12:25 - 12:30	Conclusions <u>R. Stupp</u> , Zürich, CH	

11:00 - 12:30 Type: Special Symposium Cordoba Auditorium
Title: Targeted therapy in neuro-oncology
Chair(s): P. Wen, US; P. French, NL

11:00 - 11:05 Introduction
P. French, Rotterdam, NL

11:05 - 11:25 What can we learn from patient-derived models?
J. Seoane, Barcelona, ES

11:25 - 11:45 Targeting EGFR in glioblastoma: Beyond TKI and ACT IV
M. Weller, Zürich, CH

11:45 - 12:05 Is IDH a valid therapeutic target in neuro-oncology?
M. Platten, Heidelberg, DE

12:05 - 12:25 Basket & umbrella trials in neuro-oncology
W. Wick, Heidelberg, DE

12:25 - 12:30 Conclusions and clinical perspectives
P. Wen, Boston, MA/US

11:00 - 12:30 Type: Joint Symposium Valencia Auditorium
Title: ESMO-CSCO: Liquid biopsy in the clinic: From myth to reality
Chair(s): F. Ciardiello, IT; Y.-L. Wu, CN

11:00 - 11:05 Introduction
F. Ciardiello, Naples, IT

11:05 - 11:25 Technologic advances in liquid biopsy: East meets West
X.-C. Zhang, Guangzhou, CN

11:25 - 12:05 New technologies for the analysis of liquid biopsy: A focus on colorectal cancer
N. Normanno, Napoli, IT

12:05 - 12:25 Clinical application of liquid biopsy in management of advanced NSCLC
S. Wang, Beijing, CN

12:25 - 12:30 Conclusions
Y.-L. Wu, Guangzhou, CN

11:00 - 12:00	Type: Multidisciplinary Session Title: Challenges and complex presentations: Non resectable bone sarcoma Chair(s): A.P. Dei Tos, IT	Tarragona Auditorium
11:00 - 11:05	Presentation of case/condition <u>A.P. Dei Tos</u> , Treviso, IT	
11:05 - 11:15	The pathology perspective <u>A.P. Dei Tos</u> , Treviso, IT	
11:15 - 11:17	Case RT <u>R.L. Haas</u> , Amsterdam, NL	
11:17 - 11:27	The radiation therapy perspective <u>R.L. Haas</u> , Amsterdam, NL	
11:27 - 11:37	The surgery perspective <u>A. Leithner</u> , Graz, AT	
11:37 - 11:47	The medical oncology perspective <u>W. van der Graaf</u> , Sutton, GB	
11:47 - 11:57	General Discussion	

11:00 - 12:30 Type: Special Session Bilbao Auditorium
 Title: How to conciliate the fast moving genetic landscape with everyday practice and resources
 Chair(s): S. Rauh, LU; G. Lakatos, HU

11:00 - 11:05 Introduction
G. Lakatos, Budapest, HU

11:05 - 11:25 Overview of genetic testing: Evolution in the last 5 years
I. Peták, Budapest, HU

11:25 - 11:45 What has been included in present guidelines: Impact of inclusion on oncology practice
C. Rolfo, Edegem, BE

11:45 - 12:05 Integrating personalised medicine into oncology practice: The French experience
J.-C. Soria, Villejuif, CEDEX/FR

12:05 - 12:25 Panel discussion: What are the benefits of personalised medicine for oncology practice? How can it be integrated into everyday practice?

12:25 - 12:30 Conclusions
S. Rauh, Esch Sur Alzette, LU

11:00 - 12:00 Type: Multidisciplinary Session Alicante Auditorium
 Title: Multidisciplinary approach to the management of stage III thymoma
 Chair(s): M. Garassino, IT

11:00 - 11:05 Presentation of case/condition
M. Garassino, Milan, IT

11:05 - 11:15 The medical oncology perspective
M. Garassino, Milan, IT

11:15 - 11:25 The surgery perspective
R.J. Korst, Paramus, Nj, US

11:25 - 11:35 The radiation therapy perspective
C. Le Pechoux, Villejuif, CEDEX/FR

11:35 - 12:00 General Discussion

11:00 - 12:15	Type: Proffered Paper session Title: Haematological malignancies Chair(s): M. Provencio, ES; M. Ghilmini, CH	Cartagena Auditorium
11:00 - 11:15	994O - Equivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study <u>W. Jurczak</u> ¹ , I. Moreira ² , K. Setty Govindbabu ³ , E. Munhoz ⁴ , M.-A. Echeveste ⁵ , P. Giri ⁶ , N. Castro ⁷ , J. Pereira ⁷ , A. Luiza ⁸ , S. Alexeev ⁹ , D. Osmanov ¹⁰ , P. Zhu ¹¹ , S. Alexandrova ¹¹ , A. Zobel ¹² , O. Harlin ¹² , J. Amersdorffer ¹² ; ¹ Kraków, PL, ² Porto, PT, ³ Bangalore, IN, ⁴ Curitiba, BR, ⁵ San Sebastian, ES, ⁶ Adelaide, AU, ⁷ Sao Paulo, BR, ⁸ Naharyia, IL, ⁹ St. Petersburg, RU, ¹⁰ Moscow, RU, ¹¹ Princeton, US, ¹² Holzkirchen, DE	
11:15 - 11:30	Invited Discussant 994O <u>M. Ghilmini</u> , Bellinzona, CH	
11:30 - 11:45	995O - Interim results from a phase 1 first-in-human study of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in AML/MDS <u>N. Vey</u> ¹ , J. Davidson-Moncada ² , G. Uy ³ , M. Foster ⁴ , D. Rizzieri ⁵ , J. Godwin ⁶ , M. Topp ⁷ , F. Ciceri ⁸ , M. Carrabba ⁸ , G. Martinelli ⁹ , G. Huls ¹⁰ , A. Wegener ¹¹ , M. Shannon ¹² , K. Tran ¹² , J. Sun ¹² , E. Bonvini ¹² , B. Löwenberg ¹³ , J. Wigginton ² , J. Dipersio ³ ; ¹ Marseille, FR, ² Rockville, US, ³ St. Louis, MO/US, ⁴ Chapel Hill, US, ⁵ Durham, US, ⁶ Portland, US, ⁷ Wurzburg, DE, ⁸ Milano, IT, ⁹ Milan, IT, ¹⁰ Groningen, NL, ¹¹ Paris, FR, ¹² Rockville, MD/US, ¹³ Rotterdam, NL	
11:45 - 12:00	996O - Risk of developing acute myeloid leukemia (AML) in well-differentiated thyroid cancer (WDTC) patients treated with radioactive iodine (RAI): a population-based study <u>R. Molenaar</u> ¹ , T. Radivoyevitch ² , H. Carraway ² , J. Maciejewski ² , M. Sekeres ³ , S. Mukherjee ² ; ¹ Amsterdam, NL, ² Cleveland, OH/US, ³ Cleveland, US	
12:00 - 12:15	Invited Discussant 995O and 996O <u>T. Somerville</u> , Manchester, GB	

11:00 - 12:40 Type: Special Symposium Madrid Auditorium
 Title: How to manage luminal breast cancer
 Chair(s): F. Cardoso, PT; M. Colleoni, IT

11:00 - 11:20 How to classify luminal breast cancer
J. Reis-Filho, New York, Ny, US

11:20 - 11:40 Who benefits from chemotherapy?
F. Cardoso, Lisbon, PT

11:40 - 12:00 Early response assessment
N. Harbeck, Munich, DE

12:00 - 12:20 How much endocrine therapy is long enough?
M. Colleoni, Milan, IT

12:20 - 12:40 Is there an optimal chemotherapy?
A. di Leo, Prato, IT

11:00 - 11:45 Type: Young Oncologist Brunch Salamanca Auditorium
 Title: Burn out in young oncologists: How can we combat it?
 Chair(s): T. Amaral, PT; M. Strijbos, BE

11:00 - 11:20 Introduction to psychological stress and burn-out
F. Fiore, Napoli, IT

11:20 - 11:45 Prevalence and prevention of burn-out in young oncologists
S. Banerjee, London, GB

12:30 - 14:30 Type: Patient Advocacy Track Palma Auditorium
Title: Patient outcomes research
Chair(s): I. Banks, IE; B. Ryll, SE

12:30 - 12:45 How to integrate qualitative research into clinical trials
A. Nelson, Cardiff, GB

12:45 - 13:00 What are meaningful patient outcomes and how to implement them
E. Low, London, GB

13:00 - 13:15 Risk benefit assessment tool
B. Ryll, SE

13:15 - 13:30 Measuring Quality of Life - and deltas of perceptions between HCPs and patients
L. Cannella, Rom, AF

13:30 - 14:00 Discussion

13:00 - 14:30 Type: ESMO Colloquium Sevilla Auditorium
Title: ESMO COLLOQUIUM - Systemic treatment of unresectable hepatocellular carcinoma
Chair(s): A. Vogel, DE; J.L. Raoul, FR

13:00 - 13:05 Introduction
J.L. Raoul, Marseille, FR

13:05 - 13:30 The increasing epidemics of HCC world-wide
J.L. Raoul, Marseille, FR

13:30 - 13:55 First-line systemic treatment: Can we do better than sorafenib?
A. Vogel, Hannover, DE

13:55 - 14:20 Second and later line treatments: Anti-angiogenic? MET inhibitors? Immunotherapy? Or just best supportive care?
J. Trojan, Frankfurt, DE

14:20 - 14:30 Summary and conclusion

13:00 - 14:30 Type: Industry Satellite Symposium Pamplona Auditorium
Title: Industry Satellite Symposium 29

13:00 - 14:30 Type: Industry Satellite Symposium Cordoba Auditorium
Title: Industry Satellite Symposium 30

13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 31	Valencia Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 32	Tarragona Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 33	Bilbao Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 34 Chair(s): E. Van Cutsem, BE	Alicante Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 59	Jerez Auditorium
13:15 - 14:15	Type: Poster Display session Title: Poster display session	Hall 8
13:15 - 13:15	CNS TUMOURS <u>P. Wen</u> ¹ , <u>P. French</u> ² ; ¹ Boston, MA/US, ² Rotterdam, NL	
13:15 - 13:15	337P - Molecular subtypes of gliomas defined by gene expression profiling <u>E. Deluche</u> ¹ , <u>F. Caire</u> ² , <u>V. Rigau</u> ³ , <u>S. Durand</u> ² , <u>S. Robert</u> ² , <u>B. Bessette</u> ² , <u>F. Labrousse</u> ² , <u>M.-O. Jauberteau</u> ² , <u>K. Durand</u> ² , <u>F. Lalloue</u> ² ; ¹ Limoges, CEDEX/FR, ² Limoges, FR, ³ Montpellier, FR	
13:15 - 13:15	338P - Chitosan-capped gold nanoparticles impair radioresistant glioblastoma stem-like cells <u>M. Aldea</u> , <u>M. Potara</u> , <u>O. Soritau</u> , <u>I.S. Florian</u> , <u>G. Kacso</u> ; Cluj-Napoca, RO	
13:15 - 13:15	339P - Hypoxia, Inflammation and redox status as determinants of malignant progression of cancer stem cells <u>M. Papale</u> , Roma, IT	
13:15 - 13:15	340P - The prognostic role of high mobility group box protein-1 in glioblastoma and its relationship with the inflammatory response <u>M. Yildirim</u> ¹ , <u>D. Süren</u> ² , <u>A. Alikanoğlu</u> ² , <u>Ö. Çakın</u> ² , <u>İ. Karacay</u> ² , <u>C. Sezer</u> ² , <u>V. Kaya</u> ² , <u>A. Güzel</u> ¹ ; ¹ Gaziantep, TR, ² Antalya, TR	
13:15 - 13:15	341P - Impact of hyperbaric oxygenation on the expression of PKD1 protein forms in T98G glioblastoma cell line treated with selected pentabromobenzylisothiourea (ZKK-3) <u>K. Stepien</u> , <u>R. Ostrowski</u> , <u>E. Pucko</u> , <u>E. Grzywaczewska</u> , <u>E. Matyja</u> ; Warsaw, PL	
13:15 - 13:15	343P - The role of clinical characteristics in low grade gliomas in molecular era	

A. Mura¹, E. Franceschi¹, S. Minichillo¹, A. Mandrioli¹, A. Tosoni¹, A. Fioravanti¹, A. Talacchi², L. Volpin³, G. Tallini¹, D. De Biase¹, R. Agati¹, S. Pizzolitto⁴, S. Bartolini¹, A. Paccapelo¹, A. Brandes¹; ¹Bologna, IT, ²Verona, IT, ³Vicenza, IT, ⁴Udine, IT

- 13:15 - 13:15 344P - IDH wild type low grade gliomas: Who seeks shall find
A. Mandrioli¹, E. Franceschi¹, S. Minichillo¹, A. Mura¹, A. Tosoni¹, D. De Biase¹, E. Zunarelli², G. Lanza³, D. Bartolini⁴, E.M. Silini⁵, G. Tallini¹, L. Cirillo¹, C. Bortolotti¹, D. Danieli⁶, S. Bartolini¹, A. Paccapelo¹, A. Brandes¹; ¹Bologna, IT, ²Modena, IT, ³Ferrara, IT, ⁴Cesena, IT, ⁵Parma, IT, ⁶Vicenza, IT
- 13:15 - 13:15 345P - Effect of ADM alone or combined with monoclonal anti-programmed death ligand-1 antibody on glioma cell lineU251 and T lymphocytes
S. Zheng, H. Zhang; Nanjing, CN
- 13:15 - 13:15 346P - Prognostic Impact of neutrophil to lymphocyte ratio (NLR) in patients (pts) with recurrent primary malignant brain tumours (PMBT) in phase I (Ph1) trials: The Royal Marsden (RMH) Experience
N. Coleman¹, V. Michalarea², S. Alken², R. Perez Lopez², N. Tunariu², A. Petruckevitch², U. Banerji³, J. de Bono², L. Welsh², F. Saran², J. Lopez³; ¹Dublin, IE, ²London, GB, ³Sutton, Surrey/GB
- 13:15 - 13:15 347P - Prognostic value of pre-operative neutrophil-to-lymphocyte ratio in patients with glioblastoma multiforme
Y. Kemal, O. Oltulu, E. Odabasi, O. Ozdemir, I. Yucel; Samsun, TR
- 13:15 - 13:15 348P - The prognostic role of gender and MGMT methylation status in glioblastoma patients: The female power
A. Tosoni¹, E. Franceschi¹, R. Depenni², B. Urbini³, M. Faedi⁴, M. Michiara⁵, C. Biasini⁶, E. Giombelli⁵, G. Pavesi², F. Zanelli⁷, M.A. Cavallo³, L. Tosatto⁴, A. Fioravanti¹, E. Zunarelli², G. Lanza³, D. Bartolini⁴, E.M. Silini⁵, A. Brandes¹; ¹Bologna, IT, ²Modena, IT, ³Ferrara, IT, ⁴Cesena, IT, ⁵Parma, IT, ⁶Piacenza, IT, ⁷Reggio Emilia, IT
- 13:15 - 13:15 349P - Reduced-intensity bevacizumab in progressive glioblastoma multiforme (GBM) is associated with similar overall survival versus standard-dosing
J. Gleeson¹, N. Keegan¹, E. Harrold¹, D. Kamel², N. Karadawi¹, E. Mammadov¹, D. Kelly¹, C. O'Leary¹, P. O'Halloran¹, K. Egan¹, S. Molloy¹, S. Mac Nally¹, B. Hennessy¹, O. Breathnach¹, W. Grogan¹, P. Morris¹; ¹Dublin, IE, ²Kingston, ON/CA
- 13:15 - 13:15 350P - An individualized-approach to second-line systemic anti-cancer therapy for glioblastoma
P. Gkogkou¹, K.(. Geropantas¹, T. Ajithkumar²; ¹Norwich, GB, ²Cambridge, GB
- 13:15 - 13:15 351P - Levetiracetam offers a survival advantage in patients with epilepsy related to MGMT-unmethylated glioblastoma
L. Rojas¹, A. Ruiz-Patiño¹, A. Cardona¹, O. Arrieta², Z. Zatarain-Barrón³; ¹Bogotá, CO, ²Ciudad De México, Tlalpan. D.F./MX, ³Cd De Mexico, MX
- 13:15 - 13:15 352P - The prognostic role of indicators of systemic inflammatory response in patients with glioblastoma

V. Kaya¹, M. Yildirim², G. Yazıcı³, A. Yalçın⁴, N. Orhan², A. Güzel²; ¹Antalya, TR, ²Gaziantep, TR, ³Ankrar, TR, ⁴Isparta, TR

- 13:15 - 13:15 353P - Which patients with recurrent glioblastoma will require a second surgery during their treatment? A machine learning solution
A. Ruiz-Patiño¹, A. Cardona¹, L. Rojas¹, O. Arrieta², Z. Zatarain-Barrón³; ¹Bogotá, CO, ²Ciudad De México, Tlalpan. D.F./MX, ³Cd De Mexico, MX
- 13:15 - 13:15 354P - The prognostic role of age in salvage re-irradiation applied patients with recurrent glioblastoma: A meta-analysis
E. Dereazlı¹, V. Kaya², G. Yazıcı³, M. Yildirim⁴; ¹İstanbul, TR, ²Antalya, TR, ³Ankara, TR, ⁴Gaziantep, TR
- 13:15 - 13:15 355P - Temozolomide combined with fractionated stereotactic radiotherapy for large brain metastases: A propensity-matched Study
Y. Ma, J. Xiao, N. Bi, Q. Liu, Y. Zhang, R. Zhao, S. Yang, Y. Li; Beijing, CN
- 13:15 - 13:15 356P - Worsening of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) can predict radiologic progressive disease (RPD) in glioblastoma (GBM) patients (PTS) treated with radiation therapy (RT) and temozolomide (TMZ): A mono-institutional prospective study
E. Bergo, G. Lombardi, P. Del Bianco, S. Dal Pos, F. Berti, L. Bellu, A. Pambuku, V. Zagonel; Padova, IT
- 13:15 - 13:15 357P - Dose distribution after tumor cavity injection in brain glioma patients
M. Zhao, X. Fu; Beijing, CN
- 13:15 - 13:15 358P - Retrospective analysis to ascertain whether thromboembolic events, patient gender and tumour size have prognostic implications for glioblastoma multiforme
D. Parslow, S. Pascoe; Plymouth, GB
- 13:15 - 13:15 359P - The standard and high dose chemotherapy dose intensity and their effect on the survival of medulloblastoma using nation-wide treatment protocol
J.Y. Lim, L.M.-J. Cha, S.M. Hahn, C.-O. Suh, D.-S. Kim, C.J. Lyu, J.W. Han; Seoul, KR
- 13:15 - 13:15 360P - Primary central nervous system germ cell tumours: A single institution retrospective study
J. Silva, M. Ramos, A. Azevedo, D. Salgado, I. Costa, J. Marques; Lisbon, PT
- 13:15 - 13:15 361P - Effect of silibinin nutraceutical supplementation in brain metastases of patients with advanced lung cancer
J. Bosch-Barrera¹, E. Sais¹, A. Izquierdo¹, A. Hernández¹, D. Roa¹, E. Cuyas¹, S. Pedraza¹, N. Priego², P. Ortuño¹, G. Sánchez¹, N. Cañete¹, A. Roselló¹, R. Soffietti³, J. Brunet¹, M. Valiente², J.A. Menendez¹; ¹Girona, ES, ²Madrid, ES, ³Torino, IT
- 13:15 - 13:15 362P - Melanoma with V600 BRAF mutations and brain metastases: Experience of targeted therapy in a single center
D. Naskhletashvili, L. Demidov; Moscow, RU
- 13:15 - 13:15 363P - Radioprotective effect of xenon in radiation treatment for brain metastases

M. Zinkovich, T. Protasova, A. Shikhlyarova, L. Rozenko, Y. Arapova; Rostov-On-don, RU

13:15 - 13:15 ENDOCRINE AND NEUROENDOCRINE TUMOURS

J. Strosberg, Tampa, US

13:15 - 13:15 442P - Long-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl

P. Lapuerta¹, M.H. Kulke², M. Caplin³, E. Bergsland⁴, L. Anthony⁵, K. Öberg⁶, M. Pavel⁷, D. Hörsch⁸, T. O'Dorisio⁹, J. Dillon¹⁰, K. Kassler-Taub¹¹, W. Jiang¹¹; ¹Princeton, US, ²Boston, Ma, US, ³London, GB, ⁴San Francisco, CA/US, ⁵Lexington, US, ⁶Uppsala, SE, ⁷Berlin, DE, ⁸Bad Berka, DE, ⁹Iowa City, US, ¹⁰Iowa City, IA/US, ¹¹The Woodlands, US

13:15 - 13:15 443P - Identifying symptom and quality of life improvements in patients with carcinoid syndrome treated with telotristat ethyl: Qualitative patient exit interviews from the TELESTAR Trial

F. Marteau¹, P. Williams², M. Feuilly¹, B. Arnould²; ¹Boulogne-Billancourt, FR, ²Lyon, FR

13:15 - 13:15 444P - Carcinoid syndrome: Patient outcomes from a European Neuroendocrine Tumour Society (ENETs) centre of excellence

P. d'Arienzo¹, E. Amir², A. Lewis¹, L. Magdalani¹, W. Mansoor¹, R. Hubner¹, J. Valle¹, M. McNamara¹; ¹Manchester, GB, ²Toronto, Ontario/CA

13:15 - 13:15 445P - Relationship between symptoms and health-related quality of life benefits in patients with carcinoid syndrome: Post-hoc analyses from TELESTAR

M. Pavel¹, D. Cella², J. Beaumont², S. Hudgens³, F. Marteau⁴, M. Feuilly⁴, S. Gabriel⁴, A. Houchard⁴, J. Ramage⁵, D. Hörsch⁶, M.H. Kulke⁷; ¹Berlin, DE, ²Chicago, IL, US, ³New York, Arizona/US, ⁴Boulogne-Billancourt, FR, ⁵Basingstoke, GB, ⁶Bad Berka, DE, ⁷Boston, Ma, US

13:15 - 13:15 446P - Benefit of oral monotherapy with pazopanib in metastatic gastroenteropancreatic neuroendocrine tumours

D. Katalinic¹, I. Aleric², A. Vcev²; ¹Zagreb, HR, ²Osijek, HR

13:15 - 13:15 447P - High hepatic tumor burden and cardiovascular comorbidities linked to carcinoid heart disease

M. Mesquita, C. Silva, C. Silva, M. Feres Almeida Soeiro, L. Hajjar, P. Gehm Hoff, R. Riechelmann; Sao Paulo, BR

13:15 - 13:15 448P - Bone metastases in patients with neuroendocrine neoplasms: A survey of natural history and clinical management

N. Fazio¹, P. Maisonneuve¹, A.M. Frezza¹, T. Ibrahim², A. La Salvia³, S. Tafuto⁴, S. Pusceddu¹, R. Marconcini⁵, F. Silvestris⁶, D. Campana⁷, D. Santini⁸, A. Faggiano⁹, S. Massironi¹, L. De Marinis¹⁰, G. Rubini⁶, E. Merola⁸, L. Antonuzzo¹¹, V. Amoroso¹², I. Puliafito¹³, F. Spada¹; ¹Milan, IT, ²Meldola, IT, ³Orbassano, IT, ⁴Napoli, IT, ⁵Pisa, IT, ⁶Bari, IT, ⁷Bologna, IT, ⁸Roma, IT, ⁹Naples, IT, ¹⁰Rome, IT, ¹¹Firenze, IT, ¹²Brescia, IT, ¹³Viagrande, IT

13:15 - 13:15 449P - Financial toxicity in patients with neuroendocrine tumors: Impact of a chronic disease on patients' economic situation

L. Apostolidis¹, K. Mehlis¹, M. Kudlich¹, J. Witte², J. Walther¹, W. Greiner², E. Winkler¹; ¹Heidelberg, DE, ²Bielefeld, DE

- 13:15 - 13:15 450P - Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): Incidence and impact on quality of life
A. Lamarca, L. McCallum, C. Nuttall, J. Barriuso, M. Frizziero, R. Leon, W. Mansoor, M. McNamara, R. Hubner, J. Valle; Manchester, GB
- 13:15 - 13:15 451P - Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension
J. Cwikla¹, E. Wolin², M. Pavel³, A. Phan⁴, M. Raderer⁵, E. Sedláčková⁶, G. Cadiot⁷, J. Capdevila⁸, G. Rindi⁹, C. Lombard-Bohas¹⁰, N. Liyanage¹¹, X.-M. Truong Thanh¹¹, P. Ruzsniowski¹², M. Caplin¹³; ¹Olsztyn, PL, ²New York, US, ³Erlangen, DE, ⁴Albuquerque, NM/US, ⁵Vienna, AT, ⁶Prague, CZ, ⁷Reims, FR, ⁸Barcelona, ES, ⁹Roma, IT, ¹⁰Lyon, FR, ¹¹Les Ulis, FR, ¹²Clichy, FR, ¹³London, GB
- 13:15 - 13:15 452P - Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): Time to maximum response and optimal treatment duration
A. Lamarca, J. Barriuso, L. McCallum, G. Papaxoinis, M. Nasralla, C. Nuttall, M. Frizziero, Z. Kordatou, M. McNamara, R. Hubner, P. Manoharan, W. Mansoor, J. Valle; Manchester, GB
- 13:15 - 13:15 453P - Efficacy of recombinant human endostatin combined with chemotherapy in advanced pancreatic neuroendocrine tumors
Y. Cheng, Beijing, CN/CN
- 13:15 - 13:15 454P - Comparison of clinical efficacy of SST analogues therapy (lanreotide autogel vs. octreotide LAR) in treatment of patients with advance, non-resectable pancreatic neuroendocrine tumours (pNETs)
A. Kolasinska-Cwikla¹, A. Lewczuk², J. Palucki¹, L. Sawicki¹, K. Roszkowska-Purska¹, M. Kidd³, L. Bodei⁴, I. Modlin⁵, J. Cwikla⁶; ¹Warsaw, PL, ²Gdansk, PL, ³Branford, CT/US, ⁴Milan, IT, ⁵New Haven, CT/US, ⁶Olsztyn, PL
- 13:15 - 13:15 455P - Metastatic neuroendocrine neoplasia (mNEN) treatments in over 70 years (y) old patients: A retrospective outcome analysis
A. Bongiovanni¹, F. Foca², F. Recine³, V. Fausti¹, N. Riva⁴, E. Setola⁵, M. Faedi⁶, A. Ianniello², F. Pieri⁷, R. Galassi², D. Cavaliere⁷, A. Gardini⁷, A. Tartaglia⁷, V. Lunedei⁷, L. Mercatali², D. Amadori¹, T. Ibrahim²; ¹Meldola, Forlì-Cesena/IT, ²Meldola, IT, ³Roma, IT, ⁴Meldola (fc), IT, ⁵Milan, IT, ⁶Cesena, IT, ⁷Forlì, IT
- 13:15 - 13:15 456P - Modified staging classification for gastric neuroendocrine carcinomas on the basis of the American Joint Committee on cancer
J. Xie, H. Chang-Ming, C. Zheng, P. Li, J.-X. Lin; Fuzhou, CN
- 13:15 - 13:15 457P - Predictive factors in GEP-NEN: The integrated role of Ki67, beta-catenin and morphology
M. MILIONE¹, R. Miceli¹, A. Pellegrinelli¹, G. Centonze¹, F. Barretta¹, S. Pusceddu¹, L. Giacomelli², J. Coppa¹, V. Mazzaferro¹, G. Sozzi¹, A. Anichini³, F. de Braud¹; ¹Milan, IT, ²Genoa, IT, ³Milano, IT

- 13:15 - 13:15 458P - The preoperative blood lymphocyte-to-monocyte ratio acts as a superior prognostic factor and predicts tumor metastasis in gastric neuroendocrine neoplasms after surgery
L.-L. Cao, H. Chang-Ming, J.-X. Lin, J. Lu, C. Zheng; Fuzhou, CN
- 13:15 - 13:15 459P - Follow-up and recurrence in resected gastroenteropancreatic neuroendocrine tumours: A population-based study
D. Chan¹, E. Segelov², L. Moody³, N. Liu³, H. Fischer³, P. Austin³, S. Singh⁴; ¹St Leonards, AU, ²Melbourne, NSW/AU, ³Toronto, CA, ⁴Toronto, Ontario/CA
- 13:15 - 13:15 460P - Elevated levels of 5-HIAA and CgA in patients with PanNETs from the CLARINET Study
A. Phan¹, E. Wolin², N. Liyanage³, B. Mirakhor⁴, S. Pitman Lowenthal⁴, A. Vinik⁵, G. Fisher, Jr⁶, M. Pavel⁷; ¹Albuquerque, NM/US, ²Bronx, NY/US, ³Les Ulis, FR, ⁴Basking Ridge, NJ/US, ⁵Norfolk, VA/US, ⁶Stanford, CA/US, ⁷Berlin, DE
- 13:15 - 13:15 461P - The prognostic value of cytokeratin 7, 19, thyroid transcription factor-1 and CD117 expression in lung neuroendocrine tumors of various grades.
L. Gurevich, N. Korsakova, I. Voronkova, I. Kazantseva, V. Ashevskaya, A. Titov, L. Kogoniya, M. Byakhova; Moscow, RU
- 13:15 - 13:15 462P - A nomogram based on tumor-associated neutrophil-to-lymphocyte ratio to predict survival prognosis for patients with gastric neuroendocrine neoplasms
L.-L. Cao, H. Chang-Ming, J. Lu, J. Xie, P. Li; Fuzhou, CN
- 13:15 - 13:15 463P - Plasma protein fingerprinting and machine learning for the diagnosis of small intestinal neuroendocrine tumors: The nordic NET biomarker group EXPLAIN study
M. Kjellman¹, S. Welin², U. Knigge³, H. Gronbaek⁴, H. Sorbye⁵, E. Thiis-Evensen⁶, M. Thyregod Jørgensen⁷, V. Johanson⁸, C. Schalin-Jäntti⁹, P. Myrenfors¹⁰, T. Ström¹, K. Becker¹, R. Belusa¹⁰; ¹Stockholm, SE, ²Uppsala, SE, ³Copenhagen, DK, ⁴Aarhus, SE, ⁵Bergen, NO, ⁶Oslo, SE, ⁷Odense, DK, ⁸Gothenburg, SE, ⁹Helsinki, FI, ¹⁰Kista, SE
- 13:15 - 13:15 464P - CXCR4 inhibition by ulocuplumab prevents EMT of pNET cells in vitro
E. Pellé¹, M. Cives², D. Quaresmini¹, D. Lovero¹, C. Felici¹, P. Cafforio¹, R. Palmirotta¹, F. Silvestris¹; ¹Bari, IT, ²Bari, FL/IT
- 13:15 - 13:15 465P - Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC): A European subgroup analysis
J. Smit¹, M. Brose², F. Pitoia³, C.-C. Lin⁴, I. Sugitani⁵, M. Alevizaki⁶, Y. Godbert⁷, J. Aller⁸, R. Peeters⁹, K. Pazaitou-Panayiotou¹⁰, L. Leenhardt¹¹, M. Fellous¹², Y. De Sanctis¹², M. Schlumberger¹³; ¹Nijmegen, NL, ²Philadelphia, PA/US, ³Buenos Aires, AR, ⁴Taipei, TW, ⁵Tokyo, JP, ⁶Athens, GR, ⁷Bordeaux, FR, ⁸Madrid, ES, ⁹Rotterdam, NL, ¹⁰Thessaloniki, GR, ¹¹Paris, FR, ¹²Whippany, US, ¹³Villejuif, CEDEX/FR
- 13:15 - 13:15 466P - Mixed adeno-neuroendocrine carcinoma (MANEC) of the gastroenteropancreatic (GEP) tract: A multicentre retrospective study

M. Frizziero¹, X. Wang², B. Chakrabarty², A. Childs³, T.V. Luong⁴, T. Walter⁵, M. Elshafie⁶, T. Shah⁶, P. Fulford², A. Minicozzi², W. Mansoor², T. Meyer⁴, R. Hubner², J. Valle², M. McNamara²; ¹Vipiteno, Bolzano/IT, ²Manchester, GB, ³Bt, GB, ⁴London, GB, ⁵Hamburg, DE, ⁶Birmingham, GB

- 13:15 - 13:15 467P - Incidence of adrenal gland tumor as a second primary malignancy: SEER based database
W. Rashed¹, A. Saad¹, M. Al-Husseini¹, A. Galal¹, A. Al-Tayep¹, A. El Shafie¹, M. Ali¹, A. Alfaar²; ¹Cairo, EG, ²Berlin, DE
- 13:15 - 13:15 468P - Activity of temozolomide (TMZ) in patients (PTS) with malignant pheochromocytoma or paraganglioma (MPP): A mono-institutional retrospective study
G. Lombardi, M. Ferrara, A. Pambuku, M. Lorusso, F. Boaretto, F. Schiavi, L. Biasini, F. Azzolin, G. Opocher, S. Zovato, V. Zagonel; Padova, IT
- 13:15 - 13:15 469P - Neuroendocrine carcinoma of the uterine cervix: A retrospective monocentric study
M. Creoff¹, S. Thezenas¹, A. Lapierre¹, A. Duceil¹, D. Azria², C. Bourcier¹, C. Kerr¹; ¹Montpellier, FR, ²Montpellier, CEDEX 5/FR
- 13:15 - 13:15 470TiP - AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas
M. Khasraw¹, M. Hofman², L. Chantrill³, N. Pavlakis⁴, V. GebSKI⁵, A. Gill⁵, B. Markman⁶, S. Yip⁵, E. Gibbs⁵, C. Karapetis⁷, S.F. Wong¹, D. Ransom⁸, M. MICHAEL², K. Wilson⁵, J. Simes⁵, L. Lipton⁶; ¹Geelong, VIC/AU, ²Melbourne, AU, ³Darlinghurst, NSW/AU, ⁴St Leonards, NSW/AU, ⁵Sydney, AU, ⁶Melbourne, VIC/AU, ⁷Bedford Park, SA/AU, ⁸Subiaco, WA/AU
- 13:15 - 13:15 471TiP - A multicentre, randomised, double-blind, parallel-group, placebo-controlled trial of apatinib in local progressive or metastatic radioactive iodine-refractory differentiated thyroid cancer
Y. Lin¹, S. Qin²; ¹Beijing, CN, ²Nanjing, CN
- 13:15 - 13:15 472TiP - Phase 2 clinical investigation of BPM31510 (ubidecarenone) alone and in combination with gemcitabine in patients with advanced pancreatic cancer
A. Niewiarowska¹, R. Sarangarajan², D. Lucius², N. Narain³, R. Raminathan⁴, M. Hidalgo⁵; ¹Bethlehem, PA/US, ²Framingham, MA/US, ³Natick, MA/US, ⁴Phoenix, AZ/US, ⁵Madrid, ES
- 13:15 - 13:15 GENITOURINARY TUMOURS, PROSTATE
K. Fizazi¹, D. Lorente Estelles²; ¹Villejuif, FR, ²Valencia, ES
- 13:15 - 13:15 794P - EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy
U. Vaishampayan¹, R. Montgomery², M. Gordon³, D. Smith⁴, K. Barber⁵, A. de Haas-Amatsaleh⁶, N. Thapar⁵, C. Chandhasin⁵, F. Perabo⁵, K. Chi⁷; ¹Detroit, MI/US, ²Seattle, US, ³Scottsdale, AZ/US, ⁴Ann Arbor, US, ⁵Houston, US, ⁶Houston, TX/US, ⁷Vancouver, CA
- 13:15 - 13:15 795P - An innovative Dendritic Cell Vaccine for Castration-Resistant Prostate Cancer Patients: radiological PFS results

H. Westdorp¹, I.M. van Oort¹, G. Schreibelt¹, A.L. de Goede¹, N. Mehra², C.A. Hulsbergen-van de Kaa¹, C.G. Figdor¹, F. Witjes¹, E. Aarntzen¹, R.D.M. Mus¹, M. Gotthardt¹, J.O. Barentsz¹, I.J.M. de Vries¹, W. Gerritsen¹; ¹Nijmegen, NL, ²Nijmegen, Surrey/NL

- 13:15 - 13:15 796P - Phase I expansion cohort of TAS-115, a novel oral MET/VEGFR/FMS inhibitor, for castration-resistant prostate cancer patients (CRPC pts) with bone metastases
N. Matsubara¹, Y. Naito², M. Sasaki², N. Yamamoto², S. Takahashi², H. Uemura³, T. Doi¹; ¹Kashiwa, Chiba/JP, ²Tokyo, JP, ³Yokohama, JP
- 13:15 - 13:15 797P - Phase II trial of SM88 in non-metastatic biochemical recurrent prostate cancer
G. Del Priore¹, W.-T. Chen², H. Dong², S. Hoffman³, G. Sokol⁴; ¹Atlanta, US, ²Stony Brook, NY/US, ³New York, NY/US, ⁴Bethesda, MD/US
- 13:15 - 13:15 798P - Impact of the addition of metformin (Met) to abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) progressing on Abi treatment: A phase II pilot study
M. Mark¹, D. Klingbiel², U. Mey¹, R. Winterhalder³, C. Rothermundt⁴, S. Gillissen⁴, R. von moos¹, G. Manetsch¹, R. Cathomas¹; ¹Chur, CH, ²Berne, CH, ³Luzern, CH, ⁴St. Gallen, CH
- 13:15 - 13:15 799P - Steroid switch: Reversal of resistance to abiraterone acetate (AA) and prednisolone (P) combination in metastatic castration-resistant prostate cancer (mCRPC) patients
F. Gyergyay, B. Budai, K. Biro, Z. Kürönya, K. Nagyványi, L. Geczi; Budapest, HU
- 13:15 - 13:15 800P - Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA+P)
R. Lozano Mejorada¹, N. Romero Laorden², A. Jayaram³, F. López⁴, M.I. Sáez⁵, R. Villatoro⁶, A. Montesa⁶, I. Moreno⁵, M. Ruiz Vico⁶, M. García Ferrón⁴, J. Rogado⁴, Y. Cendón Flórez⁴, P. Nombela Blanco⁴, L. Rivera⁴, G. Grau⁶, J.J. Cruz Hernandez¹, D. Lorente Estelles⁷, G. Attard⁸, E. Castro Marcos⁴, D. Olmos Hidalgo⁴; ¹Salamanca, ES, ²Madrid, Madrid/ES, ³London, GB, ⁴Madrid, ES, ⁵Malaga, ES, ⁶Málaga, ES, ⁷Valencia, ES, ⁸Sutton, Surrey/GB
- 13:15 - 13:15 801P - Effect of sequence on outcome of prostate cancer patients: retrospective study of a French cohort
R. Elaidi, Y. Belhadj, S. Oudard; Paris, FR
- 13:15 - 13:15 802P - Patient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial
K. Fizazi¹, R. Delva², G. Gravis³, G. Baciarello⁴, C. Theodore⁵, M. Gross-Goupil⁶, E. Bompas⁷, F. Joly Lobbedez⁸, Y. Tazi⁹, T. L'Haridon¹⁰, T. Nguyen Tan Hon¹¹, P. Barthelemy¹², S. Culine¹³, J.-F. Berdah¹⁴, M. Deblock¹⁵, P. Beuzeboc¹⁶, A. Fléchon¹⁷, C. Cheneau¹⁸, G. Martineau¹, I. Borget¹; ¹Villejuif, FR, ²Angers, FR, ³Marseille, CEDEX 9/FR, ⁴Villejuif, CEDEX/FR, ⁵Suresnes, FR, ⁶Bordeaux, FR, ⁷Saint-Herblain, CEDEX/FR, ⁸Caen, CEDEX 5/FR, ⁹Strasbourg, FR, ¹⁰La Roche Sur Yon, CEDEX 9/FR, ¹¹Besançon, CEDEX/FR, ¹²Strasbourg, CEDEX/FR, ¹³Paris, CEDEX 10/FR, ¹⁴Hyerès, FR, ¹⁵Vandoeuvre Les Nancy, CEDEX/FR, ¹⁶Paris, CEDEX 5/FR, ¹⁷Lyon, FR, ¹⁸Lorient, CEDEX/FR
- 13:15 - 13:15 803P - Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic "hormone-sensitive" prostate cancer

S. Feyerabend¹, F. Saad², T. Li³, T. Ito⁴, J. Diels², S. Van Sanden², P. De Porre⁵, J. Roiz⁶, S. Abogunrin⁶, K. Fizazi⁷; ¹Reutlingen, DE, ²Beerse, BE, ³Raritan, NJ/US, ⁴Buckinghamshire, GB, ⁵Antwerp, BE, ⁶London, GB, ⁷Villejuif Cedex, FR

13:15 - 13:15 804P - Practice patterns in metastatic castration-resistant prostate cancer (mCRPC): Evidence from the veterans health administration

A. Halwani¹, Z. Burningham¹, K. Rasmussen², V. Patil¹, S. Narayanan³, S.-W. Lin³, S. Carroll³, L.-I. Hsu³, J. Graff⁴, R. Dreicer⁵, S. Gupta², C. Low¹, B. Sauer¹; ¹Salt Lake City, UT/US, ²Salt Lake City, US, ³South San Francisco, CA/US, ⁴Portland, US, ⁵Charlottesville, VA/US

13:15 - 13:15 805P - Efficacy and safety of first-line combined androgen blockade in advanced prostate cancer: A meta-analysis

Y. Sun, Y. Yang, R. Chen, L. Zhao, F. Liu, S. Ren, H. Wang, X. Lu, X. Gao, C. Xu; Shanghai, CN

13:15 - 13:15 806P - Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry

E. Francini¹, S. Yip², N. Ahmed², H. Li², L. Ardolino³, C. Evan¹, M. Kaymakcalan¹, G. Shaw¹, P. Kantoff¹, M.E. Taplin⁴, N. Alimohamed⁵, A. Joshua⁶, D. Heng⁵, C. Sweeney¹; ¹Boston, MA/US, ²Calgary, AB/CA, ³Sydney, NSW/AU, ⁴Boston, US, ⁵Calgary, CA, ⁶Sydney, AU

13:15 - 13:15 807P - First interim results of the radium-223 (Ra-223) REASSURE observational study: Analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza)

L. Harshman¹, J. Logue², C. Sternberg³, S. Sundar⁴, D. Schrijvers⁵, M. Schostak⁶, J. Sylvester⁷, S. George⁸, M. Tucci⁹, C. Mantz¹⁰, P. Borrega¹¹, P. Ziem¹², R. Concepcion¹³, K. Miller¹⁴, O. Sartor¹⁵, J. Kalinovsky¹⁶, Y. De Sanctis¹⁷, B. Tombal¹⁸; ¹Boston, MA/US, ²Manchester, GB, ³Roma, IT, ⁴Nottingham, Nottinghamshire/GB, ⁵Antwerp, BE, ⁶Magdeburg, DE, ⁷Lakewood Ranch, FL/US, ⁸Buffalo, US, ⁹Orbassano, TO/IT, ¹⁰Fort Myers, FL/US, ¹¹Caceres, Cáceres/ES, ¹²Neubrandenburg, DE, ¹³Nashville, TN/US, ¹⁴Berlin, DE, ¹⁵New Orleans, LA/US, ¹⁶Bratislava, SK, ¹⁷Whippany, NJ/US, ¹⁸Brussels, BE

13:15 - 13:15 808P - A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa)

D. KILARI¹, E. Guancial², D. Sahasrabudhe², K. Bylow¹, L. Sievert², K. Schaffer², M. Riese¹, J. Burfeind¹, K. Musto¹, C. Feng², E. Messing², S. Mohile², C. Fung²; ¹Milwaukee, US, ²Rochester, NY/US

13:15 - 13:15 809P - Cabazitaxel plus prednisone and prophylaxis of neutropenia complications in the treatment of metastatic castration-resistant prostate cancer after failure to docetaxel: A multicenter, non-comparative, open-label, phase IV study

F. Maluf¹, D. Cubero², F. de Oliveira³, P. Liedke⁴, L. Brust⁵, C. Inocência⁶, F. Monteiro⁷; ¹Sao Paulo, BR, ²Santo Andre, SP/BR, ³Curitiba, BR, ⁴Porto Alegre, BR, ⁵Lageado, BR, ⁶Cuiaba, BR, ⁷Brasilia, BR

13:15 - 13:15 810P - Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 &

M. Eisenberger¹, A.-C. Hardy-Bessard², C.S. Kim³, L. Géczi⁴, D. Ford⁵, L. Mourey⁶, J. Carles⁷, P. Parente⁸, A. Font⁹, G. Kacsó¹⁰, G. Barnes¹¹, H. Wang¹², W. Zhang¹², A. Ozatilgan¹¹, J. de Bono¹³; ¹Baltimore, US, ²Plerin-Sur-mer, FR, ³Seoul, KR, ⁴Budapest, HU, ⁵Birmingham, GB, ⁶Toulouse, FR, ⁷Barcelona, ES, ⁸Box Hill, AU, ⁹Badalona, ES, ¹⁰Cluj-Napoca, RO, ¹¹Cambridge, MA/US, ¹²Bridgewater, NJ/US, ¹³London, GB

- 13:15 - 13:15 817P - Prostate: A simplified tool for predicting outcomes among patients with treatment-naïve advanced prostate cancer
O. Abdel-Rahman, Cairo, EG
- 13:15 - 13:15 813P - Real-world use of docetaxel for metastatic castration-resistant prostate cancer in China: Results from a large observational study
D. He¹, Z. Sun², J. Guo², Z. Zhang³, Y. Shan⁴, L. Ma⁵, H. Li⁵, J. Jin⁵, Y. Huang², J. Xiao³, Q. Wei⁶, D. Ye²; ¹Xi'an, CN, ²Shanghai, CN, ³Hangzhou, CN, ⁴Suzhou, CN, ⁵Beijing, CN, ⁶Chengdu, CN
- 13:15 - 13:15 811P - Cabazitaxel followed by androgen deprivation therapy (ADT) significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A randomized, open label, phase III, multicenter trial
O. André¹, A. Widmark², A. Falt¹, E. Ulvskog¹, S. Davidsson¹, C. Thellenberg Karlsson², M. Hjalml-Eriksson³; ¹Orebro, SE, ²Umea, SE, ³Stockholm, SE
- 13:15 - 13:15 812P - Health-related quality of life (HRQL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) in a prospective observational study (CAPRISTANA)
A. Pichler¹, G. Barnes², J. Katolicka³, H. Korunkova⁴, A. Tomova⁵, M. Ghosn⁶, F. El Karak⁶, I. Koroleva⁷, J. Makdessi⁶, A. Ozatilgan⁸, S. Hitier⁹, J. Carles¹⁰; ¹Leoben, AT, ²Cambridge, MA/US, ³Brno, CZ, ⁴Plzen, CZ, ⁵Plovdiv, BG, ⁶Beirut, LB, ⁷Samara, RU, ⁸Istanbul, TR, ⁹Chilly-Mazarin, FR, ¹⁰Barcelona, ES
- 13:15 - 13:15 814P - Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy+androgen deprivation therapy (ADT)
M.A. Climent Duran¹, B. Mellado², J.M. Piulats Rodriguez³, L. Heras Lopez⁴, M.J. Juan¹, M.I. Sáez⁵, O. Reig², A. Montesa⁶, J.F. Suarez², R. Hajianfar⁴, M.J. Ribal², J. Rubio¹, M. Castells², R. Villatoro⁶, S. Sandiego¹, D. Olmos Hidalgo⁷; ¹Valencia, ES, ²Barcelona, ES, ³Barcelona, Barcelona/ES, ⁴Sant Joan Despí, ES, ⁵Malaga, ES, ⁶Málaga, ES, ⁷Madrid, ES
- 13:15 - 13:15 815P - Prognostic value of systemic inflammatory biomarkers in patients with mCRPC treated with abiraterone in pre-docetaxel setting
R. Ratta¹, E. Verzoni¹, F. Pantano², P. Grassi¹, D. De Lisi², A. Onorato², M. Prisciandaro¹, R. Montone³, F. de Braud¹, D. Santini⁴, G. Procopio¹; ¹Milan, IT, ²Rome, IT, ³Milano, IT, ⁴Roma, IT
- 13:15 - 13:15 816P - 68Ga-PSMA-PET/CT as a changing practice tool in biochemically recurrent prostate cancer
P. Domingues, T. Abreu, M. Siqueira, G. Marinho, D. Rosa, H. Cottas, L. Araujo, D. Herchenhorn, F. Peixoto; Rio De Janeiro, BR

- 13:15 - 13:15 818P - PSA doubling time (PSADT) and proximal PSA predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP): Implications for patient counseling and clinical trial design
M. Markowski¹, Y. Chen², Z. Feng³, B. Trock³, J. Cullen⁴, D. Suzman³, E. Antonarakis³, C. Paller¹, M. Han³, A. Partin³, M. Eisenberger¹; ¹Baltimore, US, ²Rockville, MD/US, ³Baltimore, MD/US, ⁴Rockville, US
- 13:15 - 13:15 824P - ARV7 status and CTC count: A combined biomarker for the baseline therapeutic decision in each line of mCRPC treatment
E. Bournakis, E. Lianidou, A. Strati, M. Zavridou, A. Sfika, A. Bournakis, C. Papadimitriou; Athens, GR
- 13:15 - 13:15 819P - PSA kinetics impact on CT-PET PSMA uptake in prostate cancer
A. Sella¹, S. Kovel², T. Sella³; ¹Zerifin, IL, ²Beer Jacob, IL, ³Ramat Gan, IL
- 13:15 - 13:15 821P - A polymorphism in the promoter of the FRAS1 gene is associated with metastatic prostate cancer
C. Sweeney¹, M. Geybels², S. Coseo-Markt¹, V. Wang¹, K. Penney¹, T. Gerke³, M. Pomerantz¹, G.-S.M. Lee¹, D. Nitsch⁴, C. Huttenhower¹, L. Mucci¹; ¹Boston, MA/US, ²Seattle, WA/US, ³Tampa, FL/US, ⁴Hamburg, DE
- 13:15 - 13:15 820P - Combining functional imaging with circulating biomarker analysis to improve prognostication of metastatic castration-resistant prostate cancer (mCRPC)
V. Conteduca¹, S. Salvi², P. Caroli², E. Scarpi², G. Schepisi¹, C. Lolli¹, D. Wetterskog³, S.L. Burgio², C. Menna¹, V. Casadio², F. Matteucci⁴, G. Paganelli¹, G. Attard⁵, U. De Giorgi¹; ¹Meldola, Forlì-Cesena/IT, ²Meldola, IT, ³Sutton, GB, ⁴Meldola (fc), IT, ⁵Sutton, Surrey/GB
- 13:15 - 13:15 822P - Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes
H. Scher¹, R. Graf², A. Jendrisak², B. McLaughlin³, E. Barnett³, N. Schreiber³, J. Lee², J. Kelvin², Y. Wang², M. Landers⁴, R. Dittamore⁵; ¹New York, NY, US, ²San Diego, CA/US, ³New York, NY/US, ⁴San Diego, US, ⁵New York, US
- 13:15 - 13:15 823P - Expression of steroid hormone transporter, SLCO1B3, is mediated by a CBP/p300 regulatory mechanism in prostate cancer
E. McCrea¹, P. Huang², E. Harris², J. Strobe², T. Sissung², D. Price², C. Chau², W. Figg²; ¹Cairo, EG, ²Bethesda, MD/US
- 13:15 - 13:15 825P - Limited value of currently used germline brca mutations predictive tools in prostate cancer
L. Oliva Fernández¹, M.A. Márquez-Aragónés², N. Romero-Laorden³, B.I. Pajares Hachero¹, I. Moreno¹, M. Ruiz Vico², G. Duran Ogaya¹, C. Muriel², J. Pascual¹, C. Fernández de Souza², M.E. Domínguez Recio¹, G. Grau², M.I. Sáez¹, A. Montesa², R. Correa², D. Olmos Hidalgo³; ¹Malaga, ES, ²Málaga, ES, ³Madrid, ES
- 13:15 - 13:15 826P - Prevalence and baseline clinico-pathological associations of germline deleterious mutations in DNA repair genes (gmDDR) in a metastatic castration resistant prostate cancer (mCRPC) prospective spanish cohort (PROREPAIR-B study)

N. Romero Laorden¹, R. Lozano Mejorada², J.M. Piulats Rodriguez³, E. Vallespín⁴, A. Montesa⁵, D. Lorente Estelles⁶, J.C. Villaguzmán⁷, G. Grau⁵, A. Rodriguez-Vida⁸, K. Ibañez⁴, E. Gonzalez-Billalabeitia⁹, L. Magraner⁴, J. Garde⁶, S. Hernando Polo¹⁰, J. Arranz Arijá⁴, R. Villatoro⁵, B. Pérez Valderrama¹¹, P. Lapunzina⁴, E. Castro Marcos⁴, D. Olmos Hidalgo⁴; ¹Madrid, Madrid/ES, ²Salamanca, ES, ³Barcelona, Barcelona/ES, ⁴Madrid, ES, ⁵Málaga, ES, ⁶Valencia, ES, ⁷Ciudad Real, ES, ⁸Barcelona, ES, ⁹Murcia, ES, ¹⁰Alcorcon, Madrid/ES, ¹¹Sevilla, ES

- 13:15 - 13:15 827P - Comprehensive characterization of BRCA1 and BRCA2 alterations in circulating tumor DNA and tumor tissue in men with prostate cancer: Implications for clinical care
P. Lara¹, J. McPherson¹, W. Heyer¹, R. Hartmaier², R. Devere White¹, J. Chung², S. Ali², M. Dall'Era¹; ¹Sacramento, CA/US, ²Cambridge, MA/US
- 13:15 - 13:15 828P - Durable prostate cancer control in a randomized trial of optimal timing of dose escalated (76 Gy) radiation and 6 months ADT in prostate cancer
S. Malone¹, L. Eapen¹, C. E¹, W. Kendal¹, J. Craig¹, R. Macrae¹, G. Perry¹, J. Bowen², S. Morgan¹, O. Holmes¹, S. Grimes¹; ¹Ottawa, CA, ²Sudbury, CA
- 13:15 - 13:15 829P - Initial results from AQUARiUS, a prospective, observational, multi-centre phase IV study assessing patient-reported outcomes (PROs) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate plus prednisone (AAP) or enzalutamide (ENZ)
A. Thiery-Vuillemin¹, M.H. Poulsen², A. Reid³, E. Lagneau⁴, G. Ploussard⁵, A. Birtle⁶, L.M. Dourthe⁷, D. Beal-Ardisson⁸, E. Pintus⁹, R. Trepiakas¹⁰, M. Lukac¹¹, S. Van Sanden¹², L. Dearden¹³; ¹Besançon, FR, ²Odense, DK, ³Sutton, Surrey/GB, ⁴Dijon, FR, ⁵Toulouse, FR, ⁶Preston, GB, ⁷Strasbourg, FR, ⁸Lyon, FR, ⁹Reading, GB, ¹⁰Naestved, DK, ¹¹Prague, CZ, ¹²Beerse, BE, ¹³High Wycombe, GB
- 13:15 - 13:15 830P - Assessment of association between clinical characteristics and prostate specific antigen (PSA) progression in men with prostate cancer (PCa) receiving a leuprorelin acetate implant: Results from the non-interventional German cohort LEAN study
B. Schmitz-Dräger¹, S. Mühlich², B. Ottillinger³, M. Studen³; ¹Fürth, DE, ²Bamberg, DE, ³Holzkirchen, DE
- 13:15 - 13:15 831P - Neuropsychiatric adverse events of enzalutamide and abiraterone acetate plus prednisone treatment: Contrasting a meta-analysis of randomized clinical trials with real world reporting patterns from EUDRA
M. Sanchez Iznaola¹, R. Parra¹, G. Angela¹, J. Casariego¹, J. Muñoz Del Toro¹, P. Robinson²; ¹Madrid, ES, ²High Wycombe, GB
- 13:15 - 13:15 832P - Influence of an international consensus conference on practice patterns in advanced prostate cancer (APC)
J. Gong¹, S. Pal¹, J. Hsu², B. Tombal³, M. Sydes⁴, A. Omlin⁵, S. Gillissen⁵; ¹Duarte, CA/US, ²Duarte, US, ³Brussels, BE, ⁴London, UK/GB, ⁵St. Gallen, CH
- 13:15 - 13:15 833P - Postoperative radiation therapy after radical prostatectomy
A.D.C. Hervas Moron, C. Vallejo, J. Domínguez, F. López, M. Martin, D. Candini, E. Carrasco, S. Sancho; Madrid, ES

- 13:15 - 13:15 834TiP - Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)
J. de Bono¹, S. Bracarda², K. Chi³, C. Massard⁴, D. Olmos Hidalgo⁵, S. Sandhu⁶, C. Sternberg⁷, S. Gendreau⁸, N. Xu⁹, T. Baney⁹, D. Maslyar¹⁰, C. Sweeney¹¹; ¹London, GB, ²Arezzo, IT, ³Vancouver, British Columbia/CA, ⁴Villejuif, FR, ⁵Madrid, ES, ⁶Melbourne, VIC/AU, ⁷Roma, IT, ⁸South San Francisco, US, ⁹South San Francisco, CA/US, ¹⁰South San Francisco, California/US, ¹¹Boston, MA/US
- 13:15 - 13:15 835TiP - A phase 2 trial of ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a AR targeting agent and non-progressive on a second line taxane (SAKK 08/16)
S. Gillissen¹, S. Hayoz², A. Fuhrer², C. Biaggi Rudolf², A. Pedrazzini³, G. Procopio⁴, R. Cathomas⁵; ¹St. Gallen, CH, ²Bern, CH, ³Basel, CH, ⁴Milan, IT, ⁵Chur, CH
- 13:15 - 13:15 836TiP - The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
S. Chowdhury¹, W. Abida², J. Arranz Arija³, G. Daugaard⁴, K. Fizazi⁵, E. Gez⁶, A. Heidenreich⁷, F. Joly Lobbedez⁸, R. McDermott⁹, A. Merseburger¹⁰, J.M. Piulats Rodriguez¹¹, B. Sautois¹², S. Sridhar¹³, C. Sternberg¹⁴, S. Watkins¹⁵, A. Simmons¹⁶, S. Shetty¹⁷, A. Golsorkhi¹⁸, C. Ryan¹⁶, H. Scher¹⁹; ¹London, GB, ²New York, NY/US, ³Madrid, ES, ⁴Copenhagen, DK, ⁵Villejuif, FR, ⁶Tel Aviv, IL, ⁷Aachen, DE, ⁸Caen, CEDEX 5/FR, ⁹Dublin, Belgard Square North/IE, ¹⁰Lübeck, DE, ¹¹Barcelona, Barcelona/ES, ¹²Liège, BE, ¹³Toronto, Ontario/CA, ¹⁴Roma, IT, ¹⁵Cambridge, GB, ¹⁶San Francisco, CA/US, ¹⁷Boulder, CO/US, ¹⁸Boulder, US, ¹⁹New York, NY, US
- 13:15 - 13:15 837TiP - Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
A. Molina¹, P. Christos², Y. Whang³, L. Nordquist⁴, A. Hackett¹, H. Beltran², B. Faltas², D. Nanus², P. Giannakakou², S. Tagawa⁵; ¹New York, US, ²New York, NY/US, ³Chapel Hill, NC/US, ⁴Omaha, NE/US, ⁵New York, US/US
- 13:15 - 13:15 838TiP - ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC)
B. Tombal¹, F. Saad², M. Hussain³, C. Sternberg⁴, K. Fizazi⁵, E. Crawford⁶, K. Yamada⁷, C. Kappeler⁸, I. Kuss⁸, M. Smith⁹; ¹Brussels, BE, ²Montreal, QC/CA, ³Chicago, IL/US, ⁴Roma, IT, ⁵Villejuif, FR, ⁶Boston, MA/US, ⁷Whippany, NJ/US, ⁸Berlin, DE, ⁹Boston, US
- 13:15 - 13:15 839TiP - A phase II clinical trial of radium-223 activity in patients (pts) with metastatic castration-resistant prostate cancer (mcrpc) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status (EXCAAPE)
J. Carles Galceran¹, T. Bonfill Abella², P. Borrega³, R. Collado⁴, J. Garde⁵, M.A. Gonzalez Del Alba Baamonde⁶, E. Grande Pulido⁷, B. Mellado¹, M.J. Mendez Vidal⁸, J.M. Piulats Rodriguez⁹, R. Morales Barrera¹, E. Gallardo Diaz², P. Paredes¹, C. Suarez Rodriguez¹, O. Reig¹, S. Vazquez Estevez¹⁰; ¹Barcelona, ES, ²Sabadell, ES, ³Caceres, Cáceres/ES, ⁴Cáceres, ES, ⁵Valencia, ES, ⁶Palma De Mallorca, ES, ⁷Madrid, ES, ⁸Cordoba, ES, ⁹Barcelona, Barcelona/ES, ¹⁰Lugo, ES

- 13:15 - 13:15 840TiP - Stereotactic ablative radiotherapy (SABR) for oligoprogressive metastatic castration-resistant prostate cancer (mCRPC) during abiraterone therapy: A phase I study
U. Emmenegger¹, S. Cheng², K. Zukotynski³, P. Cheung²; ¹Toronto, Ontario/CA, ²Toronto, ON/CA, ³Hamilton, ON/CA
- 13:15 - 13:15 841TiP - A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE
C. Buonerba¹, D. Bosso¹, S. De Placido¹, G. Di Lorenzo²; ¹Napoli, IT, ²Naples, IT
- 13:15 - 13:15 842TiP - PROSABI: Prospective multi-centre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with abiraterone acetate (AA)
D. Lorente Estelles¹, J. Puente², A. Medina³, R. Lozano Mejorada⁴, L. Rivera², M.I. Pacheco², M.I. Sáez⁵, J.M. Piulats Rodriguez⁶, E.M. Fernandez Parra⁷, P. Borrega García⁸, B. Pérez Valderrama⁷, E. Gallardo Diaz⁹, R. Villatoro¹⁰, R. Morales Barrera¹¹, S. Vazquez Estevez¹², A. Pinto Marin², J.A. Contreras Ibañez¹³, N. Romero Laorden¹⁴, E. Castro Marcos²; ¹Valencia, ES, ²Madrid, ES, ³A Coruña, ES, ⁴Salamanca, ES, ⁵Malaga, ES, ⁶Barcelona, Barcelona/ES, ⁷Sevilla, ES, ⁸Cáceres, ES, ⁹Sabadell, ES, ¹⁰Málaga, ES, ¹¹Barcelona, ES, ¹²Lugo, ES, ¹³Cadiz, ES, ¹⁴Madrid, Madrid/ES
- 13:15 - 13:15 843TiP - PRORADIUM: Prospective multicentre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with radium-223
R. Morales Barrera¹, M.I. Sáez², N. Romero-Laorden³, R. Lozano Mejorada⁴, D. Lorente Estelles⁵, G. de Velasco⁶, M.A. Gonzalez Del Alba Baamonde⁷, E. Gonzalez Billalabeitia⁸, A. Medina⁹, P. Borrega García¹⁰, A. Rodriguez-Vida¹, U. Ferrandiz Brotons¹¹, O. Fernandez Calvo¹², R. García Domínguez⁴, J. Puente³, J.M. Piulats Rodriguez¹³, R. Villatoro¹⁴, E. Castro Marcos³, D. Olmos Hidalgo³; ¹Barcelona, ES, ²Malaga, ES, ³Madrid, ES, ⁴Salamanca, ES, ⁵Valencia, ES, ⁶Boston, US, ⁷Palma De Mallorca, ES, ⁸Murcia, ES, ⁹A Coruña, ES, ¹⁰Cáceres, ES, ¹¹Badalona, ES, ¹²Ourense, ES, ¹³Barcelona, Barcelona/ES, ¹⁴Málaga, ES
- 13:15 - 13:15 844TiP - PROSENZA: Prospective multi-centre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with enzalutamide (ENZ)
A. Medina¹, A. Montesa², N. Romero Laorden³, E. Gonzalez-Billalabeitia⁴, A. Rodriguez-Vida⁵, G. Grau², T. Garcés⁶, R. Morales Barrera⁵, F.J. Vazquez Mazon⁷, R. Villatoro², M.A. Gonzalez Del Alba Baamonde⁸, F. López⁶, S. Hernando Polo⁹, M. Domenech¹⁰, G. de Velasco¹¹, P. Borrega¹², R. Querol¹³, E. Velez¹⁴, E. Castro Marcos⁶, D. Olmos Hidalgo⁶; ¹A Coruña, ES, ²Málaga, ES, ³Madrid, Madrid/ES, ⁴Murcia, ES, ⁵Barcelona, ES, ⁶Madrid, ES, ⁷Elche, Alicante/ES, ⁸Palma De Mallorca, ES, ⁹Alcorcon, Madrid/ES, ¹⁰Manresa, ES, ¹¹Boston, US, ¹²Caceres, Cáceres/ES, ¹³Mataró, ES, ¹⁴Logroño, ES
- 13:15 - 13:15 GENITOURINARY TUMOURS, NON-PROSTATE
A. Necchi¹, V. Khoj²; ¹Milan, IT, ²London, GB
- 13:15 - 13:15 856P - Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with ≥6 months of follow-up in all patients

A. Apolo¹, J. Ellerton², J. Infante³, M. Agrawal⁴, M. Gordon⁵, R. Aljumaily⁶, C. Britten⁷, L. Dirix⁸, K.-W. Lee⁹, M. Taylor¹⁰, P. Schöffski¹¹, D. Wang¹², A. Ravaud¹³, A. Gelb¹⁴, J. Xiong¹⁴, G. Rosen¹⁵, M. Patel¹⁶; ¹Bethesda, US, ²Las Vegas, NV/US, ³Nashville, TN/US, ⁴Rockville, MD/US, ⁵Scottsdale, AZ/US, ⁶Oklahoma City, OK/US, ⁷Charleston, SC/US, ⁸Antwerpen, BE, ⁹Seongnam, KR, ¹⁰Portland, OR/US, ¹¹Leuven, BE, ¹²Detroit, MI/US, ¹³Bordeaux Cedex, FR, ¹⁴Billerica, US, ¹⁵Billerica, MA/US, ¹⁶Sarasota, FL/US

- 13:15 - 13:15 857P - Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status
P. Grivas¹, E. Plimack², A. Balar³, D. Castellano⁴, P. O'Donnell⁵, J. Bellmunt⁶, T. Powles⁷, N. Hahn⁸, R. de Wit⁹, D. Bajorin³, M. Ellison¹⁰, T. Frenkl¹⁰, S. Keefe¹⁰, J. Vuky¹¹; ¹Cleveland, US, ²Philadelphia, PA/US, ³New York, US, ⁴Madrid, ES, ⁵Chicago, US, ⁶Boston, MA/US, ⁷London, GB, ⁸Indianapolis, IN/US, ⁹Rotterdam, NL, ¹⁰Kenilworth, US, ¹¹Portland, US
- 13:15 - 13:15 858P - Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results
S. Tagawa¹, B. Faltas², E. Lam³, P. Saylor⁴, A. Bardia⁵, J. Hajdenberg⁶, A. Morgans⁷, E. Lim⁸, K. Kalinsky⁸, D. Petrylak⁹, M. Guarino¹⁰, M. Galsky⁸, P. Maliakal¹¹, B. Mudenda¹¹, R. Sharkey¹¹, W. Wegener¹¹, D. Goldenberg¹¹; ¹New York, US/US, ²New York, NY/US, ³Denver, US, ⁴Boston, US, ⁵Boston, MA/US, ⁶Orlando, FL/US, ⁷Nashville, US, ⁸New York, US, ⁹New Haven, CT/US, ¹⁰Newark, US, ¹¹Morris Plains, US
- 13:15 - 13:15 859P - Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels
M. Schuler¹, L. Nogova², A. Heidenreich³, D. Tai⁴, P. Cassier⁵, H. Richly¹, B.C. Cho⁶, C.M. Sayehli⁷, A. Navarro⁸, S. Bender⁹, M. Ocker¹⁰, H. Nogai¹⁰, A. Wagner¹⁰, S. Ince¹¹, P. Ellinghaus⁹, M. Joerger¹²; ¹Essen, DE, ²Köln, DE, ³Aachen, DE, ⁴Singapore, SG, ⁵La Défense, FR, ⁶Seoul, KR, ⁷Würzburg, DE, ⁸Barcelona, ES, ⁹Wuppertal, DE, ¹⁰Berlin, DE, ¹¹Whippany, US, ¹²St. Gallen, CH
- 13:15 - 13:15 860P - Phase II California cancer consortium trial of gemcitabine-eribulin combination (ge) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): Efficacy report (NCI-9653; 1UM1CA186717, NO1-CM-2011-00038)
S. Sadeghi¹, S. Groshen², R. Parikh³, A. Mortazavi⁴, T. Dorff¹, C. Hoimes⁵, L. Doyle⁶, D. Quinn¹, E. Newman⁷, P. Lara⁸; ¹Los Angeles, CA/US, ²Los Angeles, US, ³Pittsburg, PA/US, ⁴Columbus, OH/US, ⁵Cleveland, OH/US, ⁶Bethesda, US, ⁷Duarte, US, ⁸Sacramento, CA/US
- 13:15 - 13:15 861P - Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma
R. Flippot¹, R. Mouawad¹, J.-P. Spano², M. Rouprêt¹, E. Compérat¹, M.-O. Bitker¹, J. Parra¹, C. Vaessen¹, F. Allanic¹, Q. Manach¹, N. Tannir³, D. Khayat², X. Su³, G. Malouf²; ¹Paris, FR, ²Paris, CEDEX 13/FR, ³Houston, TX/US
- 13:15 - 13:15 862P - Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective

A. Gomez de Liano Lista¹, A. Necchi², P. Lavaud³, J. Carles Galceran¹, D. Castellano⁴, A. Ravaud⁵, I. Duran⁶, N. van Dijk⁷, P. Giannatempo², Y. Loriot⁸, R. Morales Barrera¹, G. De Velasco Oria De Rueda⁹, F. Lefort⁵, G. Martínez Bernal⁶, D. Raggi², M. Gross-Goupil⁵, T. Powles¹⁰, M. Van der Heijden⁷; ¹ Barcelona, ES, ² Milan, IT, ³ Paris, CEDEX 14/FR, ⁴ Madrid, ES, ⁵ Bordeaux, FR, ⁶ Sevilla, ES, ⁷ Amsterdam, NL, ⁸ Villejuif, FR, ⁹ Boston, US, ¹⁰ London, GB

- 13:15 - 13:15 863P - Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)
T. Zhang¹, M. Harrison¹, P. O'Donnell², A. Alva³, N. Hahn⁴, L. Appleman⁵, J. Cetnar⁶, J. Burke⁷, M. Fleming⁸, M. Milowsky⁹, A. Mortazavi¹⁰, N. Shore¹¹, E. Schmidt¹², C. Kresja¹³, T. Chen¹³, B. Bitman¹³, R. Izumi¹³, A. Hamdy¹³, D. George¹; ¹ Durham, NC/US, ² Chicago, IL/US, ³ Ann Arbor, MI/US, ⁴ Indianapolis, IN/US, ⁵ Pittsburgh, PA/US, ⁶ Portland, OR/US, ⁷ Aurora, CO/US, ⁸ Norfolk, VA/US, ⁹ Chapel Hill, NC/US, ¹⁰ Columbus, OH/US, ¹¹ Myrtle Beach, US, ¹² North Wales, PA/US, ¹³ Redwood City, CA/US
- 13:15 - 13:15 864P - Long non-coding RNAs are differentially expressed between bladder cancer subtypes
S. Rinaldetti¹, E. Rempel², T. Worst¹, M. Eckstein³, A. Steidler¹, C. Weiss¹, C. Bolenz⁴, A. Hartmann³, P. Erben¹; ¹ Mannheim, DE, ² Heidelberg, DE, ³ Erlangen, DE, ⁴ Ulm, DE
- 13:15 - 13:15 865P - Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration
A. Necchi¹, S. Lo Vullo¹, L. Mariani¹, M. Moschini², K. Hendricksen³, M. Rink⁴, R. Sosnowski⁵, J. Dobruch⁶, J. Raman⁷, C. Wood⁸, V. Margulis⁹, M. Rouprêt¹⁰, A. Briganti¹¹, F. Montorsi¹, E. Xylinas¹⁰, S. Shariat¹²; ¹ Milan, IT, ² Luzern, CH, ³ Amsterdam, NL, ⁴ Eppendorf, DE, ⁵ Otwock, PL, ⁶ Warsaw, PL, ⁷ Hershey, PA/US, ⁸ Houston, US, ⁹ Dallas, US, ¹⁰ Paris, FR, ¹¹ Milano, IT, ¹² Vienna, AT
- 13:15 - 13:15 867P - Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC)
B. McGregor¹, S. Ali², P. Grivas³, J. Ross⁴, P. Stephens², V. Miller², B. Forcier², J. Chung², S. Pal⁵; ¹ Boston, US, ² Cambridge, MA/US, ³ Cleveland, US, ⁴ Albany, NY/US, ⁵ Duarte, CA/US
- 13:15 - 13:15 866P - Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC)
A. Bamias¹, K. Tzannis¹, C. Bamia¹, L. Harshman², S. Crabb³, Y.-N. Wong⁴, S. Pal⁵, U. De Giorgi⁶, S. Ladoire⁷, N. Agarwal⁸, E. Yu⁹, G. Niegisch¹⁰, C. Sternberg¹¹, A. Srinivas¹², U. Vaishampayan¹³, A. Necchi¹⁴, J. Rosenberg¹⁵, T. Powles¹⁶, J. Bellmunt¹⁷, M. Galsky¹⁸; ¹ Athens, GR, ² Boston, MA/US, ³ Southampton, GB, ⁴ Philadelphia, US, ⁵ Duarte, CA/US, ⁶ Meldola, Forlì-Cesena/IT, ⁷ Dijon, Cedex/FR, ⁸ Salt Lake City, UT/US, ⁹ Seattle, US, ¹⁰ Düsseldorf, DE, ¹¹ Roma, IT, ¹² Stanford, US, ¹³ Detroit, MI/US, ¹⁴ Milan, IT, ¹⁵ New York, NY/US, ¹⁶ London, GB, ¹⁷ Boston, MA, US, ¹⁸ New York, US
- 13:15 - 13:15 868P - Comparison of circulating tumor DNA (ctDNA) profile in metastatic urothelial carcinoma (mUC) derived from the upper tract (UT) and lower tract (LT)
N. Agarwal¹, S. Pal², G. Sonpavde³, L. Kiedrowski⁴, R. Nagy⁴, K. Banks⁵, R. Lanman⁵, P. Grivas⁶; ¹ Salt Lake City, US, ² Duarte, CA/US, ³ Birmingham, AL/US, ⁴ Redwood City, US, ⁵ Redwood City, CA/US, ⁶ Cleveland, US

- 13:15 - 13:15 869P - Modeling of Tumor Kinetics and Overall Survival to Identify Predictive Factors for Efficacy of Durvalumab in Patients with Urothelial Carcinoma (UC)
Y. Zheng¹, X. Jin², R. Narwal², C.-Y.D. Jin³, A. Gupta², Y. Ben⁴, P. Mukhopadhyay², B. Higgs², L. Roskos²; ¹Mountain View, US, ²Gaithersburg, MD/US, ³Mountain View, CA/US, ⁴Gaithersburg, US
- 13:15 - 13:15 870P - Expression of Galectin-1 Determines Tumor Recurrence and Cancer-specific Survival in Patients with pT3 Upper Urinary Tract Urothelial Carcinoma
Y.-L. Su, H.-L. Luo, C.-C. Huang, M.-C. Hsieh; Kaohsiung, TW
- 13:15 - 13:15 871P - Identification of genomic features underlying response of muscle-invasive bladder cancer (MIBC) to neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) in an open-label, single-arm, phase 2 study
D. Raggi¹, A. Paoli², M. Dugo², P. Giannatempo¹, L. De Cecco², M. Colecchia², M.G. Daidone¹, A. Necchi¹, M.L. Sensi²; ¹Milan, IT, ²Milano, IT
- 13:15 - 13:15 872P - Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
T. Powles¹, R. Motzer², D. George³, E. Jonasch⁴, S. Pal⁵, N.M. Tannir⁴, S. Signoretti⁶, T. Mai⁷, C. Scheffold⁸, E. Wang⁸, D. Aftab⁸, B. Escudier⁹, T. Choueiri¹⁰; ¹London, GB, ²New York, NY/US, ³Durham, NC/US, ⁴Houston, TX/US, ⁵Duarte, CA/US, ⁶Boston, MA/US, ⁷Ann Arbor, MI/US, ⁸South San Francisco, CA/US, ⁹Villejuif, FR, ¹⁰Boston, US
- 13:15 - 13:15 873P - RX-3117, an oral hypomethylating agent to treat advanced solid tumors (st): Interim results from an ongoing phase 2a study in advanced urothelial cancer
M. Maia¹, S. Pal¹, S. Tagawa², V. Chung¹, J. Picus³, S. Gupta⁴, J. Poore⁵, C. Peterson⁵, E. Benaim⁵; ¹Duarte, CA/US, ²New York, US/US, ³St. Louis, US, ⁴Salt Lake City, US, ⁵Rockville, MD/US
- 13:15 - 13:15 874P - Immune correlates for the efficacy of PEGylated Human IL-10 (AM0010) with nivolumab in renal cell cancer
A. Naing¹, J. Infante², D. Wong³, M. Korn⁴, R. Aljumaily⁵, K. Papadopoulos⁶, K. Autio⁷, S. Pant⁵, T. Bauer², A. Drakaki⁸, N. Daver¹, A. Hung⁹, P. Van Vlasselaer⁹, G. Brown¹⁰, M. Oft⁹, N. Tannir¹; ¹Houston, TX/US, ²Nashville, TN/US, ³Los Angeles, CA/US, ⁴San Francisco, CA/US, ⁵Oklahoma City, OK/US, ⁶San Antonio, TX/US, ⁷New York, US, ⁸Los Angeles, US, ⁹Redwood City, US, ¹⁰New York, CA/US
- 13:15 - 13:15 875P - Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population
A. Necchi¹, G. Pond², S. Pal³, N. Agarwal⁴, D. Bowles⁵, E. Plimack⁶, E. Yu⁷, S. Ladoire⁸, J. Baniel⁹, S. Crabb¹⁰, G. Niegisch¹¹, A.R. Golshayan¹², S. Sridhar¹³, D. Berthold¹⁴, J. Rosenberg¹⁵, T. Powles¹⁶, A. Bamias¹⁷, L. Harshman¹⁸, J. Bellmunt¹⁹, M. Galsky²⁰; ¹Milan, IT, ²Hamilton, CA, ³Duarte, CA/US, ⁴Salt Lake City, UT/US, ⁵South Aurora, CO/US, ⁶Philadelphia, PA/US, ⁷Seattle, US, ⁸Dijon, Cedex/FR, ⁹Petach Tikva, IL, ¹⁰Southampton, GB, ¹¹Düsseldorf, DE, ¹²Charleston, US, ¹³Toronto, Ontario/CA, ¹⁴Lausanne, CH, ¹⁵New York, NY/US, ¹⁶London, GB, ¹⁷Athens, GR, ¹⁸Boston, MA/US, ¹⁹Boston, Ma, US, ²⁰New York, US

- 13:15 - 13:15 876P - Efficacy of cabozantinib (C) after PD-1/PD-L1 checkpoint inhibitors in metastatic renal cell carcinoma (mRCC): The Gustave Roussy experience
L. Derosa¹, J. Rouche¹, E. Colomba¹, G. Baciarello², B. Routy¹, L. Albiges², B. Escudier¹; ¹Villejuif, FR, ²Villejuif, CEDEX/FR
- 13:15 - 13:15 877P - Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice
K. Flannery¹, J. Black-Shinn², M. Boyd², N. Robert³, A. Kamat⁴; ¹West Point, US, ²The Woodlands, TX/US, ³Fairfax, US, ⁴Houston, TX/US
- 13:15 - 13:15 878P - Comparing ITC results from lenvatinib plus everolimus for second-line treatment of advanced/metastatic renal cell carcinoma: Crossover versus no crossover
S. Garib¹, G. Tremblay¹, G. Meier², H. McElroy³, M. Guo⁴; ¹New York, US, ²Woodcliff Lake, US, ³The Synergy, SG, ⁴London, GB
- 13:15 - 13:15 879P - Urine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC)
Y.N.S. Wong¹, K. Joshi¹, P. Khetrapal¹, M. Ismail¹, J. Linares¹, A.U. Akarca¹, J.L. Reading¹, A. Furness², A. Feber¹, U. McGovern¹, C. Swanton¹, A. Freeman¹, T.P. Briggs¹, J. Kelly¹, T. Marafioti¹, K.S. Peggs¹, T. Powles¹, B.M. Chain¹, M. Linch¹, S.A. Quezada¹; ¹London, GB, ²London, London/GB
- 13:15 - 13:15 880P - Biomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium)
S. Oudard¹, A. Mejean¹, D. Topart², R. Thuret³, C. Tournigand⁴, L. Salomon⁵, A. Thiery-Vuillemin⁶, G. Guichard⁷, S. Le Moulec¹, A. Houlgatte¹, A. Guillot⁸, N. Mottet⁹, A. Cessot¹⁰, N. Barry-Delongchamps¹, R. Elaidi¹, S. Turajlic¹¹, C. Swanton¹¹, B. Escudier¹², J.J. Patard¹³, L. Albiges¹⁴; ¹Paris, FR, ²Montpellier, CEDEX 5/FR, ³Montpellier, FR, ⁴Créteil, CEDEX/FR, ⁵Créteil, FR, ⁶Besançon, CEDEX/FR, ⁷Besançon, FR, ⁸St. Priest En Jarez, FR, ⁹St. Etienne, cédex 2/FR, ¹⁰Paris, CEDEX 14/FR, ¹¹London, GB, ¹²Villejuif, FR, ¹³Le Kremlin Bicetre, FR, ¹⁴Villejuif, CEDEX/FR
- 13:15 - 13:15 881P - Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trial
N. Lawrence¹, A. Martin², I. Davis³, S. Troon⁴, S. Sengupta⁵, E. Hovey⁶, X. Coskinas⁶, R. Kaplan⁷, A. Ritchie⁸, A. Meade⁸, T. Eisen⁹, P. Blinman⁶, M. Stockler¹; ¹Camperdown, NSW/AU, ²Camperdown, AU, ³Box Hill, AU/AU, ⁴Perth, WA/AU, ⁵Melbourne, AU, ⁶Sydney, NSW/AU, ⁷Leeds, GB, ⁸London, GB, ⁹Cambridge, Cambridgeshire/GB
- 13:15 - 13:15 882P - Potential impact of avelumab+axitinib (A+Ax) on tumor size (TS) compared with historical data of sunitinib (S) as evaluated by a modeling and simulation (MS) approach
J. Zheng¹, A. Chang², J. Larkin³, R. Motzer⁴, M. Amantea², C. Bello⁵, D. Pavlov², M. Geraldès⁶, M. Martignoni⁷, A. Di Pietro⁷, G. Andrews²; ¹New London, US, ²San Diego, CA/US, ³London, GB, ⁴New York, NY/US, ⁵New York, US, ⁶Collegeville, US, ⁷Milan, IT
- 13:15 - 13:15 883P - Synchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy

F. Donskov¹, W. Xie², J.C. Wells³, A.P. Fraccon⁴, F. Pasini⁵, C. Porta⁶, I. Stukalin³, J.L. Lee⁷, A. Bamias⁸, T. Yuasa⁹, I. Davis¹⁰, C. Pezaro¹¹, R. Kanesvaran¹², G. Bjarnason¹³, H.-W. Sim¹³, N. Agarwal¹⁴, C. Kollmannsberger¹⁵, C. Canil¹⁶, T. Choueiri¹⁷, D. Heng³; ¹Aarhus C, DK, ²Boston, MA/US, ³Calgary, CA, ⁴Padova, IT, ⁵Rovigo, RO/IT, ⁶Pavia, IT, ⁷Seoul, KP, ⁸Athens, GR, ⁹Tokyo, JP, ¹⁰Box Hill, AU/AU, ¹¹Box Hill, AU, ¹²Singapore, SG, ¹³Toronto, Ontario/CA, ¹⁴Salt Lake City, UT/US, ¹⁵Vancouver, British Columbia/CA, ¹⁶Ottawa, CA, ¹⁷Boston, US

- 13:15 - 13:15 884P - SPAZO2 (SOGUG): Comparative effectiveness of pazopanib in metastatic renal carcinoma (mRC): Ineligible (I) vs eligible (E) patients for clinical trials
- J. Arranz Arijá¹, B. Pérez Valderrama², Á. Rodríguez Sánchez³, I. Chirivella González⁴, U. Anido Herranz⁵, J.P. Maroto Rey⁶, M.J. Miranda Pallares⁷, M.A. Climent Duran⁴, G. Crespo Herrero⁸, J.A. Meana García⁹, A. Rodríguez-Vida⁶, R. Fernandez-Rodriguez¹⁰, C. Santander¹¹, G. Rubio Romero¹, S. Vazquez Estevez¹², O. Fernandez Calvo¹³, M.B. Gonzalez Gragera¹⁴, E. Almagro Casado¹⁵, S. Perez Ramirez¹, P. Borrega García¹⁶; ¹Madrid, ES, ²Sevilla, ES, ³Leon, ES, ⁴Valencia, ES, ⁵Santiago De Compostela, ES, ⁶Barcelona, ES, ⁷Reus, ES, ⁸Burgos, ES, ⁹Alicante, ES, ¹⁰Bilbao, Bizkaia/ES, ¹¹Zaragoza, ES, ¹²Lugo, ES, ¹³Ourense, ES, ¹⁴Palma De Mallorca, ES, ¹⁵Majadahonda, Madrid/ES, ¹⁶Cáceres, ES
- 13:15 - 13:15 886P - SPAZO2 (SOGUG): Comparative effectiveness of everolimus (Ev) vs axitinib (Ax) as second-line after first-line pazopanib (1stPz) in metastatic renal carcinoma (mRC)
- J. Arranz Arijá¹, B. Pérez-Valderrama², A. Rodriguez Sanchez³, J. Puertas Alvarez⁴, A. Pinto Marin¹, C. Maximiano Alonso⁵, J.C. Villa Guzman⁶, E.M. Fernandez Parra², E. Gallardo Diaz⁷, J. Gonzalez-Larriba¹, J. Tafalla García¹, J. Lambea⁸, M. Constenla Figueiras⁹, M.J. Mendez Vidal¹⁰, J.A. Virizuela Echaburu², F.J. Vazquez Mazon¹¹, O. Etxaniz Ulazia¹², M.T. Abad Villar¹³, J. Cassinello¹⁴, J.M. Jurado García¹⁵; ¹Madrid, ES, ²Sevilla, ES, ³Leon, ES, ⁴Valladolid, ES/ES, ⁵Majadahonda, Madrid/ES, ⁶Ciudad Real, Ciudad Real/ES, ⁷Sabadell, ES, ⁸Zaragoza, ES, ⁹Pontevedra, ES, ¹⁰Cordoba, ES, ¹¹Elche, Alicante/ES, ¹²Badalona, Barcelona/ES, ¹³Bilbao, ES, ¹⁴Guadalajara, ES, ¹⁵Granada, ES
- 13:15 - 13:15 885P - Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study
- M. Ekenel, E. Aydin, I. Cil, A. Zirtoglu, D. Tural, S. Karabulut; Istanbul, TR
- 13:15 - 13:15 887P - Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)
- S. Bracarda¹, L. Galli², M. Maruzzo³, G. Lo Re⁴, S. Buti⁵, A. Favaretto⁶, F. Costanzo⁷, C. Sacco⁸, M. Merlano⁹, C. Mucciarini¹⁰, E. Zafarana¹¹, S. Romito¹², A. Maestri¹³, C. Giannitto Giorgio¹⁴, M.T. Ionta¹⁵, D. Turci¹⁶, U. De Giorgi¹⁷, G. Procopio¹⁸, E. Cortesi¹⁹, C. Porta²⁰; ¹Arezzo, IT, ²Pisa, IT, ³Padova, IT, ⁴Pordenone, IT, ⁵Parma, IT, ⁶Treviso, IT, ⁷Firenze, IT, ⁸Udine, IT, ⁹Cuneo, IT, ¹⁰Carpì (modena), IT, ¹¹Prato, IT, ¹²Foggia, IT, ¹³Bologna, IT, ¹⁴Caltagirone, IT, ¹⁵Monserrato, (CA)/IT, ¹⁶Ravenna, IT, ¹⁷Meldola, Forlì-Cesena/IT, ¹⁸Milan, IT, ¹⁹Roma, IT, ²⁰Pavia, IT
- 13:15 - 13:15 888P - Change in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC)

A.-K. Lalani¹, W. Xie², D. Martini², C. Norton², J. Steinharter², D. Bossé³, J. Bellmunt⁴, E. Van Allen², B. McGregor², L. Harshman², T. Choueiri¹; ¹Boston, US, ²Boston, MA/US, ³Boston, Ontario/US, ⁴Boston, Ma, US

- 13:15 - 13:15 889P - Broad immunomodulating effect of first-line pazopanib in metastatic renal cell carcinoma patients
E. Verzoni¹, L. De Cecco², M. Dugo², D. Rinchai³, D. Bedognetti⁴, P. Grassi¹, R. Ratta¹, A. Cova², P. Squarcina², V. Huber², R. Montone², M. Sorrentino², G. Procopio¹, L. Rivoltini²; ¹Milan, IT, ²Milano, IT, ³Doha, QA, ⁴Didra, QA
- 13:15 - 13:15 890P - Prospective comparison of RECIST and alternative response assessment criteria in the evaluation of metastatic renal cell cancer patients from phase II of the multi-centre randomised STAR trial
C. Kelly-Morland¹, J. Zhong², V. Goh¹, T. Wah², C. Ralph², F. Thistlethwaite³, P. Patel⁴, P. Nathan⁵, T. Eisen⁶, W. Gregory², L. McParland², H. Cool², K.-L. Royle², E. Best², L. Whincup², F. Collinson², J. Brown⁷; ¹London, GB, ²Leeds, GB, ³Manchester, GB, ⁴Nottingham, GB, ⁵Northwood, Middlesex/GB, ⁶Cambridge, Cambridgeshire/GB, ⁷Sheffield, GB
- 13:15 - 13:15 891P - Outcomes of patients with metastatic renal cell carcinoma (mRCC) who were treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitor (ICI) therapy
A. Shah¹, E. Lemke², G. Jianjun², A. Chandamohan², M. Campbell², A. Zurita Saavedra², L. Xiao¹, J. Wang², P. Corn², E. Jonasch², P. Sharma², N. Tannir²; ¹Houston, US, ²Houston, TX/US
- 13:15 - 13:15 892P - Treatment beyond progression in patients with advanced RCC participating in the expanded access programme (EAP)
E. Cortesi¹, F. Cappuzzo², L. Galli³, A. Bearz⁴, S. Pignata⁵, A. Berruti⁶, G. Tortora⁷, D. Tassinari⁸, S. Panni⁹, A. Pazzola¹⁰, G. Surico¹¹, M. Maio¹², L. Latini¹³, G. Schinzari¹⁴, V. Adamo¹⁵, E. Ricevuto¹⁶, F. Cognetti¹⁴, U. de giorgi¹⁷, G. Carteni⁵, U. Basso¹⁸; ¹Roma, IT, ²Ravenna, IT, ³Pisa, IT, ⁴Pordenone, IT, ⁵Napoli, IT, ⁶Brescia, IT, ⁷Verona, IT, ⁸Rimini, IT, ⁹Cremona, IT, ¹⁰Sassari, IT, ¹¹Lecce, IT, ¹²Siena, IT, ¹³Macerata, IT, ¹⁴Rome, IT, ¹⁵Messina, IT, ¹⁶L'aquila, IT, ¹⁷Meldola (fc), IT, ¹⁸Padova, IT
- 13:15 - 13:15 893P - Improved long-term clinical outcomes and safety profile of sunitinib dosing schedule with 4/2 switched to 2/1 in patients with metastatic renal cell carcinoma
X. Zhang, G. Sun, J. Zhao, K. Shu, P. Zhao, J. Liu, Y. Yang, Q. Tang, J. Chen, P. Shen, H. Zeng; Chengdu, CN
- 13:15 - 13:15 894P - A retrospective study of the management of metastatic renal cell carcinoma brain tumors
G. Klausner¹, I. Troussier¹, G. Malour², L. Feuvret¹, J. Jacob¹, J.-M. Simon¹, C.H. Canova¹, I. Lamproglou¹, P.-Y. Borius¹, C. Valery¹, P. Cornu¹, M. Rouprêt¹, J.-J. Mazeron¹, J.-P. Spano², P. Maingon¹; ¹Paris, FR, ²Paris, CEDEX 13/FR
- 13:15 - 13:15 895P - SPAZO2 (SOGUG): Validation of the international metastatic database consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) in metastatic renal cell carcinoma (mRC)

B. Pérez-Valderrama¹, J. Arranz Arika², I. Chirivella González³, U. Anido Herranz⁴, J.M. Jurado García⁵, C. Suarez Rodriguez⁶, I. García Carbonero⁷, G. de Velasco², R. García Domínguez⁸, R.D. García Marrero⁹, M.A. Gonzalez Del Alba Baamonde¹⁰, C. Molins Palau³, M.E. Lazaro¹¹, J. Munoz-Langa³, E. Martinez Ortega¹², A. Hernández Jorge¹³, M. Campayo Guillaumes¹⁴, M. Sereno Moyano², R. Luque Caro⁵, Á. Rodríguez Sánchez¹⁵; ¹S, ES, ²Madrid, ES, ³Valencia, ES, ⁴Santiago De Compostela, ES, ⁵Granada, ES, ⁶Barcelona, ES, ⁷Toledo, ES, ⁸Salamanca, ES, ⁹Santa Cruz De Tenerife, ES, ¹⁰Palma De Mallorca, ES, ¹¹Vigo, Pontevedra/ES, ¹²Jaen, ES, ¹³Donostia, ES, ¹⁴Terrassa, ES, ¹⁵Leon, ES

13:15 - 13:15

896P - A Phase (Ph) 1 dose finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC)

D. McDermott¹, R. Joseph², T. Ho³, U. Vaishampayan⁴, S. Ali⁵, M. Matrana⁶, R. Alter⁷, J. Edenfield⁸, S. Blanchette⁹, L. Gan⁹, M. Atkins¹⁰; ¹Boston, MA/US, ²Jacksonville, US, ³Phoenix, AZ/US, ⁴Detroit, MI/US, ⁵Indianapolis, IN/US, ⁶New Orleans, LA/US, ⁷Hackensack, NJ/US, ⁸Greenville, SC/US, ⁹Cambridge, MA/US, ¹⁰Washington Dc, US

13:15 - 13:15

897P - Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy

R. sabbatini¹, L. Galli², S. Pignata³, G. Lo Re⁴, F. Valcamonico⁵, C. Defferrari⁶, M. Spada⁷, D. Santini⁸, C. Masini⁹, L. Ciuffreda¹⁰, E.M. Ruggeri¹¹, A. Chioni¹², L. Livi¹³, D. Fagnani¹⁴, A. Bonetti¹⁵, L. Giustini¹⁶, S. Durante¹⁷, G. Procopio¹⁸, C. Caserta¹⁹, G. Carteni³; ¹Modena, IT, ²Pisa, IT, ³Napoli, IT, ⁴Pordenone, IT, ⁵Brescia, IT, ⁶Genova, IT, ⁷Cefalù, IT, ⁸Roma, IT, ⁹Reggio Emilia, IT, ¹⁰Torino, IT, ¹¹Viterbo, IT, ¹²Grosseto, IT, ¹³Florence, IT, ¹⁴Vimercate, IT, ¹⁵Legnago (vr), IT, ¹⁶Fermo, IT, ¹⁷Arezzo, IT, ¹⁸Milan, IT, ¹⁹Terni, IT

13:15 - 13:15

898P - Immune expression profile and sunitinib benefit in metastatic clear cell renal cell carcinoma (ccRCC)

O. Reig Torras, M. Marín_aguilera, N. Jimenez, L. Paré, P. Galvan, C. Mallofre, A. Prat, B. Mellado Gonzalez; Barcelona, ES

13:15 - 13:15

899P - Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape

J. Bedke¹, M. Welslau², M. Boegemann³, M. Schostak⁴, C. Hering-Schubert⁵, A. Petzoldt⁶, T. Wolf⁷, J. Schleicher⁸, C. Doehn⁹, C. Grüllich¹⁰, V. Grünwald¹¹, T. Steiner¹², R. Ehness¹³, D. Klein¹⁴, T. Medinger¹⁴, P. Goebell¹⁵; ¹Tübingen, DE, ²Berlin, DE, ³Münster, DE, ⁴Magdeburg, DE, ⁵Eisenach, DE, ⁶Fürth, DE, ⁷Dresden, DE, ⁸Stuttgart, DE, ⁹Lübeck, DE, ¹⁰Heidelberg, Baden Württemberg/DE, ¹¹Hannover, DE, ¹²Erfurt, DE, ¹³Munich, DE, ¹⁴Freiburg, DE, ¹⁵Erlangen, DE

13:15 - 13:15

900P - Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer: Pharmacokinetic data

G. Bjarnason¹, J. Knox², C. Kollmannsberger³, D. Soulieres⁴, D.S. Ernst⁵, P. Zalewski⁶, C. Canil⁷, E. Winquist⁸, S. Hotte⁹, S. North¹⁰, D. Heng¹¹, R. Macfarlane¹², P. Venner¹⁰, A. Kapoor⁹, A. Hansen², P. Czaykowski¹³, B. Boyd², L. Wang¹⁴, N. Basappa¹⁵; ¹Toronto, Ontario/CA, ²Toronto, ON/CA, ³Vancouver, British Columbia/CA, ⁴Montreal, CA, ⁵London, Ontario/CA, ⁶Oshawa, ON/CA, ⁷Ottawa, CA, ⁸London, ON/CA, ⁹Hamilton, Ontario/CA, ¹⁰Edmonton, AB/CA, ¹¹Calgary, CA, ¹²Halifax, NS/CA, ¹³Winnipeg, CA, ¹⁴Toronto, CA, ¹⁵Edmonton, CA

- 13:15 - 13:15 901P - Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): real world data from an Italian Expanded Access Program (EAP)
G. Procopio¹, M. Prisciandaro¹, R. Iacovelli², M. Mancini², G. Fornarini³, G. Facchini⁴, G. Carteni⁴, M. Napolitano⁵, C. Sternberg², C. Caserta⁶, M. Bregni⁷, F. Massari⁸, S. Buti⁹, E. Biasco¹⁰, U. De Giorgi¹¹, F. Zustovich¹², R. Ratta¹, C. Ortega¹³, G. Tortora¹⁴, E. Verzoni¹; ¹Milan, IT, ²Roma, IT, ³Genova, IT, ⁴Napoli, IT, ⁵Modena, IT, ⁶Terni, IT, ⁷Busto Arsizio, IT, ⁸Bologna, IT, ⁹Parma, IT, ¹⁰Pisa, IT, ¹¹Meldola, Forli-Cesena/IT, ¹²Belluno, IT, ¹³Candiolo, (TO)/IT, ¹⁴Verona, IT
- 13:15 - 13:15 902P - Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry
P. Goebell¹, L. Müller², M. Staehler³, M. Müller⁴, M. Frank⁵, L. Kruggel⁵, M. Jänicke⁵, N. Marschner⁵; ¹Erlangen, DE, ²Leer, DE, ³Munich, DE, ⁴Offenburg, DE, ⁵Freiburg, DE
- 13:15 - 13:15 903P - The efficacy and safety of sorafenib in patients with renal insufficiency of advanced renal cell carcinoma: Real- world data of sorafenib in Japan
K. Tatsugami¹, M. Oya², K. Kabu², H. Akaza²; ¹Fukuoka, JP, ²Tokyo, JP
- 13:15 - 13:15 904P - Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP)
U. De Giorgi¹, G. Procopio², A. Guida³, A. Bearz⁴, S. Buti⁵, U. Basso⁶, M. Mitterer⁷, C. Ortega⁸, P. Bidoli⁹, F. Ferrau¹⁰, L. Crinò¹¹, A. Frassoldati¹², P. Marchetti¹³, E. Mini¹⁴, A. Scoppola¹³, C. Verusio¹⁵, G. Fornarini¹⁶, G. Carteni¹⁷, C. Caserta¹⁸, C. Sternberg¹³; ¹Meldola, Forli-Cesena/IT, ²Milan, IT, ³Modena, IT, ⁴Pordenone, IT, ⁵Parma, IT, ⁶Padova, IT, ⁷Merano, IT, ⁸Candiolo, (TO)/IT, ⁹Monza (mi), IT, ¹⁰Taormina, IT, ¹¹Perugia, (PG)/IT, ¹²Ferrara, IT, ¹³Roma, IT, ¹⁴Firenze, IT, ¹⁵Saronno, (VA)/IT, ¹⁶Genova, IT, ¹⁷Napoli, IT, ¹⁸Terni, IT
- 13:15 - 13:15 905P - CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure
C. Masini¹, M.G. Vitale¹, M. Maruzzo², G. Procopio³, U. De Giorgi⁴, S. Buti⁵, S. Rossetti⁶, R. Iacovelli⁷, A. Guida⁸, F. Atzori⁹, C. Mucciariini¹⁰, S. Scagliarini⁶, F. Vignani¹¹, G. Prati¹², L. Cosmai¹³, A. Berselli¹, C. Pinto¹; ¹Reggio Emilia, IT, ²Padova, IT, ³Milano, IT, ⁴Meldola, Forli-Cesena/IT, ⁵Parma, IT, ⁶Napoli, IT, ⁷Verona, IT, ⁸Modena, IT, ⁹Cagliari, IT, ¹⁰Carpi (modena), IT, ¹¹Torino, IT, ¹²Guastalla, IT, ¹³Cremona, IT
- 13:15 - 13:15 906P - Impact of haptoglobin polymorphism on survival of renal cell carcinoma patients
T. Vermassen¹, N. Lumen², J. Delanghe², S. Rottey³; ¹Gent, BE, ²Ghent, BE, ³Brussels, BE
- 13:15 - 13:15 907P - Impact of CYP3A4*22 on pazopanib pharmacokinetics in cancer patients
S. Koolen¹, A. Huitema², P. Laven¹, S. El Bouazzaoui¹, H. Yu², N. Erp³, C. Herpen³, P. Hamberg¹, H. Gelderblom⁴, N. Steeghs², S. Sleijfer¹, R. van Schaik¹, R. Mathijssen¹, S. Bins¹; ¹Rotterdam, NL, ²Amsterdam, NL, ³Nijmegen, NL, ⁴Leiden, NL
- 13:15 - 13:15 908P - Association between biopsychosocial distress (BPSD) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

C. Bergerot¹, K. Clark², K. Ashing², L. Almeida², P. Bergerot¹, R. Obenchain², N. Dizman², J. Hsu², M. Maia², E. Philip³, M. Loscalzo², S. Pal²; ¹Duarte, US, ²Duarte, CA/US, ³Notre Dame, IL/US

- 13:15 - 13:15 909P - Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma: Data from the German prospective RCC-Registry
L. Müller¹, M. Staehler², P. Goebell³, F. Overkamp⁴, M. Frank⁵, L. Krugel⁵, M. Jänicke⁵, N. Marschner⁵; ¹Leer, DE, ²Munich, DE, ³Erlangen, DE, ⁴Recklinghausen, DE, ⁵Freiburg, DE
- 13:15 - 13:15 910P - Exome sequencing of tumor samples from S1107 "Randomized phase II evaluation of tivantinib and tivantinib in combination with erlotinib in patients with papillary renal cell carcinoma (pRCC)"
P. Twardowski¹, X. Wu¹, M. Plets², C. Tangen², E. Plimack³, N. Agarwal⁴, N. Vogelzang⁵, J. Wang¹, S. Tao¹, I. Thomson⁶, P. Lara⁷; ¹Duarte, CA/US, ²Seattle, WA/US, ³Philadelphia, PA/US, ⁴Salt Lake City, UT/US, ⁵Las Vegas, NV/US, ⁶San Antonio, TX/US, ⁷Sacramento, CA/US
- 13:15 - 13:15 911P - Patients (pts) with metastatic non-clear cell renal cell carcinoma (mccRCC) treated with Nivolumab (Nivo) based immunotherapy as advanced treatment (ATL) line: analysis of a national early access program (EAP)
A. Peer¹, K. Savion¹, K. Rouvinov², R. Leibowitz-Amir³, R. Berger³, A. Sella⁴, V. Neiman⁵, E. Rosenbaum⁵, W. Mermershtain², A. Neumann¹, M. Kolin¹, R. Perets¹, D. Keizman⁶; ¹Haifa, IL, ²Beer Sheva, IL, ³Ramat Gan, IL, ⁴Zerifin, IL, ⁵Petah Tikva, IL, ⁶Kfar Saba, IL
- 13:15 - 13:15 912P - Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): a retrospective study
M. Campbell¹, M. Bilen², C. Duran³, E. Altinmakas¹, Z. Lim³, A. Shah³, E. Jonasch³, N. Tannir³; ¹Houston, US, ²Atlanta, GA/US, ³Houston, TX/US
- 13:15 - 13:15 913P - Avelumab in patients with metastatic adrenocortical carcinoma (mACC): Results from the JAVELIN solid tumor trial
C. Le Tourneau¹, C. Zarwan², C. Hoimes³, D. Wong⁴, S. Bauer⁵, M. Wermke⁶, H.J. Grote⁷, A. von Heydebreck⁷, K. Chin⁸, J. Gulley⁹; ¹Paris, FR, ²Burlington, MA/US, ³Cleveland, OH/US, ⁴Los Angeles, CA/US, ⁵Essen, DE, ⁶Dresden, DE, ⁷Darmstadt, DE, ⁸Billerica, MA/US, ⁹Bethesda, Md, US
- 13:15 - 13:15 914P - Do patients (pts) with advanced nonseminomatous germ cell tumors (aNSGCT) and unfavorable time to normalization (TTN) of tumor markers benefit with prolongation of 1-st line chemotherapy (ChT)?
A. Tryakin¹, M. Fedyanin¹, J. Sergeev¹, A. Bulanov², B. Akhmedov¹, T. Zakharova¹, V. Matveev¹, I. Fainstein¹, A. Garin¹, S. Tjulandin¹; ¹Moscow, RU, ²Teheran, IR
- 13:15 - 13:15 915P - The prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors
D. Ribnikar¹, P. Bedard², R. Hamilton³, M. Jewett³, P. Warde³, P. Chung³, L. Anson Cartwright³, A. Templeton⁴, E. Amir², A. Hansen⁵, J. Lewin⁶; ¹Ljubljana, SI, ²Toronto, Ontario/CA, ³Toronto, CA, ⁴Basel, CH, ⁵Toronto, ON/CA, ⁶Nassau, BS
- 13:15 - 13:15 916P - Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371

L. Nappi¹, M. Thi¹, L. Fazli¹, K. Chi², B. Eigl², C. Nichols³, M. Gleave¹, C. Kollmannsberger²; ¹Vancouver, BC/CA, ²Vancouver, British Columbia/CA, ³Salt Lake City, UT/US

- 13:15 - 13:15 917P - A single centre retrospective review of testosterone deficiency in germ cell cancer patients
L. Gibbs, G. Gullick, E. Allison, S. Brand, A. Addeo, A. Kuchel, J. Braybrooke; Bristol, GB
- 13:15 - 13:15 918TiP - Pembrolizumab and nanoparticle albumin bound paclitaxel (nab-paclitaxel) for metastatic urothelial carcinoma (UC) after chemotherapy failure: the open-label, single-arm, phase 2 PEANUT study
A. Necchi¹, L. Mariani¹, A. Anichini², P. Giannatempo¹, D. Raggi¹, G. Calareso², R. Salvioni²; ¹Milan, IT, ²Milano, IT
- 13:15 - 13:15 919TiP - Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial
T. Powles¹, J. Gschwend², Y. Loriot³, J. Bellmunt⁴, L. Geczi⁵, C. Vulsteke⁶, M. Abdelsalam⁷, R. Gafanov⁸, W.K. Bae⁹, J. Revesz¹⁰, Y. Yamamoto¹¹, U. Anido¹², W.-P. Su¹³, M. Fleming¹⁴, M. Markus¹⁵, D. Feng¹⁶, C. Poehlein¹⁷, A. Alva¹⁸; ¹London, GB, ²Munich, DE, ³Villejuif, FR, ⁴Boston, Ma, US, ⁵Budapest, HU, ⁶Leuven, BE, ⁷Moncton, NB/CA, ⁸Moscow, RU, ⁹Hwasun-Gun, KR, ¹⁰Miskolc, HU, ¹¹Ube, JP, ¹²Santiago De Compostela, ES, ¹³Tainan, TW, ¹⁴Norfolk, VA/US, ¹⁵Colorado Springs, CO/US, ¹⁶Kenilworth, NJ/US, ¹⁷Kenilworth, US, ¹⁸Ann Arbor, MI/US
- 13:15 - 13:15 920TiP - Afatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ErbB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial
A. Font¹, F. Real², J. Puente², F.J. Vazquez Mazon³, N. Sala⁴, J. Virizuela⁵, A. Rodriguez-Vida¹, E. Grande Pulido², D. Castellano², M. Climent⁶, E. Gallardo¹, A. González del Alba⁷, P. Fernandez⁸, P. Jares⁸, I. Aldecoa¹, N. Gibson⁹, J. Serra¹, E.R. Imedio¹⁰, E. Ehrnroth¹¹, B. Mellado¹; ¹Barcelona, ES, ²Madrid, ES, ³Elche, Alicante/ES, ⁴Girona, ES, ⁵Seville, ES, ⁶Valencia, ES, ⁷Palma De Mallorca, ES, ⁸Barcelon, ES, ⁹Biberach, DE, ¹⁰Bracknell, GB, ¹¹Copenhagen, DK
- 13:15 - 13:15 921TiP - A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274)
D. Bajorin¹, M. Galsky¹, J. Gschwend², Y. Tomita³, A. Azrilevich⁴, F. Witjes⁵; ¹New York, US, ²München, DE, ³Yamagata, JP, ⁴Princeton, US, ⁵Nijmegen, NL
- 13:15 - 13:15 922TiP - KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC)
T. Choueiri¹, T. Powles², T. Zhang³, D. Quinn⁴, J. Gschwend⁵, S. Wan⁶, C. Poehlein⁷; ¹Boston, US, ²London, GB, ³Durham, NC/US, ⁴Los Angeles, CA/US, ⁵Munich, DE, ⁶North Wales, US, ⁷Kenilworth, US
- 13:15 - 13:15 923TiP - A phase 2 BIOMarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer: the BIONIkk trial
R.T. Elaidi, S. Oudard, E. Braychenko, C.-M. Sun, C. Sautès-Fridman, Y.-A. Vano; Paris, FR
- 13:15 - 13:15 924TiP - Savolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma: SAVOIR, a randomised, phase III trial

T. Choueiri¹, R. Jakacki², D. Ghiorghiu³, V. Haddad³, A. Kohlmann³, M. Frigault⁴, L. Ottesen³; ¹Boston, US, ²Gaithersburg, MD/US, ³Cambridge, GB, ⁴San Francisco, CA/US

- 13:15 - 13:15 925TiP - A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3K α -selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy
T. Choueiri¹, C. Porta², C. Suarez Rodriguez³, R. Alter⁴, P. Czaykowski⁵, I. Duran⁵, M. Gross-Goupil⁶, E. Kalinka-Warzocha⁷, B. Melichar⁸, C. Patel⁹, R. Neuwirth⁹, A. Enke⁹, F. Zohren⁹, T. Powles¹⁰; ¹Boston, US, ²Pavia, IT, ³Barcelona, ES, ⁴Hackensack, NJ/US, ⁵Seville, ES, ⁶Bordeaux, FR, ⁷Lodz, PL, ⁸Olomouc, CZ, ⁹Cambridge, US, ¹⁰London, GB
- 13:15 - 13:15 926TiP - Phase Ib/II trial of interleukin-2 (IL-2) and nivolumab in metastatic clear cell renal cell cancer (RCC)
S. Yentz¹, A. Alva²; ¹Ann Arbor, US, ²Ann Arbor, MI/US
- 13:15 - 13:15 927TiP - Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): the open-label, single-arm, single-center, phase 2, CaboPen trial
A. Necchi¹, L. Mariani¹, M. Colecchia², P. Giannatempo¹, D. Raggi¹, G. Calareso², N. Nicolai², M. Catanzaro², T. Torelli², F. Perrone², R. Salvioni²; ¹Milan, IT, ²Milano, IT
- 13:15 - 13:15 HEAD AND NECK CANCER, EXCLUDING THYROID
J.-P. Machiels¹, M. Merlano²; ¹Brussels, BE, ²Cuneo, IT
- 13:15 - 13:15 1055P - Nivolumab vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141
L. Licitra¹, R. Ferris², G. Blumenschein Jr³, K. Harrington⁴, J. Guigay⁵, S. Kasper⁶, N. Saba⁷, R. Haddad⁸, N. Kiyota⁹, M. Monga¹⁰, M. Lynch¹⁰, L. Li¹⁰, M. Gillison¹¹, J. Fayette¹²; ¹Milan, IT, ²US, ³Houston, US, ⁴London, GB, ⁵Nice, CEDEX 2/FR, ⁶Essen, DE, ⁷Atlanta, GA/US, ⁸Boston, MA/US, ⁹Kobe, Hyogo/JP, ¹⁰Princeton, US, ¹¹Columbus, US, ¹²Lyon, CEDEX/FR
- 13:15 - 13:15 1056P - Estimated costs of treatment-related adverse events (TRAEs) for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the checkmate 141 trial
M. Venkatachalam¹, S. Bobiak², J. Shaw³, I. Santi¹, M. Contente², B. Korytowsky⁴, D. Stenehjem⁵; ¹Waltham, MA/US, ²Princeton, NJ/US, ³New York, US, ⁴Princeton, US, ⁵Salt Lake City, US
- 13:15 - 13:15 1057P - Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC)
R. Ferris¹, D. Clump², J. Ohr³, W. Gooding², S. Kim², B. Karlovits², U. Duvvuri², J. Johnson², D. Petro², D. Heron², J. Bauman⁴; ¹US, ²Pittsburgh, PA/US, ³Pittsburgh, US, ⁴Tucson, PA/US
- 13:15 - 13:15 1058P - Does hyper-progression exist among head and neck cancer patients treated with immunotherapy?

A. Ortega Franco¹, M. Plana², I. Braña², M. Taberna Sanz², M. Oliva Bernal¹, S. Vázquez², M. Domenech Vinyolas², G. Berenguer², E. Vilajosana², M. Bergamino¹, N. Baste², R. Mesia Nin²; ¹Barcelona, Barcelona/ES, ²Barcelona, ES

- 13:15 - 13:15 1059P - PD-L1 Detection and Assay Performance in Squamous Cell Carcinoma of the Head and Neck Using PD-L1 IHC 28-8 pharmDx
S. Alvarez¹, J. Chan¹, J. William², C. Felten¹, D.A. Hanks², A. Northrup², D. Jaiswal², M. Jansson², T. Phillips², A. Segal², I. Satnick², H. McDonald², H. Little², C. Pierce², B. Wynne², J. Carnahan², S. Reddy², H.D. Inzunza³, E. Oroudjev²; ¹Carpinteria, US, ²Carpinteria, CA/US, ³San Diego, US
- 13:15 - 13:15 1060P - Programmed death ligand-1 overexpression is a poor prognostic factor for Human papillomavirus-positive tonsillar squamous cell carcinoma
M.J. Kwon¹, M. Hong², S.Y. Kang²; ¹Anyang, KR, ²Seoul, KR
- 13:15 - 13:15 1061P - The prognostic role of PD-L1 expression in tumor and immune cells in oral cavity squamous cell carcinoma
S. Kutukova¹, N. Beliak¹, G. Manikhas², G. Raskin³, Y. Ivaskova⁴, N. Popova¹; ¹Saint Petersburg, RU, ²No City Provided, NA, ³St.-Petersburg, RU, ⁴Saint-Petersburg, RU
- 13:15 - 13:15 1062P - Immune profile analysis of head and neck squamous cell carcinoma before and after neoadjuvant treatment with the IRX-2 regimen
G. Wolf¹, J. Newman², N. Berinstein³, M. McNamara⁴, A. Nguyen¹, J. Egan⁵, M. Kaplan⁶; ¹Ann Arbor, US, ²Philadelphia, PA/US, ³Toronto, CA, ⁴Portland, OR/US, ⁵New York, NY/US, ⁶Stanford, CA/US
- 13:15 - 13:15 1063P - Phenotyping of the immune infiltrate in oropharyngeal squamous cell carcinoma: Focus on materials and methods
A. De Meulenaere¹, T. Vermassen¹, S. Rottey², L. Ferdinande³; ¹Gent, BE, ²Brussels, BE, ³Ghent, BE
- 13:15 - 13:15 1064P - High-dose versus low-dose cisplatin with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck (SCC): An analysis of veteran's health registry data
J. Baum¹, R. Vinnakota², Y.-H. Park², S. Bates², T. Fojo², C. Aggarwal³, S. Lunate², N. Damjanov³, R. Mamtani³, C. Langer³, R. Cohen³, K. Sigel²; ¹Philadelphia, US, ²New York, NY/US, ³Philadelphia, PA/US
- 13:15 - 13:15 1065P - 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
S. Rothschild¹, S. Helfenstein¹, O. Riesterer², U. Meier³, A. Papachristofilou¹, B. Kasenda¹, M. Pless³; ¹Basel, CH, ²Zürich, CH, ³Winterthur, CH
- 13:15 - 13:15 1066P - Hyperfractionated twice daily re-irradiation (bid re-RT) and chemotherapy (CT) for locoregionally recurrent head and neck squamous cell carcinoma (LR HNSCC): A systematic review (SR)
D. Day¹, G. Locke², K. Chan², S. Cheng², L. Wang¹, B. O'Sullivan², A. Hansen²; ¹Toronto, CA, ²Toronto, ON/CA

- 13:15 - 13:15 1067P - Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy (CCRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A randomized controlled multi-centered trial
X. He¹, H. Yin², W. Guo¹, X. Sun², X. Hu², P. Yan¹, F. Li¹, S. Huang¹, H. Zhou¹, F. Zhang³, B. Wang⁴, X. Bian¹, Q. Wei¹, J. Wu¹, F. Wang¹, D. Song¹, J. Liu¹, B. Zhou¹; ¹Nanjing, CN, ²Xuzhou, CN, ³Wuxi, CN, ⁴Yangzhou, CN
- 13:15 - 13:15 1068P - The observational ENCORE study: Cetuximab + platinum-based therapy (PBT) for first-line (1L) treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
C. Le Tourneau¹, M. Ghiani², M. Cau², R. Depenni³, G. Ronzino⁴, L. Livi⁵, V. Montesarchio⁶, M. Bretagne¹, M. Saint-Ghislain⁷, J. Schulten⁸, D. Messinger⁹, A. Sbrana¹⁰, M. Ghi¹¹; ¹Paris, FR, ²Cagliari, IT, ³Modena, IT, ⁴Lecce, IT, ⁵Florence, IT, ⁶Napoli, IT, ⁷Rouen, FR, ⁸Darmstadt, DE, ⁹Mannheim, DE, ¹⁰Pisa, IT, ¹¹Venice, IT
- 13:15 - 13:15 1069P - Primary surgery versus chemoradiotherapy for advanced oropharyngeal and hypopharyngeal cancer: A propensity-score matched study using a nationwide database
C. Cheng, Taipei, TW
- 13:15 - 13:15 1070P - Comparison of carboplatin with 5-fluorouracil (carbo-5FU) versus cisplatin as concomitant chemoradiotherapy (CRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
S. Hanemaaijer¹, I. Kok¹, R. Fehrmann¹, B. van der Vegt¹, J. Gietema¹, B. Plaat¹, M. Vugt¹, M. Vergeer², J. Voortman², C.R. Leemans², J. Buter², J. Langendijk¹, S. Oosting¹; ¹Groningen, NL, ²Amsterdam, NL
- 13:15 - 13:15 1071P - Postoperative radiotherapy with weekly cisplatin in locally advanced head and neck cancer
A.D.C. Hervas Moron, J. Domínguez, D. Candini, M. Martín, C. Vallejo; Madrid, ES
- 13:15 - 13:15 1072P - Effectiveness and toxicities of cetuximab in combination with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis
L.-R. Wu, J.-H. Xu, W.-J. Guo, X. He; Nanjing, CN
- 13:15 - 13:15 1073P - Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: Indian rural hospital experience
S. Rawat¹, D. Pawar², H. Tandon¹, S. Patel¹, S. Chaudhari²; ¹Jabalpur, IN, ²Bangalore, IN
- 13:15 - 13:15 1074P - A phase II study of combination chemotherapy with cetuximab/S-1/low dose cisplatin as neoadjuvant manner for oral squamous cell carcinoma patients
M. Nakazawa¹, T. Imai², Y. Matsumiya², M. Suematsu³, Y. Ohta⁴, T. Ohnishi⁵, M. Ohmae⁶, H. Chisoku⁷, I. Kato², S.-Y. Tada³, A. Takeshita⁸; ¹Suita, Osaka/Jp, ²Suita, JP, ³Nishinomiya, JP, ⁴Itami, JP, ⁵Ikeda, JP, ⁶Izumisano, Osaka/Jp, ⁷Higashiosaka, JP, ⁸Suita, Osaka, JP
- 13:15 - 13:15 1075P - Role of induction chemotherapy in locally advanced T4b oral cavity cancers: A single Institute experience
K.N. Lokesh¹, T. Chaudhuri², K.C. Lakshmaiah³, G. Babu², D. Lokanatha⁴, L. Jacob⁴, S. Babu², A. Rudresha¹, L. Rajeev²; ¹Bangalore, Karnatka/IN, ²Bangalore, IN, ³Beijing, CN, ⁴Bengaluru, IN

- 13:15 - 13:15 1076P - Concurrent chemoradiotherapy (CCRT) versus induction docetaxel, cisplatin and 5-fluorouracil (TPF) followed by CCRT in locally advanced hypopharyngeal and base of tongue cancer: A randomized phase II study
S.H. Lim¹, J.-M. Sun², J. Hong², D. Oh², Y.C. Ahn², M.K. Chung², H.-S. Jeong², Y.-I. Son², M.-J. Ahn², C.-H. Baek², K. Park²; ¹Hwanseong-Si, Gyeong-Ki-Do/KR, ²Seoul, KR
- 13:15 - 13:15 1077P - Do patients over 70 years with advanced head and neck squamous cell carcinoma tolerate curative intent concurrent chemo-radiation? Predictors of oncological outcomes
V. Srinivasalu¹, N. Subramaniam², N. Kumar³, D. Balasubramaniam², A. Philip², A. Susan², A. Remesan Nair², C. G Prameela², K.U. Pushpaja², K. Thankappan², W. Jose², S. Iyer², P. Keechilat²; ¹Cochin, IN, ²Kochi, IN, ³Cambridge, GB
- 13:15 - 13:15 1078P - Multidisciplinary team management in head and neck cancer: The real life experience
J.-B. Guy¹, Y. Xia¹, A. Vallard¹, S. Espenel¹, J.-C. Trone¹, J. Langrand-Escure¹, A. Hamrouni¹, M. Ben Mrad¹, C. Rancoule¹, S. Ouni¹, T. Muron¹, P. Fournel², N. Magne²; ¹Saint-Etienne, FR, ²St. Priest En Jarez, FR
- 13:15 - 13:15 1079P - Long-term response to second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Analysis of the LUX-Head & Neck 1 (LHN1) trial
J.-P. Machiels¹, G. de Castro Jr², L. de Souza Viana², R. Galiulin³, M. Tahara⁴, U. Nicolau², C. Le Tourneau⁵, K. Okami⁶, V. Vladimirov⁷, A. Izmailov⁸, K. Hoermann⁹, L. Licitra¹⁰, R. Haddad¹¹, E. Cohen¹², N. Dupuis¹³, J. Love¹⁴, E. Zografos¹⁵, E. Ehrnrooth¹⁶, J. Fayette¹⁷; ¹Brussels, BE, ²São Paulo, BR, ³Omsk, RU, ⁴Kashiwa, Chiba/JP, ⁵Paris, FR, ⁶Isehara, JP, ⁷Pyatigorsk, RU, ⁸Ufa, RU, ⁹Mannheim, DE, ¹⁰Milan, IT, ¹¹Boston, MA/US, ¹²La Jolla, IL/US, ¹³Boulder, CO/US, ¹⁴Ridgefield, CT/US, ¹⁵Athens, GL, ¹⁶Copenhagen, DK, ¹⁷Lyon, FR
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 1081P - Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy in an unselected population of metastatic head and neck cancer patients and effect of KRAS Lcs6 variation on cetuximab response
V. Bastit¹, N. Bon-Mardion¹, J.-M. Picquenot¹, V. Rainville¹, C. Moldovan², A. François¹, F. El Ouakif¹, F. Jardin¹, J.-P. Marie¹, F. Di Fiore¹, F. Clatot³; ¹Rouen, FR, ²Paris, FR, ³Rouen, CEDEX 1/FR
- 13:15 - 13:15 1082P - A pilot study of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck
L. Gui, X. He; Beijing, CN
- 13:15 - 13:15 1083P - Natural history and prognostic factors of head and neck cancer patients with bone metastases: A retrospective Italian study
S. Grisanti¹, C. Bergamini², S. Bianchi¹, A. Baiguini¹, S. Vecchio³, L. Locati⁴, A. Bonetta⁵, P.F. Conte⁶, M. Airoidi⁷, M. Merlano⁸, P. Carlini⁹, T. Ibrahim¹⁰, C. Rossetto¹¹, P. Nicolai¹, R. Maroldi¹, S. Tonoli⁵, P. Pronzato¹², S. Magrini¹, L. Licitra⁴, A. Berruti¹; ¹Brescia, IT, ²Milano, IT, ³Genova, IT, ⁴Milan, IT, ⁵Cremona, IT, ⁶Padova, IT, ⁷Torino, IT, ⁸Cuneo, IT, ⁹Rome, IT, ¹⁰Meldola, IT, ¹¹Udine, IT, ¹²La Spezia, IT

- 13:15 - 13:15 1084P - Prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) on overall survival in patients treated with chemoradiotherapy for head and neck cancer
S. Makhoulfi¹, G. Lefebvre², I. Sakji¹, F. Feutry¹, T. Leroy¹, N. Penel², B. Coche¹, J. Fourquet¹, F. Ghestem¹, M. Julieron¹, D. Chevalier¹, E. Tresch²; ¹Lille, FR, ²Lille, CEDEX/FR
- 13:15 - 13:15 1085P - Association of ERP29 genetic polymorphism in microRNA-binding site with oropharynx cancer risk and prognosis
J. Carron¹, E. Costa², L. Lopes-Aguiar¹, B. Sá Carvalho¹, J.A. Rinck-Junior¹, A. Dalla Costa¹, M. Ortega³, C. Lima¹, G. Lourenço¹; ¹Campinas, BR, ²Campinas, SP/BR, ³Bragança Paulista, BR
- 13:15 - 13:15 1086P - Diagnostic and prognostic impact of plasma osteopontin in nasopharyngeal carcinoma
J.-C. Lin, W.-Y. Wang, Y.C. Liu; Taichung, TW
- 13:15 - 13:15 1087P - Head and neck cancer (HNC) and synchronic lung cancer: Impact of the lung cancer on the management and prognosis of these patients. Data from the SYNCHRON GFPC 15-04 Study
N. Paleiron¹, L. SARAMON¹, G. Robinet², R. Gervais³, P. Fournel⁴, H. Le Caer⁵, H. Berard⁶, G. Valette¹, R. Marianowski¹, C. Chouaid⁷; ¹Brest, FR, ²Brest, Cedex 2/FR, ³Caen, CEDEX 5/FR, ⁴St. Priest En Jarez, FR, ⁵St Briec, FR, ⁶Toulon, FR, ⁷Paris, CEDEX 12/FR
- 13:15 - 13:15 1088P - An estimation of the population survival benefit of first-course chemotherapy for head and neck cancers
V. Do¹, W. Ng², S. Jacob², G. Delaney³, M. Barton⁴; ¹Westmead, NSW/AU, ²Sydney, NSW/AU, ³Liverpool, NSW/AU, ⁴Liverpool, AU
- 13:15 - 13:15 1089P - GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G polymorphisms and severity of vomiting in head and neck cancer patients treated with cisplatin chemoradiation
C. Passos Lima¹, J. Carron², L. Lopes-Aguiar², E. Costa², G. Nogueira², T. Lima², E. Pincinato², M. Visacri², J. Quintanilha², P. Moriel², G. Lourenço²; ¹Campinas, SP/BR, ²Campinas, BR
- 13:15 - 13:15 1090P - Analysis of the impact of the tumours committee on the multidisciplinary approach to head and neck epidermoid cancer in our institution
M.J. Martínez-Ortiz¹, P. Cerezuela¹, G. Marin Zafra², J. Balsalobre¹, J. Díaz-Manzano³, J. Trujillo¹; ¹Cartagena, ES, ²Murcia, ES, ³El Palmar, ES
- 13:15 - 13:15 1091P - Prognostic nutritional index (PNI) is an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer (LAHNSCC)
G. Bruixola¹, J. Caballero², F. Papaccio³, A. Petrillo³, M. Pastor², A. Cervantes¹; ¹Valencia, Valencia/ES, ²Valencia, ES, ³Napoli, IT
- 13:15 - 13:15 1092P - CASP9 c.-1339A>G and CASP3 c.-1191A>G polymorphisms in susceptibility and outcome of head and neck squamous cell carcinoma
E. Costa, L. Lopes-Aguiar, G. Nogueira, T. Lima, V. Liutti, F. Leal, V. Santos, J.A. Rinck-Junior, G. Lourenço, C. Lima; Campinas, BR
- 13:15 - 13:15 1093P - Resource-stratification of national comprehensive cancer network (NCCN®) head and neck cancers guideline

R. Carlson¹, E. Nardi², J. Bacigalupo³, S. Darlow², J. McClure², D. Pfister⁴; ¹New York, CA/US, ²Fort Washington, PA/US, ³Fort Washington, US, ⁴New York, NY/US

- 13:15 - 13:15 1094P - Long-term results of chemoradiotherapy for stage III nasopharyngeal carcinoma patients and risk grouping by pretreatment EBV viral load
P.-J. Lin, W.-Y. Wang, Y.C. Liu, J.-C. Lin; Taichung, TW
- 13:15 - 13:15 1095P - Nasopharyngeal cancer in children: Long term results the experience of the university hospital of Sfax (Tunisia)
L. Ghorbal, N. Toumi, H. Ben Salah, S. Charfi, A. Ghorbel, A. Khanfir, M. Frikha, J. Daoud; Sfax, TN
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 1098P - Incidence and impact of DPD mutation on neoadjuvant chemotherapy in head and neck cancers
S. TURKAR, A. Chougule, V. Patil, V. Noronha, A. Joshi, N. Pande, A. Chandrashekharan, K. Prabhaskar; Mumbai, IN
- 13:15 - 13:15 1099P - Radiotherapy related xerostomia in head and neck oncology: A systematic review
D. Johns, Kozhikode, IN
- 13:15 - 13:15 1100P - The phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for head and neck cancer patients
T. Yokota¹, S. Hamauchi¹, Y. Yoshida², T. Yurikusa², M. Suzuki², A. Yamashita², H. Ogawa², T. Onoe², K. Mori², T. Onitsuka²; ¹Shizuoka, Shizuoka/J, ²Shizuoka, JP
- 13:15 - 13:15 1101P - Oral mucosa dose parameters predicting grade ≥3 acute toxicity in locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemotherapy
K. Li¹, L. Yang², Y.-Y. Chen³, M. Chen³; ¹Quanzhou, CN, ²Xinyu, CN, ³Hangzhou, CN
- 13:15 - 13:15 1102P - Sinonasal non-glandular cancers relapsing after multimodal treatments
S. Cavalieri¹, R. Granata¹, L. Locati¹, C. Bergamini², S. Alfieri¹, C. Resteghini¹, D. Galbiati¹, E. Orlandi¹, N. Iacovelli¹, G. Calareso², M. Guzzo¹, P. Quattrone¹, L. Licitra¹, P. Bossi¹; ¹Milan, IT, ²Milano, IT
- 13:15 - 13:15 1103P - Survival outcome and optimal treatment of intermediate-grade salivary gland carcinoma
G. PARK, Changwon, KR
- 13:15 - 13:15 1104P - Incidence and survival of secondary malignances (SM) in oropharyngeal squamous cell carcinoma (OPSCC): A homogeneous single report institution
M. Napolitano¹, F. Bertolini¹, E. D'Angelo¹, A. Spallanzani¹, S. Tassi¹, B. Meduri¹, S. Bettelli¹, R. Depenni¹, A. Ghidini¹, F. Lohr¹, L. Presutti¹, S. Cascinu²; ¹Modena, IT, ²Ancona, IT
- 13:15 - 13:15 1105TiP - Pembrolizumab plus chemoradiation (CRT) for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Phase 3 KEYNOTE-412 trial

J.-P. Machiels¹, L. Licitra², D. Rischin³, J. Waldron⁴, B. Burtness⁵, V. Grégoire¹, T. Shekar⁶, H. Brown⁶, J. Cheng⁷, L. Siu⁸; ¹Brussels, BE, ²Milan, IT, ³East Melbourne, VIC/AU, ⁴Toronto, ON/CA, ⁵New Haven, CT/US, ⁶Kenilworth, NJ/US, ⁷North Wales, PA/US, ⁸Toronto, On, CA

13:15 - 13:15 1106TiP - Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC

L. Locati¹, C. Caballero², C. Fortpied², F. Perrone³, S. Pilotti¹, K. Harrington⁴, V. Grégoire², L. Licitra¹; ¹Milan, IT, ²Brussels, BE, ³Milano, IT, ⁴London, GB

13:15 - 13:15 1107TiP - Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant AR expressing salivary glands carcinomas (SGCs)

L. Locati, A. Gambaro, L. Licitra; Milan, IT

13:15 - 13:15 1108TiP - Chemoradiotherapy versus radiotherapy in the treatment of salivary glands and nasal tumors: The GORTEC 2016-02 study

F.R. Ferrand¹, J. Thariat², N. Vulquin³, V. Calugaru⁴, O. Malard⁵, C. Murariu⁶, F. Janot⁷, F. Louat⁸, C. Michel², J. Bourhis⁹; ¹Saint-Mandé, CEDEX 5/FR, ²Nice, FR, ³Dijon, Cedex/FR, ⁴Paris, FR, ⁵Nantes, FR, ⁶Reims, FR, ⁷Villejuif, FR, ⁸Tours, FR, ⁹Lausanne, CH

13:15 - 13:15 1109TiP - MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with Docetaxel, Cisplatin and 5-FU (DCF) in induction for locally advanced squamous cell carcinoma of the head and neck (SCCHN)

C. Even¹, M. Texier¹, C. Le Tourneau², A. Marabelle¹, N. Chaput³, J. Adam¹, A. Paci¹, S. Broutin¹, C. Ferté¹, I. Breuskin¹, D. Cupissol⁴, J. Fayette⁵; ¹Villejuif, FR, ²Paris, FR, ³Villejuif, CEDEX/FR, ⁴Montpellier, CEDEX 5/FR, ⁵Lyon, FR

13:15 - 13:15 HEALTH ECONOMICS

M. Ijzerman, Enschede, NL

13:15 - 13:15 1114P - All.Can initiative: improving efficiency in cancer care

M. Aapro¹, S. Chrostowski², F. Florindi³, B. Gandouet⁴, S. Hanna⁵, R. Hazarika⁶, R. Hess⁷, F. de Lorenzo³, V. Muthu⁶, K. Oliver⁶, A. Roediger⁸, T. Rosvall-Puplett⁹, B. Ryll¹⁰, G. Spurrier¹¹, K. Steinmann¹², T. Szucs¹³, S. Wait⁶, L. Wierinck³, W. Yared³; ¹Genolier, CH, ²Warsaw, PL, ³Brussels, BE, ⁴Toulouse, FR, ⁵Laval, CA, ⁶London, GB, ⁷Cologne, DE, ⁸Luzer, CH, ⁹Braine L'alleud, BE, ¹⁰SE, ¹¹Clermont-Ferrand, FR, ¹²Zug, CH, ¹³Basel, CH

13:15 - 13:15 1115P - Cost-effectiveness of nivolumab+ipilimumab in first-line treatment of advanced melanoma: Analysis using 28-month overall survival from CheckMate 067

J. Sabater¹, T. Baker², V. Paly², K. Gupte-Singh³, M. Lorenzi⁴, A. Jeffers⁴, H. Beyhaghi³, S. Kotapati³, S. Rao³, A. Briggs⁵; ¹Madrid, ES, ²Philadelphia, PA/US, ³Princeton, NJ/US, ⁴San Francisco, CA/US, ⁵Glasgow, GB

13:15 - 13:15 1116P - Palbociclib in advanced breast cancer: A cost-utility analysis

J. Raphael¹, J. Helou², D. Naimark²; ¹Toronto, Ontario/CA, ²Toronto, ON/CA

- 13:15 - 13:15 1117P - Real-world survival outcomes in patients with advanced urothelial cancer in Germany
G. Niegisch¹, H. Gerullis², S.-W. Lin³, J. Pavlova⁴, A. Gondos⁵, A. Rudolph⁵, G. Haas⁶, N. Hennies⁵, M. Kramer⁷; ¹Düsseldorf, DE, ²Oldenburg, DE, ³South San Francisco, US, ⁴Basel, CH, ⁵Frankfurt, DE, ⁶Frankfurt Am Main, DE, ⁷Lübeck, DE
- 13:15 - 13:15 1118P - Health related quality of life and utility weights of medical oncology inpatients
M.A. Vicente Conesa, M. Zafra Poves, M.A. Ivars, I. Ballester, A. Carmona-Bayonas, F. Ayala de la Peña; Murcia, ES
- 13:15 - 13:15 1119P - A trial-based EUROQOL EQ-5D health utility analysis in patients with classical Hodgkin's lymphoma
E. Wu¹, J. Liao², A. Balakumaran²; ¹West Point, US, ²North Wales, US
- 13:15 - 13:15 1120P - Real world comparison of common patient reported symptoms with health utility scores in cancer outpatients
M. Moskovits¹, K. Jao², C. Brown³, S. Su⁴, H. Naik⁵, L. Eng⁶, T. Wang³, Y. Leung⁴, W. Xu³, G. Liu⁶, M. Li⁴, G. Devins⁴, D. Howell⁴; ¹Haifa, IL, ²Montreal, QC/CA, ³Toronto, CA, ⁴Toronto, ON/CA, ⁵Vancouver, CA, ⁶Toronto, Ontario/CA
- 13:15 - 13:15 1121P - Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26
S. Karim¹, K. Ding¹, P. Bradbury², P. Ellis³, N. Mittman², X. Xiaoqun Sun¹, M. Millward⁴, G. Liu⁵, S. Sun⁶, M. Stockler⁷, V. Cohen⁸, N. Blais⁹, R. Sangha¹⁰, M. Boyer¹¹, R. Sasidharan¹², C. Lee¹³, F. Shepherd², G. Goss¹⁴, L. Seymour¹⁵, N. Leigh²; ¹Kingston, CA, ²Toronto, CA, ³Hamilton, CA, ⁴Nedlands, WA/AU, ⁵Toronto, Ontario/CA, ⁶Vancouver, CA, ⁷Camperdown, NSW/AU, ⁸Montreal, QC/CA, ⁹Montreal, CA, ¹⁰Edmonton, Alberta/CA, ¹¹Camperdown, AU, ¹²Auckland, NZ, ¹³Surrey, CA, ¹⁴Ottawa, CA, ¹⁵Kingston, Ontario/CA
- 13:15 - 13:15 1122P - Feasibility of routine collection of health state utilities using EQ-5D in a breast cancer outpatient clinic
S. Torres¹, M. Trudeau², K. Pritchard¹, N. Mitsakakis², N. Li², M. Krahn²; ¹Toronto, Ontario/CA, ²Toronto, ON/CA
- 13:15 - 13:15 1123P - The cost of expensive breast cancer drugs
S. Berghuis¹, H. Koffijberg¹, L. Terstappen¹, S. Sleijfer², M. Ijzerman¹; ¹Enschede, NL, ²Rotterdam, NL
- 13:15 - 13:15 1124P_PR - Impact of licensing and reimbursement discrepancies on patient access to cancer treatments across Europe and Canada
J. McKendrick¹, B. Malcolm², K. Sheahan³, I. Katsoulis¹, X. Song¹, J. van Loon¹; ¹Fleet, GB, ²Wallingford, GB, ³Uxbridge, GB
- 13:15 - 13:15 1125P - The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer

S. Hinde¹, C. Theriou², S. May³, L. Matthews³, A. Arbon³, L. Fallowfield³, D. Bloomfield³; ¹York, GB, ²Nottingham, GB, ³Brighton, GB

13:15 - 13:15 1126P - The evolution of value with filgrastim in oncology

P. Cornes¹, A. Krendyukov²; ¹Bs Da, GB, ²Holzkirchen, DE

13:15 - 13:15 1127P - Tyrosine kinase inhibitors (TKI): Awareness of drug-drug interaction

N. Ozdemir, S. Toptas, M. Sendur, O. Yazici, B. Öksüzoğlu, K. Silay, N. Zengin; Ankara, TR

13:15 - 13:15 1128P - Anti-PD1 inhibitors: Assessment of proper use, efficacy and economic impact in daily practice

A. Gobert¹, A. Jaeger¹, L. Taillade¹, N. Osman¹, D. Lassoued², C. Mateescu¹, P. Maingon¹, P. Tilleul¹, J.-P. Spano², A. Bellanger¹; ¹Paris, FR, ²Paris, CEDEX 13/FR

13:15 - 13:15 1129P - Real world treatment costs and resource utilization among patients with metastatic bladder cancer

K. Flannery¹, X. Cao², J. He², Y. Zhong², A. Shah³, A. Kamat⁴; ¹West Point, US, ²North Wales, PA/US, ³Houston, US, ⁴Houston, TX/US

13:15 - 13:15 1130P - Investigating discrepancies in assessments of PFS by study investigators and independent review

C. Jones, J. Soto Barrientos, G. Monnickendam; Fleet, GB

13:15 - 13:15 1131P - Medical costs and health care resource use (HCRU) in elderly us patients (pts) with newly diagnosed metastatic or surgically unresectable urothelial carcinoma (mUC) using surveillance, epidemiology, and end results (SEER) medicare data

A. Aly¹, C. Johnson¹, S. Yang², S. Rao³, M. Botteman¹, A. Hussain⁴; ¹Bethesda, US, ²Princeton, US, ³Princeton, NJ/US, ⁴Baltimore, US

13:15 - 13:15 1132P - Chasing the survival curve tail: The effect on cost-effectiveness of nivolumab for second-line treatment of advanced renal cell carcinoma

M. Sarfaty, A. Moore, V. Neiman, E. Rosenbaum, D. Goldstein; Petah Tikva, IL

13:15 - 13:15 1133P - Non-elective admissions in cancer care - A review of acute oncology services (AOS) implementation in a north-west region of England

S. Chow, R. Leach, C. Mitchell; Manchester, GB

13:15 - 13:15 1134P - Changing treatment patterns in metastatic colorectal cancer in EU5 countries from 2014 to 2016

N. Schmidt, L. Hoyer; Frankfurt Am Main, DE

13:15 - 13:15 IMMUNOTHERAPY OF CANCER

F. Thistlethwaite¹, D. Speiser²; ¹Manchester, GB, ²Lausanne, CH

13:15 - 13:15 1149P - Results of the randomized, placebo-controlled phase I/IIb trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

A. Stenzl¹, S. Feyerabend², I. Syndikus³, T. Sarosiek⁴, H. Kübler⁵, A. Heidenreich⁶, R. Cathomas⁷, C. Grüllich⁸, Y. Loriot⁹, J.L. Perez Gracia¹⁰, U. Klinkhardt¹¹, A. Schroeder¹¹, O. Schönborn-Kellenberger¹², V. Reus¹³, V. Reus¹³, S.D. Koch¹⁴, H.S. Hong¹⁴, T. Seibel¹³, K. Fizazi⁹, U. Gnad-Vogt¹³; ¹Grenzach, DE, ²Reutlingen, DE, ³Bebington, Merseyside/GB, ⁴Warsaw, PL, ⁵Würzburg, DE, ⁶Aachen, DE, ⁷Chur, CH, ⁸Heidelberg, Baden Württemberg/DE, ⁹Villejuif, FR, ¹⁰Pamplona, ES, ¹¹Frankfurt Am Main, DE, ¹²Heidelberg, DE, ¹³Frankfurt, DE, ¹⁴Tübingen, DE

13:15 - 13:15 1150P - Phase II clinical trial of peptide vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS

Y. YOSHITAKE¹, D. Fukuma², M. Hirayama², H. Nakayama², H. Ogi², M. Shinohara²; ¹Kumamoto City, JP, ²Kumamoto, JP

13:15 - 13:15 1151P - Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors

A. Hosono¹, T. Yoshikawa², N. Tsuchiya², N. Fujinami², K. Saito², S. Mizuno², T. Nakatsura²; ¹Kashiwa, Chiba/JP, ²Chiba, JP

13:15 - 13:15 1152P - Phase 1 study of HSP105-derived peptide vaccine for patients with advanced esophageal cancer/colo-rectal cancer

S. Wada¹, T. Kojima², T. Nakatsura², H. Bando², O. Motohashi¹, M. Shimomura², T. Yoshikawa², K. Kohashi³, A. Hori¹, H. Ono², M. Fukutani², M. Wakabayashi², S. Nomura⁴, A. Sato², T. Sasada¹, A. Ohtsu²; ¹Yokohama, JP, ²Chiba, JP, ³Fukuoka, JP, ⁴Tokyo, JP

13:15 - 13:15 1153P - An observational clinical study with RAS peptide vaccine TG01 evaluating immune response, safety and overall survival in patients with non-resectable pancreatic cancer

J.A. Eriksen¹, I. Gladhaug¹, A. Rosseland², K. Risberg Handeland¹, T. Buanes¹; ¹Oslo, NO, ²Lillestrøm, NO

13:15 - 13:15 1154P - Telomerase peptide vaccine combined with ipilimumab in metastatic melanoma: Reports from a phase I trial

E. Aamdal¹, G. Gaudernack¹, E. Inderberg¹, W. Rasch², J. Bjørheim¹, S. Aamdal¹, T.K. Guren¹; ¹Oslo, NO, ²Oslo, NO/NO

13:15 - 13:15 1155P - Results of an open label randomized phase II trial of CV9104, an mRNA-based multivalent cancer immunotherapy in patients (pts) with intermediate or high risk localized prostate cancer (PC) undergoing radical prostatectomy (RPE)

A. Stenzl¹, S. Feyerabend², H. Kübler³, M. Retz⁴, C. Grüllich⁵, M. Hipp⁶, U. Klinkhardt⁷, H.S. Hong⁶, F. Doener⁶, S.D. Koch⁶, M. Scholl⁶, S. Brutlach⁶, A. Schroeder⁷, T. Seibel⁸, N. Halama⁹, O. Schönborn-Kellenberger⁹, M. Fotin-Mleczek⁶, U. Gnad-Vogt⁸; ¹Grenzach, DE, ²Reutlingen, DE, ³Würzburg, DE, ⁴München, DE, ⁵Heidelberg, Baden Württemberg/DE, ⁶Tübingen, DE, ⁷Frankfurt Am Main, DE, ⁸Frankfurt, DE, ⁹Heidelberg, DE

13:15 - 13:15 1156P - Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients

F. Grossi¹, L. Crinò², A. Delmonte³, D. Turci⁴, G. Lo Russo⁵, F. De Marinis⁵, H. Soto Parra⁶, D. Galetta⁷, F. Cappuzzo⁴, F. Sperandi⁸, M. Tiseo⁹, G. Puppò¹⁰, F. Roila¹¹, M.R. Migliorino¹², G. Tonini¹², F. Cognetti¹³, A. Santoro⁵, D. Tassinari¹⁴, A. Scoppola¹², E. Cortesi¹²; ¹Genova, IT, ²Perugia, (PG)/IT, ³Meldola, IT, ⁴Ravenna, IT, ⁵Milano, IT, ⁶Catania, IT, ⁷Bari, IT, ⁸Bologna, IT, ⁹Parma, IT, ¹⁰Pisa, IT, ¹¹Terni, IT, ¹²Roma, IT, ¹³Rome, IT, ¹⁴Rimini, IT

13:15 - 13:15 1157P - Correlation and differences in Effect sizes between Progression Free Survival (PFS) and Overall Survival (OS) among PD-1 inhibitors

B. Gyawali, T. Shimokata, Y. Ando; Nagoya, Aichi/JP

13:15 - 13:15 1158P - Is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?

G. Ritchie¹, H. Gasper², J. Man², S. Lord², M. Friedlander², C. Lee³, I. Marschner⁴; ¹Randwick, AU, ²Sydney, AU, ³Kogarah, NSW/AU, ⁴Sydney, NSW/AU

13:15 - 13:15 1159P - Long term survival in patients responding to an Anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation

M.-L. Gauci¹, E. Lanoy², S. Champiat³, J.-M. Michot², A. Varga², R. Bahleda³, E. Angevin³, A. Gazzah², L. Verlingue¹, F. Bigot², S. Aspeslagh², E. Castanon², C. Baldini⁴, S. Postel-Vinay², C. Massard², A. Hollebecque², J.-C. Soria³, A. Marabelle²; ¹Paris, FR, ²Villejuif, FR, ³Villejuif, CEDEX/FR, ⁴Lille, CEDEX/FR

13:15 - 13:15 1160P - Meta-Analysis of Anti-PD-1/PD-L1 Therapy Related Adverse Events in Clinical Trials

Y. Wang¹, X. Wang², F. Yang², X. Guan², N. Duma³, J. Vera Aguilera³, G. Nowakowski³, A. Chintakuntlawar³, K. Price³, J. Molina³, T. Halfdanarson³, A. Grothey⁴, S. Markovic³; ¹Jacksonville, US, ²Nanjing, CN, ³Rochester, US, ⁴Rochester, MN/US

13:15 - 13:15 1161P - A standardized comparison of outcomes in patients (pts) with refractory, aggressive non-hodgkin Lymphoma (rNHL) from the SCHOLAR-1 analysis and the ZUMA-1 study of axicabtagene ciloleucel (axi-cel)

S. Neelapu¹, F. Locke², N. Bartlett³, L. Lekakis⁴, P. Reagan⁵, D. Miklos⁶, C. Jacobson⁷, I. Braunschweig⁸, O. Oluwole⁹, T. Siddiqi¹⁰, Y. Lin¹¹, M. Crump¹², J. Kuruvilla¹², E. Van den Neste¹³, B. Link¹⁴, U. Farooq¹¹, L. Navale¹⁵, W. Go¹⁵, J. Wiezorek¹⁶, C. Gisselbrecht¹³; ¹Houston, US, ²Tampa, US, ³Saint Louis, MO/US, ⁴Miami, FL/US, ⁵Rochester, NY/US, ⁶Stanford, CA/US, ⁷Boston, MA/US, ⁸Bronx, US, ⁹Nashville, TN/US, ¹⁰Duarte, US, ¹¹Rochester, US, ¹²Kingston, CA, ¹³Paris, FR, ¹⁴Iowa City, US, ¹⁵Santa Monica, CA/US, ¹⁶Thousand Oaks, CA/US

13:15 - 13:15 1162P - Predictive factors for poor progression-free survival in patients with non-small-cell lung cancer treated with nivolumab

Y. Taniguchi¹, A. Tamiya², S.-I. Isa¹, K. Nakahama¹, K. Okishio¹, T. Shiroyama³, H. Suzuki⁴, T. Inoue⁵, M. Tamiya³, K. Nishino⁵, T. Kumagai⁵, T. Hirashima³, F. Imamura⁵, S. Atagi²; ¹Sakai, JP, ²Sakai, Osaka/Jp, ³Habikino, Osaka/Jp, ⁴Habikino, JP, ⁵Osaka, JP

13:15 - 13:15 1163P - Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience

H. Herin¹, E. Castanon², V. Dyeve², S. Aspeslagh², A. Marabelle², S. Postel-Vinay², A. Varga², A. Gazzah², V. Ribrag², R. Bahleda³, J.-M. Michot², O. Mir², C. Massard², A. Hollebecque², J.-C. Soria³, C. Baldini⁴; ¹Paris, FR, ²Villejuif, FR, ³Villejuif, CEDEX/FR, ⁴Lille, CEDEX/FR

13:15 - 13:15 1164P - Patterns of progression under antiPD1/PDL1 in advanced NSCLC patients allow discriminating pseudo-progression from real progression

C. CARAMELLA¹, M. Tazdait¹, L. Mezquita¹, J. Lahmar¹, R. Ferrara², A. Marabelle¹, C. Balleyguier¹, D. Planchard¹, A. Gazzah¹, J.-C. Soria³, B. Besse¹; ¹Villejuif, FR, ²Verona, IT, ³Villejuif, CEDEX/FR

13:15 - 13:15 1165P - Immune checkpoint inhibitors following targeted therapies in MITF family translocation renal cell carcinomas

A. Boileve¹, M. Carlo², P. Barthelemy³, S. Oudard¹, D. Borchiellini⁴, M. Voss², S. George⁵, C. Chevreau⁶, J. Landman-Parker¹, M.-D. Tabone¹, D. Chism⁷, A. Amin⁸, M. Bilen⁹, D. Bosse¹⁰, T. Choueir¹¹, N. Tannir¹², G. Malouf¹³; ¹Paris, FR, ²New York, US, ³Strasbourg, CEDEX/FR, ⁴Nice, CEDEX 2/FR, ⁵Buffalo, NY/US, ⁶Toulouse, FR, ⁷Nashville, US, ⁸Charlotte, NC/US, ⁹Atlanta, GA/US, ¹⁰No City Provided, NA, ¹¹Boston, US, ¹²Houston, TX/US, ¹³Paris, CEDEX 13/FR

13:15 - 13:15 1166P - Tumor flare reaction (TFR) in cancer treatments: a systematic review

A. Taleb, Paris, FR

13:15 - 13:15 1167P - Melanoma brain metastases patients treated with stereotactic radiosurgery and ipilimumab versus stereotactic radiosurgery alone: a systematic review with meta-analysis

S. Nguyen¹, A. Castrellon², O. Vaidis³, A. Johnson⁴; ¹Orlando, US, ²Hollywood, FL/US, ³Tampa, FL/US, ⁴Houston, TX/US

13:15 - 13:15 1168P - Estimation of benefice to anti-PD-(L)1 for metastatic patients by real-time quantitative and functional estimation of immune infiltrate with RNAseq

L. Verlingue¹, L. Mahjoubi², D. Brandao², S. Michiels², S. Champiat³, S. Aspeslagh², Y. Loriot², Y. El Dakdouki², S. Postel-Vinay², C. Nicotra², H. Zouhri², G. Chartier², E. Solary², O. Bernard², D. Gautheret², E. Angevin³, A. Hollebecque², A. Marabelle², F. André³, J.-C. Soria³; ¹Paris, FR, ²Villejuif, FR, ³Villejuif, CEDEX/FR

13:15 - 13:15 1169P - Topography of Tumor Mutational Burden (TMB) and Immune-related Genomic Alterations (GA) Across Gastrointestinal Malignancies (Gim): A Study of 22,570 Cases

S. Klempner¹, G. Frampton², J. Chao³, M. Bailey⁴, P. Stephens⁵, J. Ross⁶, V. Miller², S. Ali², A. Schrock⁴; ¹Los Angeles, CA/US, ²Cambridge, MA/US, ³Duarte, US, ⁴Cambridge, US, ⁵Cambridge, Massachusetts/US, ⁶Albany, NY/US

13:15 - 13:15 1170P - Analysis of POLE mutation and tumor mutational burden (TMB) across 80,853 tumors: Implications for immune checkpoint inhibitors (ICPIs)

A. Schrock¹, D. Fabrizio¹, Y. He¹, J. Chung², M. Resnick³, P. Stephens², J. Ross⁴, V. Miller², S. Ramkissoon², J. Elvin², S. Ali², M. Fakhri⁵, S. Klempner⁶; ¹Cambridge, US, ²Cambridge, MA/US, ³Providence, RI/US, ⁴Albany, NY/US, ⁵Duarte, CA/US, ⁶Los Angeles, US

13:15 - 13:15 1171P - Checkpoint inhibitors in MSI tumors: Lessons from a monocentric experience

Y. El Dakdouki¹, L. Verlingue², C. Massard¹, A. Leary¹, L. Lacroix¹, E. Rouleau³, J.-Y. Scoazec¹, O. Caron¹, P. Benusiglio¹, P. Kannouche¹, A. Hollebecque¹, D. Malka¹, J.-C. Soria⁴, A. Marabelle¹; ¹Villejuif, FR, ²Paris, FR, ³Paris, CEDEX 5/FR, ⁴Villejuif, CEDEX/FR

- 13:15 - 13:15 1172P - Single nucleotide polymorphisms in PD-L1 and outcome in nivolumab-treated advanced non-small-cell lung cancer patients
T. Nomizo, T. Funazo, H. Ozasa, T. Tsuji, Y. Yasuda, H. Yoshida, Y. Sakamori, H. Nagai, T. Hirai, Y.H. Kim; Kyoto, JP
- 13:15 - 13:15 1173P - Efficient identification of neoantigens for personalized cancer immunotherapy in advanced refractory epithelial cancer patients
F. Chen, Z. Zou, J. Du, J. Wei, J. Shao, F. Meng, N. ding, B. Liu; Nanjing, CN
- 13:15 - 13:15 1174P - KRAS mutations (KRAS-mut) and antiPD1/PDL1 therapy in a cohort of non-small cell lung cancer (NSCLC) patients (p): Experience from a single institution
C. Erasun Lecuona¹, M.T. Moran Bueno², L. Vila³, I. Teruel³, L. Angelats³, A. Ferrando³, A. Plaja³, P. Torres³, E. Lopez³, R. Muriel³, A.M. Muñoz-Marmol³, J.L. Mate³, J.M. Velarde³, E. Carcereny Costa²; ¹Barcelona, ES, ²Badalona, Barcelona/ES, ³Badalona, ES
- 13:15 - 13:15 1175P - Comparability of programmed death-ligand 1 (PD-L1) expression on tumor-infiltrating immune cells (IC) and tumor cells (TC) in advanced urothelial bladder cancer (UBC) using clinically relevant immunohistochemistry (IHC) assays
K. Schwamborn¹, R. Knüchel², A. Hartmann³, G. Baretton⁴, F. Lasitschka⁵, P. Schirmacher⁵, T. Braunschweig², R. Tauber⁶, F. Erlmeier⁶, S. Hieke-Schulz⁷, J. Ammann⁷, W. Weichert⁶; ¹Munich, DE, ²Nürnberg, DE, ³Erlangen, DE, ⁴Dresden, DE, ⁵Heidelberg, DE, ⁶München, DE, ⁷Basel, CH
- 13:15 - 13:15 1176P - IDO-1 and PD-L1 predict response to immunotherapy in advanced non small cell lung cancer: An NGS and multiplex IHC analysis
L. Leroy¹, J. Massé¹, J. Adam², V. Brouste¹, N. Signolle², I. Soubeyran¹, V. Velasco¹, E. Khalifa¹, B. Lortal¹, A. Italiano¹, B. Besse², S. Le Moulec³; ¹Bordeaux, FR, ²Villejuif, FR, ³Paris, CEDEX 5/FR
- 13:15 - 13:15 1177P - Undiscovered immune heterogeneity in pancreatic adenocarcinoma (PDAC)
C. Ragulan¹, P. Poudel¹, K. Young², G. Nyamundanda¹, R. Lawlor³, A. Scarpa³, A. Sadanandam¹; ¹Sutton, GB, ²London, GB, ³Verona, IT
- 13:15 - 13:15 1178P - Optimized protocols to determine PD-L1 expression on tumor tissue and cytology samples from non-small cell lung cancer (NSCLC) patients using the 22C3 antibody with various immunohistochemistry (IHC) autostainers
M. Ilie¹, S. Khambata-Ford², C. Copie-Bergman³, L. Huang², R. Mogg², J. Juco², V. Hofman¹, P. Hofman¹; ¹Nice, FR, ²Kenilworth, NJ/US, ³Créteil, FR
- 13:15 - 13:15 1179P - Tumor-infiltrating lymphocytes expression in stage IIIc/IV of high-grade serous ovarian cancer: Variation with neoadjuvant chemotherapy and prognostic value
C. Bárcena, K. Rojas, L. Lema, L. Manso Sánchez, J. Rios, R. García-Martín, A. Maroto, J.L. Rodríguez-Peralto, E.M. Ciruelos Gil, D.C. Mendiola, L. Paz-Ares; Madrid, ES
- 13:15 - 13:15 1180P - Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy

P. Stanczak, M. Grzybowski, P. Wolska, A. Zdziarska, M. Mazurkiewicz, R. Blaszczyk, J. Nowicka, A. Sosnowska, K. Ramji, D. Nowis, J. Golab, A. Golebiowski, P. Dobrzanski, K. Dzwonek; Warsaw, PL

- 13:15 - 13:15 1181P - Pharmacokinetics (PK) and Pharmacodynamics (PD) of cergutuzumab amunaleukin (CA), a carcinoembryonic antigen (CEA)-targeted interleukin 2 variant (IL2v) with abolished binding to CD25
E. van Brummelen¹, U. Lassen², I. Melero³, J. Taberero⁴, K. Homicsko⁵, E. Angevin⁶, V. Teichgräber⁷, L. Jukofsky⁸, E. Rossmann⁹, G. Babitzki¹⁰, A. Patricia Silva¹¹, M. Canamero¹⁰, C. Boetsch¹¹, S. Evers⁷, J. Charo¹², G. Argiles⁴; ¹Amsterdam, NL, ²Copenhagen, DK, ³Pamplona, ES, ⁴Barcelona, ES, ⁵Lausanne, Vaud/CH, ⁶Villejuif, CEDEX/FR, ⁷Schlieren, CH, ⁸New York, US, ⁹Basel, Solna/CH, ¹⁰Penzberg, DE, ¹¹Basel, CH, ¹²Schlieren, Zurich/CH
- 13:15 - 13:15 1182P - A first-in-human study of a novel monoclonal antibody INCSHR01210 directed against programmed cell death protein 1 (PD-1) in patients with advanced or metastatic cancer
J. Lickliter¹, H. Gan², B. Gao³, P. Grimison⁴, J. Zou⁵, H. Kallender⁶, K. Sun⁶, X. Chen⁶, A. Behren⁷, P. Fernandez-Penas⁸, A. Nagrial³, M. Voskoboynik¹, K. Woods⁷, M. Millward⁹, T. Meniawy⁹; ¹Melbourne, AU, ²Heidelberg, VIC/AU, ³Blacktown, AU, ⁴Camperdown, AU, ⁵Shanghai, CN, ⁶Wilmington, US, ⁷Heidelberg, AU, ⁸Westmead, NSW/AU, ⁹Nedlands, WA/AU
- 13:15 - 13:15 1183P - Safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of PF 06801591, an anti-PD1 antibody administered intravenously (IV) or subcutaneously (SC)
M. Johnson¹, S. Hu-Lieskovan², F. Braiteh³, J. Grilley-Olson⁴, J. Chou⁵, J. Davda⁶, B. Jin⁷, A. Forgie⁵, D. Rassam⁵, S. Youssef⁵; ¹Nashville, TN/US, ²Los Angeles, CA/US, ³Las Vegas, US, ⁴Chapel Hill, NC/US, ⁵South San Francisco, CA/US, ⁶La Jolla, CA/US, ⁷Cambridge, MA/US
- 13:15 - 13:15 1184P - A phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors
M. Chenard-Poirier¹, D. Hong², R. Coleman³, J. de Bono⁴, M. Mau-Sorensen⁵, D. Collins¹, S. Lisby⁵, L. Basse⁵, U. Lassen⁵; ¹Sutton, GB, ²Houston, US, ³Houston, TX/US, ⁴London, GB, ⁵Copenhagen, DK
- 13:15 - 13:15 1185P - Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti-PD-1 monoclonal antibody, in patients (pts) with advanced solid tumors
J. Sachdev¹, A. Patnaik², J. Waypa³, J. Pelusi⁴, M. Beeram², E. Im⁵, D. Jenkins⁵, K. McEachern⁵, S. Lu⁵, W. Guo⁵, R. Tran⁵, V. Reichert⁵, D. Bobilev⁵, V. Kansra⁵, G. Weiss³; ¹Scottsdale, US, ²San Antonio, TX/US, ³Goodyear, AZ/US, ⁴Scottsdale, AZ/US, ⁵Waltham, MA/US
- 13:15 - 13:15 1186P - Phase Ia study of a humanized anti-PD-1 monoclonal antibody (JS001) in Chinese patients with refractory solid tumors
F.-H. Wang¹, C. Ren¹, Y. Zhang¹, S. Yao², H. Feng², H. Wu², H.-F. Song², R. Zhang¹, X.-L. Wei¹, X.-J. Xia¹, Q. Zhao¹, J.-P. Yun¹, B.-Y. Zou¹, M. Qiu¹, Z.-Q. Wang¹, Y.-H. Li¹, R. Xu³; ¹Guangzhou, CN, ²Shanghai, CN, ³Guangzhou, Guangdong/CN
- 13:15 - 13:15 1187P - A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma
A. Diab¹, C. Haymaker², M. Uemura², R. Murthy¹, M. James², J. Geib³, M. Cornfeld³, S. Swann³, C. Yee², J. Wargo², R. Amaria², S. Patel², H. Tawbi², I. Glitza², S. Woodman², W.-J. Hwu², M. Davies², W. Overwijk², C. Bernatchez², P. Hwu¹; ¹Houston, US, ²Houston, TX/US, ³Exton, PA/US

- 13:15 - 13:15 1188P - Clinical and immune effects patients with progressive disease treated with low dose of anti-CTLA-4, bortezomib, gemcitabine, naproxen and meloxicam
J. Marquez-Manriquez¹, J.A. Briseno², K. Quayle³, L. Fernandez³, I. Barajas³, G. Torres-Montano³, F. Durazo-Bustamante², A. Durazo-Acuna², L.-A. Rangel-Reyna³, D. Lopez-Hernandez³, A. Rodriguez-Jasso², M.-A. Trujillo-Acosta³, E. Ramos-Garcia², S. Icedo-Zamora², P.A. Diaz²; ¹Ciudad Obregon, Washington/MX, ²Ciudad Obregon, MX, ³Seattle, WA/US
- 13:15 - 13:15 1189P - 4SC-202 plus anti-PD1: Breaking PD1-refractoriness to increase efficacy of checkpoint inhibition in patients with advanced melanoma
F. Hermann, Munich, DE
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 1192P - Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis
C. Franklin¹, I. Rooms¹, M. Fiedler¹, H. Reis¹, L. Milsch¹, S. Herz¹, E. Livingstone¹, L. Zimmer², K.W. Schmid¹, U. Dittmer¹, D. Schadendorf¹, B. Schilling¹; ¹Essen, DE, ²Duisburg, DE
- 13:15 - 13:15 1193P - Pooled data analysis of the safety and tolerability of intravenous pelareorep in combination with chemotherapy in 500 + cancer patients
A. GUTIERREZ, C. Reid, M. Crawford, K. Cheetham, A. Dzugalo, M. Parsi, A. Penman, N. Noronha, D. Galindez, R. O'Flynn, M. Coffey; Calgary,, CA
- 13:15 - 13:15 1194P - Impact of prior immune checkpoint inhibitors on haematological toxicity in phase I patients receiving chemotherapy
A. Ingles Garces¹, J.E. Ang², M. Ameratunga³, M. Chenard-Poirier², D. Dolling², R. Sundar⁴, S. Kaye³, J. de Bono³, U. Banerji⁵, J. Lopez⁵; ¹Sutton, RJ/GB, ²Sutton, GB, ³London, GB, ⁴Lyngby, DK, ⁵Sutton, Surrey/GB
- 13:15 - 13:15 1195P - Compromised efficacy of PD-L1 blockade therapy in axenic (germ-free) mice with syngeneic tumors
A. Mansfield, X. Liu, S. Cao, W. Bindeman, P. Yin, L. Till, S. Harrington, H. Dong; Rochester, MN/US
- 13:15 - 13:15 1197P - iRGD enhances T cells infiltration and augments response to PD-1 gene knockout immunotherapy in gastric cancer
N. ding, S. Su, F. Meng, H. Sha, F. Chen, J. Wei, S. du, B. Liu; Nanjing, CN
- 13:15 - 13:15 1198P - Immunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer
S. Hoff¹, S. Grünewald¹, L. Röse¹, D. Zopf²; ¹Berlin, DE, ²No City Provided, NA
- 13:15 - 13:15 1199P - Effect of MEK inhibition on PD-L1 and MCH-1 expression and on cytokines production profile in NSCLC cells and in human lymphocytes
C.M. Della Corte¹, G. Barra², V. Ciaramella¹, F. Papaccio¹, G. Viscardi¹, G. Esposito¹, R. Di Liello¹, M. Orditura¹, T. Troiani¹, R. De Palma¹, F. Ciardiello², F. Morgillo¹; ¹Napoli, IT, ²Naples, IT
- 13:15 - 13:15 1200P - Exploring personalized immunotherapy opportunities in colorectal cancer

B. Navarro Rodrigo¹, S. Bobisse¹, S. Viganò¹, P. Baumgartner¹, T. Nguyen-Ngoc¹, P. Gannon¹, R. Genolet¹, B. Stevenson¹, C. Sempoux¹, M.-O. Sauvain¹, M. Hubner¹, D. Hahnloser¹, N. Demartines¹, M. Montemurro¹, L. Kandalaf¹, S. Rusakiewicz¹, A. Harari¹, G. Coukos²; ¹Lausanne, CH, ²Epalinges, CH

13:15 - 13:15 (Withdrawn)

13:15 - 13:15 1203P - Functional screening of B7H6-based chimeric antigen receptor (CAR) designs

B. Demoulin¹, L. Springuel¹, D. Daro¹, J. Bolsée¹, J. Houssa¹, F. Huberty¹, C. Jacques-Hespel¹, C. Marchand¹, J. Marijse¹, T.L.T. Nguyen¹, N. Ramelot¹, B. Violle¹, C. Lonez², D. Gilham², V. Steenwinkel¹; ¹Mont Saint Guibert, BE, ²Mont-Saint-guibert, BE

13:15 - 13:15 1204P - Concurrent immuno-radiotherapy in lung and renal cancer- a new treatment paradigm

J. Ansari¹, M. Ali², A. Alomair², A. Mohammed Ali², E. Murshid², A. Shaukat², E. Batubara², F. Bashir², A. Farrag², K. Hussein², A. Alhamad²; ¹Glasgow, GB, ²Riyadh, SA

13:15 - 13:15 1205P - Optimum fractionation of radiation dose to combine anti-PD-1 mAb in MC38 mice model

F. TENG¹, X. Wang¹, J. Yu¹, L. Kong²; ¹Jinan, CN, ²Jinan, Shandong/CN

13:15 - 13:15 1206P - Efficacy of tumor treating fields (TTFields) and anti-PD-1 in non-small-cell lung cancer (NSCLC) preclinical models

M. Giladi¹, T. Voloshin¹, O. Talytzhaki¹, U. Weinberg², E. Kirson¹; ¹Haifa, IL, ²Luzern, CH

13:15 - 13:15 1207TiP - An open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder

P. Ott¹, A. Naing², G. Ramaswamy³, K. Margolin⁴, M. Moles⁵, R. Gaynor⁶, M. Goldstein⁵, S. Hu-Lieskovan⁷; ¹Boston, MA/US, ²Houston, TX/US, ³St. Louis, US, ⁴Duarte, CA/US, ⁵Boston, US, ⁶Cambridge, US, ⁷Los Angeles, CA/US

13:15 - 13:15 1208TiP - A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors

M. Gonzalez-Cao¹, J. Martinez-Picado², M. Provencio Pulla³, B. Clotet², O. Juan⁴, J. Dalmau², T. Moran², A. Mayerhans¹, J. De Castro⁵, J. Blanco², R. Blanco¹, R. Bernabe Caro⁶, N. Karachaliou¹, J. Garcia-Corbacho¹, M.A. Molina¹, C. Brander², R. Rosell⁷; ¹Barcelona, ES, ²Badalona, ES, ³Majadahonda, Madrid/ES, ⁴Valencia, ES, ⁵Madrid, ES, ⁶Sevilla, ES, ⁷Badalona, Barcelona/ES

13:15 - 13:15 1209TiP - A first-in-human, open-label, multicenter phase 1/2a study to evaluate the safety and efficacy of increased repeated doses of the first in class RORγ agonist LYC-55716 in treating locally advanced or metastatic solid tumors

H. Wilkins¹, E. Hamilton², D. Mahalingam³; ¹San Diego, US, ²Nashville, US, ³San Antonio, US

13:15 - 13:15 1210TiP - A phase I global trial targeting multiple solid and hematologic malignancies through a NKG2D receptor-based CAR-T immunotherapy

B. VERMA¹, A. Awada², P. Aftimos², P. Lewalle², N. Meuleman², J.-P. Machiels², G. Catala³, E. Vandenneste², J. Brayer⁴, D. Sallman⁴, S. Sahebjam⁴, T. Kerre⁵, S. Rottey², K. Odunsi⁶, E. Wang⁶, U. Santanam⁷, C. Lonez⁸, D. Gilham⁸, F. Lehmann⁸; ¹Boston, US, ²Brussels, BE, ³Woluwe-Saint-lambert, BE, ⁴Tampa, FL/US, ⁵Ghent, BE, ⁶Buffalo, NY/US, ⁷Boston, MA/US, ⁸Mont-Saint-guibert, BE

- 13:15 - 13:15 1211TiP - FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition
S. Symeonides¹, T.R.J. Evans², V. Coyle³, A. Serrels⁴, F. Thomson², D. Currie², S. Dillon², J. Paul², D. Fennell⁵, C. Ottensmeier⁶; ¹Edinburgh, Midlothian/GB, ²Glasgow, GB, ³Belfast, UK/GB, ⁴Edinburgh, GB, ⁵Leicester, GB, ⁶Southampton, GB
- 13:15 - 13:15 1212TiP - PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
A. Diab¹, M. Hurwitz², N. Tannir³, C. Bernatchez³, C. Haymaker³, S. Bentebibel³, B. Curti⁴, M. Wong³, I. Gergel⁵, M. Tagliaferri⁶, J. Zalevsky⁶, U. Hoch⁶, S. Aung⁶, M. Imperiale⁶, D. Cho⁷, S. Tykodi⁸, I. Puzanov⁹, H. Kluger¹⁰, P. Hwu¹, M. Sznoi¹⁰; ¹Houston, US, ²New Haven, CT/US, ³Houston, TX/US, ⁴Portland, OR/US, ⁵San Francisco, CA/US, ⁶San Francisco, US, ⁷New York, NY/US, ⁸Seattle, WA/US, ⁹Buffalo, NY/US, ¹⁰New Haven, US
- 13:15 - 13:15 MELANOMA AND OTHER SKIN TUMOURS
S. Martin Algarra, Pamplona, ES
- 13:15 - 13:15 1227P - Avelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC)
S. D'Angelo¹, J. Russell², J. Hassel³, C. Lebbé⁴, B. Chmielowski⁵, G. Rabinowits⁶, P. Terheyden⁷, I. Brownell⁸, I. Zwiener⁹, M. Bajars¹⁰, M. Hennessy¹¹, H. Kaufman¹²; ¹New York, NY/US, ²Tampa, FL/US, ³Heidelberg, DE, ⁴Paris, FR, ⁵Los Angeles, CA/US, ⁶Boston, MA/US, ⁷Lübeck, DE, ⁸Bethesda, MD/US, ⁹Darmstadt, DE, ¹⁰Riga, LV, ¹¹Billerica, MA/US, ¹²New Brunswick, NJ/US
- 13:15 - 13:15 1228P - Long-term effects of sonidegib on tumor burden: 30-month results from the phase 2 randomized bolt trial
R. Dummer¹, M. Migden²; ¹Zürich, CH, ²Houston, TX/US
- 13:15 - 13:15 1230P - Modulation of Risk and Prognosis of Cutaneous Melanoma Patients by Genetic Polymorphisms on PDCD1 Gene
G. Gomez, J.A. Rinck-Junior, D. Da Silva, R. Mamoni, G. Lourenço, A. Moraes, C. Lima; Campinas, BR
- 13:15 - 13:15 1231P - Role of an intronic polymorphism in the CREB1 gene, involved in melanogenesis, with the risk and the aggressiveness of cutaneous melanoma
J. Silva¹, C. Oliveira², B. Sá Carvalho¹, C. Torricelli¹, G. Gomez¹, W. Oliveira¹, J. Rinck-Junior¹, A. Moraes¹, M. Ortega³, C. Lima¹, G. Lourenço¹; ¹Campinas, BR, ²Campinas, SP/BR, ³Bragança Paulista, BR
- 13:15 - 13:15 1232P - Investigation of AMBRA1 as a melanoma susceptibility gene
V. Hoiom, M. Yang, K. Nosrati, A. Azimi, S. Egyhazi Brage, R. Tuominen; Stockholm, SE

- 13:15 - 13:15 1233P - Influence of an intronic polymorphism in the MITF gene, of melanogenic pathway, in the risk and the prognosis of cutaneous melanoma
C. Torricelli¹, C. Oliveira², B. Sá Carvalho¹, J. Silva¹, G. Gomez¹, W. Oliveira¹, J.A. Rinck-Junior¹, A. Moraes¹, M. Ortega³, C. Lima¹, G. Lourenço¹; ¹Campinas, BR, ²Campinas, SP/BR, ³Bragança Paulista, BR
- 13:15 - 13:15 1234P - Hybrid-capture based genomic profiling identifies BRAF V600 and non-V600 alterations in melanoma samples negative by prior testing
L. Boussemart¹, A. Wang², M. Wong³, J. Ross⁴, P. Stephens², S. Ali², J. Sosman⁵, J. Mehnert⁶, G. Daniels⁷, K. Kendra⁸, A. Schrock⁹, V. Miller²; ¹Rennes, FR, ²Cambridge, MA/US, ³Houston, TX/US, ⁴Albany, NY/US, ⁵Chicago, US, ⁶New Brunswick, US, ⁷La Jolla, US, ⁸Columbus, US, ⁹Cambridge, US
- 13:15 - 13:15 1235P - Post-transcriptional regulation of immune checkpoint genes by mir-16 in melanoma
R. Leibowitz-Amit¹, A. Layani¹, J. Roszik², Y. Sidi¹, D. Avni¹, E. Grimm²; ¹Ramat Gan, IL, ²Houston, US
- 13:15 - 13:15 1236P - Does melanoma or other skin cancers belong to the BRCA2 phenotype?
R. Vitorino¹, F. Vaz¹, A.L. Carvalho¹, S. Bento², A. Luís¹, A. Opinião¹, A. Clara¹, J. Dupont¹, S. Santos¹, P. Machado¹, S. Fragoso¹, P. Rodrigues¹, J. Parreira¹, C. Moura¹; ¹Lisbon, PT, ²Santarem, Santarem/PT
- 13:15 - 13:15 1237P - Resected malignant melanoma at high risk of recurrence in SEER-Medicare
N. Sadetsky¹, J. Yi¹, A. Hernandez¹, D. Colburn², G. Goodman¹; ¹South San Francisco, US, ²South San Francisco, California/US
- 13:15 - 13:15 1238P - Independent prognostic impact of lympho-vascular invasion in cutaneous melanoma patients with sentinel lymph node biopsy
R. Luca, M. Rizzo, P. Mando, C. Perez de La Puente, A. Blanco, S. Rivero, G. Lutter, F. Cappuccio, M. Amat, J. Kaplan, R. Chacon, M. Chacon; Caba, AR
- 13:15 - 13:15 1239P - Validating prognostic models in metastatic uveal melanoma (MUM), an international rare cancers initiative
L. Khoja¹, E. Atenafu², A. Joshua³, I.R.C.I. Ocular Melanoma Group⁴; ¹Melbourn, GB, ²Toronto, CA, ³Sydney, AU, ⁴London, GB
- 13:15 - 13:15 1240P - Impact of an active surveillance programme on outcome of patients (pts) with uveal melanoma (UM) after primary curative therapy (PTx): results of a single-institution experience
C.L. Lee¹, G. Gullo¹, N. Horgan¹, C. Baily¹, R. Abdul Rahman², D. Smith¹, C. Buckley¹, J. Crown¹; ¹Dublin, IE, ²Dublin, Belgard Square North/IE
- 13:15 - 13:15 1241P - Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis

K. Lewis¹, J. Larkin², A. Ribas³, K. Flaherty⁴, G. McArthur⁵, P. Ascierto⁶, B. Dréno⁷, E. McKenna⁸, Q. Zhu⁹, Y. Mun¹⁰, A. Hauschild¹¹; ¹Aurora, CO/US, ²London, GB, ³Los Angeles, CA/US, ⁴Boston, MA/US, ⁵Melbourne, AU, ⁶Napoli, IT, ⁷Nantes, FR, ⁸South San Francisco, CA/US, ⁹South San Francisco, US, ¹⁰South San Francisco, California/US, ¹¹Kiel, Schleswig-Holstein/DE

- 13:15 - 13:15 1242P - Neutrophil to Lymphocyte Ratio (NLR) as an independent prognostic measure in patients receiving targeted therapy or immunotherapy for stage IV melanoma
E. Blackley, L.E. Lim, M. Moore, M. Voskoboynik, C. McLean, A. Haydon; Melbourne, AU
- 13:15 - 13:15 1243P - The prognostic significance of distant metastasis free interval (DMFI) in BRAF mutant advanced melanoma patients treated with first line targeted therapy
D. Bafaloukos¹, H. Linardou², P. Diamantopoulos¹, T. Sergentanis¹, A. Laskarakis¹, K.-M. Giati¹, A. Tarampikou², A. Anastasopoulou³, H. Gogas³; ¹Athens, GR, ²Athens, N. Faliro/GR, ³Athens, Attiki/GR
- 13:15 - 13:15 1244P - Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
A. Arance¹, R. Dummer², P. Ascierto³, H. Gogas⁴, M. Mandala⁵, G. Liskay⁶, C. Garbe⁷, D. Schadendorf⁸, I. Krajsová⁹, R. Gutzmer¹⁰, V. Chiarion Sileni¹¹, C. Dutriaux¹², J.W. de Groot¹³, N. Yamazaki¹⁴, C. Loquai¹⁵, L. de Parseval¹⁶, M. Pickard¹⁷, V. Sandor¹⁷, C. Robert¹⁸, K. Flaherty¹⁹; ¹Barcelona, ES, ²Zürich, CH, ³Napoli, IT, ⁴Athens, Attiki/GR, ⁵Bergamo, IT, ⁶Budapest, HU, ⁷Tuebingen, DE, ⁸Heidelberg, DE, ⁹Prague, CZ, ¹⁰Hannover, DE, ¹¹Padova, IT, ¹²Bordeaux, FR, ¹³Zwolle, NL, ¹⁴Tokyo, JP, ¹⁵Mainz, DE, ¹⁶Basel, CH, ¹⁷Boulder, CO/US, ¹⁸Villejuif, FR, ¹⁹Boston, MA/US
- 13:15 - 13:15 1245P - Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma
H. Gogas¹, R. Dummer², P. Ascierto³, A. Arance⁴, M. Mandala⁵, G. Liskay⁶, C. Garbe⁷, D. Schadendorf⁸, I. Krajsová⁹, R. Gutzmer¹⁰, V. Chiarion Sileni¹¹, C. Dutriaux¹², J.W. de Groot¹³, N. Yamazaki¹⁴, C. Loquai¹⁵, L. de Parseval¹⁶, M. Pickard¹⁷, V. Sandor¹⁷, C. Robert¹⁸, K. Flaherty¹⁹; ¹Athens, Attiki/GR, ²Zürich, CH, ³Napoli, IT, ⁴Barcelona, ES, ⁵Bergamo, IT, ⁶Budapest, HU, ⁷Tuebingen, DE, ⁸Essen, DE, ⁹Prague, CZ, ¹⁰Hannover, DE, ¹¹Padua, IT, ¹²Bordeaux, FR, ¹³Zwolle, NL, ¹⁴Tokyo, JP, ¹⁵Mainz, DE, ¹⁶Basel, CH, ¹⁷Boulder, CO/US, ¹⁸Villejuif, FR, ¹⁹Boston, MA/US
- 13:15 - 13:15 1246P - Loss of USP28 drives resistance to BRAF targeted therapy in melanoma
A. Saei¹, M. Palafox², T. Benoukraf¹, N. Kumari¹, P. Jaynes¹, P. Iyengar¹, J.L. Charles Richard¹, Z.F. Isa¹, B. Pang¹, M. Guzman², H. Yang¹, W.L. Tam¹, V. Serra², P. Eichhorn¹; ¹Singapore, SG, ²Barcelona, ES
- 13:15 - 13:15 1247P - Patterns of progression in metastatic melanoma patients treated with Braf and Mek inhibitors: an Italian Melanoma Intergroup (IMI) study
R. Marconcini¹, E. Marra², F. De Rosa³, L. Stucci⁴, L. Orgiano⁵, S. Ribero², F. Bloise¹, A. Antonuzzo¹, A. Falcone¹; ¹Pisa, IT, ²Turin, IT, ³Meldola, IT, ⁴Bari, IT, ⁵Monsestato, (CA)/IT
- 13:15 - 13:15 1248P - Tumor-stroma interactions as a determinant of drug resistance in BRAF-mut melanoma
I. Falcone¹, R. Loria¹, U. Cesta Incani¹, L. Ciuffreda¹, C. Bazzichetto¹, F. Conciatori¹, B. Bellei¹, D. Kovacs¹, M. Picardo¹, R. Falcioni¹, M. Milella²; ¹Rome, IT, ²Roma, IT

- 13:15 - 13:15 1249P - Extended survival analysis of ipilimumab for the treatment of advanced malignant melanoma in pretreated patients: Five-year long-term follow-up of the South African expanded access program
B. Rapoport¹, D. Vorobiof², L. Dreosti³, A. Nosworthy¹, G. Mcadam⁴, A. Jordaan⁵, M. De Necker³, J. De Beer⁶, H. Duvenhage⁷; ¹Johannesburg, ZA, ²Sandton, Gauteng/ZA, ³Pretoria, ZA, ⁴Cape Town, ZA, ⁵Durban, Kwazulu Natal/ZA, ⁶Centurion, ZA, ⁷Woodmead, ZA
- 13:15 - 13:15 1250P - Real-world use of ipilimumab and nivolumab monotherapy or in combination in patients with advanced melanoma: results from a retrospective chart review
A. Tarhini¹, C. Macahilig², C. Atzinger³, K. Gupte-Singh⁴, C. Solem³, S. Rao⁴; ¹Pittsburgh, PA/US, ²Parsippany, NJ/US, ³Bethesda, MD/US, ⁴Princeton, NJ/US
- 13:15 - 13:15 1251P - Baseline neutrophil-to-lymphocyte ratio and its values monitored over time is associated with outcome of metastatic melanoma patients treated with immunotherapy
I. Lugowska¹, B. Cybulska-Stopa², P. Jagodzinska-Mucha¹, P. Teterycz¹, H. Koseła-Paterczyk³, K. Kozak¹, K. Szamotulska³, K. Roman², T. Switaj¹, M. Ziobro², P. Rutkowski¹; ¹Warsaw, PL, ²Krakow, PL, ³Warszawa, PL
- 13:15 - 13:15 1252P - Early safety from phase 1b/3, multicenter, open-label, randomized trial of talimogene laherparepvec (T-VEC) + pembrolizumab (pembro) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): MASTERKEY-232
K. Harrington¹, A. Kong², N. Mach³, T. Rordorf⁴, J. Corral⁵, V. Espeli⁶, S. Treichel⁷, J. Cheng⁸, J. Kim⁹, J. Chesney¹⁰; ¹London, GB, ²Birmingham, GB, ³Geneva, CH, ⁴Zürich, CH, ⁵Seville, ES, ⁶Bellinzona, CH, ⁷South San Francisco, US, ⁸North Wales, PA/US, ⁹Thousand Oaks, US, ¹⁰Louisville, US
- 13:15 - 13:15 1253P - Characteristics of metastatic melanoma (MM) patients with leptomeningeal disease (LMD) and survival of &
I. Glitza, J. Ma, S. Ferguson, R. Bassett Jr, L. Haydu, M. Davies; Houston, TX/US
- 13:15 - 13:15 1254P - Tolerance and outcomes of stereotactic radiosurgery combined with anti-PD1 (pembrolizumab) for melanoma brain metastases
C. Nardin¹, C. Mateus¹, M. Texier¹, E. Lanoy¹, S. Hibat-Allah¹, S. Ammari¹, C. Robert¹, F. Dhermain²; ¹Villejuif, FR, ²Villejuif, CEDEX/FR
- 13:15 - 13:15 1255P - Dabrafenib and Trametinib combination in real life patients including brain metastases: French experience within MelBase
C. Allayous¹, B. Guillot², S. Dalac Rat³, L. Mortier⁴, C. Dutriaux⁵, M.-T. Leccia⁶, J.-P. Lacour⁷, S. Dalle⁸, P. Saiag⁹, M. Beylot-Barry¹⁰, C. Lok¹¹, J. De Quatrebarbes¹², F. Aubin¹³, T. Lesimple¹⁴, B. Dreno¹⁵, R. Porcher¹, A. Ballon¹, B. Oriano¹, C. Lebbe¹; ¹Paris, FR, ²Montpellier, FR, ³Dijon, Cedex/FR, ⁴Lille, CEDEX/FR, ⁵Bordeaux, FR, ⁶La Tronche, CEDEX 9/FR, ⁷Nice, FR, ⁸Pierre Bénite, CEDEX/FR, ⁹Boulogne-Billancourt, FR, ¹⁰Pessac, FR, ¹¹Amiens, FR, ¹²Metz-Tessy, FR, ¹³Besançon, FR, ¹⁴Rennes, FR, ¹⁵Nantes, CEDEX 1/FR
- 13:15 - 13:15 1256TiP - A Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial)

M. Gonzalez¹, A. Menzies¹, R. Saw², J. Thompson², A. Spillane², J. Howle², O. Nieweg², K. Shannon², S. Ch'Ng¹, J. Stretch³, M. Carlino², A. Guminski⁴, L. Emmett², H. Rzos², R. Scolyer⁵, G. Long²,¹ North Sydney, AU, ²Sydney, AU, ³Wollstonecraft, AU, ⁴St Leonards, NSW/AU, ⁵Camperdown, AU

13:15 - 13:15 1257TiP - KEYNOTE 029: Phase 1/2 randomized study of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma

M. Atkins¹, M. Carlino², A. Hill³, C. McNeil², A. Ribas⁴, V. Atkinson⁵, J. Cebon⁶, M. Jameson⁷, W.-J. Hwu⁸, J. Thompson⁹, J. Anderson¹⁰, B. Homet Moreno¹⁰, N. Ibrahim¹¹, G. Long²; ¹Washington Dc, US, ²Sydney, AU, ³Southport, AU, ⁴Los Angeles, CA/US, ⁵Brisbane, AU, ⁶Heidelberg, AU, ⁷Hamilton, NZ, ⁸Houston, TX/US, ⁹Seattle, WA/US, ¹⁰Kenilworth, NJ/US, ¹¹Kenilworth, US

13:15 - 13:15 1258TiP - Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial)

E. Rozeman, M. Deken, J. Gadiot, M. Geukes Foppen, L. Pronk, J. Thienen, J. Haanen, C. Blank; Amsterdam, NL

13:15 - 13:15 1259TiP - A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i)

E. Gasal¹, A.M. Arance Fernandez², P. Ascierto³, V. Atkinson⁴, R. Dummer⁵, K. Flaherty⁶, J.-J. Grob⁷, J. Hansson⁸, J. Hassel⁹, J. Larkin¹⁰, C. Lebbé¹¹, G. Long¹², P. Lorigan¹³, W. Miller¹⁴, P. Nathan¹⁵, A. Ribas¹⁶, C. Robert¹⁷, D. Schadendorf¹⁸, H. Tawbi¹⁹, A. Upalawanna²⁰; ¹East Hanover, US, ²Barcelona, ES, ³Napoli, IT, ⁴Woolloongabba, AU, ⁵Zürich, CH, ⁶Boston, MA/US, ⁷Marseille, FR, ⁸Stockholm, SE, ⁹Heidelberg, DE, ¹⁰London, GB, ¹¹Paris, FR, ¹²Sydney, AU, ¹³Manchester, GB, ¹⁴Montreal, QC/CA, ¹⁵Northwood, Middlesex/GB, ¹⁶Los Angeles, CA/US, ¹⁷Villejuif, FR, ¹⁸Essen, DE, ¹⁹Houston, TX/US, ²⁰Basel, CH

13:15 - 13:15 1260TiP - Late physical, psychological and social consequences of ipilimumab treatment in advanced melanoma

A. Boekhout¹, M. Hauptmann¹, A. van den Eertwegh¹, G. Hospers², J.W. de Groot³, M. Aarts⁴, E. Kapiteijn⁵, A. Ten Tije⁶, D. Piersma⁷, W. Kruit⁸, K. Suijkerbuijk⁹, F. Berkmortel¹⁰, G. Vreugdenhil¹¹, R. Koornstra¹², E. Fiets¹³, M. Lees¹⁴, K. Janssen⁹, L. van den Poll-Franse¹, C. Blank¹; ¹Amsterdam, NL, ²Groningen, NL, ³Zwolle, NL, ⁴Maastricht, NL, ⁵Leiden, NL, ⁶Breda, NL, ⁷Enschede, NL, ⁸Rotterdam, NL, ⁹Utrecht, NL, ¹⁰Sittard, NL, ¹¹Eindhoven, NL, ¹²Nijmegen, NL, ¹³Leeuwarden, NL, ¹⁴Rueil-Malmaison, FR

13:15 - 13:15 PALLIATIVE CARE

F. Scotté, Paris, FR

13:15 - 13:15 1390P - Efficacy of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with anorexia/cachexia and modified Glasgow Prognostic Score (mGPS) of 2: Pooled analysis of two phase 3 trials

S. Kaasa¹, B. Laird², M. Fallon², D. McMillan³, R. Skipworth², D. Currow⁴, R. Giordano⁵; ¹Oslo, NO, ²Edinburgh, GB, ³Glasgow, GB, ⁴Sydney, NSW/AU, ⁵Lugano Pazzallo, CH

- 13:15 - 13:15 1391P - Prognostic Nutritional Index (PNI) for cost effective utilisation of newer, expensive radiation technology for palliative treatment of all cancer patients with limited life expectancy
S. Sundar¹, J. Price², T. Wolfe², D. Thurairasa², E. Shawcroft²; ¹Nottingham, Nottinghamshire/GB, ²Nottingham, GB
- 13:15 - 13:15 1392P - Characterization of cachectic patients with non-small cell lung cancer (NSCLC) according to their modified Glasgow Prognostic Score (mGPS)
B. Laird¹, D. McMillan², S. Kaasa³, M. Fallon¹, R. Skipworth¹, D. Currow⁴, R. Giordino⁵; ¹Edinburgh, GB, ²Glasgow, GB, ³Oslo, NO, ⁴Sydney, NSW/AU, ⁵Lugano Pazzallo, CH
- 13:15 - 13:15 1393P - Chemotherapy in advanced cancer patients with poor performance status (PS) initiated in an integrated oncology and palliative care (PC) setting: an observational comparative study
F. Strasser¹, N. Kalbermatten Magaya², D. Hehli¹, M. Früh¹, D. Blum³; ¹St. Gallen, CH, ²Münsterlingen, CH, ³Hamburg, DE
- 13:15 - 13:15 1394P - Previous palliative care encounter is associated with lower total hospital charge and shorter length of stay in patients with metastatic cancer
Y. Liu, New York, US
- 13:15 - 13:15 1395P - Specialized ambulatory palliative care: (SAPV) 5-year results of a multi-professional care model by HomeCare linker Niederrhein gGmbH (HC) in the Lower Rhine region
U. Grabenhorst, Viersen, DE
- 13:15 - 13:15 1396P - Increasing palliative interventions at the end of life: patterns in metastatic colorectal cancer (mCRC)
R. Prince¹, A. Easson¹, S. Liang¹, M. Brar¹, S. Ramkumar¹, A. Scheer¹, R. Wong², J. Hallet¹, C. Zimmermann¹; ¹Toronto, CA, ²Toronto, ON/CA
- 13:15 - 13:15 1397P - Chronic pleural effusion in malignancy: A single center's ten years expertise with indwelling pleural catheters
N. Frost, M. Brünger, B. Temmesfeld-Wollbrück, D. Schürmann, N. Suttorp; Berlin, DE
- 13:15 - 13:15 1398P - Aggressiveness of care at the end of life in children with cancer: A nationwide cohort study
A. Cardoso¹, D. Martins Branco², A. Lacerda², B. Gomes³, S. Lopes²; ¹Penafiel, PT, ²Lisbon, PT, ³London, GB
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 PREVENTION AND SCREENING
M. Ijzerman, Enschede, NL
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 1403P - Community-based lung cancer screening of high-risk population with low-dose computed tomography in China
F. Qian, W. Yang, H. Wang, J. Teng, Y. Zhang, Q. Chen, J. Ye, J. Lou, R. Shi, L. Jiang, A. Gu, Y. Zhao, B. Jin, X. Zhang, J. Xu, Y. Lou, B. Han; Shanghai, CN

- 13:15 - 13:15 1404P - Colon cancer screening by fecal immunochemical testing in Iran
H. Salimzadeh¹, F. Bishehsari², C. Sauvaget³, M. Amani⁴, R. Hamzeloo⁴, A. Nikfarjam⁴, M. Maziar⁴, S. Merat⁴, A. Delavari⁴, R. Malekzadeh⁴; ¹Teheran, IR, ²Chicago, US, ³Lyon, FR, ⁴Tehran, IR
- 13:15 - 13:15 1405P - Diagnostic analysis of patients referred from general practitioner with serious non-organ-specific symptoms and signs of cancer: A retrospective cohort study
B. Jørgensen¹, C. Dehlendorff¹, C. Kistorp², S. Bojesen², J. Johansen², C. Feltoft²; ¹Copenhagen, DK, ²Herlev, DK
- 13:15 - 13:15 1406P - Increased mutation burden in high-risk lung tissues: Toward precision cancer risk diagnosis
E. Kubo, H. Takeshima, S. Yamashita, N. Motoi, T. Ushijima; Tokyo, JP
- 13:15 - 13:15 1407P - Change of natural history of hereditary diffuse gastric cancer after identification of a novel CDH1 mutation
N. Stjepanovic¹, S. Castro², N. Gadea², E. Carrasco², M. Codina², A. Lopez², M.E. Semidey², I.M. De Torres², M. Alsina², M. Urioste³, L. Pena³, F. Mercadillo³, S. Landolfi², J. Balmana²; ¹Barcelona, Ontario/ES, ²Barcelona, ES, ³Madrid, ES
- 13:15 - 13:15 1408P_PR - A study of body fat composition, derived from DXA-scans, in association with cancer incidence in postmenopausal women
L. Staunstrup¹, J. Christensen², J. Blair¹, H. Nielsen¹, C. Christiansen¹, C. Bager¹; ¹Herlev, DK, ²København, DK
- 13:15 - 13:15 1409P - Cervical cancer screening in France: recent change in behaviors
T. de La Motte Rouge¹, J. Viguier², J.-F. Morere³, L. Brignoli-Guibaudet⁴, J.-Y. Blay⁵, C. Lhomel⁶, F. Eisinger⁷; ¹Rennes, FR, ²Tours, FR, ³Villejuif, CEDEX/FR, ⁴Paris, FR, ⁵Lyon, FR, ⁶Neuilly-Sur-seine, FR, ⁷Marseille, CEDEX 9/FR
- 13:15 - 13:15 1410P_PR - The role of tumour marker testing in earlier diagnosis of cancer
C. Barrington, R. Frazer, E. Higgins, A. Shore; Swansea, GB
- 13:15 - 13:15 1411P - Genetic counseling, screening and risk reducing practices in patients with BRCA mutations
R. Saroufim¹, S. Daouk¹, I. Abou Dalle¹, F. Kreidieh¹, Y. Bidet², N. El Saghir¹; ¹Beirut, LB, ²Clermont-Ferrand, FR
- 13:15 - 13:15 1412P_PR - Ischemic stroke as cancer predecessor and associated predictors
J. Rogado¹, V. Pacheco¹, R. Mondejar², S. Quintas¹, P. Gullón¹, J. Dotor¹, M.D. Fenor de la Maza¹, B. Obispo¹, G. Reig-Roselló¹, T. Pascual¹, A.I. Ballesteros Garcia¹, O. Donnay¹, J.M. Sánchez-Torres¹, R. López Ruiz¹, J. Vivancos¹, R. Colomer Bosch¹; ¹Madrid, ES, ²Cuenca, ES
- 13:15 - 13:15 1413P - Gastric cancer detected after Helicobacter pylori eradication at one private screening center in Japan
T. Nakamura¹, Y. Kon², K. Konuma², T. Sanada², S. Shibata², H. Gonda², Y. Suto², Y. Amagasa², A. Suzuki², M. Fukuda², C. Aoyagi²; ¹Ota, Gunma/JP, ²Ota, JP

- 13:15 - 13:15 Knowledge of cervical cancer preventive strategies among market women in Nigeria
Y. Adetule, Ibadan, Oyo/NG
- 13:15 - 13:15 1415P - NGS and Sanger screening for BRCA1/BRCA2, CHEK2 and TP53 in Argentinian high-risk breast/ovarian cancer families and bioinformatic studies: Initial results
L. Bruno¹, P. Jablonski¹, M. Ozkul¹, G. Mercado¹, J. Sendoya², A. Llera², L. Núñez², R. Valdez², D. Mansilla², V. Cólica², P. Kalfayan², C. Ruggiero², M. Reyes², R. Cerretini²; ¹Capital Federal, AR, ²Ciudad Autónoma De Buenos Aires, AR
- 13:15 - 13:15 1416P - The change in self-perceived characteristics of health and lifestyle due to colorectal cancer screening invitation and attendance
M. Jäntti, S. Heinävaara, N. Malila, T. Sarkeala; Helsinki, FI
- 13:15 - 13:15 1417P - Multi-gene panels: new clinical experience in hereditary breast and ovarian cancer
T. Ramon y Cajal¹, A. Lasa¹, G. Llort¹, C. Lopez¹, C. Yagüe², M. Cornet¹, A. Gisbert¹, D. Fisas¹, N. Calvo¹, A. Vethencourt¹, A. Barba¹, S. Quero¹, E. Martinez¹, I. Hernan¹, A. Ruiz¹, A. Arcusa², E. Saigi¹, A. Barnadas¹, J. Surralles¹; ¹Barcelona, ES, ²Terrassa, ES
- 13:15 - 13:15 1418P - Clinical features and outcomes of reversible posterior encephalopathy syndrome following bevacizumab treatment
M. Iwamoto, H. Fujioka, K. Kimura, K. Uchiyama, R. Terasawa; Osaka, JP
- 13:15 - 13:15 1419P - Deliberative democracy and cancer screening. The use of citizens' s juries in health policy decision-making
A. Quilez Cutillas¹, P. Rosado-Varela², V. Luque-Ribelles², S. Márquez Calderón¹, E. Benitez-Rodríguez¹, J.M. Ribera-Bautista¹, J.M. Baena-Canada¹; ¹Cadiz, ES, ²Puerto Real, ES
- 13:15 - 13:15 1420P - Genetic landscape in HBOC families from Brazil: A mutational analysis
E. Dos Santos¹, B. Rossi², E.M.M. Santos², E. Rouleau³, S. Caputo⁴, C. Urbeteli de Sa², M. F. Sa Ribeiro², N. Vaz², B. Garicochea²; ¹Sao Paulo, SP/BR, ²Sao Paulo, BR, ³Paris, CEDEX 5/FR, ⁴Paris, FR
- 13:15 - 13:15 1421P - Recommended cancer screening and vulnerable populations: results from the EDIFICE 5 survey
J.-F. Morere¹, F. Eisinger², J.-Y. Blay³, S. Couraud⁴, L. Brignoli-Guibaudet⁵, C. Lhomel⁶, A. Cortot⁷, L. Greillier⁸, J. Viguier⁹; ¹Villejuif, CEDEX/FR, ²Marseille, CEDEX 9/FR, ³Lyon, FR, ⁴Pierre Bénite, CEDEX/FR, ⁵Paris, FR, ⁶Neuilly-Sur-seine, FR, ⁷Lille, FR, ⁸Marseille, FR, ⁹Tours, FR
- 13:15 - 13:15 PSYCHO-ONCOLOGY
K. Tamura, Fukuoka, JP
- 13:15 - 13:15 1423P - Loneliness and cognitive dysfunction in elderly cancer patients
A. Alkan¹, H. Selvi Öztoran², E. Karci², G. Tuncay², A. Yaşar², E. Çınar², Y. Ürün², S. Aras², M. Varlı², F. Çay Şenler²; ¹Osmaniye, TR, ²Ankara, TR
- 13:15 - 13:15 1424P - The study of emotional distress in oncology patients

K. Kondrateva, C. Valentina, T. Semiglazova, M. Vagaitseva, A. Karitskiy, E. Pestereva, A. Belyaev;
Saint-Petersburg, RU

- 13:15 - 13:15 1425P - Risk of mood disorders in long-term cancer survivors: A population-based cohort study
W.-K. Huang, Taoyuan, TW
- 13:15 - 13:15 1426P - What oncologists should know about the screening of psychological distress: One example of pilot study in Ancona
M. Romeo, R. Giampieri, L. Burattini, M. Di Pietro Paolo, A. Bittoni, S. Rinaldi, M. Torniai, R. Berardi;
Ancona, IT
- 13:15 - 13:15 1427P - Biopsychosocial factors underlying older patients treated for an incurable cancer in a two-tiered health care system in Brazil
C. Bergerot¹, K. Ashing², E. Philip³, P. Bergerot¹, N. Dizman², S. Pal², W. Dale²; ¹Duarte, US, ²Duarte, CA/US, ³Notre Dame, IL/US
- 13:15 - 13:15 1428P - Family-associated factors influence the postoperative prognosis in patients with non-small cell lung cancer
S. Takamori¹, G. Toyokawa², H. Ueo³, F. Kinoshita³, Y. Kozuma³, T. Matsubara³, N. Haratake³, T. Akamine³, F. Hirai³, T. Tagawa³, F. Shoji³, T. Okamoto³, Y. Maehara³; ¹Fukuoka-Shi, JP, ²Fukuoka, Fukuoka/Jp, ³Fukuoka, JP
- 13:15 - 13:15 1429P - (Withdrawn)
- 13:15 - 13:15 1430P - Sexual functioning and quality of life in Egyptian premenopausal patients receiving treatment for breast cancer
H. Elghazaly, M. Kelany, O. Abdel-Rahman, N. Naguib, S. Alsirafy; Cairo, EG
- 13:15 - 13:15 1431P - Primary results of a study to evaluate a decision aid for women offered neoadjuvant systemic therapy for breast cancer
N. Zdenkowski¹, P. Butow², A. Spillane², C. Douglas¹, C. Beckmore¹, M. Jones¹, F. Boyle²; ¹Newcastle, AU, ²Sydney, AU
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 1433P - Burnout syndrome: What impact on clinical research?
C. Cagnazzo¹, S. Campora², S. Pironi³, A. Guarrera⁴, A. Nuzzo⁵, G. Gentili⁶, C. Taverniti⁷, M. Manuela⁶, R. Filippi⁸; ¹Candiolo, (TO)/IT, ²Milan, IT, ³Sassuolo, IT, ⁴Firenze, IT, ⁵Candiolo, IT, ⁶Meldola, IT, ⁷Torino, IT, ⁸Torino, (TO)/IT
- 13:15 - 13:15 1434TiP - Effectiveness of the HuCare Quality Improvement Strategy on health-related quality of life in patients with cancer: Study protocol of a stepped wedge cluster randomized controlled trial (HuCare2 study)
R. Passalacqua¹, C. Caminiti², E. Iezzi²; ¹Cremona, (CR)/IT, ²Parma, IT
- 13:15 - 13:15 PUBLIC HEALTH
J. Martin-Moreno, Valencia, Valencia/ES

- 13:15 - 13:15 1445P - Inclusion of older patients with colorectal cancer in clinical trials: the SAGE prospective multicenter cohort study
F. Canoui-Poitrine¹, A. Lievre², F. Dayde¹, D. Lopez-Trabada-Ataz D³, I. Baumgartner¹, O. Dubreuil³, F. Brunetti¹, T. Aparicio⁴, R. Coriat⁵, K. Maley³, O. Colussi³, C. Tournigand⁶, E. Paillaud¹, S. Bastuji-Garin¹; ¹Créteil, FR, ²Rennes, FR, ³Paris, FR, ⁴Bobigny, CEDEX/FR, ⁵Paris, CEDEX 14/FR, ⁶Creteil Cedex, FR
- 13:15 - 13:15 1446P - Risk of second primary cancers and competing mortality in survivors of adult-onset cancer: changing pattern over three decades
Y. Ye, P. Otahal, K. Wills, A. Neil, A. Venn; Hobart, AU
- 13:15 - 13:15 1447P - Reporting of results of randomized trials in common cancers in the lay media
D. Ribnikar¹, H. Goldvaser², A. Ocana Fernandez³, A. Templeton⁴, B. Seruga¹, E. Amir⁵; ¹Ljubljana, SI, ²Toronto, CA, ³Albacete, ES, ⁴Basel, CH, ⁵Toronto, Ontario/CA
- 13:15 - 13:15 1448P - Effect of rural residence (RD) and distance travel to the cancer center (DTC) on neoadjuvant chemoradiation (NCRT) in localized rectal cancer
A. Suo¹, A. Talat², D. Le³, N. Iqbal², S. Kanthan², S. Ahmed³; ¹Calgary, CA/CA, ²Saskatoon, SK/CA, ³Saskatoon, CA
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 1450P - European survey of 907 people with cancer about the importance of nutrition
M. Muscaritoli¹, A. Molfino², F. Scala³, F. De Lorenzo¹, K. Christoforidi¹, I. Manneh-Vangramberen¹; ¹Brussels, BE, ²Roma, IT, ³Salerno, IT
- 13:15 - 13:15 1451P - Breast cancer specific survival (BCSS) in young women <40 years with node negative luminal breast cancer (BC) treated based on tumor gene expression
S. Shak¹, M. Roberts², D. Miller¹, A. Kurian³, V. Petkov⁴; ¹Redwood City, CA/US, ²Bethesda, US, ³Stanford, US, ⁴Bethesda, MD/US
- 13:15 - 13:15 1452P - Risk of malignant mesothelioma in Spain from environmental asbestos exposure
J.S. Torres-Roman¹, G. Lopez-Abente², J. Sanz-Anquela²; ¹Ica, PE, ²-, ES
- 13:15 - 13:15 1453P - Tobacco exposure and adverse pathological features in oral cancer: Does age impact survival?
V. Srinivasalu¹, N. Subramaniam², D. Balasubramaniam², N. Kumar³, S. Murthy², A. Susan², A. Philip², K. Thankappan², S. Iyer², P. Keechilat²; ¹Cochin, IN, ²Kochi, IN, ³Cambridge, GB
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 1455P - Initiation of systemic anti-cancer treatment in the inpatient setting in a tertiary hospital in London
J. Lam, K. Ng, T. Emms, R. Gillmore; London, GB
- 13:15 - 13:15 1456P - Young-age onset colorectal cancer: Analysis of incidence, clinical features and outcomes

F.K. Fujiki¹, M.F.B. Vicentini², A.C.B. Silva², E. Zambrano², L.G. Fonseca², M.I. Braghiroli², J. Sabbaga³, P.M. Hoff²; ¹São Paulo, BR, ²Sao Paulo, BR, ³Sao Paulo, SP/BR

- 13:15 - 13:15 1457P - Improved provision of written information on metastatic spinal cord compression to at-risk cancer patients at a tertiary referral centre
P. Mahaligam, K. Ng, A. McLaren, K. Fordham, J. King; London, GB
- 13:15 - 13:15 1458P - Impact of mastectomy on the social well-being and family dynamics of breast cancer female patients in the Gaza Strip
M. Elshami, E. Alaloul, E. Khader, I. Awad, A. Alhelu, H. Baraka, H. Abu Nemer, B. Böttcher, K. Elessi; Gaza, PS
- 13:15 - 13:15 1459P - Cancer incidence and mortality trends in Crete, Greece during the last two decades (1992-2013): Results from the cancer registry of Crete
V.-E. Chatzea¹, D. Sifaki-Pistolla¹, F. Koinis¹, E. Saloustris², L. Vamvakas², G. Pitsoulis¹, N. Tzanakis¹, D. Mavroudis¹, V. Georgoulis¹, C. Lionis¹; ¹Heraklion, GR, ²Heraklion, Crete/GR
- 13:15 - 13:15 1460P - Robotic anticancer drug compounding assist system for the preparation of injectable antineoplastic drugs
S. Masuda, H. Watanabe, T. Irida, K. Hata, A. Kumagai, C. Tanaka, N. Ozawa, K. Nakashima; Fukuoka, JP
- 13:15 - 13:15 1461P - Monitoring of contamination with cytostatics in pharmacies and hospitals in the Czech Republic
S. Kozakova, Brno, CZ
- 13:15 - 13:15 1462P - New treatments in Oncology: Clinical practice regarding the management of Adverse Events (AEs). Results from a survey conducted by the Hellenic Group of Young Oncologists (HeGYO)
M. Lontos¹, F. Koinis², G. Chatsidis², K. Kamposioras², G. Papaxoinis², M. Nikolaou², K. Tsigaridas², E. Voulgaris², E. Pantavou², G. Aravantinos³, A. Ardavanis², I. Boukovinas², E. Galani⁴, S. Angelaki⁵, G. Mountzios², Z. Saridaki², I. Varthalitis², N. Tsoukalas⁶; ¹Athens, Attiki/GR, ²Athens, GR, ³Kifisia, Attica/GR, ⁴Athens, N. Faliro/GR, ⁵Heraklion, Crete/GR, ⁶Kolonaki, GR
- 13:15 - 13:15 1463P - Oncologists' perspectives on biologic substitution
M. Reilly, A. Spiegel; Washington Dc, US
- 13:15 - 13:15 1464P - Ukrainian Association for helping patients with lymphoproliferative diseases: Patients support care program
I. Kryachok¹, O. Novosad², T. Skrypets¹, T. Kadnikova², I. Titorenko¹, O. Aleksik¹, K. Filonenko¹, A. Martynchuk¹, Y. Pastushenko², Y. Stepanishina¹, E. Kushchevy¹, K. Ulianchenko¹, M. Surkis¹, V. Jurchishina¹, E. Gingsburg¹; ¹Kiev, UA, ²Kyiv, UA
- 13:15 - 13:15 1465P_PR - Do oncology patients understand clinical trials? A nationwide study by Cancer Trials Ireland
C. Kelly¹, R. Feighery¹, J. McCaffrey¹, M. Higgins¹, M. Smith¹, S. O'Reilly², C. Murphy³, A. Horgan⁴, J. Walshe¹, R. McDermott⁵, D. O'Donnell¹, P. Morris¹, M. Keane⁶, M. Martin⁷, K. Duffy⁸, A. Mihai¹, J. Armstrong¹, E. Mulroe¹, V. Murphy¹, C. Kelly¹; ¹Dublin, IE, ²Cork, Cork/IE, ³Cork, IE, ⁴Waterford, CO/IE, ⁵Dublin, Belgard Square North/IE, ⁶Galway, IE, ⁷Sligo, IE, ⁸Letterkenny, Donegal/IE

- 13:15 - 13:15 1466P - Feasibility and barriers to optimal oncological treatment in solid organ transplant patients with de novo cancer
B. Rousseau¹, A. Jobard², C. Duvoux², C. Neuzillet³, P. Compagnon², D. Azoulay², A. de la Taille², L. Salomon², I. Cholley², M. Matignon², P. Grimbert², C. Tournigand⁴; ¹Créteil, CEDEX/FR, ²Creteil, FR, ³Clichy, FR, ⁴Creteil Cedex, FR
- 13:15 - 13:15 1467P - Generating patient reported outcome norms for an EU cancer population using real world data (FACT-G)
A. Rider¹, S. Simpson², B. Bennett³, K. Byrne², P. Hallworth², T. Desai², K. Cocks²; ¹Manchester, GB, ²Jb, GB, ³Bollington, GB
- 13:15 - 13:15 1468P - Development of a web-based application using machine learning algorithms to facilitate systematic literature reviews
H.-L. Wong¹, T. Luechtefeld², A. Prawira³, Z. Patterson⁴, J. Workman⁴, D. Day⁵, N. Chooback⁶, L. Nappi⁷, H. Samawi⁸, J.-M. Lavoie⁶, A. Spreafico⁹, A. Hansen⁹, S. Sahebjam¹⁰, L. Siu¹¹, S. Ivy¹², C. Paller², D. Renouf⁶; ¹Parkville, AU/AU, ²Baltimore, US, ³Toronto, Ontario/CA, ⁴Washington Dc, US, ⁵Toronto, CA, ⁶Vancouver, CA, ⁷Vancouver, BC/CA, ⁸Calgary, CA, ⁹Toronto, ON/CA, ¹⁰Tampa, FL/US, ¹¹Toronto, On, CA, ¹²Bethesda, US
- 13:15 - 13:15 1469P - Survival patterns for different types of cancers in the United States (1973-2012)
M. Gouda, Shebin El Kom, Menoufia Governorate/EG
- 13:15 - 13:15 1470P - Decisions and supports around clinical trial participation: A national study by Cancer Trials Ireland
C. Kelly¹, R. Feighery¹, J. McCaffrey¹, M. Higgins¹, M. Smith¹, S. O'Reilly², A. Horgan³, J. Walshe¹, R. McDermott⁴, D. O'Donnell¹, P. Morris¹, M. Keane⁵, M. Martin⁶, C. Murphy⁷, K. Duffy⁸, A. Mihai¹, J. Armstrong¹, E. Mulroe¹, V. Murphy¹, C. Kelly¹; ¹Dublin, IE, ²Cork, Cork/IE, ³Waterford, CO/IE, ⁴Dublin, Belgard Square North/IE, ⁵Galway, IE, ⁶Sligo, IE, ⁷Cork, IE, ⁸Letterkenny, Donegal/IE
- 13:15 - 13:15 1471P - Academic clinical research: Enough players to get out there?
C. Cagnazzo¹, S. Campora², S. Pironi³, G. Gentili⁴, A. Guarrera⁵, C. Taverniti⁶, M. Manuela⁴; ¹Candiolo, (TO)/IT, ²Milan, IT, ³Sassuolo, IT, ⁴Meldola, IT, ⁵Firenze, IT, ⁶Torino, IT
- 13:15 - 13:15 1472P_PR - Change of patient perceptions of chemotherapy side effects in breast and ovarian cancer patients
B. Ataseven, J. Frindte, P. Harter, G. Göke, J. Holtschmidt, C. Vogt, A. Traut, B. Vincenzo, M. Vincent, H. Florian, S. Kuemmel, S. Prader, M. Sporkmann, S. Schneider, A. du Bois; Essen, DE
- 13:15 - 13:15 SUPPORTIVE CARE
F. Scotté, Paris, FR
- 13:15 - 13:15 1550P - Primary prevention of nausea and vomiting induced by moderately emetogenic chemotherapies: findings from the French CONVINCENCE-ME survey
F. Scotté¹, R. Chevrier², H. Bertucat²; ¹Paris, FR, ²Clermont-Ferrand, FR

- 13:15 - 13:15 1551P - Risk factors of chemotherapy-induced nausea and vomiting during cisplatin regimen in antiemetic triplet regimen including palonosetron or granisetron: TRIPLE study (phase III)
K. SUZUKI¹, D. Tsuji², K. Ito², Y. Kawasaki³, T. Yamanaka⁴, H. Hashimoto¹, K. Goto⁵, R. Matsui⁶, N. Seki¹, T. Hama¹, N. Yamamoto⁷; ¹Tokyo, JP, ²Shizuoka, JP, ³Kyoto, JP, ⁴Yokohama, JP, ⁵Kashiwa, JP, ⁶Kashiwa, Chiba/JP, ⁷Wakayama, JP
- 13:15 - 13:15 1552P - Evaluation of Antiemetic Practices for Prevention of Chemotherapy-induced Nausea and Vomiting (CINV): Results of a European Oncology Nurse Survey
P. DIELENSEGER¹, S. Borjeson², C. Vidall³, A. Young⁴, P. Jahn⁵; ¹Villejuif, FR, ²Linköping, SE, ³Northampton, GB, ⁴Coventry, GB, ⁵Halle, DE
- 13:15 - 13:15 1553P - A pooled analysis evaluating the combination antiemetic therapy on chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk
M. Shimokawa¹, T. Kogawa², J. Nishimura³, T. Satoh⁴, K. Nakata⁵, T. Hayashi¹, R. Matsui⁶, K. Aiba⁷, K. Tamura¹; ¹Fukuoka, JP, ²Kashiwa, JP, ³Suita, JP, ⁴Suita, Osaka/JP, ⁵Sakai, JP, ⁶Kashiwa, Chiba/JP, ⁷Tokyo, JP
- 13:15 - 13:15 1554P - Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis
M. Di Maio¹, C. Baratelli², P. Bironzo³, F. Vignani², E. Bria⁴, E. Sperti⁵, M. Marcato², F. Roila⁶; ¹Napoli, IT, ²Turin, IT, ³Orbassano, TO/IT, ⁴Verona, IT, ⁵Torino, IT, ⁶Terni, IT
- 13:15 - 13:15 1555P - Pharmacokinetic (PK) study of a single oral dose of NEPA in Chinese healthy volunteers (HVs)
R. Chen¹, S. Chessari², C. Lanzarotti³, A. Bernareggi³, P. Hu¹; ¹Beijing, CN, ²Pazzallo, CH, ³Lugano, CH
- 13:15 - 13:15 1556P - Iron deficiency anaemia in oncology: an epidemiological prospective study
J. BARRIERE¹, J.-M. Ferrero², B. Hoch³, R. Largillier³, C. Hebert⁴, D. Borchiellini², P. Follana², V. Mari⁴, L. Evesque², E. Saada-Bouزيد⁴, R. Schiappa⁴, V. Raimondi⁴, E. Chamorey⁴, J. Viotti⁴; ¹Cagnes-Sur-mer, FR, ²Nice, CEDEX 2/FR, ³Mougins, FR, ⁴Nice, FR
- 13:15 - 13:15 1557P - Nutritional risk as a predictor of short-term outcomes in a prospective cohort of elderly patients with cancer
L. Sales¹, J. Oliveira Lima², A. Bergmann³, M.J. Mello¹, M. Rebello¹, Z. Cavalcanti¹, D. Sales¹, N. Cruz¹, L.C. Thuler³; ¹Recife, BR, ²Recife, PE/BR, ³Rio De Janeiro, BR
- 13:15 - 13:15 1558P - A patient-centered approach to the re-development of supportive care services for oncology adolescent and young adult (AYA) patients (pt(s)) across McGill University hospitals (Rossy Cancer Network-RCN)
P. Kavan¹, R. Fox², G. Raskovic², I. Barrera¹, W. Sateren², G. Batist¹, M. Palumbo², T. Muanza², N. Johnson², A. Mamo¹, T. Alcindor², R. Turcotte², A. Meguerditchian²; ¹Montreal, QC/CA, ²Montreal, CA
- 13:15 - 13:15 1559P - Multidimensional telemonitoring of cancer patients (pts) receiving chronomodulated (chrono) Irinotecan (I), 5-fluorouracil (F), leucovorin (L) and oxaliplatin (O; chronofLO4) combination at home

P. Innominato¹, S. Komarzynski², M. Bouchahda³, A. Ulusakarya³, M. Haydar³, A. Karaboué⁴, F. Levi²;
¹Villejuif, CEDEX/FR, ²Coventry, GB, ³Villejuif, FR, ⁴Vitry-Sur-seine, FR

13:15 - 13:15

1560P - A pilot study to evaluate the feasibility, usability, and perceived satisfaction with eCO (eCediranib-Olaparib), a mobile application for side effect monitoring and reporting, in women with recurrent ovarian cancer

J. Liu¹, C. Whalen¹, S. Morrissey¹, E. Komatsu¹, J.-M. Lee², N. Houston², R. Wenham³, D. O'Malley⁴, E. Strock⁵, R. Phillips⁶, K. Mari⁷, S. Ivy², B. Killam⁸; ¹Boston, MA/US, ²Bethesda, US, ³Tampa, US, ⁴Columbus, OH/US, ⁵Boston, US, ⁶Cambridge, US, ⁷Lyon, FR, ⁸Ashburn, US

13:15 - 13:15

1561P - Study of the satisfaction level of an education program for cancer patients

Y. Kim¹, H.Y. Lee¹, B.G. Seo¹, Y.H. Choi², K.A. Kwon¹, E.J. Son¹; ¹Busan, KR, ²Seoul, KR

13:15 - 13:15

1562P - Factors influencing the use of thromboprophylaxis in cancer outpatients: CAT AXIS, a case-vignette study on clinical practice

F. Scotté¹, I. Elalamy¹, D. Mayeur², G. Meyer¹; ¹Paris, FR, ²Le Chesnay, FR

13:15 - 13:15

1563P - Literature review of TPOR agonists for CIT

G. Soff¹, I. Ray-Coquard², L.J. Marfil-Rivera³, J. Fryzek⁴, M. Mullins⁴, L. Bylsma⁴, J. Park⁵; ¹New York, US, ²Lyon, CEDEX/FR, ³Nuevo León, MX, ⁴Ann Arbor, US, ⁵Thousand Oaks, US

13:15 - 13:15

1564P - Random optimization interactive system based on Kernel learning (RISK) for venous thromboembolism risk assessment in chemotherapy-treated cancer patients

P. Ferroni¹, F. Zanzotto², N. Scarpato², S. Riondino², F. Guadagni², M. Roselli¹; ¹Roma, IT, ²Rome, IT

13:15 - 13:15

1565P - Association between systemic inflammation and symptoms in advanced cancer patients

D. Viñal Lozano, A. Alonso-Babarro, Y. Vilches-Aguirre, L. Diez-Porres, M. Varela-Cerdeira, J. Villamayor Sanchez, L. Gutierrez Sainz, R. Madero-Jarabo; Madrid, ES

13:15 - 13:15

1566P - Outcomes of patients with malignancy admitted to the intensive care units (ICU): A prospective study

H. Assi, V. Nohra, F. Sukhon, N. Moukalled, I. Bou Akl, D. Mukherji, M. Charafeddine, N. Abdul Halim, C. El Mouhayyar, Y. Medlej, P. Bou Khalil; Beirut, LB

13:15 - 13:15

(Withdrawn)

13:15 - 13:15

1568P - Management of thrombosis in cancer patients in Greece

N. Tsoukalas¹, E. Bournakis², A. Adamidis², C. Andreadis², K. Arvaniti², A. Christopoulou², S. Douna², J.D. Moreno², G. Goumas², L. Kostadima², P. Makaronis², T. Makatsoris², D. Doufexis², G. Papatsimpas², I. Sgouros², E. Stergiou², P. Thalassinou², I. Boukovinas², P. Papakotoulas², I. Varthalitis²; ¹Kolonaki, GR, ²Athens, GR

13:15 - 13:15

1569P - Incidence and outcome of Incidental Pulmonary Embolism (IPE) in oncology patients with current macroscopic disease

M.M.M. Moe, London, Greater London/GB

- 13:15 - 13:15 1570P - Immune related adverse events associated with ipilimumab and nivolumab
B. Rapoport, R. Van Eeden, T. Smit; Johannesburg, ZA
- 13:15 - 13:15 1571P - Febrile Neutropenia: a systematic review of the first 5 years of a cancer unit
J. Pinto¹, I. Leão², F. Branco¹, J. Godinho¹, P. Simões³, F. Lopes¹, A. Escária³, F. Costa³, I. Galvão³,
J. Passos-Coelho⁴; ¹Loures, Lisboa/PT, ²V. N. Gaia, PT, ³Loures, PT, ⁴Lisbon, PT
- 13:15 - 13:15 1572P - G-CSF and G-CSF biosimilars: a meta-analysis of randomized clinical trials in breast cancer patients
E. Botteri¹, A. Krendyukov², G. Curigliano³; ¹Oslo, NO, ²Holzkirchen, DE, ³Milan, IT
- 13:15 - 13:15 1573P - Pharmacokinetic and pharmacodynamic comparability of B12019: A proposed pegfilgrastim biosimilar
K. Roth, H. Wessels, J. Hoefler, R. Jankowsky; Munich, DE
- 13:15 - 13:15 1574P - Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind, phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin
K. Horvat-Karajz¹, D. Grecea², M. Smakal³, A. Illes¹, Z. Kahan⁴; ¹Budapest, HU, ²Cluj-Napoca, RO, ³Horovice, CZ, ⁴Szeged, HU
- 13:15 - 13:15 1575P - Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer
T. Dorff¹, M. Gross¹, D. Quinn¹, J. Pinski¹, T. Schroeder², S. Groshen², C. Dieli-Conwright², J. Kiwata²;
¹Los Angeles, CA/US, ²Los Angeles, US
- 13:15 - 13:15 1576P - Body mass index (BMI), lifestyle behaviors, and perceptions in cancer survivors
L. Eng¹, S. Su², D. Pringle², M. Mahler², C. Niu², H. Naik³, R. Mohan², K. Tiessen², H. Hon², C. Brown⁴,
J. Jones⁴, D. Howell², P. Selby⁴, S. Alibhai⁴, W. Xu⁴, G. Liu¹; ¹Toronto, Ontario/CA, ²Toronto, ON/CA, ³Vancouver, CA, ⁴Toronto, CA
- 13:15 - 13:15 1577P - Barriers to improving awareness of the importance on exercise and dietary intervention, impact of it on lung cancer survivors' behavior
J.-A. Sim, Y.H. Yun, S.H. Yoo; Seoul, KR
- 13:15 - 13:15 1578P - Current perspectives of healthcare providers on weight loss and supportive nutritional care in cancer patients
F. Strasser¹, J. Arends², A. Laviano³, N. Georgiou⁴, R. Audisio⁵, M. Sawyer⁶, S. Kaasa⁷; ¹St. Gallen, CH, ²Freiburg, DE, ³Rome, IT, ⁴Schiphol Airport, NL, ⁵St. Helens, GB, ⁶Edmonton, CA, ⁷Oslo, NO
- 13:15 - 13:15 1579P - A survey of patient acceptance of skin toxicities from cetuximab-based therapy
B. Tischer¹, M. Bilang¹, P. Ronga², M. Lacouture³; ¹Munich, DE, ²Maisons-Alfort, FR, ³New York, NY/US
- 13:15 - 13:15 1580P - Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): A possible drug interaction?

M. Abu Amna, G. Bar-Sela; Haifa, IL

- 13:15 - 13:15 The potential protective effect of exogenous antioxidant “L-Carnosine” on Oxaliplatin- Induced Peripheral Neuropathy in colorectal cancer patients; A perspective on targeting Nrf 2 and NF-κB pathway.
R. Yehia, N. Sarhan, M. Schaalán, A. Shafik, S. Saleh, H. Elabhar; Cairo, EG
- 13:15 - 13:15 1582P - NeuroCog-FX study: A multicenter cohort study on cognitive dysfunction in patients with early breast cancer
O. Rick¹, M. Reuß-Borst², T. Dauelsberg³, H. Hass⁴, V. König⁵, R. Caspari⁶, G. Götz-Keil⁷, J. Pfitzner⁸, C. Kerschgens⁹, K. Fliessbach¹⁰, C. Hoppe¹⁰; ¹Bad Wildungen, DE, ²Bad Kissingen, DE, ³Nordrach, DE, ⁴Scheidegg, DE, ⁵Bad Oeynhausen, DE, ⁶Cham, DE, ⁷Bad Nauheim, DE, ⁸Graal Müritz, DE, ⁹Berlin, DE, ¹⁰Bonn, DE
- 13:15 - 13:15 1583P - Autonomic neuropathy in geriatric patients with gynecologic cancer receiving taxanes and platinum chemotherapy
G.S. Bhattacharyya¹, G. Babu², P. Parikh³, A. Vora⁴, G. Biswas⁵, H. Malhotra⁶; ¹Kolkata, West Bengal/IN, ²Bangalore, IN, ³Mumbai, IN, ⁴New Delhi, IN, ⁵Bhubaneshwar, IN, ⁶Jaipur, Rajasthan/IN
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 1586P - Potential drug interactions in older patients with cancer: Updated data from the ELCAPA cohort survey
G. Beinse¹, D. Reitter², L. Segaux², M. Carvalho-Verlinde², C. Tournigand³, B. Rousseau⁴, T. Cudennec⁵, E. Paillaud², F. Canouï-Poitaine², P. Caillet²; ¹Créteil, FR/FR, ²Créteil, FR, ³Créteil Cedex, FR, ⁴Créteil, CEDEX/FR, ⁵Boulogne-Billancourt, FR
- 13:15 - 13:15 1587P - How do Spanish medical oncologists manage breakthrough pain? A national study
E. Aranda¹, C. Camps Herrero², P. Khosravi³, M. Feyjoo⁴, A. Anton Torres⁵, P. Gascon⁶, J. Garcia Foncillas⁴, E. Diaz Rubio⁴, V. Guillem Porta², A. Carrato⁴, M. Constenla Figueiras⁷, J.J. Cruz Hernandez⁸, R. López⁹; ¹Cordoba, ES, ²Valencia, ES, ³Torrejón De Ardoz, ES, ⁴Madrid, ES, ⁵Zaragoza, ES, ⁶Barcelona, ES, ⁷Pontevedra, ES, ⁸Salamanca, ES, ⁹Santiago De Compostela, ES
- 13:15 - 13:15 1588P - Enhanced supportive care in early phase clinical trials
N. Cook, L. Carter, S. Aruketty, C. O'Brien, F. Thistlethwaite, E. Dean, M. Krebs, M. Warren, R. Berman; Manchester, GB
- 13:15 - 13:15 1589P - Cancer patient interest and perceptions of lifestyle behavior programs
L. Eng¹, S. Liu², Q. Zhang², D. Farzanfar², S. Yeung², C. Brown², W. Xu², D. Howell³, D. Goldstein², J. Jones², P. Selby², M. Giuliani², G. Liu¹; ¹Toronto, Ontario/CA, ²Toronto, CA, ³Toronto, ON/CA
- 13:15 - 13:15 1590P - The investigate relationship between severe neutropenia and ABCB1 and ABCG2 gene polymorphisms with esophageal cancer patients receiving docetaxel, cisplatin and 5-fluorouracil chemotherapy

H. Nomura¹, D. Tsuji², K. Demachi³, S. Suzuki³, N. Mochizuki³, T. Yano³, H. Daiko⁴, S. Fujii³, T. Kojima³, K. Ito², M. Yamaguchi³; ¹Kashiwa, Chiba/JP, ²Shizuoka, JP, ³Kashiwa, JP, ⁴Chu-O, JP

- 13:15 - 13:15 1591P - Hepatitis B and C reactivation rates due to cytotoxic chemotherapy in patients with solid tumors
M. Karaca¹, D. Tural², I. Cil², G. Ozet¹, O.K. Yucel³, A. Ozet¹; ¹Ankara, TR, ²Istanbul, TR, ³Antalya, TR
- 13:15 - 13:15 1592P - Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
D. Arnold¹, C. Fuchs², J. Taberero³, A. Ohtsu⁴, A. Zhu⁵, E. Garon⁶, L. Paz-Ares⁷, A. Baron⁸, T. Okusaka⁹, T. Yoshino⁴, H. Yoon¹⁰, M. Das¹¹, D. Ferry¹², Y. Zhang¹², Y. Lin¹¹, P. Binder¹², A. Sashegyi¹³, I. Chau¹⁴; ¹Lisbon, PT, ²New Haven, CT/US, ³Barcelona, ES, ⁴Kashiwa, Chiba/JP, ⁵Boston, US, ⁶Santa Monica, US, ⁷Madrid, ES, ⁸San Francisco, CA/US, ⁹Tokyo, JP, ¹⁰Rochester, MN/US, ¹¹Indianapolis, US, ¹²Bridgewater, NJ/US, ¹³Indianapolis, IN/US, ¹⁴Sutton, Surrey/GB
- 13:15 - 13:15 1593P - The preventive role of intravenous L-alanyl L-glutamine in reducing the incidence of oral mucositis in head and neck cancer patients receiving radiotherapy with or without chemotherapy
A. Elfeky, N. Sabry, A. Barakat; Tanta, EG
- 13:15 - 13:15 1594P - Biosimilar epoetin alfa (HX575) for the treatment of chemotherapy-induced anaemia: Development, approval and 10 years' clinical experience
M. Apro¹, A. Krendyukov², N. Höbel², A. Seidl³, P. Gascón⁴; ¹Genolier, CH, ²Holzkirchen, DE, ³Overhaching, DE, ⁴Barcelona, ES
- 13:15 - 13:15 1595P - Experience with the implant of vascular access devices by medical oncologist in a non-surgical scenery
A. Revuelta¹, D. Rodríguez Rubí¹, M.L. Sánchez Lorenzo², L. Ruiz Echeverría³, W. Li¹, M.P. Solís Hernández¹, L. Fález García¹, S. Fernández Arrojo¹, C. Iglesias Gómez¹, N. Villanueva Palicio¹, P. Jimenez Fonseca¹, M. Luque Cabal¹, C. Álvarez Fernández¹, M. Izquierdo⁴, J.M. Viéitez¹, E. Esteban¹; ¹Oviedo, ES, ²Madrid, ES, ³Burgos, ES, ⁴Gijón, ES
- 13:15 - 13:15 1596P - Management of chemotherapy-related side effects- do patients know where to get help?
R. Prince¹, E. Amir², S. Blacker¹, S. McEwen¹, M. Morey-Hollis¹, C. Mothersill¹, U. Saha¹, L. Wayment¹, M. Wyatt¹; ¹Toronto, CA, ²Toronto, Ontario/CA
- 13:15 - 13:15 1597P - The effects of nurses' empathy skills on attitudes towards patients with cancer
A. Alkan, Osmaniye, TR
- 13:15 - 13:15 1598P - Can postponement of death be used in shared decision making in patients treated with adjuvant chemotherapy?
N. Trabjerg, T. Hansen, K. Steffensen, A. Jakobsen, L.H. Jensen; Vejle, DK
- 13:15 - 13:15 1599P - Cancer patient attitudes and preferences towards smoking status assessment

L. Eng¹, S. Liu², Q. Zhang², D. Farzanfar², R. Milne², S. Yeung², C. Brown², D. Howell³, W. Xu², D. Goldstein², J. Jones², P. Selby², M. Giuliani², G. Liu¹; ¹Toronto, Ontario/CA, ²Toronto, CA, ³Toronto, ON/CA

- 13:15 - 13:15 1600P - Optimizing Physician Surveys in Pharmacovigilance Using ecancer Online Community
J.-J. Body¹, O. Nicolatou-Galitis², J. Sprafka³, A. Stepto⁴, R. Gleave⁵, C. Hartley⁴, D. Niepel⁶, A. Liede⁷; ¹Brussels, BE, ²Athens, Attica/GR, ³Thousand Oaks, CA/US, ⁴Bristol, GB, ⁵Cambridge, GB, ⁶Vienna, AT, ⁷South San Francisco, CA/US
- 13:15 - 13:15 1601P - Ideal cardiovascular health (ICVH) in patients with a recent diagnosis of colorectal cancer (CRC)
J. Ramos¹, A. Álvarez-Bustos¹, M. Soriano¹, B. Nuñez², J. Ros¹, P. Osorio¹, L. Gutierrez¹, R. Gómez¹, F. Hidalgo¹, A. Leon¹, M. Mendez¹, C. González¹, A. Sanchez², S. Martínez¹, I. Pagola¹, L. Brea¹, C. Fiuza-Luces¹, A. Lucia¹, A. Ruiz-Casado¹; ¹Madrid, ES, ²Majadahonda, ES
- 13:15 - 13:15 1602P - Additive effect of vinca alkaloids as the risk factor for hearing impairments in the childhood cancer survivors
L.M.-J. Cha, M. Huh, J.Y. Lim, S.M. Hahn, C.J. Lyu, J.W. Han; Seoul, KR
- 13:15 - 13:15 1603P - Development and validation of chewing swallowing inventory (CSI) in head and neck cancer patients
Y.-H. Lai, Taipei, TW
- 13:15 - 13:15 1604P - The Relationship between Oral Supportive Care and Oral Complications in Cancer Patients Receiving Chemotherapy: A Retrospective Study
T. Kataoka, Kobe, JP
- 13:15 - 13:15 1605P - Safety and effectiveness of sensor-controlled scalp cooling in women receiving chemotherapy for primary breast cancer
C. Kurbacher, S. Herz, G. Kolberg, N. Kettelhoit, A.T. Kurbacher, C. Schweitzer, J. Kurbacher; Bonn, DE
- 13:15 - 13:15 1606P - Pharmacokinetics and safety of FOLFOX therapy in patients undergoing hemodialysis
T. Funakoshi¹, T. Horimatsu², A. Yamada², T. Kirishima², T. Mizukami³, Y. Harada⁴, M. Nakajima⁵, S. Nakagawa², T. Matsubara², M. Yanagita², M. Muto²; ¹Kyoto, Shizuoka/JP, ²Kyoto, JP, ³Kawasaki, JP, ⁴Saga, JP, ⁵Ibaraki, JP
- 13:15 - 13:15 1607TiP - J-FORCE study: A randomized, double-blind, placebo-controlled phase III study evaluating olanzapine (5 mg) combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based, highly emetogenic chemotherapy
H. Hashimoto¹, S. Iwasa¹, M. Abe², T. Yanai¹, S. Zenda³, T. Yamaguchi⁴, H. Kaba¹, H. Fukuda¹, H. Terakado¹, Y. Ohe¹; ¹Tokyo, JP, ²Shizuoka, JP, ³Chiba, JP, ⁴Sendai, JP
- 13:15 - 13:15 1608TiP - Health related quality of life (HRQOL) assessment for patients with advanced renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitor (TKI) using electronic patient reported outcome (PRO) in daily clinical practice

G. Mouillet¹, A. Pozet², J. Fritsch², I. Es-Saad², S. Paget-Bailly², A. Foubert², D. Berthod², A. Anota¹, F. Bonnetain¹, A. Thiery-Vuillemin¹; ¹Besançon, CEDEX/FR, ²Besançon, FR

- 13:15 - 13:15 1609TiP - Impact of a cancer care coordination program based on health information technologies for patients treated by oral anticancer therapy: The CAPRI randomized trial
M. Ferrua¹, M. Di Palma¹, F. Lemare¹, A. Fourcade¹, B. Lalloue¹, F. Dumas - Yatim², M. Guillet - Lacaze¹, E. Minvielle¹; ¹Villejuif, FR, ²Rennes, FR
- 13:15 - 13:15 1610TiP - Oncological Home-Hospitalization: Prospective randomized trial to evaluate its implications for patient and society
L. Cool¹, J. Missiaen¹, P. Debruyne¹, K. Geldhof¹, T. Lefebvre¹, M. Desmedt², V. Foulon³, H. Pottel¹, D. Vandijck⁴, K. Van Eygen¹; ¹Kortrijk, BE, ²Hasselt, BE, ³Leuven, BE, ⁴Gent, BE
- 13:15 - 13:15 1611TiP - A novel multimodal treatment strategy for cancer cachexia; rationale and motivation for the MENAC (Multimodal – Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial
S. Kaasa¹, B. Laird², T. Balstad³, G. Stene³, V. Baracos⁴, A. Bye¹, F. Strasser⁵, M. Fallon², K. Fearon²; ¹Oslo, NO, ²Edinburgh, GB, ³Trondheim, NO, ⁴Alberta, CA, ⁵St. Gallen, CH
- 13:15 - 13:15 1612TiP - Multicenter prospective cohort study to evaluate of eye disorder induced by chemotherapy including S-1 (EyeDropS study/HGCSG1604)
M. Yagisawa¹, M. Nakamura¹, T. Muranaka², Y. Kawamoto², H. Nakatsumi², S. Yuki², T. Sasaki², T. Meguro¹, M. Dazai², A. Ishiguro¹, K. Eto³, K. Harada⁴, Y. Kobayashi⁵, T. Miyagishima⁴, I. Iwanaga⁶, M. Uebayashi⁷, K. Hatanaka⁸, N. Sakamoto¹, Y. Sakata⁹, Y. Komatsu²; ¹Sapporo, JP, ²Sapporo, Hokkaido/JP, ³Tomakomai, JP, ⁴Kushiro, JP, ⁵Kushiro, Hokkaido/JP, ⁶Kitami, Hokkaido Prefecture/JP, ⁷Kitami, JP, ⁸Hakodate, Hokkaido/JP, ⁹Misawa, Aomori/JP
- 13:15 - 13:15 1613TiP - Outpatient monitoring with an eTool: self managed or with pro active intervention?
S. Rauh¹, L. Hoehstenbach², C. Schmitz³, A. Hagemann⁴, I. Denine³; ¹Esch Sur Alzette, LU, ²Maastricht, NL, ³Esch, LU, ⁴Sittard, NL
- 13:15 - 13:15 1614TiP - A Phase I safety study of topical Calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA)
B. Berman¹, J. Konner², V. Belum³, H. Dion⁴, K. Ciccolini³, S. Kitts³, R. Ye⁴, S. Ravipaty⁴, V. Akmaev⁴, R. Sarangarajan⁴, J. Jimenez¹, N. Narain⁵, S. Goldfarb³, M. Lacouture³; ¹Miami, FL/US, ²New York, US, ³New York, NY/US, ⁴Framingham, MA/US, ⁵Natick, MA/US

14:15 - 17:15	Type: Young Oncologist Masterclass Title: Young oncologists and excellence in clinical research: ESMO YOC meets Methods in Clinical Cancer Research Workshop – MCCR Chair(s): M. Preusser, AT; L. De Mattos-Arruda, ES	Cartagena Auditorium
14:15 - 14:40	Understanding the design of clinical trials: Where to start? <u>J. de Bono</u> , London, GB	
14:40 - 14:40	Session Shooter <u>J. Corral</u> , Seville, ES	
14:40 - 14:55	Discussion	
14:55 - 15:20	Incorporation of immuno-biomarkers and immunotherapy in clinical trials <u>I. Melero</u> , Pamplona, ES	
15:20 - 15:20	Session Shooter <u>T. Amaral</u> , Lisbon, PT	
15:20 - 15:35	Discussion	
15:35 - 15:55	Break	
15:55 - 16:20	Incorporation of genomics in clinical trials <u>F. André</u> , Villejuif, CEDEX/FR	
16:20 - 16:20	Session Shooter <u>L. Poulsen</u> , Aalborg, US	
16:20 - 16:35	Discussion	
16:35 - 17:00	Perspectives in clinical trials for the next decade <u>S. Sleijfer</u> , Rotterdam, NL	
17:00 - 17:00	Session Shooter <u>A. Tyulyandina</u> , Moscow, RU	
17:00 - 17:15	Discussion	

14:30 - 16:30	Type: ESMO Clinical Practice Guidelines session Title: ESMO Clinical Practice Guidelines 2 Chair(s): C. Sessa, CH; G. Pentheroudakis, GR	Granada Auditorium
14:30 - 14:40	Introduction to the ESMO Clinical Practice Guidelines <u>G. Pentheroudakis</u> , Ioannina, GR	
14:40 - 14:50	Questionnaire <u>C. Sessa</u> , Bellinzona, CH	
14:50 - 15:00	Patient with metastatic breast cancer: Sequence of therapies case presentation <u>C. Criscitiello</u> , Milan, IT	
15:00 - 15:10	Discussant <u>N. Harbeck</u> , Munich, DE	
15:10 - 15:15	Q&A	
15:15 - 15:25	BRCA mutation carrier patient: How to manage? Case presentation <u>K. Sosinska-Mielcarek</u> , Gdansk, PL	
15:25 - 15:35	Discussant <u>S. Paluch-Shimon</u> , Ramat Gan, IL	
15:35 - 15:40	Q&A	
15:40 - 15:50	Hodgkin lymphoma case presentation <u>J. Longley</u> , Southampton, GB	
15:50 - 16:00	Discussant <u>S. Luminari</u> , Modena, IT	
16:00 - 16:05	Q&A	
16:05 - 16:15	Immunotherapy in melanoma, pseudoprogression, management of toxicities case presentation <u>E. Romano</u> , Paris, CEDEX 5/FR	
16:15 - 16:25	Discussant <u>U. Keilholz</u> , Berlin, DE	
16:25 - 16:30	Q&A	

14:45 - 16:15	Type: Special Symposium Title: Immunotherapy and targeted therapies in gynaecological malignancies Chair(s): <u>S. Banerjee</u> , GB; <u>J. Jonkers</u> , NL	Barcelona Auditorium
14:45 - 14:50	Introduction <u>S. Banerjee</u> , London, GB	
14:50 - 15:10	Immunology of gynaecological tumours <u>G. Coukos</u> , Epalinges, CH	
15:10 - 15:30	Immunotherapy in gynaecological malignancies <u>E. Pujade-Lauraine</u> , Paris, FR	
15:30 - 15:50	Clinical implications of HRD beyond BRCA <u>J. Jonkers</u> , Amsterdam, NL	
15:50 - 16:10	How to integrate PARP inhibitors into clinical practice <u>S. Banerjee</u> , London, GB	
16:10 - 16:15	Conclusions and clinical perspectives <u>J. Jonkers</u> , Amsterdam, NL	
14:45 - 16:15	Type: Poster Discussion session Title: Genitourinary tumours, non-prostate Chair(s): <u>P. Grivas</u> , US; <u>M. De Santis</u> , GB; <u>C. Porta</u> , IT	Cordoba Auditorium
14:45 - 14:45	848PD - Impact of tumor mutational burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study <u>M. Galsky</u> ¹ , <u>A. Saci</u> ² , <u>P. Szabo</u> ² , <u>A. Azrilevich</u> ² , <u>C. Horak</u> ³ , <u>A. Lambert</u> ⁴ , <u>A. Siefker-Radtke</u> ⁵ , <u>A. Necchi</u> ⁶ , <u>P. Sharma</u> ⁵ ; ¹ New York, US, ² Princeton, US, ³ Pennington, NJ/US, ⁴ Braine-L'alleud, BE, ⁵ Houston, TX/US, ⁶ Milan, IT	
14:45 - 14:45	849PD - Comparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC) <u>S. Pal</u> ¹ , <u>N. Agarwal</u> ² , <u>T. Choueiri</u> ³ , <u>P. Stephens</u> ⁴ , <u>J. Ross</u> ⁵ , <u>V. Miller</u> ⁴ , <u>S. Ali</u> ⁴ , <u>J. Chung</u> ⁴ , <u>P. Grivas</u> ⁶ ; ¹ Duarte, CA/US, ² Salt Lake City, UT/US, ³ Boston, US, ⁴ Cambridge, MA/US, ⁵ Albany, NY/US, ⁶ Cleveland, US	
14:45 - 14:45	850PD - Epithelial-mesenchymal transition (EMT), T cell infiltration, and outcomes with nivolumab (nivo) in urothelial cancer (UC) <u>M. Galsky</u> ¹ , <u>L. Wang</u> ² , <u>A. Saci</u> ³ , <u>P. Szabo</u> ³ , <u>Y. Gong</u> ² , <u>J. Zhu</u> ² ; ¹ New York, US, ² New York, NY/US, ³ Princeton, US	
14:45 - 15:05	Invited Discussant 848PD, 849PD and 850PD <u>P. Grivas</u> , Cleveland, US	

15:05 - 15:15 Q&A led by Discussant

15:15 - 15:15 851PD - Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator's choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc)

D. Petrylak¹, N. Vogelzang², Y. Fradet³, D. Bajorin⁴, R. de Wit⁵, D. Vaughn⁶, J.-L. Lee⁷, L. Fong⁸, M. Climent⁹, A. Necchi¹⁰, W. Gerritsen¹¹, H. Gurney¹², D. Quinn¹³, S. Culine¹⁴, C. Sternberg¹⁵, E. Jensen¹⁶, M. Puhlmann¹⁷, R. Perini¹⁸, J. Bellmunt¹⁹, T. Choueiri²⁰; ¹New Haven, US, ²Las Vegas, NV/US, ³Quebec City, CA, ⁴New York, US, ⁵Rotterdam, NL, ⁶Philadelphia, US, ⁷Seoul, KR, ⁸San Francisco, CA/US, ⁹Valencia, ES, ¹⁰Milan, IT, ¹¹Nijmegen, NL, ¹²Macquarie Park, NSW/AU, ¹³Los Angeles, CA/US, ¹⁴Paris, CEDEX 10/FR, ¹⁵Roma, IT, ¹⁶Kenilworth, US, ¹⁷New York, New Jersey/US, ¹⁸North Wales, US, ¹⁹Boston, MA/US, ²⁰Boston, US

15:15 - 15:15 852PD - Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study

A. Necchi¹, R. Joseph², Y. Loriot³, J. Hoffman-Censits⁴, J.L. Perez Gracia⁵, D. Petrylak⁶, Q. Zhu⁷, B. Ding⁷, C. Kaiser⁷, J. Rosenberg⁸; ¹Milan, IT, ²Jacksonville, US, ³Villejuif, FR, ⁴Philadelphia, US, ⁵Pamplona, ES, ⁶New Haven, CT/US, ⁷South San Francisco, US, ⁸New York, NY/US

15:15 - 15:15 LBA37_PR - Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial

R. de Wit¹, D. Vaughn², Y. Fradet³, J.-L. Lee⁴, L. Fong⁵, N. Vogelzang⁶, M. Climent⁷, D. Petrylak⁸, T. Choueiri⁹, A. Necchi¹⁰, W. Gerritsen¹¹, H. Gurney¹², D. Quinn¹³, S. Culine¹⁴, C. Sternberg¹⁵, Y. Mai¹⁶, M. Puhlmann¹⁷, R. Perini¹⁸, J. Bellmunt¹⁹, D. Bajorin²⁰; ¹Rotterdam, NL, ²Philadelphia, PA/US, ³Quebec City, CA, ⁴Seoul, KR, ⁵San Francisco, CA/US, ⁶Las Vegas, NV/US, ⁷Valencia, ES, ⁸New Haven, CT/US, ⁹Boston, US, ¹⁰Milan, IT, ¹¹Nijmegen, NL, ¹²Macquarie Park, NSW/AU, ¹³Los Angeles, CA/US, ¹⁴Paris, CEDEX 10/FR, ¹⁵Roma, IT, ¹⁶Kenilworth, NJ/US, ¹⁷New York, New Jersey/US, ¹⁸North Wales, US, ¹⁹Boston, Ma, US, ²⁰New York, US

15:15 - 15:35 Invited Discussant 851PD, 852PD and LBA37

M. De Santis, Coventry, GB

15:35 - 15:45 Q&A led by Discussant

15:45 - 15:45 LBA38 - Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)

T. Choueiri¹, C. Hessel², S. Halabi³, B. Sanford³, O. Hahn⁴, M. Michaelson⁵, M. Walsh⁵, T. Olencki⁶, J. Picus⁷, E. Small⁸, S. Dakhil⁹, C. Scheffold², D. George³, M. Morris¹⁰; ¹Boston, US, ²South San Francisco, CA/US, ³Durham, NC/US, ⁴Chicago, IL/US, ⁵Boston, MA/US, ⁶Columbus, OH/US, ⁷St. Louis, US, ⁸San Francisco, CA/US, ⁹Wichita, KS/US, ¹⁰New York, NY/US

- 15:45 - 15:45 LBA39 - IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)
T. Powles¹, D. McDermott², B. Rini³, R. Motzer⁴, M. Atkins⁵, L. Fong⁶, R. Joseph⁷, S. Pal⁸, A. Ravaud⁹, S. Bracarda¹⁰, C. Suarez Rodriguez¹¹, M. Maio¹², M. Gore¹, V. Grünwald¹³, M. Staehler¹⁴, J. Qiu¹⁵, A. Thobhani¹⁶, M. Huseni¹⁷, C. Schiff¹⁷, B. Escudier¹⁸; ¹London, GB, ²Boston, MA/US, ³Cleveland, OH/US, ⁴New York, NY/US, ⁵Washington Dc, US, ⁶San Francisco, CA/US, ⁷Jacksonville, US, ⁸Duarte, CA/US, ⁹Bordeaux, FR, ¹⁰Arezzo, IT, ¹¹Barcelona, ES, ¹²Siena, IT, ¹³Hannover, DE, ¹⁴Munich, DE, ¹⁵South San Francisco, CA/US, ¹⁶Welwyn Garden City, Hertfordshire/GB, ¹⁷South San Francisco, US, ¹⁸Villejuif, FR
- 15:45 - 15:45 854PD - Pazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm)
D. Bossé¹, R. McKay², K. Gray³, M. Michaelson³, C. Sleeper³, M. Walsh³, K. Krajewski³, H. Jacene³, J. Bellmunt⁴, M. Pomerantz³, L. Harshman³, T. Choueiri⁵; ¹Boston, Ontario/US, ²San Diego, US, ³Boston, MA/US, ⁴Boston, Ma, US, ⁵Boston, US
- 15:45 - 15:45 855PD - Adjuvant sunitinib (SU) in patients (pts) with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial
M. Staehler¹, R. Motzer², D. George³, H. Pandha⁴, F. Donskov⁵, B. Escudier⁶, J. Kliment⁷, A. Pantuck⁸, A. Patel⁹, L. Deannuntis¹⁰, H. Bhattacharyya², X. Lin¹¹, M. Lechuga¹², L. Serfass¹³, J.-J. Patard¹⁴, A. Ravaud¹⁵; ¹Munich, DE, ²New York, NY/US, ³Durham, NC/US, ⁴Surry, GB, ⁵Aarhus, DK, ⁶Villejuif, FR, ⁷Martin, SK, ⁸Los Angeles, CA/US, ⁹London, GB, ¹⁰Collegeville, PA/US, ¹¹La Jolla, CA/US, ¹²Milan, IT, ¹³Paris, FR, ¹⁴Mont-De-marsan, FR, ¹⁵Bordeaux, FR
- 15:45 - 16:05 Invited Discussant LBA38, LBA39, 854PD and 855PD
C. Porta, Pavia, IT
- 16:05 - 16:15 Q&A led by Discussant

14:45 - 16:15 Type: Educational session Bilbao Auditorium
Title: State of the art in the treatment of soft tissue sarcoma: ESMO guidelines
Chair(s): R.L. Haas, NL; H. Joensuu, FI

14:45 - 15:10 Histological and molecular classification
A.P. Dei Tos, Treviso, IT

15:10 - 15:35 Local treatment and strategy
S. Bonvalot, Paris, FR

15:35 - 16:00 Systemic treatment: What the patient needs to know
J. Martin Broto, Seville, ES

16:00 - 16:15 Discussion

14:45 - 16:15 Type: Special Symposium Alicante Auditorium
Title: Recent advances in endocrine malignancies
Chair(s): J. Strosberg, US; J. Capdevila, ES

14:45 - 14:50 Introduction
J. Strosberg, Tampa, US

14:50 - 15:10 Medullary thyroid cancer
J. Capdevila, Barcelona, ES

15:10 - 15:30 Malignant pheochromocytoma and paraganglioma
J. Crona, Uppsala, SE

15:30 - 15:50 Adrenocortical tumours
A. Berruti, Brescia, IT

15:50 - 16:10 Differentiated thyroid carcinoma
B. Jarzab, Warsaw, PL

16:10 - 16:15 Conclusions and clinical perspectives
J. Capdevila, Barcelona, ES

14:45 - 16:15 Type: Special Symposium Madrid Auditorium
Title: Precision medicine for metastatic breast cancer
Chair(s): C. Sotiriou, BE; T. Bachelot, FR

14:45 - 15:05 Targeting PI3K
S. Loi, Melbourne, VIC/AU

15:05 - 15:25 The genomic landscape of metastatic breast cancer
L. Yates, Cambridge, Kent/GB

15:25 - 15:45 Clinical utility of large panel of genes
P. Cassier, La Défense, FR

15:45 - 16:05 Clinical utility of circulating DNA
N. Turner, London, GB

16:05 - 16:15 Clinical perspectives: Which genomic tests should be used in mBC?
C. Sotiriou, Brussels, BE

14:45 - 16:15 Type: Educational session Tarragona Auditorium
Title: Immunotherapy in head and neck cancer
Chair(s): A. Psyrri, GR; J. Guigay, FR

14:45 - 15:10 State of the art of immunotherapy in head and neck cancer
U. Keilholz, Berlin, DE

15:10 - 15:35 How to target immuno escape after anti PD-1
R. Ferris, US

15:35 - 16:00 Rationale to combine with classical or novel therapies
A. Psyrri, Athens, GR

16:00 - 16:15 Discussion

15:00 - 16:00 Type: Poster Discussion session Sevilla Auditorium
Title: Gastrointestinal tumours, colorectal
Chair(s): T. Gruenberger, AT; G. Folprecht, DE

15:00 - 15:00 482PD - Robot-assisted vs laparoscopic vs open abdominoperineal resections for low rectal cancer: Short-term outcomes of a single-center prospective randomized controlled trial
J. Xu, Y. Wei, L. Ren, Q. Feng, J. Chen, D. Zhu, W. Chang, T. Yi, L. Yang, X. Qin; Shanghai, CN

- 15:00 - 15:00 483PD - Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial
J. Bridgewater¹, S. Pugh², A. Whitehead², L. Stanton², Z. Eminton², J. Mellor², A. Allen², M. Finch-Jones³, S. Falk³, T. Iveson², M. Rees⁴, J. Valle⁵, J. Hornbuckle⁶, T. Hickish⁷, D. Cunningham⁸, T. Maughan⁹, J. Garden¹⁰, G. Griffiths², J. Primrose²; ¹London, GB, ²Southampton, GB, ³Bristol, GB, ⁴Basingstoke, GB, ⁵Manchester, GB, ⁶Sheffield, South Yorkshire/GB, ⁷Bournemouth, GB, ⁸Sutton, GB, ⁹Oxford, GB, ¹⁰Edinburgh, GB
- 15:00 - 15:00 LBA26 - FOXFIRE-SIRFLOX-FOXFIRE global prospective randomised studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer: KRAS mutation and tumour site analysis
H. Wasan¹, R. Sharma¹, V. Heinemann², N. Sharma³, J. Taieb⁴, J. Ricke⁵, M. Peeters⁶, M. Findlay⁷, P. Virdee⁸, S. Love⁸, J. Moschandreass⁸, P. Dutton⁸, V. GebSKI⁹, A. Gray⁸, D. Price¹⁰, G. Bower¹⁰, A. Montazeri¹¹, P. Gibbs¹², G. Van Hazel¹⁰; ¹London, GB, ²Munich, DE, ³Hershey, US, ⁴Paris, FR, ⁵Magdeburg, DE, ⁶Edegem, BE, ⁷Auckland, NZ, ⁸Oxford, GB, ⁹Sydney, AU, ¹⁰Perth, WA/AU, ¹¹Wirral, Merseyside/GB, ¹²Footscray, VIC/AU
- 15:00 - 15:20 Invited Discussant 482PD, 483PD and LBA26
T. Gruenberger, Vienna, AT
- 15:20 - 15:30 Q&A led by Discussant
- 15:30 - 15:30 481PD - Sidedness influences prognosis in stage III but not in stage II colon cancer patients receiving an adjuvant therapy: A GISCAD analysis from three randomized trials including 5234 patients
S. Cascinu¹, D. Poli², A. Zaniboni³, R. Labianca⁴, A. Sobrero⁵, V. Torri⁶; ¹Modena, IT, ²Milano, IT, ³Brescia, IT, ⁴Bergamo, IT, ⁵Genova, IT, ⁶Milan, IT
- 15:30 - 15:30 484PD - Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) + ipilimumab (IPI): CheckMate 142
T. André¹, M. Overman², S. Lonardi³, M. Aglietta⁴, R. McDermott⁵, K.Y.M. Wong⁶, M. Morse⁷, A. Hendlisz⁸, R. Moss⁹, J.-M. Ledezine¹⁰, H. Tang¹⁰, Z.A. Cao¹⁰, S. Kopetz¹¹; ¹Paris, CEDEX 12/FR, ²Houston, TX/US, ³Padova, IT, ⁴Candiolo, (TO)/IT, ⁵Dublin, Belgard Square North/IE, ⁶Sydney, AU, ⁷Durham, US, ⁸Brussels, BE, ⁹New Brunswick, NJ/US, ¹⁰Princeton, US, ¹¹Houston, US
- 15:30 - 15:30 485PD - Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine in patients with stage III colorectal cancer: Updated results of Japan Clinical Oncology Group study (JCOG0910)
T. Hamaguchi¹, Y. Shimada¹, J. Mizusawa¹, T. Sato², T. Kato³, K. Takahashi¹, K. Sugihara¹, Y. Saida¹, H. Ike⁴, K. Hase⁵, T. Masaki¹, M. Shiozawa⁶, A. Sugita⁶, J. Nishimura⁷, Y. Munakata⁸, S. Ikeda⁹, K. Nakamura¹, H. Fukuda¹; ¹Tokyo, JP, ²Yamagata, JP, ³Amagasaki, Hyogo/Jp, ⁴Yokohama, JP, ⁵Saitama, JP, ⁶Kanagawa, JP, ⁷Niigata, JP, ⁸Nagano, JP, ⁹Hiroshima, JP
- 15:30 - 15:50 Invited Discussant 481PD, 484PD and 485PD
G. Folprecht, Dresden, DE

15:50 - 16:00 Q&A led by Discussant

15:00 - 16:00 Type: Multidisciplinary Session Pamplona Auditorium
Title: Management of locally advanced gastric and oesophageal adenocarcinoma
Chair(s): F. Lordick, DE

15:00 - 15:05 Presentation of case/condition
F. Lordick, Leipzig, DE

15:05 - 15:15 The medical oncology perspective
F. Lordick, Leipzig, DE

15:15 - 15:25 The radiation therapy perspective
T. Leong, Melbourne, AU

15:25 - 15:35 The surgery perspective
M. Pera, Barcelona, ES

15:35 - 16:00 General Discussion

15:00 - 16:00 Type: Multidisciplinary Session Valencia Auditorium
Title: Treating patients with melanoma brain metastases
Chair(s): M. Guckenberger, CH

15:00 - 15:04 Intro
M. Guckenberger, Zürich, CH

15:04 - 15:14 Patient with BRAF mutation under kinase inhibitor therapy and controlled systemic disease developing 3 asymptomatic 1-2cm large brain metastases
P. Ascierto, Napoli, IT

15:14 - 15:24 Patient under treatment with immunotherapy developing one single 2.5cm large symptomatic brain metastasis
M. Guckenberger, Zürich, CH

15:24 - 15:34 Primary diagnosis of malignant melanoma with 7 symptomatic brain without other visceral metastases
R. Dummer, Zürich, CH

15:34 - 16:04 Discussion

- 16:30 - 18:00 Type: Poster Discussion session
Title: NSCLC, metastatic
Chair(s): R. Dziadziuszko, PL; J. Bar, IL
Barcelona Auditorium
- 16:30 - 16:30 1301PD - Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
E. Felip Font¹, S. Gettinger², M.A. Burgio³, S. Antonia⁴, E. Holgado⁵, D. Spigel⁶, O. Arrieta⁷, M. Domine Gomez⁵, O. Aren Frontera⁸, J. Brahmer⁹, L. Chow¹⁰, L. Crino¹¹, C. Butts¹², B. Coudert¹³, L. Horn¹⁴, M. Steins¹⁵, W. Geese¹⁶, A. Li¹⁷, D. Healey¹⁸, E. Vokes¹⁹; ¹Barcelona, ES, ²New Haven, CT/US, ³Meldola, IT, ⁴Tampa, FL/US, ⁵Madrid, ES, ⁶Nashville, TN/US, ⁷Mexico City, MX, ⁸Santiago, CL, ⁹Baltimore, Md, US, ¹⁰Seattle, WA/US, ¹¹Perugia, (PG)/IT, ¹²Edmonton, CA, ¹³Dijon, Cedex/FR, ¹⁴Nashville, US, ¹⁵Heidelberg, DE, ¹⁶Princeton, NJ/US, ¹⁷Princeton, US, ¹⁸Wallingford, GB, ¹⁹Chicago, IL/US
- 16:30 - 16:30 1302PD - IFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)
N. Girard¹, C. Audigier Valette², J. Cadranel³, I. Monnet⁴, J. Hureauux⁵, W. HILGERS⁶, E. Fauchon⁷, E. Fabre³, B. Besse⁸, P. Brun⁹, D. Coëtmeur¹⁰, E. Quoix¹¹, P. Mourlanette¹², F. Barlesi¹³, S. Bordenave-Caffre¹⁴, T. Egenod¹⁵, P. missy³, F. Morin³, D. Moro-Sibilot¹⁶, O. Molinier¹⁷; ¹Bron, FR, ²Toulon, CEDEX/FR, ³Paris, FR, ⁴Créteil, FR, ⁵Angers, CEDEX 9/FR, ⁶Avignon, FR, ⁷Saint Julien En Genevois, FR, ⁸Villejuif, FR, ⁹Valence, FR, ¹⁰Saint Brieuc, FR, ¹¹Strasbourg, CEDEX/FR, ¹²Cornebarrieu, FR, ¹³Marseille, FR, ¹⁴Nantes, FR, ¹⁵Limoges, FR, ¹⁶La Tronche, FR, ¹⁷Le Mans, FR
- 16:30 - 16:30 1303PD - Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status
S. Popat¹, A. Ardizzoni², T. Ciuleanu³, M. Cobo Dols⁴, K. Laktionov⁵, M. Szilasi⁶, R. Califano⁷, E. Carcereny Costa⁸, R. Griffiths⁹, L. Paz-Ares¹⁰, C. Szczylik¹¹, J. Corral¹², D. Isla¹³, J. Jassem¹⁴, W. Appel¹⁵, J. Van Meerbeeck¹⁶, J. Wolf¹⁷, J. Jiang¹⁸, L.R. Molife¹⁸, E. Felip Font⁸; ¹London, GB, ²Bologna, IT, ³Cluj-Napoca, RO, ⁴Malaga, ES, ⁵Moscow, RU, ⁶Debrecen, HU, ⁷Manchester, GB, ⁸Barcelona, ES, ⁹Bebington, GB, ¹⁰Madrid, ES, ¹¹Warsaw, PL, ¹²Seville, ES, ¹³Zaragoza, ES, ¹⁴Gdańsk, PL, ¹⁵Preston, GB, ¹⁶Edegem, BE, ¹⁷Köln, DE, ¹⁸Princeton, NJ/US
- 16:30 - 16:50 Invited Discussant 1301PD, 1302PD and 1303PD
R. Dziadziuszko, Gdansk, PL
- 16:50 - 17:00 Q&A led by Discussant
- 17:00 - 17:00 1304PD - Correlation of radiation pneumonitis history before nivolumab and onset risk of interstitial lung disease or progression free survival of nivolumab in patients with non-small cell lung cancer
A. Tamiya¹, M. Tamiya², K. Nakahama¹, Y. Taniguchi¹, T. Shiroyama³, S.-I. Isa¹, T. Inoue², K. Nishino², T. Kumagai², H. Suzuki⁴, T. Hirashima³, F. Imamura², S. Atagi⁵; ¹Sakai, JP, ²Osaka, JP, ³Habikino, Osaka/JP, ⁴Habikino, JP, ⁵Sakai, Osaka/JP

- 17:00 - 17:00 1305PD - Whole body PD-1 and PD-L1 PET in pts with NSCLC
A.-L. Niemeijer¹, E. Smit¹, I. Bahce¹, O. Hoekstra¹, M. Huisman¹, G.A. van Dongen¹, B. Windhorst¹, N. Hendrikse¹, A. Poot¹, D. Vugts¹, D. Leung², W. Hayes², R. Smith², L. Wilson², E. Thunnissen¹, J. De Langen¹; ¹Amsterdam, NL, ²Princeton, NJ/US
- 17:00 - 17:00 1306PD - Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)
R. Ferrara¹, C. CAMELLA², M. Texier², C. Audigier Valette³, L. Tessonier⁴, L. Mezquita², J. Lahmar², J. Mazieres⁵, G. Zalcman⁶, S. Brosseau⁷, V. Westeel⁸, S. Le Moulec⁹, L. Leroy⁹, B. Duchemann¹⁰, R. Veillon¹¹, D. Planchard², M.-E. Boucher², S. Koscielny², J.-C. Soria¹², B. Besse²; ¹Verona, IT, ²Villejuif, FR, ³Toulon, CEDEX/FR, ⁴Toulon, FR, ⁵Toulouse, FR, ⁶Paris, CEDEX 18/FR, ⁷Paris, FR, ⁸Besançon, CEDEX/FR, ⁹Bordeaux, FR, ¹⁰Bobigny, CEDEX/FR, ¹¹Pessac, FR, ¹²Villejuif, CEDEX/FR
- 17:00 - 17:00 LBA52 - Randomized double blind phase IIb trial in advanced NSCLC patients who did not progress after first line platinum based chemotherapy: Vx-001, a therapeutic cancer vaccine, vs placebo as maintenance therapy
C. Gridelli¹, T. Ciuleanu², M. Domine Gomez³, A. Szczesna⁴, I. Bover⁵, M. Cobo Dols⁶, N. Kentepozidis⁷, S. Viteri⁸, C. Manegold⁹, D. Khayat¹⁰, J.-Y. Douillard¹¹, K. Kosmatopoulos¹², V. Georgoulis¹³; ¹Avellino, IT, ²Cluj-Napoca, RO, ³Madrid, ES, ⁴Otwock, PL, ⁵Palma De Mallorca, ES, ⁶Malaga, ES, ⁷Athens, GR, ⁸Barcelona, ES, ⁹Mannheim, DE, ¹⁰Paris, CEDEX 13/FR, ¹¹Lugano - Viganello, CEDEX/CH, ¹²Paris, FR, ¹³Heraklion, GR
- 17:00 - 17:20 Invited Discussant 1304PD, 1305PD, 1306PD and LBA52
J. Bar, Ramat Gan, IL
- 17:20 - 17:30 Q&A led by Discussant
- 17:30 - 17:30 1300PD - Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine
A. Kron¹, R. Riedel¹, S. Michels², J. Fassunke¹, S. Merkelbach-Bruse¹, M. Scheffler², L. Nogova², R. Fischer², F. Ueckerth¹, D. Abdulla², F. Kron¹, B. Pauli¹, B. Kaminsky³, J. Braess⁴, U. Graeven⁵, C. Grohe⁶, S. Krueger⁷, R. Büttner¹, J. Wolf²; ¹Cologne, DE, ²Köln, DE, ³Solingen, DE, ⁴Regensburg, DE, ⁵Mönchengladbach, DE, ⁶Berlin, DE, ⁷Düsseldorf, DE
- 17:30 - 17:30 LBA53 - A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatosen (OGX-427) in advanced squamous cell lung cancers
P. Schmid¹, F. Blackhall², D. Muthukumar³, J. Lester⁴, S. Khan⁵, J. Adams⁶, M. Illsley⁷, C. Macgregor⁸, W. Owadally⁹, S.-J. Sarker¹, L. Smith¹, A. Prendergast¹, C. Ackerman¹, K. Mousa¹, L. Lim Farah¹; ¹London, GB, ²Manchester, GB, ³Colchester, GB, ⁴Wales, GB, ⁵Nottingham, GB, ⁶Reading, GB, ⁷Guildford, GB, ⁸Inverness, GB, ⁹Bristol, GB
- 17:30 - 17:30 1307PD - Detection of driver and resistance mutations in leptomeningeal metastases of NSCLC by next-generation sequencing of cerebrospinal fluid circulating tumor cells

Y.-S. Li¹, B.-Y. Jiang¹, W.-B. Guo¹, X.-C. Zhang¹, J.-J. Yang¹, Y. Shao², B. Huang¹, Y.-H. Liu¹, Y.-L. Wu¹; ¹Guangzhou, CN, ²Nanjing, CN

17:30 - 17:30 1308PD - Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small cell lung cancer (NSCLC)

B. Besse¹, A. Shaw², B. Solomon³, T. Bauer⁴, R. Chiari⁵, C.-C. Lin⁶, M. Satouchi⁷, J. Clancy⁸, L. James⁹, A. Abbattista¹⁰, E. Felip Font¹¹; ¹Villejuif, FR, ²Boston, MA/US, ³Melbourne, VIC/AU, ⁴Nashville, TN/US, ⁵Perugia, IT, ⁶Taipei, TW, ⁷Akashi, JP, ⁸Princeton, NJ/US, ⁹New York, US, ¹⁰Milan, IT, ¹¹Barcelona, ES

17:30 - 17:50 Invited Discussant 1300PD, LBA53, 1307PD and 1308PD

J. Mazieres, Toulouse, FR

17:50 - 18:00 Q&A led by Discussant

16:30 - 18:20 Type: Presidential Symposium Madrid Auditorium
 Title: Presidential Symposium II
 Chair(s): F. Ciardiello, IT; A. Cervantes, ES

16:30 - 16:45 236O_PR - MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer

A. di Leo¹, M. Toi², M. Campone³, J. Sohn⁴, S. Paluch-Shimon⁵, J. Huober⁶, I.H. Park⁷, O. Tredan⁸, S.-C. Chen⁹, L. Manso¹⁰, O. Freedman¹¹, G. Jaliffe¹², T. Forrester¹³, M. Frenzel¹⁴, S. Barriga¹⁵, I. Smith¹⁴, N. Bourayou¹⁶, M. Goetz¹⁷; ¹Prato, IT, ²Kyoto, JP, ³Saint-Herblain, CEDEX/FR, ⁴Seoul, KR, ⁵Ramat Gan, IL, ⁶Ulm, DE, ⁷Gyeonggi-Do, KR, ⁸Lyon, CEDEX/FR, ⁹Taipei, TW, ¹⁰Madrid, ES, ¹¹Oshawa, CA, ¹²Mexico City, MX, ¹³Indianapolis, IN/US, ¹⁴Indianapolis, US, ¹⁵Windlesham, GB, ¹⁶Neuilly-Sur-seine, FR, ¹⁷Rochester, US

16:45 - 17:00 Invited Discussant 236O

N. Turner, London, GB

17:00 - 17:15 928O_PR - Neoadjuvant chemotherapy followed by surgery (NACT-surgery) versus concurrent cisplatin and radiation therapy (CTRT) in patients with stage IB2 to IIB squamous carcinoma of cervix: A randomized controlled trial (RCT)

S. Gupta, P. Parab, R. Kerkar, U. Mahantshetty, A. Maheshwari, S. Sastri, R. Engineer, R. Hawaldar, J. Ghosh, S. Gulia, S. Godbole, N. Kumar, J. Malliga, R. Dalvi, Y. Kembhavi, M. Gaikar, R. Ranade, H. Tongaonkar, R. Badwe, S. Shrivastava; Mumbai, IN

17:15 - 17:30 Invited Discussant 928O_PR

D. Lorusso, Milan, IT

17:30 - 17:45 LBA4_PR - RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma

D. Petrylak¹, K. Chi², A. Drakaki³, C. Sternberg⁴, R. de Wit⁵, H. Nishiyama⁶, E. Yu⁷, D. Castellano⁸, S. Hussain⁹, I. Percent¹⁰, A. Fléchon¹¹, A. Bamias¹², M. van der Heijden¹³, N. Matsubara¹⁴, B. Alekseev¹⁵, R. Walgren¹⁶, O. Hamid¹⁶, A. Zimmermann¹⁶, K. Bell-Mcguinn¹⁶, T. Powles¹⁷; ¹New Haven, CT/US, ²Vancouver, CA, ³Los Angeles, US, ⁴Roma, IT, ⁵Rotterdam, NL, ⁶Tsukuba, JP, ⁷Seattle, US, ⁸Madrid, ES, ⁹Liverpool, GB, ¹⁰Port Charlotte, US, ¹¹Lyon, FR, ¹²Athens, GR, ¹³Amsterdam, NL, ¹⁴Kashiwa, Chiba/JP, ¹⁵Moscow, RU, ¹⁶Indianapolis, US, ¹⁷London, GB

17:45 - 17:55 Invited Discussant LBA4_PR
Y. Loriaut, Villejuif, FR

17:55 - 18:10 LBA5 - CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups

B. Escudier¹, N. Tannir², D. McDermott³, O. Frontera⁴, B. Melichar⁵, E. Plimack⁶, P. Barthelemy⁷, S. George⁸, V. Neiman⁹, C. Porta¹⁰, T. Choueiri¹¹, T. Powles¹², F. Donskov¹³, P. Salman⁴, C. Kollmannsberger¹⁴, B. Rini¹⁵, S. Mekan¹⁶, M.B. McHenry¹⁶, H. Hammers¹⁷, R. Motzer¹⁸; ¹Villejuif, FR, ²Houston, TX/US, ³Boston, MA/US, ⁴Santiago, CL, ⁵Olomouc, CZ, ⁶Philadelphia, PA/US, ⁷Strasbourg, CEDEX/FR, ⁸Buffalo, US, ⁹Petah Tikva, IL, ¹⁰Pavia, IT, ¹¹Boston, US, ¹²London, GB, ¹³Aarhus C, DK, ¹⁴Vancouver, British Columbia/CA, ¹⁵Cleveland, OH/US, ¹⁶Princeton, NJ/US, ¹⁷Dallas, MD/US, ¹⁸New York, NY/US

18:10 - 18:20 Invited Discussant LBA5
M. Schmidinger, Vienna, AT

16:30 - 18:00 Type: Educational session Sevilla Auditorium
Title: State of the art of melanoma therapy
Chair(s): D. Schadendorf, DE; R. Dummer, CH

16:30 - 16:50 Is there still a role for surgery?
A. Testori, Milan, IT

16:50 - 17:10 Adjuvant therapy: Still a role for interferon?
A.M.M. Eggermont, Villejuif, FR

17:10 - 17:30 Targeted therapy: Still a role in 1st line?
D. Schadendorf, Essen, DE

17:30 - 17:50 Immunotherapy: Still a role for ipilimumab?
O. Michielin, Lausanne, CH

17:50 - 18:00 Discussion

16:30 - 18:00	Type: Educational session Title: Complications and toxicities: Tips for daily practice Chair(s): M. Apro, CH; K. Tamura, JP	Pamplona Auditorium
16:30 - 16:50	Skin toxicities: Prevention and management <u>C. Robert</u> , Villejuif, FR	
16:50 - 17:10	Management of opioid induced nausea and vomiting <u>D. Walsh</u> , Dublin, OH/IE	
17:10 - 17:30	Bone metastases: How to evaluate the fracture risk: Surgery? Cementoplasty? Radiation? <u>H. Shibata</u> , Akita, JP	
17:30 - 17:50	Rehabilitation and nutritional support for patients with advanced cancer <u>J. Arends</u> , Freiburg, DE	
17:50 - 18:00	Discussion	

16:30 - 18:00	Type: Proffered Paper session Title: Developmental therapeutics Chair(s): J. Schellens, NL; U. Banerji, GB	Cordoba Auditorium
16:30 - 16:45	LBA17 - Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patients with advanced or metastatic solid tumors <u>N. Yamamoto</u> ¹ , K. Muro ² , H. Ishii ³ , T. Kato ⁴ , T. Tsushima ⁵ , M. Takenoyama ⁶ , S. Oizumi ⁷ , T. Kawakami ⁸ , T. Doi ⁹ ; ¹ Tokyo, JP, ² Nagoya, Aichi/Jp, ³ Matsuyama, JP, ⁴ Yokohama, JP, ⁵ Shizuoka, JP, ⁶ Fukuoka, JP, ⁷ Sapporo, Hokkaido/Jp, ⁸ Chiyodaku, JP, ⁹ Kashiwa, Chiba/Jp	
16:45 - 17:00	LBA18 - Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations <u>P. Ascierto</u> ¹ , P. Bono ² , S. Bhatia ³ , I. Melero ⁴ , M. Nyakas ⁵ , I.-M. Svane ⁶ , J. Larkin ⁷ , C. Gomez-Roca ⁸ , D. Schadendorf ⁹ , R. Dummer ¹⁰ , A. Marabelle ¹¹ , C. Hoeller ¹² , M. Maurer ¹³ , C. Harbison ¹⁴ , P. Mitra ¹³ , S. Suryawanshi ¹³ , K. Thudium ¹³ , E. Muñoz Couselo ¹⁵ ; ¹ Napoli, IT, ² Helsinki, FI, ³ Seattle, WA/US, ⁴ Pamplona, ES, ⁵ Oslo, NO, ⁶ Herlev, DK, ⁷ London, GB, ⁸ Toulouse, Haute-Garonne/FR, ⁹ Essen, DE, ¹⁰ Zürich, CH, ¹¹ Villejuif, FR, ¹² Vienna, AT, ¹³ Princeton, NJ/US, ¹⁴ Princeton, US, ¹⁵ Barcelona, ES	
17:00 - 17:15	Invited Discussant LBA17 and LBA18 <u>A. Italiano</u> , Bordeaux, FR	
17:15 - 17:30	LBA19 - A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC A. Drilon ¹ , S. Liu ² , R. Doebele ³ , C. Rodriguez ⁴ , M. Fakih ⁵ , K. Reckamp ⁵ , L. Bazhenova ⁶ , B.C. Cho ⁷ , E. Kowack ⁸ , J. Oliver ⁸ , P. Multani ⁸ , M.-J. Ahn ⁷ , <u>L. Bazhenova</u> ⁹ ; ¹ New York, NY/US, ² Washington Dc, US, ³ Aurora, CO/US, ⁴ Seattle, WA/US, ⁵ Duarte, CA/US, ⁶ San Diego, US, ⁷ Seoul, KR, ⁸ San Diego, CA/US, ⁹ La Jolla, CA/US	
17:30 - 17:45	365O - Phase 1 safety and clinical activity of BLU-554 in advanced hepatocellular carcinoma (HCC) <u>R. Kim</u> ¹ , D. Sarker ² , T. Macarulla ³ , T. Yau ⁴ , S.P. Choo ⁵ , T. Meyer ² , A. Hollebecque ⁶ , J. Whisenant ⁷ , M. Sung ⁸ , J.-H. Yoon ⁹ , H.Y. Lim ⁹ , A. Zhu ¹⁰ , J.-W. Park ¹¹ , S. Faivre ¹² , V. Mazzaferro ¹³ , H. Shi ¹⁴ , O. Schmidt-Kittler ¹⁴ , C. Clifford ¹⁴ , B. Wolf ¹⁴ , Y.-K. Kang ¹⁵ ; ¹ Tampa, US, ² London, GB, ³ Barcelona, ES, ⁴ Hong Kong, HK, ⁵ Singapore, SG, ⁶ Villejuif, FR, ⁷ Salt Lake City, US, ⁸ New York, NY/US, ⁹ Seoul, KR, ¹⁰ Boston, US, ¹¹ Goyang, KR, ¹² Paris, FR, ¹³ Milan, IT, ¹⁴ Cambridge, US, ¹⁵ Seoul, Songpa-gu/KR	
17:45 - 18:00	Invited Discussant LBA19 and 365O <u>J. Rodon</u> , Barcelona, ES	

16:30 - 17:30	Type: Multidisciplinary Session Title: Managing colorectal cancer evolution Chair(s): A. Bardelli, IT	Valencia Auditorium
16:30 - 16:35	Presentation of case/condition <u>A. Bardelli</u> , Candiolo, (TO)/IT	
16:35 - 16:45	Colorectal cancer evolution in response to treatment: Evolving intra-tumour heterogeneity <u>A. Bardelli</u> , Candiolo, (TO)/IT	
16:45 - 16:55	Classification and molecular diagnosis of colorectal cancer: Inter-tumour heterogeneity <u>R. Dienstmann</u> , Barcelona, ES	
16:55 - 17:05	Clinical implications of inter- and intra-tumour heterogeneity <u>S. Tejpar</u> , Leuven, BE	
17:05 - 17:30	General Discussion	

16:30 - 18:00 Type: Proffered Paper session Tarragona Auditorium
Title: Endocrine and neuroendocrine tumours
Chair(s): M. Ducreux, FR; I. Chau, GB

16:30 - 16:42 4270 - Pembrolizumab for patients with PD-L1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
J. Mehnert¹, H. Rugo², B. O'Neil³, A. Santoro⁴, J. Schellens⁵, R. Cohen⁶, T. Doi⁷, P. Ott⁸, M. Pishvaian⁹, I. Puzanov¹⁰, K. Aung¹¹, C. Hsu¹², C. Le Tourneau¹³, J.-C. Soria¹⁴, E. Elez¹⁵, K. Tamura¹⁶, M. Gould¹⁷, G. Zhao¹⁷, K. Stein¹⁷, S. Piha-Paul¹⁸; ¹New Brunswick, US, ²San Francisco, CA/US, ³Indianapolis, IN/US, ⁴Rozzano-Milano, IT, ⁵Amsterdam, NL, ⁶Philadelphia, PA/US, ⁷Kashiwa, Chiba/Jp, ⁸Boston, MA/US, ⁹Washington, DC/US, ¹⁰Buffalo, NY/US, ¹¹Toronto, NB/CA, ¹²Taipei, TW, ¹³Paris, FR, ¹⁴Villejuif, CEDEX/FR, ¹⁵Barcelona, ES, ¹⁶Tokyo, JP, ¹⁷Kenilworth, NJ/US, ¹⁸Houston, TX/US

16:42 - 16:54 4280 - Immune landscape of pancreatic neuroendocrine tumours (PanNETs)
K. Young¹, C. Ragulan², G. Nyamundanda², Y. Patil², R. Lawlor³, D. Cunningham², N. Starling¹, A. Scarpa³, A. Sadanandam²; ¹London, GB, ²Sutton, GB, ³Verona, IT

16:54 - 17:06 4290 - A phase II trial of palbociclib in metastatic grade 1/2 pancreatic neuroendocrine tumors: The PALBONET study on behalf of the Spanish Taskforce Group of Neuroendocrine Tumors (GETNE)
E. Grande Pulido¹, A. Teule², T. Alonso-Gordoa¹, P. Jiménez-Fonseca³, M. Benavent⁴, J. Capdevila², A. Custodio¹, R. Vera⁵, J. Munariz⁶, A. La Casta-Muñoz⁷, R. Garcia-Carbonero¹; ¹Madrid, ES, ²Barcelona, ES, ³Oviedo, ES, ⁴Sevilla, ES, ⁵Pamplona, ES, ⁶Castellón, ES, ⁷San Sebastian, ES

17:06 - 17:21 Invited Discussant 4270, 4280 and 4290
I. Chau, Sutton, Surrey/GB

17:21 - 17:33 4300 - Different RNA expression profile defines prognosis in grade 1/2 neuroendocrine neoplasms of small intestine origin: The GETNE-NETSEQ study
J. Capdevila¹, F. Mancuso¹, S. Landolfi¹, F. Salva¹, C. Miguel², P. Jiménez-Fonseca², R. Garcia-Carbonero³, C. López López⁴, A. Casteras¹, T. Sauri Nadal¹, P. Nuciforo¹, A. Vivancos¹, I. Matos¹; ¹Barcelona, ES, ²Oviedo, ES, ³Madrid, ES, ⁴Santander, ES

17:33 - 17:45 4310 - Genomic subtypes of pulmonary large cell neuroendocrine carcinoma (LCNEC) may predict chemotherapy outcome
J. Derks¹, N. Leblay², R.J. van Suylen³, E. Thunnissen⁴, M. den Bakker⁵, H.J.M. Groen⁶, E. Smit⁴, R. Damhuis⁷, E. van den Broek⁷, A. Charbrier², M. Foll², J. McKay², L. Fernandez-Cuesta², E.-J. Speel¹, A.-M. Dingemans¹; ¹Maastricht, NL, ²Lyon, FR, ³S'herthogenbosch, NL, ⁴Amsterdam, NL, ⁵Rotterdam, NL, ⁶Groningen, NL, ⁷Utrecht, NL

17:45 - 18:00 Invited Discussant 4300 and 4310
M. Cives, Bari, FL/IT

16:30 - 17:45 Type: Poster Discussion session Bilbao Auditorium
Title: Basic science

Chair(s): C. Isacke, GB; D. Tuveson, US; C. Dive, GB

- 16:30 - 16:30 1703PD - Landscape of DNA damage response (DDR) genes alterations in the prospective MOSCATO and MATCH R trials
Y. El Dakdouki¹, L. Verlingue², C. Massard¹, R. Bahleda³, A. Hollebecque¹, L. Mahjoubi¹, E. Rouleau⁴, L. Lacroix¹, N. Auger¹, J.-Y. Scoazec¹, E. Solary¹, A. Marabelle¹, F. André³, J.-C. Soria³, S. Postel-Vinay¹; ¹Villejuif, FR, ²Paris, FR, ³Villejuif, CEDEX/FR, ⁴Paris, CEDEX 5/FR
- 16:30 - 16:30 1705PD - Detection of therapeutic targets in carcinomas of unknown primary
B. Clynick¹, B. Dessauvague², G. Strerrett², N. Harvey², S. Subramaniam², J. Herron², R. Allcock¹, B. Guo¹, C. Saunder², W. Erber², K. Meehan²; ¹Perth, AU, ²Perth, WA/AU
- 16:30 - 16:30 5PD - The acquired resistance to the combination of the anti-EGFR cetuximab and the MEK-inhibitor refametinib in KRAS mutated colorectal cancer cell lines depends on PI3K-signalling
P.P. Vitiello¹, G. Martini¹, C. Cardone², D. Ciardiello¹, V. Belli¹, N. Matrone¹, T. Troiani¹, S. Napolitano¹, V. Sforza¹, G. Papaccio¹, V. Desiderio¹, V. De Falco¹, E. Giunta¹, F. Morgillo¹, M.R. Diadema¹, P. Vitale¹, N. Zanaletti¹, F. Ciardiello², E. Martinelli²; ¹Napoli, IT, ²Naples, IT
- 16:30 - 16:45 Invited Discussant 1703PD, 1704PD and 5PD
C. Dive, Manchester, GB
- 16:45 - 16:55 Q&A led by Discussant
- 16:55 - 16:55 3PD - New targets in triple negative breast cancer: Role of oncostatin M receptor pathway
M. Muñoz Caffarel¹, A. Araujo¹, C. Lawrie¹, I. Álvarez López², R. Rezola¹, A. Abaurrea¹; ¹San Sebastian, ES, ²Donostia, ES
- 16:55 - 16:55 4PD - GGNBP2 suppresses tumor growth and cancer stem cell load of triple negative breast cancer by controlling STAT3 pathway
J. Zhang, Tianjin, CN
- 16:55 - 16:55 1704PD - Tumor microenvironment biomarkers as therapeutic strategies for TNBC
F. Rojo¹, M. Ruíz-Borrego², M. Hui³, J. Trigo Perez⁴, A. Cazet³, M. Karsdal⁵, A. Urruticoechea⁶, S. Antolin⁷, J.A. García-Saenz¹, S. O'toole³, A. Blach⁸, L. Perez-Ramos⁸, S. Bezares⁸, M. Sánchez-Aragó⁸, R. Caballero⁸, C. Bager⁵, A. Swarbrick³, M. Martin Jimenez¹; ¹Madrid, ES, ²Sevilla, ES, ³New South Wales, AU, ⁴Malaga, ES, ⁵Herlev, DK, ⁶Barcelona, ES, ⁷Coruña, ES, ⁸San Sebastian De Los Reyes, ES
- 16:55 - 17:10 Invited Discussant 3PD, 4PD and 1704PD
C. Isacke, London, GB
- 17:10 - 17:20 Q&A led by Discussant

- 17:20 - 17:20 6PD - FPA150, a novel B7-H4 therapeutic antibody with checkpoint blockade and ADCC activities
C. Kaplan¹, D. Houser¹, F. Kemp¹, N. Nielson², A. Hsu¹, K. Legris¹, G. Brattich¹, H. Xiang¹, A. Ahene¹, U. Jeffrey¹, D. Bellovin¹, L. Borges¹; ¹San Francisco, US, ²Lebanon, NH/US
- 17:20 - 17:20 1706PD - Analysis of stroma and immune-related gene expression patterns during breast cancer (BC) progression
L. Molinero¹, J. Albanell², H. Koeppen³, E. Martinez de Dueñas⁴, D. Halligan⁵, A. Guerrero⁶, J.I. Chacón López-Muñiz⁷, R. Perez⁸, S. Antolin⁹, I. Blancas López-Barajas¹⁰, M. Muñoz², A. Oltra¹¹, M.H. López de Ceballos¹², M. Sánchez-Aragó¹³, R. Caballero¹³, E. Carrasco⁸, A.M. González-Angulo¹⁴, A. Lluch⁶, E. Mittendorf¹⁴, F. Rojo⁸; ¹South San Francisco, CA/US, ²Barcelona, ES, ³South San Francisco, US, ⁴Castellon, ES, ⁵Edinburgh, GB, ⁶Valencia, ES, ⁷Toledo, ES, ⁸Madrid, ES, ⁹Coruña, ES, ¹⁰Granada, ES, ¹¹Alicante, ES, ¹²CÁceres, ES, ¹³San Sebastian De Los Reyes, ES, ¹⁴Texas, US
- 17:20 - 17:20 1707PD - Orthotopic versus subcutaneous NET: tumor tissue characteristics result in different answers when ADC is used to validate early therapy response following Peptide Receptor Radionuclide Therapy (PRRT)
E. Koziolk, J. Albrecht, S. Exner, V. Prasad, C. Grötzing, W. Brenner; Berlin, DE
- 17:20 - 17:35 Invited Discussant 6PD, 1706PD and 1707PD
D. Tuveson, New York, NY/US
- 17:35 - 17:45 Q&A led by Discussant

16:30 - 18:00	Type: Special Session Title: Cost, value and assessment tools of therapies in modern oncology Chair(s): E.G.E. de Vries, NL; N. Cherny, IL	Alicante Auditorium
16:30 - 16:35	Introduction <u>N. Cherny</u> , Jerusalem, IL	
16:35 - 16:50	Principles and reflections on cost, value and sustainability of anticancer therapies <u>I. Tannock</u> , Toronto, Ontario/CA	
16:50 - 17:05	ESMO Magnitude of Clinical Benefit Scale (MCBS): New version: 1.1 <u>N. Cherny</u> , Jerusalem, IL	
17:05 - 17:20	Integrating MCBS in ESMO Guidelines <u>G. Pentheroudakis</u> , Ioannina, GR	
17:20 - 17:35	Implementation of the ESMO-MCBS scale <u>E.G.E. de Vries</u> , Cluj-Napoca, RO	
17:35 - 18:00	Discussion and conclusions, led by <u>E.G.E. de Vries</u> , Cluj-Napoca, RO	

16:30 - 18:30	Type: Special Session Title: 4th ESMO Integrated Oncology & Palliative Care Community Session and Awards Chair(s): F. Strasser, CH; G. Kreye, AT	Salamanca Auditorium
16:30 - 16:35	Introduction and current developments in cancer palliative care <u>F. Strasser</u> , St. Gallen, CH	
16:35 - 16:45	Proactive Referral to Palliative Care: Model of a new Integrated Palliative Care and Oncology Service <u>J. Wood</u> , London, GB	
16:45 - 16:50	Discussion	
16:50 - 17:00	2017 WHO Cancer Resolution: Timely access, treatment and Palliative Care <u>A. Ilbawi</u> , Geneva, CH	
17:00 - 17:05	Discussion	
17:05 - 17:20	What does ESMO offer in Palliative Care <u>R. Canario</u> , Porto, PT	
17:20 - 17:30	Invited discussion on selected abstracts from ESMO 2017 produced in ESMO Designated Centres of Integrated Oncology & Palliative Care <u>G. Kreye</u> , Krems, AT	
17:30 - 18:00	Audience discussion	
18:00 - 18:05	Conclusions <u>F. Strasser</u> , St. Gallen, CH	
18:05 - 18:30	Designated Centre and Palliative Care Fellowship Awards <u>F. Strasser</u> ¹ , <u>G. Kreye</u> ² ; ¹ St. Gallen, CH, ² Krems, AT	

16:45 - 17:45 Type: Controversy session
Title: Single agent or combination chemotherapy in the adjuvant therapy for pancreatic cancer
Chair(s): T. Seufferlein, DE
Granada Auditorium

16:45 - 16:55 Introduction and 1st vote
T. Seufferlein, Ulm, DE

16:55 - 17:15 Monotherapy
M. Hidalgo, Madrid, ES

17:15 - 17:35 Combination
T. Conroy, Vandoeuvre Les Nancy, CEDEX/FR

17:35 - 17:45 2nd vote and conclusions
T. Seufferlein, Ulm, DE

17:30 - 18:30 Type: Young Oncologist Vesalius Talk
Title: How active participation in ESMO has impacted my career
Chair(s): C. Zielinski, AT
Foyer Ibiza

17:30 - 17:35 Introduction
C. Zielinski, Vienna, AT

17:35 - 18:00 Discussion
E. Martinelli¹, R. Califano², E. De Azambuja³; ¹Naples, IT, ²Manchester, GB, ³Brussels, BE

18:00 - 19:30 Type: Patient Advocacy Track Palma Auditorium
Title: Rare cancers: More common than you think, more difficult to serve
Chair(s): K. Oliver, GB; J.-Y. Blay, FR

18:00 - 18:15 The EURORDIS table: Similarities and differences of rare cancers and rare diseases
K. Oliver, GB

18:15 - 18:30 Joint actions on rare cancers
P.G. Casali, Milan, IT

18:30 - 18:45 What EUROCAN, the European Reference Network for Rare Cancers, will do for patients
J.-Y. Blay, Lyon, FR

18:45 - 19:00 The importance of adaptive pathways in rare cancers
F. Pignatti, London, GB

19:00 - 19:30 Discussion

18:30 - 20:00 Type: Industry Satellite Symposium Sevilla Auditorium
Title: Industry Satellite Symposium 35

18:30 - 20:00 Type: Industry Satellite Symposium Pamplona Auditorium
Title: Industry Satellite Symposium 36

18:30 - 20:00 Type: Industry Satellite Symposium Cordoba Auditorium
Title: Industry Satellite Symposium 37

18:30 - 20:00 Type: Industry Satellite Symposium Granada Auditorium
Title: Industry Satellite Symposium 38

18:30 - 20:00 Type: Industry Satellite Symposium Valencia Auditorium
Title: Industry Satellite Symposium 39

18:30 - 20:00 Type: Industry Satellite Symposium Tarragona Auditorium
Title: Industry Satellite Symposium 40

18:30 - 20:00 Type: Industry Satellite Symposium Bilbao Auditorium
Title: Industry Satellite Symposium 41

11-09-2017

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Valencia Auditorium
Title: Liver dominant disease
Chair(s): G. Folprecht, DE

08:00 - 08:10 Liver dominant disease
R. Adam, Paris, FR

08:10 - 09:00 Discussion led by Chair
G. Folprecht, Dresden, DE

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Tarragona Auditorium
Title: Do we need to test for PD-L1 and how do we choose?
Chair(s): M. Reck, DE

08:00 - 08:10 Do we need to test for PD-L1 and how do we choose?
K. Kerr, Aberdeen, GB

08:10 - 09:00 Discussion led by Chair
M. Reck, Grosshansdorf, DE

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Bilbao Auditorium
Title: How to best manage oligometastatic disease
Chair(s): R. Rouzier, FR

08:00 - 08:10 How to best manage oligometastatic disease
F. Cardoso, Lisbon, PT

08:10 - 09:00 Discussion led by Chair
R. Rouzier, Paris, FR

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Alicante Auditorium
Title: Gut microbiota: Will it help to improve cancer immunotherapy?
Chair(s): C. Robert, FR

08:00 - 08:10 Gut microbiota: Will it help to improve cancer immunotherapy?
T. Gajewski, Chicago, IL, US

08:10 - 09:00 Discussion led by Chair
C. Robert, Villejuif, FR

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Cartagena Auditorium
 Title: Management of elderly patients with head and neck cancer
 Chair(s): J. Guigay, FR

08:00 - 08:10 Management of elderly patients with head and neck cancer
J. Langendijk, Groningen, NL

08:10 - 09:00 Discussion led by Chair
J. Guigay, Nice, CEDEX 2/FR

08:00 - 09:00 Type: Challenge Your Expert (CYE) session Salamanca Auditorium
 Title: The new EU clinical trials and data protection regulations
 Chair(s): C. Dittrich, AT

08:00 - 08:10 The new EU clinical trials and data protection regulations
A. Negrouk, Brussels, BE

08:10 - 09:00 Discussion led by Chair
C. Dittrich, Vienna, AT

08:15 - 09:00 Type: Keynote Lecture Barcelona Auditorium
 Title: Does immunotherapy cure advanced cancer?
 Chair(s): I.-M. Svane, DK

08:15 - 09:00 Does immunotherapy cure advanced cancer?
J. Haanen, Amsterdam, NL

- 09:15 - 10:45 Type: Proffered Paper session Barcelona Auditorium
Title: NSCLC, metastatic 2
Chair(s): T. Reungwetwattana, TH; L. Paz-Ares, ES
- 09:15 - 09:30 LBA50 - Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014
T. Mok¹, D.-W. Kim², Y.-L. Wu³, K. Nakagawa⁴, T. Mekhail⁵, E. Felip⁶, F. Cappuzzo⁷, J. Paolini⁸, T. Usari⁸, K. Wilner⁹, F. Blackhall¹⁰, B. Solomon¹¹, T. Mok¹²; ¹Hong Kong, CN, ²Seoul, KR, ³Guangzhou, CN, ⁴Osaka, JP, ⁵Orlando, US, ⁶Barcelona, ES, ⁷Ravenna, IT, ⁸Milan, IT, ⁹San Diego, CA/US, ¹⁰Manchester, GB, ¹¹Melbourne, VIC/AU, ¹²New Territories, HK
- 09:30 - 09:45 1298O_PR - Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study
S. Gadgeel¹, S. Peters², T. Mok³, A. Shaw⁴, D.-W. Kim⁵, S.-H.I. Ou⁶, M. Perol⁷, R. Dziadziuszko⁸, J.S. Ahn⁵, R. Rosell⁹, A. Zeaiter¹⁰, E. Mitry¹⁰, E. Nueesch¹⁰, B. Balas¹⁰, R. Camidge¹¹; ¹Ann Arbor, US, ²Lausanne, CH, ³New Territories, HK, ⁴Boston, MA/US, ⁵Seoul, KR, ⁶Orange, US, ⁷Lyon, CEDEX/FR, ⁸Gdansk, PL, ⁹Badalona, Barcelona/ES, ¹⁰Basel, CH, ¹¹Aurora, CO/US
- 09:45 - 10:00 1299O_PR - Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)
S. Novello¹, J. Mazieres², I.-J. Oh³, J. de Castro⁴, M. Migliorino⁵, A. Helland⁶, R. Dziadziuszko⁷, F. Griesinger⁸, A. Kotb⁹, A. Zeiter⁹, A. Cardona⁹, B. Balas⁹, H. Johannsdottir⁹, A. Das-Gupta⁹, J. Wolf¹⁰; ¹Torino, IT, ²Toulouse, FR, ³Hwasun, KR, ⁴Madrid, ES, ⁵Rome, IT, ⁶Oslo, NO, ⁷Gdansk, PL, ⁸Oidenburg, DE, ⁹Basel, CH, ¹⁰Köln, DE
- 10:00 - 10:20 Invited Discussant LBA50, 1298O and 1299O
L. Paz-Ares, Madrid, ES
- 10:20 - 10:35 LBA51 - Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)
D. Planchard¹, E. Smit², H.J.M. Groen³, J. Mazieres⁴, B. Besse¹, A. Helland⁵, V. Giannone⁶, A. D'Amelio⁶, P. Zhang⁷, B. Mookerjee⁸, B. Johnson⁹; ¹Villejuif, FR, ²Amsterdam, NL, ³Groningen, NL, ⁴Toulouse, FR, ⁵Oslo, NO, ⁶East Hanover, NJ/US, ⁷East Hanover, US, ⁸New Jersey, US, ⁹Ann Arbor, NJ/US
- 10:35 - 10:45 Invited discussant LBA51
O.T. Brustugun, Oslo, NO

09:15 - 10:45 Type: Special Symposium Sevilla Auditorium
Title: Immunobiology in prostate cancer
Chair(s): A. Alimonti, CH; H. Beltran, US

09:15 - 09:20 Introduction
H. Beltran, New York, NY/US

09:20 - 09:40 Basic immunobiology in prostate cancer
A. Alimonti, Bellinzona, CH

09:40 - 10:00 Immunogenomics and prostate cancer
J. de Bono, London, GB

10:00 - 10:20 Vaccination in prostate cancer
J. Gulley, Bethesda, Md, US

10:20 - 10:40 Checkpoint inhibitors in prostate cancer
W. Gerritsen, Nijmegen, NL

10:40 - 10:45 Conclusions & clinical perspectives
H. Beltran, New York, NY/US

09:15 - 10:45 Type: Special Symposium Cordoba Auditorium
Title: Are grade III / IV toxicities the only ones that matter?
Chair(s): M. Apro, CH; S. Kaasa, NO

09:15 - 09:20 Introduction
S. Kaasa, Oslo, NO

09:20 - 09:40 Why do grade I/II toxicities matter
B. Seruga, Ljubljana, SI

09:40 - 10:00 What toxicities matter to the patients
C. Roffiaen, Milan, IT

10:00 - 10:20 How does EMA look at toxicity/benefit ratios in cancer treatment
F. Pignatti, London, GB

10:20 - 10:40 Drug interactions that matter
T. Lembrecht Jørgensen, Odense, DK

10:40 - 10:45 Conclusions and perspectives
M. Apro, Genolier, CH

09:15 - 10:45	Type: Educational session Title: B cell receptor as a therapeutic target Chair(s): A. Ferreri, IT; L. De La Cruz Merino, ES	Granada Auditorium
09:15 - 09:40	Diagnosis and classification of the pathologic subtypes of large B cell lymphoma: Immunophenotyping, gene expression profiling and mutational analyses <u>S. Montes</u> , Santander, ES	
09:40 - 10:05	Current therapies against B cell receptor <u>A. Ferreri</u> , Milan, IT	
10:05 - 10:30	Overcoming resistance in B cell receptor therapeutics <u>S. Rule</u> , Plymouth, GB	
10:30 - 10:45	Discussion	

- 09:15 - 10:45 Type: Proffered Paper session Madrid Auditorium
Title: Gastrointestinal tumours, colorectal 2
Chair(s): J. Taieb, FR; C.-H. Koehne, DE
- 09:15 - 09:30 486O - Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study
D. Modest¹, L. Fischer von Weikersthal², T. Decker³, U. Vehling-Kaiser⁴, J. Uhlig⁵, M. Schenk⁶, J. Freiberg-Richter⁷, B. Peuser⁸, C. Denzlinger⁹, C. Peveling Genannt Reddemann¹⁰, U. Graeven¹¹, G. Schuch¹², I. Schwaner¹², A. Stahler¹, A. Jung¹³, S. Held¹⁰, S. Stintzing¹, C. Giessen-Jung¹, V. Heinemann¹; ¹Munich, DE, ²Amberg, DE, ³Ravensburg, DE, ⁴Landshut, DE, ⁵No City Provided, NA, ⁶Regensburg, DE, ⁷Dresden, DE, ⁸Leipzig, DE, ⁹Stuttgart, DE, ¹⁰Leverkusen, DE, ¹¹Mönchengladbach, DE, ¹²Berlin, DE, ¹³München, DE
- 09:30 - 09:45 478O - Efficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S)
J. Tabernero¹, F. Ciardiello², C. Montagut¹, C. Ding³, S. Kopetz⁴, T. Tuxen Poulsen⁵, A. Bardelli⁶, L. Wyrwicz⁷, A. Cubillo⁸, C. Santos¹, G. Fumi⁹, V. Zagonel¹⁰, J. Bennouna¹¹, S. Siena¹², A. Falcone¹³, M. Benavent¹⁴, G. Argiles¹, M. Kragh¹⁵, I. Horak⁵, M. Dvorkin¹⁶; ¹Barcelona, ES, ²Naples, IT, ³Somerville, New Jersey, US, ⁴Houston, US, ⁵Ballerup, DK, ⁶Candiolo, (TO)/IT, ⁷Warsaw, PL, ⁸Madrid, ES, ⁹Terni, IT, ¹⁰Padova, IT, ¹¹Nantes, CEDEX/FR, ¹²Milan, IT, ¹³Pisa, IT, ¹⁴Sevilla, ES, ¹⁵-, DK, ¹⁶Omsk, RU
- 09:45 - 10:00 Invited Discussant 486O and 478O
C.-H. Koehne, Oldenburg, DE
- 10:00 - 10:15 479O - Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial
J. Mooi¹, P. Wirapati², R. Asher³, C. Lee⁴, P. Savas⁵, T. Price⁶, S. Tejpar⁷, J. Mariadason⁸, N. Tebbutt⁸; ¹Heidelberg, AU, ²Lausanne, CH, ³Sydney, NSW/AU, ⁴Kogarah, NSW/AU, ⁵Melbourne, VIC/AU, ⁶Woodville, SA/AU, ⁷Leuven, BE, ⁸Heidelberg, VIC/AU
- 10:15 - 10:30 480O - Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy
C. Gallois¹, J. Taieb¹, D. Le Corre¹, K. Le Malicot², J. Tabernero³, C. Mulot¹, J.-F. Seitz⁴, T. Aparicio⁵, G. Folprecht⁶, C. Lepage⁷, E. Mini⁸, J.-L. Van Laethem⁹, J.F. Emile¹⁰, P. Laurent-Puig¹; ¹Paris, FR, ²Dijon, FR, ³Barcelona, ES, ⁴Marseille, CEDEX 5/FR, ⁵Bobigny, CEDEX/FR, ⁶Dresden, DE, ⁷Dijon, Cedex/FR, ⁸Firenze, IT, ⁹Brussels, BE, ¹⁰Boulogne-Billancourt, FR
- 10:30 - 10:45 Invited Discussant 479O and 480O
A. Falcone, Pisa, IT

- 09:15 - 10:45 Type: Joint Symposium Tarragona Auditorium
Title: ESMO-SEOM: Integrating biomarkers into oncology
Chair(s): F. Ciardiello, IT; M. Martin Jimenez, ES
- 09:15 - 09:20 Introduction
M. Martin Jimenez, Madrid, ES
- 09:20 - 09:40 General vision of biomarkers in oncology: Design of clinical studies for biomarker discovery
J.L. Perez Gracia, Pamplona, ES
- 09:40 - 10:00 Biomarkers in breast cancer
A. Prat, Barcelona, ES
- 10:00 - 10:20 Biomarkers in lung cancer
S. Peters, Lausanne, CH
- 10:20 - 10:40 Biomarkers in unknown origin cancer
M. Esteller, Barcelona, ES
- 10:40 - 10:45 Conclusions
F. Ciardiello, Naples, IT
- 09:15 - 10:45 Type: Poster Discussion session Bilbao Auditorium
Title: Immunotherapy of cancer
Chair(s): P. Nathan, GB; F. Thistlethwaite, GB
- 09:15 - 09:15 1138PD - Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)
J. Ross¹, M. Goldberg², L. Albacker², L. Gay³, V. Agarwala⁴, J. Elvin², J.-A. Vergilio², J. Suh², S. Ramkissoon², E. Severson², S. Daniel², S. Ali², A. Schrock⁵, G. Frampton², D. Fabrizio⁵, V. Miller², G. Singal⁵, A. Abernethy⁴, P. Stephens²; ¹Albany, NY/US, ²Cambridge, MA/US, ³Cambridge, CA, ⁴New York, US, ⁵Cambridge, US
- 09:15 - 09:15 1139PD - Analyzing biomarkers of cancer immunotherapy (CIT) response using a real-world clinico-genomic database
G. Singal¹, P. Miller², V. Agarwala³, G. Li¹, A. Gossai³, L. Albacker⁴, M. Goldberg⁴, J. He¹, S. Frank³, D. Bourque⁴, I. Ivanov³, D. Fabrizio¹, T. Caron³, A. Parker¹, A. Guria¹, V. Miller⁴, J. Elvin⁴, J. Ross⁵, A. Abernethy³, P. Stephens⁴; ¹Cambridge, US, ²Boston, US, ³New York, US, ⁴Cambridge, MA/US, ⁵Albany, NY/US
- 09:15 - 09:15 1140PD - Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) – analysis of somatic alterations (SAs)
A. Singavi¹, S. Menon², D. KILARI¹, A. Alqwasmi², P. Ritch¹, J. Thomas², A. Martin², C. Oxencis², S. Ali³, B. George²; ¹Milwaukee, US, ²Milwaukee, WI/US, ³Cambridge, US

- 09:15 - 09:30 Invited Discussant 1138PD, 1139Pd and 1140PD
C. Blank, Amsterdam, NL
- 09:30 - 09:40 Q&A led by Discussant
- 09:40 - 09:40 1141PD - CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study
J. Powderly¹, M. Patel², J. Lee³, J. Brody⁴, F. Meric-Bernstam⁵, E. Hamilton⁶, S. Ponce Aix⁷, J. Garcia-Corbacho⁸, Y.-J. Bang⁹, M.-J. Ahn⁹, S.Y. Rha⁹, K.-P. Kim⁹, M. Gil Martin⁸, H. Wang¹⁰, A. Lazorchak¹¹, T. Wyant¹², A. Ma¹¹, S. Agarwal¹³, D. Tuck¹⁴, A. Daud¹⁵; ¹Huntersville, US, ²Sarasota, FL/US, ³Pittsburgh, PA/US, ⁴New York, US, ⁵Houston, US, ⁶Nashville, TN/US, ⁷Madrid, ES, ⁸Barcelona, ES, ⁹Seoul, KR, ¹⁰Bridgewater, NJ/US, ¹¹Lexington, MA/US, ¹²Lexington, US, ¹³Waltham, MA/US, ¹⁴New York, Massachusetts/US, ¹⁵San Francisco, US
- 09:40 - 09:40 1142PD - Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb
O. Hamid¹, W. Ros², J. Thompson³, S. Hu-Lieskovan¹, F. Eskens⁴, A. Diab⁵, T. Doi⁶, J. Wasser⁷, J.-P. Spano⁸, N. Rizvi⁹, E. Angevin¹⁰, A. Chiappori¹¹, P. Ott¹², B. Ganguly¹³, C. Fleener¹⁴, V. Dell¹⁵, K. Liao¹⁵, T. Joh¹⁵, J. Chou¹⁶, A. El-Khoueiry¹; ¹Los Angeles, CA/US, ²Amsterdam, NL, ³Seattle, WA/US, ⁴Rotterdam, NL, ⁵Houston, US, ⁶Kashiwa, Chiba/JP, ⁷Farmington, CT/US, ⁸Paris, CEDEX 13/FR, ⁹New York, NY, US, ¹⁰Villejuif, CEDEX/FR, ¹¹Tampa, FL/US, ¹²Boston, MA/US, ¹³South San Francisco, US, ¹⁴Groton, US, ¹⁵La Jolla, US, ¹⁶South San Francisco, CA/US
- 09:40 - 09:40 1143PD - Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)
P. Konstantinopoulos¹, J. Sachdev², L. Schwartzberg³, U. Matulonis¹, P. Sun⁴, J.Y. Wang⁴, W. Guo⁴, D. Bobilev⁴, G. Aktan⁵, V. Karantza⁵, B. Dezube⁶, S. Vinayak⁷; ¹Boston, MA/US, ²Scottsdale, US, ³Memphis, TN/US, ⁴Waltham, MA/US, ⁵Kenilworth, NJ/US, ⁶Waltham, US, ⁷Cleveland, OH/US
- 09:40 - 09:55 Invited Discussant 1141PD, 1142PD and 1143PD
P. Nathan, Northwood, Middlesex/GB
- 09:55 - 10:05 Q&A led by Discussant
- 10:05 - 10:05 1145PD - Adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic ovarian cancer: A pilot study
M. Pedersen¹, M. Westergaard², M. Nielsen², T. Borch², L. Poulsen², H. Hendel², T. Juhler-Nøttrup³, Ö. Met², M. Donia², I.-M. Svane²; ¹Copenhagen, DK, ²Herlev, DK, ³Copenhagen Ø, DK
- 10:05 - 10:05 1146PD - Adjuvant therapy with autologous dendritic cell (DC) vaccine based on cancer-testis antigens (CaTeVac) in melanoma patients

A. Novik¹, I. Baldueva², S. Protsenko³, T. Nehaeva¹, A. Danolova¹, N. Pipia¹, N. Olisova¹, M. Kornienko¹, T. Danilova¹; ¹Saint Petersburg, RU, ²St. Petersburg, RU, ³Saint-Petersburg, RU

10:05 - 10:20 Invited Discussant 1144PD, 1145PD and 1146PD

F. Thistlethwaite, Manchester, GB

10:20 - 10:30 Q&A led by Discussant

10:30 - 10:30 1147PD - Germline determinants of immune related adverse events (irAEs) in melanoma immunotherapy response

T. Kirchhoff¹, R. Ferguson², D. Simpson², E. Kazlow¹, C. Martinez², M. Vogelsang², M. Wilson², A. Pavlick², J. Weber², I. Osman²; ¹New York, NY/US, ²New York, US

10:30 - 10:30 1148PD - Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C

R. Rai¹, O. Ezeoke², J. McQuade³, L. Zimmer⁴, C. Koo⁵, J. Park⁶, L. Ardolino⁷, D. Yip⁸, S. Goldinger⁹, J. Cohen¹⁰, M. Millward¹¹, V. Atkinson¹², A. Kane⁷, P. Ascierto¹³, C. Garbe¹⁴, R. Gutzmer¹⁵, D. Johnson¹⁶, M. Hellman², G. Long¹⁷, A. Menzies¹⁸; ¹North Sydney, ACT/AU, ²New York, NY/US, ³Houston, TX/US, ⁴Duisburg, DE, ⁵Melbourne, VIC/AU, ⁶Westmead, AU, ⁷Sydney, NSW/AU, ⁸Garran, ACT/AU, ⁹Zürich, CH, ¹⁰Boston, MA/US, ¹¹Nedlands, WA/AU, ¹²Woolloongabba, AU, ¹³Napoli, IT, ¹⁴Tübingen, DE/DE, ¹⁵Hannover, DE, ¹⁶Nashville, TN/US, ¹⁷Sydney, AU, ¹⁸North Sydney, AU

10:30 - 10:40 Invited Discussant 1147PD and 1148PD

J. Haanen, Amsterdam, NL

10:40 - 10:45 Q&A led by Discussant

09:30 - 10:30 Type: Multidisciplinary Session Pamplona Auditorium
 Title: Treatment of young women with breast cancer
 Chair(s): O. Pagani, CH

09:30 - 09:35 Presentation of case/condition
O. Pagani, Bellinzona, CH

09:35 - 09:45 Issues on systemic treatment
O. Pagani, Bellinzona, CH

09:45 - 09:55 Issues on genetics
S. Delaloge, Villejuif, FR

09:55 - 10:05 Issues on fertility
F. Peccatori, Milan, IT

10:05 - 10:30 General Discussion

09:30 - 10:30 Type: Special Session Valencia Auditorium
 Title: Overcoming drug resistance
 Chair(s): U. McDermott, GB; R. Marais, GB

09:30 - 09:50 Genome-wide genetic screens: Defining and overcoming the drug resistance landscape
U. McDermott, Manchester, GB

09:50 - 10:10 Cancer evolution as a therapeutic target
A. Bardelli, Candiolo, (TO)/IT

10:10 - 10:30 Cell context, mutation and treatment response across ovarian cancer subtypes
D. Huntsman, Vancouver, British Columbia/CA

09:30 - 10:30 Type: Challenge Your Expert (CYE) session Alicante Auditorium
 Title: Integration of molecular imaging into drug development
 Chair(s): U. Banerji, GB

09:30 - 09:40 Integration of molecular imaging into drug development
E.G.E. de Vries, Cluj-Napoca, RO

09:40 - 10:30 Discussion led by Chair
U. Banerji, Sutton, Surrey/GB

09:30 - 10:30 Type: Challenge Your Expert (CYE) session Salamanca Auditorium
 Title: Management of typical and atypical lung neuroendocrine tumours
 Chair(s): M. Pavel, DE

09:30 - 09:40 Management of typical and atypical lung neuroendocrine tumours
M. Caplin, London, GB

09:40 - 10:30 Discussion led by Chair
M. Pavel, Berlin, DE

09:30 - 10:30 Type: Young Oncologist Special session Room 1&2
 Title: Your choice of career path in oncology
 Chair(s): L. Poulsen, US

09:30 - 09:30 Topic 1 - Table 1: Clinical oncology and palliative care
S. Rauh, Esch Sur Alzette, LU

09:30 - 09:30 Topic 1 - Table 2: Clinical oncology and palliative care
M. Strijbos, Brasschaat, BE

09:30 - 09:30 Topic 2 - Table 1: Clinical and translational research
F. Cardoso, Lisbon, PT

09:30 - 09:30 Topic 2 - Table 2: Clinical and translational research
G. Argilés Martínez, Barcelona, ES

09:30 - 09:30 Topic 3 - Table 1: Industry as a career path
E. Mitry, Basel, CH

09:30 - 09:30 Topic 3 - Table 2: Industry as a career path
S. Maier, Plainsboro, US

09:30 - 09:30 Topic 4 - Table 1: Basic science
W. Berger, Vienna, AT

09:30 - 09:30 Topic 4 - Table 2: Basic science
E. Høgdall, Copenhagen, DK

11:00 - 12:30 Type: Special Symposium
 Title: Impact of tumour heterogeneity on precision medicine in kidney and bladder cancers
 Chair(s): L. Albiges, FR; C. Porta, IT Barcelona Auditorium

11:00 - 11:05 Introduction
C. Porta, Pavia, IT

11:05 - 11:25 What is the current status of precision medicine
C. Massard, Villejuif, FR

11:25 - 11:45 The impact of tumour heterogeneity on precision medicine
M. Gerlinger, London, GB

11:45 - 12:05 Is genomic classification going to help in RCC?
L. Albiges, Villejuif, CEDEX/FR

12:05 - 12:25 Is genomic classification going to help in bladder cancer?
J. Bellmunt, Boston, Ma, US

12:25 - 12:30 Conclusions and clinical perspectives
L. Albiges, Villejuif, CEDEX/FR

11:00 - 12:00 Type: Multidisciplinary Session
 Title: Synchronous liver metastases in rectal cancer: Which treatment first?
 Chair(s): R. Glynne-Jones, GB Sevilla Auditorium

11:00 - 11:05 Presentation of case/condition
R. Glynne-Jones, Northwood, Middlesex/GB

11:05 - 11:15 The surgical oncology perspective
T. Gruenberger, Vienna, AT

11:15 - 11:25 The medical oncology perspective
P. Pfeiffer, Odense C, DK

11:25 - 11:35 Summary
R. Glynne-Jones, Northwood, Middlesex/GB

11:35 - 12:00 General Discussion

11:00 - 12:15 Type: Poster Discussion session
 Title: Melanoma and other skin tumours
 Chair(s): D. Schadendorf, DE; C. Hoeller, AT; S. Goldinger, CH Pamplona Auditorium

- 11:00 - 11:00 1217PD - Comprehensive genomic profiling (CGP) and tumor mutational burden (TMB) assessment in subtypes of metastatic melanoma
J. Ross¹, J. Carlson¹, J. Elvin², J.-A. Vergilio², J. Suh², S. Ramkissoon², E. Severson², S. Daniel², S. Ali², A. Schrock³, D. Fabrizio², G. Frampton², V. Miller², P. Stephens², L. Gay², D. Johnson⁴; ¹Albany, NY/US, ²Cambridge, MA/US, ³Cambridge, US, ⁴Nashville, TN/US
- 11:00 - 11:00 1218PD - Precision medicine for the treatment of metastatic uveal melanoma: A pilot study
S. Leyvraz, M. Schuette, D. Rieke, T. Kessler, S. Ochsenreither, V. Amstislavskiy, T. Risch, C. Wierling, K. Joehrens, C.A. Peuker, M. Lamping, S. Burock, G. Poch, F. Kiecker, R. Schaefer, B. Lange, H. Lehrach, A. Joussen, U. Keilholz, M.-L. Yaspo; Berlin, DE
- 11:00 - 11:00 1219PD - Combined radiofrequency ablation and ipilimumab in uveal melanoma: Results from the SECIRA-UM trial
E. Rozeman¹, W. Prevo¹, M. Meier¹, K. Sikorska¹, B. van de Wiel¹, A. Broeks¹, H. van Tinteren¹, E. Kapiteijn², J. Thienen¹, J. Haanen¹, C. Blank¹; ¹Amsterdam, NL, ²Leiden, NL
- 11:00 - 11:15 Invited Discussant 1217PD, 1218PD and 1219PD
D. Schadendorf, Essen, DE
- 11:15 - 11:25 Q&A led by Discussant
- 11:25 - 11:25 1220PD - Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma
A. Menzies¹, M. Gonzalez¹, A. Guminski², O. Nieweg³, K. Shannon³, J. Thompson³, R. Kefford⁴, S. Ch'Ng³, J. Stretch¹, A. Spillane³, J. Lee³, H. Lee³, R. Kapoor³, L. Emmett³, H. Rizos³, R. Saw³, R. Scolyer⁵, G. Long³; ¹North Sydney, AU, ²St Leonards, NSW/AU, ³Sydney, AU, ⁴Macquarie Park, NSW/AU, ⁵Camperdown, AU
- 11:25 - 11:25 1221PD - (Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses
E. Rozeman¹, L. Fanchi¹, A. van Akkooi¹, P. Kvistborg¹, J. Thienen¹, B. Stegenga², B. Lamon³, J. Haanen¹, T. Schumacher¹, C. Blank¹; ¹Amsterdam, NL, ²Utrecht, NL, ³Princeton, New Jersey/US
- 11:25 - 11:25 1222PD - Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)
J.-J. Grob¹, D. Schadendorf², J. Wagstaff³, I. Márquez-Rodas⁴, C. Lebbe⁵, P. Ascierto⁶, F.S. Hodi⁷, K. Grossmann⁸, J. Hassel⁹, D. Walker¹⁰, R. Bhore¹⁰, J. Larkin¹¹, J. Wolchok¹²; ¹Marseille, FR, ²Essen, DE, ³Swansea, GB, ⁴Madrid, ES, ⁵Paris, FR, ⁶Napoli, IT, ⁷Boston, US, ⁸Salt Lake City, US, ⁹Heidelberg, DE, ¹⁰Princeton, US, ¹¹London, GB, ¹²New York, US
- 11:25 - 11:25 1223PD - Quality-adjusted survival of combined nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone vs IPI among treatment-naïve patients (pts) with advanced melanoma (MEL): a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis

M. Botteman¹, R. Shah¹, K. Gupte-Singh², L. Luo³, J. Sabater⁴, S. Rao², D. McDermott⁵, M. Atkins⁶, M. Regan⁵; ¹Bethesda, US, ²Princeton, NJ/US, ³Bethesda, MD/US, ⁴Princeton, US, ⁵Boston, MA/US, ⁶Washington Dc, US

11:25 - 11:40 Invited Discussant 1220PD, 1221PD 1222PD and 1223PD

C. Hoeller, Vienna, AT

11:40 - 11:50 Q&A led by Discussant

11:50 - 11:50 1224PD - Analysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002

A. Daud¹, I. Puzanov², R. Dummer³, D. Schadendorf⁴, O. Hamid⁵, C. Robert⁶, F.S. Hodi⁷, J. Schachter⁸, J. Sosman⁹, A. Pavlick¹⁰, R. Gonzalez¹¹, C. Blank¹², L. Cranmer¹³, S. O'day¹⁴, A. Salama¹⁵, K. Margolin¹⁶, J. Yang¹⁷, B. Homet Moreno¹⁸, N. Ibrahim¹⁷, A. Ribas⁵; ¹San Francisco, US, ²Buffalo, NY/US, ³Zürich, CH, ⁴Essen, DE, ⁵Los Angeles, CA/US, ⁶Villejuif, FR, ⁷Boston, US, ⁸Ramat Gan, IL, ⁹Nashville, TN/US, ¹⁰New York, US, ¹¹Aurora, CO/US, ¹²Amsterdam, NL, ¹³Seattle, US, ¹⁴Santa Monica, US, ¹⁵Durham, US, ¹⁶Duarte, CA/US, ¹⁷Kenilworth, US, ¹⁸Kenilworth, NJ/US

11:50 - 11:50 1225PD - Prognostic impact of early complete metabolic response on FDG-PET, in BRAF V600 mutant metastatic melanoma patients treated with combination vemurafenib & cobimetinib

W. Xu¹, J. Frederickson², J. Callahan¹, A. Ribas³, R. Gonzalez⁴, A. Pavlick⁵, O. Hamid³, T. Gajewski⁶, I. Puzanov⁷, A. Daud⁸, D. Colburn⁹, N. Choong¹⁰, M. Wongchenko¹¹, R. Hicks¹, G. McArthur¹²; ¹Melbourne, VIC/AU, ²South San Francisco, CA/US, ³Los Angeles, CA/US, ⁴Aurora, CO/US, ⁵New York, US, ⁶Chicago, IL, US, ⁷Buffalo, NY/US, ⁸San Francisco, US, ⁹South San Francisco, California/US, ¹⁰South San Francisco, US, ¹¹Hillsboro, US, ¹²Melbourne, AU

11:50 - 11:50 1226PD - Five-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K-mutant advanced or metastatic melanoma

D. Schadendorf¹, K. Flaherty², P. Nathan³, P. Hersey⁴, C. Garbe⁵, M. Milhem⁶, L. Demidov⁷, P. Mohr⁸, J. Hassel⁹, P. Rutkowski¹⁰, R. Dummer¹¹, J. Utikal⁹, F. Kiecker¹², J. Larkin¹³, A. D'Amelio Jr¹⁴, Y. Huang¹⁵, B. Mookerjee¹⁴, C. Robert¹⁶; ¹Essen, DE, ²Boston, MA/US, ³Northwood, Middlesex/GB, ⁴Sydney, AU, ⁵Tübingen, DE/DE, ⁶Iowa, US, ⁷Moscow, RU, ⁸Buxtehude, DE, ⁹Heidelberg, DE, ¹⁰Warsaw, PL, ¹¹Zürich, CH, ¹²Berlin, DE, ¹³London, GB, ¹⁴New Jersey, US, ¹⁵East Hanover, NJ/US, ¹⁶Villejuif, FR

11:50 - 12:05 Invited Discussant 1224PD, 1225PD and 1226PD

S. Goldinger, Zürich, CH

12:05 - 12:15 Q&A led by Discussant

11:00 - 12:30 Type: Educational session Cordoba Auditorium
Title: Treating your patients using epigenetics
Chair(s): K. Helin, DK; D. Huntsman, CA

11:00 - 11:35 Targeting epigenetic enzymes in cancer
K. Helin, Copenhagen, DK

11:35 - 12:10 Protein methyltransferase inhibitors in preclinical models and clinical studies
P. Trojer, Cambridge, US

12:10 - 12:30 Discussion

11:00 - 12:00 Type: Multidisciplinary Session Granada Auditorium
Title: Management of high risk early stage endometrial cancer
Chair(s): M.R. Mirza, DK

11:00 - 11:05 Presentation of case/condition
M.R. Mirza, Copenhagen, DK

11:05 - 11:15 The surgery perspective
V. Di Donato, Roma, IT

11:15 - 11:25 The radiation therapy perspective
R. Nout, Leiden, NL

11:25 - 11:35 The medical oncology perspective
M.R. Mirza, Copenhagen, DK

11:35 - 12:00 General Discussion

11:00 - 12:30	Type: Proffered Paper session Title: Immunotherapy of cancer Chair(s): I.-M. Svane, DK; T. Powles, GB	Madrid Auditorium
11:00 - 11:15	1144O - Phase III randomized controlled trial of adjuvant chemoimmunotherapy in patients with resected primary lung cancer <u>H. Kimura</u> ¹ , Y. Matsui ² , T. Nakajima ³ , T. Iizasa ³ , A. Ishikawa ³ ; ¹ Chiba, JP, ² Nitona-Cho -, Chiba, JP, ³ Chu-O-ku, Chiba, JP	
11:15 - 11:30	1135O - Phase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN) <u>E. Cohen</u> ¹ , D. Hong ² , T. Wise Draper ³ , W. Nassib William ² , D. Schrijvers ⁴ , R. Mesia Nin ⁵ , M. Scott ⁶ , P. Lyne ⁶ , G. Mugundu ⁶ , P. McCoon ⁶ , C. Cook ⁶ , M. Mehta ⁶ , U. Keilholz ⁷ ; ¹ La Jolla, IL/US, ² Houston, US, ³ Cincinnati, US, ⁴ Antwerp, BE, ⁵ Barcelona, ES, ⁶ Waltham, US, ⁷ Berlin, DE	
11:30 - 11:45	Invited Discussant 1144O and 1135O <u>T. Powles</u> , London, GB	
11:45 - 12:00	1136O - Nivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer <u>B. Glisson</u> ¹ , E. Massarelli ² , W. William ³ , F. Johnson ³ , M. Kies ³ , R. Ferrarotto ³ , M. Guo ³ , S.A. Peng ³ , J.J. Lee ³ , H. Tran ³ , Y. Kim ³ , C. Haymaker ³ , C. Bernatchez ³ , M. Curran ³ , B. Sanchez Espiridion ³ , J. Rodriguez Canales ³ , I. Wistuba ³ , S. van der Burg ⁴ , J. Wang ³ , C. Melief ⁴ ; ¹ Houston, US, ² Duarte, CA/US, ³ Houston, TX/US, ⁴ Leiden, NL	
12:00 - 12:15	1137O - Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC) <u>R. Figlin</u> ¹ , C. Nicolette ² , N. Tannir ³ , S. Tykodi ⁴ , D. Chen ⁵ , V. Master ⁶ , B. Lane ⁷ , M. Debenedette ² , T. Monesmith ² , W. Tan ² , S. Leland ² , C. Wood ⁸ ; ¹ Los Angeles, US, ² Durham, US, ³ Houston, TX/US, ⁴ Seattle, WA/US, ⁵ Philadelphia, US, ⁶ Atlanta, US, ⁷ Grand Rapids, US, ⁸ Houston, US	
12:15 - 12:30	Invited Discussant 1136O and 1137O <u>H. Gogas</u> , Athens, Attiki/GR	

11:00 - 12:30 Type: Joint Symposium Valencia Auditorium
 Title: ESMO-MASCC: Emerging issues in cancer supportive care and survivorship
 Chair(s): N. Cherny, IL; I. Olver, AU

11:00 - 11:05 Introduction
N. Cherny, Jerusalem, IL

11:05 - 11:25 Safe monitoring of immunotherapy
I. Olver, Adelaide, South Australia/AU

11:25 - 11:45 Steroids and supportive care
N. Cherny, Jerusalem, IL

11:45 - 12:05 Financial toxicity
R. Sullivan, London, GB

12:05 - 12:25 Return to work after cancer
F. Pimentel, Lisbon, PT

12:25 - 12:30 Conclusions
I. Olver, Adelaide, South Australia/AU

11:00 - 12:30 Type: Special Symposium Tarragona Auditorium
 Title: Access to innovative drugs in the EU
 Chair(s): R. Giuliani, IT; M. Ijzerman, NL

11:00 - 11:05 Introduction
M. Ijzerman, Enschede, NL

11:05 - 11:25 Challenges in clinical research methodology
P. Bruzzi, Genoa, IT

11:25 - 11:45 Challenges in regulation
R. Giuliani, Roma, IT

11:45 - 12:05 Challenges in reimbursement
M. Ijzerman, Enschede, NL

12:05 - 12:25 The European cancer patient's perspective
B. Ryll, SE

12:25 - 12:30 Conclusions and clinical perspectives
R. Giuliani, Roma, IT

11:00 - 12:30	Type: Poster Discussion session Title: Sarcoma Chair(s): S. Bonvalot, FR; R. Maki, US; M. Eriksson, SE	Bilbao Auditorium
11:00 - 11:00	1475PD - A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide and cisplatin (API), followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Update at 10 years <u>P. Pautier</u> ¹ , C. Brard ² , A. Floquet ³ , L. Gladieff ⁴ , M. Rios ⁵ , S. Piperno-Neumann ⁶ , D. Berton-Rigaud ⁷ , J.-Y. Blay ⁸ , M. Fabbro ⁹ , J.-P. Lotz ¹⁰ , A. Vinceneux ¹¹ , F. Bertucci ¹² , T. De La Motte Rouge ¹³ , C. Guillemet ¹⁴ , C. Genestie ² , F. Duffaud ¹⁵ ; ¹ Villejuif, CEDEX/FR, ² Villejuif, FR, ³ Bordeaux, CEDEX/FR, ⁴ Toulouse, Haute-Garonne/FR, ⁵ Vandoeuvre Les Nancy, CEDEX/FR, ⁶ Paris, CEDEX 5/FR, ⁷ Saint-Herblain, CEDEX/FR, ⁸ Lyon, FR, ⁹ Montpellier, CEDEX 5/FR, ¹⁰ Paris, FR, ¹¹ Tours, CEDEX 9/FR, ¹² Marseille, CEDEX 9/FR, ¹³ Rennes, FR, ¹⁴ Rouen, FR, ¹⁵ Marseille, CEDEX 5/FR	
11:00 - 11:00	1476PD - Tumour necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma (STS) <u>J. Lewin</u> ¹ , S. Salah ² , E. Amir ³ , A. Razak ² ; ¹ Nassau, BS, ² Toronto, CA, ³ Toronto, Ontario/CA	
11:00 - 11:00	1477PD - Prognosis of desmoid tumours initially managed with surveillance only at all anatomical locations <u>W. van Houdt</u> ¹ , A. Patel ¹ , R. Jones ¹ , M. Smith ¹ , A. Miah ¹ , C. Benson ¹ , S. Zaidi ¹ , C. Messiou ¹ , E. Moskovic ¹ , D. Strauss ¹ , A. Hayes ¹ , O. Husson ¹ , W. van der Graaf ² ; ¹ London, GB, ² Sutton, GB	
11:00 - 11:00	1478PD - Adult Translocation-related soft tissue sarcomas (TRS): Presentation, management and outcome of 2,143 cases confirmed by expert pathologists <u>N. Penel</u> ¹ , J.-M. Coindre ² , A. Giraud ² , P. Terrier ³ , D. Ranchere-Vince ⁴ , F. Collin ⁵ , S. Le Guellec ⁶ , C. Bazille ⁷ , M. Lae ⁸ , G. De Pinieux ⁹ , I. Ray-Coquard ¹⁰ , S. Bonvalot ⁸ , A. Le Cesne ³ , Y.-M. Robin ¹¹ , E. Stoeckle ² , F. Ducimetiere ¹⁰ , M. Toulmonde ¹² , J.-Y. Blay ⁴ ; ¹ Lille, CEDEX/FR, ² Bordeaux, FR, ³ Villejuif, FR, ⁴ Lyon, FR, ⁵ Dijon, FR, ⁶ Toulouse, FR, ⁷ Caen, FR, ⁸ Paris, FR, ⁹ Tours, FR, ¹⁰ Lyon, CEDEX/FR, ¹¹ Lille, FR, ¹² Bordeaux, CEDEX/FR	
11:00 - 11:20	Invited Discussant 1475PD, 1476PD, 1477PD and 1478PD <u>S. Bonvalot</u> , Paris, FR	
11:20 - 11:30	Q&A led by Discussant	
11:30 - 11:30	1479PD - Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib <u>Y. Kurokawa</u> ¹ , T. Doi ² , A. Sawaki ³ , Y. Komatsu ⁴ , M. Ozaka ⁵ , T. Takahashi ⁶ , Y. Naito ⁵ , S. OKUBO ⁵ , T. Nishida ⁵ ; ¹ Suita, Osaka/JP, ² Kashiwa, Chiba/JP, ³ Kurashiki, Okayama/JP, ⁴ Sapporo, Hokkaido/JP, ⁵ Tokyo, JP, ⁶ Suita, JP	
11:30 - 11:30	1480PD - A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival	

S. Chawla¹, B. Van Tine², S. Pollack³, K. Ganjoo⁴, A. Elias⁵, R. Riedel⁶, S. Attia⁷, E. Choy⁸, S. Okuno⁹, M. Agulnik¹⁰, M. von Mehren¹¹, M. Livingston¹², V. Keedy¹³, C. Verschraegen¹⁴, T. Philip¹⁵, C. Bohac¹⁶, H. Lu¹⁷, M. Chen¹⁷, R. Maki¹⁸; ¹San Francisco, US, ²St Louis, US, ³Seattle, US, ⁴Palo Alto, US, ⁵Aurora, US, ⁶Durham, US, ⁷Jacksonville, FL/US, ⁸Boston, US, ⁹Rochester, US, ¹⁰Chicago, US, ¹¹Philadelphia, PA/US, ¹²Charlotte, US, ¹³Nashville, US, ¹⁴Cincinnati, US, ¹⁵New Hyde Park, NY/US, ¹⁶Thousand Oaks, California/US, ¹⁷South San Francisco, CA/US, ¹⁸New York, NY, US

11:30 - 11:30 1481PD - Efficacy and safety of palbociclib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib
A. Italiano¹, A. Adenis², J.-Y. Blay³, F. Duffaud⁴, M. Rios⁵, E. Bompas⁶, O. Bouche⁷, M. Pulido¹, A. Le Cesne⁸; ¹Bordeaux, FR, ²Lille, CEDEX/FR, ³Lyon, FR, ⁴Marseille, CEDEX 5/FR, ⁵Vandoeuvre Les Nancy, CEDEX/FR, ⁶Saint-Herblain, CEDEX/FR, ⁷Reims, FR, ⁸Villejuif, FR

11:30 - 11:30 1482PD - Notch pathway inhibition with LY3039478 in soft tissue sarcoma (STS) and gastrointestinal stromal tumours (GIST)
O. Mir¹, A. Azaro², J. Merchan³, R. Chugh⁴, J.C. Trent⁵, J. Rodon², U. Ohnmacht⁶, C. Smith⁷, G. Oakley III⁸, A. Le Cesne¹, J.-C. Soria⁹, K. Benhadji¹⁰, C. Massard⁹; ¹Villejuif, FR, ²Barcelona, ES, ³Miami, US, ⁴Ann Arbor, US, ⁵Houston, TX/US, ⁶Bad Homburg, DK, ⁷Windlesham, GB, ⁸Indianapolis, US, ⁹Villejuif, CEDEX/FR, ¹⁰Neuilly-sur-seine, FR

11:30 - 11:50 Invited Discussant 1479PD, 1480PD, 1481PD and 1482PD
R. Maki, New York, NY, US

11:50 - 12:00 Q&A led by Discussant

12:00 - 12:00 1483PD - Imatinib in combination with everolimus in patients with progressive advanced chordoma: results from an Italian phase 2 clinical trial
S. Stacchiotti¹, C. Morosi¹, A. Casale¹, E. Palassini¹, A.M. Frezza¹, A. Messina², A. Gronchi¹, G. Garrone¹, E. Venturelli¹, S. Pilotti¹, E. Tamborini², P. Casali¹; ¹Milan, IT, ²Milano, IT

12:00 - 12:00 1484PD - A matching-adjusted indirect comparison of trabectedin and pazopanib for the treatment of advanced, metastatic, leiomyosarcomas
R. Jones¹, J.-Y. Blay², A. Le Cesne³, J. Martin-Broto⁴, M.J. Pontes⁵, J.M. Fernandez Santos⁵, B. García San Andrés⁵, G. Wang⁶, S. Wang⁷, C.R. Shin⁸, R. Maki⁹, S. Patel¹⁰, G.D. Demetri¹¹; ¹London, GB, ²Lyon, FR, ³Villejuif, FR, ⁴Seville, ES, ⁵Madrid, ES, ⁶Spring House, US, ⁷Horsham, PA/US, ⁸Horsham, US, ⁹New York, NY, US, ¹⁰Houston, TX/US, ¹¹Boston, MA/US

12:00 - 12:00 LBA57 - Results of the LMS03 phase II study evaluating gemcitabine combined with pazopanib as a 2nd-line treatment for metastatic/relapsed leiomyosarcomas (uterine or soft tissue) after failure of anthracycline-based chemotherapy: The UNICANCER SARCOME 11 study

P. Pautier¹, N. Penel², I. Ray-Coquard³, A. Italiano⁴, E. Bompas⁵, C. Delcambre⁶, J.-O. Bay⁷, F. Bertucci⁸, J. Delays⁹, C. Chevreau¹⁰, D. Cupissol¹¹, L. Bozec Le Moal¹², J.-C. Eymard¹³, A. Thyss¹⁴, N. Isambert¹⁵, C. Guillemet¹⁶, M. Rios¹⁷, S. Piperno-Neumann¹⁸, G. Chenuc⁹, F. Duffaud¹⁹; ¹Villejuif, CEDEX/FR, ²Lille, CEDEX/FR, ³Lyon, CEDEX/FR, ⁴Bordeaux, FR, ⁵Saint-Herblain, CEDEX/FR, ⁶Caen, CEDEX 5/FR, ⁷Clermont-Ferrand, FR, ⁸Marseille, CEDEX 9/FR, ⁹Paris, FR, ¹⁰Toulouse, FR, ¹¹Montpellier, CEDEX 5/FR, ¹²St. Cloud, FR, ¹³Reims, CEDEX/FR, ¹⁴Nice, CEDEX 2/FR, ¹⁵Dijon, Cedex/FR, ¹⁶Rouen, FR, ¹⁷Vandoeuvre Les Nancy, CEDEX/FR, ¹⁸Paris, CEDEX 5/FR, ¹⁹Marseille, CEDEX 5/FR

12:00 - 12:20 Invited Discussant 1483PD, 1484PD and LBA57

M. Eriksson, Lund, SE

12:20 - 12:30 Q&A led by Discussant

11:00 - 12:00 Type: Poster Discussion session Alicante Auditorium
Title: Endocrine and neuroendocrine tumours
Chair(s): B. Jarzab, PL; R. Garcia-Carbonero, ES

11:00 - 11:00 432PD - Prognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC)

I. Matos¹, F. Mancuso¹, C. Iglesias¹, P. Nuciforo¹, C. Zafón¹, H.G. Palmer¹, Z. Ogbah¹, L. Muños¹, G. Villacampa Javierre¹, C. Peña², M. Brose³, M. Schlumberger⁴, A. Vivancos¹, J. Capdevila¹; ¹Barcelona, ES, ²Whippany, NJ/US, ³Philadelphia, PA/US, ⁴Villejuif, CEDEX/FR

11:00 - 11:00 433PD - Comprehensive genomic profiling of metastatic and relapsed thyroid gland carcinomas is associated with tumor type and reveals new routes to targeted therapies

J. Ross¹, L. Gay², P. Vanden Borre², N. Almog², A. Schrock³, J.-A. Vergilio², J. Suh², S. Ramkissoon², E. Severson², S. Daniel², S. Ali², V. Miller², P. Stephens², J. Elvin², D. Bowles⁴; ¹Albany, NY/US, ²Cambridge, MA/US, ³Cambridge, US, ⁴South Aurora, CO/US

11:00 - 11:00 434PD - Impact of duration of dose interruption on the efficacy of lenvatinib (LEN) in a phase 3 study in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)

M. Tahara¹, M. Brose², L. Wirth³, T. Suzuki⁴, K. Fujino⁴, N. Batty⁵, C. Dutcus⁶, A. Gianoukakis⁷; ¹Kashiwa, Chiba/JP, ²Philadelphia, PA/US, ³Boston, MA/US, ⁴Tokyo, JP, ⁵Woodcliff Lake, US, ⁶Woodcliff Lake, New Jersey/US, ⁷Torrance, US

11:00 - 11:00 436PD - Preliminary safety and efficacy of rovalpituzumab tesirine in patients with delta-like protein 3-expressing advanced solid tumors

R. Aggarwal¹, A. Mansfield², H. Beltran³, A. Farago⁴, C.L. Hann⁵, F. Kaye⁶, K. Lewis⁷, J. Niu⁸, S. Richey⁹, D. Smith¹⁰, H.P. Soares¹¹, A. Spira¹², M. Taylor¹³, S.N. Waqar¹⁴, S. Lally¹⁵, M. Rossi¹⁵, L. Saunders¹⁵, S.J. Dylla¹⁵, E. Kavalierchik¹⁵, L. Anthony¹⁶; ¹San Francisco, US, ²Rochester, MN/US, ³New York, NY/US, ⁴Boston, MA/US, ⁵Baltimore, US, ⁶Gainesville, US, ⁷Aurora, CO/US, ⁸Gilbert, US, ⁹Fort Worth, US, ¹⁰Vancouver, US, ¹¹Tampa, US, ¹²Fairfax, US, ¹³Portland, US, ¹⁴St. Louis, US, ¹⁵South San Francisco, US, ¹⁶Lexington, US

11:00 - 11:20 Invited Discussant 432PD, 433PD, 434PD and 436PD

B. Jarzab, Warsaw, PL

11:20 - 11:30 Q&A led by Discussant

11:30 - 11:30 437PD - Integrative DNA methylome and miRNA transcriptome analysis for new biomarker discovery in entero-pancreatic neuroendocrine tumours (EP-NETS)

J. Barriuso¹, A. Lamarca¹, V. Heredia², L. Guerra-Pastrian², C. Alvarez-Escola², J. Castell², A. Custodio², M. Miguel², M. Mendiola², J. Feliu²; ¹Manchester, GB, ²Madrid, ES

11:30 - 11:30 438PD - Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE: The NETTER-1 phase III trial

J. Strosberg¹, E. Wolin², B. Chasen¹, M.H. Kulke³, D. Bushnell⁴, M. Caplin⁵, R. Baum⁶, P. Kunz⁷, T. Hobday⁸, A. Hendifar⁹, K. Öberg¹⁰, M. Lopera Sierra², P. Ruzsniwski¹¹, E. Krenning¹²; ¹Tampa, US, ²New York, US, ³Boston, Ma, US, ⁴Iowa, US, ⁵London, GB, ⁶Bad Berka, DE, ⁷Stanford, AE, ⁸Rochester, MN/US, ⁹Los Angeles, US, ¹⁰Uppsala, SE, ¹¹Clichy, FR, ¹²Rotterdam, NL

11:30 - 11:30 439PD - Peptide receptor radionuclide therapy of neuroendocrine neoplasms using lutetium-177 and yttrium-90 labeled somatostatin analogs: A single center experience in over 1000 patients

A. Singh¹, H. Kulkarni¹, T. Langbein¹, C. Lehmann¹, K. Niepsch¹, D. Müller¹, M. Hommann¹, D. Kaemmerer¹, A. Jochems², P. Lambin², D. Hörsch¹, R. Baum¹; ¹Bad Berka, DE, ²Maastricht, NL

11:30 - 11:30 440PD - Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: Analysis of the completed TELESTAR extension period

D. Hörsch¹, M.H. Kulke², M. Caplin³, L. Anthony⁴, E. Bergsland⁵, K. Öberg⁶, R. Warner⁷, P. Kunz⁸, E. Grande Pulido⁹, J. Valle¹⁰, J. Dillon¹¹, P. Lapuerta¹², P. Banks¹³, S. Jackson¹³, M. Pavel¹⁴; ¹Bad Berka, DE, ²Boston, Ma, US, ³London, GB, ⁴Lexington, US, ⁵San Francisco, CA/US, ⁶Uppsala, SE, ⁷New York, NY/US, ⁸Stanford, AE, ⁹Madrid, ES, ¹⁰Manchester, GB, ¹¹Iowa City, IA/US, ¹²Princeton, US, ¹³The Woodlands, Texas/US, ¹⁴Berlin, DE

11:30 - 11:30 441PD - Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours (GEP-NETS): Consensus guidelines from the Commonwealth NET collaboration (CommNETs) in conjunction with the North American NET Society (NANETS)

S. Singh¹, L. Moody², D. Chan³, D. Metz⁴, J. Strosberg⁵, E. Segelov⁶; ¹Toronto, Ontario/CA, ²Toronto, CA, ³St Leonards, AU, ⁴Philadelphia, US, ⁵Tampa, US, ⁶Melbourne, NSW/AU

11:30 - 11:50 Invited Discussant 437PD, 438PD, 439PD, 440D and 441PD

R. Garcia-Carbonero, Madrid, ES

11:50 - 12:00 Q&A led by Discussant

11:00 - 11:45 Type: Young Oncologist Brunch Salamanca Auditorium
 Title: Critically ill cancer patients: Patient selection for admission to ICU
 Chair(s): J. Corral, ES; A. Tyulyandina, RU

11:00 - 11:20 Which factors influence decision making for ICU admission in cancer patients?
P. Schellongowski, Vienna, AT

11:20 - 11:25 Interactive case – case presentation
M.A. Ozturk, Istanbul, TR

11:25 - 11:45 Interactive case discussion (including audience)
P. Schellongowski, Vienna, AT

12:30 - 14:30 Type: Patient Advocacy Track Cartagena Auditorium
 Title: The Hans Keulen Memorial Debate: Lost in rehabilitation
 Chair(s): K. Oliver, GB; F. Meunier, BE

12:30 - 14:00 Moderated discussion with special guests
I. Lebrocqy¹, L. Travado², T. Spanic³, S. Rauh⁴, K. Oliver⁵; ¹No City Provided, NA, ²Lisbon, PT, ³Ljubljana, SI, ⁴Esch Sur Alzette, LU, ⁵GB

13:00 - 14:30 Type: Industry Satellite Symposium Sevilla Auditorium
 Title: Industry Satellite Symposium 42

13:00 - 14:30 Type: Industry Satellite Symposium Pamplona Auditorium
 Title: Industry Satellite Symposium 43

13:00 - 14:30 Type: Industry Satellite Symposium Cordoba Auditorium
 Title: Industry Satellite Symposium 44

13:00 - 14:30	Type: ESMO Colloquium Title: ESMO COLLOQUIUM – Rational for Chemo-Immunotherapy combination treatment in Solid Tumours Chair(s): J. Bennouna, FR; J. Vansteenkiste, BE	Granada Auditorium
13:00 - 13:05	Introduction <u>J. Bennouna</u> , Nantes, CEDEX/FR	
13:05 - 13:30	Optimizing immunotherapy: Rationale for a combination therapy approach <u>E. Giovannetti</u> , Amsterdam, NL	
13:30 - 13:55	Selecting the optimal combination partner for today's immunotherapeutic approaches <u>M. Del Re</u> , Pisa, IT	
13:55 - 14:20	Modulating Immune response to checkpoint inhibitor including epigenetic alteration <u>J. Vansteenkiste</u> , Leuven, BE	
14:20 - 14:30	Summary and Conclusion <u>J. Bennouna</u> , Nantes, CEDEX/FR	
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 46	Valencia Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 47	Tarragona Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 48 Chair(s): M. Perol, FR	Bilbao Auditorium
13:00 - 14:30	Type: Industry Satellite Symposium Title: Industry Satellite Symposium 49	Alicante Auditorium
13:15 - 14:15	Type: Poster Display session Title: Poster display session	Hall 8
13:15 - 13:15	BASIC SCIENCE	
13:15 - 13:15	7P - GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells <u>N. Yan</u> ¹ , Y. Cao ² , L. Xu ¹ , F. Zhang ¹ ; ¹ Shanghai, CN, ² Nanchang, CN	
13:15 - 13:15	8P - The impact of rotenone-modulated oxidative stress on the survival of human breast cancer stem cells (CD24-/CD44+) <u>S. Wanandi</u> , R. Syahrani, S. Jusman; Jakarta, ID	

- 13:15 - 13:15 9P - Kynurenine-3-monooxygenase (KMO) protein promotes triple negative breast cancer progression
C.-Y. Liu, T.-T. Huang, C.-H. Lee, W.-L. Wang, H.-C. Lee, L.-M. Tseng; Taipei, TW
- 13:15 - 13:15 10P - PIM1 kinase promotes cell migration via SHP2 in triple-negative breast cancer
F. Braso Maristany, J. Quist, C. Wells, A. Grigoriadis, P. Marra, A. Tutt; London, GB
- 13:15 - 13:15 11P - SHP-1 agonist SC-43 enhanced the anti-tumor effect of docetaxel through suppressing p-STAT3 in triple negative breast cancer cells
K.-F. Chen¹, C.-Y. Liu¹, T.-I. Chao¹, P.-Y. Chu², T.-T. Huang¹, W.-L. Wang¹, C.-H. Lee¹, K.-Y. Lau¹, W.-C. Tsao¹, C.-W. Shiau¹, L.-M. Tseng¹; ¹Taipei, TW, ²Changhua City, TW
- 13:15 - 13:15 12P - Delineating the mechanisms of resistance to panHER inhibitors in HER2+ breast cancer cells
O. Kutuk¹, H. Basaga², Y. Ozmay¹, B. Karakas²; ¹Adana, TR, ²Istanbul, TR
- 13:15 - 13:15 13P - AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression
J.M. Cejalvo¹, E. Tormo², A. Adam², F. Rojo³, B. Pineda², S. Zazo³, P. Gonzalez-Alonso³, M. Sabbaghi⁴, E. Alonso², A. Rovira⁴, J. Albanell⁴, B. Bermejo De Las Heras¹, O. Burgues², A. Lluch², J.A. Perez Fidalgo¹, P. Eroles²; ¹Valencia, Valencia/ES, ²Valencia, ES, ³Madrid, ES, ⁴Barcelona, ES
- 13:15 - 13:15 14P - Alterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (T-ADCC) in a lapatinib-resistant HER2+ breast cancer cell line model
N. Gaynor¹, M. Guibourdenche¹, B. Browne¹, L. O'Driscoll¹, N. O'Brien², N. O'Donovan¹, J. Crown¹, D. Collins¹; ¹Dublin, IE, ²Los Angeles, CA/US
- 13:15 - 13:15 15P - Estrogen-dependent breast cancer: The importance of androgen receptor in exemestane treatment
C. Amaral¹, T. Augusto¹, F. Roleira², E. Tavares-Da-Silva², G. Correia-Da-Silva¹, N. Teixeira¹; ¹Porto, PT, ²Coimbra, PT
- 13:15 - 13:15 16P - Phosphatidylinositol 3-kinase (PI3K α)/AKT axis blockade with tasisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
A. Diana¹, F. Morgillo¹, C.M. Della Corte², C. Di Mauro², V. Ciaramella¹, G. Barra², V. Belli¹, E. Franzese¹, R. Bianco¹, E. Maiello³, F. De Vita², F. Ciardiello², M. Orditura¹; ¹Napoli, IT, ²Naples, IT, ³San Giovanni Rotondo, IT
- 13:15 - 13:15 18P - Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin
D. Fanale, L. Incorvaia, R. Maragliano, N. Barraco, A. Listi, A. Galvano, S. Rizzo, V. Calò, V. Bazan, A. Russo; Palermo, IT
- 13:15 - 13:15 19P - An endothelial premetastatic-like niche is promoted by tumor-secreted factors derived from highly metastatic breast cancer cells in vitro
M. Gallardo Vera, A. Zentella Dehesa; Cd De México, MX
- 13:15 - 13:15 20P - Selective accumulation of the rat adherent natural killer cells in mammary tumor tissues
S. Gu, Hamamatsu, JP

- 13:15 - 13:15 21P - Inhibition of nitric oxide synthase (NOS) reduces the effect of stress hormone signalling in breast cancer
R. Flaherty¹, B. Patel², M. Allen², M. Flint²; ¹Brighton, UK/GB, ²Brighton, GB
- 13:15 - 13:15 22P - The interplay between TP53 and mevalonate pathway in ovarian cancer
M. abdullah, M. Abed, A. Richardson; Stoke On Trent, GB
- 13:15 - 13:15 23P - Epigenomic landscape of breast cancer in very young women
S. Oltra Sanchis¹, M. Chilet¹, M. Martinez¹, K. Flower², E. Alonso¹, O. Burgues¹, A. Lluch³, J. Flanagan², G. Ribas¹; ¹Valencia, ES, ²London, GB, ³Valencia, Valencia/ES
- 13:15 - 13:15 24P - Evaluation of cell free circulating DNA in plasma by digital PCR for early diagnosis in Peruvian breast cancer patients
A. Aguilar, A. Murillo, J. Ponce, J. Araujo, J. Pinto, C. Vigil, R. Fujita, J. Buleje; Lima, PE
- 13:15 - 13:15 25P - Breast cancer predisposing germline mutations identified by exome sequencing
E. Kuligina, A. Sokolenko, I. Bizin, M. Anisimova, A. Romanko, E. Imyanitov; Saint Petersburg, RU
- 13:15 - 13:15 26P - Global transcriptome deregulation of breast cancer in very young women samples
V. Vidal Tomas¹, S. Oltra Sanchis¹, M. Martinez¹, E. Alonso¹, O. Burgues¹, A. Lluch², M. Chilet¹, G. Ribas¹; ¹Valencia, ES, ²Valencia, Valencia/ES
- 13:15 - 13:15 27P - Integrated system-level analyses of androgen receptor variant networks to identify novel prostate cancer-relevant genes that serve as prognostic biomarkers
F. Magani¹, E. Bray², S. Peacock², N. Zhao², K. Burnstein²; ¹Miami, US, ²Miami, FL/US
- 13:15 - 13:15 28P - ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer
R. Oksala¹, M. Karimaa¹, M. Ramela¹, R. Riikonen¹, R. Huhtaniemi¹, P. Rummakko², G. Wohlfahrt², A. Vuorela², M. Mustonen², P. Kallio¹; ¹Turku, FI, ²Espoo, FI
- 13:15 - 13:15 29P - Determining the role of the ETS factor ELF3 in normal and malignant prostate
L. Archer, F. Frame, N. Maitland; York, GB
- 13:15 - 13:15 30P - Treatment-induced hypoxia attenuates enzalutamide response and promotes resistance in pre-clinical models of prostate cancer
P. Maxwell¹, M. Labonte¹, M. McKechnie¹, O. Duddy¹, C. Armstrong¹, C.W. Ong¹, A. Zoubeidi², J. Worthington³, D. Waugh¹; ¹Belfast, GB, ²Vancouver, CA, ³Coleraine, GB
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 32P - Prognostic impact of KRAS mutation in cell-free DNA in patients with pancreatic cancer
M.K. Kim¹, S.M. Woo², B. Park², K.-A. Yoon³, Y.H. Kim², J. Joo², S.J. Park², S.-Y. Kong²; ¹Gyeonggi-Do, KR, ²Goyang, KR, ³Seoul, KR

- 13:15 - 13:15 33P - Isoform-specific functions in pancreatic adenocarcinoma
H. Arasanz, M. Zuazo-Ibarra, M. Gato-Cañas, M. Ibáñez-Vea, G. Fernández-Hinojal, J. Fernández-Irigoyen, E. Santamaria, G. Kochan, R. Vera, D. Escors; Pamplona, ES
- 13:15 - 13:15 34P - High chemopreventive and therapeutic efficacy of Id1 inhibition in KRAS-mutant (KM) adenocarcinoma (AD) non-small cell lung cancer (NSCLC)
M. Roman Moreno, S. Vicent, I. Lopez, I. Baraibar Argota, E. Fraile, I. Gil Bazo; Pamplona, ES
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 36P - Synergistic effect of vismodegib and cisplatin in NSCLC models via autophagy
F. Papaccio¹, L. Mele¹, C.M. Della Corte², D. Liccardo¹, M. La Noce¹, V. Desiderio¹, V. Tirino¹, F. Ciardiello², F. Morgillo¹; ¹Napoli, IT, ²Naples, IT
- 13:15 - 13:15 37P - Association of the rs4567312 variant in the leptin receptor gene with plasma leptin concentrations and lung cancer incidence in the PREDIMED study
J.B. Ramirez Sabio¹, J. Sorlí², C. Ortega-Azorín², P. Carrasco², E. Asensio², R. Barragán², R. Fernández-Carrión², C. Gallego², J. González-Arráez², J.A. Perez Fidalgo³, Ó. Coltell⁴, D. Corella²; ¹Sagunt, ES, ²Valencia, ES, ³Valencia, Valencia/ES, ⁴Castellón, ES
- 13:15 - 13:15 38P - Two-step microarray analysis of cell-free miRNA in plasma of lung cancer patients
I. Zaporozhchenko¹, E. Morozkin¹, A. Ponomaryova², E. Rykova¹, N. Cherdynseva², V. Vlassov¹, P. Laktionov¹; ¹Novosibirsk, RU, ²Tomsk, RU
- 13:15 - 13:15 39P - DNA methylation of the CYP1A1 and GSTP1 genes and incidence of major cancers (lung, breast and colon) in the PREDIMED-Valencia study
J.B. Ramirez Sabio¹, J. Sorlí², C. Ortega-Azorín², I. González-Monje², E. Asensio², R. Barragán², R. Fernández-Carrión², C. Gallego², R. Estruch³, Ó. Coltell⁴, O. Portolés², D. Corella²; ¹Sagunt, ES, ²Valencia, ES, ³Barcelona, ES, ⁴Castellón, ES
- 13:15 - 13:15 40P - Regulation of glucose transporters by protein kinases in cancer cells
A. Henriques, P. Matos, P. Jordan; Lisboa, PT
- 13:15 - 13:15 41P - Signal transduction pathways regulating alternative splicing of tumor-related RAC1b
V. Gonçalves, P. Matos, A. Henriques, J. Pereira, P. Jordan; Lisboa, PT
- 13:15 - 13:15 42P - Preserving tumor heterogeneity: A microfluidic reactor for ex vivo preservation of colorectal cancer biopsies
G. Llamazares, C. Sostres, A. Vígueras, A. Lué, J. Calavia, C. Alcaine, R. Guerrero, A. Gonzales, M. Ramírez, A. Lacueva, S. González, A. Lanás, I. Ochoa, L. Fernández; Zaragoza, ES
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 44P - Role of ICAM-1/LFA-1 interaction in the angiogenic and desmoplastic response in liver metastasis
A. Alonso, I. Romayor, A. Benedicto, I. Hernandez-Unzueta, J. Marquez, B. Arteta; Leioa, ES

- 13:15 - 13:15 45P - Role of discoidin domain receptors in extracellular matrix remodeling during tumor-host interaction in liver metastasis
I. Romayor, A. Alonso, I. Hernandez-Unzueta, A. Benedicto, J. Marquez, B. Arteta; Leioa, ES
- 13:15 - 13:15 46P - Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells
X. Li, A. Xu, H. Li, B. Zhang, B. Cao, J. Huang; Beijing, CN
- 13:15 - 13:15 47P - GATA6 exhibits tumor suppressive effects in hepatocellular carcinoma
H.W. Tan, C. Leung, K. Chan, I. Ng, R. Lo; Hong Kong, HK
- 13:15 - 13:15 48P - The effects of 5-fluorouracil (5-FU) on TGF- β -related signaling molecules
T. Wang, Y. Takikawa; Morioka, JP
- 13:15 - 13:15 49P - Gene mutations involved in drug resistance in liver cancer cells using a new rna-seq data analysis workflow
E. AKHAN GUZELCAN, M. Shojaei, A. Acar, R. Cetin Atalay; Ankara, TR
- 13:15 - 13:15 50P - Camouflaging iRGD-EGFR anchored human cytotoxic T-lymphocyte membranes to the surface of nanoparticles combined with low-dose irradiation: New approach to enhance drug-delivery targeting in gastric cancer
L. Zhang¹, H. Sha¹, R. Li¹, J. Wei¹, X. Qian², B. Liu¹; ¹Nanjing, CN, ²Nanjing, Jiangsu Province/CN
- 13:15 - 13:15 51P - Delivery of paclitaxel-loaded erythrocytes-based nanoparticles using injectable albumin hydrogel for regional chemotherapy
H. qian, Q. Liu, R. Li, L. Yu, B. Liu; Nanjing, CN
- 13:15 - 13:15 52P - Effect of apatinib combined with 5-fluorouracil (5-FU) on proliferation, apoptosis and invasiveness of gastric cancer cells
P. ZHAO¹, J. Zhang², X. Pang¹, L. Zhao¹, Q. Li¹, B. Cao¹; ¹Beijing, CN, ²Tai'an, CN
- 13:15 - 13:15 53P - One tumour, two clones: An in vitro model of intra-tumour heterogeneity
A. Salawu¹, M. Fernando², D. Hughes², M. Reed³, P. Woll¹, K. Sisley²; ¹Sheffield, South Yorkshire/GB, ²Sheffield, GB, ³Brighton, GB
- 13:15 - 13:15 54P - Docosahexaenoic acid mediates susceptible cell death through differential regulation of p62/p-eIF2 α /NRF2 in LMP1-expressing nasopharyngeal carcinoma cells
K. Lim¹, K. Jing², S. Shin¹, S.-H. Han¹, Y.-S. Yoo¹, Y.-J. Jeon¹, J.-Y. Heo¹, G.-R. Kweon¹, S.-K. Park¹, J.-I. Park¹; ¹Daejeon, KR, ²Zhanjiang, CN
- 13:15 - 13:15 55P - Inhibition of the ubiquitin-conjugating enzyme E2B restores the BCNU sensitivity of cancer cells by regulating MGMT ubiquitination
S.H. Hsu, S.-H. Chen, L.-T. Chen, J.-Y. Chang; Tainan, TW
- 13:15 - 13:15 56P - Oral squamous cell carcinoma cells were sensitized to cetuximab by Eribulin via induction of the mesenchymal-to-epithelial transition

H. Kitahara, M. HIRAI, S. Kawashiri, H. Nakamura; Kanazawa, JP

- 13:15 - 13:15 57P - In vivo study of the vaccine adjuvants prothymosin alpha and prothymosin alpha(100-109) in melanoma
P. Samara¹, K. Ioannou¹, N. Kavrohorianou¹, S. Haralambous¹, P. Selemenakis¹, A. Kotsinas¹, H. Kalbacher², W. Voelter², O. Tsitsilonis³; ¹Athens, GR, ²Tuebingen, DE, ³Athens, Ilissia/GR
- 13:15 - 13:15 58P - Melanoma affects clock gene machinery of several organs in tumor-bearing mice
L. de Assis, M.N. Moraes, K.K. Magalhães-Marques, S. Da Silveira Cruz-Machado, A.M. Castrucci; Sao Paulo, BR
- 13:15 - 13:15 59P - Is there receptor tyrosine kinases expression on lymphocytes in patients with renal cell carcinoma? First-in-human study
D. Khochenkov, M. Volkova, A. Olshanskaia, S. Aschuba, Y. Khochenkova, A. Anastasia Bondarenko, I. Tsimafeyeu; Moscow, RU
- 13:15 - 13:15 60P - Understanding and targeting Met signalling in bladder cancer
W. Badreldin, T. Powles, L. Menard, C. Ho-Yen, S. Kermorgant; London, GB
- 13:15 - 13:15 61P - Integrated molecular signatures of TERT promoter deregulation predict disease outcomes in non-muscle invasive bladder cancer
R. Leão¹, D. Lee¹, A. Figueiredo², M. Komosa¹, C. Zhang³, J. Apolónio¹, N. Nunes¹, T. Hermanns⁴, P. Wild⁴, C. Poyet⁴, R. Hamilton¹, P. Castelo-Branco¹, U. Tabori¹; ¹Toronto, CA, ²Coimbra, PT, ³Toronto, ON/CA, ⁴Zurich, CH
- 13:15 - 13:15 62P - Dose- and regimen-dependent effects of dexamethasone on extracellular matrix of brain tissue
A. Tsidulko¹, T. Pankova¹, C. Bezier², G. de La Bourdannaye³, A. Suhovskih¹, G. Kazanskaya¹, S. Aidagulova¹, E. Grigorieva¹; ¹Novosibirsk, RU, ²Paris, FR, ³Toulouse, FR
- 13:15 - 13:15 63P - Clinical dysregulation of DNA repair by the polynucleotide kinase/phosphatase-XRCC4-DNA ligase IV in neurological disease
D. Aceytuno¹, C. Piatt¹, Z. Havali-Shahriari², R. Edwards², M. Rey¹, R. Mani², S. Fang¹, M. Hammel³, M. Weinfeld², J. Tainer⁴, D. Schriemer¹, S. Lees-Miller¹, J.N. Glover²; ¹Calgary, CA, ²Edmonton, CA, ³Berkeley, US, ⁴Houston, US
- 13:15 - 13:15 64P - Effects of rottlerin and genistein through EF2K on proliferation, invasion and cell cycle/death in neuroblastoma cells
M. Erdogan, O. Alkan Yilmaz; Izmir, TR
- 13:15 - 13:15 65P - Influence of emotiogenic brain structures on tumor growth in the experiment
E. Korobeynikova, E. Rostorguev, N. Kuznetsova; Rostov-On-don, RU
- 13:15 - 13:15 66P - Systematic evaluation of the immune microenvironment of neuroendocrine tumours (NET)
C. Vesely¹, A. Childs², Y.N.S. Wong¹, O. Ogunbiyi¹, T.V. Luong¹, C. Thirlwell¹, M. Caplin¹, T. Marafioti¹, S.A. Quezada¹, T. Meyer¹; ¹London, GB, ²Bt, GB

- 13:15 - 13:15 67P - Developing a prediction model for response to lenalidomide treatment in refractory/relapsed multiple myeloma patients
Y.-J. Chung, S.-H. Yim, S.-H. Jung; Seoul, KR
- 13:15 - 13:15 68P - Combinatorial inhibition of mTOR and exportin-1 (XPO1) represses cell survival via metabolic modulation of pro-survival pathways in mantle cell lymphomas
K. Sekihara¹, K. Saitoh¹, H. Yang¹, T. Miida¹, M. Andreeff², Y. Tabe¹; ¹Tokyo, JP, ²Houston, TX/US
- 13:15 - 13:15 69P - CD200 and indoleamine 2,3-dioxygenase-1 (IDO-1) overexpression in relapsed acute myeloid leukemia patients
A. Memarian¹, S. Abdolmaleki¹, M. Mirahmadian², M. Jeddi-Tehrani²; ¹Gorgan, IR, ²Tehran, IR
- 13:15 - 13:15 70P - Correlation between types of acute lymphoblastic leukemia with socio demographic factors
M. Sen, J. Basak, A. Mukhopadhyay; Kolkata, IN
- 13:15 - 13:15 71P - CALR mutations and their link with cellular calcium during megakaryocyte hyperplasia in MPNs
M. Morlan Mairal¹, P. Papadopoulos², J. Hetmanski³, P. Caswell³, M. Krstic-Demonacos¹, A. Aziz¹; ¹Salford, GB, ²Madrid, ES, ³Manchester, GB
- 13:15 - 13:15 72P - Approach based on magnetic nanocomplexes improves antitumor efficacy of dendritic cells immunotherapy in mice
M. Inomistova, N. Khranovska, O. Skachkova, O. Makeenko, V. Orel; Kiev, UA
- 13:15 - 13:15 75P - Signs of tumor-specific immune processes in the regression of large rat tumors under the influence of low-intensity EMR EHF and magnetite nanoparticles
G. Zhukova, A. Shikhliarova, T. Barteneva, M. Bragina, E. Shirnina, I. Novikova; Rostov-On-don, RU
- 13:15 - 13:15 76P - Stimulation of RAC1/PAK1 signalling upregulates DNA damage repair genes via the BCL6/STAT5-switch
P. Barros, A. Amaral, L. Abrantes, T. Oliveira, H. Louro, M. Silva, P. Jordan, M. Gama-Carvalho, P. Matos; Lisboa, PT
- 13:15 - 13:15 77P - Deciphering the regulation of the metastasis suppressor, NDRG1 in different cancer-types and its functional implications
K.C. Park¹, Z. Kovacevic², D. Richardson²; ¹Sydney, AU, ²Sydney, NSW/AU
- 13:15 - 13:15 78P - Registration-based automated lesion detection and therapy evaluation of tumors in whole body PET-MR images
H. Ahlström, S. Ekström, T. Sjöholm, R. Strand, J. Kullberg, E. Johansson, P. Hagmar, F. Malmberg; Uppsala, SE
- 13:15 - 13:15 79P - 1,3,5 s-triazine containing analogues a prime Src family inhibitor: Design synthesis docking, anticarcinoma and angiogenic inhibition efficacy on cancer grafted CAM
P. Pathak¹, A. Balkrishna², P. Shukla¹, V. Kumar¹, A. Kumar³, A. Singh⁴, A. Verma¹; ¹Allahabad, IN, ²Haridwar, IN, ³Meerut, IN, ⁴Delhi, IN
- 13:15 - 13:15 (Withdrawn)

- 13:15 - 13:15 81P - A new isoquinoline alkaloid bersavine as a possible anticancer agent
K. Habartová, R. Havelek, M. Seifrtova, A. Hostalkova, L. Cahlikova, M. Rezacova; Hradec Kralove, CZ
- 13:15 - 13:15 82P - Tactics of surgical treatment of tumors of the sacrum
I. Khujanazarov, I. Alimov, S. Ishmuhammedov, M. Gafur-Akhunov; Tashkent, UZ
- 13:15 - 13:15 83P - The impact of co-culture of NSCLC tumor cells and fibroblasts on drug response
S. Abreu¹, V. Espírito Santo¹, A. Oleksijew², E. Oswald³, M. Estrada¹, S. Rebelo¹, K. Vaidya², J. Schuler³, P. Alves¹, E. Boghaert², C. Brito¹; ¹Oeiras, PT, ²Chicago, US, ³Freiburg, DE
- 13:15 - 13:15 BIOMARKERS
S. Singh, Hamilton, CA
- 13:15 - 13:15 88P - PALB2 reversion mutations in breast, prostate, and ovarian carcinomas
L. Gay¹, S. Daniel², J. Suh², S. Ramkissoon², J.-A. Vergilio², E. Severson², P. Stephens², J. Ross³, J. Elvin²; ¹Cambridge, CA, ²Cambridge, MA/US, ³Albany, NY/US
- 13:15 - 13:15 89P - Pan-cancer genomic analysis of MSI-H tumors reveals commonly altered pathways
S. Trabucco¹, S. Maund², R. Hartmaier³, K. Gowen¹, J. Sun³, G. Frampton³, P. Stephens³, P. Hegde², S.-M. Huang²; ¹Cambridge, US, ²South San Francisco, US, ³Cambridge, MA/US
- 13:15 - 13:15 90P - Molecular feature and clinical use development of gene expression profile "TP53 signature" in early stage breast cancer
S. Yamaguchi¹, S. Takahashi², T. Nomizu³, Y. Kakugawa⁴, T. Ishida⁵, S. Kato¹, C. Ishioka⁵; ¹Tokyo, JP, ²Sendai, Miyagi/JP, ³Koriyama, JP, ⁴Natori, JP, ⁵Sendai, JP
- 13:15 - 13:15 91P - Potential biomarkers of response to DKK1 blockade with DKN-01 in combination with paclitaxel in advanced esophagogastric cancer (EGC) patients (pts)
D. Duda¹, C. Sirard²; ¹Boston, MA/US, ²Cambridge, US
- 13:15 - 13:15 92P - Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial
S.P. Gampenrieder¹, G. Rinnerthaler¹, H. Hackl², M. Steiner¹, C. Monzo Fuentes¹, C. Hufnagl¹, C. Hauser-Kronberger¹, A. Egle¹, R. Greil¹; ¹Salzburg, AT, ²Innsbruck, AT
- 13:15 - 13:15 93P - Characterization of a novel tumor-suppressor gene CHL1 at 3p26.3 in esophageal squamous cell carcinoma
H. Wang, Zhengzhou, CN
- 13:15 - 13:15 94P - The role of vitamin D receptor polymorphisms in predicting response to therapy in non-muscle invasive bladder carcinoma
K.Y. Loh, Z. Wang, Y.K. Lim, R. Mahendran, E. Kesavan, E. Chiong; Singapore, SG
- 13:15 - 13:15 95P - Gene signatures as potential predictive markers of response to neoadjuvant chemotherapy in ER+/HER2+ breast cancer patients

E. Risi¹, A. Grilli², I. Migliaccio³, C. Biagioni³, C. Guarducci³, M. Bonechi³, A. McCartney³, S. Vitale⁴, L. Biganzoli³, S. Biccato², A. di Leo³, L. Malorni³; ¹Prato, PO/IT, ²Modena, IT, ³Prato, IT, ⁴Siena, IT

13:15 - 13:15 96P - Predictive biomarkers for adjuvant therapy in gastric adenocarcinoma

E. Pectasides¹, V. Kotoula², M. Bobos³, I. Chatzidakis⁴, S. Chrisafi³, G. Fountzilas³; ¹Boston, MA/US, ²Thessaloniki, Central Macedonia/GR, ³Thessaloniki, GR, ⁴Athens, GR

13:15 - 13:15 97P - Large-scale DNA organization is a prognostic marker of breast cancer survival

M. Guillaud¹, M. Keyes², Q. Ye³, A. Carraro³, A. Harrison³, M. Hayes³, A. Nichol³, S. Leung³; ¹Vancouver, CA, ²V, CA, ³Vancouver, BC/CA

13:15 - 13:15 98P - Telomere associated variables and their potential in CLL prognosis

N. De Pedro, J.C. Estrada, M. Chiesa, M. Diez, I. Garcia, R. González, B. Garcia, J. García, L. Esteban, L. Otero, P. Najarro; Madrid, ES

13:15 - 13:15 99P - Micro-RNA profile in advanced metastatic breast cancer as a predictive tool for response to bevacizumab-paclitaxel

M. Mendiola, V. Heredia-Soto, J. Herranz, R. Martín, P. Zamora Auñón, B. Castelo, A. Pinto Marin, M. Miguel, R. Crespo, A. Ramírez de Molina, D. Hardisson, E. Espinosa, A. Redondo; Madrid, ES

13:15 - 13:15 100P - Biomarkers of immune therapy in CUP

J. Xiu¹, Z. Gatalica²; ¹Phoenix, US, ²Phoenix, AZ/US

13:15 - 13:15 101P - A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma

D. Melisi¹, G. Piro¹, F. Simionato¹, C. Carbone¹, M. Frizziero², G. Malleo¹, S. Zanini¹, R. Casolino¹, R. Santoro¹, M. Mina¹, C. Zecchetto¹, V. Merz¹, A. Scarpa¹, C. Bassi¹, G. Tortora¹; ¹Verona, IT, ²Vipiteno, Bolzano/IT

13:15 - 13:15 102P - Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST)

D. Fabrizio¹, C. Malboeuf¹, D. Lieber¹, S. Zhong¹, J. He¹, E. White¹, M. Coyne², J. Silterra², T. Brennan², J. Ma², M. Kennedy², E. Schleifman³, S. Paul³, Y. Li³, D. Shames³, C. Cummings³, E. Peters³, M. Kowanzetz³, D. Lipson², G. Otto¹; ¹Cambridge, US, ²Cambridge, MA/US, ³South San Francisco, US

13:15 - 13:15 103P - Comparison of continuous measures across diagnostic PD-L1 assays using image analysis

T. Wiestler¹, M. Widmaier¹, J. Walker², C. Barker², M. Scott², F. Sekhavati¹, A. Budco¹, K. Schneider¹, K. Steele³, M. Rebelatto⁴; ¹Munich, DE, ²Cambridge, GB, ³Gaithersburg, MD/US, ⁴Gaithersburg, US

13:15 - 13:15 104P - Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA-CD3 TCB) for the treatment of CEA-positive solid tumors

I. Melero¹, N. Segal², J. Saro³, W. Ros⁴, M. Martinez-Garcia⁵, G. Argiles⁵, V. Moreno⁶, S. Ponce⁶, A. Marabelle⁷, J. Cleary⁸, H. Hurwitz⁹, J. Eder¹⁰, C. Jamois¹¹, E. Andersson¹², S. Bouseida¹³, F. Sandoval¹³, M. Bacac¹⁴, T. Nayak¹³, V. Karanikas³, E. Calvo⁶; ¹Pamplona, ES, ²New York, NY/US, ³Schlieren, CH, ⁴Amsterdam, NL, ⁵Barcelona, ES, ⁶Madrid, ES, ⁷Villejuif, FR, ⁸Boston, Ma, US, ⁹Durham, NC/US, ¹⁰New Haven, Ct, US, ¹¹Basel, Switzerland/CH, ¹²Munich, DE, ¹³Basel, CH, ¹⁴Zurich, CH

- 13:15 - 13:15 105P - Baseline gut microbiota in metastatic melanoma patients treated with ipilimumab: Relation with clinical response and colitis
N. Chaput¹, P. Lepage², C. Coutzac³, E. Soularue⁴, V. Asvatourian³, E. Lanoy³, C. Mateus³, F. Carbonnel⁴, C. Robert³; ¹Villejuif, CEDEX/FR, ²Jouy-En-josas Cedex, FR, ³Villejuif, FR, ⁴Kremlin Bicêtre, FR
- 13:15 - 13:15 106P - The association between PD-L1 expression, EGFR mutation and ALK translocation in a series of 982 lung cancers
M. Evans¹, B. O'Sullivan¹, M. Smith¹, F. Hughes¹, N. Trim¹, T. Mullis¹, L. Pallan², P. Tanriere¹; ¹Birmingham, GB, ²Birmingham, West Midlands/GB
- 13:15 - 13:15 107P - Association of tumor and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with response to nivolumab treatment in NSCLC patients
S. Sahba, A.-L. Niemeijer, J. De Langen, E. Thunnissen; Amsterdam, NL
- 13:15 - 13:15 108P - Characterisation of heterogeneity in microsatellite instable (MSI) tumours associated with distinct cell types and immune phenotypes
E. Fontana¹, P. Poudel², G. Nyamundanda², Y. Patil², C. Ragulan³, A. Sadanandam²; ¹Sutton, Surrey/GB, ²Sutton, GB, ³London, GB
- 13:15 - 13:15 109P - Clinical implication of PLR and PD-L1 in breast cancer patients
S. Wang¹, Q. Lu¹, T. Qin¹, F. Xu¹, Y. Zeng¹, W. Xia¹, Q. Zheng¹, K. Lee¹, K. Zhang¹, G. Qin¹, M.T. Kong², R. Hong¹, Y. Shi³, Z. Yuan³; ¹Guangzhou, CN, ²Macau, MO, ³Guangzhou, Guangdong/CN
- 13:15 - 13:15 110P - Prognostic and predictive value of lymphovascular invasion and lymph node status among breast cancer subtypes
G.-S. Liao, H.-M. Hsu, M.-S. Dai, J.-C. Yu; Taipei, TW
- 13:15 - 13:15 111P - PD-L1 expression in TNBC: A predictive biomarker of response to neoadjuvant chemotherapy?
A. Botticelli¹, B. Cerbelli², A. Pernazza², C.E. Onesti¹, P. Sciattella², L. Costarelli², M. Monti², D. Campagna², F. Mazzuca¹, L. Fortunato², P. Marchetti¹, G. D'Amati²; ¹Roma, IT, ²Rome, IT
- 13:15 - 13:15 112P - Pathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC)
I. Gataa¹, L. Mezquita², E. Auclin³, S. Le Moulec⁴, P. Alemany², M. Kossai², J. Massé⁴, C. CARAMELLA², J. Remon Masip², J. Lahmar², R. Ferrara⁵, A. Gazzah², J.-C. Soria⁶, D. Planchard², B. Besse², J. Adam²; ¹Paris, CEDEX 14/FR, ²Villejuif, FR, ³Paris, FR, ⁴Bordeaux, FR, ⁵Verona, IT, ⁶Villejuif, CEDEX/FR

- 13:15 - 13:15 113P - Could a systemic inflammation response index (SIRI) predict overall survival (OS) in metastatic pancreatic cancer (PC)?
V. Pacheco Barcia¹, O. Donnay¹, R. Mondejar², J. Rogado¹, M.D. Fenor de la Maza¹, R. Colomer¹; ¹Madrid, ES, ²Cuenca, ES
- 13:15 - 13:15 114P - Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intra-patient heterogeneity in metastatic breast cancer (MBC): A European TRANSCAN program
A. Gennari¹, E. Brain², O. Nanni³, E. Muñoz Couselo⁴, N. Harbeck⁵, R. Geiss², A. Rocca³, J. Cortés⁴, T. Degenhardt⁵, A. Piccardo¹, J.-L. Albérini², F. Matteucci³, A. Decensi¹, D.S. Corradengo¹, D. Andreis³, D. Marra¹, G. Gebhart⁶, C. Brambati⁷, D. Amadori⁸, P. Bruzzi⁹; ¹Genova, IT, ²St. Cloud, FR, ³Meldola (fc), IT, ⁴Barcelona, ES, ⁵Munich, DE, ⁶Brussels, BE, ⁷Saint Genis Pouilly, FR, ⁸Meldola, Forlì-Cesena/IT, ⁹Genoa, IT
- 13:15 - 13:15 115P - Evaluation of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs)
A. Prawira¹, A. Stundzia², P. Dufort², J. Halankar², D. Paravasthu², A. Spreafico³, A. Hansen³, A.R. Abdul Razak⁴, P. Bedard¹, M. Butler¹, S. Lheureux¹, A. Oza¹, R. Jang³, K. Suta³, S. Boross-Harmer³, J. Cipollone³, H. Chow³, U. Metser³, L. Siu⁵; ¹Toronto, Ontario/CA, ²Toronto, CA, ³Toronto, ON/CA, ⁴Newcastle Upon Tyne, GB, ⁵Toronto, On, CA
- 13:15 - 13:15 116P - Clinical and pre-clinical biomarkers of Regorafenib (REG) efficacy in metastatic colorectal cancer (mCRC) in a phase II trial
K. Khan¹, D. Cunningham², G. Vlachogiannis¹, S. Hedayat¹, M. Rata¹, D.-M. Koh¹, N. Tunariu¹, Y. Jamin¹, D. Collins¹, I. Chau³, S. Rao¹, D. Watkins³, N. Starling¹, C. Peckitt², N. Fotiadis¹, C. Saffery¹, J. Hahne¹, M. Fassan⁴, C. Braconi¹, N. Valeri²; ¹London, GB, ²Sutton, GB, ³Sutton, Surrey/GB, ⁴Padua, IT
- 13:15 - 13:15 117P - Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial
F.-C. Bidard¹, P. cottu¹, C. Dubot², L. Venat-Bouvet³, A. Lortholary⁴, H. Bourgeois⁵, M. Bollet⁶, V. Servent Hanon⁷, E. Luporsi-Gely⁸, M. Espie⁹, S. Guiu¹⁰, V. D'Hondt¹¹, V. Dieras¹², M.P. Sablin¹, S. Neffati¹, F. Berger¹, J.-Y. Pierga¹, W. Jacot¹¹; ¹Paris, FR, ²St. Cloud, FR, ³Limoges, FR, ⁴Nantes, CEDEX 2/FR, ⁵Le Mans, FR, ⁶Levallois-Perret, FR, ⁷Lille, CEDEX/FR, ⁸Vandoeuvre Les Nancy, CEDEX/FR, ⁹Paris, CEDEX 10/FR, ¹⁰Montpellier, FR, ¹¹Montpellier, CEDEX 5/FR, ¹²Paris, CEDEX 5/FR
- 13:15 - 13:15 118P - Nationwide external quality assessment (EQA) of EGFR testing in circulating tumor DNA: The French experience
M. Denis¹, A. Vallée², S. Charpentier², I. Nanni-Métellus³, L. Lacroix⁴, C. Jovelet⁴, M. Francilette⁴, D. Fetique⁵, J.-P. Belloq⁵, E. Rouleau⁶; ¹Nantes, CEDEX 1/FR, ²Nantes, FR, ³Marseille, FR, ⁴Villejuif, FR, ⁵Strasbourg, FR, ⁶Paris, CEDEX 5/FR
- 13:15 - 13:15 119P - IL-8 as a pharmacodynamic biomarker for TGF-β2 antisense (trabedersen) therapy: Results of a phase II trial
L. Hwang¹, W. Wang¹, S. Qazi¹, K. Ng¹, O. D'cruz¹, V. Trieu²; ¹Costa Mesa, US, ²Costa Mesa, CA/US

- 13:15 - 13:15 120P - Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial
S. Stintzing¹, B. Price², L. Knight², A. McCavigan², S. Walker³, P. Harkin², R. Kennedy², D. Neureiter⁴, S. Held⁵, A. Jung⁶, T. Kirchner¹, V. Heinemann¹; ¹Munich, DE, ²Craigavon, GB, ³New York, California/US, ⁴Salzburg, AT, ⁵Leverkusen, DE, ⁶München, DE
- 13:15 - 13:15 121P - Influence of HIF-2alpha deregulation and overexpression of VEGF ligands on the response to aflibercept: Identification of predictive biomarkers
A. LARSEN¹, S. Thouroude¹, L. Louadj¹, M. Sabbah¹, E. Dochy², A. de Gramont³, J. Denis¹, A. Bouygues¹; ¹Paris, FR, ²Bruxelles, BE, ³Levallois-Perret, FR
- 13:15 - 13:15 122P - Cell-free (cf)DNA analysis identifies PIK3CA/AKT1 mutations associated with greater PFS improvement from the addition of ipatasertib (IPAT) to paclitaxel (P) in triple-negative breast cancer (TNBC)
M. Wongchenko¹, R. Dent², S.-B. Kim³, C. Saura⁴, M. Oliveira⁴, J. Baselga⁵, A. Kapp⁶, W. Chan⁶, S. Singel⁶, D. Maslyar⁶, S. Gendreau⁶; ¹Hillsboro, US, ²Singapore, SG, ³Seoul, KR, ⁴Barcelona, ES, ⁵New York, US, ⁶South San Francisco, US
- 13:15 - 13:15 123P - Genotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004
C. Montagut Viladot¹, A. Bardelli², T. Tuxen Poulsen³, R. Dienstmann¹, M. Kragh⁴, S. Kopetz⁵, K. Koefoed³, F. Ciardiello⁶, C. Ding⁷, J. Vidal¹, J. Clausell-Tormos³, G. Siravegna⁸, T. Lindsted³, M.W. Pedersen³, G. Rospo⁸, G. Argilés Martinez¹, P. Nadler³, I. Horak³, J. Taberero¹; ¹Barcelona, ES, ²Candiolo, (TO)/IT, ³Ballerup, DK, ⁴-, DK, ⁵Houston, US, ⁶Naples, IT, ⁷Somerville, New Jersey, US, ⁸Candiolo, IT
- 13:15 - 13:15 124P - Role of circulating miRNAs as prognostic biomarkers in resected early-stage non-small cell lung cancer
P. Ulivi¹, E. Petracci¹, V. Ludovini², G. Marisi¹, A. Delmonte¹, N. De Luigi¹, D. Calistri¹, L. Crinò², D. Amadori³, R. Chiari⁴, S. Baglivo⁴, F. Grignani⁴; ¹Meldola, IT, ²Perugia, (PG)/IT, ³Meldola, Forlì-Cesena/IT, ⁴Perugia, IT
- 13:15 - 13:15 125P - Targeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes
A. Jassowicz¹, L. Liu², H. Huang³, D. Hong⁴, A. Naing³, V. Subbiah³, S. Piha-Paul³, J. Toung², R. Vijayaraghavan², R. Zhang², H. Kang², S. Fu³, A. Tsimberidou³, C. Lu³, C. Eng³, S. Moulder³, S. Kopetz⁴, R. Amaria³, F. Meric-Bernstam⁴, F. Janku³; ¹Heidelberg, DE, ²San Francisco, US, ³Houston, TX/US, ⁴Houston, US
- 13:15 - 13:15 126P - Single-cell combined mutation and gene expression studies of circulating tumor-associated cells in non-small cell lung cancer
J. Mong, J. Shi, T.M. Chin, S.-W. Wong, A. Tee, D. Chan, K. Wong, S. Yeap, L. Ngo, Y.-O. Tan, M. Hu, J. Ying, M.-H. Tan; Singapore, SG
- 13:15 - 13:15 127P - EGFR copy number aberrations detected in cfDNA from advanced NSCLC patients

G. O'Kane¹, T. Li², M. Tsao³, G. Liu³, T. Pugh², N. Leigh²; ¹Dublin, IE, ²Toronto, CA, ³Toronto, Ontario/CA

- 13:15 - 13:15 128P - Detection of esophageal cancer patients using circulating serum microRNA from the result of comprehensive analysis
K. Kato¹, K. Sudo¹, N. Boku², S. Abe¹, Y. Saito¹, K. Koyanagi¹, H. Daiko¹, J. Kawauchi³, S. Takizawa³, H. Sakamoto¹, S. Niida⁴, F. Takeshita¹, J. Matsuzaki¹, T. Ochiya¹; ¹Tokyo, JP, ²Kawasaki, Kanagawa/JP, ³Kamakura, JP, ⁴Ohbu, JP
- 13:15 - 13:15 129P - First prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis
J. Garcia Foncillas¹, J. Tabernero², E. Aranda Aguilar³, M. Benavides⁴, C.J. Camps⁵, R. López⁶, C. Montagut², A. Anton Torres⁷, G. Lopez Vivanco⁸, E. Diaz Rubio¹, F. Rojo¹, A. Vivancos²; ¹Madrid, ES, ²Barcelona, ES, ³Cordoba, ES, ⁴Malaga, ES, ⁵Valencia, ES, ⁶Santiago De Compostela, ES, ⁷Zaragoza, ES, ⁸Barakaldo, ES
- 13:15 - 13:15 130P - EGFR plasma testing in routine practice by real-time PCR in lung cancer patients: Experience of 262 patients
P. Taniere¹, P. Taniere¹, M. Smith¹, B. O'Sullivan¹, F. Hughes¹, T. Mullis¹, N. Trim¹, S. Bajjal¹, Q. Ghafoor², G. Middleton³; ¹Birmingham, GB, ²Birmingham, Birmingham/GB, ³Birmingham, West Midlands/GB
- 13:15 - 13:15 131P - Circulating tumor cells as liquid biopsy for castration resistant prostate cancer patients treated with cabazitaxel
S. Salvi¹, V. Conteduca², V. Casadio¹, P. Fici¹, G. Gurioli¹, F. Martignano¹, U. Basso³, G. Fornarini⁴, C. Lollì², G. Schepisi², S. Testoni¹, D. Calistri¹, U. De Giorgi²; ¹Meldola, IT, ²Meldola, Forlì-Cesena/IT, ³Padova, IT, ⁴Genova, IT
- 13:15 - 13:15 132P - Biomarker analysis using circulating tumor DNA in patients treated with sorafenib for advanced hepatocellular carcinoma
S.R. Park¹, C.R. Oh¹, S.-Y. Kong², M.K. Kim³, K.-A. Yoon¹, E. Cho⁴, J.-H. Jang⁴, J. Lee⁴, B.-Y. Ryoo¹; ¹Seoul, KR, ²Goyang, KR, ³Gyeonggi-Do, KR, ⁴Yongin, KR
- 13:15 - 13:15 133P - Heparinase enables reliable quantification of circulating tumor DNA from heparin plasma samples by droplet digital PCR
D. Sefrioui¹, L. Beaussire¹, F. Clatot², A. Perdrix¹, P. Michel¹, F. Di Fiore¹, N. Sarafan-Vasseur¹; ¹Rouen, FR, ²Rouen, CEDEX 1/FR
- 13:15 - 13:15 134P - Circulating tumour DNA (ctDNA) in the clinical management of patients (pts) with advanced non-small cell lung cancer (NSCLC): A single centre experience
M. Uccello¹, M. Kushnir², G. Mak³, C. Murias Henriquez⁴, C. Abbosh², D. Papadatos-Pastos², T. Newsom-Davis², T. Ahmad², C. Swanton², M. Forster⁵, R. Lanman⁶, I. Faull⁷, H.-T. Arkenau²; ¹Catania, IT, ²London, GB, ³London, UK/GB, ⁴Las Palmas, Canary Island/ES, ⁵London, London/GB, ⁶Redwood City, CA/US, ⁷Madrid, Barcelona/ES

- 13:15 - 13:15 135P - Genome-wide methylation analysis reveals a prognostic classifier for non-metastatic colorectal cancer (ProMCol)
M. Gündert, D. Edelmann, A. Benner, L. Jansen, M. Jia, V. Walter, P. Knebel, E. Herpel, J. Chang-Claude, M. Hoffmeister, H. Brenner, B. Burwinkel; Heidelberg, DE
- 13:15 - 13:15 136P - Epigenetic biomarkers in breast cancer: Preliminary results from H3K27m3 assessment in endocrine-treatment resistance
M. Fontes e Sousa, S. Lobo, S. Salta, P. Lopes, J. Lobo, S. Sousa, R. Henrique, C. Jeronimo; Porto, PT
- 13:15 - 13:15 137P - Bioinformatic estimate of biomarker-positive populations in genomics-driven trials using precision trial designer (PTD)
L. Mazzarella¹, G. Melloni², A. Guida¹, G. Curigliano¹, E. Botteri³, A. Esposito¹, M. Kamal⁴, C. Le Tourneau⁴, L. Riva¹, P. Pelicci¹; ¹Milan, IT, ²Boston, MA/US, ³Oslo, NO, ⁴Paris, FR
- 13:15 - 13:15 138P - Detection of microsatellite instability (MSI) in colorectal cancer samples with the automated Idylla MSI Test
G. Maertens, B. De Craene, E. Rondelez, K. Peeters, L. Vandebroek, L. Van Puymbroek, G. Vandercruyssen, E. Sablon; Mechelen, BE
- 13:15 - 13:15 139P - Gene expression BIRC5, Erb-b2/Her2-neu, ESR1, PGR1, MMP11, MDR1, MRP1, MXR at the CTCs in the primary breast cancer
Y. Shliakhtunou, Vitebsk, BY
- 13:15 - 13:15 140P - Metabolic syndrome and inflammation in castration resistant prostate cancer (CRPC) patients (pts) treated with abiraterone (abi) and enzalutamide (enza)
V. Conteduca¹, O. Caffo², L. Galli³, A. Maugeri⁴, E. Scarpi⁴, F. Maines², V. Chiuri⁵, C. Lolli¹, S. Kinspergher², G. Schepisi¹, M. Santoni⁶, D. Santini⁷, L. Fratino⁸, S.L. Burgio⁴, S. Salvi⁴, C. Menna¹, U. De Giorgi¹; ¹Meldola, Forlì-Cesena/IT, ²Trento, IT, ³Pisa, IT, ⁴Meldola, IT, ⁵Lecce, IT, ⁶Ancona, IT, ⁷Roma, IT, ⁸Aviano, IT
- 13:15 - 13:15 141P - Ischemic stroke and cancer correlation: A stroke unit experience
M. Rodrigues, R. Costa, S. Brito, A. Pissarra, A. Lourenço, F. Grenho, L. Campos; Lisbon, PT
- 13:15 - 13:15 142P - Longitudinal exploratory analysis of prior- surgery everolimus circulating and clinical biomarkers in locally advanced and metastatic renal cell carcinoma patients (RCC)
R. Elaidi¹, D. Helley¹, L. Mauge¹, C. Badoual¹, E. Tartour¹, E. Braychenko¹, L. Albiges², B. Escudier³, S. Oudard¹; ¹Paris, FR, ²Villejuif, CEDEX/FR, ³Villejuif, FR
- 13:15 - 13:15 143P - A comparison of treatment recommendations by molecular tumor boards worldwide
D. Rieke, S. Leyvraz, S. Burock, U. Keilholz; Berlin, DE
- 13:15 - 13:15 144P - Identification of germline mutation using 30-gene sequencing and clinical characteristic of Chinese with hereditary breast cancer
A. Kwong¹, V. Shin², C.-H. Au³, T.-L. Chan³, E. Ma³; ¹Hong Kong, HK, ²Pokfulam, HK, ³Happy Valley, HK
- 13:15 - 13:15 145P - Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT

S. Schwartz¹, F. Cecchi², Y. Tian³, K. Scott³, M. Di Bartolomeo⁴, F. Morano⁴, G. Fucà⁴, A. Martinetti⁵, F. De Braud⁴, F. Dominoni⁶, M. MILIONE⁴, M.A. Calegari⁷, A. Orlandi⁷, C. Barone⁷, F. Pietrantonio⁴, T. Hembrough²; ¹Rockville, US, ²New York, US, ³Rockville, MD/US, ⁴Milan, IT, ⁵No City Provided, NA, ⁶Milano, IT, ⁷Roma, IT

13:15 - 13:15 146P - Predicting response to chemotherapy in gastric cancer patients randomized to docetaxel: A reevaluation of the ITACA-S trial

F. Cecchi¹, D. Catenacci², S. Schwartz³, S. Sellappan³, Y. Tian⁴, R. Miceli⁵, F. Pietrantonio⁵, A. Pellegrinelli⁵, A. Martinetti⁶, M. Di Bartolomeo⁵, T. Hembrough¹; ¹New York, US, ²Chicago, IL/US, ³Rockville, US, ⁴Rockville, MD/US, ⁵Milan, IT, ⁶No City Provided, NA

13:15 - 13:15 147P - The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer

D. Naruge¹, C. Morizane², M. Ueno³, H. Takahashi⁴, Y. Kawamoto⁵, K. Sudo⁶, S. Shimizu⁷, T. Nakajima⁸, S. Itoh⁹, H. Ishii¹⁰, T. Kato¹¹, T. Kudo¹², M. Izumi⁶, T. Sudo⁶, S. Nomura², T. Kuwata¹³, S. Fujii¹³, K. Shitara⁴, A. Ohtsu⁴, T. Yoshino⁴; ¹Mitaka, Tokyo, JP, ²Tokyo, JP, ³Yokohama, JP, ⁴Kashiwa, Chiba/Jp, ⁵Sapporo, Hokkaido/Jp, ⁶Chiba, JP, ⁷Saitama, JP, ⁸Kanagawa, JP, ⁹Fukuoka, JP, ¹⁰Matsuyama, JP, ¹¹Amagasaki, Hyogo/Jp, ¹²Suita, Osaka/Jp, ¹³Kashiwa, JP

13:15 - 13:15 BREAST CANCER, EARLY STAGE

E. De Azambuja¹, C. Criscitiello²; ¹Brussels, BE, ²Milan, IT

13:15 - 13:15 164P - Impact of lack of surgery on outcomes in elderly patients with non-metastatic breast cancer (BC): A population based study using the SEER 18 data base

C. Truica¹, M. Yin²; ¹New York, US, ²Hershey, PA/US

13:15 - 13:15 166P - Eight-year follow up results of the OTOASOR trial: The optimal treatment of the axilla – surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer. A randomized, single centre, phase III, non-inferiority trial

Á. Sávolt, G. Peley, C. Polgár, B. Györfy, Z. Mátrai; Budapest, HU

13:15 - 13:15 167P - Time to surgery in early breast cancer treated with neoadjuvant chemotherapy

M. Cinausero¹, G. Galli², D. Basile¹, L. Gerratana¹, G. Fasola¹, F. De Braud², M. Sant², B. Paolini², S. Di Cosimo², F. Puglisi¹; ¹Udine, IT, ²Milan, IT

13:15 - 13:15 168P - Updated results of the Breast cancer task force phase II study of neoadjuvant weekly carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts)

C. Fontaine¹, N. Cappoen², V. Renard³, H. Van Den Bulk⁴, P. Vuylsteke⁵, P. Glorieux⁶, L. Decoster², M. Vanhoeij², J. De Grève², A. Awada⁷, H. Wildiers⁸; ¹Brussels, BE, ²Jette, BE, ³Gent, BE, ⁴Bonheiden, BE, ⁵Namur, BE, ⁶Arlon, BE, ⁷Brussel, BE, ⁸Leuven, BE

13:15 - 13:15 169P - Neoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial

S. Di Cosimo¹, N. Laverde², M. Cazzaniga³, D. Generali⁴, G.V. Bianchi¹, E. Tagliabue², V. Torri¹, F. Crippa¹, B. Paolini¹, G. Scaperrotta¹, A. Gulino⁵, C. Tripodo⁵, M. Colombo¹, S. Folli¹, F. de Braud¹; ¹ Milan, IT, ² Milano, IT, ³ Monza, IT, ⁴ Cremona, (CR)/IT, ⁵ Palermo, IT

- 13:15 - 13:15 170P - Impact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis
C. Criscitiello¹, M. Golshan², W. Barry², G. Viale¹, S. Wong², M. Santangelo³, G. Curigliano¹; ¹ Milan, IT, ² Boston, US, ³ Naples, IT
- 13:15 - 13:15 171P - Composite index of risk shows that benefit from adjuvant dose dense chemotherapy is not confined to triple negative breast cancer
F. Puglisi¹, M. Ceppi², L. Gerratana¹, F. Cognetti³, S. De Placido⁴, P. Bruzzi², M. De Laurentiis⁴, G. Bisagni⁵, G. Cavazzini⁶, A. Durando⁷, A. Turletti⁷, E. Valle⁸, F. Montemurro⁹, S. Barni¹⁰, A. Ardizzoni¹¹, G. Colantuoni¹², T. Gamucci¹³, L. Del Mastro²; ¹ Udine, IT, ² Genova, IT, ³ Roma, IT, ⁴ Napoli, IT, ⁵ Reggio Emilia, IT, ⁶ Mantova, IT, ⁷ Torino, IT, ⁸ Cagliari, IT, ⁹ Candiolo, (TO)/IT, ¹⁰ Treviglio, (BG)/IT, ¹¹ Bologna, IT, ¹² Avellino, IT, ¹³ Sora, Frosinone/IT
- 13:15 - 13:15 172P - The prognostic impact of chemotherapy induced amenorrhea in women treated with early stage breast cancer
C. Ordu¹, K. Pilanci², F. Elbüken², G. Alço², Ü. Köksal², S. İlgün², D. Sarsenov², A. Aydın², A. Öztürk², Z. Erdoğan², F. Ağaçayak², C. Tecimer², Y. Eralp², F. Aktepe², V. Özmen²; ¹ Istanbul, Balıkesir Province/TR, ² Istanbul, TR
- 13:15 - 13:15 173P - Determinants and outcomes associated with delays in adjuvant chemotherapy among breast cancer patients
M. Chavez Mac Gregor, X. Lei, H. Zhao, S. Giordano; Houston, TX/US
- 13:15 - 13:15 174P - Adjuvant chemotherapy in pT1ab node-negative triple negative breast carcinomas: Results of a national multi-institutional retrospective study
A. De Nonneville¹, A. Gonçalves², C. Zemmour², M. Cohen², J.M. Classe³, F. Reyat⁴, P.E. Colombo⁵, E. Jouve⁶, S. Giard⁷, E. Barranger⁸, R. Sabatier¹, F. Bertucci¹, J.M. Boher², G. Houvenaeghel²; ¹ Marseille, CEDEX 9/FR, ² Marseille, FR, ³ Saint Herbain, FR, ⁴ Paris, FR, ⁵ Montpellier, FR, ⁶ Toulouse, FR, ⁷ Lille, FR, ⁸ Nice, CEDEX 2/FR
- 13:15 - 13:15 175P - OHERA: A real world study of cardiac events in &
E. Lidbrink¹, J. Erfan², E. Chmielowska³, B. Otremba⁴, A. Bouhlel⁵, S. Lauer⁵, M. Liste Hermoso⁵, E. Nüesch⁵, M. Shing⁶, V. Misra⁷; ¹ Stockholm, SE, ² Nyiregyhaza, HU, ³ Torun, PL, ⁴ Oldenburg, DE, ⁵ Basel, CH, ⁶ San Francisco, US, ⁷ Manchester, GB
- 13:15 - 13:15 176P - Clinical outcomes of delayed start of trastuzumab treatment in patients with early breast cancer: ml25232 study
S. Beslija¹, T. Ceric¹, B. Hasanbegovic¹, A. Kurtovic-Kozaric¹, A. Pasic¹, N. Mahic¹, M. Kalamujic¹, A. Cardzic¹, J. Alidzanovic², I. Marjanovic³, A. Mekic-Abazovic⁴; ¹ Sarajevo, BA, ² Tuzla, BA, ³ Mostar, BA, ⁴ Zenica, BA

- 13:15 - 13:15 177P - Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial
S. Delaloge¹, Y. Ye², D. Cella³, M. Buyse⁴, A. Chan⁵, C. Barrios⁶, F.A. Holmes⁷, J. Mansi⁸, H. Iwata⁹, B. Ejlertsen¹⁰, B. Moy¹¹, G. von Minckwitz¹², S. Chia¹³, M. Gnant¹⁴, S. Smichkoska¹⁵, A. Cicenieni¹⁶, S. Moran², A. Auerbach², L. Fallowfield¹⁷, M. Martin Jimenez¹⁸; ¹Villejuif, FR, ²Los Angeles, CA/US, ³Chicago, IL/US, ⁴San Francisco, CA/US, ⁵Perth, AU, ⁶Porto Alegre, BR, ⁷Houston, TX/US, ⁸London, GB, ⁹Chikusa-Ku, Nagoya, JP, ¹⁰Copenhagen, DK, ¹¹Boston, MA/US, ¹²Neu-Isenburg, DE, ¹³Vancouver, BC/CA, ¹⁴Vienna, AT, ¹⁵Skopje, MK, ¹⁶Vilnius, LT, ¹⁷Brighton, GB, ¹⁸Madrid, ES
- 13:15 - 13:15 178P - Second interim analysis of HerSCin, a German non-interventional study of subcutaneous trastuzumab for HER2-positive early breast cancer in routine clinical practice
K. Lüdtke-Heckenkamp¹, S. Kümme², A. Ruf-Dördelmann³, A. Distelrath⁴, J. Wacker⁵, S. Schmatloch⁶, S. Busch-Liles⁷, M. Schmidt⁸; ¹Georgsmarienhütte, DE, ²Essen, DE, ³Karlsruhe, DE, ⁴Fulda, DE, ⁵Bruchsal, DE, ⁶Kassel, DE, ⁷Grenzach Wyhlen, DE, ⁸Mainz, DE
- 13:15 - 13:15 179P - Timing of initiation of trastuzumab (T) and long-term outcome of patients (pts) with early-stage (ES) HER2-positive (HER2+) breast cancer (BrCa): Impact of neo-adjuvant (NAdj) versus adjuvant (Adj) strategy
G. Gullo¹, N. Walsh¹, D. Fennelly¹, D. Tryphonopoulos², J. Walshe¹, K. O'Mahony¹, N. Silva¹, L. Hammond¹, J. Ballot¹, C. Quinn¹, C. Buckley¹, J. Crown¹; ¹Dublin, IE, ²Athens, GR
- 13:15 - 13:15 180P - Adjuvant endocrine treatment: Stop or continue?
E. Muller¹, A. van de Wouw², D. van Dreuten¹; ¹Doetinchem, NL, ²Venlo, NL
- 13:15 - 13:15 181P - Use and effectiveness of adjuvant ovarian function suppression (OFS) in premenopausal women with early breast cancer
A. Ferreira¹, J. Ribeiro¹, A. Mayer¹, M. Brito¹, A. Miranda¹, J. Fernandes¹, J. Passos-Coelho¹, L. Costa¹, I. Vaz-Luís²; ¹Lisbon, PT, ²Villejuif, FR
- 13:15 - 13:15 182P - A phase II randomised study of Adjuvant hypo-fractionated radiotherapy with concurrent vs sequential letrozole in post-menopausal women with hormone receptor positive breast cancer: Report of pulmonary toxicity and cosmetic outcome
R. Upadhyay¹, D.N. Sharma², P. Julka², G. Rath²; ¹New Delhi, Delhi/IN, ²New Delhi, IN
- 13:15 - 13:15 183P - Intrinsic tumor features underlying clinical subtype discordance in early breast cancer
V. Kotoula¹, E. Giannoulatou², K. Papadopoulou¹, I. Tikas¹, K. Manousou¹, M. Bobos¹, S. Lakis¹, G. Lazaridis¹, I. Efstratiou¹, F. Zagouri¹, G. Pentheroudakis³, H. Gogas⁴, C. Christodoulou¹, A. Koutras¹, A. Psyrris¹, C. Papandreou⁵, P. Papakostas¹, D. Bafaloukos¹, D. Pectasides¹, G. Fountzilas⁶; ¹Athens, GR, ²Darlinghurst, NSW/AU, ³Ioannina, GR, ⁴Athens, Attiki/GR, ⁵Larissa, GR, ⁶Thessaloniki, GR
- 13:15 - 13:15 184P - Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by immunohistochemistry: A retrospective study in Spanish population
S. Perez Ramirez, M. del Monte-Millán, S. López-Tarruella, I. Márquez-Rodas, Y. Jerez, F. Lobo Samper, Y. Izarzugaza Peron, N. Martínez Jañez, J.A. García-Saenz, F. Moreno Antón, P. Zamora Auñón, M. Arroyo Yustos, M.Á. Lara Álvarez, E.M. Ciruelos Gil, L. Manso Sánchez, M.J. Echarri González, J.A. Guerra Martínez, C. Jara Sánchez, V. Valentín Maganto, M. Martin Jimenez; Madrid, ES

- 13:15 - 13:15 185P - The first report of multicenter validation study of 95-gene classifier, a multi-gene prognostic assay of estrogen receptor positive and node negative breast cancer patients
T. Kinoshita¹, K. Aogi², M. Takahashi², K.-I. Ito³, T. Oba³, N. Shiroma⁴, K. Arihiro⁴, F. Tsukamoto⁵, S. Shiino¹, M. Yoshida¹, S. Ohsumi²; ¹Tokyo, JP, ²Matsuyama, JP, ³Matsumoto, JP, ⁴Hiroshima, JP, ⁵Osaka, Osaka/JP
- 13:15 - 13:15 186P - Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms
A. Picornell¹, I. Echavarria Diaz-Guardamino¹, E. Alvarez Castillo¹, S. Lopez-Tarruella Cobo¹, Y. Jerez¹, K. Hoadley², J. Parker², M. del Monte-Millán¹, R. Ramos Medina¹, J. Gayarre¹, I. Ocaña¹, M. Cebollero¹, T. Massarrah¹, F. Moreno Antón¹, J.A. García-Saenz¹, H. Gomez Moreno³, A.I. Ballesteros Garcia¹, M. Ruíz-Borrego⁴, C. Perou², M. Martin Jimenez¹; ¹Madrid, ES, ²Chapel Hill, NC/US, ³Lima, PE, ⁴Sevilla, ES
- 13:15 - 13:15 187P - Summary of head-to-head comparisons of patient (pt) risk classifications by the 21-gene recurrence score (RS) assay and other genomic assays for early breast cancer (EBC)
Z. Varga¹, P. Sinn², D. McCullough³, A. Lau³, M. Stöppler³, F. Baehner³, C. Chao³, A. Seidman⁴; ¹Pecs, HU, ²Heidelberg, DE, ³Redwood City, CA/US, ⁴New York, NY/US
- 13:15 - 13:15 188P - The impact of Oncotype DX breast cancer assay results on clinical practice: A UK experience
V. Crolley¹, H. Marashi², S. Rawther³, M. Parton¹, J. Graham⁴, A. Vinayan⁵, S. Sutherland¹, A. Rigg¹, A. Wadhawan⁶, C. Harper-Wynne⁷, E. Spurrell¹, H. Bond⁸, F. Raja¹, J. King¹; ¹London, GB, ²Glasgow, GB, ³Sheffield, GB, ⁴Northallerton, GB, ⁵Stevenage, GB, ⁶Cardiff, GB, ⁷Maidstone, GB, ⁸Truro, GB
- 13:15 - 13:15 189P - Enhancing decision-making about adjuvant chemotherapy in ER+, HER2- early breast cancer (EBC) following EndoPredict testing
L. Fallowfield¹, S. May¹, L. Matthews¹, V. Jenkins¹, J. Mackay², A. Arbon¹, B. Hack¹, J. Hall³, C. Harper-Wynne⁴, S. Hinde⁵, A. Moss⁶, E. Thanopoulou⁷, S. Westwell⁸, D. Wlaszly¹, R. Simcock¹, D. Bloomfield¹, G. Patel⁹; ¹Brighton, GB, ²London, London/GB, ³Dartford, GB, ⁴Maidstone, GB, ⁵York, GB, ⁶Brighton, Merseyside/GB, ⁷Guildford, GB, ⁸Eastbourne, GB, ⁹London, GB
- 13:15 - 13:15 190P - Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
V. Allouchery¹, L. Beaussire¹, A. Perdrix¹, D. Sefrioui¹, L. Augusto¹, C. Guillemet¹, N. Sarafan-Vasseur¹, F. Di Fiore¹, F. Clatot²; ¹Rouen, FR, ²Rouen, CEDEX 1/FR
- 13:15 - 13:15 191P - Pathological proliferation score to predict genomic risk categories in early stage breast cancer
A. Bulbul¹, D. Tsao-Wei², E.A. Mino¹, A. Mustafa³, S. Rashad⁴, H. Abboud⁵, S. Chouial¹, T. Braik¹, K. Masoud¹, D. Tripathy⁶; ¹Carlsbad, NM/US, ²Los Angeles, CA/US, ³Jammu, IN, ⁴Chicago, IL/US, ⁵Monee, IL/US, ⁶Houston, TX/US
- 13:15 - 13:15 192P - Population sizes of patients (pts) with node negative (N0), HR+, HER2- primary breast cancer (BC), using standard and TAILORx 21-gene recurrence score (RS) cut-off values (COV)

J.-U. Blohmer¹, M. Verrill², C. Fortmann³, C. Chao³, J. Gligorov⁴; ¹Berlin, DE, ²Newcastle Upon Tyne, GB, ³Redwood City, CA/US, ⁴Paris, FR

13:15 - 13:15 193P - Oncotype DX score, menopausal status and body mass index

S. Picardo¹, J. Sui², M. Grealley¹, B. Woulfe³, L. Prior¹, L. Corrigan¹, C. O'Leary¹, W. Mullally², J. Walshe¹, J. McCaffrey¹, M. O'Connor⁴, D. O'Mahony⁵, L. Coate¹, R. Gupta³, S. O'Reilly⁵; ¹Dublin, IE, ²Cork, IE, ³Limerick, IE, ⁴Waterford, CO/IE, ⁵Cork, Cork/IE

13:15 - 13:15 194P - Comparisons of tumor-infiltrating lymphocytes and 21-gene recurrence score in ER-positive/HER2-negative breast cancer

S.G. Ahn, Y.J. Cha, C. Yoon, S.J. Bae, J. Kim, J. Jeong; Seoul, KR

13:15 - 13:15 195P - The 70-gene signature in node positive breast cancer: 10-year follow-up of the observational RASTER study

S. Vlieg¹, V. Retel¹, C. Drukker², J.M. Bueno-De-Mesquita¹, E. Rutgers¹, H. van Tinteren¹, M.J. van de Vijver¹, J. Wesseling¹, W. van Harten¹, S. Linn¹; ¹Amsterdam, NL, ²Dordrecht, NL

13:15 - 13:15 196P - Higher expression of estrogen response genes in the primary tumor is associated with a greater risk for late recurrence in patients with ER+/HER2-breast cancer

R. Bense¹, E.G.E. de Vries², C. Schröder¹, R. Fehrmann¹; ¹Groningen, NL, ²Cluj-Napoca, RO

13:15 - 13:15 197P - Understanding BRCA1 and BRCA2 mutated breast cancer cases in Romania: First report on founder mutations in Romanians

A. Eniu¹, L. Pop¹, A. Stoian¹, E. Dronca¹, R. Matei¹, M. Ligtenberg², H. Ouchene², A. Onisim¹, O. Rotaru¹, R. Eniu³, N. Antone¹; ¹Cluj-Napoca, RO, ²Nijmegen, NL, ³Cardiff, GB

13:15 - 13:15 198P - The prevalence of CD146 expression in breast cancer subtypes and its relation to outcome

I. de Kruijff, A. Timmermans, M. den Bakker, A. Trapman, R. Foekens, E. Oomen-De Hoop, M. Smid, A. Tjon A Fat - Hollestelle, C. van Deurzen, M. Meijer - van Gelder, J. Foekens, J. Martens, S. Sleijfer; Rotterdam, NL

13:15 - 13:15 199P - Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer

L. Gerratana, D. Basile, S. Zago, M.G. Vitale, G. Pelizzari, M. Bonotto, C. Bozza, M. Bartoletti, V. Fanotto, C. Lisanti, M. Cinausero, S. Barban, M. Lera, I. Venuti, M. Mansutti, A.M. Minisini, G. Fasola, F. Curcio; Udine, IT

13:15 - 13:15 200P - Vitamin D as a prognostic factor in triple negative early breast cancer

S. Morales, A. Gasol Cudos, A. Novell Alvarez, F. Vilardell Villellas, M.J. Panades Siurana, C. Canosa Morales, J. Mele Olive, E. Iglesias Martinez; Lleida, ES

13:15 - 13:15 201P - CDK12: New breast and ovarian cancer predisposition gene in Tatar population?

E. Shagimardanova¹, O. Brovkina², M. Gordiev¹, R. Enikeev¹, L. Shigapova¹, D. Khodyrev², O. Gusev¹, A. Kedrova², V. Kosiy², A. Nikitin²; ¹Kazan, RU, ²Moscow, RU

13:15 - 13:15 202P - Prognostic value of master transcriptional regulators (MTRs) in early stage breast cancer

S. Barron¹, K. Jirstrom², B. Nodin², H. Jernstrom², C. Ingvar², B. Moran¹, C.-J.A. Wang¹, T. Loughman¹, B. Fender¹, P. Dynoodt¹, C. Lopez-Ruiz¹, W. Gallagher¹; ¹Dublin, IE, ²Lund, SE

- 13:15 - 13:15 203P - Survival outcomes of all patients treated with breast carcinosarcoma at a UK specialist cancer centre over a 10 year period (2004–2014)
M. Alameddine¹, J. Chan², F. Alam²; ¹Wirral, Merseyside/GB, ²Wirral, GB
- 13:15 - 13:15 204P - ESR1, Ph-mTOR, CDK4/6 and PD-L1 expression as prognostic (and potentially druggable) drivers for pure invasive lobular breast carcinoma (ILC): Preliminary results of prognostic outliers according to a clinical-pathological model
L. Carbognin¹, M. Brunelli¹, E. Manfrin¹, A. Calio¹, I. Sperduti², M.V. Dieci³, G. Griguolo³, V. Guarneri⁴, R. Nortilli¹, S. Pilotto¹, E. Fiorio¹, V. Parolin¹, E. Orvieto³, F. Pellini¹, G. Pollini¹, P.F. Conte³, A. Scarpa¹, G. Tortora¹, E. Bria¹; ¹Verona, IT, ²Rome, IT, ³Padova, IT, ⁴Padua, IT
- 13:15 - 13:15 205P - The pregnancy and fertility (PREFER) study: A prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts)
C. Dellepiane¹, M. Lambertini², V. Fontana¹, F. Poggio¹, E. Blondeaux¹, B. Conte¹, A. D'Alonzo¹, M. Vaglica¹, C. Bighin¹, G. Iacono¹, A. Abate¹, S. Pastorino¹, M.C. Pescio¹, P. Anserini¹, L. Del Mastro¹; ¹Genova, IT, ²Brussels, BE
- 13:15 - 13:15 206P - Incidence of permanent alopecia following adjuvant chemotherapy in women with early stage breast cancer
J. Crown, J. Walshe, D. Fennelly, J.-C. Long, S. Cairney, D. McDonnell, J. Ballot, D. Wildes, E. Sills, G. Gullo; Dublin, IE
- 13:15 - 13:15 207P - Significant changes in dietary intake and physical activity after breast cancer diagnosis in a Chinese breast cancer cohort study
Y. Lei, W. Yeo, S.C. Ho, C.-K.I. Lee, K.L. Cheung, R. Lee, Y.-Q. He; Hong Kong, HK
- 13:15 - 13:15 208P - Prevention of cardiotoxicity in breast cancer patients: A randomized prospective study
A. Elkhateeb, D. Diab, H. Ibrahim, N. Gado, Y. Ali, A. Ibrahim; Cairo, EG
- 13:15 - 13:15 209P - Quality-of-life results from a randomized, phase-II-study of the therapeutic cancer vaccine L-BLP25 (Stimuvax®) in the preoperative treatment of women with primary breast cancer (ABCSCG-34)
V. Bjelic-Radicic¹, C. Singer², G. Pfeiler², M. Hubalek³, R. Bartsch², H. Stöger¹, A. Pichler⁴, E. Petru¹, R. Greil⁵, V. Wette⁶, A. Petzer⁷, P. Sevelde², D. Egle⁸, P. Dubsy², F. Fitzal⁷, R. Jakesz², M. Balic¹, S. Frantal², L. Sölkner², M. Gnant²; ¹Graz, AT, ²Vienna, AT, ³Schwaz, AT, ⁴Leoben, AT, ⁵Salzburg, AT, ⁶No City Provided, NA, ⁷Linz, AT, ⁸Innsbruck, AT
- 13:15 - 13:15 210P - Dedicated breast PET for predicting residual disease after breast cancer neoadjuvant chemotherapy
S. Sasada¹, T. Kadoya², N. Goga², A. Emi², K. Kajitani², N. Masumoto², R. Haruta², T. Kataoka², M. Okada²; ¹Hiroshima, Hiroshima/JP, ²Hiroshima, JP
- 13:15 - 13:15 212TiP - IMpassion031: A phase III study comparing neoadjuvant atezolizumab (atezo) vs placebo in combination with anthracycline/nab-paclitaxel (nab-pac)-based chemotherapy in early triple-negative breast cancer (eTNBC)

E.A. Mittendorf¹, C. Barrios², N. Harbeck³, K.H. Jung⁴, D. Miles⁵, S. Saji⁶, H. Zhang⁷, A.-N. Duc⁸, S. Rafii⁹, C. Lai¹⁰; ¹Houston, US, ²Porto Alegre, BR, ³Munich, DE, ⁴Seoul, KP, ⁵Northwood, GB, ⁶Fukushima, JP, ⁷Houston, TX/US, ⁸Basel, CH, ⁹Welwyn Garden City, GB, ¹⁰South San Francisco, US

- 13:15 - 13:15 213TiP - PIONEER- Pre-operative wlnDow study of letrozole plus PR agonist megestrol acetate versus letrozole alONE in post-menopausal patients with ER-positive breast cancer
S. Kumar¹, G. Dougall², A.-L. Vallier², L. Jones², W. Qian², E. Provenzano¹, C. Caldas¹, P. Pantziarka³, J. Carroll², R. Baird¹; ¹Cambridge, Cambridgeshire/GB, ²Cambridge, GB, ³Kingston Upon Thames, GB
- 13:15 - 13:15 214TiP - VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral metronomic vinorelbine to endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial
B. Adamo¹, J.A. Perez Fidalgo², E. Ciruelos³, M. Vidal⁴, S. Blanch⁵, A. Lopez⁶, P. Gomez Pardo⁴, L. Murillo⁷, K. Amillano⁸, N. Martínez Jañez³, X. Gonzalez⁴, J. Canes Ruiz⁹, A. Prat⁴; ¹Messina, IT, ²Valencia, Valencia/ES, ³Madrid, ES, ⁴Barcelona, ES, ⁵Valencia, ES, ⁶Leon, ES, ⁷Zaragoza, ES, ⁸Reus, ES, ⁹Barcelona, BARCELONA/ES
- 13:15 - 13:15 215TiP - PALLAS: PALbociclib CoLLaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer
E. Mayer¹, A. Demichele², G. Pfeiler³, W. Barry¹, O. Metzger⁴, P. Rastogi⁵, F. Symmans⁶, H. Burstein¹, K. Miller⁷, S. Loibl⁸, S. Schmatloch⁹, T. Goulioti¹⁰, D. Zardavas¹⁰, C. Fesl³, M. Koehler¹¹, C. Huang Bartlett¹¹, X. Huang¹², M. Piccart¹⁰, E. Winer¹, M. Gnant³; ¹Boston, MA/US, ²Philadelphia, PA/US, ³Vienna, AT, ⁴Boston, US, ⁵Pittsburgh, US, ⁶Houston, TX/US, ⁷Indianapolis, IN/US, ⁸Neu-Isenburg, DE, ⁹Kassel, DE, ¹⁰Brussels, BE, ¹¹New York City, US, ¹²San Diego, US
- 13:15 - 13:15 216TiP - OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
A. Tutt¹, B. Kaufman², J. Garber³, R. Gelber⁴, E. McFadden⁵, C. Goessl⁶, G. Viale⁷, C. Geyer⁸, D. Zardavas⁹, A. Arahmani⁹, D. Fumagalli⁹, E. De Azambuja⁹, N. Ponde⁹, P. Herbolzheimer⁶, W. Wu¹⁰, J. Constantino¹¹, P. Rastogi¹²; ¹London, GB, ²Ramat Gan, IL, ³Boston, Ma, US, ⁴Boston, MA/US, ⁵Inverness, GB, ⁶Gaithersburg, US, ⁷Milan, IT, ⁸Richmond, VA/US, ⁹Brussels, BE, ¹⁰Gaithersburg, MD/US, ¹¹Philadelphia, US, ¹²Pittsburgh, US
- 13:15 - 13:15 BREAST CANCER, LOCALLY ADVANCED
F. André¹, L. Yates²; ¹Villejuif, CEDEX/FR, ²Cambridge, Kent/GB
- 13:15 - 13:15 218P - Prognostic estimates of Ki-67 percentage drop after neoadjuvant chemotherapy (NAC) in luminal B (lumB) and triple negative breast cancer (TNBC)
J. Pascual, B. Rojas-Garcia, V. Peg, S. Diaz-Botero, E. Zamora, E. Muñoz Couselo, M. Oliveira, P. Gomez Pardo, J. Perez Garcia, F. Ruiz-Pace, C. VIAPLANA, S. Escrivá, L. Garrigos, M. Arumi, M. Espinosa-Bravo, J. Cortés, I. Rubio, C. Saura, R. Dienstmann, M. Bellet Ezquerro; Barcelona, ES
- 13:15 - 13:15 219P - Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer

A. Matikas¹, J. Lövrot¹, A. Ramberg², M. Eriksson², T. Lindsten², T. Lekberg¹, I. Hedenfalk³, N. Loman³, J. Bergh⁴, A. Erlandsson⁵, T. Hatschek⁴, T. Foukakis¹; ¹Stockholm, SE, ²Karlstad, SE, ³Lund, SE, ⁴Stockholm, Solna/SE, ⁵Örebro, SE

- 13:15 - 13:15 220P - Safe resection margins in breast-conserving surgery
Y. Kostiuchenko¹, I. Motuzyuk², O. Sydorhuk², N. Kovtun², M. Krotevich²; ¹Kiev, UA, ²Kyiv, UA
- 13:15 - 13:15 221P - A clinically applicable model to predict risk of relapse in patients treated for locally advanced breast cancer: Potential utilization in future clinical trials
O. Aseyev¹, L. Simmonds², M. Gertler², S. Verma²; ¹Ottawa, CA, ²Ottawa, ON/CA
- 13:15 - 13:15 222P - Role of radiotherapy and its impact on survival of male breast cancer: Experience from a tertiary cancer center
R. Upadhyay¹, P. Julka², G. Rath²; ¹New Delhi, Delhi/IN, ²New Delhi, IN
- 13:15 - 13:15 223P - Early characteristics of breast neoplasms on contrast-enhanced ultrasonography and its clinical value
S. Qin, Z. Jie; Nanjing, CN
- 13:15 - 13:15 224P - Synchronous and metachronous breast cancer in Ukraine
I. Motuzyuk¹, O. Sydorhuk¹, N. Kovtun¹, Y. Kostiuchenko²; ¹Kyiv, UA, ²Kiev, UA
- 13:15 - 13:15 225P - Clinical outcomes of single versus double hormone receptor positive breast cancer patients treated with neoadjuvant chemotherapy
J. Raphael¹, S. Nofech-Mozes², M. Trudeau²; ¹Toronto, Ontario/CA, ²Toronto, ON/CA
- 13:15 - 13:15 226P - The correlation between toll-like receptor genes polymorphisms, tumor microenvironment characteristics and the effectiveness of preoperative chemotherapy for locally advanced breast cancer
N. Verovkina, L. Sivak, S. Lyalkin, Z. Rossokcha, P. Fedorovna; Kiev, UA
- 13:15 - 13:15 227P - Triple negative breast cancer: 10-year survival update of the applied treatment strategy in Kuwait
M.S. Fayaz¹, G. Demian², M. El-Sherify³, M. Aziz¹, H. Eissa⁴; ¹Shuwaikh, KW, ²Kuwait, KW, ³Damietta, El-Gamalia/EG, ⁴Cairo, EG
- 13:15 - 13:15 228P - A decade of HER2-targeted therapy in older patients with invasive breast cancer at Institut Curie
R. Geiss¹, J.-Y. Pierga², E. Auclin², G. De Lempdes¹, F. Rollot Trad², P. Cottu², C. Giard¹, D. Stevens¹, E. Brain¹; ¹St. Cloud, FR, ²Paris, FR
- 13:15 - 13:15 229P - Dedicated breast PET to predict pathological complete response after neoadjuvant chemotherapy for breast cancer
M. Fujiwara, N. Masumoto, S. Sasada, T. Kadoya, M. Okada; Hiroshima, JP
- 13:15 - 13:15 230P - Efficacy and safety profile of the adriamycin/cyclophosphamide (AC) followed by docetaxel/cisplatin (DC) in locally advanced breast cancer

T. Abdelhamid¹, M. Saber², A. Abdel-Samie Gaber², M. Selim¹, O. Youssef¹, A. Salama¹, N. Aly Eldin¹;
¹Cairo, EG, ²Giza, EG

13:15 - 13:15 (Withdrawn)

13:15 - 13:15 232P - Pregnancy associated breast cancer spotlights

M. Shalaby, S. Lasheen, S. Talima; Cairo, EG

13:15 - 13:15 233TiP - KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)

P. Schmid¹, J. Cortes Castan², J. Bergh³, L. Pusztai⁴, C. Denkert⁵, S. Verma⁶, H. McArthur⁷, J. Zhao⁸, G. Aktan⁹, T. Dang¹⁰, R. Dent¹¹; ¹London, GB, ²Madrid, ES, ³Stockholm, Solna/SE, ⁴New Haven, CT/US, ⁵Heidelberg, DE, ⁶Calgary, Alberta/CA, ⁷Los Angeles, US, ⁸Kenilworth, NJ/US, ⁹North Wales, PA/US, ¹⁰North Wales, US, ¹¹Singapore, SG

13:15 - 13:15 234TiP - KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

J. Cortes Castan¹, Z. Guo², V. Karantza², G. Aktan²; ¹Madrid, ES, ²Kenilworth, NJ/US

13:15 - 13:15 235TiP - A Phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/-endocrine therapy), or non-small-cell lung cancer (NSCLC)

A. Prat¹, D. Yee², M.P. Sablin³, H. Iwata⁴, E. Johnston⁵, T. Bogenrieder⁶, J. Serra¹, K. Stucke-Straub⁷, P. Lo Russo⁸; ¹Barcelona, ES, ²Minnesota, MN/US, ³Paris, FR, ⁴Nagoya, JP, ⁵Indianapolis, IN/US, ⁶Vienna, AT, ⁷Biberach, DE, ⁸Connecticut, CT/US

13:15 - 13:15 BREAST CANCER, METASTATIC

F. André¹, L. Yates²; ¹Villejuif, CEDEX/FR, ²Cambridge, Kent/GB

13:15 - 13:15 247P - A single-arm, phase ii study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC)

H. McArthur¹, C. Barker², A. Gucalp³, L. Lebron Zapata², Y.H. Wen², A. Phung², M. Wilgucki², M. Henrich², B. Arnold¹, Z. Zhang², A. Ho¹; ¹Los Angeles, US, ²New York, US, ³New York, NY/US

13:15 - 13:15 248P - Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis

R. Finn¹, K. Gelmon², J. Ettl³, J. Asselah⁴, A. Castellon⁵, A. Ruiz Simón⁶, A. Joy⁷, D. Lu⁸, E. Gauthier⁹, A. Mori¹⁰, H. Rugo¹¹, V. Diéras¹²; ¹Los Angeles, CA/US, ²Vancouver, British Columbia/CA, ³Munich, DE, ⁴Montreal, QC/CA, ⁵Hollywood, FL/US, ⁶València, ES, ⁷Edmonton, AB/CA, ⁸La Jolla, CA/US, ⁹San Francisco, US, ¹⁰Milan, IT, ¹¹San Francisco, CA/US, ¹²Rennes, FR

- 13:15 - 13:15 249P - Analysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease
J. Cortés¹, H. Rugo², S. Tolane³, V. Dieras⁴, D. Patt⁵, H. Wildiers⁶, S. Nanda⁷, A. Koustenis⁸, M. Dickler⁹, J. Baselga¹⁰; ¹Barcelona, ES, ²San Francisco, CA/US, ³Boston, MA/US, ⁴Paris, CEDEX 5/FR, ⁵Austin, TX/US, ⁶Leuven, BE, ⁷Bridgewater, US, ⁸New York, Indiana/US, ⁹New York, US, ¹⁰New York, NY/US
- 13:15 - 13:15 250P - A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
T. Saeki¹, H. Mukai², J. Ro³, Y.-C. Lin⁴, Y. Fujiwara⁵, S. Nagai¹, K.S. Lee⁶, J. Watanabe⁷, S. Ohtani⁸, S.-B. Kim⁶, K. Kuroi⁹, K. Tsugawa¹⁰, Y. Tokuda¹¹, H. Iwata¹², Y.H. Park⁶, Y. Yang¹³, Y. Nambu⁵; ¹Saitama, JP, ²Kashiwa, JP, ³Goyang, KR/KR, ⁴Taoyuan, TW, ⁵Tokyo, JP, ⁶Seoul, KR, ⁷Shizuoka, JP, ⁸Hiroshima, Hiroshima/JP, ⁹Bunkyo, JP, ¹⁰Kawasaki, JP, ¹¹Isehara, Kanagawa/JP, ¹²Nagoya, JP, ¹³Taichung, TW
- 13:15 - 13:15 251P - Efficacy and safety of olaparib combined with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: The final analysis of a Japanese phase I/II trial
K. Aogi¹, K. Yonemori², M. Takahashi³, N. Masuda⁴, Y. Naito², S. Shimizu⁵, R. Nakamura⁶, H. Yamamoto⁷, A. Hamada², H. Michimae², K. Tamura², T. Sukigara², R. Nagasaka², Y. Fujiwara²; ¹Matsuyama, JP, ²Tokyo, JP, ³Sapporo, JP, ⁴Osaka, JP, ⁵Yokohama, JP, ⁶Chiba, JP, ⁷Kumamoto, JP
- 13:15 - 13:15 252P - Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
N. Iyengar¹, L. Smyth¹, D. Lake¹, A. Gucaip¹, J. Singh¹, T. Traina¹, P. Defusco¹, M. Dickler², M. Fornier¹, S. Goldfarb¹, K. Jhaveri², S. Modi¹, T. Troso-Sandoval¹, K. Jack¹, G. Ulaner¹, M. Jochelson¹, J. Baselga¹, L. Norton¹, C. Hudis¹, C. Dang¹; ¹New York, NY/US, ²New York, US
- 13:15 - 13:15 253P - Abemaciclib plus fulvestrant in patients (pts) with HR+/HER2- endocrine therapy naïve (EN) advanced breast cancer - an exploratory analysis of MONARCH 2
P. Kaufman¹, H. Iwata², P. Nikolinakos³, J. Beck⁴, H. Koh⁵, J. Gonzalez-Trujillo⁶, Y. Lin⁷, S. Barriga⁸, D. Headley⁷, N. Bourayou⁹, A. Llombart Cussac¹⁰, G. Sledge Jr.¹¹; ¹Lebanon, NH/US, ²Nagoya, JP, ³Athens, US, ⁴Fayetteville, US, ⁵Bellflower, US, ⁶Leon Guanajuato, MX, ⁷Indianapolis, US, ⁸Windlesham, GB, ⁹Neuilly-Sur-seine, FR, ¹⁰Valencia, ES, ¹¹Stanford, CA/US
- 13:15 - 13:15 254P - Matching-adjusted indirect treatment comparison of ribociclib and palbociclib as first-line treatments for HR+, HER2- ABC
A. Forsythe¹, D. Chandiwana², M. Dolph¹, G. Tremblay¹, M. Monaco³; ¹New York, US, ²East Hanover, US, ³Camberley, GB
- 13:15 - 13:15 255P - Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers

M. Beeram¹, E. Hamilton², M. Blum Murphy³, D. Hausman⁴, J. Infante², R. Korn⁵, A. Patnaik¹, S. Piha-Paul⁶, D. Rasco¹, G. Rowse⁷, J. Thimmarayappa⁸, A. Tolcher¹, F. Meric-Bernstam³; ¹San Antonio, TX/US, ²Nashville, TN/US, ³Houston, US, ⁴Seattle, US, ⁵Scottsdale, AZ/US, ⁶Houston, TX/US, ⁷Vancouver, BC/CA, ⁸Seattle, WA/US

- 13:15 - 13:15 256P - Efficacy of palbociclib plus fulvestrant in advanced Hormone Receptor-positive (HR+) metastatic breast cancer (MBC) pretreated with everolimus: Real-life data from the french temporary authorization for use (TAU) at the Institut de Cancérologie de l'Ouest
P. Du Rusquec¹, C. Palpacuer¹, L. Champion¹, A. Patsouris², P. Augereau², C. Gourmelon¹, M. Robert³, L. Dumas¹, C. Folliard², M. Campone³, J.-S. Frenel³; ¹Nantes, FR, ²Angers, FR, ³Saint-Herblain, CEDEX/FR
- 13:15 - 13:15 257P - A phase 1 study of BYL719, an α -isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies
J. Tomomatsu¹, S. Iwasa¹, H. Saka², S. Takahashi¹, K. Nakano¹, S. Morita², M. Inoue², H. Nakahama¹, Y. Kogure², T. Kakizume¹, K. Natsume¹, T. Aoki¹, C. Quadt³, Y. Yamada¹, Y. Ando⁴; ¹Tokyo, JP, ²Nagoya, JP, ³Basel, CH, ⁴Nagoya, Aichi/JP
- 13:15 - 13:15 258P - Phase 1 study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents β -catenin translocation in advanced solid tumors
J. Diamond¹, G. Eckhardt², L. Gluck³, M. Gutierrez⁴, C. Peterson⁵, R. Pila⁶, E. Benaim⁵; ¹Aurora, CO/US, ²Aurora, US, ³Greenville, US, ⁴Hackensack, US, ⁵Rockville, MD/US, ⁶Rockville, US
- 13:15 - 13:15 259P - Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study
M. Cazzaniga¹, G. Mustacchi², M. Giordano³, O. Garrone⁴, M. Donadio⁵, L. del mastro⁶, L. Livi⁷, C. Natoli⁸, A. Michelotti⁹, A. Turletti⁵, R. Ferdinando¹⁰, M. De Laurentiis¹⁰, P. Marchetti¹¹, M. Montemurro¹², E. Romagnoli¹³, S. De Placido¹⁰, P. Pronzato¹⁴, L. Biganzoli¹⁵, G. Bisagni¹⁶, E. Bria¹⁷; ¹Monza, IT, ²Trieste, IT, ³San Fermo Della Battaglia, CO/IT, ⁴Cuneo, IT, ⁵Torino, IT, ⁶Genova, IT, ⁷Florence, IT, ⁸Chieti, IT, ⁹Pisa, IT, ¹⁰Napoli, IT, ¹¹Roma, IT, ¹²Lausanne, CH, ¹³Macerata, IT, ¹⁴La Spezia, IT, ¹⁵Prato, IT, ¹⁶Reggio Emilia, IT, ¹⁷Verona, IT
- 13:15 - 13:15 260P - M-bioscore: A practical tool for predicting outcomes among patients with previously untreated metastatic breast cancer
O. Abdel-Rahman, Cairo, EG
- 13:15 - 13:15 261P - Is PFS a more relevant endpoint than OS in 1L HR+, HER2- MBC? A systematic literature review
A. Forsythe¹, D. Chandiwana², J. Barth³, M. Thabane³, J. Baek⁴, A. Shor¹, G. Tremblay¹; ¹New York, US, ²East Hanover, US, ³Dorval, QC/CA, ⁴East Hanover, NJ/US
- 13:15 - 13:15 262P - PFS/TTP as a potential surrogate for OS in HR+, HER2- MBC
A. Forsythe¹, D. Chandiwana², J. Barth³, M. Thabane³, J. Baek⁴, A. Shor¹, G. Tremblay¹; ¹New York, US, ²East Hanover, US, ³Dorval, QC/CA, ⁴East Hanover, NJ/US

- 13:15 - 13:15 263P - Survival gains from advances in first-line systemic therapy for HER2-positive metastatic breast cancer in the U.S., 1995-2015
J. Roth¹, P. Bajaj², S. Sullivan³, C. Reyes², V. Antao⁴, A. Stein², R. Mahtani⁵, S. Ramsey³; ¹Seattle, US, ²South San Francisco, US, ³Seattle, WA/US, ⁴South San Francisco, CA/US, ⁵Deerfield Beach, FL/US
- 13:15 - 13:15 264P - Progression-free survival (PFS) and site of first progression in HER2+ metastatic breast cancer (MBC) patients (pts) with (w) or without (w/o) brain metastases: A pooled analysis of tucatinib phase I studies
S. Moulder¹, E. Hamilton², C. Ferrario³, A. Conlin⁴, I. Krop⁵, M. Chamberlain⁶, T. Gray⁶, V. Borges⁷; ¹Houston, TX/US, ²Nashville, TN/US, ³Montreal, QC/CA, ⁴Portland, US, ⁵Boston, US, ⁶Seattle, US, ⁷Aurora, CO/US
- 13:15 - 13:15 265P - Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study
E. JACQUET¹, A. Lardy-Cleaud¹, B. PISTILLI², P. Cottu³, S. Delaloge², M. Debled⁴, L. Vanlemmens⁵, G. Anne-Valérie⁶, M. Leheurteur⁷, L. Laborde⁸, W. Jacot⁹, D. Berchery¹⁰, B. Coudert¹¹, J.-M. Ferrero¹², D. Parent¹³, V. Diéras¹⁴, M. Velten¹⁵, C. Courtinard¹⁶, M. Robain¹⁶, T. Bachelot¹⁷; ¹Lyon, FR, ²Villejuif, FR, ³Paris, CEDEX 5/FR, ⁴Bordeaux, CEDEX/FR, ⁵Lille, CEDEX/FR, ⁶Caen, FR, ⁷Rouen, FR, ⁸Marseille, FR, ⁹Montpellier, CEDEX 5/FR, ¹⁰Toulouse, FR, ¹¹Dijon, Cedex/FR, ¹²Nice, CEDEX 2/FR, ¹³Reims, FR, ¹⁴Rennes, FR, ¹⁵Strasbourg, FR, ¹⁶Paris, FR, ¹⁷Lyon, CEDEX/FR
- 13:15 - 13:15 266P - Use of everolimus in advanced hormone receptor positive metastatic breast cancer in a multicenter national observational study
A. Lardy-Cleaud¹, P. cottu², S. Frank³, O. Le Saux¹, S. Chabaud¹, D. Parent⁴, B. Pistilli⁵, M. Debled⁶, A. Mailliez⁷, C. Veyret⁸, T. Petit⁹, L. Uwer¹⁰, S. Guiu¹¹, M. Ung¹², E. Chamorey¹³, P. Arveux¹⁴, T. Guesmia², P. Augereau¹⁵, G. Simon², T. Bachelot¹⁶; ¹Lyon, FR, ²Paris, FR, ³Paris, CEDEX 10/FR, ⁴Reims, FR, ⁵Macerata, IT, ⁶Bordeaux, CEDEX/FR, ⁷Lille, CEDEX/FR, ⁸Rouen, CEDEX 1/FR, ⁹Strasbourg, CEDEX/FR, ¹⁰Vandoeuvre Les Nancy, CEDEX/FR, ¹¹Mont Pellier, FR, ¹²Toulouse, FR, ¹³Nice, FR, ¹⁴Dijon, FR, ¹⁵Angers, FR, ¹⁶Lyon, CEDEX/FR
- 13:15 - 13:15 267P - Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?
S. Kümmel¹, C. Jackisch², V. Müller³, A. Schneeweiss⁴, S. Klawitter⁵, M. Lux⁶; ¹Essen, DE, ²Offenbach, DE, ³Hamburg, DE, ⁴Heidelberg, DE, ⁵Grenzach Wyhlen, DE, ⁶Erlangen, DE
- 13:15 - 13:15 268P - What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice?
P. Bajaj¹, D. Latremouille-Viau², A. Guerin², C. Reyes¹, A. Stein¹, A. Kurian³, P. Cortazar¹; ¹South San Francisco, US, ²Montreal, CA, ³Stanford, US
- 13:15 - 13:15 269P - Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience
N. Battisti¹, D. Okonji², T. Manickavasagar², K. Mohammed², M. Allen², A. Ring²; ¹Sutton, Surrey/GB, ²London, GB

- 13:15 - 13:15 270P - Untreated hormone receptor positive/HER2-negative metastatic breast cancer survival with front-line chemotherapy and maintenance endocrine therapy
R. Sabatier¹, A. Meskine¹, M.A. Cappiello², J.-M. Extra¹, C. Tarpin², F. Rousseau², M. Provansal¹, F. Bertucci², P. Viens², A. Gonçalves¹; ¹Marseille, FR, ²Marseille, CEDEX 9/FR
- 13:15 - 13:15 271P - Can we predict subsequent brain metastasis in patients with metastatic breast cancer?
S.F. El Zawawy, Alexandria, EG
- 13:15 - 13:15 272P - Pathological characteristics and prognosis of a cohort of 57 patients (pts) with de novo oligometastatic breast cancer (OMBC)
S. Chretien¹, N. Kotecki², J. Wallet¹, C. Desmedt³, A. Mailliez², C. Regis¹, D. Pasquier¹, Y.-M. Robin¹, J. Bonnetterre²; ¹Lille, FR, ²Lille, CEDEX/FR, ³Brussels, BE
- 13:15 - 13:15 273P - External validation of modified breast graded prognostic assessment for breast cancer patients with brain metastases
G. Griguolo¹, W. Jacot², E. Kantelhardt³, M.V. Dieci¹, C. Bourcier⁴, C. Thomssen³, C. Bailleux⁵, F. Miglietta¹, A. Braccini², P.F. Conte¹, J.-M. Ferrero⁶, V. Guarneri⁷, A. Darlix⁴; ¹Padova, IT, ²Montpellier, CEDEX 5/FR, ³Halle, DE, ⁴Montpellier, FR, ⁵Nice, FR, ⁶Nice, CEDEX 2/FR, ⁷Padua, IT
- 13:15 - 13:15 274P - Baseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry
P. Kaufman¹, S. Hurvitz², J. O'Shaughnessy³, G. Mason⁴, D. Yardley⁵, A. Brufsky⁶, H. Rugo⁷, M. Cobleigh⁸, S. Swain⁹, D. Tripathy¹⁰, L. Chu¹¹, V. Antao¹¹, B. Yoo¹¹, M. Jahanzeb¹²; ¹Lebanon, NH/US, ²Los Angeles, CA/US, ³Dallas, US, ⁴West Lafayette, IN/US, ⁵Nashville, TN/US, ⁶Pittsburgh, PA/US, ⁷San Francisco, CA/US, ⁸Chicago, IL/US, ⁹Washington Dc, DC/US, ¹⁰Houston, TX/US, ¹¹South San Francisco, CA/US, ¹²Deerfield Beach, FL/US
- 13:15 - 13:15 275P - First-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry
M. Jahanzeb¹, D. Tripathy², S. Hurvitz³, J. O'Shaughnessy⁴, G. Mason⁵, D. Yardley⁶, A. Brufsky⁷, H. Rugo⁸, M. Cobleigh⁹, S. Swain¹⁰, L. Chu¹¹, V. Antao¹¹, B. Yoo¹¹, P. Kaufman¹²; ¹Deerfield Beach, FL/US, ²Houston, TX/US, ³Los Angeles, CA/US, ⁴Dallas, US, ⁵West Lafayette, IN/US, ⁶Nashville, TN/US, ⁷Pittsburgh, PA/US, ⁸San Francisco, CA/US, ⁹Chicago, IL/US, ¹⁰Washington Dc, DC/US, ¹¹South San Francisco, CA/US, ¹²Lebanon, NH/US
- 13:15 - 13:15 276P - Defining priorities for research: Interim results of the Canadian metastatic breast cancer priority setting partnership
N. Nixon¹, S. Verma², C. Simmons³, J. Lemieux⁴; ¹Calgary, CA, ²Calgary, Alberta/CA, ³Vancouver, CA, ⁴Quebec, CA
- 13:15 - 13:15 277P - Real-world treatment patterns and outcomes among elderly metastatic triple negative breast cancer patients in the United States
S. Satram-Hoang¹, P. Bajaj², A. Stein², K. Hoang³, F. Momin³, P. Cortazar², C. Reyes²; ¹Granite Bay, US, ²South San Francisco, US, ³Granite Bay, CA/US

- 13:15 - 13:15 278P - Effect of neoadjuvant chemotherapy on disease free survival and over all survival in triple-negative breast cancer patients
J. Gill¹, A. Mishra²; ¹Bhopal, IN, ²Bhopal, Madhya Pradesh/IN
- 13:15 - 13:15 279P - Real-world everolimus experience in postmenopausal HR+ HER2- advanced breast cancer women: Treat ER+ight Canadian prospective observational study 2nd subgroup analysis
C. Doyle¹, N. Califaretti², S. Dent³, E. Chouinard⁴, S. Perri⁵, S. Chia⁶; ¹Quebec City, CA, ²Kitchener, ON/CA, ³Ottawa, Ontario/CA, ⁴Cambridge, CA, ⁵Dorval, CA, ⁶Vancouver, BC/CA
- 13:15 - 13:15 280P - FICHE-YOUNG: First-line treatment CHOICE in hormone receptor positive (HR+)/HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis
B. PISTILLI¹, A. Lardy-Cleaud², E. JACQUET², S. Delalogue¹, P. Cottu³, M. Debled⁴, L. Vanlemmens⁵, M. Leheurteur⁶, F. Divanon⁷, A. Gonçalves⁸, C. Laurent⁹, B. Coudert¹⁰, E. Chamorey¹¹, L. Champion¹², M.-A. Mouret-Reynier¹³, M. Breton¹⁴, T. Petit¹⁵, G. Simon¹⁶, C. Cailliot¹⁶, T. Bachelot¹⁷; ¹Villejuif, FR, ²Lyon, FR, ³Paris, CEDEX 5/FR, ⁴Bordeaux, CEDEX/FR, ⁵Lille, CEDEX/FR, ⁶Rouen, CEDEX 1/FR, ⁷Caen, FR, ⁸Marseille, FR, ⁹Nancy, FR, ¹⁰Dijon, Cedex/FR, ¹¹Nice, FR, ¹²Nantes, FR, ¹³Clermont-Ferrand, FR, ¹⁴Rennes, FR, ¹⁵Strasbourg, CEDEX/FR, ¹⁶Paris, FR, ¹⁷Lyon, CEDEX/FR
- 13:15 - 13:15 281P - Cell-free circulating DNA as independent prognostic markers in metastatic breast cancer
J. Cheng¹, H. Surowy¹, M. Wallwiener¹, T. Holland-Letz¹, K. Cuk¹, S. Schott¹, A. Trumpp¹, K. Pantel², C. Sohn¹, A. Schneeweiss¹, B. Burwinkel¹; ¹Heidelberg, DE, ²Hamburg, DE
- 13:15 - 13:15 282P - Gene alteration in triple negative breast cancer patients in a phase I/II study of combination therapy with eribulin and olaparib
A. Shimomura¹, K. Yonemori¹, N. Masuda², K. Aogi³, M. Takahashi⁴, Y. Naito¹, S. Shimizu⁵, R. Nakamura⁶, A. Hamada¹, H. Michimae¹, J. Hashimoto¹, H. Yamamoto⁷, C. Shimizu¹, K. Tamura¹, Y. Fujiwara¹; ¹Tokyo, JP, ²Osaka, JP, ³Matsuyama, JP, ⁴Sapporo, JP, ⁵Yokohama, JP, ⁶Chiba, JP, ⁷Kumamoto, JP
- 13:15 - 13:15 283P - Neutrophil-lymphocyte ratio (NLR) as a prognostic factor in metastatic breast cancer
F. Ayala de la Peña, J.C. Yufera Soler, M.A. Ivars, A. Fernandez Sanchez, E. Navarro Manzano, P. De la Morena Barrio, E. Garcia-Garre, E. Garcia-Martinez, G. Marin Zafra, R. Salguero Aguilar, T. Garcia Garcia; Murcia, ES
- 13:15 - 13:15 284P - Real-life study of BRCA genetic screening in metastatic breast cancer
G. Meynard¹, C. Villanueva², A. Thierry-Vuillemin², L. Mansi², P. Montcuquet², N. Meneveau³, L. Chaigneau³, F. Bazan², H. Almotlak², E. Dobi², T. Nguyen Tan Hon², E. Klajer², C. Fagnoni-Legat¹, S. Paget-Bailly¹, A. Meurisse¹, M.-A. Collonge-Rame¹, C. Populaire-Ventron¹, X. Pivot², E. Curtit²; ¹Besançon, FR, ²Besançon, CEDEX/FR, ³Besançon, FR
- 13:15 - 13:15 285P - Higher MCTS1 mRNA level in breast cancer may associate with an unfavorable outcome
Y. Shi, N. Liao, G. Zhang, C. Ren, L. Wen, W. Zhu, X. Chen; Guangzhou, CN
- 13:15 - 13:15 286P - Holistic therapeutic strategy of TNBC necessitates in depth molecular classification: A prospective study

R. Bhattacharyya, K. Banerjee, M. Sen, A. Mukhopadhyay; Kolkata, IN

- 13:15 - 13:15 287P - Neutrophil-to-lymphocyte ratio in metastatic breast cancer: Association with clinico-pathological features and outcome
M. Bartoletti, L. Gerratana, S. Zago, D. Basile, M.G. Vitale, G. Pelizzari, M. Bonotto, C. Bozza, V. Fanotto, C. Lisanti, M. Cinausero, S. Barban, M. Lera, I. Venuti, M. Mansutti, A.M. Minisini, G. Fasola, F. Curcio, F. Puglisi; Udine, IT
- 13:15 - 13:15 288P - Prognosis after loco-regional recurrence of breast cancer: 35 years longitudinal data from the Stockholm cancer register
C. Falato¹, L. Eriksson¹, A. Sofiadis¹, S. Taylor², A. Nordblom¹, I. Fredriksson¹, J. Hartman¹, J. Bergh¹, T. Foukakis¹; ¹Stockholm, SE, ²Toronto, CA
- 13:15 - 13:15 289P - The CAN BEAR study: A systematic review and meta-analysis investigating adverse events (AEs) of targeted agents added to endocrine therapy (ET) in patients (pts) with hormone-receptor positive (HR+) metastatic breast cancer (MBC)
S. Martel¹, M. Bruzzone², M. Ceppi², C. Maurer³, N. Falbel Ponde³, A. Ferreira⁴, G. Viglietti⁵, L. Delmastro⁶, C. Prady¹, E. De Azambuja⁵, M. Lambertini⁵; ¹Greenfield Park, CA, ²Genova, IT, ³Bruxelles, BE, ⁴Lisbon, PT, ⁵Brussels, BE, ⁶San Martino-Ist, IT
- 13:15 - 13:15 290P - OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice (TPC)
M. Robson¹, K. Ruddy², S.-A. Im³, E. Senkus-Konefka⁴, B. Xu⁵, S. Domchek⁶, N. Masuda⁷, S. Delaloge⁸, W. Li⁹, N. Tung¹⁰, A. Armstrong¹¹, W. Wu¹², C. Goessi¹², A. Degboe¹², P.F. Conte¹³; ¹New York, US, ²Rochester, US, ³Seoul, KR, ⁴Gdańsk, PL, ⁵Beijing, CN, ⁶Philadelphia, US, ⁷Osaka, JP, ⁸Villejuif, FR, ⁹Changchun, CN, ¹⁰Boston, MA/US, ¹¹Manchester, GB, ¹²Gaithersburg, US, ¹³Padova, IT
- 13:15 - 13:15 291P - PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L)
V. Diéras¹, N. Harbeck², A. Joy³, K. Gelmon⁴, J. Etti⁵, S. Verma⁶, D. Lu⁷, E. Gauthier⁸, P. Schnell⁹, A. Mori¹⁰, H. Rugo¹¹, R. Finn¹²; ¹Rennes Cedex, FR, ²München, DE, ³Edmonton, AB/CA, ⁴Vancouver, British Columbia/CA, ⁵Munich, DE, ⁶Calgary, Alberta/CA, ⁷La Jolla, CA/US, ⁸San Francisco, US, ⁹New York, NY/US, ¹⁰Milan, IT, ¹¹San Francisco, CA/US, ¹²Santa Monica, CA/US
- 13:15 - 13:15 292P - Prospective observational study of peripheral neuropathy in breast cancer patients treated with eribulin
Y. Sakata, H. Iwata, H. Ikezawa, R. Fudetani, D. Tonoda, Y. Uchida, H. Hasegawa, T. Matsuoka; Tokyo, JP
- 13:15 - 13:15 293P - Overall survival and quality of life in patients with metastatic breast cancer treated with nab-paclitaxel: Final results of the non-interventional study NABUCCO
K. Potthoff¹, A. Nusch², U. Söling³, R. Hansen⁴, C. Salat⁵, S. Grebhardt⁶, J. Harde⁶, N. Marschner⁶; ¹Heidelberg, DE, ²Velbert, DE, ³Kassel, DE, ⁴Kaiserslautern, DE, ⁵München, DE, ⁶Freiburg, DE

- 13:15 - 13:15 294P - Assessment of gastric pH changes and food intake on ribociclib bioavailability: In silico and clinical evaluations
T. Samant¹, M. Elmeliegy², S. Dhuria³, Y. Lu², M. Laisney⁴, S. Yang², A. Grandeur⁴, M. Mueller-Zsigmondy⁴, K.-I. Umehara⁴, F. Huth⁴, M. Miller², C. Germa²; ¹Bangkok, TH, ²East Hanover, NJ/US, ³South San Francisco, US, ⁴Basel, CH
- 13:15 - 13:15 295P - Pneumocystis jiroveci pneumonia (PCP) in patients receiving weekly chemotherapy for metastatic breast cancer
S. Wijaya¹, E. Harrison¹, M. Moody¹, C. Wilson¹, L. Hughes-Davies¹, C. Caldas², H. Earl², R. Baird²; ¹Cambridge, GB, ²Cambridge, Cambridgeshire/GB
- 13:15 - 13:15 296P - Detection of early cardiac effects of docetaxel plus trastuzumab and pertuzumab through strain rate imaging in patients with HER2-positive metastatic breast cancer
V. Michalaki¹, G. Koutroulis¹, I. Psychogios¹, E. Karvouni¹, I. Vasiliou¹, C. Papadimitriou²; ¹Athens, GR, ²Athens, Attiki/GR
- 13:15 - 13:15 297P - Evaluation of drug-drug interactions (DDI) between tucatinib and capecitabine (C) in patients with advanced HER2+ metastatic breast cancer from a phase 1b study
A. Vo¹, D. Leviten², M. Insko¹, T. Sierra², A. Dozier², L. Walker¹, S. Peterson¹; ¹Seattle, US, ²Seattle, WA/US
- 13:15 - 13:15 298P - Outcomes of intracranial stereotactic radiotherapy (SRT) in metastatic breast cancer (BC)
G. Kothari, K. Mohammed, G. Ross; London, GB
- 13:15 - 13:15 299P - Eribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort
J. MARTIN-BABAU¹, M. Robert², V. Seegers³, M.-J. Paillard⁴, X. Pivot⁴, C. Gourmelon⁵, L. Uwer⁶, C. Korenbaum⁷, T. Petit⁸, J.-C. Thery⁹, M. Som¹⁰, C. Lefeuvre-Plesse¹⁰, C. Perret¹¹, H. Simon¹¹, A.-C. Hardy-Bessard¹, H. Desclos¹², H. Bourgeois¹³, M. Campone², O. Tredan¹⁴, A. Patsouris³; ¹St. Brieuc, FR, ²Saint-Herblain, CEDEX/FR, ³Angers, FR, ⁴Besançon, CEDEX/FR, ⁵Nantes, FR, ⁶Vandoeuvre Les Nancy, CEDEX/FR, ⁷Strasbourg, FR, ⁸Strasbourg, CEDEX/FR, ⁹Rouen, FR, ¹⁰Rennes, FR, ¹¹Brest, FR, ¹²St. Malo, FR, ¹³Le Mans, FR, ¹⁴Lyon, CEDEX/FR
- 13:15 - 13:15 300P - Long-term responders to trastuzumab monotherapy in the first-line metastatic setting: characteristics and survival data (SAKK 22/99 Trial)
S. Schmid¹, D. Klingbiel², A. Goldhirsch³, C. Oehlschlegel¹, E. Munzone³, F. Nolè³, B. Pestalozzi⁴, S. Aebi⁵, C. Rochlitz⁶, R. von Moos⁷, K. Zaman⁸, C. Mamot⁹, P. Weder¹, B. Thuerlimann¹, O. Pagani¹⁰, T. Ruhstaller¹; ¹St. Gallen, CH, ²Berne, CH, ³Milan, IT, ⁴Zürich, CH, ⁵Luzern, CH, ⁶Basel, CH, ⁷Chur, CH, ⁸Lausanne, CH, ⁹Aarau, CH, ¹⁰Bellinzona, CH
- 13:15 - 13:15 301P - Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Old drugs, new opportunities Preliminary results of the VICTOR-6 study

M. Cazzaniga¹, K. Cagossi², M.R. Valerio³, S. Russo⁴, V. Casadei⁵, G. Scognamiglio⁶, L. Cavanna⁷, D. Toniolo⁸, E. De Conciliis⁹, E. Melegari¹⁰, L. Stocchi¹¹, V. Gebbia¹², A.M. Vandone¹³, M.C. Cursano¹⁴, G. Pinotti¹⁵, R. Rossello¹⁶, S. Ortu¹⁷, B. Pellegrino¹⁸, S. Saracchini¹⁹, V. Torri²⁰; ¹Monza, IT, ²Modena, IT, ³No City Provided, NA, ⁴Gela, IT, ⁵Pesaro, IT, ⁶Como, IT, ⁷Piacenza, IT, ⁸Rho, (MI)/IT, ⁹Asti, IT, ¹⁰Meldola, IT, ¹¹Cattolica, IT, ¹²Palermo, IT, ¹³Cuneo, IT, ¹⁴Roma, IT, ¹⁵Varese, IT, ¹⁶Taormina, IT, ¹⁷Olbia, IT, ¹⁸Parma, IT, ¹⁹Aviano, IT, ²⁰Milan, IT

13:15 - 13:15 302P - Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer (JBCRG-C06; Safari): A subgroup analysis

H. Kawaguchi¹, K. Aogi¹, N. Masuda², T. Nakayama², Y. Ito³, S. Ohtani⁴, N. Sato⁵, T. Takano³, S. Saji⁶, E. Tokunaga⁷, Y. Hasegawa⁸, M. Hattori⁹, T. Fujisawa¹⁰, S. Morita¹¹, H. Yamashita¹², T. Yamashita¹³, Y. Yamamoto¹⁴, D. Yotsumoto¹⁵, M. Toi¹¹, S. Ohno¹⁶; ¹Matsuyama, JP, ²Osaka, JP, ³Tokyo, JP, ⁴Hiroshima, Hiroshima/JJ, ⁵Niigata, JP, ⁶Fukushima, JP, ⁷Fukuoka, JP, ⁸Hirosaki, JP, ⁹Nagoya, Aichi/JJ, ¹⁰Gunma, JP, ¹¹Kyoto, JP, ¹²Sapporo, JP, ¹³Yokohama, JP, ¹⁴Kumamoto, JP, ¹⁵Kagoshima, JP, ¹⁶Fukuoka, Fukuoka/JJ

13:15 - 13:15 303P - Durable complete response in HER2-positive breast cancer: A multicenter retrospective analysis

A. Shimomura¹, N. Niihara², Y. Fukatsu¹, M. Sawaki³, R. Ogiya⁴, H. Yasojima⁵, T. Fujisawa⁶, M. Yamamoto⁷, M. Tsuneizumi⁸, A. Kitani⁹, J. Watanabe¹⁰, A. Matsui¹¹, Y. Takahashi¹², S. Takashima¹³, T. Shien¹², K. Tamura¹, S. Saji¹⁴, N. Masuda⁵, Y. Tokuda², H. Iwata³; ¹Tokyo, JP, ²Isehara, Kanagawa/JJ, ³Nagoya, JP, ⁴Isehara, JP, ⁵Osaka, JP, ⁶Gunma, JP, ⁷Sapporo, JP, ⁸Shizuoka, JP, ⁹Kagoshima, JP, ¹⁰Shizuoka, Shizuoka/JJ, ¹¹Meguro, JP, ¹²Okayama, JP, ¹³Matsuyama, JP, ¹⁴Fukushima, JP

13:15 - 13:15 304P - Characterization of breast cancer responses to metformin

A. Makhtar, Sheffield, GB

13:15 - 13:15 305P - Paclitaxel every-3-weeks versus weekly paclitaxel and versus weekly vinorelbine in metastatic breast cancer

L. Katselashvili, I. Kiladze, M. Katcharava, N. Jokhadze, T. Melkadze, A. Matitashvili, M. Zhvania, N. Sharikadze, F. Todua; Tbilisi, GE

13:15 - 13:15 306P - All oral combination of vinorelbine and capecitabine as a first line treatment in patients (pts) with metastatic breast cancer (MBC)

S. Shehata, M. Khalaf; Assiut, EG

13:15 - 13:15 307P - Retrospective observational study to evaluate the use of halaven plus trastuzumab for the treatment of HER2(+) metastatic breast cancer (MBC) in Spain: HALATRUST study

M.J. Echarri González¹, F. Ayala de la Peña², R. Márquez Vázquez³, J.A. García-Saenz³, E. Galve Calvo⁴, J.J. Illarramendi Mañas⁵, E. Millastre Bocos⁶, M. Margelí Vila⁷, P. Sánchez Rovira⁸, J.I. Chacón López-Muñiz⁹, P. Cerezuela Fuentes¹⁰, R. Andrés Conejero⁶, L. Cerrato Crespan³, I. Marrodán Ciordia¹¹, A. Ocana Fernandez¹², I. Álvarez López¹³, J.E. Alés Martínez¹⁴, L. Palomar Abad¹⁵, L. Orcajo Rincon³, J. Rodríguez-Villanueva³; ¹Leganés, ES, ²Murcia, ES, ³Madrid, ES, ⁴Bilbao, ES, ⁵Pamplona, ES, ⁶Zaragoza, ES, ⁷Badalona, ES, ⁸Jaén, ES, ⁹Toledo, ES, ¹⁰Cartagena, ES, ¹¹Baracaldo, ES, ¹²Albacete, ES, ¹³Donostia, ES, ¹⁴Ávila, ES, ¹⁵Valencia, ES

- 13:15 - 13:15 308P - Lower response to T-DM1 in metastatic breast cancer patients with HER2 IHC score of 2 and FISH positive compared with IHC score of 3
S. Yazaki, J. Hashimoto, S. Ogita, E. Nakano, T. Yamauchi; Tokyo, JP
- 13:15 - 13:15 309P - Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13 - AMBRA study
G. Mustacchi¹, M. Cazzaniga², E. Bria³, G. Bisagni⁴, L. Biganzoli⁵, P. Pronzato⁶, S. De Placido⁷, E. Romagnoli⁸, F. Montemurro⁹, P. Marchetti¹⁰, M. De Laurentiis⁷, F. Riccardi⁷, A. Turletti¹¹, A. Michelotti¹², C. Natoli¹³, L. Livi¹⁴, L. Del Mastro¹⁵, M. Donadio¹¹, O. Garrone¹⁶, M. Giordano¹⁷; ¹Trieste, IT, ²Monza, IT, ³Verona, IT, ⁴Reggio Emilia, IT, ⁵Prato, IT, ⁶La Spezia, IT, ⁷Napoli, IT, ⁸Macerata, IT, ⁹Candiolo, (TO)/IT, ¹⁰Roma, IT, ¹¹Torino, IT, ¹²Pisa, IT, ¹³Chieti, IT, ¹⁴Florence, IT, ¹⁵Genova, IT, ¹⁶Cuneo, IT, ¹⁷San Fermo Della Battaglia, CO/IT
- 13:15 - 13:15 310P - Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. An indirect comparison with network meta-analysis
C. Cherubini¹, L. Gianni¹, L. Stocchi², V. Arcangeli¹, O. Carminati³, M. Papi¹, G. Pasini¹, M. Fantini¹, S.V.L. Nicoletti¹, D. Tassinari¹; ¹Rimini, IT, ²Cattolica, IT, ³Vittorio Veneto, (TV)/IT
- 13:15 - 13:15 311TiP - FRIEND: A randomized pilot study to compare the efficacy and tolerability of fulvestrant 500mg with exemestane as first line endocrine therapy for post-M ER positive HER2 negative ABC patients relapse after adjuvant non-steroidal aromatase inhibitors (NSAI)
J. wang, B. Xu, Q. Li, P. Zhang, P. Yuan, F. Ma, Y. Luo, R. Cai, Y. Fan, S. Chen, Q. Li; Beijing, CN
- 13:15 - 13:15 312TiP - VinoMetro: Phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy
T. Elger¹, T. Decker², T. Fehm³, S. Fuxius⁴, N. Harbeck⁵, I. Juhasz-Böss⁶, V. Möbus⁷, C. Thomssen⁸, M. Seehase¹, L. Schollenberger¹, C. Ruckes¹, M. Schmidt¹; ¹Mainz, DE, ²Ravensburg, DE, ³Tübingen, DE, ⁴Berlin, DE, ⁵Munich, DE, ⁶Homburg, DE, ⁷Frankfurt, DE, ⁸Halle, DE
- 13:15 - 13:15 313TiP - Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2- metastatic breast cancer (Chloe trial)
T. Shien¹, A. Shimomura², Y. Uemura², H. Kato³, M. Kitada⁴, Y. Kikawa⁵, E. Shiba⁶, T. Yoshida⁷, T. Morimoto⁶, T. Toyama⁸, T. Aihara⁶, H. Mukai⁹; ¹Okayama, JP, ²Tokyo, JP, ³Sapporo, JP, ⁴Asahikawa, JP, ⁵Kobe, JP, ⁶Osaka, JP, ⁷Kanagawa, JP, ⁸Nagoya, JP, ⁹Kashiwa, JP
- 13:15 - 13:15 314TiP - Selecting patients with oligo-metastatic breast cancer harboring homologous recombination deficiency (HRD) for intensified chemotherapy: The OLIGO-study
T. Steenbruggen, A. Scholten, M.-J. Vrancken-Peeters, I. Mandjes, M. Holtkamp, J. Wesseling, S. Linn, G. Sonke; Amsterdam, NL
- 13:15 - 13:15 315TiP - AGATA molecular screening program: Implementing precision medicine in patients with advanced breast cancer in Spain

S. Pernas Simon¹, P. Villagrasa Gonzalez¹, A. Vivancos¹, A. Prat¹, M. Scaltriti², O. Burgues³, J. Rodon¹, J. Canes Ruiz⁴, A. Lluch⁵, A. Llombart⁶, J. Dorca⁷, A. Perelló Martorell⁸, M. Oliveira¹, A. Montañó⁹, L. Garcia-Estevez¹⁰, P. Nuciforo¹, G. Ribas³, I. Rapado¹⁰, L. de la Pena¹¹, E. Ciruelos¹⁰; ¹Barcelona, ES, ²New York, NY/US, ³Valencia, ES, ⁴Barcelona, BARCELONA/ES, ⁵Valencia, Valencia/ES, ⁶Lerida, ES, ⁷Girona, ES, ⁸Palma De Mallorca, ES, ⁹Sevilla, ES, ¹⁰Madrid, ES, ¹¹Barcelona, Spain/ES

- 13:15 - 13:15 316TiP - BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC)
- T. Dalvi¹, K. Gelmon², R. Dent³, M. Pegram⁴, S. Loibl⁵, Y. Tazir⁶, A. Milner⁷, J. Lewis⁷; ¹Gaithersburg, US, ²Vancouver, British Columbia/CA, ³Singapore, SG, ⁴Stanford, CA/US, ⁵Neu-Isenburg, DE, ⁶Wedel, DE, ⁷Cambridge, GB
- 13:15 - 13:15 317TiP - IMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC)
- D. Miles¹, F. Andre², J. Gligorov³, S. Verma⁴, B. Xu⁵, D. Cameron⁶, C. Barrios⁷, A. Schneeweiss⁸, V. Easton⁹, I. Dolado⁹, J. O'Shaughnessy¹⁰; ¹Northwood, Middlesex/GB, ²Villejuif, FR, ³Paris, FR, ⁴Calgary, Alberta/CA, ⁵Beijing, CN, ⁶Edinburgh, GB, ⁷Porto Alegre, BR, ⁸Heidelberg, DE, ⁹Basel, CH, ¹⁰Dallas, US
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 319TiP - CompLEEment-1: Phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
- M. De Laurentiis¹, M. Martin Jimenez², A. Ring³, P. Cottu⁴, K. Zhou⁵, J. Wu⁵, J.P. Zarate⁶, C. Zamagni⁷; ¹Naples, IT, ²Madrid, ES, ³London, GB, ⁴Paris, CEDEX 5/FR, ⁵East Hanover, US, ⁶Alger, DZ, ⁷Bologna, IT
- 13:15 - 13:15 320TiP - A phase II trial of mirvetuximab soravtansine in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) including a lead-in cohort to establish activity in patients with metastatic TNBC
- S. Damodaran¹, F. Symmans², T. Helgason¹, E.A. Mittendorf¹, D. Tripathy², K. Hess², J. Litton¹, S. Moulder²; ¹Houston, US, ²Houston, TX/US
- 13:15 - 13:15 321TiP - SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer
- P. Villagrasa Gonzalez¹, A. Prat¹, M. Oliveira¹, L. de la Pena², X. Gonzalez¹, J. Cortes Castan³, J. Rios³, J. Vázquez¹, N. Martínez Jañez³, A. Perelló Martorell⁴, I. Garau⁴, E. Martinez de Dueñas⁵, S. Morales⁶, M. Melé⁷, B. Bermejo De Las Heras⁸, E. Ciruelos³; ¹Barcelona, ES, ²Barcelona, Spain/ES, ³Madrid, ES, ⁴Palma De Mallorca, ES, ⁵Castellon, ES, ⁶Lleida, ES, ⁷Reus, ES, ⁸Valencia, Valencia/ES
- 13:15 - 13:15 322TiP - PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2-metastatic breast cancer

D. Zardavas¹, M. Regan², R. Maibach³, B. Ruepp³, A. Hiltbrunner³, L. Blacher³, R. Gelber², G. Gebhart¹, A. di Leo⁴, F. Hilbers¹, M. Colleoni⁵, G. Zoppoli⁶, G. Bertelli⁷, J. Bliss⁸, F. Duhoux¹, M. Piccart¹, L. Malorni⁴; ¹Brussels, BE, ²Boston, MA/US, ³Bern, CH, ⁴Prato, IT, ⁵Milan, IT, ⁶Genova, GE/IT, ⁷Swansea, GB, ⁸Sutton, GB

13:15 - 13:15 323TiP - EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), high-risk, early breast cancer (EBC)

M. Martin Jimenez¹, T. Bachelot², C. Barrios³, K. Blackwell⁴, S. Chia⁵, M. De Laurentiis⁶, S. Hurvitz⁷, W. Janni⁸, B. Kaufman⁹, S. Loi¹⁰, P. Schmid¹¹, D. Slamon¹², K. Hazell¹³, S. Mondal¹³, M. Shilkrut¹³, C. Germa¹⁴, G. Hortobagyi¹⁵; ¹Madrid, ES, ²Lyon, CEDEX/FR, ³Porto Alegre, BR, ⁴Durham, NC/US, ⁵Vancouver, BC/CA, ⁶Naples, IT, ⁷Los Angeles, US, ⁸Ulm, DE, ⁹Ramat Gan, IL, ¹⁰Melbourne, VIC/AU, ¹¹London, GB, ¹²Los Angeles, CA/US, ¹³East Hanover, US, ¹⁴East Hanover, NJ/US, ¹⁵Houston, TX/US

13:15 - 13:15 324TiP - PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer

O. Metzger¹, S. Mandrekar², E. Ciruelos³, S. Loibl⁴, P. Valagussa⁵, A. Demichele⁶, E. Lim⁷, D. Tripathy⁸, E. Winer⁹, C. Huang¹⁰, M. Khoeler¹⁰, L. Carey¹¹, P. Francis¹², K. Miller¹³, S. Goel⁹, M. Goetz², A. Prat¹⁴, S. Loi¹², I. Krop¹, L. Gianni⁵; ¹Boston, US, ²Rochester, US, ³Madrid, ES, ⁴Neu-Isenburg, DE, ⁵Milan, IT, ⁶Philadelphia, PA/US, ⁷Sydney, AU, ⁸Houston, TX/US, ⁹Boston, MA/US, ¹⁰New York, US, ¹¹Chapel Hill, NC/US, ¹²Melbourne, VIC/AU, ¹³Indianapolis, IN/US, ¹⁴Barcelona, ES

13:15 - 13:15 DEVELOPMENTAL THERAPEUTICS

R. Plummer¹, U. Lassen²; ¹Newcastle Upon Tyne, Tyne and Wear/GB, ²Copenhagen, DK

13:15 - 13:15 376P - Preclinical evaluation of the anti-CLDN18.2 antibody, IMAB362, in pancreatic carcinoma

C. Heinz, R. Mitnacht-Kraus, M. Kreuzberg, S. Wöll, U. Sahin, Ö. Türeci; Mainz, DE

13:15 - 13:15 377P - Preclinical characterization of IMAB362-vcMMAE, an anti-CLDN18.2 antibody–drug conjugate

M. Kreuzberg, R. Mitnacht-Kraus, U. Sahin, Ö. Türeci; Mainz, DE

13:15 - 13:15 378P - Preclinical characterization of IMAB362 for the treatment of gastric carcinoma

R. Mitnacht-Kraus, M. Kreuzberg, M. Utsch, U. Sahin, Ö. Türeci; Mainz, DE

13:15 - 13:15 379P - A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study

M. Joerger¹, R. Soo², B.C. Cho³, A. Navarro⁴, C.M. Sayehli⁵, H. Richly⁶, D. Tai², D.-W. Kim³, J. Wolf⁷, P. Cassier⁸, S. Bender⁹, P. Ellinghaus⁹, S. Ince¹⁰, P. Rajagopalan¹⁰, M. Ocker¹¹, M. Schuler⁶; ¹St. Gallen, CH, ²Singapore, SG, ³Seoul, KR, ⁴Barcelona, ES, ⁵Würzburg, DE, ⁶Essen, DE, ⁷Köln, DE, ⁸La Défense, FR, ⁹Wuppertal, DE, ¹⁰Whippany, US, ¹¹Berlin, DE

13:15 - 13:15 380P - A phase 1b study evaluating the safety and pharmacokinetics (PK) of regorafenib (REG) in combination with cetuximab (CTX) in patients with advanced solid tumors

C. Weekes¹, A. Lockhart², H.-J. Lenz³, J. Lee⁴, A. Cleton⁵, F. Huang⁶, I. Sturm⁵; ¹Boston, MA/US, ²Miami, FL/US, ³Los Angeles, CA/US, ⁴Pittsburgh, PA/US, ⁵Berlin, DE, ⁶Whippany, NJ/US

- 13:15 - 13:15 381P - Clinical study of apatinib in the treatment of malignant pleural effusion and malignant celiac effusion
M. Xin, Shijiazhuang, CN
- 13:15 - 13:15 382P - Evaluation of NRP-1 TM domain targeting peptide in melanoma
M. Pierdant, L. Aurore, V.D.H. Michael, D. Bagnard; Strasbourg, FR
- 13:15 - 13:15 383P - A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours
A. El-Helali¹, R. Plummer², G. Jayson³, V. Coyle⁴, Y. Drew⁵, N. Mescallado³, N. Harris⁵, A. Clamp³, J. McCann¹, R. Kennedy⁶, A. Cranston⁶, R. Wilson¹; ¹Belfast, GB, ²Newcastle Upon Tyne, Tyne and Wear/GB, ³Manchester, GB, ⁴Belfast, UK/GB, ⁵Newcastle Upon Tyne, GB, ⁶Craigavon, GB
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 385P - Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors
E. Ghazaly¹, V. Woodcock², P. Spiliopoulou³, L. Spiers², J. Moschandreass⁴, L. Griffiths⁴, C. Gnanarajan¹, D. Harrison⁵, T.R.J. Evans³, S. Blagden⁴; ¹London, GB, ²Oxford, Oxfordshire/GB, ³Glasgow, GB, ⁴Oxford, GB, ⁵Fife, GB
- 13:15 - 13:15 386P - Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers
L. Diaz¹, A. Marabelle², T.W. Kim³, R. Geva⁴, E. Van Cutsem⁵, T. André⁶, P. Ascierto⁷, M. Maio⁸, J.-P. Delord⁹, M. Gottfried¹⁰, R. Guimbaud¹¹, D. Jaeger¹², E. Elez¹³, T. Yoshino¹⁴, A. Joe¹⁵, B. Lam¹⁵, J. Ding¹⁵, S. Pruitt¹⁶, S.P. Kang¹⁵, D. Le¹⁷; ¹New York City, US, ²Villejuif, FR, ³Seoul, KR, ⁴Tel Aviv, IL, ⁵Leuven, BE, ⁶Paris, CEDEX 12/FR, ⁷Napoli, IT, ⁸Siena, IT, ⁹Toulouse, Haute-Garonne/FR, ¹⁰Kfar Saba, IL, ¹¹Toulouse, CEDEX 3/FR, ¹²Heidelberg, DE, ¹³Barcelona, ES, ¹⁴Kashiwa, Chiba/JP, ¹⁵Kenilworth, NJ/US, ¹⁶Kenilworth, US, ¹⁷Baltimore, MD/US
- 13:15 - 13:15 387P - Preliminary results from subsets of patients (pts) with advanced gastric cancer (GC) and esophageal carcinoma (EC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
J. Desai¹, M. Millward², Y. Chao³, H. Gan⁴, M. Voskoboinik⁵, B. Markman¹, A. Townsend⁶, V. Atkinson⁷, A. Zhu⁸, J. Song⁹, Q. Qi¹⁰, A. Kang¹⁰, S. Deva¹¹; ¹Melbourne, VIC/AU, ²Nedlands, WA/AU, ³Taipei, TW, ⁴Heidelberg, VIC/AU, ⁵Melbourne, AU, ⁶Woodville, SA/AU, ⁷Woolloongabba, AU, ⁸Boston, US, ⁹Fort Lee, US, ¹⁰Beijing, CN, ¹¹Auckland, NZ
- 13:15 - 13:15 388P - Preliminary results from a subset of patients (pts) with advanced head and neck squamous carcinoma (HNSCC) in a dose-escalation and dose-expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)

L. Horvath¹, J. Desai², S. Sandhu², A. O'Donnell³, A. Hill⁴, S. Deva⁵, B. Markman², M. Jameson⁶, Z. Chen⁷, X. Tan⁷, J. Hou⁸, A. Lim⁹; ¹Camperdown, AU, ²Melbourne, VIC/AU, ³Wellington, NZ, ⁴Southport, AU, ⁵Auckland, NZ, ⁶Hamilton, NZ, ⁷Beijing, CN, ⁸Emeryville, US, ⁹Nedlands, AU

- 13:15 - 13:15 389P - Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
- T. Meniawy¹, G. Richardson², A. Townsend³, J. Desai⁴, H. Gan⁵, M. Friedlander⁶, L. Horvath⁷, M. Jameson⁸, S. Sandhu⁴, Z. Wu⁹, Z. Qin¹⁰, K. Kang¹⁰, B. Markman⁴; ¹Nedlands, WA/AU, ²Cabrini Hospital Malvern, AU, ³Woodville, SA/AU, ⁴Melbourne, VIC/AU, ⁵Heidelberg, VIC/AU, ⁶Randwick, AU, ⁷Camperdown, AU, ⁸Hamilton, NZ, ⁹Fort Lee, US, ¹⁰Beijing, CN
- 13:15 - 13:15 390P - A phase I study of durvalumab (D) in combination with olaparib (O) and cediranib (C) in recurrent women's cancers
- A. Zimmer¹, C. Peer², L. Cao², E. Kohn², S. Lipkowitz³, C. Annunziata³, J. Trepel², M.-J. Lee², L. Mikkilineni², M. Gatti-Mays², A. Nunes², S. Soltani², W. Figg², N. Houston³, E. Nichols³, J.-M. Lee³; ¹Cairo, EG, ²Bethesda, MD/US, ³Bethesda, US
- 13:15 - 13:15 391P - Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer
- S. Westin¹, J. Litton¹, R. Williams², P. Soliman², M. Frumovitz², K. Schmeler², A. Jazaeri¹, A. Sood², K. Lu², S. Moulder², R. Murthy², A. Rodriguez², C. Samuel², L. Engerman², A. Cyriac², P. Rugman³, J. Lindemann⁴, E. McMurtry⁵, G. Mills², R. Coleman²; ¹Houston, US, ²Houston, TX/US, ³Cambridge, GB, ⁴Melbourn, UK/GB, ⁵Macclesfield, GB
- 13:15 - 13:15 392P - Generation of a novel preclinical PK/PD model provides insights into PARP inhibitor clinical monotherapy activity
- M. O'Connor, E. Cadogan, E. Leo, A. Hughes, M. Learoyd, H. Xu, J. Li, J. Yates; Cambridge, GB
- 13:15 - 13:15 393P - Pharmacodynamic (PD) biomarkers for the p70S6K/Akt inhibitor, M2698: Translation from animal to human and relevance to dose selection
- W. Xiong¹, H. Tian², A. Clark², J. Shaw², R. Kaleta², I. Celik³, P. Girard²; ¹Lausanne, CH, ²Billerica, US, ³Darmstadt, DE
- 13:15 - 13:15 394P - Phase 1 study of ipatasertib (AKT inhibitor) for investigating safety, tolerability, pharmacokinetics (PK), efficacy, and biomarkers in Japanese patients (pts) with solid tumors including castration-resistant prostate cancer (CRPC)
- S. Takahashi¹, Y. Fujiwara¹, N. Matsubara², J. Tomomatsu¹, S. Iwasa¹, A. Yamasaki¹, C. Endo¹, S. Yokoyama¹, T. Doi²; ¹Tokyo, JP, ²Kashiwa, Chiba/JP
- 13:15 - 13:15 395P - DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR-TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model
- T. Jimbo, T. Taira, T. Komatsu, K. Kumazawa, N. Maeda, N. Haginoya, T. Suzuki, M. Ota, Y. Totoki, C. Wada, K. Inaki, T. Isoyama, M. Uno; Tokyo, JP
- 13:15 - 13:15 (Withdrawn)

- 13:15 - 13:15 397P - Immune related adverse events (irAEs) in early phase immunotherapy (IO) trials: Implications for recommended phase 2 dose (RP2D) determination
Y. Kanjanapan¹, D. Day², M. Butler¹, L. Wang², A. Joshua³, D. Hogg², N. Leigh², A. Razak², A. Hansen⁴, S. Boujos⁴, M.A. Chappell², K. Chow⁴, M. Paolo⁴, B. Sherwin², L.-A. Stayner⁴, L. Soutani⁴, A. Zambrana², L. Siu⁵, P. Bedard¹, A. Spreafico⁴; ¹Toronto, Ontario/CA, ²Toronto, CA, ³Sydney, AU, ⁴Toronto, ON/CA, ⁵Toronto, On, CA
- 13:15 - 13:15 398P - Drug-induced electrolyte abnormalities in oncology phase I trials: Analysis of 1088 cases treated at The Royal Marsden Hospital
A. Ingles Garces¹, J.E. Ang², M. Ameratunga³, M. Chenard-Poirier², D. Dolling², N. Diamantis⁴, S. Seeramreddi³, R. Sundar⁵, J. de Bono³, J. Lopez⁴, U. Banerji⁴; ¹Sutton, RJ/GB, ²Sutton, GB, ³London, GB, ⁴Sutton, Surrey/GB, ⁵Lyngby, DK
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 400P - LCZ 696, administered during doxorubicin, trastuzumab or pertuzumab treatment, prevents cardiotoxicity in our in vitro model
N. Maurea¹, R. Paciello², G. Piscopo¹, A. Rienzo¹, G. Sorrentino¹, C. Maurea¹, R. Caputo¹, M. De Laurentiis¹, P. Maiolino¹, C. Coppola¹, C. De Lorenzo²; ¹Napoli, IT, ²Naples, IT
- 13:15 - 13:15 401P - MEK inhibitor retinopathy
T. Shukair, Madrid, ES
- 13:15 - 13:15 402P - A Phase I/II study everolimus in combination with paclitaxel-carboplatin in patients with advanced adenocarcinoma of the stomach
H. Loong¹, F. Mo², L. Li², C. Lee², K.-C. Lam², J. Koh², P. Chiu², A. Teoh², A. Chan², E. Ng², W. Yeo²; ¹Shatin, HK, ²Hong Kong, HK
- 13:15 - 13:15 403P - Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC)
N. Segal¹, J. Saro², I. Melero³, W. Ros⁴, G. Argiles⁵, A. Marabelle⁶, M. Rodriguez Ruiz³, J. Albanell⁵, E. Calvo⁷, V. Moreno⁷, J. Cleary⁸, J. Eder⁹, V. Karanikas², S. Bouseida¹⁰, F. Sandoval¹⁰, D. Sabanes¹⁰, S. Sreckovic¹⁰, H. Hurwitz¹¹, L. Paz-Ares⁷, J. Tabernero⁵; ¹New York, NY/US, ²Schlieren, CH, ³Pamplona, ES, ⁴Amsterdam, NL, ⁵Barcelona, ES, ⁶Villejuif, FR, ⁷Madrid, ES, ⁸Boston, Ma, US, ⁹New Haven, Ct, US, ¹⁰Basel, CH, ¹¹Durham, NC/US
- 13:15 - 13:15 404P - Dose escalation study of vemurafenib with crizotinib or sorafenib in patient with BRAF-mutated advance cancers
D. Sakamuri¹, S. Kato², H. Huang³, A. Naing³, V. Holley³, S. Patel³, S. Piha-Paul³, A. Tsimberidou³, D. Hong¹, F. Meric-Bernstam¹, F. Janku³; ¹Houston, US, ²La Jolla, US, ³Houston, TX/US
- 13:15 - 13:15 405P - Hepatic functional imaging and genomics to predict irinotecan pharmacokinetics and pharmacodynamics: The PREDICT IR study

M. MICHAEL¹, W. Liaw², S.-A. McLachlan¹, E. Link³, A. Matera³, M. Thompson³, M. Jefford³, R. Hicks³, C. Cullinane³, I. Campbell³, P. Beale⁴, C. Karapetis⁵, T. Price⁶, M. Burge⁷; ¹Melbourne, AU, ²Sydney, AU, ³Melbourne, VIC/AU, ⁴Sydney, NSW/AU, ⁵Adelaide, SA/AU, ⁶Woodville, SA/AU, ⁷Brisbane, QLD/AU

13:15 - 13:15 406P - Ongoing phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors; Interim results

J. Wang¹, J. Nemunaitis², G. Chiorean³, P. Lorusso⁴, K. Courtney⁵, A. Olguin⁶, J. Bullington⁶, S. Shemesh⁶, J. Chen⁶, C. Brooks⁷, T. Bauer⁸; ¹Sarasota, FL/US, ²Dallas, US, ³Seattle, WA/US, ⁴New Haven, CT/US, ⁵Dallas, TX/US, ⁶New York, NY/US, ⁷New York, US, ⁸Nashville, TN/US

13:15 - 13:15 407P - Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM-151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells

S. Napolitano¹, G. Martini¹, E. Martinelli², C.M. Della Corte², V. Belli¹, N. Matrone¹, F. Morgillo¹, F. Ciardiello², T. Troiani¹; ¹Napoli, IT, ²Naples, IT

13:15 - 13:15 408P - Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients

M. Blanco Codesido, A. Calvo Ferrandiz, S. Lopez-Tarruella Cobo, R. Alvarez, Y. Jerez, I. Marquez Rodas, S. Perez Ramirez, A. Muñoz, A. Calles, P. Sabin Domínguez, C. López, A. Picornell, B. Puente, C. Rubio, M. Herencia, T. Massarrah, M. Martin Jimenez; Madrid, ES

13:15 - 13:15 409P - Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies

J. Tsurutani¹, T. Doi², H. Iwata³, S. Takahashi⁴, S. Modi⁵, K. Tamura⁴, K. Shitara², H. Taniguchi⁶, S. Taira⁴, B. Li⁵, A. Shimomura⁴, Y. Sato⁴, K. Akiyama⁴, Y. Fujisaki⁴, C. Lee⁷, A. Yver⁸, K. Nakagawa¹; ¹Osaka, JP, ²Kashiwa, Chiba/Jp, ³Nagoya, JP, ⁴Tokyo, JP, ⁵New York, NY/US, ⁶Nagoya, Aichi/Jp, ⁷Edison, NJ/US, ⁸Edison, US

13:15 - 13:15 410P - Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis

A. Olszanski¹, R. Gonzalez², P. Corrie³, A. Pavlick⁴, M. Middleton⁵, P. Lorigan⁶, R. Plummer⁷, S. Skaria⁸, C. Herbert⁹, M. Gore¹⁰, S. Agarwala¹¹, A. Daud¹², S. Zhang¹³, B. Bahamon¹³, L. Rangachari¹³, E. Hoberman¹³, M. Kneissl¹³, D. Rasco¹⁴; ¹Philadelphia, PA/US, ²Denver, US, ³Cambridge, Cambridgeshire/GB, ⁴New York, US, ⁵Oxford, GB, ⁶Manchester, GB, ⁷Newcastle Upon Tyne, Tyne and Wear/GB, ⁸Chelmsford, GB, ⁹Bristol, GB, ¹⁰London, GB, ¹¹Pennsylvania, US, ¹²San Francisco, US, ¹³Cambridge, US, ¹⁴San Antonio, TX/US

13:15 - 13:15 411P - Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor with a novel mode of action

D. Weber¹, R. Lehal¹, V. Frismantas², J.-P. Bourquin³, M. Bauer¹, M. Murone¹, F. Radtke⁴; ¹Basel, CH, ²Zürich, CH, ³Zuerich, CH, ⁴Lausanne, CH

13:15 - 13:15 412P - Design and development of potent E1 ubiquitin activating enzyme inhibitor, CPL-410-005, as novel anticancer therapy

A. Stanczak¹, A. Górnicka², B. Stypik², M. Mroczkiewicz², J. Pieczykolan², K. Dubiel², M. Wieczorek¹; ¹Warsaw, PL, ²Lomianki, PL

- 13:15 - 13:15 413P - RX-3117, a novel hypomethylating agent, shows promising therapeutic activity in combination with nab-paclitaxel and check-point inhibitors in preclinical models
J. Frank¹, Y.B. Lee¹, D.J. Kim², E. Benaim¹; ¹Rockville, MD/US, ²Rockville, US
- 13:15 - 13:15 414P - A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
M. Toulmonde¹, S. Cousin², A. Bessede³, M. Homerin⁴, N. Stojkowitz⁵, M. Lusky⁵, M. Pulido³, A. Italiano³; ¹Bordeaux, CEDEX/FR, ²Lille, FR, ³Bordeaux, FR, ⁴Paris, FR, ⁵Illkirch-Graffenstaden, FR
- 13:15 - 13:15 415P - Population pharmacokinetic analysis of OT-101 (trabedersen) in patients with advanced tumors
W. Wang¹, K. Ng¹, D. Nam¹, V. Trieu², L. Hwang³; ¹Costa Mesa, US, ²Teheran, IR, ³City Of Industry, CA/US
- 13:15 - 13:15 416P - An open-label, multicenter phase 1b study of radium-223 + paclitaxel in cancer patients with bone metastases
R. Geva¹, J. Lopez², S. Danson³, H. Joensuu⁴, A. Peer⁵, S. Harris⁶, F. Souza⁷, B.A. Ploeger⁸, K. Pereira⁹, R. Perets⁵; ¹Tel Aviv, IL, ²Sutton, Surrey/GB, ³Sheffield, South Yorkshire/GB, ⁴Helsinki, FI, ⁵Haifa, IL, ⁶Sutton, GB, ⁷Whippany, US, ⁸Berlin, DE, ⁹São Paulo, BR
- 13:15 - 13:15 417TiP - A phase 1 study of oral LOXO 292 in adult patients with advanced solid tumors, including RET-fusion non-small cell lung cancer, medullary thyroid cancer and other tumors with increased RET activity
A. Drilon¹, T. Bauer², V. Subbiah³, M. Cabanillas³, N. Lahkani⁴, L. Wirth⁵, G. Oxnard⁶, S. Smith⁷, T. Eary⁷, S. Cruickshank⁸, M. Nguyen⁷, S. Rothenberg⁹; ¹New York, NY/US, ²Nashville, TN/US, ³Houston, TX/US, ⁴Grand Rapids, MI/US, ⁵Boston, MA/US, ⁶Boston, US, ⁷Stamford, CT/US, ⁸Palo Alto, US, ⁹Stamford, US
- 13:15 - 13:15 418TiP - Phase 1/2 study of the selective TRK inhibitor larotrectinib, in pediatric patients with cancer
S. Gallego Mélcon¹, M. Casanova², S. Bielack³, J. Chisholm⁴, C. van Tilburg⁵, N. Federman⁶, C. Albert⁷, L. Mascarenhas⁸, B. Turpin⁹, R. Nagasubramanian¹⁰, N. Shukla¹¹, S. Spunt¹², M. Cox¹³, D. Hawkins¹⁴, A. Pappo¹⁵, F. Doz¹⁶, G. Bisogno¹⁷, S. Dubois¹⁸, T. Laetsch¹⁹, B. Georger²⁰; ¹Barcelona, ES, ²Milano, IT, ³Stuttgart, DE, ⁴Sutton, GB, ⁵Heidelberg, DE, ⁶Los Angeles, US, ⁷Seattle, US, ⁸Los Angeles, CA/US, ⁹Cincinnati, OH/US, ¹⁰Orlando, FL/US, ¹¹New York City, NY/US, ¹²Palo Alto, CA/US, ¹³South San Francisco, CA/US, ¹⁴Seattle, WA/US, ¹⁵Memphis, TN/US, ¹⁶Paris, FR, ¹⁷Padova, IT, ¹⁸Boston, MA/US, ¹⁹Dallas, US, ²⁰Villejuif, FR
- 13:15 - 13:15 419TiP - Chemosensitization of carboplatin by NOX66: Pharmacokinetics and safety
I. Minns, G. Kelly; Sydney, AU
- 13:15 - 13:15 420TiP - Phase 1b/2 study to assess the safety, tolerability, and clinical activity of BGB-290 in combination with temozolomide in patients with locally advanced or metastatic solid tumors
M. Johnson¹, B. Benson², R. Wei², R. Brachmann², M. Galsky³; ¹Nashville, TN/US, ²Emeryville, US, ³New York, US

- 13:15 - 13:15 421TiP - Phase 1b/2 study to assess the clinical effects of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with first-line or recurrent/refractory glioblastoma
P. Wen¹, K. Shih², D. Schiff³, R. Brachmann², R. Weitzman², T. Cloughesy⁴; ¹Boston, MA/US, ²Emeryville, US, ³Charlottesville, US, ⁴Los Angeles, US
- 13:15 - 13:15 422TiP - PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors
J. Garcia-Corbacho¹, A. Spira², V. Boni³, J. Feliu³, M. Middleton⁴, H. Burris⁵, A. Yang Weaver⁶, M. Will⁶, J. Harding⁷, F. Meric-Bernstam⁸, V. Heinemann⁹; ¹Barcelona, ES, ²Fairfax, US, ³Madrid, ES, ⁴Oxford, GB, ⁵Nashville, US, ⁶South San Francisco, US, ⁷New York, US, ⁸Houston, US, ⁹Munich, DE
- 13:15 - 13:15 423TiP - The first-in-human, dose-finding PROCLAIM-CX-072 trial to assess the antitumor activity and tolerability of the probody therapeutic CX-072 as monotherapy and in combination with ipilimumab or vemurafenib in solid advanced tumors and lymphomas
V. Boni¹, J. Garcia-Corbacho², J. Feliu¹, J. Wydmanski³, Z. Horvath⁴, I. Bondarenko⁵, B. Irving⁶, M. Will⁶, E.G.E. de Vries⁷, F. Thistlethwaite⁸; ¹Madrid, ES, ²Barcelona, ES, ³Katowice, PL, ⁴Debrecen, HU, ⁵Dnepropetrovsk, UA, ⁶South San Francisco, US, ⁷Cluj-Napoca, RO, ⁸Manchester, GB
- 13:15 - 13:15 424TiP - Phase 1b multi-indication study of the antibody drug conjugate anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies
A.A. Adjei¹, A. Walter², L. Cupit³, J. Siegel³, A. Holynskij⁴, B. Childs⁵, C. Elbi³; ¹Rochester, MN/US, ²Berlin, DE, ³Whippany, NJ/US, ⁴Whippany, US, ⁵New York, New York/US
- 13:15 - 13:15 425TiP - A phase 1 study of SY-1365, a selective CDK7 inhibitor, in adult patients with advanced solid tumors
A. Tolcher¹, K. Do², E. di Tomaso³, N. Waters³, K. Stephens³, D. Roth³, G. Shapiro²; ¹San Antonio, TX/US, ²Boston, US, ³Cambridge, US
- 13:15 - 13:15 426TiP - First-in-human study of AMC303 as monotherapy in patients with advanced solid tumor of epithelial origin
E. Calvo¹, P. Aftimos², A. Azaro³, M. de Miguel¹, C. Jungels², P. Nuciforo³, P. Ehmer⁴, H. Bender⁵, K. Dembowski⁵; ¹Madrid, ES, ²Brussels, BE, ³Barcelona, ES, ⁴Saarbrücken, DE, ⁵Eggenstein-Leopoldshafen, DE
- 13:15 - 13:15 NEW DIAGNOSTIC TOOLS
J. Seoane, Barcelona, ES
- 13:15 - 13:15 1261P - mRNA capture sequencing enabled liquid biopsy screening
J. Vandesompele, Ghent, BE
- 13:15 - 13:15 1262P - Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients
K. Otsuji¹, T. Sasaki¹, A. Tanaka¹, A. Kunita¹, M. Ikemura¹, K. Matsusaka², K. Tada¹, M. Fukayama¹, Y. Seto¹; ¹Tokyo, JP, ²Chiba, JP

- 13:15 - 13:15 1263P - BRCA1 large gene rearrangements (LGRs) in Russian breast cancer patients: the development of the droplet digital PCR assay for LGR detection and the identification of recurrent exon 8 deletions
E. Imyanitov¹, E. Preobrazhenskaya², I. Bizin², E. Kuligina², E. Anisimova¹, S. Laptiyev², E. Suspitsin², S. Aleksakhina², A. Togo², A. Sokolenko²; ¹Saint Petersburg, RU, ²St.-Petersburg, RU
- 13:15 - 13:15 1264P - Clinical evaluation of low density array based EGFR mutation detecting kit using tissue samples and liquid biopsies
J. Hernández-Losa¹, Y. Ruano², R. Somoza¹, A. Muro², S. Ramón Y Cajal¹, J.L. Rodríguez-Peralto²; ¹Barcelona, ES, ²Madrid, ES
- 13:15 - 13:15 1265P - Correlation of somatic genomic alterations between tissue genomics and circulating tumor DNA (ctDNA) employing next generation sequencing (NGS) analysis in lung and gastrointestinal cancers
M. Toor¹, W. bahaj², Z. Ahmed¹, L. Kujtan¹, T. Pluard³, M. McNally¹, L. Cummings¹, E. Island¹, J. Forster¹, K. Kennedy³, J. Subramanian³, A. Masood⁴; ¹Kansas City, US, ²Mecca, SA, ³Kansas City, MO/US, ⁴Baltimore, MD/US
- 13:15 - 13:15 1266P - Analytical and clinical validation of a next-generation sequencing-based circulating tumor DNA (ctDNA) assay assures its clinical application
W. Liu, S. Mu, J. Yao, H. Chen, Z. Hu, J. Hu, G. Chirn, H. Kang, K. Wang, M. Yao; Shanghai, CN
- 13:15 - 13:15 1267P - Combination of solid and liquid biopsy genomic profiling for tumor heterogeneity characterization
J. Garcia Foncillas, L. Álvarez, A. Rodrigo, A. Terrádez; Madrid, ES
- 13:15 - 13:15 1268P - Retrospective analysis of a SHIVA01 trial cohort using functional mutational analysis successfully predicted treatment outcome
G. Tarcic¹, C. Le Tourneau², M. Kamal², O. Edelheit¹, Z. Barbash¹, M. Vidne¹, S. Dureau², B. Miron¹, C. Callens², N. Servant², I. Bieche²; ¹Jerusalem, IL, ²Paris, FR
- 13:15 - 13:15 1269P - Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers
O. Caba¹, A.L. Irigoyen², C. Jimenez-Luna³, M. Benavides⁴, F. Ortuño³, C. Guillen-Ponce⁵, I. Rojas³, E. Aranda Aguilar⁶, J.C. Prados³; ¹Jaen, ES, ²Toledo, ES, ³Granada, ES, ⁴Malaga, ES, ⁵Madrid, ES, ⁶Cordoba, ES
- 13:15 - 13:15 1270P - 3D Cultured Tumour from Patients to Predict Treatment Response
W. Vader, L. Price, B. Herpers, S. Basten; Leiden, NL
- 13:15 - 13:15 1271P - 5-ALA administration for photodynamic diagnosis of peritoneal metastases due to advanced gastric cancer: A randomised, double-blind, multicentre phase I/II study
T. Takahashi¹, K. Fujitani², T. Omori², K. Nishikawa², T. Hayashi³, T. Namikawa⁴, E. Otsuji⁵, S. Takiguchi⁶, Y. Doki¹; ¹Suita, JP, ²Osaka, JP, ³Ibaraki, JP, ⁴Nankoku, JP, ⁵Kyoto, JP, ⁶Nagoya, JP
- 13:15 - 13:15 1272P - Diagnostic performance of dedicated breast PET scanner with a ring detector
R. HASHIMOTO, S. Akashi-Tanaka, C. Watanabe, H. Masuda, K. Taruno, T. Takamaru, Y. Ide, T. Kuwayama, Y. Hirota, Y. Kobayashi, T. Sawada, M. Hirose, S. Nakamura; Tokyo, JP

- 13:15 - 13:15 **SARCOMA**
H. Gelderblom, Leiden, NL
- 13:15 - 13:15 1485P - Localized undifferentiated endometrial sarcomas (LUES): Results of a French Sarcoma Group (FSG) retrospective series of 39 patients (pts)
M. Meurer¹, F. Duffaud², S. Salas¹, F. Bertucci³, A. Floquet⁴, N. Penel⁵, I. Ray-Coquard⁶, A. Italiano⁷, J.-Y. Blay⁸, P. Pautier⁹, M. Delannes¹⁰, S. Piperno-Neumann¹¹, J. Mancini¹, M. Auriche¹²; ¹Marseille, FR, ²Marseille, CEDEX 5/FR, ³Marseille, CEDEX 9/FR, ⁴Bordeaux, CEDEX/FR, ⁵Lille, CEDEX/FR, ⁶Lyon, CEDEX/FR, ⁷Bordeaux, FR, ⁸Lyon, FR, ⁹Villejuif, CEDEX/FR, ¹⁰Toulouse, FR, ¹¹Paris, CEDEX 5/FR, ¹²Villejuif, FR
- 13:15 - 13:15 1486P - An epidemiological insight into epithelioid sarcoma (ES): The open issue of distal-type (DES) versus proximal-type (PES)
A.M. Frezza, L. Botta, S. Pasquali, S. Stacchiotti, A. Gronchi, P.G. Casali, A. Trama, W.G. Rarecarenet; Milan, IT
- 13:15 - 13:15 1487P - Natural history of alveolar soft part sarcoma (ASPS): Impact of brain metastases and role of anti-angiogenic therapies (AAT)
G. Malouf¹, G. Beinse², O. Mir³, J. Adam³, P. Terrier³, J.-P. Spano⁴, C. Honore³, A. Italiano⁵, J.-M. Coindre⁵, J.-Y. Blay⁶, A. Lecesne³; ¹Paris, FR, ²Créteil, FR/FR, ³Villejuif, FR, ⁴Paris, CEDEX 13/FR, ⁵Bordeaux, FR, ⁶Lyon, FR
- 13:15 - 13:15 1488P - Treatment patterns, clinical outcomes and prognostic factors of visceral angiosarcoma (V-AS): A report from the Asian Sarcoma Consortium (ASC)
A. Pang¹, R. Ngan², S.H. Tan¹, T. Hirose³, M. Endo⁴, M. Farid¹, W.L. Goh¹, H. Loong⁵, S. Mingmalairak⁶, C.-C. Chang⁷, S. Teo¹, M. Maw⁸, A. Leung², J. Chan⁹, M. Puhaindran¹, A. Kawai³, T. Chen⁷, R. Quek¹, V. Sriuranpong⁶; ¹Singapore, SG, ²Hong Kong, HK, ³Tokyo, JP, ⁴Fukuoka, JP, ⁵Shatin, HK, ⁶Bangkok, TH, ⁷Taipei, TW, ⁸Yangon, MM, ⁹Hong Kong Sar, HK
- 13:15 - 13:15 1489P - High dose loco-regional chemotherapy for locally advanced angiosarcoma: A multicenter study
E. Huis in 't Veld¹, D. Grunhagen², K. Verhoef², H. Smith¹, A. van Akkooi³, R. Jones¹, F. Van Coevorden³, A. Hayes¹, W. van Houdt¹; ¹London, GB, ²Rotterdam, NL, ³Amsterdam, NL
- 13:15 - 13:15 1490P - Primary cardiac sarcoma (PCS): A multi-national retrospective review of clinical experience
T. Chen¹, H. Loong², A. Zer³, R. Barua⁴, J. Buttany⁴, R. Cusimano⁴, Y.-C. Liang¹, C.-H. Chang¹, Z. Iakobishvili³, A. Razak⁵, J. Lewin⁶; ¹Taipei, TW, ²Shatin, HK, ³Tel Aviv, IL, ⁴Toronto, ON/CA, ⁵Toronto, CA, ⁶Nassau, BS
- 13:15 - 13:15 1491P - Primary cardiac sarcoma: A retrospective study in two Korean tertiary centers
H. Ahn¹, H.K. Kim², K.H. Yoo¹, Y.S. Kim¹, S.J. Lee²; ¹Incheon, KR, ²Seoul, KR
- 13:15 - 13:15 1492P - The differences in recurrence and survival of extremity liposarcoma subtypes
M. Vos¹, H. Kosela Paterczyk², P. Rutkowski², G. van Leenders¹, M. Normantowicz², A. Lecyk², S. Sleijfer¹, K. Verhoef¹, D. Grünhagen¹; ¹Rotterdam, NL, ²Warsaw, PL

- 13:15 - 13:15 1493P - The sarcoma policy checklist: Focusing policy efforts on sarcoma
B. Kasper¹, P.G. Casali², N. Drove³, S. Dumont⁴, M. Eriksson⁵, A. Gronchi², E. Lecoite⁶, C. Valverde Morales⁷, R. Wilson⁸, S. Boldon⁹, S. Wait⁹, M. Wartenberg¹⁰; ¹Mannheim, DE, ²Milan, IT, ³Madrid, ES, ⁴Paris, CEDEX 12/FR, ⁵Lund, SE, ⁶Rennes, FR, ⁷Barcelona, ES, ⁸Shropshire, GB, ⁹London, GB, ¹⁰DE
- 13:15 - 13:15 1494P - Dermatofibrosarcoma protuberans might not benefit from postoperative radiotherapy after local resection with negative margin
J. Chen, K.X. Du, J.Y. He, Q.Q. Peng, L.R. Tan, J.L. Li, K.X. Du; Fuzhou, CN
- 13:15 - 13:15 1495P - Low-dose chemotherapy with methotrexate and vinblastine for desmoid tumors: A single institution experience
J. Souza, H. Lourenço, G. Mendes; Rio De Janeiro, BR
- 13:15 - 13:15 1496P - EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: Clinical profile and response to systemic therapy
N. Touati¹, P. Schoffski², S. Litière¹, I. Judson³, S. Sleijfer⁴, W. van der Graaf⁵, A. Italiano⁶, N. Isambert⁷, T. Gil¹, J.-Y. Blay⁸, D. Stark⁹, T. Brodowicz¹⁰, S. Marraud¹, A. Gronchi¹¹; ¹Brussels, BE, ²Leuven, BE, ³London, GB, ⁴Rotterdam, NL, ⁵Sutton, GB, ⁶Bordeaux, FR, ⁷Dijon, Cedex/FR, ⁸Lyon, FR, ⁹Leeds, GB, ¹⁰Vienna, AT, ¹¹Milan, IT
- 13:15 - 13:15 1497P - Efficacy and safety of patients treated long-term with trabectedin (t) on the expanded access program: A retrospective analysis
E. Davis¹, S. Schuetze², S. Patel³, R. Maki⁴, R. Jones⁵, C.R. Shin⁶, R. Knoblauch⁷, G. Wang⁸, M. Smith⁹, G.D. Demetri¹⁰, P. Merriam¹⁰; ¹Ann Arbor, US, ²Ann Arbor, MI/US, ³Houston, TX/US, ⁴New York, NY, US, ⁵London, GB, ⁶Horsham, US, ⁷Raritan, New Jersey/US, ⁸Spring House, US, ⁹Raritan, US, ¹⁰Boston, MA/US
- 13:15 - 13:15 1498P - Efficacy and safety of trabectedin in an elderly patient subgroup (≥65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) from the Expanded Access Program (EAP)
R. Jones¹, R. Maki², S. Patel³, G. Wang⁴, C.R. Shin⁵, R. Knoblauch⁶, G.D. Demetri⁷; ¹London, GB, ²New York, NY, US, ³Houston, TX/US, ⁴Spring House, US, ⁵Horsham, US, ⁶Raritan, New Jersey/US, ⁷Boston, MA/US
- 13:15 - 13:15 1499P - The routine real-life use of trabectedin (T) in patients with advanced soft tissue sarcoma (STS) across Europe: An analysis of overall vs. per country results from Y-IMAGE study
N. Penel¹, C. Benson², B. Kasper³, A. Buonadonna⁴; ¹Lille, CEDEX/FR, ²London, GB, ³Mannheim, DE, ⁴Aviano, PN/IT
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 1501P - Safety and efficacy of pazopanib (PAZ) in advanced soft tissue carcinoma (aSTS) by prior lines of therapy, age, and dose modifications: PALETTE subgroup analyses
A. Le Cesne¹, S. Bauer², G.D. Demetri³, W. van der Graaf⁴, G. Han⁵, L. Dezzani⁶, Q. Ahmad⁶, H. Gelderblom⁷; ¹Villejuif, FR, ²Essen, DE, ³Boston, MA/US, ⁴Sutton, GB, ⁵East Hanover, NJ/US, ⁶East Hanover, US, ⁷Leiden, NL

- 13:15 - 13:15 1502P - Evolution in neutrophil-to-lymphocyte ratio (NLR) among advanced soft tissue sarcoma (STS) patients treated with pazopanib within EORTC 62043/62072 trials
E. De Maio¹, N. Touati¹, S. Litière¹, S. Sleijfer², W. van der Graaf³, A. Le Cesne⁴, L. D'Ambrosio⁵, P.G. Casali⁶, A. Italiano⁷, I. Desar⁸, A. Gronchi⁶; ¹Brussels, BE, ²Rotterdam, NL, ³Sutton, GB, ⁴Villejuif, FR, ⁵Candiolo, (TO)/IT, ⁶Milan, IT, ⁷Bordeaux, FR, ⁸Nijmegen, NL
- 13:15 - 13:15 1503P - Benefit of the use of tyrosine kinase inhibitors (TKIs) in patients (pts) with METAstatic Soft Tissue SARcoma (STS) in a Real-Life Setting: an ancillary analysis of the METASARC Study
S. Cousin¹, M. Savina², A. Le Cesne³, J.-Y. Blay⁴, I. Ray-Coquard⁵, O. Mir³, M. Toulmonde⁶, P. Terrier³, D. Ranchere-Vince⁴, P. Meeus⁵, E. Stoeckle², C. Honore³, P. Sargos², M.P. Sunyach⁴, C. Le Pechoux⁷, A. Giraud², C. Bellera², F. le loarer², A. Italiano²; ¹Lille, FR, ²Bordeaux, FR, ³Villejuif, FR, ⁴Lyon, FR, ⁵Lyon, CEDEX/FR, ⁶Bordeaux, CEDEX/FR, ⁷Villejuif, CEDEX/FR
- 13:15 - 13:15 1504P - Response to apatinib in advanced alveolar soft part sarcoma
C. Tu, F. Tang, Y. Zhou, L. Min, Y. Luo, W. Zhang, R. Shi, H. Duan; Chengdu, CN
- 13:15 - 13:15 1505P - Analysis of expression of immunomodulation factors in alveolar soft-part sarcoma: a retrospective study from the Spanish Group for Research on Sarcoma (GEIS)
N. Hindi¹, A. Fernandez-Serra², J. Martinez-Trufero³, A. Carranza-Carranza¹, A. Lopez-Pousa⁴, J. Lavernia², J.L. Arranz⁵, R. López Alegret³, J. Martinez-Garcia⁶, C. Valverde Morales⁴, J.M. Cano⁷, M.A. Vaz⁵, D. Moura¹, S. Bagué⁴, R. Gonzalez-Campora¹, J.A. Lopez-Guerrero², J. Martin-Broto¹; ¹Sevilla, ES, ²Valencia, ES, ³Zaragoza, ES, ⁴Barcelona, ES, ⁵Madrid, ES, ⁶Murcia, ES, ⁷Ciudad Real, ES
- 13:15 - 13:15 1506P - PD-L1 inhibition – a new therapeutic opportunity in cutaneous angiosarcoma?
R. Hamacher¹, D. Kämpfe², M. Ahrens³, K. Reuter-Jessen⁴, M. Schuler⁵, H.-U. Schildhaus⁴, S. Bauer⁵; ¹Vienna, AT, ²Lüdenscheid, DE, ³Frankfurt Am Main, DE, ⁴Göttingen, DE, ⁵Essen, DE
- 13:15 - 13:15 1507P - Pembrolizumab (PEM) in patients with advanced/metastatic bone sarcoma (BS) or soft tissue sarcoma (STS): Named patient use by the Medical University of Vienna
S. Schur, T. Brodowicz, B. Gad, R. Hamacher, G. Amann, S. Lang; Vienna, AT
- 13:15 - 13:15 1509P - Characteristics and prognosis of gastrointestinal stromal tumor in the pre-imatinib era: An analysis based on the Kinki GIST registry in Japan
T. Hashimoto¹, T. Takahashi¹, Y. Kurokawa², J. Fujita³, S. Hirota⁴, T. Nishida⁵, T. Tsujinaka⁶; ¹Suita, JP, ²Suita, Osaka/Jp, ³Sakai, JP, ⁴Nishinomiya, JP, ⁵Tokyo, JP, ⁶Kaizuka, Osaka/Jp
- 13:15 - 13:15 1510P - Early response evaluation by 18F-FDG-PET influences management in gastrointestinal stromal tumor patients treated with neo-adjuvant intent
S. Farag¹, L.-F. de Geus-Oei², W. van der Graaf³, F. Van Coevorden¹, D. Grunhagen⁴, A. Reyners⁵, P. Boonstra⁵, I. Desar⁶, H. Gelderblom², N. Steeghs¹; ¹Amsterdam, NL, ²Leiden, NL, ³Sutton, GB, ⁴Rotterdam, NL, ⁵Groningen, NL, ⁶Nijmegen, NL
- 13:15 - 13:15 1511P - Surgery in the treatment of metastatic and recurrent Gastrointestinal Stromal Tumors
M. Gluzman¹, R. Orlova², V. Kashchenko¹; ¹Saint-Petersburg, RU, ²Saint Petersburg, RU

- 13:15 - 13:15 1512P - Clinicopathologic features and long-term follow-up of metastatic gastrointestinal stromal tumor (GIST) patients (pts) with durable response (≥ 5 years) to frontline imatinib (IM): A case-control study from GEIS
C. Serrano¹, A. Lopez Pousa², I. Pajares³, C. Valverde Morales², J. Duran⁴, J. Rubió-Casadevall⁵, M.J. Safont⁶, V. Martinez⁷, R. Díaz Beveridge⁶, A. Estival⁸, D. Vicente Baz⁹, A. Sebio Garcia², N. Hindi⁹, S. Landolfi², D. Olivares², A. Garcia-Valverde², P. Ledesma⁴, J. Arribas², J. Carles Galceran², J. Martin Broto¹⁰; ¹Barcelona, Barcelona/ES, ²Barcelona, ES, ³Zaragoza, ES, ⁴Palma, ES, ⁵Gerona, ES, ⁶Valencia, ES, ⁷Madrid, ES, ⁸Badalona, Barcelona/ES, ⁹Sevilla, ES, ¹⁰Seville, ES
- 13:15 - 13:15 1513P - Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) receiving placebo or regorafenib in the phase 3 GRID trial
C. Kappeler¹, A. Wagner¹, G.D. Demetri²; ¹Berlin, DE, ²Boston, MA/US
- 13:15 - 13:15 1514P - Serum miRNA abundances discriminate imatinib-naive patients with advanced gastrointestinal stromal tumors (GIST) from those in remission on Imatinib therapy
H. Kosela Paterczyk, A. Paziewska, M. Kulecka, J. Karczmarski, M. Dabrowska, A. Kluska, A. Balabas, M. Piatkowska, M. Mikula, P. Rutkowski, J. Ostrowski; Warsaw, PL
- 13:15 - 13:15 1515P - LncRNA H19, HOTAIR and MALAT1 as prognostic molecular biomarkers in GIST
N. Barraco, L. Incorvaia, G. Badalamenti, F. Passiglia, A. Listi, R. Maragliano, E. Musso, E. Bronte, D. Cabibi, V. Calò, M. Castiglia, D. Fanale, A. Galvano, V. Gristina, S. Ingrao, L. Insalaco, D. Massihnia, A. Perez, V. Bazan, A. Russo; Palermo, IT
- 13:15 - 13:15 1516P - Predictive factors of response to Sunitinib in metastatic Gastrointestinal Stromal Tumors (mGISTs): A retrospective analysis
L. Incorvaia¹, G. Badalamenti¹, E. Musso¹, I. de luca¹, A. Casarin¹, G. Assanto¹, A. Galvano¹, F. Passiglia¹, N. Barraco¹, B. Vincenzi², G. Grignani³, M. Pantaleo⁴, L. Gatto⁴, S. Rizzo¹, D. Fanale¹, M. Castiglia¹, A. Guarini¹, A. Russo¹; ¹Palermo, IT, ²Roma, IT, ³Candiolo, (TO)/IT, ⁴Bologna, IT
- 13:15 - 13:15 1517P - Analysis of PD-L1 Expression in Patients with Gastrointestinal Stromal Tumors
A.B. Kinupe Abrahao¹, R. Jamani², E. Hsieh², Y.-J. Ko²; ¹Toronto, CA, ²Toronto, ON/CA
- 13:15 - 13:15 1518P - Gastrointestinal stromal tumors secrete Ghrelin and express ghrelin receptors – needs linguistic correction
C. zhu, Beijing, CN
- 13:15 - 13:15 1519P - Primary pleomorphic sarcoma (PS) and leiomyosarcoma (LMS) of bone: Retrospective analysis of an original series
G.G. Baldi¹, A. Franchi², G. Soccianti², D. Campanacci², D. Greto², L. Livi², G. Roselli², F. Galardi³, S. Bazzurri³; ¹Prato, PO/IT, ²Florence, IT, ³Prato, IT
- 13:15 - 13:15 1520P - Development of a new promising rescue agent for high dose methotrexate (HDMTX) treatment in osteosarcoma: A safety and dose finding study
M. Eriksson¹, M. Rychłowska-Pruszyńska², M. Csoka³, E. Kabickova⁴, P. Mudry⁵; ¹Lund, SE, ²Warsaw, PL, ³Budapest, HU, ⁴Prague, CZ, ⁵Brno, CZ

- 13:15 - 13:15 1521P - Role of intraarterial cisplatin and intravenous adriamycin as neoadjuvant and adjuvant chemotherapy in non-metastatic osteosarcoma
A. Mishra¹, J. Gill², Y. Mishra²; ¹Bhopal, Madhya Pradesh/IN, ²Bhopal, IN
- 13:15 - 13:15 1522P - Biomarkers of malignant cell growth used to assess the risk of osteosarcoma development
B. Sultonov, D. Polatova, K. Abdikarimov, U. Islamov; Tashkent, UZ
- 13:15 - 13:15 1523P - Efficacy of second line treatment with etoposide and ifosfamide in adult patients with advanced Ewing Sarcoma family tumors
M. Nardo¹, E. Zambrano¹, M.F. Vicentini², D. Tolo¹, V. Camargo¹, O. Feher¹, R. Munhoz³; ¹Sao Paulo, BR, ²São Paulo, BR, ³Sao Paulo, SP/BR
- 13:15 - 13:15 1524P - AG-120, a novel IDH1 targeted molecule, inhibits invasion and migration of chondrosarcoma cells in vitro
V. HEREDIA, M. Mendiola, E. Ortiz, D. Bernabéu, J. Pozo-Kreiling, M. Miguel, R. Crespo, A. Berjón, V. Martínez-Marín, A. Redondo; Madrid, ES
- 13:15 - 13:15 1525TiP - Geriatric assessment of elderly chemotherapy-naïve patients treated with trabectedin for advanced soft tissue sarcomas (STS): The E-TRAB study of the German Interdisciplinary Sarcoma Group (GISG-13)
B. Kasper¹, P. Reichardt², M. Schuler³, P. Hohenberger¹; ¹Mannheim, DE, ²Berlin-Buch, DE, ³Berlin-Zehlendorf, DE
- 13:15 - 13:15 1526TiP - CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)
S. Fröhling¹, T. Barth², S. Gröschel¹, G. Folprecht³, S. Richter³, R. Mayer-Steinacker², M. Schultheiss², P. Möller², S. Bauer⁴, J. Siveke⁴, S. Dettmer¹, D. Richter¹, C. Heining¹, P. Horak¹, H. Glimm¹, D. Jäger¹, C. Von Kalle¹, R. Schlenk¹; ¹Heidelberg, DE, ²Ulm, DE, ³Dresden, DE, ⁴Essen, DE
- 13:15 - 13:15 TRANSLATIONAL RESEARCH
R. Giavazzi, Milan, IT
- 13:15 - 13:15 1634P - FGFR pathway genomic aberrations and response to FGFRs inhibitors
M. Faure¹, A. Hollebecque², R. Bahleda³, J.-C. Soria³, V. Dyeve²; ¹Marseille, FR, ²Villejuif, FR, ³Villejuif, CEDEX/FR
- 13:15 - 13:15 1635P - FGFR 360° resistance: Establishing a translational research framework in FGFR-altered (FGFRalt) patients (pt) treated with fibroblast growth factor receptor inhibitors (FGFRinh)
C. Hierro¹, M. Sánchez-Guixé¹, F. Ruiz-Pace¹, J. Jimenez¹, L. Maynes¹, A. Azaro¹, J. Martin-Liberal¹, M. Ochoa de Olza¹, I. Braña¹, M. Vieito¹, A. Villanueva², H.G. Palmer¹, J. Arribas¹, P. Nuciforo¹, A. Vivancos¹, E. Garralda¹, R. Dienstmann¹, J. Tabernero¹, V. Serra¹, J. Rodon¹; ¹Barcelona, ES, ²Hospitalet De Llobregat, ES
- 13:15 - 13:15 1636P - EPHA2 receptor is involved in in vivo acquired resistance to anti-Epidermal Growth Factor Receptor (EGFR) treatment in metastatic colorectal cancer (mCRC)

G. Martini¹, V. Belli¹, P.P. Vitiello¹, T. Troiani¹, C. Cardone², S. Napolitano¹, N. Matrone¹, V. Sforza¹, R. Franco², F. Morgillo¹, D. Ciardiello¹, E. Giunta¹, V. De Falco¹, N. Zanaletti¹, P. Vitale¹, E. Martinelli², F. Ciardiello²; ¹Napoli, IT, ²Naples, IT

- 13:15 - 13:15 1637P - Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial
C. Cardone¹, M.C. Paul², V. Moreno-Viedma², G. Martini³, P.P. Vitiello³, D. Ciardiello³, V. Sforza³, T. Troiani³, S. Napolitano³, P. Vitale³, N. Zanaletti³, A. Rachiglio³, D. Rizzi⁴, E. Maiello⁵, N. Normanno³, M. Sibilia², F. Ciardiello¹, E. Martinelli¹; ¹Naples, IT, ²Vienna, AT, ³Napoli, IT, ⁴Bari, IT, ⁵San Giovanni Rotondo, IT
- 13:15 - 13:15 1638P - Clinical value of cfDNA and CTCs in EGFR mutations detected in advanced NSCLC
S. Calabuig Fariñas¹, E. Jantus-Lewintre¹, A. Fernández¹, C. Mayo de las Casas², A. Blasco¹, C. Aguilar¹, N. Jordana², A. Balada², M. Garzón Ibañez², F. Zhang¹, N. Dong¹, M.A. Molina², R. Rosell³, C. Camps Herrero¹; ¹Valencia, ES, ²Barcelona, ES, ³Badalona, Barcelona/ES
- 13:15 - 13:15 1639P - Tucatinib, a HER2 selective kinase inhibitor, is active in patient derived xenograft (PDX) models of HER2-amplified colorectal, esophageal and gastric cancers
S. Peterson¹, P. de Vries², J. Piasecki², R. Rosler²; ¹Seattle, US, ²Seattle, WA/US
- 13:15 - 13:15 1640P - PI3K/RICTOR-mTORC2 axis as a driver of prognosis and potential druggable target in squamous cell lung carcinoma (SqCLC)
S. Pilotto¹, M. Simbolo¹, A. Gkountakos¹, C. Vicentini¹, I. Sperduti², V. Ludovini³, R. Chiari⁴, S. Novello⁵, M. Milella⁶, A. Mafficini¹, L. Carbognin¹, E. Caregnato¹, A. Santo¹, M. Infante¹, M. Brunelli¹, V. Corbo¹, A. Scarpa¹, G. Tortora¹, E. Bria¹; ¹Verona, IT, ²Rome, IT, ³Perugia, (PG)/IT, ⁴Perugia, IT, ⁵Torino, IT, ⁶Roma, IT
- 13:15 - 13:15 1641P - Combination of duligotuzumab, anti HER3 antibody or taselesib, Pi3k inhibitor with trastuzumab shows synergistic antitumoral activity in HER2 positive gastric cancer cells (GCC)
M.M. Laterza¹, V. Ciaramella¹, F. Morgillo¹, V. Belli¹, G. Tirino¹, L. Pompella¹, A. Petrillo¹, B. Savastano¹, A. Pappalardo¹, M. Orditura¹, F. Ciardiello², F. De Vita²; ¹Napoli, IT, ²Naples, IT
- 13:15 - 13:15 1642P - The TLR9 agonist lefitolimod modulates tumor microenvironment and improves anti-tumor effect of checkpoint inhibitors in vivo
K. Kapp, B. Volz, D. Oswald, B. Wittig, M. Schmidt; Berlin, DE
- 13:15 - 13:15 1643P - Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with nivolumab
M. Tiseo¹, F. Facchinetti¹, F. Gelsomino¹, S. Buti¹, M. Veneziani¹, A. Squadrilli¹, P. Bordi¹, M. Bersanelli², A. Cosenza¹, L. Ferri¹, E. Rapacchi¹, G. Mazzaschi¹, F. Leonardi¹, F. Quaini¹, A. Ardizzoni³, G. Missale¹; ¹Parma, IT, ²Noceto, PR/IT, ³Bologna, IT
- 13:15 - 13:15 1644P - Monitoring the effect of cytostatic treatment by immune activity
T. Hansen, L. Nederby, T. Bechmann, E. Jakobsen, A. Zedan, I. Mejlholm, J. Henriksen, K. Steffensen, C. Thomsen, L. Raunkilde, L.H. Jensen, A. Jakobsen; Vejle, DK

- 13:15 - 13:15 1645P - Analysis of programmed death-ligand 1 (PD-L1) expression, transforming growth factor (TGF)- β gene expression signatures (GES) and tumor-infiltrating immune cells (IC) in hepatocellular carcinoma (HCC): Rationale for targeting PD-L1- and TGF- β
Y. Zhang¹, B. Naughton², P.A. Rolfe², E. Frick-Krieger³, I. Dussault², L. Terracciano⁴, C. Ihling³; ¹ Billerica, US, ²Billerica, MA/US, ³Darmstadt, DE, ⁴Basel, CH
- 13:15 - 13:15 1646P - Clinical factors associated with mutation burden in non-small cell lung cancer
A. Ono¹, M. Serizawa², K. Omae², M. Isaka², H. Kojima², S. Takahashi², K. Nakashima², S. Omori², K. Wakuda², H. Kenmotsu², T. Naito², H. Murakami², K. Urakami², Y. Ohde², T. Nakajima², M. Kusuhara², K. Yamaguchi², T. Takahashi²; ¹Shizuoka, Shizuoka/JP, ²Shizuoka, JP
- 13:15 - 13:15 1647P - Integrative analysis of NSCLC identifies tumor genetic profiles associated with PD-L1 expression.
M. Saigi Morgui¹, C. Pereira², E. Pros², E. Brambilla³, J. Albuquerque², N. Baixeras², M. Sánchez-Céspedes², E. Nadal¹; ¹Barcelona, Barcelona/ES, ²Hospitalet De Llobregat, ES, ³La Tronche, CEDEX 9/FR
- 13:15 - 13:15 1648P - B7-H3 (CD276) on circulating epithelial tumor cells (CETCs) correlates with proliferation marker Ki-67 and may be associated with aggressiveness of tumor in breast cancer patients
M. Pizon, D. Schott, U. Pachmann, K. Pachmann; Bayreuth, DE
- 13:15 - 13:15 1649P - Survival of non-small cell lung cancer patients predicted from expression of PD-L1, HLA class I and MICA/B on tumor cells
R. Okita¹, A. Maeda², T. Yukawa², K. Shimizu², Y. Nojima², S. Saisho², M. Nakata²; ¹Kurashiki, Okayama/JP, ²Kurashiki, JP
- 13:15 - 13:15 1650P - YKL-39 induces monocytes migration and angiogenesis and inversely correlates with metastasis in patients with breast cancer
I. Mitrofanova¹, L. Tengfei², M. Zavyalova¹, N. Litviakov¹, M. Buldakov¹, N. Cherdyntseva¹, J. Kzhyshkowska²; ¹Tomsk, RU, ²Mannheim, DE
- 13:15 - 13:15 1651P - Pre-treatment neutrophil lymphocyte ratio/platelet lymphocyte ratio as surrogate markers of survival in non-metastatic head and neck cancer patients: An observational study
V. Agarwal, R. Rao, H.R. Abin, V. Rao, R. Nayar, V. Mani, A. Ram, B. Ajaikumar; Bangalore, IN
- 13:15 - 13:15 1652P - Enhanced antitumor activity of fixed-dose combinations of celecoxib and antihypertensives
C. Lee¹, L. Hwang², O. D'Cruz¹, K. Ng¹, V. Trieu³; ¹Costa Mesa, US, ²City Of Industry, CA/US, ³Teheran, IR
- 13:15 - 13:15 1653P - Overexpression of toll-like receptor 9 (TLR9) in elderly cancer patients when compared to cancer-free elderly control group
L. Torres¹, L. Sales¹, M. Santaliz de Godoy Moreno¹, C. Resende Lira¹, G. Delgado Soriano¹, E. Bezerra Cintra Jr¹, K. Jatahy¹, M.J. Mello¹, L.C. Thuler², J. Oliveira Lima³; ¹Recife, BR, ²Rio De Janeiro, BR, ³Recife, PE/BR

- 13:15 - 13:15 1654P - NSCLC patient immune cell profiling and response of tumor antigen specific CD8 T cells to checkpoint receptor antagonists
J. Lee¹, X. Wu², L. Liu², M. Breyer², H.K. Kim¹, J.H. Cho¹, J. Lee¹, Y.S. Shin¹, J. Kim¹, Y. Zhao²; ¹Seoul, KR, ²Indianapolis, IN/US
- 13:15 - 13:15 1655P - Effect of neoadjuvant chemotherapy on correlation of tumor-associated macrophages with angiogenesis and lymphangiogenesis in human breast cancer
I. Mitrofanova¹, M. Zavyalova¹, M. Buldakov¹, N. Cherdynitseva¹, J. Kzhyskowska²; ¹Tomsk, RU, ²Mannheim, DE
- 13:15 - 13:15 1656P - Myeloid-derived suppressor cells are associated with a decrease of tumor antigen-specific Th1 immunity in non-small cell lung cancer
O. Adotevi¹, E. Lauret Marie Joseph², C. Laheurte², M. Dosset², E. Fabre-Guillevin³, P. Jacoulet², G. Eberts², G. Helluin², L. Boullerot², L. Rangan², Y. Godet², V. Westeel¹; ¹Besançon, CEDEX/FR, ²Besançon, FR, ³La Défense, FR
- 13:15 - 13:15 1657P - Revealing potential immune responses (IRs) in patients with advanced colorectal cancer (aCRC) on first line chemotherapy: A prospective study of neutrophil to lymphocyte ratio, immune function and outcome
S. Turnbull¹, E. West¹, K. Scott¹, E. Tidswell¹, A. Melcher², M. Seymour³, C. Ralph³, J. Seligmann³; ¹Leeds, GB, ²London, GB, ³Leeds, Yorkshire/GB
- 13:15 - 13:15 1658P - Somatic loss of the wild-type BRCA1 allele is not necessarily the first event in the pathogenesis of hereditary ovarian cancer: Implications for novel mechanism of acquired platinum resistance
E. Imyanitov¹, E. Savonevich², A. Ivantsov³, G. Raskin⁴, E. Kuligina⁴, T. Gorodnova⁴, E. Preobrazhenskaya⁴, M. Kleshchov⁴, V. Tiurin⁴, A. Togo⁴, A. Sokolenko⁴; ¹Saint Petersburg, RU, ²Grodno, BY, ³Saint-Petersburg, RU, ⁴St.-Petersburg, RU
- 13:15 - 13:15 1659P - Role of UBR5 mutations in DNA damage response in mantle cell lymphoma
O. Kutovaya, S. Hung, E. Vigano, R. Gascoyne, G. Morin, C. Steidl; Vancouver, CA
- 13:15 - 13:15 1660P - ATM role in prostate cancer (PrCa) progression and survival
Y. Cendón Flórez¹, P. Nombela Blanco¹, A. Medina², N. Romero Laorden³, J. Puente¹, P. López Casas¹, A. Gutiérrez Pecharromán⁴, R. Sanchez-Escribano⁵, L. Magraner¹, E. Gallardo Diaz⁶, N. Lainez⁷, P. Jiménez Gallego⁸, R. Lozano Mejorada⁹, E. Almagro Casado¹⁰, R. Luque Caro¹¹, M. Domenech¹², A. Hernández Jorge¹³, E. Castro Marcos¹, M.D.P. González-Peramato Gutierrez¹, D. Olmos Hidalgo¹; ¹Madrid, ES, ²A Coruña, ES, ³Madrid, Madrid/ES, ⁴Móstoles, ES, ⁵Burgos, ES, ⁶Sabadell, ES, ⁷Pamplona, ES, ⁸Las Palmas De Gran Canaria, ES, ⁹Salamanca, ES, ¹⁰Majadahonda, Madrid/ES, ¹¹Granada, ES, ¹²Manresa, ES, ¹³Donostia, ES
- 13:15 - 13:15 1661P - Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancer
D. Sinha¹, M. Kalimutho², A. Lopez², K.K. Khanna²; ¹Brisbane, AU, ²Brisbane, QLD/AU
- 13:15 - 13:15 1662P - Synergistic antitumor effects of OT-101 (trabedersen), a transforming growth factor-beta 2 (TGF-β2) antisense oligonucleotide (ASO) and chemotherapy in preclinical tumor models

- O. D'Cruz¹, C. Lee², V. Trieu², L. Hwang¹; ¹Costa Mesa, US, ²Costa Mesa, CA/US
- 13:15 - 13:15 1663P - Targeting thioredoxin reductase 1 in novel combination therapies in p53 mutant triple negative breast cancer
P. Raninga, M. Kalimutho, D. Sinha, A. Bain, K. Tonissen, K.K. Khanna; Brisbane, AU
- 13:15 - 13:15 1664P - Liprin- α 4 could be a potential therapeutic target for pancreatic cancer
A. Yamasaki¹, H. Onishi², M. Kawamoto¹; ¹Fukuoka, JP, ²Fukuoka, Fukuoka/JF
- 13:15 - 13:15 1665P - Dual targeting of cystathionine β -synthase (CBS) and cystathionine γ -lyase (CSE) by miR-4317 displays a synergistic efficacy in repressing breast cancer progression
R. Youness, R. Assal, E. Khallaf, H. Hafez, A. Abdelmotaal, M. Gad; Cairo, EG
- 13:15 - 13:15 1666P - Met/Axl system as a dual target in the mesothelioma pathway and invasiveness
G. Viscardi¹, V. Ciaramella¹, C.M. Della Corte², F. Papaccio¹, G. Esposito¹, R. Di Liello², T. Troiani¹, M. Orditura¹, F. Ciardiello², F. Morgillo¹; ¹Napoli, IT, ²Naples, IT
- 13:15 - 13:15 1667P - Targeting CXCR4 and FAK in non-small cell lung carcinomas with co-inactivated p53 and PTEN tumor suppressors
A. Podolski-Renic¹, M. Dragoj¹, S. Stojkovic¹, J. Dinic¹, J. Bankovic¹, E. Sereti², S. Jovanovic Stojanov¹, K. Dimas², M. Pesic¹, T. Stankovic¹; ¹Belgrade, RS, ²Larissa, GR
- 13:15 - 13:15 1668P - Pin1 protein: A druggable target in high grade serous ovarian cancer
C. Russo Spena¹, L. De Stefano¹, B. Salis¹, F. Rizzolio²; ¹Trieste, IT, ²Venice, IT
- 13:15 - 13:15 1669P - RalB GTPase: A potential novel target for RAS mutant colorectal cancer
H. Khawaja, P. O'Reilly, D. McArt, T. Harrison, P. Johnston, S. Van Schaebybroeck; Belfast, GB
- 13:15 - 13:15 1670P - Serial genotypic characterization of circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) undergoing treatment with abiraterone acetate (abi) or enzalutamide (enza)
N. Dizman¹, J. Patel², M. He³, B. Foulk², D. Smirnov², J. Hsu⁴, P. Twardowski³, M. Kortylewski⁴, V. Bhargava², J. Jones³, S. Pal³; ¹Istanbul, TR, ²Spring House, US, ³Duarte, CA/US, ⁴Duarte, US
- 13:15 - 13:15 1671P - A novel circulating cell free DNA-based assay can predict tumor response to systematic chemotherapy
T. Toshima¹, T. Nagasaka¹, Y. Mori¹, T. Kawai¹, K. YASUI¹, T. Fuji¹, F. Taniguchi¹, K. Kimura¹, H. Kishimoto¹, Y. Umeda¹, A. Goel², T. Fujiwara¹; ¹Okayama, JP, ²Texas, TX/US
- 13:15 - 13:15 1672P - ctDNA might expand therapeutic options for second line treatment of KRAS mutant mCRC
P. gazzaniga¹, C. Raimondi¹, C. Nicolazzo¹, A. Gradilone², E. Cortesi¹; ¹Roma, IT, ²Rome, IT
- 13:15 - 13:15 1673P - Ex vivo expansion of circulating tumor cells for individualized drug susceptibility in patients with advanced or recurrent oesophageal cancer
V. Kumar¹, R. Sagar², P. Kumar²; ¹Bangalore, Karnatka/IN, ²Bangalore, IN

- 13:15 - 13:15 1674P - Exploratory study of CK-M30 and pHH3 expression in Circulating Tumor Cells (CTCs) as biomarkers of docetaxel (DOC) efficacy in metastatic castration resistant prostate cancer (mCRPC)
P. Nombela Blanco¹, R. Lozano Mejorada², D. Lorente Estelles³, A. Reid⁴, N. Romero Laorden⁵, G. Attard⁴, Y. Cendón Flórez¹, J. Mateo⁶, S. Sandhu⁷, C. Massard⁸, A. Montesa⁹, P. Flohr⁶, M.I. Sáez¹⁰, M.I. Pacheco¹, E. Castro Marcos¹, J. de Bono¹¹, D. Olmos Hidalgo¹; ¹Madrid, ES, ²Salamanca, ES, ³Valencia, ES, ⁴Sutton, Surrey/GB, ⁵Madrid, Madrid/ES, ⁶Sutton, GB, ⁷Melbourne, VIC/AU, ⁸Villejuif, FR, ⁹Málaga, ES, ¹⁰Malaga, ES, ¹¹London, GB
- 13:15 - 13:15 1675P - Risk of recurrence prediction and optimum treatment planning for early stage breast cancer patients: A cost-effective, accurate and broad based solution for Asia
S. Somashekhar¹, M.M. Bakre², C. Ramkumar², C. Basavaraj², A. Arun Kumar², L. Madhav², C. Prakash², N. Naidu²; ¹Bengaluru, IN, ²Bangalore, IN
- 13:15 - 13:15 1676P - Comparison of progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS on prior therapy: A pooled analysis from 4 contemporary prospective studies
A. Seeber¹, G. Chahine², F. Nasr², A. Dean³, M. Miranova³, G. Jameson⁴, N. Robert⁵, G. Gastl¹, H. Zwierzina¹; ¹Innsbruck, AT, ²Beirut, LB, ³Subiaco, AU, ⁴Scottsdale, US, ⁵Fairfax, US
- 13:15 - 13:15 1677P - Effect of enoxaparin, omeprazole, gemcitabine and bortezomib in refractory patients
J. Marquez-Manriquez, Ciudad Obregon, Washington/MX
- 13:15 - 13:15 1678P - A new chemotherapy-based combination to prevent osteosarcoma progression
M. Monchanin¹, P. Berchard², M. Vienne², J.B. Langlois³, N. Gadot², A. Bernet², J.-Y. Blay¹, A. Dutour⁴; ¹Lyon, FR, ²Lyon Cedex, FR, ³Bron, FR, ⁴Lyon, CEDEX/FR
- 13:15 - 13:15 1679P - Mutant KIT translocates into the nucleus and induces NFKBIB expression that leads to KIT expression in imatinib-resistant gastrointestinal stromal tumors
Y.-S. Hsueh¹, H.H. Chang¹, Y.-S. Shan¹, H.S. Sun¹, J.A. Fletcher², C.-F. Li¹, L.-T. Chen¹; ¹Tainan, TW, ²Boston, MA/US
- 13:15 - 13:15 1680P - Reversion of epithelial-mesenchymal transition (EMT) as a mechanism of action of cabazitaxel in castration-resistant prostate cancer
N. Jiménez, M. Marín-Aguilera, O. Reig, P. Fernández, S. García-Recio, M. Pereira, A. Prat, B. Mellado Gonzalez; Barcelona, ES
- 13:15 - 13:15 1681P - Globally optimizing therapeutic combinations against bortezomib-resistant multiple myeloma using a quantitative parabolic optimization platform (QPOP)
M. Rashid¹, T.B. Toh¹, N.L. Abdullah¹, A. Silva², Y. Zhang¹, P.F. Tan¹, A.L. Teh¹, N. Karnani¹, S. Jha¹, C.-M. Ho², W.J. Chng¹, H. Dean¹, E. Chow¹; ¹Singapore, SG, ²Los Angeles, US
- 13:15 - 13:15 1682P - Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
J. Chen, I. Guccini, D. Di Mitri, D. Brina, A. Alimonti; Bellinzona, CH
- 13:15 - 13:15 1683P - Metabolomics in cancer cachexia

J. Lopez-Martin¹, M. Cala², E. Prieto-García¹, C. Gonzalez Riano², C.V. Díaz-García¹, A. García², V. Pardo Marqués¹, F. Ruperez Pascualena², I. García-Ruiz¹, C. Pernaut¹, I. Otero¹, L. Parrilla Rubio¹, M. Riesco¹, J. Adeva Alfonso¹, C. Barbas², M.T. Agulló-Ortuño¹; ¹Madrid, ES, ²Boadilla Del Monte, ES

13:15 - 13:15 1684P - Association between the Dietary Inflammatory Index (DII), urinary enterolignans and C-reactive protein in the National Health and Nutrition Examination Survey-2003-2008

N. Shivappa¹, M. Wirth², A. Murphy², T. Hurley², J. Hebert²; ¹Columbia, US, ²Columbia, SC/US

13:15 - 13:15 1685P - Fullerene/iron nanocomposite modulates doxorubicin-induced cardiotoxicity

M. Seke¹, D. Petrovic², M. Labudovic Borovic¹, D. Jovic³, I. Borisev³, Z. Kanacki³, D. Zikic³, A. Djordjevic³; ¹Belgrade, RS, ²Sombor, RS, ³Novi Sad, RS

13:15 - 13:15 1686P - Ability of TMPRSS2-ERG (TE) expression to predict taxane benefit depending on prior abiraterone or enzalutamide therapy in castration-resistant prostate cancer

M. Marín-Aguilera¹, O. Reig¹, A. Font², A. Rodríguez-Vida¹, C. Suárez¹, M. Domenech¹, N. Jiménez¹, I. Victoria¹, S. López¹, M. Milà-Guasch¹, E. Felip², O. Etxaniz², J. Carles¹, F. Racca¹, N. Sala-González³, A. González del Alba⁴, P. Fernández¹, A. Prat¹, B. Mellado¹; ¹Barcelona, ES, ²Badalona, ES, ³Girona, ES, ⁴Palma De Mallorca, ES

13:15 - 13:15 1688P - Identification of patient population with longer survival when treated with S-1 plus cisplatin via predictive enrichment strategy analysis of the FLAGS and DIGEST phase III trial

M. Takeuchi¹, M. Takeuchi¹, J. Ajani²; ¹Tokyo, JP, ²Lyngby, DK

13:15 - 13:15 1689P - HMGA1 is a new biomarker of liposarcoma progression

R. Loria¹, V. Laquintana¹, G. Bon¹, D. Trisciuglio¹, R. Covello², C. Amoreo¹, V. Ferraresi², C. Zoccali¹, M. D'Incalci³, R. Biagini², R. Falcioni¹; ¹Rome, IT, ²Roma, IT, ³Milan, IT

13:15 - 13:15 1690P - hsa_circ_0004870 is related to AR-V7 expression and may confer resistance to enzalutamide in castration-resistant prostate cancer

J. Greene¹, A.-M. Baird², L. Brady³, S. Gray³, S. Finn³, R. McDermott¹; ¹Dublin, Belgard Square North/IE, ²Brisbane, Queensland/AU, ³Dublin, IE

13:15 - 13:15 1691P - Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX

C. Vivaldi, E. Arrigoni, R. Morganti, S. Catanese, L. Fidilio, I. Pecora, G. Restante, L. Fornaro, S. Crucitta, M. Lencioni, E. Rofi, E. Vasile, A. Falcone, R. Danesi, M. Del Re; Pisa, IT

13:15 - 13:15 1692P - Clinical significance of the expression of membrane receptors of the alternative nuclear factor-kappaB pathway in non-small cell lung cancer

F.-I. Dimitrakopoulos¹, V. Tzelepi², A. Kottorou¹, A. Antonacopoulou², A. Koutras¹, T. Makatsoris¹, H. Kalofonos¹; ¹Patras, Rion/GR, ²Patras, GR

13:15 - 13:15 1693P - Development of TP53 signature diagnostic system using multiplex RT-PCR and observational study to confirm the prognostic value of TP53 signature in breast cancer

S. Takahashi¹, T. Fukui², T. Nomizu³, Y. Kakugawa⁴, T. Ishida⁵, S. Yamaguchi⁶, S. Kato⁶, N. Ohuchi⁵, N. Gondo², C. Ishioka⁵; ¹Sendai, Miyagi/JP, ²Kyoto, JP, ³Koriyama, JP, ⁴Natori, JP, ⁵Sendai, JP, ⁶Tokyo, JP

- 13:15 - 13:15 1694P - Expression of estrogen receptors and beta-III tubulin in non-small cell lung cancer tissue
E. Ponomarenko, I. Mamichev, T. Bogush, O. Ryabinina, J. Dyakova, D. Novikov, B. Polotsky, M. Davydov; Moscow, RU
- 13:15 - 13:15 1695P - Deciphering the antitumor efficacy and mechanistic delineation of epigenetic inhibitors in AML using patient tumor derived ex vivo phenotypic assay based platform
P. Majumder¹, P. Radhakrishnan², S. Thiagarajan³, M. Biswas³, D. Malhotra³, B. Ulaganathan², B. Majumder³, G. Babu³; ¹Woburn, US, ²Woburn, MA/US, ³Bangalore, IN
- 13:15 - 13:15 1696P - Proteomics of triple negative breast cancer developing metastases to central nervous system
K. Rojas¹, L. Trilla-Fuertes¹, A. Gámez¹, J. Sepulveda Sanchez¹, L. Manso Sánchez¹, G. Prado-Vásquez¹, C. Chiva², A. Zapater-Moros¹, S. Llorente-Armijo¹, D.C. Mendiola¹, E. Sabido², J.A. Fresno¹, E.M. Ciruelos Gil¹, L. Paz-Ares¹; ¹Madrid, ES, ²Barcelona, ES
- 13:15 - 13:15 1697P - Assessing functional Androgen Receptor (AR) pathway activity using a computational model
A. van Brussel, M. Inda, E. Den Biezen, D. van Strijp, J. Wrobel, H. van Ooijen, R. Hoffmann, W. Verhaegh, A. van de Stolpe; Eindhoven, NL
- 13:15 - 13:15 1698P - Evaluation of deamination bias from formalin-fixed tissues of small cell lung cancer with a dual strand targeted amplicon sequence
T. Amano¹, H. Nishihara², H. Yokouchi³, H. Suzuki⁴, H. Akita², N. Sato²; ¹Sapporo, Hokkaido/JP, ²Sapporo, JP, ³Fukushima, Fukushima/JP, ⁴Fukushima, JP
- 13:15 - 13:15 1699P - Functional genomic mRNA (FGmRNA) profiling of &
K. Moek¹, D.J. de Groot¹, E.G.E. de Vries², R. Fehrmann¹; ¹Groningen, NL, ²Cluj-Napoca, RO
- 13:15 - 13:15 TUMOUR BIOLOGY AND PATHOLOGY
A. Bardelli, Candiolo, (TO)/IT
- 13:15 - 13:15 1708P - Anti-tumor activity of alectinib in the orthotopic in vivo imaging model with NCOA4-RET fusion positive tumor cells
S. Yano¹, S. Arai², K. Kita², A. Tanimoto², S. Takeuchi²; ¹Kanazawa, Ishikawa/JP, ²Kanazawa, JP
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 1710P - Cathepsin S regulates cell migration and invasion through mediating store-operated calcium entry and the focal adhesion proteins
H.-H. Lin, M.-R. Shen, J.-Y. Chang; Tainan, TW
- 13:15 - 13:15 1711P - Type VI collagen (COL6) as part of tumorigenesis: Focus on quantifying specific COL6 protein fragments in serum
A. Wardak, N. Willumsen, D. Mogensen, S. Nielsen, C. Jensen, S. Kehlet, M. Karsdal; Herlev, DK

- 13:15 - 13:15 1712P - The combination analysis of tumor infiltration lymphocyte with Neutrophil to lymphocyte ratio may predict prognosis of colorectal cancer in stage I-III
S.M.R. Mortazavizadeh¹, Y. Ayoughi¹, M. Moghimi²; ¹Yazd, IR, ²Safaieeh, IR
- 13:15 - 13:15 1713P - Prognostic value of NK and T-lymphocyte markers in operable non-small cell lung cancer (NSCLC)
M. Skrzypski¹, A. Szymanowska-Narloch¹, A. Kowalczyk¹, A. Maciejewska¹, M. Marczyk², J. Polańska², W. Biernat¹, W. Rzyman¹, J. Jassem³; ¹Gdansk, PL, ²Gliwice, PL, ³Gdańsk, PL
- 13:15 - 13:15 1714P - KRAS in non-small cell lung cancer
I. Amanam¹, R. Gupta¹, I. Mambetsariyev¹, M. Koczywas², M. Cristea², E. Massarelli², K. Reckamp², R. Salgia³; ¹Duarte, US, ²Duarte, CA/US, ³Chicago, IL/US
- 13:15 - 13:15 1715P - PIK3CA mutation and PDL1 expression in lung squamous cell carcinoma surgically resected
L. Gutierrez Sanz¹, C. Salas², I. Martinez², D. Garcia², F.F. Franco³, I. Curto³, M. Mendez³, L. Gonzalez³, M. Provencio³, P. Martin²; ¹Majadahonda, Madrid/ES, ²Madrid, ES, ³Majadahonda, ES
- 13:15 - 13:15 1716P - TRKA expression and NTRK1 gene copy number across solid tumors
G. Mauri¹, E. Valtorta², A. Sartore-Bianchi², G. Cerea¹, A. Amatu¹, M. Schirru², G. Marrapese², V. Fiorillo², P. Recchimuzzo², I. Stella², S. Veronese¹, F. Tosi², M. Maiolani², M. Truini², S. Siena²; ¹Milan, IT, ²Milano, IT
- 13:15 - 13:15 1717P - The correlation between MMR gene expression MSH2/MSH6 and VEGF A/VEGF B in gastro-esophageal cancer
A. Dracea, M. Danciulescu, A. Dricu, F. Burada, M. Ioana; Craiova, RO
- 13:15 - 13:15 1718P - Liver-type glutaminase (GAB) suppresses malignant phenotype of glioblastoma cells
E. Majewska¹, M. Szeliga¹, J. Márquez², J. Albrecht¹; ¹Warsaw, PL, ²Malaga, ES
- 13:15 - 13:15 1719P - Alteration of p53 mRNA expression in neuroblastoma and its impact in disease outcome
M. Inomistova, N. Khranovska, O. Skachkova, G. Klymniuk, S. Pavlyk; Kiev, UA
- 13:15 - 13:15 1720P - Downregulation of BRCA1 protein in clear cell renal cellular carcinoma
E. Sarnowska, N. Rusetska, M. Szymanski, I. Jancewicz, M. Chmielarczyk, R. Konopinski, M. Leszczynski, A. Chrzan, M. Ligaj, A. Maassen, T. Sarnowski, J. Siedlecki; Warsaw, PL
- 13:15 - 13:15 1721P - The role of PD-L1 in a high-grade invasive human oral squamous cell carcinoma microenvironment
M. HIRAI, H. Kitahara, Y. Kobayashi, S. Kawashiri, H. Nakamura; Kanazawa, JP
- 13:15 - 13:15 1722P - Loss of SWI/SNF chromatin remodelling complex is linked to advanced urinary bladder cancer
M. Szymanski, E. Sarnowska, A. Ornoch, N. Rusetska, S. Abramowicz, A. Chrzan, M. Ligaj, A. Maassen, J. Siedlecki, T. Sarnowski; Warsaw, PL

- 13:15 - 13:15 1723P - The role of hepatocyte nuclear factor 1 homeobox B (HNF1B) loss in chromophobe RCC (ChRCC) development
E. Jonasch¹, G. Fuller¹, I. McCutcheon¹, Z. Ding¹, L. Zhou¹, X. Liu¹, W. Kong², R. Powell³, I.-Y. Park³, N. Tannir¹, W. Rathmell⁴, B. Dong², S. Matin¹, X. Tong³, Y. Huang², P. Tong¹, J. Wang¹, C. Walker³, M. Sun¹; ¹Houston, TX/US, ²Shanghai, CN, ³Houston, US, ⁴Nashville, US
- 13:15 - 13:15 1724P - Some mechanisms of increasing malignancy of B16/F10 melanoma in female mice with chronic pain
I. Kotieva, O. Kit, E. Frantsiyants, I. Kaplieva, L. Trepitaki, V. Bandovkina, N. Cheryarina, Y. Pogorelova, L. Vladimirova; Rostov-On-don, RU
- 13:15 - 13:15 1725P - Impact of global epigenetics machinery on clinical outcome of colorectal cancer patients treated with fluoropyrimidine-based therapy
M. Fouad, S. Salem, M. Hussein, A.-R. Zekri, D. Mohammed, H. Hafez, S. Shouman; Cairo, EG
- 13:15 - 13:15 1726P - Comparison of breast cancer subtypes between young and elderly women
I. Kiladze, A. Mariamidze, M. McHedlishvili, K. Tsomaia, F. Todua; Tbilisi, GE
- 13:15 - 13:15 1727P - Distribution of the PAM50 breast cancer subtypes within each pathology-based group: a combined analysis of 15,339 patients across 29 studies
J.M. Cejalvo¹, T. Pascual², A. Fernández-Martínez³, B. Adamo⁴, N. Chic³, M. Vidal³, L. Rodelo³, M. Muñoz³, A. Prat³; ¹Valencia, Valencia/ES, ²Madrid, ES, ³Barcelona, ES, ⁴Messina, IT
- 13:15 - 13:15 1728P - Genetic association of matrix metalloproteinase MMP- 1, MMP-3 and MMP-9 Genes with HCV-related hepatocellular carcinoma in Egyptian patients
A. Alhanafy¹, B. Montaser², W. Fathy², N. Elabd², S. Tayel²; ¹Shebin El Kom, EG, ²Sheben Elkom, EG
- 13:15 - 13:15 1729P - Heterogeneity of epigenetic and EMT marks observed in hepatocellular carcinoma with keratin 19 proficiency
T. Nagasaka¹, T. Okada¹, N. Yokomichi², F. Taniguchi¹, T. Tushima¹, K. YASUI¹, T. Fujii¹, Y. Mori¹, T. Kawai¹, Y. Umeda¹, T. Yagi¹, T. Fujiwara¹, A. Goel³; ¹Okayama, JP, ²Hamamatsu, JP, ³Texas, TX/US
- 13:15 - 13:15 (Withdrawn)
- 13:15 - 13:15 1731P - Rare malignancy rare site: Extranodal lymphomas
S. Gupta, A. Murali; Faridabad, IN
- 13:15 - 13:15 1732P - Descriptive analysis of families with TP53 mutations: Is there a genotype/phenotype correlation?
J. Silva¹, B. Filipe¹, A. Luís¹, A. Clara¹, S. Bento², P. Machado¹, P. Rodrigues¹, J. Parreira¹, F. Vaz¹; ¹Lisbon, PT, ²Santarem, Santarem/PT

14:15 - 15:45	Type: Young Oncologist Special session Title: Fellowships in Europe: Educational opportunities for Young Oncologists Chair(s): C. Zielinski, AT; V. Guarneri, IT	Salamanca Auditorium
14:15 - 14:20	Introduction <u>V. Guarneri</u> , Padua, IT	
14:20 - 14:35	Overview ESMO Fellowship Programme and Leaders Generation Programme <u>C. Zielinski</u> , Vienna, AT	
14:35 - 14:50	Practical tips from a former fellow <u>V. Gambardella</u> , Valencia, ES	
14:50 - 15:00	Best fellowship project 1 <u>V. Conteduca</u> , Meldola, Forli-Cesena/IT	
15:00 - 15:10	Best fellowship project 2 <u>P. Szturz</u> , Brno, South Moravian/CZ	
15:10 - 15:25	How my ESMO Fellowship and the Leaders Generation Programme impacted my career <u>L. De Mattos-Arruda</u> , Barcelona, ES	
15:25 - 15:45	Awards: Presentation of the 2017 fellows and Best Exam Award 2016	
14:45 - 16:15	Type: Educational session Title: Challenges in oncogene addicted NSCLC Chair(s): S. Peters, CH; P. Jänne, US	Barcelona Auditorium
14:45 - 15:10	New drivers, new perspectives <u>T.S.K. Mok</u> , Shatin, HK	
15:10 - 15:35	Strategies against mechanisms of resistance <u>P. Jänne</u> , Boston, Ma, US	
15:35 - 16:00	The role of immunotherapy in oncogene addicted NSCLC <u>S. Peters</u> , Lausanne, CH	
16:00 - 16:15	Discussion	
14:45 - 16:15	Type: Special Session Title: When clinical practice demands to go beyond statistics: Adjuvant chemotherapy of colon cancer. The 3 vs 6 month story Chair(s): A. Sobrero, IT; A. Cervantes, ES	Madrid Auditorium

- 14:45 - 14:50 Introduction
A. Sobrero, Genova, IT
- 14:50 - 14:55 LBA22 - Updated results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer
T. Iveson¹, R. Kerr², M. Saunders³, N. Hollander⁴, J. Taberero⁵, A. Haydon⁶, B. Glimelius⁷, A. Harkin⁸, C. Scudder⁹, K. Boyd⁸, A. Waterston⁸, L. Medley¹⁰, C. Wilson¹¹, R. Ellis¹², S. Essapen¹³, A. Dhadda¹⁴, M. Harrison¹⁵, S. Falk¹⁶, S. Abdel-Raouf¹⁷, J. Paul⁸; ¹Southampton, GB, ²Oxford, Oxfordshire/GB, ³Manchester, GB, ⁴Naestved, DK, ⁵Barcelona, ES, ⁶Melbourne, AU, ⁷Uppsala, SE, ⁸Glasgow, GB, ⁹Oxford, GB, ¹⁰London, Cheltenham/GB, ¹¹Cambridge, GB, ¹²Truro, Cornwall/GB, ¹³Guildford, GB, ¹⁴Cottingham, East Yorkshire/GB, ¹⁵Middlesex, GB, ¹⁶Bristol, GB, ¹⁷Essex, GB
- 14:55 - 15:00 LBA23 - FOLFOX4/XELOX in stage II–III colon cancer: Efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial
R. Labianca¹, S. Lonardi², G. Rosati³, M. Di Bartolomeo⁴, M. Ronzoni⁴, N. Pella⁵, M. Scartozzi⁶, M. Banzi⁷, M.G. Zampino⁴, F. Pasini⁸, P. Marchetti⁹, M. Cantore¹⁰, A. Zaniboni¹¹, L. Rimassa¹², L. Ciuffreda¹³, S. Barni¹⁴, V. Zagonel², E. Maiello¹⁵, E. Rulli¹⁶, A. Sobrero¹⁷; ¹Parabiago (milano), IT, ²Padova, IT, ³Potenza, IT, ⁴Milan, IT, ⁵Udine, IT, ⁶Ancona, IT, ⁷Reggio Emilia, IT, ⁸Rovigo, RO/IT, ⁹Roma, IT, ¹⁰Carrara, IT, ¹¹Brescia, IT, ¹²Rozzano, (MI)/IT, ¹³Torino, IT, ¹⁴Treviglio, (BG)/IT, ¹⁵San Giovanni Rotondo, IT, ¹⁶Milano, IT, ¹⁷Genova, IT
- 15:00 - 15:05 LBA24 - Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration
T. Yoshino¹, T. Yamanaka², M. Kotaka³, D. MANAKA⁴, T. Eto⁵, J. Hasegawa⁶, A. Takagane⁷, M. Nakamura⁸, T. Kato⁹, Y. Munemoto¹⁰, F. Nakamura¹¹, H. Bando¹², H. Taniguchi⁴, M. Gamoh¹³, M. Shiozawa¹⁴, J. Sakamoto¹⁵, S. Saji¹⁵, T. Mizushima¹⁶, A. Ohtsu¹, M. Mori¹⁷; ¹Kashiwa, Chiba/Jp, ²Yokohama, JP, ³Kobe, Hyogo/Jp, ⁴Kyoto, JP, ⁵Tsuchiura, JP, ⁶Saki, JP, ⁷Hakodate, JP, ⁸Matsumoto, JP, ⁹Amagasaki, Hyogo/Jp, ¹⁰Fukui, Fukui/Jp, ¹¹Sapporo, JP, ¹²Kanazawa, JP, ¹³Osaki, Miyagi/Jp, ¹⁴Kanagawa, JP, ¹⁵Tokyo, JP, ¹⁶Suita, Osaka/Jp, ¹⁷Suita, JP
- 15:05 - 15:10 4730 - Three versus six months' adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results
J. Taieb¹, F. Bonnetain², L. Mineur³, J. Bennouna⁴, J. Desrame⁵, R. Faroux⁶, S. Fratte⁷, J. Dauba⁸, D. Vernerey⁹, C. Louvet¹, C. Lepere¹, O. Dupuis¹⁰, Y. Becouarn¹¹, M. Mabro¹², J. Egreteau¹³, O. Bouche¹⁴, G. Deplanque¹⁵, M. Ychou¹⁶, A. de Gramont¹⁷, T. André¹⁸; ¹Paris, FR, ²Besançon, CEDEX/FR, ³Avignon, FR, ⁴Nantes, CEDEX/FR, ⁵Lyon, CEDEX 8/FR, ⁶La Roche Sur Yon, CEDEX 9/FR, ⁷Belfort, FR, ⁸Mont De Marsan, FR, ⁹Besançon, FR, ¹⁰Le Mans, FR, ¹¹Bordeaux, CEDEX/FR, ¹²Suresnes, FR, ¹³Lorient, FR, ¹⁴Reims, FR, ¹⁵Vevey, CH, ¹⁶Montpellier, CEDEX 5/FR, ¹⁷Levallois-Perret, FR, ¹⁸Paris, CEDEX 12/FR
- 15:10 - 15:20 LBA21_PR - Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)

A. Grothey¹, A. Sobrero², J. Meyerhardt³, T. Yoshino⁴, J. Paul⁵, J. Taieb⁶, I. Souglakos⁷, R. Kerr⁸, R. Labianca⁹, A. Shields¹⁰, F. Bonnetain¹¹, T. Yamanaka¹², I. Boukovinas¹³, Q. Shi¹, J. Meyers¹, D. Niedzwiecki¹⁴, V. Torri¹⁵, D. Sargent¹, T. André¹⁶, T. Iveson¹⁷; ¹Rochester, MN/US, ²Genova, IT, ³Boston, MA/US, ⁴Kashiwa, Chiba/JP, ⁵Glasgow, GB, ⁶Paris, FR, ⁷Heraklion, Crete/GR, ⁸Oxford, Oxfordshire/GB, ⁹Bergamo, IT, ¹⁰Detroit, US, ¹¹Besançon, CEDEX/FR, ¹²Yokohama, JP, ¹³Athens, GR, ¹⁴Durham, NC/US, ¹⁵Milan, IT, ¹⁶Paris, CEDEX 12/FR, ¹⁷Southampton, GB

15:20 - 15:30 Discussion by the clinician
T. Maughan, Oxford, GB

15:30 - 15:40 Discussion by the statistician
M. Buyse, San Francisco, CA/US

15:40 - 16:15 Moderated panel discussion on clinical conditions and Q&A
A. Cervantes¹, J. Meyerhardt², A. Shields³, A. Sobrero⁴, I. Souglakos⁵; ¹Valencia, Valencia/ES, ²Boston, MA/US, ³Detroit, US, ⁴Genova, IT, ⁵Heraklion, GR

14:45 - 16:15 Type: Special Symposium Sevilla Auditorium
Title: Cancer evolution and metastasis: From single cells to population dynamics
Chair(s): I. Bozic, US; R. Giavazzi, IT

14:45 - 14:50 Introduction
R. Giavazzi, Milan, IT

14:50 - 15:10 Cancer evolution and metastasis: from single cells to population dynamics
I. Bozic, Seattle, Wa, US

15:10 - 15:30 Quantifying the evolutionary dynamics of tumor growth and metastasis
C. Curtis, Standford, Ca, US

15:30 - 15:50 Metastasis as an evolutionary process
S. Turajlic, London, GB

15:50 - 16:10 Single cell analysis and cancer
T. Voet, Leuven, BE

16:10 - 16:15 Conclusions and clinical perspectives
I. Bozic, Seattle, Wa, US

14:45 - 16:15 Type: Poster Discussion session Pamplona Auditorium
Title: Non-metastatic NSCLC and other thoracic malignancies
Chair(s): M. Garassino, IT; C. Le Pechoux, FR; F. Blackhall, GB; P. Baas, NL

- 14:45 - 14:45 1278PD - Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial
J. Remon Masip¹, A. Martinez-Marti¹, E. Carcereny Costa², J. Zeron-Medina Cuairan¹, I. Sansano¹, J.L. Mate³, N. Pardo¹, S. Cedres¹, A. Navarro¹, A.M. Martinez de castro¹, T. Moran³, E. Felip Font¹; ¹Barcelona, ES, ²Badalona, Barcelona/ES, ³Badalona, ES
- 14:45 - 14:45 1274PD - Analysis of immunoregulatory biomarkers in early stages of non-small cell lung cancer
A. Moreno Manuel¹, S. Calabuig Fariñas¹, A. HERREROS POMARES¹, S. Gallach Garcia¹, F. Aranda², A. Blasco¹, E. Carreras², F. Lozano², A. Cunquero Tomas¹, M. Martorell¹, E. Jantus-Lewintre¹, C. Camps Herrero¹; ¹Valencia, ES, ²Barcelona, ES
- 14:45 - 14:45 1275PD - Stemness characterization of tumorspheres from non-small cell lung cancer: Differential expression in CSC-related markers and signaling pathways
A. HERREROS POMARES, S. Calabuig Fariñas, E. Escorihuela, H. Amado, R. Guijarro, S. Gallach Garcia, A. Navarro, E. Jantus-Lewintre, C. Camps Herrero; Valencia, ES
- 14:45 - 14:55 Invited Discussant 1278PD, 1274PD and 1275PD
M. Garassino, Milan, IT
- 14:55 - 15:00 Q&A led by Discussant
- 15:00 - 15:00 1287PD - Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC: A multicenter phase II SAKK
A. Curioni-Fontecedro¹, H.-B. Ris², A. Xyrafas³, H. Bouchaab², H. Gelpke⁴, N. Mach⁵, O. Matzinger⁶, N. Stojcheva³, M. Frueh⁷, R. Cathomas⁸, S. Berardi Vilei³, L. Bubendorf⁹, M. Pless⁴, D. Betticher¹⁰, S. Peters²; ¹Zurich, CH, ²Lausanne, CH, ³Bern, CH, ⁴Winterthur, CH, ⁵Geneva, CH, ⁶Vevey, CH, ⁷St. Gallen, CH, ⁸Chur, CH, ⁹Basel, CH, ¹⁰Fribourg, CH
- 15:00 - 15:00 1277PD - A phase II randomized trial of adjuvant chemotherapy for the patients completely resected pathological stage IB (T &
T. Okamoto¹, T. Yano², M. Shimokawa³, S. Takeo³, K. Yamazaki³, K. Sugio¹, M. Takenoyama³, A. Nagashima⁴, T. Tagawa³, Y. Emi³, Y. Maehara³; ¹Yufu, JP, ²Beppu, JP, ³Fukuoka, JP, ⁴Kitakyushu, JP
- 15:00 - 15:00 1288PD - Randomized phase ii trial comparing chemoradiotherapy with chemotherapy for completely resected unsuspected N2-positive non-small cell lung cancer
J.-M. Sun, M.-J. Ahn, J.S. Ahn, H.K. Kim, Y.C. Ahn, J.I. Zo, Y.M. Shim, K. Park; Seoul, KR
- 15:00 - 15:00 1289PD - Clinical course in patients with stage III non-small cell lung cancer and interstitial lung disease treated with chemoradiotherapy: a retrospective analysis in a single institute
H. Kobayashi¹, T. Naito¹, K. Omae², S. Omori¹, K. Nakashima¹, K. Wakuda¹, A. Ono³, H. Kenmotsu¹, H. Murakami³, M. Endo¹, H. Harada¹, T. Takahashi¹; ¹Shizuoka, JP, ²Sunto-Gun, JP, ³Shizuoka, Shizuoka/JP
- 15:00 - 15:20 Invited Discussant 1287PD, 1277PD, 1278PD, 1288PD and 1289PD

C. Le Pechoux, Villejuif, CEDEX/FR

15:20 - 15:30 Q&A led by Discussant

15:30 - 15:30 1528PD - Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)

Q.S.-C. Chu¹, C. van Herpen², N. Leigh³, B. Markman⁴, S. Clarke⁵, R. Juergens⁶, P. Basciano⁷, D. Lathers⁷, S. Tannenbaum-Dvir⁷, K. Urbanska⁷, G. Kollia⁷, C. Darby⁷, D. Williams⁷, G. Kolaitis⁷, N. Ready⁸; ¹Edmonton, CA, ²Nijmegen, NL, ³Toronto, CA, ⁴Melbourne, VIC/AU, ⁵St Leonards, NSW/AU, ⁶Hamilton, ON/CA, ⁷Princeton, NJ/US, ⁸Durham, NC/US

15:30 - 15:30 1529PD - Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC)

M.E. Olmedo Garcia¹, M. Forster², E. Calvo¹, V. Moreno¹, M.P. Lopez Criado¹, J.A. Lopez-Vilarino de Ramos¹, C. Kahatt³, P. Lardelli⁴, X.E. Luepke-Estefan¹, A. Soto-Matos¹; ¹Madrid, ES, ²London, London/GB, ³Colmenar Viejo, ES, ⁴Colmenar Viejo, Madrid/ES

15:30 - 15:30 1530PD - Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)

D. Daniel¹, C. Rudin², L. Hart³, D. Spigel⁴, M. Edelman⁵, J. Goldschmidt⁶, R. Bordoni⁷, B. Glisson⁸, T. Burns⁹, A. Dowlati¹⁰, G. Dy¹¹, T. Beck¹², R. Jotte¹³, S. Liu¹⁴, A. Kapoun¹⁵, L. Faoro¹⁶, A. Chiang¹⁷; ¹Chattanooga, US, ²New York, NY/US, ³Fort Myers, FL/US, ⁴Nashville, TN/US, ⁵Philadelphia, US, ⁶Blacksburg, US, ⁷Marietta, US, ⁸Houston, US, ⁹Pittsburgh, US, ¹⁰Cleveland, OH/US, ¹¹Buffalo, US, ¹²Fayetteville, US, ¹³Denver, US, ¹⁴Washington, US, ¹⁵Redwood City, US, ¹⁶South San Francisco, CA/US, ¹⁷New Haven, US

15:30 - 15:30 1531PD - Clinical outcomes for EGFR-mutant adenocarcinomas (AC) that transform to small cell lung cancer (SCLC)

N. Marcoux¹, Z. Piotrowska¹, A. Farago², A. Hata², M. Mooradian², B. Drapkin², A. Muzikansky², S. Gettinger³, M. Mino-Kenudson², L. Sequist²; ¹Boston, US, ²Boston, MA/US, ³New Haven, CT/US

15:30 - 15:50 Invited Discussant 1528PD, 1529PD, 1530PD and 1531PD

F. Blackhall, Manchester, GB

15:50 - 16:00 Q&A led by Discussant

16:00 - 16:00 1617PD - Multiplexed targeted proteomics signature for serum diagnostic of malignant pleural mesothelioma

F. Cerciello¹, M. Choi², K. Lomeo³, J. Amann³, E. Felley-Bosco¹, R. Stahel¹, B. Robinson⁴, J. Creaney⁴, H. Pass⁵, O. Vitek², D. Carbone³; ¹Zürich, CH, ²Boston, MA/US, ³Columbus, OH/US, ⁴Nedlands, AU, ⁵New York, US

- 16:00 - 16:00 1618PD - Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)
- S. Novello¹, A. Nowak², F. Grosso³, N. Steele⁴, S. Popat⁵, L. Greillier⁶, T. John⁷, N. Leigh⁸, M. Reck⁹, N. Pavlakis¹⁰, J.B. Sorensen¹¹, D. Planchard¹², G.L. Ceresoli¹³, B. Hughes¹⁴, J. Mazieres¹⁵, M. Socinski¹⁶, U. von Wangenheim¹⁷, J. Barrueco¹⁸, N. Morsli¹⁹, G. Scagliotti¹; ¹Torino, IT, ²Crawley, WA/AU, ³Alessandria, IT, ⁴Glasgow, GB, ⁵London, GB, ⁶Marseille, FR, ⁷Heidelberg, VIC/AU, ⁸Toronto, CA, ⁹Grosshansdorf, DE, ¹⁰St Leonards, NSW/AU, ¹¹Copenhagen, DK, ¹²Villejuif, FR, ¹³Bergamo, IT, ¹⁴North Ryde, AU, ¹⁵Toulouse, FR, ¹⁶Pittsburgh, PA/US, ¹⁷Biberach, DE, ¹⁸Ridgefield, US, ¹⁹Paris, FR
- 16:00 - 16:00 1619PD - Malignant pleural mesothelioma immune microenvironment and checkpoint expression before and after systemic cytotoxic treatment
- G. Zago, F. Lunardi, F. Calabrese, S. Vuljan, L. Urso, S. Frega, A. Pavan, V. Polo, L. Bonanno, I. Attili, F. Rea, P.F. Conte, G. Pasello; Padova, IT
- 16:00 - 16:10 Invited Discussant 1617PD, 1618PD and 1619PD
- P. Baas, Amsterdam, NL
- 16:10 - 16:15 Q&A led by Discussant

14:45 - 16:15	Type: Special Symposium Title: Emerging topics in developmental therapeutics Chair(s): A. Chalmers, GB; U. Lassen, DK	Cordoba Auditorium
14:45 - 14:50	Introduction <u>U. Lassen</u> , Copenhagen, DK	
14:50 - 15:05	DNA and RNA basic strategies in early drug development <u>R. Bernards</u> , Amsterdam, NL	
15:05 - 15:20	Combined modality of radiation DDR <u>A. Chalmers</u> , Glasgow, GB	
15:20 - 15:35	Targeting metabolism <u>E. Gottlieb</u> , Technion, IL	
15:35 - 15:50	Developmental therapeutics in rare tumours <u>N. Gaspar</u> , Villejuif, FR	
15:50 - 16:05	Targeting the P53 pathway <u>L. Saraiva</u> , Porto, PT	
16:05 - 16:15	Conclusions and clinical perspectives <u>A. Chalmers</u> , Glasgow, GB	

14:45 - 16:15 Type: Joint Symposium Bilbao Auditorium
 Title: ESMO-ESOI: Colorectal cancer imaging: New opportunities to guide treatment decisions
 Chair(s): E. Voest, NL; R. Beets-Tan, NL

14:45 - 14:50 Introduction
E. Voest, Amsterdam, NL

14:50 - 15:10 Rectal cancer: Organ preservation and the role of imaging
R. Beets-Tan, Maastricht, NL

15:10 - 15:30 CRC liver metastases: Detection & treatment response evaluation with modern imaging
D. Regge, Candiolo, IT

15:30 - 15:50 CRC liver metastases: Interventional treatment
T. Helmberger, Munich, DE

15:50 - 16:10 PET/MRI: Combining molecular and functional imaging
V. Goh, London, GB

16:10 - 16:15 Conclusions and clinical perspectives
R. Beets-Tan, Maastricht, NL

14:45 - 16:15 Type: Educational session Alicante Auditorium
 Title: The “micro-economics” of cancer: How the medical oncologist should micro-manage limited resources
 Chair(s): F. De Lorenzo, IT; P.G. Casali, IT

14:45 - 15:10 Micro-allocation of limited resources in the clinic
P.G. Casali, Milan, IT

15:10 - 15:35 How should the medical oncologist negotiate with local health administrators
J. Borras, Barcelona, ES

15:35 - 16:15 Round-table discussion: Bedside rationing of resources

- 15:00 - 16:20 Type: Proffered Paper session Granada Auditorium
Title: Head and neck cancer, excluding thyroid
Chair(s): A. Psyrri, GR; C. Le Tourneau, FR
- 15:00 - 15:12 LBA45_PR - Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
E. Cohen¹, K. Harrington², C. Le Tourneau³, J. Dinis⁴, L. Licitra⁵, M.-J. Ahn⁶, A. Soria⁷, J.-P. Machiels⁸, N. Mach⁹, R. Mehra¹⁰, B. Burtneess¹¹, Y. Wang¹², A. Tuozzo¹², R. Swaby¹², D. Soulieres¹³, ¹La Jolla, IL/US, ²London, GB, ³Paris, FR, ⁴Porto, PT, ⁵Milan, IT, ⁶Seoul, KR, ⁷Madrid, ES, ⁸Brussels, BE, ⁹Geneva, CH, ¹⁰Philadelphia, PA/US, ¹¹New Haven, CT/US, ¹²Kenilworth, NJ/US, ¹³Montreal, CA
- 15:12 - 15:24 1043O - Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes
R. Haddad¹, G. Blumenschein Jr², J. Fayette³, J. Guigay⁴, A. Colevas⁵, L. Licitra⁶, S. Kasper⁷, E. Vokes⁸, F. Worden⁹, N. Saba¹⁰, M. Tahara¹¹, F. Concha-Benavente¹², M. Monga¹³, M. Lynch¹³, L. Li¹³, J. Shaw¹⁴, M. Gillison¹⁵, K. Harrington¹⁶, R. Ferris¹⁷; ¹Boston, MA/US, ²Houston, US, ³Lyon, FR, ⁴Nice, CEDEX 2/FR, ⁵Stanford, CA/US, ⁶Milan, IT, ⁷Essen, DE, ⁸Chicago, IL/US, ⁹Ann Arbor, MI/US, ¹⁰Atlanta, GA/US, ¹¹Kashiwa, Chiba/JP, ¹²Pittsburgh, PA/US, ¹³Princeton, US, ¹⁴New York, US, ¹⁵Columbus, US, ¹⁶London, GB, ¹⁷US
- 15:24 - 15:39 Invited Discussant LBA45 and 1043O
S. Faivre, Paris, FR
- 15:39 - 15:51 1042O - Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study
D. Zandberg¹, A. Algazi², A. Jimeno³, J. Good⁴, J. Fayette⁵, N. Bouganim⁶, N. Ready⁷, P. Clement⁸, T. Goswami⁹, A. Jarkowski⁹, J. Armstrong⁹, K. Asubonteng⁹, G. Melillo¹⁰, R. Mesia¹¹; ¹Baltimore, US, ²San Francisco, US, ³Colorado, US, ⁴Birmingham, GB, ⁵Lyon, CEDEX/FR, ⁶Montreal, CA, ⁷Durham, NC/US, ⁸Leuven, BE, ⁹Gaithersburg, US, ¹⁰Gaithersburg, Maryland/US, ¹¹Barcelona, ES
- 15:51 - 16:03 1044O - Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results
R. Bahleda¹, F. Braiteh², A. Balmanoukian³, I. Braña⁴, F.S. Hodi⁵, L. Garbo⁶, B. Liu⁷, L. Molinero⁷, C. O'Hear⁷, X. Shen⁸, M. Fassio⁹, A. Colevas¹⁰; ¹Villejuif, CEDEX/FR, ²Las Vegas, US, ³Los Angeles, CA/US, ⁴Barcelona, ES, ⁵Boston, US, ⁶Albany, NY/US, ⁷South San Francisco, CA/US, ⁸South San Francisco, US, ⁹South San Francisco, California/US, ¹⁰Stanford, CA/US
- 16:03 - 16:18 Invited Discussant 1042O and 1044O
L. Licitra, Milan, IT

15:00 - 16:00 Type: Multidisciplinary Session Valencia Auditorium
 Title: Management of brain metastases
 Chair(s): T. Bachelot, FR

15:00 - 15:05 Presentation of case/condition
T. Bachelot, Lyon, CEDEX/FR

15:05 - 15:15 The medical oncology perspective
T. Bachelot, Lyon, CEDEX/FR

15:15 - 15:25 The radiation therapy perspective
F. Dhermain, Villejuif, FR

15:25 - 15:35 The neurosurgery perspective
C. Watts, Cambridge, GB

15:35 - 16:00 General Discussion

15:00 - 16:00 Type: Multidisciplinary Session Tarragona Auditorium
 Title: Management of M0 patient with rising PSA
 Chair(s): K. Fizazi, FR

15:00 - 15:05 Presentation of case/condition
K. Fizazi, Villejuif, FR

15:05 - 15:15 The clinical problem: A multi-disciplinary issue
K. Fizazi, Villejuif, FR

15:15 - 15:25 How can PET imaging help?
U. Haberkorn, Heidelberg, DE

15:25 - 15:35 How can MRI imaging help?
N. Tunariu, London, GB

15:35 - 16:00 General Discussion

16:00 - 17:30 Type: Young Oncologist Forum Salamanca Auditorium
 Title: Management skills that help you organise your everyday life in oncology
 Chair(s): R. Vidra, RO; M. Petrova, BG

16:00 - 16:20 How to profit from opportunities in a competitive environment
E. Martinelli, Naples, IT

16:20 - 16:20 Session Shooter
G. Argiles Martinez, Barcelona, ES

16:20 - 16:40 Time management: Handling priorities and necessities
E. De Azambuja, Brussels, BE

16:40 - 16:40 Session Shooter
C. Cardone, Naples, IT

16:40 - 17:00 Finding a mentor
R.A. Stahel, Zurich, CH

17:00 - 17:00 Session Shooter
M.A. Ozturk, Istanbul, TR

17:00 - 17:20 Leadership: How to run a complex team
C. Zielinski, Vienna, AT

17:20 - 17:20 Session Shooter
T. Amaral, Lisbon, PT

17:20 - 17:30 Discussion

- 16:30 - 17:45 Type: Presidential Symposium Madrid Auditorium
Title: Presidential Symposium III
Chair(s): F. Ciardiello, IT; R. Marais, GB
- 16:30 - 16:45 LBA7_PR - BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence
K. Lewis¹, M. Maio², L. Demidov³, M. Mandala⁴, P. Ascierto⁵, C. Herbert⁶, A. Mackiewicz⁷, P. Rutkowski⁸, A. Guminski⁹, G. Goodman¹⁰, B. Simmons¹⁰, C. Ye¹⁰, Y. Yan¹⁰, D. Schadendorf¹¹; ¹Aurora, CO/US, ²Siena, IT, ³Moscow, RU, ⁴Bergamo, IT, ⁵Napoli, IT, ⁶Bristol, GB, ⁷Poznan, PL, ⁸Warsaw, PL, ⁹St Leonards, NSW/AU, ¹⁰South San Francisco, US, ¹¹Essen, DE
- 16:45 - 17:00 LBA6_PR - COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma
A. Hauschild¹, M. Santinami², G. Long³, V. Atkinson⁴, M. Mandala⁵, V. Chiarion Sileni⁶, M. Nyakas⁷, C. Dutriaux⁸, A. Haydon⁹, C. Robert¹⁰, L. Mortier¹¹, J. Schachter¹², R. Ji¹³, P. Zhang¹³, B. Mookerjee¹⁴, J. Legos¹⁵, R. Kefford¹⁶, R. Dummer¹⁷, J. Kirkwood¹⁸; ¹Kiel, Schleswig-Holstein/DE, ²Milan, IT, ³Sydney, AU, ⁴Woolloongabba, AU, ⁵Bergamo, IT, ⁶Padova, IT, ⁷Oslo, NO, ⁸Bordeaux, FR, ⁹Melbourne, AU, ¹⁰Villejuif, FR, ¹¹Lille, CEDEX/FR, ¹²Ramat Gan, IL, ¹³East Hanover, US, ¹⁴New Jersey, US, ¹⁵East Hanover, New Jersey/US, ¹⁶Macquarie Park, NSW/AU, ¹⁷Zürich, CH, ¹⁸Pittsburgh, PA/US
- 17:00 - 17:15 Invited Discussant LBA7_PR and LBA6_PR
A.M.M. Eggermont, Villejuif, FR
- 17:15 - 17:30 LBA8_PR - Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)
J. Weber¹, M. Mandala², M. Del Vecchio³, H. Gogas⁴, A. Arance⁵, L. Cowey⁶, S. Dalle⁷, M. Schenker⁸, V. Chiarion-Sileni⁹, I. Márquez-Rodas¹⁰, J.-J. Grob¹¹, M. Butler¹², M. Middleton¹³, M. Maio¹⁴, V. Atkinson¹⁵, P. Queirolo¹⁶, V. de Pril¹⁷, A. Qureshi¹⁷, J. Larkin¹⁸, P. Ascierto¹⁹; ¹New York, US, ²Bergamo, IT, ³Milan, IT, ⁴Athens, Attiki/GR, ⁵Barcelona, ES, ⁶Dallas, TX/US, ⁷Pierre Bénite, FR, ⁸Craiova, RO, ⁹Padua, IT, ¹⁰Madrid, ES, ¹¹Marseille, FR, ¹²Toronto, ON/CA, ¹³Oxford, Oxfordshire/GB, ¹⁴Siena, IT, ¹⁵Queensland, AU, ¹⁶Genova, IT, ¹⁷Princeton, NJ/US, ¹⁸London, GB, ¹⁹Napoli, IT
- 17:30 - 17:45 Invited Discussant LBA8_PR
R. Dummer, Zürich, CH

16:30 - 18:00 Type: Educational session Sevilla Auditorium
Title: Update on new therapies for triple negative breast cancer (TNBC)
Chair(s): P. Schmid, GB; F. Penault-Llorca, FR

16:30 - 16:55 PARP inhibitors
J. Garber, Boston, Ma, US

16:55 - 17:20 Immunotherapeutics
P. Schmid, London, GB

17:20 - 17:45 Androgen receptor
H. Bonnefoi, Bordeaux, CEDEX/FR

17:45 - 18:00 Discussion

16:30 - 18:00 Type: Educational session Pamplona Auditorium
Title: Lung cancer screening
Chair(s): K. Nackaerts, BE; E. Felip Font, ES

16:30 - 16:55 Overview of clinical trials: What are the randomised data?
K. Nackaerts, Leuven, BE

16:55 - 17:20 Implementation issues of lung cancer screening in Europe
U. Pastorino, Milan, IT

17:20 - 17:45 Biomarkers in lung cancer screening
L. Montuenga, Pamplona, ES

17:45 - 18:00 Discussion

16:30 - 18:00 Type: Poster Discussion session Cordoba Auditorium
Title: Gastrointestinal tumours, non-colorectal
Chair(s): S. Cascinu, IT; Y.-K. Kang, KR; D. Cunningham, GB; E. Van Cutsem, BE

16:30 - 16:30 620PD - YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD)

A. Cubillo Gracian¹, A. Dean², A. Muñoz¹, M. Hidalgo¹, R. Pazo-Cid³, M. Martin⁴, T. Macarulla Mercade⁵, L. Lipton⁶, M. Harris⁷, J.L. Manzano-Mozo⁸, J. Maurel⁵, C. Guillen-Ponce¹, N. Tebbutt⁹, P. Cooray¹⁰, D. Sohal¹¹, M. Zalupski¹², T. Kolevska¹³, R. Stagg¹⁴, D. Goldstein¹⁵; ¹Madrid, ES, ²Subiaco, WA/AU, ³Zaragoza, ES, ⁴Sant Pau, ES, ⁵Barcelona, ES, ⁶Melbourne, VIC/AU, ⁷Monash, AU, ⁸Badalona, ES, ⁹Heidelberg, VIC/AU, ¹⁰Box Hill, VIC/AU, ¹¹Cleveland, US, ¹²Ann Arbor, US, ¹³Vallejo, US, ¹⁴New York, CA/US, ¹⁵Sydney, NSW/AU

16:30 - 16:30 621PD - A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)

P. Hammel¹, J.-B. Bachet², F. Portales³, L. Mineur⁴, J.-P. Metges⁵, C. de la Fouchardiere⁶, C. Louvet⁷, F. El Hajbi⁸, R. Faroux⁹, R. Guimbaud¹⁰, D. Tougeron¹¹, J. Volet¹², T. Lecomte¹³, C. Tournigand¹⁴, C. Rebischung¹⁵, W. Berlier¹⁶, A. Gupta¹⁷, J. Cros¹, T. André¹⁸, I. El-Hariry¹⁶; ¹Clichy, FR, ²Paris, CEDEX 13/FR, ³Montpellier, FR, ⁴Avignon, FR, ⁵Brest, FR, ⁶Lyon, CEDEX/FR, ⁷Paris, FR, ⁸Lille, FR, ⁹La Roche Sur Yon, CEDEX 9/FR, ¹⁰Toulouse, CEDEX 3/FR, ¹¹Poitiers, CEDEX/FR, ¹²Reims, FR, ¹³Chambray-Lès-tours, FR, ¹⁴Creteil Cedex, FR, ¹⁵Grenoble, FR, ¹⁶Lyon, FR, ¹⁷Cambridge, US, ¹⁸Paris, CEDEX 12/FR

16:30 - 16:30 622PD - nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial

P. Philip¹, J. Lacy², F. Portales³, A. Sobrero⁴, R. Pazo-Cid⁵, J.L. Manzano-Mozo⁶, E. Kim⁷, S. Dowden⁸, A. Zakari⁹, C. Borg¹⁰, E. Terrebbonne¹¹, F. Rivera Herrero¹², J. Shiansong Li¹³, T.J. Ong¹³, T. Nydam¹⁴, P. Hammel¹⁵; ¹Detroit, MI/US, ²New Haven, CT/US, ³Montpellier, FR, ⁴Genova, IT, ⁵Zaragoza, ES, ⁶Badalona, ES, ⁷Charlotte, NC/US, ⁸Calgary, Alberta/CA, ⁹Orlando, FL/US, ¹⁰Besançon, FR, ¹¹Giround, FR, ¹²Santander, ES, ¹³Summit, NJ/US, ¹⁴Summit, US, ¹⁵Clichy, FR

16:30 - 16:30 623PD - A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC)

M. Hidalgo¹, R. Pazo-Cid², C. Guillen-Ponce¹, R. López³, R. Vera⁴, M. Reboredo⁵, A. Muñoz¹, E. Martínez de Castro⁶, R. Díaz Beveridge⁷, A. La Casta⁸, J. Martin-Valades¹, A. Cubillo¹, J. Martínez-Galán⁹, I. Ales¹⁰, J. Sastre¹, T. Macarulla Mercade¹¹; ¹Madrid, ES, ²Zaragoza, ES, ³Santiago De Compostela, ES, ⁴Pamplona, ES, ⁵A Coruna, ES, ⁶Santander, ES, ⁷Valencia, ES, ⁸Donostia, ES, ⁹Granada, ES, ¹⁰Málaga, ES, ¹¹Barcelona, ES

16:30 - 16:50 Invited Discussant 620PD, 621PD, 622PD and 623PD

S. Cascinu, Ancona, IT

16:50 - 17:00 Q&A led by Discussant

17:00 - 17:00 1733PD - New promising combination therapy of a mitochondrial metabolism inhibitor with mFOLFIRINOX in pancreatic cancer

A. Alistar¹, B. Pasche², R. D'Agostino², T. Pardee³, S. Luther³, R. Desnoyer⁴; ¹Morristown, US, ²Winston Salem, US, ³Cranbury, US, ⁴Winston Salem, NC/US

- 17:00 - 17:00 1734PD - Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients
E. Carrier¹, V. Picozzi², M. Pishvaian³, K. Mody⁴, J. Winter⁵, J. Glaspy⁶, T. Larson⁷, W.C. Conway⁸, K. Lipson⁹, S. Porter⁹, E. Kouchakji⁹; ¹San Francisco, US, ²Seattle, WA/US, ³Washington, DC/US, ⁴Jacksonville, FL/US, ⁵Philadelphia, PA/US, ⁶Los Angeles, CA/US, ⁷Minnesota, MN/US, ⁸New Orleans, LA/US, ⁹San Francisco, CA/US
- 17:00 - 17:10 Invited Discussant 1733PD and 1734PD
E. Van Cutsem, Leuven, BE
- 17:10 - 17:20 Q&A led by Discussant
- 17:20 - 17:20 624PD - A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection
P.-J. Chen¹, P.-H. Lee¹, K.-H. Han², J. Fan³, T.T. Cheung⁴, R.-H. Hu¹, S.W. Paik², W.-C. Lee¹, G.-Y. Chau¹, L.-B. Jeng⁵, H.J. Wang², J.Y. Choi², C.-L. Chen⁶, M. Cho⁷, M.-C. Ho¹, C.-C. Wu⁵, K.S. Lee², Y. Mao⁸, F.-C. Hu¹, K.-L. Lai¹; ¹Taipei, TW, ²Seoul, KR, ³Shang-Hai, CN, ⁴Hk, HK, ⁵Taichung, TW, ⁶Kaohsiung, TW, ⁷Pusan, KR, ⁸Beijing, CN
- 17:20 - 17:20 625PD - Protein biomarkers as predictors of outcome with regorafenib (REG) in patients (pts) with hepatocellular carcinoma (HCC) in the RESORCE trial
M. Teufel¹, K. Köchert², G. Meinhardt³, R. Finn⁴, J. Llovet⁵, J. Bruix⁶; ¹Whippany, NJ/US, ²Berlin, DE, ³New York, NJ/US, ⁴Los Angeles, CA/US, ⁵New York, US, ⁶Barcelona, ES
- 17:20 - 17:30 Invited Discussant 624PD and 625PD
D. Cunningham, Sutton, GB
- 17:30 - 17:40 Q&A led by Discussant
- 17:40 - 17:40 626PD - A randomized phase III trial comparing 4 courses and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1)
T. Yoshikawa¹, M. Terashima², J. Mizusawa³, S. Nunobe³, Y. Nishida⁴, M. Kaji⁵, N. Fukushima⁶, S. Hato⁷, Y. Choda⁸, H. Yabusaki⁹, K. Yoshida¹⁰, S. Ito¹¹, A. Takeno¹², T. Yasuda¹³, Y. Kawachi¹⁴, H. Katayama³, H. Fukuda³, N. Boku¹⁵, T. Sano³, M. Sasako¹⁶; ¹Yokohama, JP, ²Shizuoka, Shizuoka/Jp, ³Tokyo, JP, ⁴Sapporo, JP, ⁵Toyama, JP, ⁶Yamagata, Yamagata/Jp, ⁷Matsuyama, JP, ⁸Hiroshima, JP, ⁹Niigata, JP, ¹⁰Gifu, JP, ¹¹Nagoya, JP, ¹²Amagasaki, Hyogo/Jp, ¹³Akashi, JP, ¹⁴Nagaoka, JP, ¹⁵Kawasaki, Kanagawa/Jp, ¹⁶Nishinomiya, JP
- 17:40 - 17:40 627PD - Comparison of the eighth and seventh editions of the American Joint Committee on Cancer TNM staging systems for gastric cancer: Proposal for a simplified and improved TNM staging system
J. Lin, H. Chang-Ming, J.-X. Lin, C. Zheng, P. Li; Fuzhou, CN
- 17:40 - 17:50 Invited Discussant 626PD and 627PD

Y.-K. Kang, Seoul, Songpa-gu/KR

17:50 - 18:00 Q&A led by Discussant

16:30 - 18:00 Type: Educational session Granada Auditorium
 Title: Neuroendocrine neoplasms of the gastroenteropancreatic system: From the bench to the bed
 Chair(s): J. Valle, GB; I. Chau, GB

16:30 - 16:55 Pathological characterisation of gastroenteropancreatic neuroendocrine neoplasms: Present and future
A. Couvelard, Clichy, FR

16:55 - 17:20 Present and future of nuclear medicine approach in neuroendocrine tumour management: From diagnosis to treatment
L. Bodei, Milan, IT

17:20 - 17:45 Evidence-based decisions in systemic management of gastroenteropancreatic neuroendocrine tumours
J. Valle, Manchester, GB

17:45 - 18:00 Discussion

16:30 - 17:30 Type: Multidisciplinary Session Valencia Auditorium
 Title: Clinical challenges in head and neck cancer
 Chair(s): M. Merlano, IT

16:30 - 16:35 Presentation of case/condition
M. Merlano, Cuneo, IT

16:35 - 16:45 The surgery perspective
C. Simon, Lausanne, CH

16:45 - 16:55 The radiation therapy perspective
V. Grégoire, Brussels, BE

16:55 - 17:05 The medical oncology perspective
M. Merlano, Cuneo, IT

17:05 - 17:30 General Discussion

16:30 - 17:50 Type: Poster Discussion session Tarragona Auditorium
 Title: Haematological malignancies

Chair(s): E. Terpos, GR; C. Buske, DE; L. De La Cruz Merino, ES

- 16:30 - 16:30 997PD - Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM)
S. Usmani¹, A. Jakubowiak², A. Chari³, S. Lonial⁴, M.-V. Mateos⁵, L. Benboubker⁶, K. Wu⁷, N. Khokhar⁷, J. Wang⁸, P. Doshi⁷, P. Moreau⁹; ¹Charlotte, US, ²Chicago, IL/US, ³New York, NY/US, ⁴Atlanta, GA/US, ⁵Salamanca, ES, ⁶Tours, FR, ⁷Spring House, PA/US, ⁸Raritan, NJ/US, ⁹Nantes, FR
- 16:30 - 16:30 998PD - Management of infusion-related reactions (IRRs) in patients (pts) receiving daratumumab plus standard of care for the treatment of multiple myeloma (MM) in the phase 3 studies CASTOR and POLLUX
P. Moreau¹, N. Rabin², T. Plesner³, K. Weisel⁴, P. Sonneveld⁵, M.-V. Mateos⁶, J. Schecter⁷, H. Amin⁷, S. Trivedi⁸, M. Dimopoulos⁹; ¹Nantes, FR, ²London, GB, ³Vejle, DK, ⁴Tübingen, DE, ⁵Rotterdam, NL, ⁶Salamanca, ES, ⁷Raritan, Nj, US, ⁸Spring House, Pa, US, ⁹Athens, GR
- 16:30 - 16:30 999PD - Comparison of efficacy of new therapies between younger and older patients with relapsed and refractory multiple myeloma: A meta-analysis
T. LANDRE¹, C. Al-Nawakil², F. Karaoud¹, C. Taleb¹; ¹Sevran, FR, ²Bobigny, FR
- 16:30 - 16:45 Invited Discussant 997PD, 998PD and 999PD
E. Terpos, Athens, Neo Psychiko/GR
- 16:45 - 16:50 Q&A led by Discussant
- 16:50 - 16:50 1000PD - Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study
M. Provencio Pulla¹, A. Santoro², L. Mollica³, S. Leppä⁴, G. Follows⁵, G. Lenz⁶, W.S. Kim⁷, A. Nagler⁸, P. Panayiotidis⁹, J. Demeter¹⁰, M. Özcan¹¹, M. Kosinova¹², K. Bouabdallah¹³, F. Morschhauser¹⁴, T. Ishida¹⁵, L. Huang¹⁶, J. Garcia-Vargas¹⁶, B. Childs¹⁷, P.L. Zinzani¹⁸, M. Dreyling¹⁹; ¹Majadahonda, Madrid/ES, ²Rozzano, (MI)/IT, ³Montreal, CA, ⁴Helsinki, FI, ⁵Cambridge, GB, ⁶Münster, DE, ⁷Seoul, KR, ⁸Tel-Hashomer, IL, ⁹Athens, GR, ¹⁰Budapest, HU, ¹¹Ankara, TR, ¹²Kemerovo, RU, ¹³Pessac, FR, ¹⁴Lille, FR, ¹⁵São Paulo, BR, ¹⁶Whippany, NJ/US, ¹⁷New York, New York/US, ¹⁸Bologna, IT, ¹⁹Munich, DE
- 16:50 - 16:50 1001PD - Tumor gene expression signatures of BCR/PI3K dependence in association with copanlisib monotherapy activity in heavily pretreated patients with indolent NHL and follicular lymphoma
L. Liu¹, K. Köchert², H. Seidel², J. Garcia-Vargas¹, B. Childs³, G. Follows⁴, K. Bouabdallah⁵, M. Dreyling⁶, C. Peña¹; ¹Whippany, NJ/US, ²Berlin, DE, ³New York, New York/US, ⁴Cambridge, GB, ⁵Pessac, FR, ⁶Munich, DE
- 16:50 - 16:50 1002PD - Standardized mortality ratios and event-free survival as new prediction tools of early increase in mortality in follicular lymphoma

F. Franco¹, A. Royuela¹, M. Torrente¹, J. Gómez-Codina², M. Llanos Rodríguez³, J. Gumá Padró⁴, C. Quero Blanco⁵, D. Aguiar⁶, A. Rueda Domínguez⁷, M. Provencio Pulla⁸; ¹Madrid, ES, ²Valencia, ES, ³Santa Cruz De Tenerife, ES, ⁴Reus, ES, ⁵Malaga, ES, ⁶Las Palmas De Gran Canaria, ES, ⁷Marbella, ES, ⁸Majadahonda, Madrid/ES

16:50 - 17:05 Invited Discussant 1000PD, 1001PD and 1002PD

L. De la Cruz Merino, Sevilla, ES

17:05 - 17:10 Q&A led by Discussant

17:10 - 17:10 1003PD - A multicentre phase II trial addressing lenalidomide (LEN) maintenance in patients with relapsed diffuse large b-cell lymphoma (rDLBCL) who are not eligible for autologous stem cell transplantation (ASCT)

M. Sassone¹, F. Zaja², A. Re³, M. Spina⁴, A. Di Rocco⁵, A. Fabbri⁶, C. Stelitano⁷, M. Frezzato⁸, C. Rusconi⁹, R. Zambello¹⁰, T. Calimeri¹, L. Scarfò¹, C. Cecchetti¹, M. Chiozzotto², M. Ponzoni¹, A. Ferreri¹; ¹Milan, IT, ²Udine, IT, ³Brescia, IT, ⁴Aviano, PNI/IT, ⁵Roma, IT, ⁶Siena, IT, ⁷Reggio Calabria, IT, ⁸Vicenza, IT, ⁹Milano, IT, ¹⁰Padova, IT

17:10 - 17:10 1004PD - Follicular lymphoma: clinical and molecular characteristics of histologic transformation

M. Mendez Garcia¹, M. Sánchez-Beato Gomez², J. González Rincón², J. Gomez Codina³, M. Llanos Rodríguez⁴, A. Rueda Domínguez⁵, C. Quero Blanco⁶, L. De la Cruz Merino⁷, J. Gumá Padró⁸, M. Provencio Pulla⁹; ¹Madrid, ES, ²Majadahonda, ES, ³Valencia, ES, ⁴Santa Cruz De Tenerife, ES, ⁵Marbella, ES, ⁶Malaga, ES, ⁷Sevilla, ES, ⁸Reus, ES, ⁹Majadahonda, Madrid/ES

17:10 - 17:10 1005PD - Prognostic nomogram for overall survival in previously untreated patients with diffuse large B-cell lymphoma

Y. Han, Y. Qin, P. Liu, J. Yang, X. He, S. Zhou, L. Gui, S. Yang, C. Zhang, Y. Huang, S. Jiang, Y. Shi, Q. Wang, Y. Sun, Y.-K. Shi; Beijing, CN

17:10 - 17:10 1006PD - Does the omission of vincristine affect outcome and survival in patients with diffuse large B-cell lymphoma?

C. Mörth¹, A. Valachis¹, A. Abu Sabaa², G. Hedström², M. Flogegård², G. Enblad²; ¹Eskilstuna, SE, ²Uppsala, SE

17:10 - 17:25 Invited Discussant 1003PD, 1004PD, 1005PD and 1006PD

C. Buske, Ulm, DE

17:25 - 17:30 Q&A led by Discussant

17:30 - 17:30 1007PD - Preliminary results of novel safety interventions in adult patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) in the ZUMA-3 Trial

B. Shah¹, W. Stock², W. Wierda³, M. Topp⁴, M.J. Kersten⁵, R. Houot⁶, N. Boissel⁷, H. Holmes⁸, G. Schiller⁹, A. Mardiros¹⁰, J. Rossi¹⁰, Y. Jiang¹⁰, T. Shen¹⁰, J. Aycock¹¹, S. Stout¹⁰, J. Wiezorek¹², R. Jain¹²; ¹Tampa, US, ²Chicago, US, ³Houston, US, ⁴Wurzburg, DE, ⁵Amsterdam, NL, ⁶Rennes, FR, ⁷Paris, FR, ⁸Dallas, US, ⁹Los Angeles, US, ¹⁰Santa Monica, CA/US, ¹¹Santa Monica, US, ¹²Thousand Oaks, CA/US

17:30 - 17:30

1008PD - ZUMA-4 preliminary results: phase 1 study of KTE-C19 chimeric antigen receptor T cell therapy in pediatric and adolescent patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL)

D. Lee¹, A. Wayne², V. Huynh³, R. Handgretinger⁴, R. Pieters⁵, G. Michele⁶, A. Baruchel⁷, T. Feuchtinger⁸, Y. Bertrand⁹, M. Hemiston¹⁰, P. Brown¹¹, J. Rossi¹², Y. Jiang¹², L. Navale¹², S. Stout¹², J. Aycock¹³, A. Mardiros¹², J. Wiezorek¹⁴, R. Jain¹⁴; ¹Charlottesville, US, ²Los Angeles, CA/US, ³Irvine, US, ⁴Tübingen, DE, ⁵Utrecht, NL, ⁶Marseille, FR, ⁷Paris, FR, ⁸Tuebingen, NL, ⁹Lyon, FR, ¹⁰San Francisco, CA/US, ¹¹Baltimore, MD/US, ¹²Santa Monica, CA/US, ¹³Santa Monica, US, ¹⁴Thousand Oaks, CA/US

17:30 - 17:30

1009PD - Treatment patterns in elderly patients (pts) with acute myeloid leukemia (AML) in routine clinical care in the united states (US)

J. Bell¹, A. Galaznik¹, E. Farrelly², M. Pollack³, A. Raju², A. Ogbonnaya², M. Eaddy², R. Fram⁴, D. Faller¹; ¹Cambridge, MA/US, ²Palm Harbor, FL/US, ³Tampa, US, ⁴Waltham, MA 02451/US

17:30 - 17:45

Invited discussant 1007PD, 1008PD and 1009PD

J. DE LA SERNA, Madrid, ES

17:45 - 17:50

Q&A led by Discussant

- 16:30 - 18:00 Type: Proffered Paper session Alicante Auditorium
Title: Public health policy and health economics
Chair(s): R. Giuliani, IT; C. Uyl-De Groot, NL
- 16:30 - 16:42 1435O_PR - Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs
C. Molto Valiente¹, A. Tibau¹, A. Ocana Fernandez², A. Templeton³, L. del Carpio Huerta¹, J. Del Paggio⁴, A. Barnadas¹, C. Booth⁵, E. Amir⁶; ¹Barcelona, ES, ²Albacete, ES, ³Basel, CH, ⁴Kingston, CA, ⁵Kingston, Ontario/CA, ⁶Toronto, Ontario/CA
- 16:42 - 16:54 1436O_PR - How to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS
M. Grande¹, J. Fernandez¹, B. Dahmani¹, S. Stanel¹, N. Albin², L. Guillevin¹, C. Belorgey¹, A. D'ANDON¹; ¹St. Denis, FR, ²Rouen, CEDEX/FR
- 16:54 - 17:06 1437O_PR - Clinical benefit of randomized controlled trials (RCT) supporting US Food and Drug Administration (FDA) conversion from accelerated to full approval
M. Borrell Puy¹, C. Molto Valiente¹, A. Ocana Fernandez², A. Templeton³, B. Seruga⁴, I. Gich¹, A. Barnadas¹, E. Amir⁵, A. Tibau¹; ¹Barcelona, ES, ²Albacete, ES, ³Basel, CH, ⁴Ljubljana, SI, ⁵Toronto, Ontario/CA
- 17:06 - 17:21 Invited Discussant 1435O, 1436O and 1437O
C. Uyl-De Groot, Rotterdam, NL
- 17:21 - 17:33 1438O_PR - Report on ESMO/SIOPE European Landscape project key results: Mapping the status and needs in AYA cancer care
E. Saloustros¹, D. Stark², K. Michailidou³, G. Mountzios⁴, L. Brugières⁵, F. Peccatori⁶, S. Jezdic⁷, S. Essiaf⁸, J.-Y. Douillard⁹, S. Bielack¹⁰; ¹Heraklion, Crete, GR, ²Leeds, GB, ³Nicosia, CY, ⁴Athens, GR, ⁵Villejuif, FR, ⁶Milan, IT, ⁷Lugano - Viganello, CH, ⁸Brussels, BE, ⁹Lugano - Viganello, CEDEX/CH, ¹⁰Stuttgart, CH
- 17:33 - 17:45 1439O_PR - Paediatric radiation therapy across Europe: A European questionnaire survey supported by the SIOPE, ESTRO, PROS and several national paediatric hematology-oncology societies (NAPHOS)
C. demoor-goldschmidt¹, C. Carrie², G. Whitfield³, P. Meijnders⁴, K. Dieckmann⁵, B. Timmermann⁶, L. Zaletel⁷, P. Banovic⁸, M. Solak Mekic⁹, Y. Lassen¹⁰, K. Alexopoulou¹¹, J. Giral¹², J. Vizkeleti¹³, L. Jarusevicius¹⁴, B. Ondrova¹⁵, P. Daly¹⁶, P. Brandal¹⁷, G. Janssens¹⁸, U. Ricardi¹⁹, R. Dieter-Kortmann²⁰; ¹Villejuif, FR, ²Lyon, FR, ³Manchester, GB, ⁴Antwerp, BE, ⁵Vienna, AT, ⁶Essen, DE, ⁷Ljubljana, SI, ⁸Banja Luka, BA, ⁹Zagreb, HR, ¹⁰Aarhus, DK, ¹¹Athens, GR, ¹²Barcelona, ES, ¹³Budapest, HU, ¹⁴Kaunas, LT, ¹⁵Prague, CZ, ¹⁶Dublin, IE, ¹⁷Oslo, NO, ¹⁸Utrecht, NL, ¹⁹Turin, IT, ²⁰Leipzig, DE
- 17:45 - 18:00 Invited Discussant 1438O_PR and 1439O_PR
P. Bruzzi, Genoa, IT

18:30 - 20:00 Type: Industry Satellite Symposium Pamplona Auditorium
 Title: Industry Satellite Symposium 50

18:30 - 20:00 PRRT: Expanding future treatment options in GEPNETs
M. Caplin, London, GB

18:30 - 20:00 Type: Industry Satellite Symposium Cordoba Auditorium
 Title: Industry Satellite Symposium 51

18:30 - 20:00 Type: Industry Satellite Symposium Granada Auditorium
 Title: Industry Satellite Symposium 52

18:30 - 20:00 Biosimilars in Breat Cancer: Expanding Options from Supportive to Therapeutic Care
M. Pegram, Stanford, CA/US

18:30 - 20:00 Type: Industry Satellite Symposium Valencia Auditorium
 Title: Industry Satellite Symposium 53

18:30 - 20:00 Type: Industry Satellite Symposium Tarragona Auditorium
 Title: Industry Satellite Symposium 54

18:30 - 20:00 Type: Industry Satellite Symposium Bilbao Auditorium
 Title: Industry Satellite Symposium 55

18:30 - 20:00 After the Clinical Trial: How Evidence from Clinical Practice is Transforming Patient Care
S.P. Johnsen, Aarhus, DK

18:30 - 20:00 Type: Industry Satellite Symposium Alicante Auditorium
 Title: Industry Satellite Symposium 56

12-09-2017

09:00 - 12:30	Type: Congress highlights Title: Congress Highlights 1 - The best of ESMO 2017 Chair(s): R. Marais, GB; F. Ciardiello, IT	Barcelona Auditorium
09:00 - 09:20	Basic Science <u>A. Berns</u> , Amsterdam, NL	
09:20 - 09:40	Translational research <u>I. Malanchi</u> , London, GB	
09:40 - 10:10	GU tumours <u>A. Omlin</u> , St. Gallen, CH	
10:10 - 10:30	CNS tumours <u>M. Preusser</u> , Vienna, AT	
10:30 - 10:50	Break	
10:50 - 11:10	Head and neck cancer <u>J.-P. Machiels</u> , Brussels, BE	
11:10 - 11:30	Developmental therapeutics <u>J. Schellens</u> , Amsterdam, NL	
11:30 - 12:00	Breast cancer early and metastatic <u>G. Curigliano</u> , Milan, IT	
12:00 - 12:30	Thoracic malignancies <u>L. Paz-Ares</u> , Madrid, ES	

09:00 - 12:30	Type: Congress highlights Title: Congress Highlights 2 - The best of ESMO 2017 Chair(s): A. Sobrero, IT; J. Tabernero, ES	Sevilla Auditorium
09:00 - 09:20	Gastrointestinal tumours, colorectal <u>R. Adams</u> , Cardiff, GB	
09:20 - 09:50	GI non-colorectal and NETs and endocrine tumours <u>M. Ducreux</u> , Villejuif, FR	
09:50 - 10:10	Sarcoma <u>H. Gelderblom</u> , Leiden, NL	
10:10 - 10:30	Gynaecological cancers <u>A. Oaknin</u> , Barcelona, ES	
10:30 - 10:50	Break	
10:50 - 11:10	Supportive and palliative care <u>F. Scotté</u> , Paris, FR	
11:10 - 11:30	Public health and health economics <u>C. Uyl-De Groot</u> , Rotterdam, NL	
11:30 - 11:50	Haematological malignancies <u>F. Peyrade</u> , Nice, CEDEX 2/FR	
11:50 - 12:10	Immunotherapy of cancer <u>I.-M. Svane</u> , Herlev, DK	
12:10 - 12:30	Melanoma and other skin tumours <u>S. Martin Algarra</u> , Pamplona, ES	